Title,Acronym,Status,Study Results,Phases,Funded Bys,URL,trial_id,outcome,study_type,study_design
Duvelisib to Combat COVID-19,nan,not yet recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04372602,NCT04372602,overall survival|length of hospital stay|length of icu stay|duration of ventilator use|duration of vasopressors use|duration on renal replacement therapy|viral kinetics as measured by virologic failure|number of adverse events as measured by ctcae v. 5.0,interventional,"allocation: randomized|intervention model: single group assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Observational Cohort of COVID-19 Patients at Raymond-Poincare,COVID-RPC,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04364698,NCT04364698,"clinical, biological and radiological characteristics|patients' journey description|treatments effects",observational,observational model: cohort|time perspective: prospective
Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial,DART,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04482621,NCT04482621,change in clinical state as assessed by a 6-point ordinal scale|safety as assessed by adverse events|change in oxygenation index|change in fraction of inspired oxygen|time (days) to clinical improvement|overall survival|length of stay in hospital|ventilator free days|time to polymerase chain reaction (pcr) negativity|percentage of patients with national early warning score 2 of 3 or more,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
COVID-19 Surveillance Based on Smart Wearable Device,COVID-19SWD,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04459637,NCT04459637,"deterioration of the condition|mortality|the information analysis degree, the proportion of signal loss, the proportion of wrong signal,",observational,observational model: cohort|time perspective: prospective
A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,nan,recruiting,No Results Available,phase 2,Other|NIH,https://ClinicalTrials.gov/show/NCT04425538,NCT04425538,time to improvement in oxygenation|28-day mortality|assessment of cytokine and inflammatory profile at baseline and at 48 hours after therapy|qualitative and quantitative toxicity|incidence and duration of supplemental oxygen administration|incidence and duration of non-invasive ventilation or by non-rebreather mask or high-flow nasal cannula|incidence and duration of mechanical ventilation|incidence and duration of vasopressor support|incidence and duration of extracorporeal membrane oxygenation|duration of fever|correlation of cytokine profile to clinical outcomes specified in primary and secondary objectives|duration of hospitalization|secondary infections,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Safety & Performance Evaluation of Seraph 100 in Treatment of Pts With COVID-19,CP022,not yet recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04547257,NCT04547257,change in organ failure|change in organ failure|all-cause mortality|change in viral load|organ dysfunction-free days|icu complications|ventilator-free days (vfds|length of stay (los) at icu|prognosis factors,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Safety and Efficacy of Tramadol in COVID-19 Egyptian Patients,nan,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04454307,NCT04454307,number of covid-19 pcr negative cases,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Safety and Efficacy of C21 in Subjects With COVID-19,nan,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04452435,NCT04452435,change from baseline in c-reactive protein (crp) after treatment with c21 200 mg daily dose (100 mg b.i.d.),interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Application of Desferal to Treat COVID-19,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04333550,NCT04333550,mortality rate|change in patients clinical manifestation|change in patients pao2|length of hospitalization|c-reactive protein|lymphocyte count|length of intensive care unit stay,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Dornase Alpha for the Treatment of COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04432987,NCT04432987,response|survival,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Impact of COVID-19 Outbreak on Non-COVID-19 Patients,NoCOVImpact,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04537559,NCT04537559,"intra-hospital mortality|composite outcome (worsening during hospitalization)|pathologies leading to hospitalization|overall mortality at 3 months (90 days)|potentially avoidable readmission rate|mortality rate by pathology at 3 months|length of stay|rate of transfer to intermediate or intensive care|rate of transfer to rehabilitation care|specific gravity outcomes for patients with pneumonia : curb 65 scale (confusion, urea, respiratory rate, blood pressure, age [>65])|specific gravity outcomes for patients with cardiac failure : killip class|specific gravity outcomes for patients with cardiac failure : weight variation|specific gravity outcomes for patients with cardiac failure or lung disease|leukocytes serum level|polynuclear neutrophils serum level|lymphocytes serum level|hemoglobin serum level|thrombocytes serum level|quick serum level|inr (international normalized ratio)|fibrinogen serum level|ptt serum level (partial thromboplastin time)|d-dimers serum level|glucose serum level|glycated hemoglobin serum level (hba1c)|c-reactive protein serum level (crp)|sodium serum level|potassium serum level|chlorides serum level|calculated osmolality serum level|phosphates serum level|corrected calcium serum level|urea serum level|creatinine serum level|egfr (ckd-epi) serum level|albumin serum level|prealbumin serum level|cyanocobalamin serum level|folate serum level|25-hydroxy vitamin d (d2 + d3) serum level|probnp (brain natriuretic peptid) serum level|ultra sensitive troponin t serum level|asat (aspartate transaminase) serum level|alat (alanine aminotransferase) serum level|alkaline phosphatases serum level|gamma glutamyl transpeptidase. serum level|total bilirubin serum level|ferritin serum level|tsh serum level|arterial ph|arterial pco2 (carbon dioxide partial pressure)|arterial po2 (oxygen partial pressure)|arterial lactate|arterial hco3 (bicarbonate)|protein serum level|arterial pressure|cardiac rates|respiratory rates|temperature|oxygen saturation|peak flow|specific scales : vas of pain|specific scales : fim|specific scales : sofa score|specific scales : mna|specific scales : nrs|serum or urine positive bacteriologic sample|patient questionnaire",observational,observational model: cohort|time perspective: retrospective
Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19,nan,"active, not recruiting",No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04336904,NCT04336904,time from randomization to clinical recovery|time from randomization to negativity in rt-pcr nucleic acid test|incidence of deterioration/aggravation of pneumonia|time from randomization to resolution of pyrexia|time from randomization to relief of cough|time from randomization to relief of dyspnoea|rate of auxiliary oxygen therapy|icu admission rate|mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia,nan,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04445272,NCT04445272,to calulate the time of intubation|to calculate the time with oxygen therapy|to calculate the time with non-invasive mechanical ventilation|to evaluate mortality rate|to calculate respiratory function parameters|to evaluate radiological lung extension|to evaluate radiological evolution|to describe the duration of hospitalization and icu use|to evaluate the requirement of additional organ support|to evaluate the effect of iv tocilizumab on the serum levels of inflammatory markers|to calculate the number of adverse events in patients with covid-19 pneumonia treated with tocilizumab|to assess time to reverse-transcriptase polymerase chain reaction (rt-pcr) virus negativity|to evaluate the effect of iv tocilizumab on the serum levels of inflammatory|to calculate the number of serious adverse events in patients with covid-19 pneumonia treated with tocilizumab|to calculate the number of adverse events of special interest in patients with covid-19 pneumonia treated with tocilizumab|to evaluate respiratory function,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04354831,NCT04354831,overall mortality within 60 days|length of icu stay during current admission for covid,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
CORonavirus (COVID-19) Diagnostic Lung UltraSound Study,COR-DLUS,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04351802,NCT04351802,diagnosis of covid-19 on lung ultrasound|difference in diagnosis of covid-19 on lung ultrasound vs. chest x-ray|diagnosis of alternative condition to covid-19 on lung ultrasound vs. chest x-ray|ability of surveillance lung ultrasound to predict clinical trajectory / outcome in patients with covid-19|consistency of lung ultrasound interpretation in patients presenting with suspected covid-19,observational,observational model: cohort|time perspective: prospective
AZD1222 Vaccine for the Prevention of COVID-19,nan,not yet recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04540393,NCT04540393,incidence of saes following the first vaccination and throughout the study duration (day 180) [safety and tolerability].|incidence of solicited aes for 7 following each vaccination [safety and tolerability].|sars-cov-2 antigen-specific antibody levels|the rate of participants seroconverting from negative to positive sars-cov-2 s antigen|the rate of participants seroconverting from negative to positive sars-cov-2 n|quantity of sars-cov-2 neutralizing antibodies|count of peripheral blood mononuclear cells (pbmcs)|quantity of seasonal coronavirus antigens|quantity of antibodies to the chadox1vector and the persistence of these antibodies over time,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04345445,NCT04345445,the proportion of patients requiring mechanical ventilation|mean days of ventilation|the proportion of patients requiring icu admission|overall 28-day survival|change in symptom severity assessed by the world health organization (who) coronavirus disease 2019 (covid19) ordinal scale measured daily up to 7 days from baseline|duration of hospital and icu stay,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: treatment
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04359095,NCT04359095,"mortality|number of participants with treatment related severe adverse events as assessed by the ncorp guidance for collection of adverse events related to covid-19 infection|time to death|number of participants that are transferred to the intensive care unit (icu)|number of participants that need mechanical ventilation support with endotracheal intubation.|number of participants cured assessed by nasopharyngeal swab, oropharyngeal swab, and blood aspiration for covid19 (rt-pcr) without clinical symptoms and normal chest x ray|number of participants with any adverse event related to treatment assessed by the ncorp guidance for collection of adverse events related to covid-19 infection",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Long-term Outcomes in Patients With COVID-19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04508712,NCT04508712,physical functions|respiratory function|cognitive function|depression status|sensory functions|heart function,observational,observational model: case-only|time perspective: prospective
Isotretinoin in Treatment of COVID-19,Randomized,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04361422,NCT04361422,clinical clearance,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04460547,NCT04460547,"geographical distribution of the interventional studies after 11th of march 2020.|geographical distribution of the observational studies after 11th of march 2020.|monthly research study completion rate as per geographic distribution of the research.|statistical correlation of the interventional studies research with developed, developing and under developed countries.|statistical correlation of the observational studies research with developed, developing and under developed countries.|statistical correlation of the drug based interventional studies research with developed, developing and under developed countries.|statistical correlation of the diagnostic test based interventional studies research with developed, developing and under developed countries.|statistical correlation of the device based interventional studies research with developed, developing and under developed countries.",observational,observational model: cohort|time perspective: retrospective
"Gut Microbiota, ""Spark and Flame"" of COVID-19 Disease",nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04355741,NCT04355741,differences in gut microbiota composition between covid-19 patients with different degrees of disease severity.|differences in gut microbiota composition between covid-19 patients in relation to mortality.|differences in gut microbiota composition between covid-19 patients in relation to length of stay in hospitals.|differences in gut microbiota composition between covid-19 patients in relation to duration of mechanical ventilation.,observational,observational model: case-only|time perspective: cross-sectional
Inhaled Nitric Oxide for Preventing Progression in COVID-19,NO-COVID-19,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04388683,NCT04388683,"prevention of progressive systemic de-oxygenation, with escalation to higher levels of oxygen and ventilatory support or death, assessed using a 7-point severity scale.|prevention of progression assessed by an alternate severity scale|time to reaching maximal severity score|proportion of patients in each stage at maximum severity|pao2/fio2 or sao2/fio2 ratio, measured daily|length of hospital stay (death assigned as worst case)|frequency of intubation, ecmo, or need to intubate with ""do not resuscitate"" order|mortality|il6 level|tnf-alpha level|fibrinogen level|crp level|ferritin level|d-dimer level",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Developement and Evaluation of Serological Assays for COVID-19,SEROCOV,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04377763,NCT04377763,sensibility and specificity|delay between the first symptoms and the positive serological result,observational,observational model: cohort|time perspective: retrospective
Utility of Lactoferrin as an Adjunct Therapeutic Agent for COVID-19,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04421534,NCT04421534,time to clinical improvement|rate of virological cure,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
A Trial of NT-I7 in COVID-19 (SPESELPIS),nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04501796,NCT04501796,evaluate the safety of a single dose of nt-i7 in a dose escalation fashion|evaluate the immunological effects of nt-i7 cumulatively for all doses on peripheral lymphocyte counts in covid-19 patients.,interventional,"allocation: randomized|intervention model: sequential assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
COVID-19 Symptom Tracker,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04331509,NCT04331509,physical health symptoms|lack of physical health symptoms|fever,observational,observational model: cohort|time perspective: prospective
Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04428801,NCT04428801,"tolerability and acute safety of admsc infusion by assessment of the total number of aes/saes related and non-related with the medication|the overall proportion of subjects who develop any aes/saes related and non-related with the admsc infusions as compared to the control group|covid-19 incidence rates in both the study and control groups|the proportion of subjects who are infected by sars-cov-2 measured by pcr or other nuclear level-based sars-cov-2 virus testing in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the cdc standard method.|the proportion of subjects who are infected by sars-cov-2 virus develop symptoms including mild, classic, severe and critical sever cases between study group and control group.|change of proportion of subjects who are infected by sars-cov-2 and develop igm/igg antibodies against sars-cov-2 between study group and control group.|change of lymphocyte count in white blood cell counts from the baseline|change of pao2 arterial blood gases from the baseline|compare the proportion of subjects who develop severe covid-19 pneumonia cases for both study and control groups|covid-19 mortality rates for both study and control groups|change of c-reactive protein (crp) (mg/l) from the baseline|change of d-dimer (mg/l) from the baseline|change of procalcitonin (ug)/l from the baseline|change of pro-type b natriuretic peptide (pro-bnp) (pg/ml) from the baseline|change of bilirubin (mg/dl) from the baseline|change of creatinine (mg/dl) from the baseline|change in blood test values for cytokine panels (il-1œ≤, il-6, il-8, il-10, tnfœ±) from the baseline|the proportion of subjects from sars-cov-2 rt-pcr positive to negativity in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the cdc standard method. as compared to control group|quantifying viral rna in stool for baseline and final follow-up.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: treatment"
COVID-19: A Prevalence Study of Two ART Centres After the Pandemic Lockdown in the USA (COVID-19 Free Clinics),nan,completed,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04466644,NCT04466644,prevalence of contagiousness in asymptomatic individuals by pcr with nasopharyngeal swabs|ratio of asymptomatic immunized (igg) population|to validate saliva specimens as a biological sample for covid-19 testing,observational,observational model: other|time perspective: prospective
Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04431908,NCT04431908,"sensitivity, specificity and accuracy|repeatability|validation|asymptomatic sensitivity, specificity and accuracy",observational,observational model: cohort|time perspective: prospective
Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04343183,NCT04343183,decrease incidence of intubation by 30% or greater|decrease renal injury,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04347915,NCT04347915,the rate of subjects tested as negative sars-coronavirus-2 (sars-cov-2)|the rate of subjects tested as negative sars-coronavirus-2 (sars-cov-2) in consecutive two days of real-time rt-pcr tests|the rate of subjects indicated by the improvement of lung invasive|the change of viral load,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,C-19-ACS,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04333407,NCT04333407,all-cause mortality at 30 days after admission|absolute change in serum troponin from admission to peak value|discharge rate|intubation rate,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1),nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04470622,NCT04470622,"proportion of subjects alive and discharged from the hospital.|time to death or respiratory failure, defined as any of the following: endotracheal intubation and mechanical ventilation; oxygen delivered by high-flow nasal cannula; noninvasive positive pressure ventilation; extracorporeal membrane oxygenation (ecmo).|time to discharge from hospital.|change from baseline in interleukin 6 (il-6).|incidence of treatment-emergent adverse events.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation,VPCOVID,not yet recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04452669,NCT04452669,reduction in respiratory failure|reduction in cardiac/circulatory failure|improvement in oxygenation|improved clinical outcomes,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial),IMPACT,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04406389,NCT04406389,"30-day mortality|length of intensive care unit (icu) stay in days|number of documented venous thromboembolism (vte), arterial thrombosis (stroke, myocardial infarction, other) and microthrombosis events|number of major and clinically relevant non-major bleeding events",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 Endoscopy Survey,COVID-19 Endo,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04342637,NCT04342637,effect of gi societies recommendations on prevention of sars-cov-2 infection|to measure the percentage change in performed endoscopic procedure in response to covid-19|effect of covid-19 precautions on procedure time|effect of covid-19 precautions on time of disinfection|effect of covid-19 precautions on procedure success|effect of covid-19 precautions on complications|effect of covid-19 precautions on working time|effect of covid-19 precautions on staff number,observational,observational model: cohort|time perspective: prospective
The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04291053,NCT04291053,mortality rate|clinical status assessed according to the official guideline|the differences in oxygen intake methods|duration (days) of supplemental oxygenation|duration (days) of mechanical ventilation|the mean pao2/fio2|length of hospital stay (days)|length of icu stay (days)|pulmonary function,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 Convalescent Plasma (CCP) Transfusion,nan,recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04412486,NCT04412486,change in pao2/fio2 after ccp transfusion.|change in pulse oximetry status after ccp transfusion.|change in ao2 after ccp transfusion.|change in respiratory rate after ccp transfusion.|change in intubation status after ccp transfusion.|change in sequential organ failure assessment (sofa).|change in 8-point ordinal clinical deterioration scale.|length of icu/hospital stay.|development of plasma transfusion reactions.|development of immune complex disorders.|change in anti cov-2 igm and igg levels.,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04552366,NCT04552366,incidence of the ae in all groups|seroconversion rate of the igg antibody against sars-cov-2|geomean titers of the igg antibody against sars-cov-2|seroconversion rate of the neutralizing antibody against sars-cov-2|geomean titers of the neutralizing antibody against sars-cov-2|incidence of serious adverse events (sae) in all groups|cellular immune response by elispot|geomean titers of neutralizing antibody response to ad5-vector|cellular immune response by ics|geomean titers of the iga antibody against sars-cov-2,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19,COVID-19,recruiting,No Results Available,not applicable,Industry|Other,https://ClinicalTrials.gov/show/NCT04336462,NCT04336462,recovery time|clinical symptom remission time|fever duration|leicester cough questionaire (lcq)|minimum oxygen|negative conversion rate|white blood cell(wbc)|red blood cells(rbc)|hemoglobin(hb )|platelets(plt)|lymphocyte count|the percentage of lymphocyte|neutrophils|c-reactive protein (crp)|myocardial enzyme|liver function|renal function|muscle enzyme,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Pegylated Interferon Lambda for Treatment of COVID-19 Infection,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04534673,NCT04534673,viral shedding in days since initial diagnosis|rate of adverse events and severe adverse events|time to clinical recovery|rate of non-invasive or mechanical ventilation|length of hospital stay|all-cause mortality|undetectable covid-19 virus levels,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19,Mir-Age,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04393038,NCT04393038,"rate of patients with no invasive or non-invasive mechanical ventilation (imv and niv, respectively), but excluding simple nasal/mask oxygen supplementation, and who are alive|rate of patients hospitalized|percentage of patients reporting each severity rating on a 7-point ordinal scale|change from enrolment in inflammatory markers in plasma and in immune phenotype and assessment of cell-activation markers in pbmcs|rate of patients requiring oxygen supplementation|time to hospitalization|time to assisted ventilation and oxygen supplementation|change from baseline in microrna-124 levels|change from baseline in crp, troponin i & t and d-dimer|sars-cov-2 viral load|number and rates of participants with treatment emergent adverse event",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Setting up a COVID-19 Care Facility at a Prison in Pakistan,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04404179,NCT04404179,recovery|mortality|icu admission,observational,observational model: case-only|time perspective: prospective
Serological Surveillance for COVID-19 in Central North Carolina,nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04490174,NCT04490174,anti-sars-cov-2 antibodies|positive sars-cov-2 pcr|clinical questionnaires and elisa antibody testing resu|detection of anti-sars-cov-2 antibodies by elisa assay algorithm|clinical questionnaires and elisa antibody testing results,observational,observational model: cohort|time perspective: prospective
Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19,COVID-19,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04474483,NCT04474483,cumulative incidence of treatment-emergent adverse events|hospitalization|covid-19 related symptoms|rate of resolution of covid-19 related symptoms|mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
The Role of Resistant Starch in COVID-19 Infection,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04342689,NCT04342689,rates of hospitalization for a covid-19 related complication|time to clinical recovery (ttcr)|symptom severity score,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19,COVIDOSE-2,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04479358,NCT04479358,time to recovery|achievement of recovery|overall survival|hospital length of stay|clinical response: maximum temperature (tmax) response|clinical response: rate of non-elective invasive mechanical ventilation|clinical response: duration of non-elective invasive mechanical ventilation|clinical response: time to non-elective invasive mechanical ventilation|clinical response: rate of vasopressor/inotrope utilization|clinical response: duration of vasopressor/inotrope utilization|clinical response: time to vasopressor/inotrope utilization|clinical response: duration of increased supplemental oxygen from baseline|biochemical response: c-reactive protein response rate|safety: rate of secondary infection,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION),CONDITION,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04389658,NCT04389658,prevalence of contagiousness in asymptomatic individuals by pcr|ratio of asymptomatic immunized (iga/igm and igg) population|description of demographic characteristics,observational,observational model: other|time perspective: retrospective
Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04363346,NCT04363346,number of participants with dose limiting toxicity events|the time in days from the 1st ft516 infusion to the elimination of viral shedding in nasal pharyngeal and stool samples|the time in days from the 1st ft516 infusion to discontinued need for supplemental oxygen|the time in days from the 1st ft516 infusion to hospital discharge,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
C5a Receptor Expression - COVID-19 (C5-COV),C5-COV,recruiting,No Results Available,not applicable,Other|Industry,https://ClinicalTrials.gov/show/NCT04369820,NCT04369820,show an overexpression of c5a receptor in patients with ards secondary to covid-19 compared to control patients (patients with covid-19 without respiratory distress and healthy volunteers).,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
TXA127 for the Treatment of Severe COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04401423,NCT04401423,change of serum creatinine|number of participants requiring intubation and ventilatory support|change in number of deceased participants|number of participants requiring dialysis|number of participants requiring a vasopressors|change in blood inflammatory markers|percent change in supplemental oxygen requirements,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Relation Between Lab Finding and COVID-19 Severity,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04470557,NCT04470557,estimation of severity of patients with covid-19 in relation to laboratory findings.,observational,observational model: other|time perspective: cross-sectional
Genosvid Diagnostic Test for Early Detection of COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04558372,NCT04558372,diagnostic accuracy of electronic nose signal in covid-19,interventional,"allocation: non-randomized|intervention model: single group assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: diagnostic"
Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments (INOSARS) for Hospitalized Patients With COVID-19,nan,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04514302,NCT04514302,"proportion of patients with improvement in clinical status|time to clinical improvement|proportion of patients that reach a score of 6, 7 or 8 in the niaid 8-point ordinal scale|duration of hospitalization|sars-cov-2 pcr negativization rate|proportion of patients with clinical improvement at day 7|proportion of patients with immediate adverse events (< 24 hours)|proportion of patients with late adverse events (1 - 28 days)",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04392141,NCT04392141,mortality rate|change in patients clinical manifestation|length of hospitalization|c-reactive protein|lymphocyte count|serum lactate dehydrogenase|serum interleukin-6|erythrocyte sedimentation rate,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Online Learning of Veterinary Anatomy During COVID-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04418284,NCT04418284,measure the students' interest in studying anatomy on-line.|assess the easiness of using technology during studying anatomy online|assess the student satisfaction regarding the provided study materials,observational,observational model: other|time perspective: cross-sectional
Vitamin D Supplementation in Patients With COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04449718,NCT04449718,length of hospitalization|mortality|number of cases admitted to intensive care unit (icu)|length of use of mechanic ventilator|number and severity of symptoms|inflammatory markers|c-reactive protein|vitamin d|creatinine|calcium|physical activity,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
DAS181 for Severe COVID-19: Compassionate Use,nan,completed,No Results Available,not applicable,Other|Industry,https://ClinicalTrials.gov/show/NCT04324489,NCT04324489,improved clinical status|return to room air|sars-cov-2 rna|discharge|death,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Multi-site Adaptive Trials for COVID-19,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04370262,NCT04370262,mortality|virologic response to study treatment detected in blood|virologic clearance in nasal swab and/or lower respiratory secretions|clinical severity,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
"A Prospective ""Universal"" Observational Database for COVID-19",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04347993,NCT04347993,need for hospitalization|duration of hospitalization|need for icu/ventilator support|duration of icu/ventilator support|overall survival,observational,observational model: case-only|time perspective: prospective
Expanded Access to Convalescent Plasma for Treatment of COVID-19,nan,available,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04472572,NCT04472572,nan,expanded access:treatment ind/protocol,nan
Genetic Bases of COVID-19 Clinical Variability,GEN-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04549831,NCT04549831,to identify the genetic determinants of covid-19 severity|to identify the genetic determinants of covid-19 clinical trajectories.,observational,observational model: case-control|time perspective: prospective
COVID-19 Infection in Healthcare Workers,HOP-COVID,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04386759,NCT04386759,sars-cov-2 infection|individual factors|hospital ward level,observational,observational model: cohort|time perspective: other
PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04497324,NCT04497324,transfusion-related serious adverse events|all-cause in-hospital mortality|length of hospital stay|length of icu stay|need of invasive mechanical ventilation|duration of mechanical ventilation|clinical improvement at 14 days,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Descriptive and Retrospective Analysis of Acute Myocarditis Associated With Pandemic COVID-19 in Children,HEART-COVID,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04420468,NCT04420468,acute myocarditis|multi-systemic inflammatory syndrome|kawasaki disease|results of sars-cov-2,observational,observational model: cohort|time perspective: retrospective
Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19,ONSCOVID19,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04323228,NCT04323228,change from baseline score of nutrition risk screening-2002 (nrs-2002) at end of the trial|change from baseline serum ferritin level at end of the trial|change from baseline serum interleukin-6 concentration at end of the trial|change from baseline serum c-reactive protein concentration at end of the trial|change from baseline serum tumor necrosis factor-œ± concentration at end of the trial|change from baseline serum monocyte chemoattractant protein 1 (mcp-1) at end of the trial|change from baseline weight at end of the trial|height|change from baseline bmi at end of the trial|change from baseline mid arm circumference at end of the trial|change from baseline triceps skin-fold thickness at end of the trial|change from baseline mama at end of the trial|change from baseline percentage of peripheral o2 saturation at end of the trial|change from baseline degree of body temperature at end of the trial|change from baseline count the total leukocyte at end of the trial|change from baseline differential lymphocytic count at end of the trial|change from baseline neutrophil count at end of the trial|change from baseline neutrophil to lymphocyte ratio at end of the trial,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: supportive care"
Impact of COVID-19 on Marshallese Communities in the U.S.,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04474496,NCT04474496,"effects of covid-19 on social determinants of health|effects of covid-19 on general health status and mental health|effects of covid-19 on disease management|effects of covid-19 on diet and physical activity behaviors|covid-19 screening, testing, and prevention|trusted sources of covid-19 information|impacts of covid-19 on daily life|covid-19 attitudes, fears, and beliefs",observational,observational model: other|time perspective: cross-sectional
Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19,COVID-19,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04376788,NCT04376788,improvement of condition|change in organs function with pfs and os,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients,MIA-COVID-19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04366882,NCT04366882,"determination of cause of death and contributing factors based on clinical, radiological, microbiological and histopathological data of the deceased patient|detailed description of the postmortem radiological changes induced by covid-19|detailed description of the postmortem histopathological changes induced by covid-19|postmortem quantity of viral rna|postmortem disease mechanisms at cellular level",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
Study of Open Label Losartan in COVID-19,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04335123,NCT04335123,"number of participants with treatment-related adverse events as assessed by protocol definition of ae|number of days on supplemental oxygen in respiratory failure due to covid-19|incidence of mechanical ventilation use|days on mechanical ventilation|incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|days on non-invasive positive pressure ventilation or high flow nasal cannula|incidence of transfer to icu from non-icu hospital bed|icu length of stay (days)|30-day mortality rate|hospital length of stay (days)|cumulative incidence of severe adverse events|cumulative incidence of adverse events|change from baseline in oxygenation|incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|incidence (and length in days) of extracorporeal membrane oxygenation use|incidence (and length in days) of renal replacement therapy use|intolerance of high dose (50mg) losartan after tolerating 25mg",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Ivermectin and Nitazoxanide Combination Therapy for COVID-19,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04360356,NCT04360356,"number of patients with covid-19-negative pcr|number of patients with improved respiratory rate|number of patients with improved pao2|number of patients with normalized serum il6|number of patients with normalized serum tnfœ±|number of patients with normalized serum iron|number of patients with normalized serum ferritin|number of patients with normalized international normalized ratio ""inr"" for prothrombin time|number of patients with normalized complete blood count ""cbc""|the mortality rate among treated patients",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,nan,"active, not recruiting",No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04434248,NCT04434248,"rate of viral elimination by day 10 [pilot stage, dose selection]|time to viral elimination [pivotal stage]|time to clinical improvement [pivotal stage]|rate of viral elimination|time to normalization of clinical symptoms|duration of oxygen therapy|change in the level of lung damage according to ct|rate of transfer to the intensive care unit|rate of the use of non-invasive lung ventilation|rate of the use of mechanical ventilation|mortality|peak plasma concentration (cmax)|time to peak plasma concentration (tmax)|area under the plasma concentration versus time curve (auc0-t)|trough plasma concentration (ctrough)",interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Dapagliflozin in Respiratory Failure in Patients With COVID-19,DARE-19,recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04350593,NCT04350593,"time to first occurrence of either death from any cause or new/worsened organ dysfunction through 30 days of follow up, defined as at least one of the following:|hierarchical composite outcome measures including time to death from any cause, time to new/worsened organ dysfunction, clinical status at day 30 and time to hospital discharge|time to hospital discharge|total number of days alive, out of hospital, and/or free from mechanical ventilation|total number of days alive, not in the icu, and free from mechanical ventilation (as defined in the primary outcome measure)|time to death from any cause|time to new/worsened organ dysfunction|time to acute kidney injury (defined as doubling of s-creatinine compared to baseline)",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.,PLASCOSSA,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04372979,NCT04372979,survival time without needs of a ventilator.|morbidity|mortality|length of stay|effect on viral pharyngeal specimen clearance|effect on viral blood specimen clearance|effect on hemostasis disorders|kinetics of appearance of neutralizing antibodies|transfusion endotheliopathy effect|transfusion biological inflammation effect|transfusion hemovigilance|decrease in the consumption of antibiotics,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04456413,NCT04456413,"hospitalization rate|time to symptoms resolution|overall survival|rate of virologic clearance by nasopharyngeal swab at 2 and 4 weeks|rate of nasopharyngeal swab positivity in donors|rate of donor titers level|impact of donor titers level on efficacy|patients' anti-sars-cov2 titer assessment pre-infusion for the treatment group, at 2 weeks , 4 weeks and 2 months.",interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: treatment
Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients,nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04464395,NCT04464395,incidence of treatment-emergent adverse events to determine single dose of cpi-006 that is safe in patients with covid-19|immunoglobulin anti-sars cov-2 levels|negative nasal swab polymerase chain reaction (pcr) sars cov-2 viral tests|duration of symptoms|time to discharge|rate of medical procedures,interventional,intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
"Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19",nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04467151,NCT04467151,"disease progression measured by who scale|comparison of maximum who score per group|comparison of decrease of median and maximum who score per group|comparison of time to clinical improvement per group|comparison of time to reach score of ""6"" or greater on the who scale",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04343755,NCT04343755,"for patients hospitalized for covid-19 but not intubated|primary objective for patients with covid-19 already intubated|duration of hospitalization|duration of mechanical ventilation|time to symptoms resolution|overall survival|rate of virologic clearance by nasopharyngeal swab at day 10|impact of donor titers level on efficacy|impact of donor titers level on safety|recipient anti-sars-cov2 titer assessment on days 0 (pre-infusion),3,10,30, 60",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With COVID-19",nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04425629,NCT04425629,"proportion of patients with treatment-emergent serious adverse events (saes)|proportion of patients with infusion-related reactions|proportion of patients with hypersensitivity reactions|time-weighted average change from baseline in viral shedding as measured by quantitative reverse transcription quantitative polymerase chain reaction (rt-qpcr) in nasopharyngeal (np) swab samples|proportion of patients with at least one covid-19 related medically attended visit|time-weighted average change from baseline in viral shedding measured by rt-qpcr in saliva samples|time-weighted average change from baseline in viral shedding measured by rt-qpcr in nasal swab samples|time to negative rt-qpcr in all tested samples with no subsequent positive rt-qpcr in any tested samples|time to negative rt-qpcr in np swabs with no subsequent positive rt-qpcr|change from baseline in viral shedding as measured by rt-qpcr in np swabs|change from baseline in viral shedding as measured by rt-qpcr in saliva samples|change from baseline in viral shedding as measured by rt-qpcr in nasal swabs|correlation of rt-qpcr results over time between different sample types (np, nasal, and saliva)|concordance of rt-qpcr results over time between different sample types (np, nasal, and saliva)|time-weighted average change from baseline in viral shedding|proportion of patients with at least two covid-19 related medically attended visits|total number of covid-19 related medically-attended visits|proportion of patients admitted to a hospital due to covid-19|proportion of patients admitted to an intensive care unit (icu) due to covid-19|proportion of patients at least 1 outpatient or telemedicine visit due to covid-19|proportion of patients requiring mechanical ventilation due to covid-19|number of days of hospitalization due to covid-19|number of deaths due to any cause (all-cause mortality)|time to first onset of symptoms consistent with covid-19 (asymptomatic cohort only)|duration of symptoms consistent with covid-19|serum concentration of regn10933 over time|serum concentration of regn10987 over time|assessment of pharmacokinetic (pk) parameter: maximum serum concentration observed (cmax) of regn10933|assessment of pk parameter: maximum serum concentration observed (cmax) of regn10987|assessment of pk parameter: cmax-to-dose ratio (cmax/dose) of regn10933|assessment of pk parameter: cmax-to-dose ratio (cmax/dose) of regn10987|assessment of pk parameter: time to cmax (tmax) for regn10933|assessment of pk parameter: time to cmax (tmax) for regn10987|assessment of pk parameter: area under the curve (auc) computed from time zero to the time of the last positive concentration (auclast) for regn10933|assessment of pk parameter: auc computed from time zero to the time of the last positive concentration (auclast) for regn10987|incidence of anti-drug antibodies (ada) to regn10933|incidence of anti-drug antibodies (ada) to regn10987",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Hyperimmune Plasma for Critical Patients With COVID-19,COV19-PLASMA,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04321421,NCT04321421,death|time to extubation|length of intensive care unit stay|time to cpap weaning|viral load|immune response,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19,nan,"active, not recruiting",No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04527133,NCT04527133,time to elimination of sars-cov-2 virus|time to crp normalization|time to d-dimer normalization|time to body temperature normalization|change in absolute neutrophil count (anc)|change in white blood cells (wbc)|change of crp|change of d-dimer|change in fibrinogen|change of quick's value|change of international normalized ratio (inr)|changes of lung injury on ct scan|frequency of clinical status improvement by 2 scores in accordance with the who-osci or discharge from the hospital|frequency of deterioration of the patients' status|frequency of aes and saes,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
"Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Patients With Acute COVID-19 Disease",nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04432298,NCT04432298,"proportion of subjects who never received mechanical ventilation and/or ecmo and alive|proportion of subjects alive, discharged home, and not on supplemental oxygen|time to recovery based on a modified 8-point ordinal scale|days in icu/ccu (either on or off mechanical ventilation and/or ecmo)|days on mechanical ventilation and/or ecmo|time to death from any cause|changes in pao2/fio2 ratio, both as categorical and continuous variable|change in (non-invasive) oxygen supplementation requirements",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
COVID-19 Household Transmission Study,CO-HOST,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04445233,NCT04445233,secondary household infection rate|secondary household infection rate - risk factors|sensitivity of self-collected nasal swabs,observational,observational model: cohort|time perspective: prospective
ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease,nan,terminated,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04329611,NCT04329611,"composite of hospitalization, invasive mechanical ventilation or death within 30 days|mortality|symptom duration|disposition at 30 days defined as recovered, ongoing symptoms but not hospitalized, hospitalized, or deceased (categorical)",interventional,"allocation: randomized|intervention model: single group assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Detection of Anti-COVID-19 Antibody Levels in an Hospital Population,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04387929,NCT04387929,sars-cov-2 levels of igg antibodies|sars-cov-2 viral load in nasopharyngeal swab of igg positive subjects|epidemiology correlations,observational,observational model: cohort|time perspective: prospective
Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection,ENACOVID,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04325633,NCT04325633,mortality all causes at day30|number of days alive free of mechanical ventilation|number of days alive outside|number of days alive outside hospital|maximal changes in sofa score|time to negativation of virus titer in the nasopharyngeal aspirate (npa),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Treatment of Patients With COVID-19 With Convalescent Plasma,COOPCOVID-19,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04415086,NCT04415086,"time elapsed until clinical improvement or hospital discharge|acute adverse events|clinical status|duration of clinical events|sars-cov-2 in nasopharyngeal swab|igg, igm and iga titers for sars-cov-2|neutralizing antibodies",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
TCM Differentiation and Treatment Protocol of COVID-19,TDATPOC,completed,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04306497,NCT04306497,the relief of main symptoms/ disappearance rate of time|chest ct absorption|evaluation standard of comprehensive curative effect|virus antigen negative conversion rate|the number of severe and critical conversion cases|incidence of complications|traditional chinese medicine syndrome score,observational,observational model: cohort|time perspective: other
Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04321993,NCT04321993,"clinical status of subject at day 15 (on a 7 point ordinal scale).|status on an ordinal scale assessed daily while hospitalized and on days 15 and 29 and 180.|length of time to clinical improvement|number of participants with normal pulmonary function and normal o2 saturation on days 11, 15 and 29|number of participants that developed acute respiratory distress syndrome (ards) after treatment|length of time to clinical progression|cause of death (if applicable)|sequential organ failure assessment (sofa) score, daily while hospitalized and on days 15 and 29. (initial, highest, deltas and mean)|length of time to normalization of fever|length of time to normalization of oxygen saturation|duration of supplemental oxygen (if applicable)|duration of mechanical ventilation (if applicable)|duration of hospitalization|adverse events",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04351659,NCT04351659,success rate in production of sars-cov-2 specific t cells from convalescent donor,observational,observational model: cohort|time perspective: prospective
Antiviral Effects of TXA as a Preventative Treatment Following COVID-19 Exposure,TXACOVIDPREV,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04550338,NCT04550338,conversion from negative to positive covid-19 test,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Special Chinese Medicine Out-patient Programme for Discharged COVID-19 Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04544605,NCT04544605,change in cm diagnostic pattern & clinical characteristics using cm syndrome differentiation assessment|change in body constitution scores using body constitution questionnaires assessment|lung function questionnaire in lung function assessment|blood pressure in 6-minute walk test (6mwt)|pulse in 6-minute walk test (6mwt)|spo2 in 6-minute walk test (6mwt)|distance walked in 6-minute walk test (6mwt)|number of rests in 6-minute walk test (6mwt)|mrc dyspnoea scale in 6-minute walk test (6mwt)|borg scale of perceived exertion in 6-minute walk test (6mwt)|peak expiratory flow (pef) in spirometry assessment|forced expiratory volume in 1 second (fev1) in spirometry assessment|force vital capacity (fvc) in spirometry assessment|fev1/fvc ratio (%) in spirometry assessment|quality of life (who-qol bref hk)|assessment on western medicine visit frequency,observational,observational model: case-only|time perspective: other
Traditional Chinese Medicine for Severe COVID-19,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04323332,NCT04323332,length of hospital stay (days)|duration (days) of supplemental oxygenation|ct imaging changes|mortality rate|time to clinical improvement (ttci)|the pneumonia severity index scores|time to covid-19 nucleic acid testing negativity in throat swab|blood immune cell count|serum inflammatory markers|erythrocyte sedimentation rate|platelet and d-dimer changes|creatinine changes|muscle enzymes changes|usage of antibiotics|usage of glucocorticoids|frequency of adverse events,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,APLICOV-PC,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04382066,NCT04382066,frequency of occurrence of neutropenia ‚â• grade 3|frequency of occurrence of thrombocytopenia ‚â• grade 3|frequency of occurrence of anemia ‚â• grade 3|frequency of occurrence of lymphopenia ‚â• grade 3|frequency of occurrence of cpk increase ‚â• grade 3|frequency of occurrence of increase alt and / or ast ‚â• grade 3|frequency of occurrence of increase total bilirubin or direct bilirubin ‚â• grade 3|frequency of occurrence of neurotoxicity ‚â• grade 3|frequency of occurrence of qt-qtc interval extension ‚â• grade 3|frequency of occurrence of other adverse events ‚â• grade 3|percentage of patients in whom treatment cannot be completed.|percentage of patients with adverse events.|percentage of patients with serious adverse events.|percentage of patients with ecg abnormalities.|change in the viral load of sars-cov-2|time to negative pcr test for covid-19|mortality|percentage of patients requiring invasive mechanical ventilation and / or icu admission|percentage of patients requiring non-invasive mechanical ventilation|percentage of patients requiring oxygen therapy,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 Ozanimod Intervention Study,COZI,not yet recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04405102,NCT04405102,daily patient progression assessed with the world health organization-adapted 6-points ordinal scale|the mean oxygen flow required to maintain the oxygen saturation (spo2) target at 92%|rate of non invasive ventilation (niv) / high flow nasal therapy (hfnt) use|rate of intubation|ventilator-free days at day 28|rate of icu admission/length of stay/mortality|severity index measurement,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being,COVIDeF,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04352348,NCT04352348,identification of prognostic factors for progression to a severe form of covid-19 infection|clinical aggravation of the infection|discharge of hospitalization|death|description of clinical manifestations|description of biological manifestations|description of radiological manifestations|description of physiological manifestations|patient-related prognostic factors|virus-related risk factors|comparison of the results of different diagnosis tests,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: basic science
Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),nan,"active, not recruiting",No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04390178,NCT04390178,disease progression|adverse events (ae)|time ro resolution of fever and symptoms|clearance of viraemia|inflammatory parameters|antibody response to sars-cov-2,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04528368,NCT04528368,area under the curve of sars-cov-2 viral load obtained from nasopharyngeal and /or oropharyngeal swabs.|assessment of clinical improvement using an ordinal severity scale|evaluate oxygen saturation|evaluate oxygen supplementation|assess respiratory rate|evaluate the pao2 / fio2 ratio (for patients on mechanical mechanisms)|length of hospital stay|length of stay in intensive care|assess the rate of orotracheal intubation|change in the profile of cytokines/chemokines in both groups|presence of antibodies against sars-cov-2 in serum after convalescent plasma administration|death rate|rate of transfusion reactions to convalescent plasma infusion,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,pVAC,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04546841,NCT04546841,safety- eastern cooperative oncology group (ecog) status|safety -vital signs 2|safety -vital signs 3|safety-blood chemistry and coagulation 1|safety-blood chemistry and coagulation 2|safety-hematology 1|safety-hematology 2|safety-hematology 3|safety-hematology 4|covac-1 specific t-cell response,interventional,intervention model: sequential assignment|masking: none (open label)|primary purpose: prevention
Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04465695,NCT04465695,clinical alleviation of symptoms|hospitalisation|time to negative viral load|inflammatory changes|mortality|adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04339660,NCT04339660,"the immune function (tnf-œ± „äåil-1œ≤„äåil-6„äåtgf-œ≤„äåil-8„äåpct„äåcrp)|blood oxygen saturation|rate of mortality within 28-days|size of lesion area by chest imaging|cd4+ and cd8+ t cells count|peripheral blood count recovery time|duration of respiratory symptoms (fever, dry cough, difficulty breathing, etc.)|covid-19 nucleic acid negative time",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, outcomes assessor)|primary purpose: treatment"
Clinical Characteristics and Outcomes of 187 Critically Ill Patients With Coronavirus Disease 2019 (COVID-19),nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04454372,NCT04454372,outcome 30 days after icu admission,observational,observational model: cohort|time perspective: retrospective
Colchicine in COVID-19: a Pilot Study,COLVID-19,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04375202,NCT04375202,"rate of entering the critical stage|trend of white blood cell count|change of the ""sequential organ failure assessment"" (sofa)|rate of biochemical criterion (ck, alt, ferritin) recovery|rate of disease remission|toxicity of colchicine",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Antibody Responses in Contacts of COVID-19 Patients,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04444310,NCT04444310,measure level of abs in asymptomatic close contacts of covid 19 patients.,observational,observational model: cohort|time perspective: prospective
Study of COVID-19 DNA Vaccine (AG0302-COVID19),nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04527081,NCT04527081,incidence of treatment-emergent adverse events [safety and tolerability]|immunogenicity|change in gmt of anti-sars-cov-2 spike (s) glycoprotein-specific antibody|change in gmt of anti-sars-cov-2 spike (s) glycoprotein receptor binding domain-specific antibody|change in gmt of anti-sars-cov-2 b cell epitope antibody|change in igg subclasses (igg1 and igg2) of anti-sars-cov-2 spike (s) glycoprotein-specific antibody|change in the neutralizing activity against pseudovirus of sars-cov-2|change in binding inhibition of sars-cov-2 spike (s) glycoprotein and ace2|change in ifn-œ≥ production against sars-cov-2 spike (s) glycoprotein by t cells in peripheral blood mononuclear cells|adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
COVID-19 and Vaccination Attitudes,VACAT,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04352582,NCT04352582,how vaccination and other attitudes are affected by covid,observational,observational model: other|time perspective: prospective
Co-infection Management in COVID-19 Critically Ill,nan,completed,No Results Available,not applicable,Other|Industry,https://ClinicalTrials.gov/show/NCT04382092,NCT04382092,% of covid-19 co-infections|% of antibiotic switches following fa results,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Study of COVID-19 DNA Vaccine (AG0301-COVID19),nan,"active, not recruiting",No Results Available,phase 1|phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04463472,NCT04463472,incidence of treatment-emergent adverse events [safety and tolerability]|immunogenicity|change in gmt of anti-sars-cov-2 spike (s) glycoprotein-specific antibody|change in gmt of anti-sars-cov-2 spike (s) glycoprotein receptor binding domain-specific antibody|change in gmt of anti-sars-cov-2 b cell epitope antibody|change in igg subclasses (igg1 and igg2) of anti-sars-cov-2 spike (s) glycoprotein-specific antibody|adverse events,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: prevention
Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy,nan,withdrawn,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04412252,NCT04412252,clinical status using ordinal scale|status of alive and not using mechanical ventilation or extracorporeal membrane oxygenation (ecmo)|status of discharged or not requiring supplemental oxygen|mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection,Anosmie-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04354857,NCT04354857,sars-cov-2 infection status|olfactory and gustatory loss|ability to detect odor|ability to detect salty taste|ability to detect sweet taste|severity of infection according to hospitalization rate,observational,observational model: cohort|time perspective: prospective
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,nan,withdrawn,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04287686,NCT04287686,time course of body temperature (fever)|viral load over time|p/f ratio over time|sequential organ failure assessment score(sofa score) over time|pulmonary severity index (psi)|image examination of chest over time|proportion of subjects who progressed to critical illness or death|time from first dose to conversion to normal or mild pneumonia|t-lymphocyte counts over time|c-reactive protein levels over time|angiotensin ii (ang ii) changes over time|angiotensin 1-7 (ang 1-7) changes over time|angiotensin 1-5 (ang 1-5) changes over time|renin changes over time|aldosterone changes over time|angiotensin-converting enzyme (ace) changes over time|angiotensin-converting enzyme 2 (ace2) changes over time|interleukin 6 (il-6) changes over time|interleukin 8 (il-8) changes over time|soluble tumor necrosis factor receptor type ii (stnfrii) changes over time|plasminogen activator inhibitor type-1 (pai-1) changes over time|von willebrand factor (vwf) changes over time|tumor necrosis factor-œ± (tnf-œ±) changes over time|soluble receptor for advanced glycation end products (srage) changes over time|surfactant protein-d (sp-d) changes over time|angiopoietin-2 changes over time|frequency of adverse events and severe adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2,Bacterial ACE2,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04375046,NCT04375046,time course of body temperature (fever)|viral load over time|p/f ratio over time|sequential organ failure assessment score(sofa score) over time|pulmonary severity index (psi)|image examination of chest over time|proportion of subjects who progressed to critical illness or death|time from first dose to conversion to normal or mild pneumonia|t-lymphocyte counts over time|c-reactive protein levels over time|angiotensin ii (ang ii) changes over time|angiotensin 1-7 (ang 1-7) changes over time|angiotensin 1-5 (ang 1-5) changes over time|renin changes over time|aldosterone changes over time|angiotensin-converting enzyme (ace) changes over time|angiotensin-converting enzyme 2 (ace2) changes over time|interleukin 6 (il-6) changes over time|interleukin 8 (il-8) changes over time|soluble tumor necrosis factor receptor type ii (stnfrii) changes over time|plasminogen activator inhibitor type-1 (pai-1) changes over time|von willebrand factor (vwf) changes over time|tumor necrosis factor-œ± (tnf-œ±) changes over time|soluble receptor for advanced glycation end products (srage) changes over time|surfactant protein-d (sp-d) changes over time|angiopoietin-2 changes over time|frequency of adverse events and severe adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Favipiravir Therapy in Adults With Mild COVID-19,Avi-Mild,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04464408,NCT04464408,"pcr negative|time from randomization to clinical recovery|symptoms progression based on clinical evaluation using simple scoring system.|rate of daily requirement of using antipyretics, analgesics, or antibiotics.|28 days mortality.|rate of requirement of hospitalization, icu admission or mechanical ventilation.|incidence of treatment-related adverse events [safety and tolerability]",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,COPEP,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04364022,NCT04364022,"21-day incidence of covid-19 in individuals exposed to sars-cov- 2 who are asymptomatic at baseline (intent-to-treat (itt) analysis).|21-day incidence of covid-19 in individuals exposed to sars-cov- 2 who are asymptomatic, pcr-confirmed sars-cov-2 negative and have negative sars-cov-2 serology at baseline (modified itt)|21-day incidence of sars-cov-2 infection in individuals exposed to sars-cov-2 who are asymptomatic, pcr-confirmed sars-cov-2 negative and have negative sars-cov-2 serology at baseline (modified itt)|severity of clinical covid-19 on a 7-point ordinal scale",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino),Mon-Covid,terminated,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04361916,NCT04361916,spo2 at hospital entry|in-hospital mortality|need of intubation|percentage of hospitalized patients among those with recommendation of hospitalization,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
Predictive Immune Biomarkers for COVID-19 Pathogenesis,COVIDBioToul,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04385108,NCT04385108,immune signature|dosage of cytokines and chemokines in plasma samples|analysis of the early dynamics of sars-cov-2-specific humoral immunity,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: basic science
COVID-19 Plasma Collection,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04344015,NCT04344015,number of patients who screen eligible for donation|number of patients who consent to plasma donation|number of plasma donations received|safety of donation procedures,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA),AVISA,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04355338,NCT04355338,incidence of sars-cov-2 infection|incidence of covid-19|incidence of hospitalization due to covid-19|level of neutralizing antibodies|previous sars-cov-2 infection,observational,observational model: cohort|time perspective: prospective
Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04344145,NCT04344145,burnout|emotional distress|insomnia|needs and difficulties in work situations,observational,observational model: case-control|time perspective: cross-sectional
VITACOV: Vitamin D Polymorphisms and Severity of COVID-19 Infection,VITACOV,not yet recruiting,No Results Available,nan,Other|Industry,https://ClinicalTrials.gov/show/NCT04370808,NCT04370808,differences in vitamin d blood levels between covid-19 patients with different degrees of disease severity.|differences in genetic variants in vitamin d-related genes between covid-19 patients with different degrees of disease severity.|differences in vitamin d blood levels between covid-19 patients in relation to mortality.|differences in vitamin d blood levels between covid-19 patients in relation to length of stay in hospitals.|differences in vitamin d blood levels between covid-19 patients in relation to duration of mechanical ventilation.|differences in genetic variants in vitamin d-related genes between covid-19 patients in relation to mortality.|differences in genetic variants in vitamin d-related genes between covid-19 patients in relation to length of stay in hospitals.|differences in genetic variants in vitamin d-related genes between covid-19 patients in relation to duration of mechanical ventilation.,observational,observational model: case-only|time perspective: prospective
DAS181 for STOP COVID-19,nan,withdrawn,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04354389,NCT04354389,percent of subjects return to room air (rtra)|percent of subjects who have recovered|improved covid-19 clinical classification|return to room air (rtra)|percent of subjects who achieve clinical stability|sars-cov-2 rna undetectable|clinical deterioration|percent of subjects discharged|death (all cause),interventional,"allocation: randomized|intervention model: sequential assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,nan,not yet recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04381052,NCT04381052,cumulative incidence of serious adverse events associated with clazakizumab or placebo|cumulative incidence of intubation|time to extubation|length of intensive care unit (icu) stay|number of patients who present a decrease in c-reactive protein (crp)|number of patients with acute kidney injury (aki)|number of patients with a need for renal replacement therapy (rrt)|duration of renal replacement therapy (rrt)|patient survival|number of patients with hemodialysis|number of patients with continuous renal replacement therapies (crrt)|number of patients with peritoneal dialysis,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),TOCIVID-19,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04317092,NCT04317092,"one-month mortality rate|interleukin-6 level|lymphocyte count|crp (c-reactive protein) level|pao2 (partial pressure of oxygen) / fio2 (fraction of inspired oxygen, fio2) ratio (or p/f ratio)|change of the sofa (sequential organ failure assessment)|number of participants with treatment-related side effects as assessed by common terminology criteria for adverse event (ctcae) version 5.0|radiological response|duration of hospitalization|remission of respiratory symptoms",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Therapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis,PLASMA,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04480632,NCT04480632,in-hospital mortality|incidence of renal replacement therapy|incidece of adverse events,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia",PANAMO,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04333420,NCT04333420,mortality|treatment emergent adverse events|safety parameters,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04324996,NCT04324996,clinical response|side effects in the treatment group,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04433013,NCT04433013,proportion of participants who test negative for covid-19|time taken in days for relief of clinical symptoms|proportion of participants with mild symptoms of covid-19 progressing to moderate or severe illness|proportion of participants who test positive for covid-19 with ct value>30,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, outcomes assessor)|primary purpose: treatment"
Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,nan,completed,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04391712,NCT04391712,patient disposition post treatment|oxygenation|il-6 levels|chest xray radiographic results|brescia-covid respiratory severity scale|smart-cop score|psi score|crp levels,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Participants With Coronavirus Disease (COVID-19),nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04495101,NCT04495101,percentage of participants dying or requiring icu admission|percentage of participants who are dependent on invasive mechanical ventilation|change from baseline in national early warning score (news)|time to clinical response as assessed by: news ‚â§ 2 maintained for 24 hours|time to hospital discharge|duration of icu stay|duration of any oxygen use|duration of mechanical ventilation|mean change from baseline in ordinal scale|absolute value change from baseline in ordinal scale|percentage of participants in each severity category of the 7-point ordinal scale|time to sustained normalization of temperature|percentage of participants who sustained normalization of temperature|number of participants who develop acute respiratory distress syndrome (ards)|length of time to clinical progression|mortality through day 29,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19",nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04426695,NCT04426695,proportion of patients with treatment-emergent serious adverse events (saes)|proportion of patients with infusion-related reactions|proportion of patients with hypersensitivity reactions|time-weighted average change from baseline in viral shedding as measured by quantitative reverse transcription polymerase chain reaction (rt-qpcr) in nasopharyngeal (np) swab samples|proportion of patients with at least 1-point improvement on a 7-point ordinal scale in clinical status|time-weighted average change from baseline in viral shedding as measured by rt-qpcr in saliva samples|time-weighted average change from baseline in viral shedding as measured by rt-qpcr in nasal samples|time to negative rt-qpcr in all tested samples with no subsequent positive rt-qpcr in any tested samples|time to negative rt-qpcr in np swabs with no subsequent positive rt-qpcr|change from baseline in viral shedding as measured by rt-qpcr in np swabs|time-weighted average change in viral shedding|change from baseline in viral shedding as measured by rt-qpcr in saliva samples|change from baseline in viral shedding as measured by rt-qpcr in nasal swabs|correlation of rt-qpcr results over time between different sample types|concordance of rt-qpcr results over time between different sample types|proportion of patients with at least 2-point improvement on a 7-point ordinal scale in clinical status|time to no longer requiring oxygen supplementation|number of days of supplemental oxygen use|proportion of patients initiating high-intensity oxygen therapy|number of days of high-intensity oxygen therapy|proportion of patients initiating mechanical ventilation|number of days of mechanical ventilation|number of ventilator-free days|number of days of hospitalization|proportion of patients re-admitted to hospital after discharge through the end of study|proportion of patients admitted into an intensive care unit (icu)|days of icu stay|number of deaths due to any cause (all-cause mortality)|overall survival|serum concentration of regn10933 over time|serum concentration of regn10987 over time|incidence of anti-drug antibodies (ada) to regn10933|incidence of anti-drug antibodies (ada) to regn10987|assessment of pharmacokinetic (pk) parameter: maximum serum concentration observed (cmax) of regn10933|assessment of pk parameter: maximum serum concentration observed (cmax) of regn10987|assessment of pk parameter: cmax-to-dose ratio (cmax/dose) for regn10933|assessment of pk parameter: cmax-to-dose ratio (cmax/dose) for regn10987|assessment of pk parameter: time to cmax (tmax) for regn10933|assessment of pk parameter: time to cmax (tmax) for regn10987|assessment of pk parameter: area under the curve (auc) computed from time zero to the time of the last positive concentration (auclast) for regn10933|assessment of pk parameter: auc computed from time zero to the time of the last positive concentration (auclast) for regn10987|assessment of pk parameter: auc from time zero extrapolated to infinity (aucinf) for regn10933|assessment of pk parameter: auc from time zero extrapolated to infinity (aucinf) for regn10987|assessment of pk parameter: aucinf-to-dose ratio (aucinf/dose) of regn10933|assessment of pk parameter: aucinf-to-dose ratio (aucinf/dose) of regn10987|assessment of pk parameter: observed terminal half-life [t1/2] for regn10933|assessment of pk parameter: observed terminal half-life [t1/2] of regn10987|assessment of pk parameter: clearance (cl) for regn10933|assessment of pk parameter: clearance (cl) of regn10987|assessment of pk parameter: volume of distribution at steady state (vss) of regn10933|assessment of pk parameter: volume of distribution at steady state (vss) of regn10987|assessment of pk parameter: mean residence time (mrt) of regn10933|assessment of pk parameter: mean residence time (mrt) of regn10987,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Hyperimmune Plasma in Patients With COVID-19 Severe Infection,COV2-CP,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04385043,NCT04385043,decrease in mortality|lymphocytes|pcr levels vs control|pcr levels vs before treatment|ab levels and clinical improvement|inflammatory cytokines vs controls|inflammatory cytokines vs before treatment,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Chloroquine Phosphate Prophylactic Use in Health Personnel Exposed to COVID-19 Patients,nan,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04443270,NCT04443270,negative polymerase chain reaction assay at day 0|polymerase chain reaction assay at day 60|clinical improvement related to covid-19|heart rhythm negative adverse event related to the chloroquine phosphate prophylactic use|heart rhythm negative adverse event related to the chloroquine phosphate prophylactic|covid-19 symptomatic onset rate,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
COVID-19: Study of INFLAmmasome and PLAtelets Functions,CO-QUETTES,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04397822,NCT04397822,activation of platelet nlrp3 inflammasome,observational,observational model: cohort|time perspective: prospective
Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04384497,NCT04384497,number and proportion of patients with progression to ventilation or sustained requirement of supplementary oxygen therapy|adverse events|dose of plasma needed to clear viremia|clearance of viremia|fever and symptoms|inflammatory parameters|antibody response to sars-cov-2,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,nan,completed,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04542694,NCT04542694,time to clinical improvement|rate of clinical status improvement|rate of viral elimination by day 10|time before the end of fever|change in the level of lung damage according to ct|rate of transfer to the intensive care unit|rate of the use of non-invasive lung ventilation|rate of the use of mechanical ventilation|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19),nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04432324,NCT04432324,percentage of participants dying or requiring icu admission|percentage of participants who are dependent on high flow oxygen devices or invasive mechanical ventilation|change from baseline in national early warning score (news)|time to clinical response as assessed by: news ‚â§ 2 maintained for 24 hours|time to hospital discharge|duration of icu stay|duration of any oxygen use|duration of mechanical ventilation|absolute value and mean change from baseline in ordinal scale|percentage of participants in each severity category of the 7-point ordinal scale|time to sustained normalization of temperature|percentage of participants with normalization of fever|number of participants who develop acute respiratory distress syndrome (ards)|length of time to clinical progression,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Safety and Efficacy of Ruxolitinib for COVID-19,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04348071,NCT04348071,"phase 2: cumulative incidence of grade 3 and 4 adverse events (aes)|phase 2: cumulative incidence of serious adverse events (saes)|phase 2: changes in white blood cell count (cbc) through day 15|phase 2: changes in hemoglobin through day 15|phase 2: changes in platelets through day 15|phase 2: changes in creatinine through day 15|phase 2: changes in glucose through day 15|phase 2: changes in prothrombin time (pt) through day 15|phase 2: changes in total bilirubin through day 15|phase 2: changes in alt through day 15|phase 2: changes in ast through day 15|phase 2: changes in white blood cell count (cbc) through end of study (eos)|phase 2: changes in hemoglobin through end of study (eos)|phase 2: changes in platelets through end of study (eos)|phase 2: changes in creatinine through end of study (eos)|phase 2: changes in glucose through end of study (eos)|phase 2: changes in prothrombin time (pt) though end of study (eos)|phase 2: changes in total bilirubin through end of study (eos)|phase 2: changes in alt through end of study (eos)|phase 2: changes in ast through end of study (eos)|phase 3: percentage of patients reporting each severity on an 8-point ordinal scale at day 15|phase 2: change in the 8-point ordinal scale|phase 2: change in national early warning score (news)|phase 3: change in the 8-point ordinal scale|phase 3: change in national early warning score (news)|phase 3: time to an improvement of one category using the 8-point ordinal scale|phase 3: time to an improvement of two categories using the 8-point ordinal scale|phase 3: time to discharge or to a news ‚â§2 and maintained for 24 hours, whichever occurs first|phase 3: cumulative incidence of grade 3 and 4 adverse events (aes)|phase 3: cumulative incidence of serious adverse events (saes)|phase 3: duration of hospitalization|phase 3: duration of new oxygen use|phase 3: duration of new ventilator or ecmo use|phase 3: incidence of discontinuation or temporary suspension of drug for any reason|phase 3: incidence of new oxygen use|phase 3: incidence of new ventilator use|phase 3: number of oxygen free days|phase 3: number of ventilator or ecmo free days|phase 3: 14 day mortality rate|phase 3: 28 day mortality rate|phase 3: changes in white blood cell count (cbc) through day 15|phase 3: changes in hemoglobin through day 15|phase 3: changes in platelets through day 15|phase 3: changes in creatinine through day 15|phase 3: changes in glucose through day 15|phase 3: changes in prothrombin time (pt) through day 15|phase 3: changes in total bilirubin through day 15|phase 3: changes in alt through day 15|phase 3: changes in ast through day 15|phase 3: changes in white blood cell count (cbc) through end of study (eos)|phase 3: changes in hemoglobin through end of study (eos)|phase 3: changes in platelets through end of study (eos)|phase 3: changes in creatinine through end of study (eos)|phase 3: changes in glucose through end of study (eos)|phase 3: changes in prothrombin time (pt) though end of study (eos)|phase 3: changes in total bilirubin through end of study (eos)|phase 3: changes in alt through end of study (eos)|phase 3: changes in ast through end of study (eos)",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Safety and Efficacy of Baricitinib for COVID-19,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04340232,NCT04340232,"phase 2: cumulative incidence of grade 3 and 4 adverse events (aes)|phase 2: cumulative incidence of serious adverse events (saes)|phase 2: changes in white blood cell count (cbc) through day 15|phase 2: changes in hemoglobin through day 15|phase 2: changes in platelets through day 15|phase 2: changes in creatinine through day 15|phase 2: changes in glucose through day 15|phase 2: changes in prothrombin time (pt) through day 15|phase 2: changes in total bilirubin through day 15|phase 2: changes in alt through day 15|phase 2: changes in ast through day 15|phase 2: changes in white blood cell count (cbc) through end of study (eos)|phase 2: changes in hemoglobin through end of study (eos)|phase 2: changes in platelets through end of study (eos)|phase 2: changes in creatinine through end of study (eos)|phase 2: changes in glucose through end of study (eos)|phase 2: changes in prothrombin time (pt) though end of study (eos)|phase 2: changes in total bilirubin through end of study (eos)|phase 2: changes in alt through end of study (eos)|phase 2: changes in ast through end of study (eos)|phase 3: percentage of patients reporting each severity on an 8-point ordinal scale at day 15|phase 2: change in the 8-point ordinal scale|phase 2: change in national early warning score (news)|phase 3: change in the 8-point ordinal scale|phase 3: change in national early warning score (news)|phase 3: time to an improvement of one category using the 8-point ordinal scale|phase 3: time to an improvement of two categories using the 8-point ordinal scale|phase 3: time to discharge or to a news ‚â§2 and maintained for 24 hours, whichever occurs first|phase 3: cumulative incidence of grade 3 and 4 adverse events (aes)|phase 3: cumulative incidence of serious adverse events (saes)|phase 3: duration of hospitalization|phase 3: duration of new oxygen use|phase 3: duration of new ventilator or ecmo use|phase 3: incidence of discontinuation or temporary suspension of drug for any reason|phase 3: incidence of new oxygen use|phase 3: incidence of new ventilator use|phase 3: number of oxygen free days|phase 3: number of ventilator or ecmo free days|phase 3: 14 day mortality rate|phase 3: 28 day mortality rate|phase 3: changes in white blood cell count (cbc) through day 15|phase 3: changes in hemoglobin through day 15|phase 3: changes in platelets through day 15|phase 3: changes in creatinine through day 15|phase 3: changes in glucose through day 15|phase 3: changes in prothrombin time (pt) through day 15|phase 3: changes in total bilirubin through day 15|phase 3: changes in alt through day 15|phase 3: changes in ast through day 15|phase 3: changes in white blood cell count (cbc) through end of study (eos)|phase 3: changes in hemoglobin through end of study (eos)|phase 3: changes in platelets through end of study (eos)|phase 3: changes in creatinine through end of study (eos)|phase 3: changes in glucose through end of study (eos)|phase 3: changes in prothrombin time (pt) though end of study (eos)|phase 3: changes in total bilirubin through end of study (eos)|phase 3: changes in alt through end of study (eos)|phase 3: changes in ast through end of study (eos)",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19),nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04547140,NCT04547140,percentage of participants dying or requiring icu admission|percentage of participants who are dependent on high flow oxygen devices or invasive mechanical ventilation|change from baseline in national early warning score (news)|time to clinical response as assessed by: news ‚â§ 2 maintained for 24 hours|time to hospital discharge|duration of icu stay|duration of any oxygen use|duration of mechanical ventilation|mean change from baseline in ordinal scale|absolute value change from baseline in ordinal scale|percentage of participants in each severity category of the 7-point ordinal scale|time to sustained normalization of temperature|percentage of participants with normalization of fever|number of participants who develop acute respiratory distress syndrome (ards)|length of time to clinical progression,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Favipiravir in Hospitalized COVID-19 Patients,FIC,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04359615,NCT04359615,time to clinical improvement|mortality|oxygen saturation by pulse oximetry (spo2) improvement|incidence of new mechanical ventilation use|duration of hospitalization|cumulative incidence of serious adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
COVID-19 Treatment in South Africa,nan,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04532931,NCT04532931,incidence of sars-cov-2 clearance|time to clearance of nasal sars-cov-2|median quantity of sars-cov-2|proportion of days with fever after randomization|proportion of days with respiratory symptoms after randomization|flu-pro¬© plus|serious adverse events|adverse events resulting in treatment discontinuation|adverse events considered related to the investigational products|lrti|maximum score on who ordinal scale for clinical improvement during study participation|cumulative incidence of hospitalization|days of hospitalization|cumulative incidence of mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Losmapimod Safety and Efficacy in COVID-19,LOSVID,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04511819,NCT04511819,day 28 mortality|clinical status assessment|respiratory failure assessment|treatment survival|treatment-emergent adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Azithromycin in Hospitalized COVID-19 Patients,AIC,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04359316,NCT04359316,time to clinical improvement|mortality|spo2 improvement|incidence of new mechanical ventilation use|duration of hospitalization|cumulative incidence of serious adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Vitamin D and COVID-19 Trial,VIVID,not yet recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04536298,NCT04536298,hospitalization or death in index cases|self-reported disease severity in index cases|time to hospitalization or death in index cases|icu admission/ventilation support in index cases|sars-cov-2 infection in close household contacts|self-reported disease severity in close household contacts,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Thymosin Alpha 1 to Prevent COVID-19 Infection in Elderly Renal Dialysis Patients,Ta1,not yet recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04428008,NCT04428008,"reduction in documented infection with covid-19 reduction in infection with covid-19|need for hospitalization|hospital length of stay|need for icu admission|icu length of stay|need for mechanical ventilation|duration of mechanical ventilation|recovery time from covid-19|change in any existing comorbidities or occurrence of newly diagnosed disease|incidence of non-covid-19 infections|change in lymphocyte subsets (cd4, cd8)|mortality|treatment-emergent adverse events|treatment-emergent changes in vital signs|treatment-emergent laboratory parameters",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19),nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04547127,NCT04547127,all-cause mortality rate|change from baseline in national early warning score (news)|time to clinical response as assessed by news ‚â§ 2 maintained for 24 hours|time to hospital discharge|time to icu discharge|duration of all oxygen use|duration of mechanical ventilation|absolute value change from baseline in ordinal scale|mean change from baseline in ordinal scale|percentage of participants in each severity category of the 7-point ordinal scale,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression,COVID-19 NGS,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04364828,NCT04364828,viral evolution|immune response|disease severity,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: diagnostic
"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",COVIFERON,completed,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04343768,NCT04343768,time to clinical improvement|mortality|spo2 improvement|incidence of new mechanical ventilation use|duration of hospitalization,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19,nan,not yet recruiting,No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04497948,NCT04497948,"acalabrutinib and acp-5862 plasma pk parameter: auc12h|acalabrutinib and acp-5862 plasma pk parameter: auclast|acalabrutinib and acp-5862 plasma pk parameter: cmax|type, frequency, severity, and relationship to study intervention of any treatment-emergent aes or abnormalities of laboratory tests, saes, or aes leading to discontinuation of study intervention|proportion of participants alive and free of respiratory failure at days 14 and 28|percent change from baseline in crp at days 3, 5, 7, 14, 28|time to improvement- clinical improvement of ‚â• 2 points(from first dose date)on a 9-point category ordinal scale or live discharge from the hospital or considered fit for discharge(a score of 0,1,or2 on the ordinal scale)whichever comes first,by day 28",interventional,allocation: non-randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Adaptive COVID-19 Treatment Trial 3 (ACTT-3),nan,recruiting,No Results Available,phase 3,NIH,https://ClinicalTrials.gov/show/NCT04492475,NCT04492475,"time to recovery|change from baseline in alanine aminotransferase (alt)|change from baseline in aspartate aminotransferase (ast)|change from baseline in c-reactive protein (crp)|change from baseline in creatinine|change from baseline in d-dimer concentration|change from baseline in hemoglobin|change from baseline in international normalized ratio (inr)|change from baseline in platelets|change from baseline in total bilirubin|change from baseline in white blood cell count (wbc) with differential|change in national early warning score (news) from baseline|cumulative incidence of grade 3 and 4 clinical and/or laboratory adverse events (aes)|cumulative incidence of serious adverse events (saes)|duration of hospitalization|duration of invasive mechanical ventilation|duration of new non-invasive ventilation or high flow oxygen use|duration of new oxygen use|duration of new ventilator or extracorporeal membrane oxygenation (ecmo) use|duration of non invasive ventilation/high flow oxygen use|duration of oxygen use|incidence of discontinuation or temporary suspension of investigational therapeutics|incidence of new non-invasive ventilation or high flow oxygen use|incidence of new oxygen use|incidence of new ventilator or extracorporeal membrane oxygenation (ecmo) use|mean change in the ordinal scale|participant's clinical status at day 15 by ordinal scale|percentage of subjects reporting each severity rating on an 8 point ordinal scale|subject 14-day mortality|subject 28-day mortality|time to an improvement of one category using an ordinal scale|time to an improvement of two categories using an ordinal scale|time to discharge or to a national early warning score (news) of </= 2 and maintained for 24 hours, whichever occurs first|time to recovery for participants not on mechanical ventilation (baseline ordinal score of 4, 5, or 6)",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04459520,NCT04459520,behavioral intentions|personal decisions subscale|social expectations subscale|voting behavior question|protest question|transportation,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: screening
Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection,nan,available,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04355793,NCT04355793,nan,expanded access:treatment ind/protocol,nan
The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04364815,NCT04364815,efficacy of hcq prophylaxis in preventing covid-19 infection|efficacy of study drug as post-exposure prophylaxis in preventing covid-19 related symptoms (to be reported as absolute number and frequency of events)|time to covid-19 infection in patients receiving study drug (in days)|safety and tolerability of study drug (to be reported as absolute number and frequency of events),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: prevention"
Classification of COVID-19 Infection in Posteroanterior Chest X-rays,nan,completed,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04358536,NCT04358536,identification of covid-19,observational,observational model: cohort|time perspective: retrospective
A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19),nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04504032,NCT04504032,number of participants with grade 3 or grade 4 adverse events (aes)|number of participants with aes leading to study discontinuation|number of participants with serious adverse events (saes)|proportion of participants with disease progression|median time to disease resolution|proportion of participants who achieve disease resolution|mean gates medical research institute ordinal scale score|change from baseline in gates medical research institute ordinal scale score|mean world health organization ordinal scale score|change from baseline in world health organization ordinal scale score|incidence of hospitalization|number of days of hospitalization,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,HAHPS,"active, not recruiting",No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04329832,NCT04329832,covid ordinal outcomes scale at 14 days|hospital-free days at 28 days (number of days patient not in hospital)|ventilator-free days at 28 days (number of days patient not on a ventilator)|icu-free days at 28 days (number of days patient not in an icu)|time to a 1-point decrease in the who ordinal recovery score,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 Antibody Plasma Research Study in Hospitalized Patients,UNC CCP RCT,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04524507,NCT04524507,cumulative incidence of serious adverse events (saes) at study day 14|days to hospital discharge (or discharge equivalent) following first dose of ccp,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Keto-diet for Intubated Critical Care COVID-19,KICC-COVID19,withdrawn,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04358835,NCT04358835,change in the partial pressure of carbon dioxide (paco2)|change in minute ventilation|change in respiratory system compliance|change in driving pressure|change in ventilator synchrony|change in mean arterial pressure|change in the fraction of inspired oxygen percentage of oxygen (fio2)|change in the partial pressure of carbon dioxide (pao2) to the fraction of inspired oxygen percentage of oxygen (fio2) ratio|change in hydrogen ion activity (ph)|change in bicarbonate (hco3)|change in red blood cell count|change in white blood cell count|change in white cell differential|change in hemoglobin levels|change in hematocrit|change in mean cell volume|change in mean cell hemoglobin|change in mean cell hemoglobin concentration|change in platelet count|change in red cell distribution width|change in blood albumin level|change in serum alkaline phosphatase level|change in serum aspartate transaminase level|change in serum alanine aminotransferase level|change in blood urea nitrogen levels|change in serum calcium level|change in serum chloride level|change in serum potassium level|change in serum creatinine level|date patient is re-intubated or need mechanical ventilation for a second time|length of intensive care unit stay|the total hospital stay|disposition at discharge|change in heart rate|change in the dosage of vasopressor medication,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19,EPCOvid-1,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04388410,NCT04388410,severity and death|adverse events that require study treatment interruption|time to clinical improvement|antibodies against sars-cov-2|disease progression 1|disease progression 2|time on mechanical ventilation|number of days with fever|adverse events attributed to the study intervention,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Immunosupressive Treatment in COVID-19 Patients,SAM-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04382781,NCT04382781,invasive ventilation or death|ventilation|death|secondary infections|digestive tract hemorrhage|change in 7 points scale,observational,observational model: cohort|time perspective: retrospective
Adaptive COVID-19 Treatment Trial 2 (ACTT-2),nan,"active, not recruiting",No Results Available,phase 3,NIH,https://ClinicalTrials.gov/show/NCT04401579,NCT04401579,"time to recovery|change from baseline in alanine transaminase (alt)|change from baseline in aspartate transaminase (ast)|change from baseline in creatinine|change from baseline in glucose|change from baseline in hemoglobin|change from baseline in platelets|change from baseline in prothrombin time (pt)|change from baseline in total bilirubin|change from baseline in white blood cell count (wbc) with differential|change in national early warning score (news) from baseline|cumulative incidence of grade 3 and 4 clinical and/or laboratory adverse events (aes)|cumulative incidence of serious adverse events (saes)|duration of hospitalization|duration of new non-invasive ventilation or high flow oxygen use|duration of new oxygen use|duration of new ventilator or extracorporeal membrane oxygenation (ecmo) use|duration of oxygen use|incidence of discontinuation or temporary suspension of investigational therapeutics|incidence of new non-invasive ventilation or high flow oxygen use|incidence of new oxygen use|incidence of new ventilator or extracorporeal membrane oxygenation (ecmo) use|mean change in the ordinal scale|participant's clinical status at day 15 by ordinal scale|percentage of subjects reporting each severity rating on an 8 point ordinal scale|subject 14-day mortality|subject 28-day mortality|time to an improvement of one category using an ordinal scale|time to an improvement of two categories using an ordinal scale|time to discharge or to a national early warning score (news) of </= 2 and maintained for 24 hours, whichever occurs first|change from baseline in c-reactive protein (crp)|change from baseline in d-dimer concentration",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04252118,NCT04252118,size of lesion area by chest radiograph or ct|side effects in the mscs treatment group|improvement of clinical symptoms including duration of fever and respiratory|time of nucleic acid turning negative|rate of mortality within 28-days|cd4+ and cd8+ t celll count|alanine aminotransferase|c-reactive protein|creatine kinase,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Adaptive COVID-19 Treatment Trial (ACTT),nan,completed,No Results Available,phase 3,NIH,https://ClinicalTrials.gov/show/NCT04280705,NCT04280705,"time to recovery|change from baseline in alanine transaminase (alt)|change from baseline in aspartate transaminase (ast)|change from baseline in creatinine|change from baseline in glucose|change from baseline in hemoglobin|change from baseline in platelets|change from baseline in prothrombin time (pt)|change from baseline in total bilirubin|change from baseline in white blood cell count (wbc) with differential|change in national early warning score (news) from baseline|clinical status using ordinal scale|cumulative incidence of grade 3 and 4 clinical and/or laboratory adverse events (aes)|cumulative incidence of serious adverse events (saes)|discontinuation or temporary suspension of investigational therapeutics|duration of hospitalization|duration of new non-invasive ventilation or high flow oxygen use|duration of new oxygen use|duration of new ventilator or extracorporeal membrane oxygenation (ecmo) use|incidence of new non-invasive ventilation or high flow oxygen use|incidence of new oxygen use|incidence of new ventilator or extracorporeal membrane oxygenation (ecmo) use|mean change in the ordinal scale|percentage of subjects reporting each severity rating on an 8-point ordinal scale|subject 14-day mortality|subject 29-day mortality|time to an improvement of one category using an ordinal scale|time to an improvement of two categories using an ordinal scale|time to discharge or to a national early warning score (news) of </= 2 and maintained for 24 hours, whichever occurs first",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection,nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04362865,NCT04362865,characterize immune response|b- and t-cell arm immune response|immune response and outcome,observational,observational model: cohort|time perspective: prospective
Clinical Trial to Evaluate the Safety and Immunogenicitiy of the COVID-19 Vaccine,COVID-19-101,recruiting,No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04497298,NCT04497298,"to assess the safety and tolerability of the covid-19 vaccine following one or two consecutive intramuscular injections in healthy volunteers|to assess induction of sars-cov-2 spike protein-binding antibodies upon one or two administrations of the covid-19 vaccine by means of elisa up to study day 390|to assess induction of sars-cov-2 neutralizing antibodies upon one or two administrations of the covid-19 vaccine by means of serum neutralization assay up to study day 390|to assess sars-cov-2 spike protein-specific, cell-mediated immune responses induced by one or two doses of vaccine, by means of intracellular staining|to assess sars-cov-2 spike protein-specific, cell-mediated immune responses induced by one or two doses of vaccine, by means of flow cytometry|to assess potential measles virus shedding by means of rt-qpcr of saliva, nasal swab, urine, or blood samples in sentinel groups on day 0 and up to day 42",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Clinical and Biological Predictors of COVID-19 Disease in Older Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04348396,NCT04348396,descriptive-epidemiological analysis of health conditions|evaluation of frailty condition|identification of biomarkers of inflammation|assessment of functional capacity|evaluation of drug consumption|evaluation of inflamma-mirs,observational,observational model: case-only|time perspective: prospective
Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS,nan,recruiting,No Results Available,phase 2|phase 3,Industry|Other,https://ClinicalTrials.gov/show/NCT04449588,NCT04449588,"time to recovery of peripheral capillary oxygen saturation (spo2) from baseline|28-day all-cause mortality rate|percentage of subjects achieving recovery in spo2|mean change of pao2/fio2|mechanical ventilation time|time of oxygen therapy|lymphocyte count|change in inflammation indicators (crp or il-6) from baseline|improvement in body temperature|mean change from baseline in the clinical improvement based on ordinal scale recommended by the who r&d blueprint during treatment period|improvement at day3, 7, 11 & day14 based on ordinal scale recommended by the who r&d blueprint during treatment period|time to get categories 1 to 4 in the 8-points ordinal scale|time to attain an improvement of 1 point on the ordinal scale",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
A Longitudinal Study of COVID-19 Sequelae and Immunity,nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04411147,NCT04411147,medical sequelae in covid- 19 survivors|risk factors for medical sequelae in covid-19 survivors|antibody and cell-mediated immune responses to sarscov-2|antibody and cell-mediated immune responses to sarscov-2 over time|incidence of reinfection with covid-19|incidence of clinical silent infection|mental health status in covid-19 survivors and contacts,observational,observational model: cohort|time perspective: prospective
COVID-19: Respiratory and Sleep Follow-up,Co-SURVIVORS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04406324,NCT04406324,"diffusion capacity for carbon monoxide (co) 3 months after covid diagnosis|prevalence of sleep disordered breathing (sdb) 3 months after covid diagnosis|prevalence of sleep disorders 3 months after covid diagnosis|prevalence of ventilatory muscle function impairments, 3 months after covid diagnosis|prevalence of cardiac impairments 3 months after covid diagnosis|follow-up of pulmonary diffusion capacity of carbon monoxide|follow-up of sleep disorders treatment compliance|follow-up of sleep disorders treatments efficacy|hla alleles aspect of covid clinical presentation|kir loci aspect of covid clinical presentation|metabolomic aspect of covid clinical presentation",observational,observational model: cohort|time perspective: prospective
Data Collection on the Model Schools Pediatric Health Initiative at 5 SBHC Sites: COVID-19 Questionnaire,SBHC,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04534595,NCT04534595,direct experience with covid-19 virus|family's overall experience with covid-19 pandemic|child's experience with cancellations and access to services|caregiver's experience during covid-19|stress or unpleasant experiences endured by the caregiver during covid-19|activities the caregiver engaged in during covid-19|describe the caregiver's parenting during covid-19|the impact of school closure on the child|describing the child's character|childs daily routine|childs interest about covid-19|covid-19 preventative measures.|how can the sbhc help?,observational,observational model: case-only|time perspective: prospective
The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04475107,NCT04475107,"proportion (%) of patients with virological clearance of sars-cov-2 at day 7 post-dose*|viral load reduction of sars-cov-2 at day 3, 7, 10, and 14 post-dose compared to the baseline|proportion (%) of patients with virological clearance of sars-cov-2 at day 3, 10, and 14 post-dose*|change in who ordinal scale for clinical improvement at day 3, 7, 10, 14, and 28 post-dose from the baseline|change in news score at day 3, 7, 10, 14, and 28 post-dose from the baseline|time to achieve normalization of body temperature, post-dose|time to achieve normalization of respiratory rate, post-dose|time to achieve normalization of oxygen saturation, post-dose",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Changes in Dietary Behaviours During the COVID-19 Outbreak Confinement in the Adult Population (COVIDiet_Int),COVIDiet_Int,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04449731,NCT04449731,adherence to the mediterranean diet before and during the covid-19 confinement|eating behaviours|level of physical activity during the covid-19 confinement|weight gain during the covid-19 confinement,observational,observational model: ecologic or community|time perspective: cross-sectional
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04410354,NCT04410354,"number of subjects not hospitalized or, if hospitalized, free of respiratory failure|adverse events|national institute of allergy and infectious disease (niaid) 8-point ordinal scale|temperature|death|mechanical ventilation|vasopressor support|oxygen therapy|cessation of viral shedding|change in oxygen saturation/fraction of inspired oxygen",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04330586,NCT04330586,rate of sars-cov-2 eradication at day 14 from study enrollment|rate of sars-cov-2 eradication at day 7 from study enrollment|time to sars-cov-2 eradication (days)|viral load area-under-the-curve (auc) reduction versus control|time to clinical improvement (days)|proportion of clinical failure,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),COVID_MSV,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04361942,NCT04361942,proportion of patients who have achieved withdrawal of invasive mechanical ventilation|rate of mortality|proportion of patients who have achieved clinical response|proportion of patients who have achieved radiological responses,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Loneliness During Strict and Lifted Social Distancing Protocols Against the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04444115,NCT04444115,ucla loneliness scale-8 (uls-8)|patient health questionnaire-9 (phq-9)|generalized anxiety disorder-7 (gad-7),observational,observational model: ecologic or community|time perspective: prospective
Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage,COVID CALL 15,recruiting,No Results Available,nan,Other|Industry,https://ClinicalTrials.gov/show/NCT04331171,NCT04331171,to assess of the evolution of the number of calls to emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|to assess of the evolution of the proportion of relevant calls to emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|to assess the evolution over time of the covid 19 epidemic|to assess the evolution over space of the covid 19 epidemic|to assess symptoms|to assess the users population,observational,observational model: cohort|time perspective: prospective
COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04397328,NCT04397328,"incidence of symptomatic fever >37.8, dry cough, or shortness of breath (resident/patient report or nurse observation) respiratory infection with confirmed pcr+ result for sars-cov-2.|requirement for admission to acute care hospital and/or icu admission or death|asymptomatic pcr+ sars-cov-2 test result|time to clinical recovery (ttcr).",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Hemostasis in COVID-19: an Adaptive Clinical Trial,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04466670,NCT04466670,hospital discharge - alive / death|length of mechanical ventilation free days|length of renal replacement therapy free days|number of documented venous thromboembolism or arterial thrombosis,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,CALAVI US,"active, not recruiting",No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04380688,NCT04380688,occurrence of adverse events and serious adverse events|proportion of subjects alive and free of respiratory failure|percent change from baseline in crp|change from baseline in ferritin|change from baseline in absolute lymphocyte counts|all cause mortality|proportion of subjects alive and discharged from icu|time from randomization to first occurrence of respiratory failure or death on study due to any cause|number of days alive and free of respiratory failure|number of days with respiratory failure|number of days hospitalized|number of days in icu (length of stay)|number of days alive outside of hospital|relative change from baseline in oxygenation index (spo2/fio2)|time to clinical improvement of at least 2 points (from randomization) on a 9-point category ordinal scale|time to spo2 > 94% on room air|pharmacokinetics of acalabrutinib and its active metabolite acp- 5862,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,CALAVI,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04346199,NCT04346199,subject alive and free of respiratory failure|proportion of subjects alive and free of respiratory failure|percent change from baseline in crp|change from baseline in ferritin|chnage from baseline in absolute lymphocyte counts|all cause mortality|proportion of subjects alive and discharged from icu|time from randomization to first occurrence of respiratory failure or death on study due to any cause|number of days alive and free of respiratory failure|number of days with respiratory failure|number of days hospitalized|number of days in icu (length of stay)|number of days alive outside of hospital|relative change from baseline in oxygenation index (pao2/fio2)|occurrence of adverse events and serious adverse events|pharmacokinetics of acalabrutinib and its active metabolite acp- 5862 (cmax)|pharmacokinetics of acalabrutinib and its active metabolite acp- 5862 (tmax)|pharmacokinetics of acalabrutinib and its active metabolite acp- 5862 (auc),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04521309,NCT04521309,28 days mortality|requirement of supplemental oxygen support|number of days on assisted ventilation|days to step down|days to hospital discharge|adverse events during hospital stay|change in c-reactive protein (crp) levels|change in neutrophil lymphocyte ratio|change in ferritin levels|change in lactate dehydrogenase (ldh) levels|change in radiological (x-ray) findings|days to negative sars-cov-2 polymerase chain reaction (pcr) test|anti-sars-cov-2 antibody|change in fever|change in sodium levels|change in potassium levels|change in chloride levels|change in bicarbonate levels,interventional,allocation: randomized|intervention model: sequential assignment|masking: single (participant)|primary purpose: treatment
Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,SEN-CoV-Fadj,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04390594,NCT04390594,sars-cov-2 viral load level|vital status|proportion of patients with serious adverse events reported during the clinical trial.|length of hospitalization|length of hospitalization in a resuscitation unit|duration of oxygen therapy|maximum quick sofa (qsofa) score during hospitalisation|clinical status on the seven-category ordinal scale,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Cardiac Injury in COVID-19: a Pathology Study,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04367792,NCT04367792,"cardiac pathological findings from series of 60 patients dying from covid-19 disease|viral load in cardiac tissues and the extent of damage|co-localize the sars-cov-2 using rnascope in situ hybridization, with its entry receptor ace2 and serine protease tmprss2 in different cell types found in the heart|multi-organ involvement obtained from hystological analyses of paraffine blocks from different organs (ie kidney, spleen, bowel,....)",observational,observational model: case-control|time perspective: retrospective
"Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19",COVHYP,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04374695,NCT04374695,prior treatment by acei|prior treatment by arb|baseline characteristics and comorbidities|major clinical adverse events,observational,observational model: case-control|time perspective: retrospective
COVID-19 - Cytokine Storm,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04474067,NCT04474067,clinical outcomes of patients with covid-19 using the national early warning score 2 (news2) system|clinical outcomes of patients with covid-19 using the new nih patient classification of severity of illness|mortality|cytokine/chemokine/hematopoietic growth factors/ complement and other immune modulators in patients with covid-19,observational,observational model: case-control|time perspective: prospective
Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms,COVIDLight,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04418505,NCT04418505,time to recovery|time to elimination of covid-19 related symptoms|mean number of days with mild covid-19 related symptoms|mean number of days with mild overall respiratory symptoms|time to symptom reduction|time to elimination of symptoms|average number of days with mild respiratory symptoms|oxygen saturation|hospitalization rate|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19",COVID-Aging,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04359953,NCT04359953,"two-weeks survival rate|rate of undetectable rt-pcr of sars-cov-2|rate of death|hypotension|hypothermia and hyperthermia|pneumonia severity according to who|pneumonia severity according to psi (hung et al 2017)|rate of no cough|rate of no dyspnea|rate of no fever|rate of no requiring supplemental oxygen|rate of sars-cov-2 undetectable|recovery time|critical admission rate|mechanical ventilation rate|changes in activity of daily living (adl) activity of daily living)|changes in activity of daily living iadl (instrumental activity of daily living)|the number and dose of added corticosteroids, immonumodulators or immunosuppressants",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Brainstem Dysfunction in COVID-19 Critically Ill Patients: a Prospective Observational Study,BRAINSTEM-COV,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04527198,NCT04527198,"brainstem dysfunction prevalence|brainstem dysfunction prevalence after sedation weaning|link between brainstem dysfunction and clinical dysautonomia|link between brainstem dysfunction and clinical dysautonomia after sedation weaning|characterization of brainstem dysfunction in covid-19 patients: eeg power|characterization of brainstem dysfunction in covid-19 patients: eeg power after sedation weaning|characterization of brainstem dysfunction in covid-19 patients: eeg functional connectivity|characterization of brainstem dysfunction in covid-19 patients: eeg functional connectivity, after sedation weaning|characterization of brainstem dysfunction in covid-19 patients: eeg complexity|characterization of brainstem dysfunction in covid-19 patients: eeg complexity after sedation weaning|characterization of brainstem dysfunction in covid-19 patients: multivariate classification|characterization of brainstem dysfunction in covid-19 patients: multivariate classification after sedation weaning|duration of mechanical ventilation|mortality|duration of hospitalisation|duration of coma, disturbance of consciousness, delirium|neurological functional evolution with mrankin|neurological functional evolution with gose",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Prazosin to Prevent COVID-19 (PREVENT-COVID Trial),PREVENT,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04365257,NCT04365257,"death|hospitalized, requiring mechanical ventilation and/or high flow nasal cannula and/or icu/ccu admission (or equivalent) and/or ecmo|hospitalized, requiring supplemental oxygen, not requiring icu/ccu level care (or interventions listed under outcome 2)|cumulative incidence of grade 3 and 4 adverse events|number of participants with serious adverse events|incidence of symptomatic hypotension or hypotension requiring cessation of prazosin|number of participants with laboratory abnormalities in peripheral blood|duration of laboratory abnormalities in peripheral blood|number of participants with laboratory abnormalities in plasma|duration of laboratory abnormalities in plasma",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04361318,NCT04361318,"number of patients with covid-19-negative pcr|number of patients with improved respiratory rate|number of patients with improved pao2|number of patients with normalized serum il6|number of patients with normalized serum tnfœ±|number of patients with normalized serum iron|number of patients with normalized serum ferritin|number of patients with normalized international normalized ratio ""inr"" for prothrombin time|number of patients with normalized complete blood count ""cbc""|the mortality rate among treated patients",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
"Development and Validation of a Prediction Model for the Transition From Mild to Moderate Form of COVID-19, Using Data From Chest CT",PREDICTCovid19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04481620,NCT04481620,occurrence of significant clinical degradation|occurrence of a severe form|occurrence of an orotracheal intubation|occurrence of an acute respiratory distress syndrom|average length of stay in hospital|mortality|evolution of the imaging parameters,observational,observational model: cohort|time perspective: retrospective
Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19),COALITION-V,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04466540,NCT04466540,hospitalization|uncontrolled asthma after ‚â• 5 days of starting study medication|pneumonia|otitis media|fever resolution time|time to improve respiratory symptoms|hospitalization in the intensive care unit|need for orotracheal intubation|mechanical ventilation time|mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Interferon Beta 1a in Hospitalized COVID-19 Patients,IB1aIC,enrolling by invitation,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04350671,NCT04350671,time to clinical improvement|mortality|spo2 improvement|incidence of new mechanical ventilation use|duration of hospitalization|cumulative incidence of serious adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Telmisartan for Treatment of COVID-19 Patients,nan,recruiting,No Results Available,phase 4,Industry|Other,https://ClinicalTrials.gov/show/NCT04355936,NCT04355936,"c reactive protein|admission to intensive care unit (icu)|occurrence of mechanical ventilation|death|composite occurrence of admission to icu, mechanical ventilation or death (what occur first)|time from randomization to discharge|proportion of patients not requiring supplemental oxygen at day 15|significative differences in serum lactate dehydrogenase",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Atovaquone for Treatment of COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04456153,NCT04456153,viral load,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1),CONCOR-1,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04348656,NCT04348656,intubation or death in hospital|need for intubation|time to intubation|ventilator-free days|in-hospital death|time to in-hospital death|death at 30 days|length of stay in intensive care unit (icu)|length of stay in hospital|need for extracorpeal membrane oxygenation (ecmo)|need for renal replacement therapy|development of myocarditis|adverse events and serious adverse events|ccp transfusion-associated adverse events (ae),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Emotional Support and Stress Management in Patients Diagnosed With COVID-19,WWCOVID-19,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04482023,NCT04482023,rate of care actions identified by nurses|rate of care actions taken by nurses,observational,observational model: case-only|time perspective: cross-sectional
Umifenovir in Hospitalized COVID-19 Patients,UAIIC,enrolling by invitation,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04350684,NCT04350684,time to clinical improvement|mortality|spo2 improvement|incidence of new mechanical ventilation use|duration of hospitalization|cumulative incidence of serious adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Niclosamide for Mild to Moderate COVID-19,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04399356,NCT04399356,change in respiratory viral clearance (by pcr)|fecal viral clearance (by pcr)|reduction (change) in respiratory viral shedding (by pcr)|reduction (change) in gi viral shedding (by pcr)|progression to severe covid-19 disease|time to resolution of a fever,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID),nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04350073,NCT04350073,"metabolic and nutritional needs of covid-19 patients: measured by changes of resting energy expenditure(ree) over time, as measured by the indirect calorimetry q-nrg device|metabolic and nutritional needs of covid-19 patients:changes of the respiratory exchange ratio (rer) as measured by the indirect calorimetry q-nrg device|cardiac output and cardiac measures (non-invasive) in covid-19 patients|muscle mass and quality changes from covid-19: measured via changes of intramuscular adipose tissue (imat) content from ct scans of the psoas at the level of l3/th3|muscle mass, quality, glycogen changes in covid-19: via metabolic/muscle imaging derived from muscle-specific ultrasound of leg/intercostal/head muscles|body composition in covid-19 patients: measured via multifrequency bioimpedance spectroscopy|phase angle in covid-19 patients: measured via multifrequency",observational,observational model: cohort|time perspective: prospective
Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults,COVID-AGE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04362943,NCT04362943,mortality|x-ray changes|disability changes|ambulation changes|lymphocyte count changes|c-reactive protein changes|ferritin changes|d-dimer changes,observational,observational model: other|time perspective: retrospective
Ruxolitinib to Combat COVID-19,nan,withdrawn,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04354714,NCT04354714,overall survival|length of hospital stay|length of icu stay|duration of ventilator use|duration of vasopressors use|duration on renal replacement therapy|viral kinetics as measured by virologic failure|number of adverse events as measured by ctcae v. 5.0|proportion of participants with detectable virus,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders (COVID-19),COVID-OLFA,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407494,NCT04407494,diagnostic values of anosmia and ageusia for covid-19|diagnostic values of coda,observational,observational model: cohort|time perspective: prospective
CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch,CoronaWatch,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04376853,NCT04376853,biomarker|protective factors|smartwatch compliance|arrhythmias|qt time changes|longitudinal risk models,observational,observational model: cohort|time perspective: prospective
Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,nan,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04381884,NCT04381884,reduction in sars-cov-2 viral load|number of patients with partial or complete response in covid-19 clinical symptoms|number of patients with worsening in the clinical condition|number of patients with adverse events as a measure of safety and tolerability|ivermectin concentrations measured in plasma|evaluation of reactivity of the antibodies against sars-cov-2,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19,COVID-PREVENT,not yet recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04416048,NCT04416048,"composite endpoint of venous thromboembolism (dvt and/or fatal or non-fatal pe), arterial thromboembolism, new myocardial infarction, non-hemorrhagic stroke, all-cause mortality or progression to intubation and invasive ventilation|development of disseminated intravascular coagulation (dic) according to the isth criteria|number of days requiring invasive ventilation|number of days requiring non-invasive ventilation|improvement on a seven-category ordinal scale recommended by the who as clinical improvement scale for patients with respiratory infections",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Crizanlizumab for Treating COVID-19 Vasculopathy,CRITICAL,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04435184,NCT04435184,soluble p-selectin level|d-dimer level|vwf level|crp level|change in clinical status as assessed by the world health organization (who) ordinal scale for covid-19 trials|time to hospital discharge|safety of crizanlizumab as assessed by adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND),nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04394884,NCT04394884,"to characterize the immunologic mechanisms by which btk inhibition may ameliorate hyper- inflammatory responses in patients with covid-19.|1. characterization of tlr3 and tlr7/8-dependent immunologic phenotypes in covid-19 patients before and after btk inhibition.|2. evaluation of mechanisms of immune cell-specific activation, cytokine production, exhaustion and apoptosis in covid-19 patients before and after btk inhibition.|3. transcriptional, chromatin, and epigenetic profiling of immune cells at the single cell level in covid-19 patients before and after btk inhibition.|4. longitudinal evaluation of tcr and bcr repertoire development in covid-19 patients before and after btk inhibition.|5. characterization of sars- cov-2 serological responses in covid-19 patients with and without btk inhibition.|6. characterization of genetic variants that correlate with disease severity and/or response to btk inhibition treatment.|7. evaluation of soluble biomarkers as surrogate markers of hyper- inflammation/prognosis and of response to btk inhibition therapy in covid-19 patients",observational,observational model: cohort|time perspective: prospective
Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).,MARACOVID,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04441385,NCT04441385,"proportion of patients developing severe ards.|all-cause mortality.|percentage of patients requiring tracheal intubation, use of non-invasive ventilation niv or high flow nasal cannula (hfnc) devices during the study period|percentage of patients who progress to severe ards, death or icu admission.|differences in time to clinical improvement|change in clinical status of subject on a 7-point ordinal scale.|percentage of patients requiring immunosuppressive/immunomodulatory treatment as a rescue medication.|proportion of patients developing adverse effects, serious adverse reactions, laboratory or physical examination findings, ekg abnormalities acquired during the trial, death and adverse events leading to early discontinuation of treatment.",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,COVIDAXIS,"active, not recruiting",No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04328285,NCT04328285,"occurrence of an symptomatic or asymptomatic sars-cov-2 infection among healthcare workers (hcws)|evaluation of the occurrence of adverse events in each arm,|evaluation of the discontinuation rates of the investigational drug in each arm,|evaluation of the adherence of participants to study drug,|evaluation of the incidence of symptomatic cases of sars-cov-2 infection in each arm,|evaluation of the incidence of asymptomatic cases of sars-cov-2 infection in each arm|evaluation of the incidence of severe cases of sars-cov-2 infection in each arm.|corrected qt interval (ms)",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: prevention"
Endothelial Function and COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04525443,NCT04525443,reactive hyperemia index (rhi)|percentage of covid-19 patients with impaired endothelial vasodilator function.|percentage of non-covid-19 patients with impaired endothelial vasodilator function.,observational,observational model: case-control|time perspective: prospective
Repurposing of Chlorpromazine in Covid-19 Treatment,reCoVery,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04366739,NCT04366739,"time to response (ttr)|objective response rate (orr)|all-cause mortality|duration in days required for hospital discharge|duration in days required for national early warning score ‚â§ 2 maintained 24 hours|number of days without oxygen therapy|incidence of oxygen use, niv or high flow oxygen therapy|duration in days of oxygen prescription, niv or high flow oxygen therapy|biochemical response: rate of patients positive for sars-cov-2 pcr on a nasopharyngeal sample|biochemical response: viral load of sars-cov-2 on a nasopharyngeal sample|biochemical response: serum viral load of sars-cov-2|biochemical response: c-reactive protein (crp)|biochemical response: blood test for lymphocytes (lymphopenia)|parenchymal involvement (chest ct)|define the optimal dose of cpz and its tolerance: rates of serious adverse events|define the optimal dose of cpz and its tolerance: rates of non-serious side effects|define the optimal dose of cpz and its tolerance: anxiety assessment on global anxiety - visual analog scale (ga-vas)|define the optimal dose of cpz and its tolerance: rates of drug discontinuation|define the optimal dose of cpz and its tolerance: biological anomalies|define the optimal dose of cpz and its tolerance: ecg abnormalities|define the optimal dose of cpz and its tolerance: plasma cpk assessment|define the optimal dose of cpz and its tolerance:plasma cpz assessment|define the optimal dose of cpz and its tolerance: cpz dose administered",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion,PROTECT,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04389359,NCT04389359,time to confirmed diagnosis of covid-19|all-cause mortality|severity of covid-19 disease|incidence of covid-19 complications,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Effector and Regulatory T Cell Receptor Repertoire Analyses in Patients Affected by COVID-19,CovRep,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04379466,NCT04379466,a list of covid-19 specific tcr sequences|one or more measures from peripheral blood immunophenotyping that is/are associated with covid-19 outcome|group of covid-19 specific tcr sequences that is associated with covid-19 outcome,observational,observational model: cohort|time perspective: prospective
Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,CPC-SARS,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04405310,NCT04405310,death|lenth of stay icu|days of mechanical ventilation|suplemental oxigen support|viral load by rt-pcr|inflamatory biomarkers|sofa (sequencial organ failure assesment),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Safety and Efficacy of Maraviroc and/or Favipiravir vs Currently Used Therapy in Severe COVID-19 Adults,COMVIVIR,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04475991,NCT04475991,patients free of mechanical ventilation or death|time of clinical improvement|rate of change in phosphorilated ccr5|rate of change in peripheral blood levels of proinflammatory cytokines and chemokynes|change in the trafficking and activation pattern of peripheral leukocytes,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,nan,"active, not recruiting",No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04315298,NCT04315298,"percent change in c-reactive protein (crp) levels in patients with serum il-6 level greater than the upper limit of normal|proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with critical covid-19 receiving mechanical ventilation at baseline|proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with covid-19 receiving mechanical ventilation at baseline|time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical patients with serum il-6 levels greater than the upper limit of normal|time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale reporting in severe or critical patients with all il-6 levels|time to resolution of fever for at least 48 hours without antipyretics in patients with documented fever|time to resolution of fever for at least 48 hours without antipyretics by clinical severity|time to resolution of fever for at least 48 hours without antipyretics by baseline il-6 levels|time to improvement in oxygenation for at least 48 hours|time to improvement in oxygenation for at least 48 hours by clinical severity|time to improvement in oxygenation for at least 48 hours by baseline il-6 levels|time to resolution of fever and improvement in oxygenation for at least 48 hours|mean change in the 7-point ordinal scale|percentage of patients in each clinical status category using the 7-point ordinal scale|time to discharge or to a national early warning score 2 (news2) of ‚â§2 and maintained for 24 hours|change from baseline in news2 scoring system|number of days with fever|proportion of patients alive, off oxygen|number of days of resting respiratory rate >24 breaths/min|number of days with hypoxemia|number of days of supplemental oxygen use|time to saturation ‚â•94% on room air|number of ventilator free days in the first 28 days|number of patients requiring initiation of mechanical ventilation|number of patients requiring non-invasive ventilation|number of patients requiring the use of high flow nasal cannula|number of patients admitted into an intensive care unit (icu)|number of days of hospitalization among survivors|number of deaths due to any cause|proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale|proportion of patients who recover|proportion of deaths|proportion of patients alive not receiving mechanical ventilation|proportion of patients alive not requiring extracorporeal membrane oxygenation (ecmo)|proportion of patients with a 2-point improvement in clinical status on the 7-point ordinal scale|time to at least 1-point improvement in clinical status assessment on the 7-point ordinal scale|time to at least 2-point improvement in clinical status assessment on the 7-point ordinal scale|proportion of patients receiving mechanical ventilation|proportion of patients receiving ecmo|proportion of patients discharged and alive|time to recovery|time to death due to any cause|number of ventilator free days|proportion of patients with serious adverse events|proportion of patients with grade 4 neutropenia (anc <500/mm3)|proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection|proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia (anc <500/mm3)|proportion of patients with hypersensitivity reactions|proportion of patients with infusion reactions|proportion of patients with gastrointestinal perforation|white blood cell count|hemoglobin levels|platelet count|creatinine levels|total bilirubin level|alanine aminotransferase (alt) level|aspartate aminotransferase (ast) level",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Validation of COVID-19 Tests,nan,"active, not recruiting",No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04404062,NCT04404062,identification of asymptomatic carriers of sars-cov-2|validation of the ability of the immunoassay kit to detect antibodies to sars-cov-2|development of a quantitative laboratory reference test for the measurement of sars-cov-2|exploration of sars-cov-2 epidemiology,observational,observational model: cohort|time perspective: prospective
"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults",nan,not yet recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04516746,NCT04516746,to estimate the efficacy of 2 im doses of azd1222 compared to placebo for the prevention of covid-19 in adults ‚â• 18 years of age|to assess the safety and tolerability of 2 im doses of azd1222 compared to placebo in adults ‚â• 18 years of age|to assess the reactogenicity of 2 im doses of azd1222 compared to placebo in adults ‚â• 18 years of age (substudy only)|to estimate the efficacy of 2 im doses of azd1222 compared to placebo for the prevention of sars-cov-2 asymptomatic infection|to estimate the efficacy of 2 im doses of azd1222 compared to placebo for the prevention of symptomatic covid-19 using cdc criteria|to estimate the efficacy of 2 im doses of azd1222 compared to placebo for the prevention of university of oxford defined symptomatic covid-19|to estimate the efficacy of 2 im doses of azd1222 compared to placebo for the prevention of severe or critical symptomatic covid-19|to estimate the efficacy of 2 im doses of azd1222 compared to placebo for the prevention of covid-19-related emergency department visits|to assess antibody responses to azd1222 s antigen following 2 im doses of azd1222 or placebo (substudy and illness visits only)|to determine anti-sars-cov-2 neutralizing antibody levels in serum following 2 im doses of azd1222 or placebo (sub-study and illness visits only),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
PROLIFIC ChemoprophylaxisTrial (COVID-19),nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04352933,NCT04352933,time to positive covid-19 disease|number of covid-19 test positive cases|number of covid-19 serological test positive cases|severity of covid-19 disease between each arm|number of common covid-19 complications between each arm,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,CRISIS,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04425252,NCT04425252,safety/tolerability measured by rates of post randomization adverse events and hematology/chemistry safety labs.|hospitalization status|duration of hospitalization|news2 score|mortality|sars-cov-2 nasopharyngeal viral load|inflammatory markers|dho concentration|brequinar concentration,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19),nan,not yet recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04452942,NCT04452942,changes on eicosanoid lipid mediators|changes on plasma levels of a panel of 40 human cytokines and chemokines|severe clinical outcome,observational,observational model: cohort|time perspective: prospective
The COVID-19 Mobile Health Study (CMHS),CMHS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04275947,NCT04275947,accuracy of ncapp covid-19 risk diagnostic model,observational,observational model: cohort|time perspective: prospective
COVID-19 Pandemic and Worldwide Organ Procurement,COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04416256,NCT04416256,organ transplantation activity during covid-19 pandemic|further analysis on organ transplantation with stratification,observational,observational model: cohort|time perspective: prospective
Vitamin D and COVID-19 Management,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04385940,NCT04385940,symptoms recovery|hospitalization|blood white blood cell count (wbc)|duration of mechanical ventilation|duration of hospitalization|intensive care unit (icu) admission|duration of icu stay|blood c-reactive protein (crp)|blood lymphocyte count|blood ferritin|blood platelet count|blood interleukin-6 (il-6)|blood tumor necrosis factor alpha (tnf),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Hydroxychloroquine in COVID-19 Patients,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04394442,NCT04394442,time to viral clearance|% of mortality|length of stay|time to be afebrile|need for mechanical ventilation,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Methodist Health System COVID-19 Patient Registry,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04477889,NCT04477889,patient characteristics|treatment measures and intervention strategies|clinical and survival outcomes,observational,observational model: other|time perspective: prospective
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT),nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04377620,NCT04377620,proportion of participants who have died due to any cause|number of ventilator free days|number of icu free days|oxygen free days|vasopressor free days|hospital free days|improvement in the covid-19 ordinal scale|change in sofa score|number of treatment-related adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19,nan,"active, not recruiting",No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04501783,NCT04501783,time to clinical improvement|time to viral clearance|rate of clinical improvement at separate time points|rate of viral clearance at separate time points|time to body temperature normalization|rate of resolution of lung changes on ct|rate of adverse drug reactions (adr) and serious adr|rate of severe adr|rate therapy termination due to adr,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19),CCOVID-19,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04535869,NCT04535869,rate of virological cure by rt -pcr for covid -19using the triple therapy as compared to standard treatment|resolution of pneumonia by high resolution computed tomography,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Dynamic Evaluation of COVID-19 Diagnostic Tests,TRODVID-19,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04337996,NCT04337996,comparison of the proportion of patients classified as covid-19 positive according to the 2 strategies|positive or negative covid-19 test|positive or negative character of the antibodies test|biological parameters|medical-economic comparison,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Rapid Experimental Medicine for COVID-19,DEFINE,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04473053,NCT04473053,the safety of the candidate therapies in covid-19 patients by measuring physiological changes in the circulatory and respiratory system.|the safety of the candidate therapies in covid-19 patients by recording the number of treatment related adverse events.|measuring the pk of the proposed trial treatments in covid-19 patients.|measure a change in the expression of key coagulation biomarkers in the blood of covid-19 patients during and after treatment period.|measure a change in the expression of key cytokines in the blood of covid-19 patients during and after treatment period.|to evaluate the improvement or deteroriation of patients in each treatment arm.|to evaluate the number of oxygen-free days.|to evaluate incidence of any form of new ventilation use.|to evaluate ventilator-free days|change in the ratio of the oxygen saturation to fraction of inspired oxygen concentration (spo2/fio2)|to evaluate sars-cov-2 viral load.|to evaluate time to discharge|to evaluate the use of renal dialysis or haemofiltration for each treatment arm.,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Treatment of COVID-19 Patients With Anti-interleukin Drugs,COV-AID,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04330638,NCT04330638,"time to clinical improvement|time to improvement in oxygenation|mean change in oxygenation|number of days with hypoxia|number of days of supplemental oxygen use|time to absence fever for more than 48h without antipyretics|number of days with fever|time to halving of crp levels compared to peak value during trial|time to halving of ferritin levels compared to peak value during trial|incidence of aes (adverse events)|incidence of saes (serious adverse events)|duration of hospital stay|duration of hospital stay in survivors|mean change of sofa score (sequential organ failure assessment) between day 1 and day 7|mean change of sofa score between day 1 and day 15|percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum il-1|percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum il-6|incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum il-1|incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum il-6|time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|time to first use of salvage systemic steroids in ventilated patients|number of ventilator free days|duration of mechanical ventilation in ventilated patients|duration of icu stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|time to progression to ards in ventilated patients, according to the adapted berlin criteria|time to progression to ards in ventilated patients according to il-1|time to progression to ards in ventilated patients according to il-6|all-cause mortality rate (excluding group that entered during ventilation)|percentage of patients in clinical status on 6-point ordinal scale|incidence of lung function abnormalities|incidence of lung fibrosis on chest ct scan|all-cause mortality rate",interventional,allocation: randomized|intervention model: factorial assignment|masking: none (open label)|primary purpose: treatment
Lanadelumab for Treatment of COVID-19 Disease,COVID_LAN,recruiting,No Results Available,phase 1|phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04422509,NCT04422509,oxygen|adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults",nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04341168,NCT04341168,clinical course of covid-19|analysis of development of antibodies to sars-cov-2|estimation of viral load|detection of viral coinfections|measurement of cytokine and chemokine response|characterisation of virus-host-interaction|identification of disease patterns in proteome|analysis of change in lymphocyte subtypes|analysis of histological changes in severe lung disease|detection of bacterial coinfections,observational,observational model: cohort|time perspective: prospective
COVID-19 Patient Positioning Pragmatic Trial,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04359797,NCT04359797,modified who ordinal scale|fio2,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: supportive care
Allocetra-OTS in COVID-19,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04513470,NCT04513470,assessment of safety by determining the number of participants with any adverse events (ae) and serious adverse events (sae)|preliminary efficacy: recovery from covid-19 as determined by negative pcr or asymptomatic by the nih classification for the severity of illness|mortality|preliminary efficacy: to assess prevention of respiratory deterioration associated with covid-19 by measuring the pao2/fio2 ratio|hospitalization|life support|clinical status by the new nih patient classification for the severity of illness|clinical status by news2|support measurements: percentage of subjects reporting each severity rating on a 7-point ordinal scale|support measurements: improvement of severity rating on a 7-point ordinal scale|virus clearance|exploratory: serum cytokines/chemokines and immunomodulating factors|exploratory: complete blood counts|exploratory: histone and cell-free dna levels,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04363372,NCT04363372,change in mean clinical status score in each treatment arm|number of adverse events in each treatment arm|number of patients with an improvement in clinical status score in each treatment arm|number of patients with a deterioration in clinical status score in each treatment arm|number of patients with at least 95% oxygen saturation on room air in each treatment arm|time to patients with at least 95% oxygen saturation on room air in each treatment arm|number of patients with an improvement in the national early warning score (news) 2 in each treatment arm|number of patients with an deterioration in the national early warning score (news) 2 in each treatment arm|number of patients requiring continuous positive airway pressure in each treatment arm|number of patients requiring intermittent positive pressure ventilation in each treatment arm|time to patients requiring continuous positive airway pressure in each treatment arm|time to patients requiring intermittent positive pressure ventilation in each treatment arm|time to discharge in each treatment arm|number of deaths in each treatment arm,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Famotidine Outpatient COVID-19 Treatment Study,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04389567,NCT04389567,symptomatic improvement|peripheral blood oxygen saturation,observational,observational model: case-only|time perspective: retrospective
Leflunomide in Mild COVID-19 Patients,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04361214,NCT04361214,tolerability of high dose leflunomide as measured by leflunomide dose modifications|tolerability of high dose leflunomide as measured by discontinuation of leflunomide|tolerability of high dose leflunomide as measured by adverse events|rate of hospitalization due to covid-19 as measured by number of patients hospitalized|time to defervescence as measured in days while on treatment protocol|resolution of other covid-19 symptoms measured in days while on treatment protocol,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Preventing COVID-19 With High-dose Vitamin D Supplements,PROTECT,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04483635,NCT04483635,change in incidence of laboratory-confirmed covid-19 infection|distribution of disease severity|duration of covid-19 positivity|number of participants with covid-19 positive igg serology|number of workday absences due to covid-19 suspected/confirmed infection|number of workday absences for any reason|changes in adverse health events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: prevention"
"Novel COVID-19, A National Analysis",nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04413045,NCT04413045,patient prognosis score|oxygen saturation|laboratory data|radiological features|hospital stay|liver function|kidney function,observational,observational model: other|time perspective: retrospective
Beat COVID-19 - Observational Trial,JUPITER,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04337762,NCT04337762,health outcomes,observational,observational model: case-control|time perspective: prospective
Treating COVID-19 With Hydroxychloroquine (TEACH),nan,suspended,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04369742,NCT04369742,cumulative incidence of saes through day 30|cumulative incidence of grade 3 or 4 aes through day 30|incidence of discontinuation of therapy (for any reason)|severe disease progression composite outcome|cumulative incidence of events|hospital length of stay|days of fever|days of non-invasive ventilator use|days of non-rebreather mask oxygen supplementation|score on cytokine release syndrome (crs) grading scale|percentage of subjects reporting each severity score on 8 point ordinal scale day 1 and eot (end of treatment - day 6)|percentage of subjects with qtc prolongation at eot|cumulative incidence of mortality|cumulative incidence of icu admission|cumulative incidence of invasive mechanical ventilation|cumulative incidence of ecmo|cumulative incidence of hypotension requiring vasopressor support|sars-cov-2 viral eradication from nasopharyngeal specimens at eot|change in alanine aminotransferase (alt) levels|change in aspartate aminotransferase (ast) levels|change in creatinine levels|change in glucose levels|change in white blood cell (wbc) count|change in hemoglobin levels|change in platelet count|change in total bilirubin levels|change in lactate dehydrogenase (ldh) levels|change in c-reactive protein (crp) levels|change in interleukin 6 (il-6) levels,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Duke COVID-19 Shared Data and Specimen Repository,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04368234,NCT04368234,"development of data repository to provide a secure, centralized storage location for covid-19 related specimens",observational,observational model: cohort|time perspective: prospective
"A COVID-19 Symptom, Exposure and Immune Response Registry",nan,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04348942,NCT04348942,registry data,observational,observational model: cohort|time perspective: prospective
COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION (SOT) : AN INTERNATIONAL WEB-BASED SURVEY,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04367896,NCT04367896,management of solid organ transplant during covid-19 pandemic|equity of resource distribution|equity rank of resource distribution,observational,observational model: other|time perspective: prospective
COPING With COVID-19( CWC-19),nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04343690,NCT04343690,change in stress level as measured by survey|change wellness as measured by survey,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Complementary Intervention for COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04487964,NCT04487964,"increased number of people recovering from covid-19|decrease number of patients that require respiratory support ,|decrease duration of hospital stay",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
COVID-19 Pandemic and Academic Performance of Veterinary Students,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04387214,NCT04387214,measure the effect of covid-19 pandemic on the academic performance of veterinary medical students|measure the average studying time|evaluate on-line education during covid-19 pandemic lockdown|evaluate on-line education in practical lessons during covid-19 pandemic lockdown,observational,observational model: other|time perspective: cross-sectional
A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness,CONCOR-1,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04418518,NCT04418518,intubation or death in hospital|need for intubation|time to intubation|ventilator-free days|in-hospital death|time to in-hospital death|death at 30 days|length of stay in intensive care unit (icu)|length of stay in hospital|need for extracorpeal membrane oxygenation (ecmo)|need for renal replacement therapy|development of myocarditis|adverse events and serious adverse events|ccp transfusion-associated adverse events (ae),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Hypertonic Saline for COVID-19 Symptoms,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04465604,NCT04465604,improvement of respiratory symptoms|improvement of respiratory signs|icu admission|mechanical ventilation,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Evaluation of the Immune Response to SARS-CoV-2 Among Patients With Covid-19 in Costa Rica,RESPIRA,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04537338,NCT04537338,covid-19 seroconversion,observational,observational model: case-control|time perspective: other
Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04485429,NCT04485429,rate of invasive mechanical ventilation|severity assessment by ordinal severity scale|severity assessment by sofa score|length of hospital stay|length of stay in intensive care|death rate,interventional,allocation: randomized|intervention model: factorial assignment|masking: none (open label)|primary purpose: treatment
COVID-19: A POC Test Under Research & Evaluation,CAPTURE,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04408066,NCT04408066,performance of the lumiradx assay versus reference methods with regards to clinical sensitivity and specificity for the detection of the sars-cov-2 igg/igm and viral antigen in patient samples.,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: diagnostic
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-79,nan,not yet recruiting,No Results Available,phase 3,Other|NIH,https://ClinicalTrials.gov/show/NCT04498273,NCT04498273,primary,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19),COVIDoth√®que,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04347850,NCT04347850,number of confirmed covid-19|number of severe covid-19|identification and validation of predictive biomarkers of a poorer respiratory evolution associated with positive testing for sars-cov-2 infection|evaluate the morbidity and mortality and these risk factors linked to covid-19 in the congenital heart disease population in france|identify the characteristics of physiotherapy care for patients with covid-19 in intensive care|to assess the accuracy and prognostic performance of clinical and biological parameters measured on admission to the emergency department to stratify patients suspected of covid-19|evaluate diagnostic tests for olfactory function in relation to the rt-pcr procedure|assessment of extra vascular lung water and pulmonary permeability by transpulmonary thermodilution in critically ill patients with coronavirus disease 2019 pneumonia under invasive mechanical ventilation|description of trans pulmonary motor pressure in covid 19+ patients in severe stage in intensive care|immuno-monitoring of covid-19 positive patients|characterization in clinical proteomics of the sars-cov-2 spike protein|diagnosis of endocrine dysfunctions in covid-19|describe the occurrence of covid19 infection in patients with systemic lupus erythematosus treated with hydroxychloroquine over the long term|acral cutaneous thrombotic vasculopathy and covid-19 infection : search for acquired thrombophilia and interferon-alpha signature|evaluation of a covid-19 screening strategy combining chest low dose ct and rt-pcr test for patients admitted for surgical or interventional procedures during the covid 19 outbreak,observational,observational model: cohort|time perspective: prospective
Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).,nan,not yet recruiting,No Results Available,phase 2|phase 3,Industry|Other,https://ClinicalTrials.gov/show/NCT04452474,NCT04452474,"percentage of subjects achieving a change in their clinical status defined as improvement for at least 2 categories of the 5-points clinical status scale relative to baseline or in the ""not hospitalized"" category|subjects' clinical status distribution based on 5-point clinical status scale during the study|28-day case fatality rates",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Anxiety And Depression During COVID-19 IN INDIA,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04369300,NCT04369300,prevalence (magnitude) of anxiety of general adult population during covid-19|prevalence (magnitude) of depression and anxiety of general adult population during covid 19,observational,observational model: other|time perspective: cross-sectional
Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),SARPAC,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04326920,NCT04326920,"improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in covid-19 patients with acute hypoxic respiratory failure|incidence of ae (adverse event)|incidence of saes (serious adverse event)|clinical status using 6-point ordinal scale|clinical status using clincal sign score|clinical status using sofa score (sequential organ failure assessment score),|clinical status using news2 score (national early warning score)|incidence of severe or life-threatening bacterial, invasive fungal or opportunistic infection|number of patients requiring initiation of mechanical ventilation|number of deaths due to any cause at 4 weeks|number of deaths due to any cause at 20 weeks|number of patients developing features of secondary haemophagocytic lymphohistiocytosis|long term clinical status defined by 6-point ordinal scale|long term clinical status defined by chest x-ray|long term clinical status defined lung function",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),nan,"active, not recruiting",No Results Available,phase 2|phase 3,Industry|Other,https://ClinicalTrials.gov/show/NCT04380519,NCT04380519,"proportion of patients, responded to the study therapy, in each of the treatment groups|changes of patients' clinical status on a 6 points ordinal scale over time|mortality rate over the follow-up period|improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|proportion of patients received tocilizumab or sarilumab due to covid-19",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
MSCT Chest in Suspected COVID-19 Patients,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04492865,NCT04492865,accuracy of non contrast msct chest in covid-19|msct chest can be used as an alternative diagnostic tool for covid-19 cases.,observational,observational model: cohort|time perspective: prospective
Low Dose Whole Lung Radiotherapy for Older Patients With COVID-19 Pneumonitis,nan,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04493294,NCT04493294,mortality rate|duration of hospitalization|time to recovery|oxygen saturation rate|patient inflammatory status,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Hyperbaric Oxygen for COVID-19 Patients,nan,terminated,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04332081,NCT04332081,mortality|need for mechanical ventilation|days on invasive mechanical ventilation,interventional,allocation: non-randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19),COLOR-19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04377477,NCT04377477,lenght of hospital stay (days)|number of intensive care unit admissions|variation of the brescia covid-19 respiratory severity scale after treatment|occurence of ctcae 5.0 adverse events|variation of the chest x-ray radiological findings according to brixia scoring system,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
A Pilot Study of Sildenafil in COVID-19,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04304313,NCT04304313,"rate of disease remission|rate of entering the critical stage|time of entering the critical stage|rate of no fever|rate of respiratory symptom remission|rate of lung imaging recovery|rate of c-reactive protein (crp) recovery|rate of biochemical criterion (ck, alt, mb) recovery|rate of undetectable viral rna (continuous twice)|time for hospitalization|rate of adverse event",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Cardiovascular Effects of COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04365699,NCT04365699,proportion of subjects with decreased left ventricular ejection fraction ‚â•10% from baseline at time of hospitalization|incidence of adverse events for patients receiving at-001|change in left ventricular ejection fraction|change in left ventricular end-diastolic diameter|change in left ventricular end-systolic diameter|change in biomarkers of cardiac injury|frequency of atrial fibrillation|frequency of heart block|frequency of non-sustained ventricular tachycardia|frequency of sustained ventricular tachycardia|frequency of ventricular fibrillation|proportion of subjects requiring mechanical ventilation|proportion of subjects with decrease in left ventricular ejection fraction ‚â•10% from baseline at time of hospitalization,interventional,allocation: non-randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Abatacept for Patients With COVID-19 and Respiratory Distress,nan,withdrawn,No Results Available,phase 1|phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04477642,NCT04477642,"mechanical ventilation-free survival|duration of days on a ventilator|days until pulse oxygen is > 93% on room air|days until supplemental oxygen is no longer required|duration of fever >= 38¬∞c|overall survival|infusion reactions|secondary infections|change in clinical status, based on 7-point ordinal scale|viral load|radiographic improvement",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of a Plant Polyphenol for COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04400890,NCT04400890,hospitalization rates for covid-19|icu admission rates|invasive ventilation rates,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
COVID-19 and Liver Injury in Patients With or Without Underlying Liver Disease: A Multi-centre Retrospective-prospective Observational Study,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04422379,NCT04422379,covid-19 positive case,observational,observational model: cohort|time perspective: other
Arrhythmias in Patients With COVID-19,ACOVID,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04395664,NCT04395664,in-hospital mortality during hospitalization and a confirmed covid-19 diagnosis|incident intensive care unit admission during hospitalization and a confirmed covid-19 diagnosis|incident pulmonary embolism during hospitalization and a confirmed covid-19 diagnosis|incident cardiac arrest during hospitalization and a confirmed covid-19 diagnosis|incident hypoxic respiratory failure during hospitalization and a confirmed covid-19 diagnosis,observational,observational model: cohort|time perspective: prospective
Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program,nan,available,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04363034,NCT04363034,nan,expanded access:intermediate-size population,nan
SCB-2019 as COVID-19 Vaccine,nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04405908,NCT04405908,incidence of solicited adverse events (aes) after vaccination|incidence of unsolicited aes after vaccination|immunogenicity(anti-scb-2019 antibody titers)|incidence of serious aes (saes) and adverse events of special interest (aesis)|immunogenicity( serum anti sars-cov-2 neutralizing antibody titers (ace2 receptor-based) )|immunogenicity(serum anti sars-cov-2 neutralizing antibody titers (cell based) )|immunogenicity(serum anti sars-cov-2 whole virus antibody titers)|antibody kinetics of each scb 2019 vaccine formulation after first and second doses,interventional,"allocation: randomized|intervention model: sequential assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: prevention"
Immune Biomarkers of Outcome From COVID-19,IBOC,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04436484,NCT04436484,mortality|disease severity,observational,observational model: cohort|time perspective: prospective
To Observe Whether Isoflurane Can Treat COVID-19 Patients,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04492943,NCT04492943,survival outcome|covid-19 testing methods|covid-19 clearance,observational,observational model: cohort|time perspective: retrospective
Zilucoplan¬Æ in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure,ZILU-COV,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04382755,NCT04382755,"mean change in oxygenation|median change in oxygenation|number of ae's (adverse events)|number of sae's (serious adverse events)|mean change in 6-point ordinal scale change|time since randomization until improvement in oxygenation|number of days with hypoxia|number of days of supplemental oxygen use|time to absence of fever (defined as 37.1¬∞c or more) for more than 48h without antipyretic|number of days with fever|mean change in crp levels between day 1 and day 6|mean change in crp levels between day 1 and day 15 (or discharge whichever comes first)|mean change in ferritin levels between day 1 and day 6|mean change in ferritin levels between day 1 and day 15 (or discharge, whichever comes first)|incidence of ae's|incidence of sae's|incidence of susar's (suspected unexpected serious adverse reaction)|incidence of sar's (serious adverse reaction)|duration of hospital stay|duration of hospital stay in survivors|mean change of sofa score between day 1 and day 6 (or on discharge, whichever is first)|mean change of sofa score between day 1 and day 15 or on discharge, whichever is first)|percentage of patients reporting each severity rating on a 6-point ordinal scale at randomization, day 6 and 15 (or discharge, whichever comes first) and day 28 (phone call)|6-point ordinal scale at 6 and 15 days (or discharge whichever comes first) and day 28 (phone call), in relation to serum d-dimers and complement c5a levels at randomization|incidence of nosocomial bacterial or invasive fungal infection for 28 days (phone call) after enrolment in trial|time since randomization until first use of high-flow oxygen devices in non-ventilated patients|time since randomization until first use of non-invasive mechanical ventilation in non-ventilated patients|time since randomization until first use of invasive mechanical ventilation in non-ventilated patients|number of ventilator-free days|duration of invasive and non-invasive mechanical ventilation in ventilated patients|duration of icu stay in patients that enrolled in trial on invasive or non-invasive mechanical ventilation for less than 24h prior to or after randomization|time since randomization to progression to ards (acute respiratory distress syndrome)|time to progression to ards in ventilated patients according to d-dimers at randomization|time to progression to ards in ventilated patients according to complement c5a at randomization|all-cause mortality rate (excluding group that entered during ventilation)|all-cause mortality rate (including group that entered during ventilation)|percentage of patients in clinical status on 6-point ordinal scale|incidence of lung function abnormalities at follow up|incidence of lung fibrosis on chest ct scan at follow up|all cause mortality for the entire study population",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections",REMDECO-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04365725,NCT04365725,clinical course on day 15.|clinical course on day 3.|clinical course on day 8|clinical course on day 11.|clinical course on day 29.|duration of treatment|sepsis-related organ failure assessment score|duration without mechanical ventilation|mortality|cumulative incidence of grade 3 and 4 adverse events (aes).,observational,observational model: cohort|time perspective: retrospective
Awake Prone Position for Early Hypoxemia in COVID-19,APPEX-19,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04344587,NCT04344587,change in respiratory status|length of time participant spends in the prone position|length of time participant spends in the supine position|length of time participant spends lying on side|length of time participant spends sitting up|length of time participant spends standing or walking|dyspnea or difficult/labored breathing|discomfort with proning|length of hospital stay|invasive mechanical ventilation|loss of iv access as a consequence of turning in bed|acute respiratory distress syndrome (ards) diagnosis|hospital mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,nan,enrolling by invitation,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04441996,NCT04441996,change in plasma viscosity|all cause mortality|bleeding and thromboembolic complications|time to treatment failure|duration of icu stay|duration of hospital stay|discharge disposition|change in clinical status|change in body temperature|change in systolic blood pressure|change in diastolic blood pressure|change in heart rate|change in respiratory rate|change in ventilator days|change in ventilator oxygen percent (fio2)|change in positive end-expiratory pressure (peep)|change in vasopressor requirements|change in need for treatment from a registered respiratory therapist (rrt)|change in sequential organ failure assessment (sofa) score|change in partial pressure of arterial oxygen (pao2)/percentage of inspired oxygen (fio2) ratio|change in ventilatory ratio|change in white blood count (wbc)|change in hemoglobin (hb)|change in hematocrit (hct)|change in platelet count|change in mean platelet volume (mvp)|change in blood urea nitrogen (bun)|change in creatinine|change in bilirubin|change in total protein|change in albumin|change in c-reactive protein (crp)|change in interleukin 6 (il-6)|change in prothrombin time (pt)|change in international normalized ratio (inr)|change in activated partial thromboplastin time (aptt)|change in anti-factor xa (anti-xa)|change in fibrinogen|change in d-dimer,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Camostat Mesylate in COVID-19 Outpatients,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04353284,NCT04353284,change in sars-cov-2 viral load|change in positive covid-19 status|change in covid-19 symptom severity|change in covid-19 symptom frequency|change in body temperature,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04337541,NCT04337541,"the primary endpoint is the difference in sars-cov-2 infection between the two groups after 1 months and is a combined endpoint consisting of primary outcome components 1, 2 and/or 3:|positive oropharyngeal/nasal swab (pcr);",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Convalescent Plasma for the Treatment of COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04389710,NCT04389710,number of patients who receive covid-19 convalescent plasma transfusions in acute care facilities infected with sars-cov-2|number and type of adverse events associated with covid-19 convalescent plasma in patients with covid-19|length of hospital stay|length of intensive care unit stay|length of intubation|survival to discharge|changes in complete blood count in patients after receiving convalescent plasma|abnormal changes in basic metabolic panel (bmp) measures in patients after receiving convalescent plasma|changes in c-reactive protein (crp) in patients after receiving convalescent plasma|changes in d-dimer in patients after receiving convalescent plasma|changes in fibrinogen in patients after receiving convalescent plasma|changes in prothrombin time (pt) in patients after receiving convalescent plasma|changes in partial thromboplastin time (ptt) in patients after receiving convalescent plasma,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Clinical Course and Treatment of COVID-19 Inpatients in Hospital,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04527497,NCT04527497,convalescence/death|length of stay in the intensive care unit|length of stay in hospital,observational,observational model: cohort|time perspective: prospective
GRAd-COV2 Vaccine Against COVID-19,nan,recruiting,No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04528641,NCT04528641,"assess the safety, tolerability and reactogenicity of grad-cov2: occurrence of solicited local ae signs and symptoms|assess the safety, tolerability and reactogenicity of grad-cov2: occurrence of solicited systemic ae signs and symptoms|assess the safety, tolerability and reactogenicity of grad-cov2: occurrence of unsolicited ae|assess the safety of grad-cov2 by laboratory measures: full blood count; blood biochemistry (sodium, potassium, albumin, liver function tests; renal function, lactate dehydrogenases (ldh), alkaline phosphatases (alp)).|assess the safety, tolerability and reactogenicity of grad-cov2: occurrence of serious ae|immunogenicity",interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: prevention
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE),nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04351243,NCT04351243,incidence of mortality|incidence of subjects who are alive and not on mechanical ventilation|number of ventilator-free days|time to hospital discharge,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Diagnostics of COVID-19/DARTS (Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak),nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04351646,NCT04351646,antibody titres to sars-cov-2,observational,observational model: cohort|time perspective: prospective
Attitude and Perception Towards COVID-19 Pandemic,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04400812,NCT04400812,knowledge about covid-19 by questionnaire|perception about covid-19 by questionnaire|attitude towards covid-19 by questionnaire,observational,observational model: other|time perspective: cross-sectional
Geriatric Population COVID-19 Observational Study (GEROCOVIDobs),GEROCOVIDobs,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04379440,NCT04379440,"health status (who classification)|incidence of serious adverse events|covid-19 prevalent symptoms at onset|covid-19 prognostic factors|incidence of covid-19 in the rsa cohort|affective/mood state change from baseline in the "" at home "" cohort|cognitive function in the ""dementia"" and ""at home "" cohorts|daily life function in the ""dementia"" and ""at home "" cohorts|instrumental daily life function in the ""dementia"" and ""at home "" cohorts|residual signs and symptoms in the "" outcomes "" cohort|incidence of outcomes in the "" outcomes "" cohort per frailty status|incidence of outcomes in the "" outcomes "" cohort per comorbidity burden at baseline",observational,observational model: cohort|time perspective: other
Atorvastatin as Adjunctive Therapy in COVID-19,STATCO19,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04380402,NCT04380402,"proportion of patients that progress to severe or critical requiring icu admission and/or emergency salvage therapy, or death|overall score of patients in each arm on day 7 based on who ordinal scale for clinical improvement|overall score of patients in each arm on day 30 based on who ordinal scale for clinical improvement|proportions of patients in each arm who test negative for sars-cov-2 on day 7",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Safety in Convalescent Plasma Transfusion to COVID-19,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04333355,NCT04333355,side effects|heart failure|pulmonary edema|allergic reaction|viral load of sars-cov-2,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
The Role of Ultrasound in COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04377035,NCT04377035,in-hospital mortality during hospitalization and a confirmed covid-19 diagnosis|incident ards (adult respiratory distress syndrome) and intensive care unit admission during hospitalization and a confirmed covid-19 diagnosis|incident hypoxic respiratory failure during hospitalization and a confirmed covid-19 diagnosis|incident pulmonary embolism during hospitalization and a confirmed covid-19 diagnosis|incident cardiac arrest during hospitalization and a confirmed covid-19 diagnosis|death from any cause after hospital admission with a confirmed covid-19 diagnosis at follow-up|incident stroke after hospital admission with a confirmed covid-19 diagnosis at follow-up|incident heart failure after hospital admission with a confirmed covid-19 diagnosis at follow-up|incident myocardial infarction after hospital admission with a confirmed covid-19 diagnosis at follow-up,observational,observational model: cohort|time perspective: prospective
Dietary Intake and Eating Habits During the COVID-19 Pandemic,COVIDiet,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407533,NCT04407533,dietary intake|diet quality|eating habits,observational,observational model: ecologic or community|time perspective: prospective
SCIL-1Ra in COVID-19 Feasibility & PK/PD,SCIL_COV19,"active, not recruiting",No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04462757,NCT04462757,plasma il-1ra levels|plasma il-6 levels|plasma markers|safety endpoints related to the serious adverse reactions of the imp|safety endpoints related to the anaphylactic reactions of the imp|safety endpoints related to neutropenia caused by the imp|safety endpoints related to any severe laboratory abnormalities|feasibility endpoints related to imp and deviations|exploratory data on clinical efficacy by time to recovery|exploratory data on clinical efficacy|exploratory data on clinical efficacy of the ordinal scale,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: health services research
Evaluating the Immune Response for COVID-19,COVIDIMMUNE,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04348422,NCT04348422,proportion of symptomatic patients with immune response (igm/igg/iga)|proportion of asymptomatic patients with immune response (igm/igg/iga)|time to igm|time to igg|time to iga|serology kits inter-observer agreement,observational,observational model: cohort|time perspective: prospective
A Randomized Trial of Anticoagulation Strategies in COVID-19,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04359277,NCT04359277,"composite incidence of: all-cause mortality, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, stroke, or shock|score on who ordinal scale|incidence of acute kidney injury (kdigo criteria for acute kidney injury (aki))|requirement of invasive mechanical ventilation or extracorporeal membrane oxygenation (ecmo)|cardiac injury|hypercoagulability|disseminated intravascular coagulation (dic) score|length of hospital stay",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Administration of Chlorpromazine as a Treatment for COVID-19,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04354805,NCT04354805,clinical improvement,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Detection of COVID-19 Subjects Using DiaNose Exhalation Test,nan,not yet recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04476927,NCT04476927,collecting and analyzing of dianose sensors signals from potential voc markers in the breath samples of all subjects to build and validate a predictive algorithmic model for diagnosing covid 19.,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,ReCOVery-SIRIO,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04351763,NCT04351763,clinical improvement|mean change in the 7-point ordinal scale|mortality|time to resolution of fever|clinical improvement or fever resolution|tachyarrhythmias|mortality or tachyarrhythmias|time to clinical improvement from admission using the 7-point ordinal scale|change in news2 score|duration of hospitalization|po2/fio2,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Hydroxychloroquine for the Treatment of Mild COVID-19 Disease,COMIHY,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04340544,NCT04340544,"difference in time to resolution of clinical signs and symptoms of mild covid-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment|difference between hydroxychloroquine- and placebotreated patients on an ordinal outcome scale until day 28 (death, admission to intensive care, hospitalization, continuing disease, recovered)|all-cause mortality within 28 days",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Tofacitinib for Treatment of Moderate COVID-19,I-TOMIC,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04415151,NCT04415151,disease severity|clinical improvement|time to recovery|time to clinical improvement|clinical status|mortality|mechanical ventilatory support|mechanical ventilatory support duration|freedom from mechanical ventilation|adverse events|additional intervention|viral titer,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
CAP-1002 in Severe COVID-19 Disease,nan,available,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04338347,NCT04338347,nan,expanded access:intermediate-size population|treatment ind/protocol,nan
Accelerated Prone Position Ventilation of Patients With COVID-19,PROVENT-COVID,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04384900,NCT04384900,"days alive without respiratory life support (invasive mechanical ventilation) at day 28.|days alive and out of hospital on day 28 after randomisation.|days alive at day 28 without life support (vasopressor/inotropic support, invasive mechanical ventilation or renal replacement therapy).|number of participants with one or more sars as described in section 6.1 plus incidence of new persistent nerve injury or grade 3 or 4 (full-thickness skin loss or worse) pressure wounds.|28-days all-cause mortality.",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Etoposide in Patients With COVID-19 Infection,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04356690,NCT04356690,change in pulmonary status|change in ferritin levels|change in c-reactive protein levels|change in d-dimer levels|change in white blood cell count|incidence of serious adverse events|overall survival|length of hospitalization|duration of ventilation|ventilator free days|improvement in arterial oxygen partial pressure (pao2) to fractional inspired oxygen (fio2),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
Antiviral Agents Against COVID-19 Infection,REVOLUTIOn,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04468087,NCT04468087,phase ii first step: change in area under the curve of sars-cov 2 viral load|phase ii second step: change in area under the curve of sars-cov 2 viral load|phase iii: number of free days from respiratory support,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection,COVERSCAN,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04369807,NCT04369807,"characterise prevalence and severity of organ volume change and damage (heart, kidneys and liver)|characterise prevalence and severity of organ volume change and damage (lung, pancreas and spleen)|change from baseline in liver-specific biomarkers: volume, iron corrected t1(ct1), fat content and t2star|change from baseline in organ-specific biomarkers characterising organ volume change in the heart and spleen along with organ volume and damage in the kidney, liver and pancreas assessed by volume, iron corrected t1 (ct1) and fat infiltration|change in patient reported outcome measured by the dyspnea-12 questionnaire|change in patient reported outcome measured by the st. george's respiratory questionnaire (sgrq)|change in patient reported outcome measured by the eq-5d-5l questionnaire|degree of change in liver mr-derived biomarkers",observational,observational model: cohort|time perspective: prospective
Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04509999,NCT04509999,proportion x 100 = percent of patients with improved covid-19 symptoms,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Treatment of Angiotensin Peptide (1-7) for COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04375124,NCT04375124,mortality,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients,PRANA,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04458298,NCT04458298,"number of participants with treatment emergent adverse events graded as assessed by ctcae version 4.0|time to improvement (2 points) in clinical status assessment using the world health organization 7-point ordinal scale (who 7os)|time to resolution of fever for at least 48 hours without antipyretics for patients with documented fever (>=37.2 degree celsius [oral], or >=37.8 degree celsius [rectal], or >=38.0 degree celsius [tympanic])|time to improvement in oxygenation for at least 48 hours|change from baseline in the world health organization (who)-7 point ordinal scale|time to discharge from clinic or hospital or to national early warning score 2 (news2) of <=2 and maintained for 24 hours|percentage of patients alive and not using supplemental oxygen at time of discharge from hospital/clinic or day 30|number of days of resting respiratory rate of more than 24 breath/min|number of days with hypoxemia|number of days of supplemental oxygen use|number of ventilator-free days|number of days in intensive care unit (icu)|number of days of hospitalization for survivors|number of participants with all cause deaths|percent change from baseline in proinflammatory cytokines|incidence of drug-related serious adverse events (saes)",interventional,"allocation: randomized|intervention model: sequential assignment|masking: double (participant, investigator)|primary purpose: treatment"
Noncoding RNAs in COVID-19 and COVID-19 Related Kidney Dysfunction,MiRCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04381351,NCT04381351,predicitive value of noncoding rnas in covid-19 associated organ dysfunction,observational,observational model: cohort|time perspective: prospective
Cyclosporine in Patients With Moderate COVID-19,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04412785,NCT04412785,"safety-oxygen, icu transfer and ventilation|safety-changes in absolute lymphocyte count|safety-changes in creatinine clearance|safety-secondary bacterial infections|laboratory measurements of safety and antiviral efficacy related to covid-19-sars-cov-2 by measuring the clearance of sars-cov-2 from respiratory secretions|laboratory measurements-d-dimer levels|laboratory measurements-ferritin|laboratory measurements- il-6",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Effect of Quercetin on Prophylaxis and Treatment of COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04377789,NCT04377789,prevalence of covid-19 calculated using a questionnaire|standardized mortality rate|morbidity rate,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Respiratory Physiotherapy in Severe COVID-19 Patients,FTR-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04459819,NCT04459819,number of physiotherapy treatments|type of physiotherapy treatments|time of the first physiotherapy treatment|first time standing|first time walking|first time sitting out of bed|6 minutes walking test (6mwt)|1 minute sit-to-stand test (1m-stst)|upper extremity muscles strength|lower extremity muscles strength|functional independence in adl|icu stay length|length of hospitalization|duration of invasive mechanical ventilation (imv)|patients returned home|patients discharged to in-patient rehabilitation|patients transferred to other hospitals|exitus,observational,observational model: case-only|time perspective: retrospective
Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04443725,NCT04443725,virological cure,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients),nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04383002,NCT04383002,covid-19 pcr status at completion of treatment (day 7) from tracheal aspirate,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Hexoskin Feasibility Study With COVID-19 Patients,nan,not yet recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04453891,NCT04453891,"qualitative assessment of the feasibility of the hexoskin platform and virtual recruitment process via three subjective feedback questionnaires provided to all patients enrolled in the study.|ensure the collection of high-quality data during wake and sleep activities, registered as overall > 90% good quality cardiac data and overall > 90% good quality respiratory data per recording.|ensure adequate patient compliance, qualified as > 75% of total recording hours completed, and > 75% of daily questionnaires completed.|investigate the predictive power of hexoskin physiological data, patient information and symptoms information to correctly classify patient disease progression quantified as the area under the receiver operator characteristics curve (auc roc > 0.70).",observational,observational model: cohort|time perspective: prospective
Survey: COVID-19 Patients Managed in the Operating Theatre of Belgian Hospitals,COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04376398,NCT04376398,global evaluation of the implication of the belgian anesthesiologists during covid-19 pandemic|if any compare our results with other countries,observational,observational model: case-only|time perspective: prospective
ACT-20 in Patients With Severe COVID-19 Pneumonia,nan,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04398303,NCT04398303,mortality at day 30|ventilated subjects - ventilator free days|ventilated subjects - improvement in ventilator settings|high-flow o2 support subjects - step-down o2 therapy|high flow o2 support subjects - respiration rate|both ventilated and high-flow o2 support subjects - icu-free days|both ventilated and high-flow o2 support subjects - pulmonary function improvement|both ventilated and high-flow o2 support subjects - increased berlin score,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Epidemiological Analysis of Ambulant Patients in a COVID-19 Outpatient Clinic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04521088,NCT04521088,possible risk factors|frequency of positive test results after prescribed protective measures|frequency of positive test results within the family or other social groups|number of covid-19 tests in the outpatient clinic,observational,observational model: cohort|time perspective: prospective
The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04327674,NCT04327674,flus findings and respiratory failure|flus findings and chest x-ray.|flus findings and admission to intensive care.|flus findings and sar-cov-2 pcr-test result.,observational,observational model: cohort|time perspective: prospective
Influence of COVID-19 Infection in Thromboembolic Venous Disease: National Cohort Study,TVP-COVID-RIV,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04361981,NCT04361981,deep venous disease incidence|30-days mortality|icu admission|anticoagulant treatment,observational,observational model: cohort|time perspective: prospective
Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04424797,NCT04424797,incidence of intubation|maximum oxygen requirement|length of stay|ventilator-free days|treatment failure of prone positioning due to worsening spo2 status while prone|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04451889,NCT04451889,number of covid-19 participants with notable differences in the pcle images in comparison with the pcle images of non-covid-19 participants|number of participants with the correspondence of pcle images to high resolution computer tomography and morphologic data as a measure of specificity and sensitivity of the method,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Ramipril for the Treatment of COVID-19,RAMIC,enrolling by invitation,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04366050,NCT04366050,composite of mortality or need for icu admission or ventilator use,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Registry to Study Factors That May Impact COVID-19 Occurrence and Severity,nan,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04368065,NCT04368065,covid-19 symptom occurrence and severity|covid-19 treatments|hospitalization,observational,observational model: cohort|time perspective: prospective
Remote-by-Default Care in the COVID-19 Pandemic,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04435041,NCT04435041,recap early warning score,observational,observational model: other|time perspective: other
A Study of LAM-002A for the Prevention of Progression of COVID-19,nan,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04446377,NCT04446377,viral load change|viral load auc|safety and tolerability measured in proportion of teaes,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Mesenchymal Stem Cell Infusion for COVID-19 Infection,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04444271,NCT04444271,overall survival|clinical improvement|time of covid19 pcr negativity|radiological improvement (day 15 and day 30 assessment)|days required to discharge from hospital,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Ozone Auto-hemotherapy for COVID-19 Pneumonia,COVID-OZONE,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04370223,NCT04370223,rate of patients achieving improvement in clinical condition at day 14 after recruitment|mortality at day 28|rate of patients achieving improvement in clinical condition at day 28 after recruitment|rate of patients achieving improvement in clinical condition at day 7 after recruitment|time to clinical improvement or hospital discharge|number of ventilator-free days at 28 days|hospital length of stay|time to a 2-fold decrease in ferritin|time to a 2-fold decrease in c-protein reactive|time to a 2-fold decrease in dimer-d|time to a 2-fold decrease in lactate dehydrogenase|time to a 2-fold decrease in neutrophils to lymphocytes ratio,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia,SCOPE,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04341675,NCT04341675,"proportion of patients who are alive and free from advanced respiratory support measures at day 28.|proportion of patients who require escalation in care|change over time in study-specific biomarkers (ldh, ferritin, d-dimer, lymphocyte count)|proportion of patients surviving to hospital discharge|drug safety profile|duration of advanced respiratory support|duration of hospital stay|time from treatment initiation to death|time to resolution of fever|proportion of patients who require initiation of off-label therapies",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Trial of Imatinib for Hospitalized Adults With COVID-19,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04394416,NCT04394416,the proportion of patients with a two-point change using the 8-category ordinal scale|all-cause mortality|time to a 2-point clinical change|hospitalization|duration of ecmo or invasive mechanical ventilation|duration of icu stay|sars-cov-2 negative|negative oropharyngeal or nasopharyngeal swab|serious adverse events (saes)|discontinuation due to adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04397757,NCT04397757,"participants with serious adverse events.|comparison of clinical severity score between patients on the experimental versus control arms;|clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration by comparing treatment vs control arms|clinical status assessment using the national early warning score (news) of convalescent plasma administration by comparing treatment vs control arms|oxygen-free days of convalescent plasma administration by comparing treatment vs control arms|incidence of new oxygenation use up to day 29 of convalescent plasma administration by comparing treatment vs control arms|duration of new oxygen use up to day 29 of convalescent plasma administration by comparing treatment vs control arms|non-invasive ventilation/high flow oxygen days up to day 29 of convalescent plasma administration by comparing treatment vs control arms|incidence of non-invasive ventilation/high flow oxygen up to day 29 of convalescent plasma administration by comparing treatment vs control arms|duration of non-invasive ventilation/high flow oxygen up to day 29 of convalescent plasma administration by comparing treatment vs control arms|ventilator/ecmo free days to day 29 of convalescent plasma administration by comparing treatment vs control arms|incidence of new mechanical ventilation or ecmo use of convalescent plasma administration by comparing treatment vs control arms|duration of new mechanical ventilation or ecmo use of convalescent plasma administration by comparing treatment vs control arms|duration of hospitalization of convalescent plasma administration by comparing treatment vs control arms|mortality of convalescent plasma administration by comparing treatment vs control arms|cumulative incidence of saes through day 29 of convalescent plasma administration by comparing treatment vs control arms|cumulative incidence of grade 3 and grade 4 clinical and/or laboratory adverse events through day 29 of convalescent plasma administration by comparing treatment vs control arms|changes in wbc with differential through day 29 of convalescent plasma administration by comparing treatment vs control arms|changes in hemoglobin measurement through day 29 of convalescent plasma administration by comparing treatment vs control arms|changes in platelets measurement through day 29 of convalescent plasma administration by comparing treatment vs control arms|changes in creatinine measurement through day 29 of convalescent plasma administration by comparing treatment vs control arms|changes in glucose measurement through day 29 of convalescent plasma administration by comparing treatment vs control arms|changes in bilirubin measurement through day 29 of convalescent plasma administration by comparing treatment vs control arms|changes in alt measurement laboratory adverse events through day 29 of convalescent plasma administration by comparing treatment vs control arms|changes in ast measurement through day 29 of convalescent plasma administration by comparing treatment vs control arms|changes in pt measurement laboratory adverse events through day 29 of convalescent plasma administration by comparing treatment vs control arms",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),PATCH,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04329923,NCT04329923,median release from quarantine time|rate of hospital discharge|rate of infection|rate of housemate infection|rate of hospitalization|cohort 1 adverse event rate|time to condition appropriate for discharge|rate of icu admission|time to pcr negativity|cohort 2 adverse events|scheduled shifts missed|cohort 3 adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial,GETAFE,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04361643,NCT04361643,clinical improvement|immune-inflammatory improvement|mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Inflammatory Regulation Effect of NAC on COVID-19 Treatment,INFECT-19,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04455243,NCT04455243,time to recovery,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
"Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04472013,NCT04472013,mri imaging data|proteomic analysis|peripheral blood leukocyte cytof mass cytometry analysis for cell population frequency|codex (high dimensional microscopy) workflow analysis of defined regions on brain autopsy specimens,observational,observational model: cohort|time perspective: prospective
Desidustat in the Management of COVID-19 Patients,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04463602,NCT04463602,change in clinical status of subject on a 7-point ordinal scale|pcr test|supplemental oxygen|mechanical ventilation|incidence of treatment-emergent adverse events|laboratory assessments|c-reactive protein (crp)|interleukin 6 (il-6)|d-dimer,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19",CODIV-ACE,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04318418,NCT04318418,severe covid-19|death,observational,observational model: cohort|time perspective: retrospective
The Evaluation of Hemostasis in Hospitalized COVID-19 Patients,TARGET-COVID,recruiting,No Results Available,nan,Other|Industry,https://ClinicalTrials.gov/show/NCT04493307,NCT04493307,frequency of hypercoagulability as measured by thromboelastography measured by teg and platelet aggregation.|frequency of high platelet reactivity (hpr)|frequency of thrombo-inflammatory syndrome|correlation between teg6s parameters and clinical outcomes|correlation between hpr and clinical outcomes|determine response to anticoagulation therapy|determine level of platelet aggregation|determine platelet thrombi and fibrin rich platelet thrombus area under the curve,observational,observational model: other|time perspective: prospective
Chloroquine for Mild Symptomatic and Asymptomatic COVID-19,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04333628,NCT04333628,change in virus duration (viral shedding)|change in the number of patients going from asymptomatic to moderately disease,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04541979,NCT04541979,"time to cessation of oxygen therapy dnase i to that of placebo (nacl, 0.9%) on time to cessation of oxygen therapy hospitalized patients with covid-19 and respiratory dysfunction.|28-day mortality|number of days alive and without ventilator treatment|number of days alive and without high flow nasal oxygen treatment (optiflow)|number of days alive and free of stay in the icu|number of days alive and outside hospital|number of days alive and free of a new episode and with oxygen saturation ‚â§93% after primary endpoint has been met|number of days alive and without need of supplemental oxygen|number of patients with adverse reactions",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04285801,NCT04285801,28 day mortality|vasopressor days|days on mechanical ventilation|sequential organ function assessment score|ecmo use|percentage nitric oxide use|percentage free from oxygen supplement,observational,observational model: case-only|time perspective: retrospective
Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia,CELMA,not yet recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04429763,NCT04429763,clinical deterioration or death,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04365738,NCT04365738,dyspnea|chest expansion|fatigue severity|visual analog scale for pain|hospital anxiety and depression scale,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (investigator)|primary purpose: treatment
Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19,TREATNOW,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04372628,NCT04372628,"modified covid ordinal outcomes scale: study day 15|modified covid ordinal outcome scale: study day 8|modified covid ordinal outcome scale: study day 29|proportion of patients hospitalized: day 1 to 29|time to hospitalization day 1 to day 29|time to symptom resolution: day 1 to day 29|all-cause, all-location mortality: day 1 to day 29|oxygen-free days: day 1 to day 29|fever-free days: day 1 to day 29|ventilator-free days: day 1 to day 29|icu-free days: day 1 to day 29|hospital-free days: day 1 to day 29",interventional,"allocation: randomized|intervention model: sequential assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Longitudinal Population-based Observational Study of COVID-19 in the UK Population,COVIDENCE UK,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04330599,NCT04330599,incidence of confirmed covid-19|incidence of probable or suspected covid-19|incidence of covid-19 requiring hospitalisation|incidence of covid-19 requiring ventilatory support|incidence of fatal covid-19|symptom duration per covid-19 episode|symptom severity per covid-19 episode|incidence of seroconversion to sars-cov-2|incidence of recurrent covid-19|eq-5d-3l health-related quality of life score|health care costs associated with incident covid-19|impact of the covid-19 pandemic and the societal response on participants' financial status|incidence of covid-19 on participant's physical health|impact of covid-19 on participants' mental health|impact of covid-19 on physical health of offspring born to participants during follow-up,observational,observational model: cohort|time perspective: prospective
Utility of Lactoferrin as a Preventive Agent for Healthcare Workers Exposed to COVID-19,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04427865,NCT04427865,incidence of sars-cov-2|severity of disease in confirmed infected participants,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19,PENFS COVID-19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04514627,NCT04514627,"hypoxemia via oxygen level, or saturation (spo2) in percent|progression to mechanical ventilation, ecls or death|oxygen requirements|days of hospitalization|time to hospital discharge|time to resolution of fever|days of resting respiratory rate|serious adverse events or patient or worsening condition|erythrocyte sedimentation rate (esr)|c-reactive protein (crp)|ferritin|d-dimer|creatine phosphokinase, total (ck)|troponin|lactate dehydrogenase (ldh)|procalcitonin (pct)|b-type natriuretic peptide (bnp)|n-terminal pro b-type natriuretic peptide (nt-probnp)|interleukin-6 (il-6), high sensitive elisa|complete blood count (cbc) with differential|comprehensive metabolic panel (cmp)|7-point ordinal scale of clinical status|modified borg dyspnea scale (mbs)",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
A Study of Baricitinib (LY3009104) in Participants With COVID-19,COV-BARRIER,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04421027,NCT04421027,"percentage of participants who die or require non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation (including extracorporeal membrane oxygenation [ecmo])|percentage of participants with at least 1-point improvement on niaid-os or live discharge from hospital|number of ventilator-free days|time to recovery|overall improvement on the niaid-os|duration of hospitalization|percentage of participants with a change in oxygen saturation from <94% to ‚â•94% from baseline|mortality|duration of stay in the intensive care unit (icu) in days|time to clinical deterioration (one-category increase on the niaid-os)|time to resolution of fever, in participants with fever at baseline|mean change from baseline on the national early warning score (news)|time to definitive extubation|time to independence from non-invasive mechanical ventilation|time to independence from oxygen therapy in days|number of days with supplemental oxygen use|number of days of resting respiratory rate <24 breaths per minute",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Prevalence of DVT or PE in Patients Infected With COVID-19 Admitted to Hospital,SCREENING,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04380792,NCT04380792,vte events and complications,observational,observational model: other|time perspective: retrospective
Predicting the Need for Intubation in Hospitalised COVID-19 Patients (PRED ICU COVID19),nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04376879,NCT04376879,the number of intubations in covid-19 patients initially hospitalised in wards|the number of intubations in covid-19 patients initially hospitalised in wards.,observational,observational model: cohort|time perspective: prospective
Prognostic Factors in Patients Admitted to an Urban Teaching Hospital With COVID-19 Infection,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04484545,NCT04484545,mortality,observational,observational model: cohort|time perspective: retrospective
Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter,COSA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04361500,NCT04361500,survival|length of icu stay|length of hospital stay|length of ventilator therapy|adverse events,observational,observational model: case-only|time perspective: prospective
Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,HCQ4COV19,completed,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04304053,NCT04304053,study 1- clinical and virological outcome in exposed contacts|study 1- transmission of sars-cov-2 in exposed contacts|study 2- virological outcome in index cases|study 2- clinical outcome in index cases,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19),COLHEART-19,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04355143,NCT04355143,"composite of all-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (mcs)|delta (peak minus baseline) troponin level|delta (baseline to peak) brain natriuretic peptide (bnp) level|change in left ventricular ejection fraction (lvef) on echocardiography|delta (peak minus baseline) c-reactive protein (crp) inflammatory biomarker level|delta (peak minus baseline) d-dimer inflammatory biomarker level|time (days) to primary endpoint|number of participants requiring mechanical ventilation|number of participants requiring mechanical circulatory support (mcs)|re-hospitalization at 90 days|all-cause mortality",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19),nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04480424,NCT04480424,all-cause mortality rate through day 29|time to actual icu discharge|duration of mechanical ventilation|time to actual hospital discharge|duration of any oxygen use|absolute value and mean change from baseline in ordinal scale|percentage of participants in each severity category of the 7-point ordinal scale|overall number of participants who develop acute respiratory distress syndrome (ards)|number of participants who develop ards distributed by severity|change from baseline in sequential organ failure assessment (sofa) score|change from baseline in national early warning score (news)|time to clinical response as assessed by: news ‚â§ 2 maintained for 24 hours,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04362085,NCT04362085,"composite outcome of icu admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days.|all-cause death|composite outcome of icu admission or all-cause death|major bleeding|number of participants who received red blood cell transfusion|number of participants with transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate.|renal replacement therapy|number of hospital-free days alive up to day 28|number of icu-free days alive up to day 28|number of ventilator-free days alive up to day 28|number of organ support-free days alive up to day 28|number of participants with venous thromboembolism|number of participants with arterial thromboembolism|number of participants with heparin induced thrombocytopenia|changes in d-dimer up to day 3",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19),CATCH COVID-19,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04372004,NCT04372004,detection of viral infection using serology and viral-rna detection kits|temporal trend of antibodies in blood,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: diagnostic
High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04351620,NCT04351620,tolerability of high dose hcq as measured by hcq dose modification|tolerability of high dose hcq as measured by discontinuation of hcq|tolerability of high dose hcq as measured by adverse events|rate of hospitalization due to covid-19 as measured by number of patients hospitalized|time to defervescence as measured in days while on treatment protocol|resolution of other covid-19 symptoms measured in days while on treatment protocol,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19,nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04360278,NCT04360278,collection of convalescent plasma,observational,observational model: cohort|time perspective: prospective
"BNP, Serum Troponin and D-dimer as Risk Factors in Patients With COVID-19",nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04433026,NCT04433026,"measurement of n-terminal pro-b type natriuretic peptide, troponin-i and d-dimer in covid-19 patients|cardiac complications in covid-19 patients associated with more adverse effects",observational,observational model: case-only|time perspective: retrospective
Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04319315,NCT04319315,number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice,observational,observational model: other|time perspective: prospective
Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04363216,NCT04363216,clinical improvement|patient status upgraded to icu level [clinical decline]|oxygen supplementation|days with fever|days to discharge|saes,interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
"Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19",nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04403386,NCT04403386,levels of senescent cd16+cd8+ t cells prior to covid-19 disease and time to covid-19 disease morbidity (antibody positvity).,observational,observational model: cohort|time perspective: prospective
A RCT - Safety & Efficacy of Tocilizumab - Tx of Severe COVID-19: ARCHITECTS,ARCHITECTS,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04412772,NCT04412772,clinical status (on a 7-point ordinal scale) at day 28|clinical improvement|mechanical ventilation|oxygenation,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Effect of Vitamin D on Morbidity and Mortality of the COVID-19,COVID-VIT-D,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04552951,NCT04552951,mortality|admission to intensive care unit (icu)|time of hospitalization|clinical changes|radiological changes|calcidiol changes|inflammation markers changes (crp)|inflammation markers changes (il-6)|inflammation markers changes (leucocytes)|inflammation markers changes (d-dimer)|general biochemical parameters changes (creatinine)|general biochemical parameters changes (ferritin)|general biochemical parameters changes (bilirubin)|general biochemical parameters changes (albumin)|general biochemical parameters changes (haemoglobin)|general biochemical parameters changes (hdl cholesterol)|general biochemical parameters changes (procalcitonin)|general biochemical parameters changes (protonin)|general biochemical parameters changes (calcium)|general biochemical parameters changes (phosphate)|general biochemical parameters changes (po2),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: treatment"
Thorax Computed Tomography Severity Score and Outcome in COVID-19 Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04424849,NCT04424849,invasive respiratory support in patients with covid-19|mortality in patients with covid-19,observational,observational model: cohort|time perspective: retrospective
Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,HyAzOUT,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04334382,NCT04334382,hospitalization within 14 days of enrollment|duration of covid-19-attributable symptoms|hospital-free days at 28 days|ventilator-free days at 28 days|icu-free days at 28 days,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04438057,NCT04438057,time to resolution of symptoms|saes within 24 hours of plasma infusion|decrease in inflammatory markers|hospitalization within 28 days,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients,COVID19-HOPE,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04374903,NCT04374903,time to clinical improvement (ttci)|clinical failure defined as death or need for intubation and mechanical ventilation|adverse effects|qt interval prolongation|failure to continue assigned therapy|time to viral clearance,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,COVID'HEMOS,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04367662,NCT04367662,clinical worsening (yes/no) of the patient during hospitalization|d-dimers plasma levels in blood|fibrin monomers plasma levels in blood|antithrombin plasma levels in blood|prothrombin fragment 1 plasma levels in blood|prothrombin fragment 2 plasma levels in blood|thrombin generation test plasma levels in blood|microvesicles of platelet plasma levels in blood|cross-linked platelets plasma levels in blood|willebrand factor plasma levels in blood|factor viii plasma levels in blood,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Assessment of Mental Health in Healthcare Workers Exposed to COVID-19 Patients,BADS-PTSD,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04473118,NCT04473118,"to reflect the effect of covid-19 on the burnout, anxiety, depression and stress levels of healthcare professionals during the covid-19 crisis|to reflect the effect of covid-19 on the post-trauma stress disorder levels of healthcare professionals following the covid-19 crisis",observational,observational model: cohort|time perspective: prospective
Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04463420,NCT04463420,dyspnea|long of hospitalization|radiological treatment response|mortality|allergic drug|laboratory treatment response|o2 saturation without supplemental oxygen|drug reactions adverse,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients,MOPHYDA,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04354597,NCT04354597,effect of hcq and az in preventing infection with covid-19 among healthcare workers working with covid-19 patients|safety of hcq and az|oxygen requirement|icu admission|mortality rate,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,GARGLES,completed,Has Results,phase 2,Other,https://ClinicalTrials.gov/show/NCT04410159,NCT04410159,number of participants with early viral clearance|number of participants with negative rt-pcr results|number of patients that progress to more severe disease|number of patients with abnormal radiological findings|number of patients with abnormal laboratory findings,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19,KONS-COVID19,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04357990,NCT04357990,number of days until complete resolution of symptoms per group|number of hospital admissions per group|number of days until a reduction in symptoms per group|number of adverse events per group,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients,nan,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04393311,NCT04393311,"time to recovery|covid-19 disease severity scale score on day 8|covid-19 disease severity scale score on day 15|covid-19 disease severity scale score on day 22|covid-19 disease severity scale score on day 29|incidence of mortality at day 29|incidence of in-hospital mortality|number of days alive and not on mechanical ventilator or ecmo in the 28 days following first dose|number of patients with resolution of symptoms defined as score of 8 on the 8-point ordinal scale at day 29|number of patients alive and free of respiratory failure defined as score of 4, 5, 6, 7, or 8 on the 8-point ordinal scale at day 29|duration of mechanical ventilation|duration of ecmo|duration of noninvasive ventilation|duration of icu stay|duration of hospital stay|change in oxygen saturation",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04500132,NCT04500132,rate of transition to ards,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
"Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial",CoVUm,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04368013,NCT04368013,mortality,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: screening
Convalescent Plasma as a Possible Treatment for COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04442191,NCT04442191,"oxygen supplementation|28-day and in-hospital mortality rate|number of participants transferred to the intensive care unit (icu)|number of participants intubated|length of hospital stay in days|type of respiratory support|c-reactive protein (crp)|lymphocyte count|length or respiratory support required, in days|lactate dehydrogenase (ldh)|ferritin|d-dimer|white blood cell (wbc) count",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04392414,NCT04392414,"the number and proportion of patients with the normal body temperature (‚â§37.2 c) at the day 1, 2, 3, 4, 5, 6, 7 after the start of therapy|days before mechanical ventilation|days of need for oxygen therapy|days of stay in the icu|days of hospitalization|changes of the titer of the sars-cov-2 antibodies in the blood plasma of patients|dynamics of the cytokine profile|incidence of the cytokine storm development and the need of administering cytokine storm inhibitors|dynamics of the level of c-reactive protein|30-day mortality rate",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19,nan,available,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04358211,NCT04358211,nan,expanded access:intermediate-size population|treatment ind/protocol,nan
Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19,nan,"active, not recruiting",No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04362189,NCT04362189,interleukin-6|c reactive protein|oxygenation|tnf alpha|il-10|return to room air (rtra)|ekg qt interval|leukocyte differential|glucose|calcium|albumin|total protein|sodium|total carbon dioxide|potassium|chloride|bun|creatinine|alkaline phosphatase|alanine aminotransferase|total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|lymphs|monocytes|eosinophils|basophils|absolute neutrophils|absolute lymphs|absolute monocytes|absolute eosinophils|absolute basophils|immature granulocytes|platelets|prothrombin time|inr|nk cell surface antigen (cd3-cd54+)|cd4+/cd8+ ratio|myoglobin|troponin|creatinine kinase mb|serum ferritin|adverse events|7-point ordinal scale|d-dimer|chest x-ray|ct scan|pcr test for sars-cov-2,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,nan,"active, not recruiting",No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04391127,NCT04391127,"mean days of hospital stay|rate of respiratory deterioration, requirement of invasive mechanical ventilation or dead|mean of oxygenation index delta|mean time to viral pcr negativization",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,APN01-COVID-19,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04335136,NCT04335136,all cause-death or invasive mechanical ventilation|ldh level|mortality|vfd|time to death,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients,nan,completed,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04389645,NCT04389645,ip-10 levels,observational,nan
Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients,ETHIC,not yet recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04492254,NCT04492254,hospital admission|death|bleeding (as defined by isth criteria)|diagnosis of vte,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,GO2 PEEP,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04331366,NCT04331366,change in oxygen saturation by pulse oximetry|change in respiratory rate|change in heart rate|change in blood pressure|change in subjective work of breathing|change in partial pressure of oxygen (pao2)|change in partial pressure of carbon dioxide (paco2)|change in ph|change in bicarbonate (hco3)|change in oxygen saturation (o2sat) by arterial blood gas test,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04457726,NCT04457726,"dose-limiting toxicities|national early warning score (news)|time to improvement by one category on a who ordinal scale|time-to-sars-cov-2 negativity after infusion of sars-cov-2 specific t cells|duration of persistence of sars-cov-2 specific t cells in the recipient's blood circulation|time-to-normalization of cytokine level, lymphocyte subsets, and gene transcriptome after t cell infusion|overall survival (os) at 3 months after infusion of sars-cov-2 specific t cells",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19,nan,"active, not recruiting",No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04358549,NCT04358549,time to viral clearance|status of clinical recovery as measured by the study-specific 6-point ordinal scale on day 15|clinical effect of favipiravir + soc compared to soc measured by the national early warning score 2 (news2)|characterize the pharmacokinetics (pk) of favipiravir in plasma: cmax)|characterized the pharmacokinetics (pk) of favipiravir in plasma: cmin|characterized the pharmacokinetics (pk) of favipiravir in plasma: auc,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Convalescent Plasma for the Treatment of Patients With COVID-19,nan,no longer available,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04372368,NCT04372368,nan,expanded access:treatment ind/protocol,nan
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,CATCO,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04330690,NCT04330690,efficacy of interventions as assessed by all-cause mortality|time to improvement of one category from admission|subject clinical status|change in subject clinical status|oxygen free days|incidence of oxygen use|duration of oxygen use|incidence of new mechanical ventilation|duration of mechanical ventilation|duration of hospitalization|mortality|cumulative incidence of grade 3 and 4 adverse events (aes) and serious adverse events (saes),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
XPro1595 for the Treatment of Pulmonary Complications From COVID-19,nan,not yet recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04370236,NCT04370236,"proportion of participants with disease progression from randomization to 28 days post-randomization|proportion of participants with all-cause mortality|proportion of participants who transfer to icu level care by day 28 (icu level care is defined as a hospital setting where patient to nurse ratio is < 4);|proportion of participants with a new onset of neurologic disease (requiring medical intervention), including stroke by day 28;|proportion of participants with evidence of new chf or new mi requiring medical intervention by day 28;|proportion of participants with a new onset embolus or thrombus by day 28;|proportion of participants who develop a need for renal replacement therapy (defined as need for any type of dialysis including intermittent or continuous peritoneal or hemodialysis) by day 28;|proportion of participants with an increase in the who ordinal scale of clinical improvement score at any time during the study;|length of hospital stay defined as the number of days in hospital from time of randomization to time of discharge or death, whichever occurs first;|change from baseline in inflammation markers over time.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Feasibility and Safety of High-intensity Exercise Training in Patients Surviving COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04549337,NCT04549337,10-point likert scale|participant adherence to the training dose|participant adherence to the training intensity|adverse effects|rate of perceived exertion|post covid-19 functional scale,interventional,"allocation: randomized|intervention model: crossover assignment|masking: double (participant, outcomes assessor)|primary purpose: prevention"
Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation,nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04456452,NCT04456452,incidence and severity of adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia,CORTICOVIDHUGO,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04359511,NCT04359511,"clinical improvement defined by the improvement of 2 points on a 7-category ordinal scale, at 14 days.|proportion of patients free of oxygen at day 14 and 28|proportion of patients discharged alive from hospital at day 14 and 28|time to discharge for patients alive|proportion of patients that were hospitalized to icu or who died at day 14 and 28|14 and 28 day mortality rate|the time until weaning from oxygen therapy|the proportion of patients with clinical degradation of at least 1 point on the ordinal scale to 7 categories on d14 and d28",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19),nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04396106,NCT04396106,proportions (active vs. placebo) of subjects with progressive respiratory insufficiency.|proportions (active vs. placebo) of subjects experiencing treatment-emergent adverse events|time to clinical recovery|proportions (active vs. placebo) of subjects with respiratory failure or death,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",COVIDOSE,completed,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04331795,NCT04331795,clinical response|biochemical response|overall survival|survival to hospital discharge|progression of covid-19 pneumonitis|rate of non-elective mechanical ventilation|duration of mechanical ventilation|time to mechanical ventilation|rate of vasopressor/inotrope utilization|duration of vasopressor/inotrope utilization|time to vasopressor or inotropic utilization|number of icu days|duration of increased supplemental oxygen requirement from baseline,interventional,allocation: non-randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,nan,"active, not recruiting",No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04333225,NCT04333225,rate of covid-19 positive conversion|time-to-first clinical event,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Austrian CoronaVirus Adaptive Clinical Trial (COVID-19),ACOVACT,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04351724,NCT04351724,"sustained improvement (>48h) of one point on the who scale|time to improvement on who scale|mean change in the ranking on an ordinal scale from baseline|time to discharge or a national early warning score (news) ‚â§2 (maintained for 24h), whichever occurs first|change from baseline in national early warning score (news)|oxygenation free days|incidence of new oxygen use during the trial|duration of oxygen use during the trial|ventilator free days until day 29|incidence of new mechanical ventilation use during the trial|duration of mechanical ventilation use during the trial|viral load/viral clearance|duration of hospitalization|mortality|obesity - mortality|obesity - duration of hospitalization|obesity - icu admission|obesity - new oxygen use|drug-drug interactions with lopinavir/ritonavir|renin angiotensin system (ras) fingerprint",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04452617,NCT04452617,occurrence of severe cardiac arrhythmia: torsade de pointes and cardiac arrest or sudden death|assessment of qtc interval prolongation during the treatment period compared to baseline ecg,observational,observational model: cohort|time perspective: retrospective
Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease,nan,"active, not recruiting",No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04429867,NCT04429867,impact of hydroxychloroquine in hospitalized patients with covid-19 and risk factors for severe/critical disease.|hospital length of stay|30-day mortality|resolution of symptoms|incidence of qtc >500ms after initiation of therapy|incidence of discontinuation of therapy,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,RCT,"active, not recruiting",No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04344444,NCT04344444,most severe outcome,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Clazakizumab vs. Placebo - COVID-19 Infection,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04494724,NCT04494724,primary endpoint|requirement for mechanical ventilation and/or extracorporeal membrane oxygenation (ecmo)|infusion-related reactions during 24 hours from the time of infusion|patient survival at 28 days|patient survival at 60 days|requirement for open-label clazakizumab|time in the intensive care unit (icu)|time in the hospital|time to mechanical ventilation|clinical status improvement assessed by the world health organization (who) clinical progression scale at day 14|clinical status improvement assessed by world health organization (who) clinical progression scale at day 28|change in radiologic assessment of lung edema (rale) at day 14|change in radiologic assessment of lung edema (rale) at day 28,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04405843,NCT04405843,time to event|clinical condition on day 2|clinical condition on day 5|clinical condition on day 8|clinical condition on day 11|clinical condition on day 15|clinical condition on day 21|proportion of subjects with additional care|proportion of subjects who die|duration of additional care|adverse events|proportion of subjects who discontinue intervention,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
A Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19Ôºâ,nan,not yet recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04425772,NCT04425772,"change (reduction) in viral load from baseline|proportion of subjects change from mild or moderate type to severe type|proportion of subjects change from severe type to critical type|novel coronavirus nucleic acid conversion rate|novel coronavirus nucleic acid negative conversion time|the time and proportion of improvement in pulmonary imaging|time and proportion of temperature return to normal|time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.)|time and rate of improvement of diarrhea, myalgia, fatigue and other symptoms|changes of blood oxygen detection index|frequency of requirement for supplemental oxygen or non-invasive ventilation|frequency of adverse events",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial,DISTANSE COVID,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04359264,NCT04359264,"symptoms consisent with covid-19|number of close contacts|number of participants with positive test for covid-19|self-reported health based on the single question: ""in general, would you say your health is..""|ability to make ends meet based on the single question: ""at the end of the month, are you able to make ends meet?""",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: prevention"
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04377659,NCT04377659,progression of respiratory failure or death,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,CYTOCOV-19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04344080,NCT04344080,percentage of patients with a significant stabilization of hemodynamics for at least 24 hours|change in organ dysfunction|lactate clearance|renal replacement therapy|extracorporeal membrane oxygenation|icu length of stay|time on mechanical ventilation|cumulative catecholamine dose|overall and icu mortality|change of plasma interleukin-6 (il6) level|change of plasma interleukin-10 (il10) level|change of plasma procalcitonin (pct) level|change of hla-dr level|change of tnf alpha level after ex-vivo stimulation,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Immune Profiling of COVID19-patients Admitted to ICU,IMPROVISE,recruiting,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04473131,NCT04473131,to create an immune profile for each covid19-positive patient during their icu stay|to correlate patients' immune profile to disease severity and patient's outcome,observational,observational model: cohort|time perspective: prospective
Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients,nan,not yet recruiting,No Results Available,phase 1|phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04352465,NCT04352465,change in clinical conditions|change of clinical symptoms - respiratory rate|hypoxia|changes of blood oxygen|inflammatory parameters|evolution of acute respiratory syndrome|hospital discharge|icu discharge|rate of mortality,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses,BLEEDING,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04380779,NCT04380779,bleeding events and complications,observational,observational model: other|time perspective: retrospective
Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04474457,NCT04474457,"time to recovery (discharge)|decrease in viral load|adverse event (ae), serious adverse event (sae) and discontinuation of treatment|frequency of occurrence of lymphopenia from baseline|frequency of occurrence of thrombocytopenia from baseline|changes in alanine aminotransferase (alt) levels from baseline|changes in aspartate aminotransferase (ast) levels from baseline|changes in c-reactive protein (crp) levels from baseline|changes in level of d-dimer levels from baseline|changes in prothrombin time (pt) values from baseline|changes in partial thromboplastin time (ptt) values from baseline|changes in blood pressure from baseline|changes in respiratory rate from baseline|changes in pulse oximetry from baseline|changes in fever from baseline",observational,observational model: cohort|time perspective: prospective
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04486313,NCT04486313,reducing the time to sustained response|reducing the rate of progression,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
"Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia",nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04348448,NCT04348448,intensive care treatment|icu stay times|% died after 1 month after treatment|hospitalization|adverse event,observational,observational model: cohort|time perspective: prospective
COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses,SEROBL-COVID19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04483908,NCT04483908,qualitative method validation (yes/ no)|quantitative method validation (antibody concentrations)|immune cell repertoire sequencing,observational,observational model: cohort|time perspective: prospective
Natural Language Processing (NLP) Analysis of Free Text Notes to Investigate Coronavirus (COVID-19),nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04432961,NCT04432961,research database of ehr records from covid-19 patients processed using nlp tools for named entity recognition and linking adapted to cuh emr data to identify variables of interest|a set of annotation guidelines to produce human-expert (gold) labelled data for a subset of the ehr|a comparison of the nlp output to terms in the structured problem list to identify missing terms in the structured problem list,observational,observational model: case-only|time perspective: retrospective
Registry of CytoSorb Therapy in COVID-19 ICU Patients,CTC REGISTRY,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04391920,NCT04391920,icu mortality|duration of ecmo after start of cytosorb|duration of mechanical ventilatory support after start of cytosorb|duration of pharmacologic hemodynamic support after start of cytosorb|change in serum concentrations of inflammatory biomarkers after start of cytosorb,observational,observational model: cohort|time perspective: prospective
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise,VENTED,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04427566,NCT04427566,"mortality rate of subjects treated with whole lung low-dose radiation|survival rate of subjects treated with whole lung low-dose radiation|change in number of intensive care unit days|change in number of days using supplemental oxygen|change in oxygenation index/oxygen saturation index for 14 days post treatment or until extubated|quantitation of lung involvement using chest ct|quantitation of lung opacities using chest ct|sars-cov2 viral titers|incidence of adverse events, including severity and duration, for administration of low dose radiation to lungs|change in performance status after low dose radiation to lungs",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
A Phase 1 Study to Assess BAT2020 in Hospitalized Patients Infected With SARS-CoV-2 (COVID-19),nan,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04432766,NCT04432766,"incidence of adverse events (aes)|duration of survival and free of respiratory failure|percentage of patients reporting each severity rating on an 8-point ordinal scale|change in national early warning score (news) from baseline|frequency of respiratory progression|number of participants with treatment-related adverse events as assessed by oropharyngeal swabs, nasopharyneal and blood samples for virology|cumulative incidence of grade 3 and 4 adverse events (aes)|grade 4 aes are defined as events that are potentially life threatening|cumulative incidence of serious adverse events (saes)|duration of hospitalization|duration of new non-invasive ventilation or high flow oxygen use|duration of new oxygen use|duration of new ventilator or extracorporeal membrane oxygenation (ecmo) use|incidence of new non-invasive ventilation or high flow oxygen use|incidence of new oxygen use|incidence of new ventilator or extracorporeal membrane oxygenation (ecmo) use|number of non-invasive ventilation/high flow oxygen free days|number of oxygenation free days|ventilator/extracorporeal membrane oxygenation (ecmo) free days|subject 28-day mortality|viral load change from baseline",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04382586,NCT04382586,respiratory failure-free survival rate at day 28|median reduction in days spent on supplemental oxygen|all-cause mortality|proportion of participants experiencing respiratory failure or death|mechanical ventilation-free survival|days on mechanical ventilation|duration of hospitalization|time to discharge|pao2:fio2 and/or oxygenation index|change from baseline to day 14 in who - 8 point ordinal scale,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04429711,NCT04429711,viral clearance at day 6|viral shedding duration|symptoms clearance time,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients.,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04365634,NCT04365634,"find the prediction factors associated with hospitalized death of patients with covid-19 by univariate and multivariate analysis|demographics and clinical characteristics|laboratory parameters and radiography image features|treatment, complications and clinical outcomes",observational,observational model: case-control|time perspective: retrospective
PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04347954,NCT04347954,mean change in viral titers of sars-cov-2|frequency of adverse effects of interest after nasal sprays|frequency of symptoms related to sars-cov-2|compliance with study drug administration|change from baseline in university of pennsylvania smell identification test (upsit),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19,nan,not yet recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04536090,NCT04536090,changes in viral load from baseline to end of treatment - mean viral load|changes in viral load from baseline to end of treatment - area under the viral load vs. time profiles|changes in viral load from baseline to end of treatment - time profiles of viral load|changes in viral load from baseline to end of treatment - time to viral negativity|time to clinical recovery|all-cause mortality|progression to supplementary oxygen requirement|incidence of mechanical ventilation|incidence of icu admission|time to hospital discharge|changes in serum c reactive protein levels (crp)|changes in d-dimer levels|changes in soluble low-density lipoprotein receptor (sldlr) expression and proprotein convertase subtilisin/kexin type 9 (pcsk9) and soluble angiotensin converting enzyme 2 (sace2) levels|changes in ldl-cholesterol|changes in creatinine|changes in liver enzymes,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),nan,terminated,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04307693,NCT04307693,"viral load|viral load change|time to clinical improvement (ttci)|percentage of progression to supplemental oxygen requirement by day 7|time to news2 (national early warning score 2) of 3 or more maintained for 24 hours by day 7|time to clinical failure, defined as the time to death, mechanical ventilation, or icu admission|rate of switch to lopinavir/ritonavir or hydroxychloroquine by day 7|adverse effects|concentration of lopinavir/ritonavir and hydroxychloroquine",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04344236,NCT04344236,viral load (and/or cycle time to pcr as a proxy for quantitative viral load) in the nasopharynx and oropharynx|oxygen requirement of the patient|oxygen saturation of the patient,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19,nan,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04385849,NCT04385849,preliminary safety and efficacy evaluation of n-803 by adverse event (ae) incidence|preliminary safety and efficacy evaluation of n-803 by subject clinical status using a the 7-point ordinal scale.|preliminary safety and efficacy evaluation of n-803 by changes in lymphocyte counts|further evaluate efficacy of n-803 using changes to the national early warning score (news)|further evaluate the safety of n-803 using change from baseline in hemoglobin|further evaluate the safety of n-803 using change from baseline in platelets|further evaluate the safety of n-803 using change from baseline in white blood cell count,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Short-term Physical Function Outcomes in Severe COVID-19 Patients Admitted to ICU for Invasive Mechanical Ventilation,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04400461,NCT04400461,medical research council sum score (mrc- ss).|the functional status score for the icu (fss-icu)|age|sex|body mass index|baseline mobility|apache ii score|length of stay in icu|number of days on mechanical ventilation|polyneuropathy diagnosis|number of days on neuromuscular blockers|episodes of prone positioning|length of stay in hospital|continuation of care,observational,observational model: cohort|time perspective: cross-sectional
Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19,COVID19,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04467047,NCT04467047,overall survival|changes on inflammatory c-reactive protein|hospital stay|oxygenation index (pao2/fio2)|improvement in liao's score (2020)|radiological improvement|time of covid19 pcr negativity,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection,nan,recruiting,No Results Available,phase 3,Industry|Other,https://ClinicalTrials.gov/show/NCT04363814,NCT04363814,clinical recovery|clinical worsening|clinical severity|time to symptoms remission|medication use|hospitalization time|blood routine test|heart rate|blood pressure|cardiac auscultation|oxygen saturation|adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,CORONA,"active, not recruiting",No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04397562,NCT04397562,mortality rate|7-point ordinal scale|duration of hospital stay|rate of subjects required icu stay|duration of icu stay|rate of subjects with covid-19 progression to critical (respiratory failure required invasive ventilation or septic shock or multiple organ failures|rate of subjects requiring the rescue therapy|duration of oxygen supplementation|rate of subjects requiring the invasive ventilation|duration of invasive ventilation,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients,OAHU-COVID19,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04345692,NCT04345692,i. clinical status|oxygenation|mechanical ventilation|hospitalization|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study),nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04364763,NCT04364763,"evaluate the effect of rbt-9 versus placebo on clinical status of covid-19 patients as measured using the 8-point world health organization (who) ordinal clinical scale|time to first occurrence of death from any cause or new/worsened organ dysfunction|all-cause survival|oxygen saturation (spo2)/fraction of inspired oxygen (fio2) ratio|fever incidence|acute kidney injury (aki) incidence|new or worsening congestive heart failure (hf)|hospitalization status|ventricular tachycardia or fibrillation lasting at least 30 seconds and/or associated with hemodynamic instability or pulseless electrical activity, or resuscitated cardiac arrest|oxygen-free days|intensive care unit (icu) status|days on ventilator|time to and duration of vasopressor or inotrope utilization|dialysis status",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,CAPSID,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04433910,NCT04433910,"composite endpoint of survival and no longer fulfilling criteria of severe covid-19.|time to clinical improvement|frequency and severity of adverse events by ctcae v5.0, (key secondary endpoint)|case fatality rate|length of hospital stay length of hospital stay (if applicable)|length of stay in icu|duration of ventilation support / ecmo|time until negative sars-cov-2 pcr (nasopharyngeal sample)|predictive value of comorbidities|predictive value of coagulation markers|predictive value of inflamation|percentage of former covid-19 patients willing to donate qualifying for plasma donation.|amount of plasma units that could be collected for the clinical trial|titer of anti-sars-cov-2 in transfused plasma units|impact of donor characteristics on anti-sars-cov-2 humoral response|course of anti-sars-cov-2 titer in both patient groups at different time points related to transfusion of convalescent plasma|correlation of anti-sars-cov-2 titer in transfused plasma units and primary and key secondary outcomes.|effect of timing of plasma transfusions",interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: treatment
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,nan,completed,No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04411628,NCT04411628,number of participants with one or more serious adverse event(s) (saes) considered by the investigator to be related to study drug administration|pharmacokinetics (pk): area under the concentration-time curve (auc) of ly3819253|pharmacodynamics (pd): change from baseline to day 29 in viral load,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: basic science"
Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization,HITCH,recruiting,No Results Available,phase 2,U.S. Fed,https://ClinicalTrials.gov/show/NCT04397718,NCT04397718,"a composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ecmo) at day 15 after randomization.|time to clinical improvement|inpatient mortality|duration of hospitalization|duration of intubation for mechanical ventilation.|time to normalization of temperature.|maximum severity of covid19 illness.|a composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ecmo) at day 30 after randomization.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,COVID-Lambda,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04331899,NCT04331899,duration of viral shedding of sars-cov-2 by qrt-pcr,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
"Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19",ARCHAIC,terminated,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04362332,NCT04362332,composite endpoint with disease progression defined as a news2score ‚â• 7 within 14 days or resulting in admission to intensive/medium care unit or resulting in death within 14 days.|side effects,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Non-contact ECG Sensor System for COVID19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04341506,NCT04341506,ecg changes associated with covid-19,observational,observational model: cohort|time perspective: prospective
Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death,nan,withdrawn,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04323631,NCT04323631,number patients developing severe infection or death,interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04434131,NCT04434131,correlation between the nab dose titer in the convalescent plasma and change or lack of change when comparing pre-treatment and day one nab titers to inpatients with documented coivd-19 infection|rapid deterioration as evidenced by increase in ordinal or news score within 4 hours of transfusion|number of participants with clearance of viral shedding of sarscov-2 in nasopharyngeal or nasal samples,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,BLAZE-1,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04427501,NCT04427501,"change from baseline to day 11 in severe acute respiratory syndrome coronavirus 2 (sars-cov-2) viral load|percentage of participants with sars-cov-2 viral load greater than a prespecified threshold|change from baseline to day 11 in sars-cov-2 viral load among participants enrolled with recent symptoms prior to randomization|percentage of participants demonstrating symptom resolution|percentage of participants demonstrating symptom improvement|pharmacokinetics (pk): mean concentration of ly3819253 and ly3819253 in the presence of ly3832479|pk: mean concentration of ly3832479 in the presence of ly3819253|percentage of participants who experience covid-related hospitalization, covid-related emergency room (er) visit, or death|change from baseline to day 7 in sars-cov-2 viral load|percentage of participants enrolled with recent symptoms prior to randomization who experience covid-related hospitalization, covid-related er visit, or death",interventional,"allocation: randomized|intervention model: sequential assignment|masking: double (participant, investigator)|primary purpose: treatment"
Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,PrEP_COVID,suspended,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04331834,NCT04331834,"confirmed cases of a covid-19|sars-cov-2 seroconversion|occurrence of any adverse event related with hydroxychloroquine treatment|incidence of sars-cov-2 infection and covid-19 among healthcare workers|risk ratio for the different clinical, analytical and microbiological conditions to develop covid-19|covid-19 biobank",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Characterizing the Perioperative Epidemiology of SARS-CoV-2 (COVID-19) Spread for Quality Improvement of Perioperative Infection Control Program,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04443803,NCT04443803,perioperative transmission of sars-cov-2,observational,observational model: case-only|time perspective: prospective
Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk,PREVENT,withdrawn,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04371926,NCT04371926,time to reach normal body temperature|development of covid-19 symptoms during hcq preventive therapy in staff|covid-19 test result at follow-up in patients|worsening of symptoms in covid-19 patients,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (investigator)|primary purpose: prevention
Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults,nan,not yet recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04386252,NCT04386252,confirm safety|suggestion of efficacy|optimal dose of sars-cov-2 antigen|advantage of administering vaccine admixed with gm-csf|frequency of detecting igg against sars-cov-2 in blood after vaccination,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
"Coronavirus Disease 2019 (COVID-19) During Pregnancy: Prevalence of Seroconversion, Effect on Maternal and Perinatal Outcomes and Risk of Vertical Transmission (COVID-MAP)",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04465474,NCT04465474,"seroconversion during pregnancy - dss1|seroconversion during pregnancy - at delivery|pregnancy loss|pregnancy course and perinatal outcome|vertical transmission|potential mechanisms for vertical transmission 1) placental barrier, 2) immune response and 3) fetal damage of vertical transmission and mechanism in sars-cov-2 infection.",observational,observational model: other|time perspective: other
Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04313322,NCT04313322,clinical outcome|ct scan|rt-pcr results,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19",nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04542850,NCT04542850,the incidence of treatment emergent adverse events (safety and tolerability) of 5-ala-phospate + sfc in patients with acute moderate or severe respiratory illness secondary to infection with sars-cov-2 virus (covid-19).|sum covid-19 modified ordinal scale for clinical improvement maximum daily score over 28 days of dosing for moderate group and for severe group|rate of change in covid-19 modified ordinal scale for clinical improvement maximum daily score over 28 days of dosing for individual subjects in moderate group and in severe group|patient and subgroup profile of covid-19 modified ordinal scale for clinical improvement score vs. days hospitalized|overall survival|results of investigator¬¥s assessment of patient¬¥s oxygen therapy|results of mechanical ventilation settings|results of duration of ventilation|the time to resolution of patient¬¥s symptoms|results of patient¬¥s oxygen saturation (respiratory parameters)|length of hospitalization|the total time in icu|results of investigator¬¥s assessment of patient¬¥s condition using (q)sofa score|results of patient¬¥s pt parameter|results of patient¬¥s d-dimer parameter|results of patient¬¥s ptt parameter|results of patient¬¥s sars-cov-2 viral load status (efficacy)|results of patient¬¥s procalcitonin level.|results of patient¬¥s il-6 level|results of patient¬¥s serum ferritin level|results of patient¬¥s c-reactive protein (crp) level|results of patient¬¥s t helper cells (cd4/cd8) level.|results of patient¬¥s bilirubin level.|results on patient¬¥s leucocytes|results on patient¬¥s neutrophils|results on patient¬¥s lymphocyte|results on patient¬¥s platelets|results on patient¬¥s hemoglobin|results on patient¬¥s albumin|results on patient¬¥s ast|results on patient¬¥s alt|results on patient¬¥s total bilirubin|results on patient¬¥s blood urea nitrogen|results on patient¬¥s serum creatinine|results on patient¬¥s creatinine kinase|results on patient¬¥s ldh|results on patient¬¥s myoglobin glucose|results on patient¬¥s aptt|results on patient¬¥s urine|results on hepatic function|results on patient¬¥s renal function|results on patient¬¥s iron parameters|results on patient¬¥s physical examination|results on patient¬¥s co-infections|results on patient¬¥s care level|results on patient¬¥s mean arterial pressure(map)|results on patient¬¥s heart rate (hr)|results on patient¬¥s respiratory rate (rr)|results on patient¬¥s 12-lead ecg|organ damage,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734‚Ñ¢) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04501952,NCT04501952,composite endpoint measuring proportion of participants hospitalized or death from any cause by day 14.|proportion of participants experiencing treatment-emergent adverse events|all-cause mortality at day 28|rate of hospitalization by day 28|time-weighted average change in severe acute respiratory syndrome coronavirus (sars-cov-2) viral load from baseline to day 7|time to resolution of covid-19-related symptoms|proportion of participants progressing to requiring oxygen supplementation by day 28,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04313023,NCT04313023,severity of covid-19|incidence of sars-cov-2 infection|icu admission|mechanical ventilation|mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04336254,NCT04336254,ttci|lung lesion|immune function|time of sars-cov-2 clearance|blood test|spo2|rr|body temperature|side effects in the treatment group|c-reactive protein (mg/l),interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
"Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19",nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04466280,NCT04466280,pcr test|laboratory treatment response|drug reactions adverse|allergic drug|radiological treatment response,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: prevention"
Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals,PROFISCOV,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04456595,NCT04456595,incidence of covid-19 cases after two-doses immunization schedule|frequency of adverse events up to seven days after immunization|incidence of covid-19 cases after 14-days of first immunization|incidence of covid-19 cases after 14-days of last immunization|combined incidence of sars-cov-2 infection|frequency of adverse events up to 28 days after immunization|incidence of severe covid-19 cases|seroconversion rate|cell-mediated immune profile,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19",TOCOVID,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04332094,NCT04332094,in-hospital mortality|need for mechanical ventilation in the intensive care unit,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734‚Ñ¢) in Participants With Severe Coronavirus Disease (COVID-19),nan,completed,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04292899,NCT04292899,the odds of ratio for improvement on a 7-point ordinal scale on day 14|proportion of participants experiencing any treatment-emergent adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection,PREPCOV,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04481633,NCT04481633,rate of patients with positive anti-covid19 serology|rate of patients with symptomatic or severe (hospitalization) form of infection,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19,#StayHome,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04385264,NCT04385264,"proportion of poor outcomes (in index cases)|secondary household attack rate (in household contacts)|subjective disease severity (in index cases)|rate of acute respiratory distress syndrome (in index cases)|severity of radiological lung pathology (in index cases)|objective disease severity (in index cases)|safety: unintended toxic hcq accumulation (in index cases)|safety: adverse events (in index cases)|social distancing knowledge, attitudes and practices amongst index cases and household contacts",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04370782,NCT04370782,time to resolution of symptoms relative to baseline (day 1 of trial)|number of participants hospitalized and/or requiring repeat er visits|icu length of stay|ventilator|severity of symptoms|number of participants with adverse events due to drug regimen|number of participants with qtc prolongation >500ms,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation",nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04539262,NCT04539262,time-weighted average change from baseline in severe acute respiratory syndrome coronavirus 2 (sars-cov-2) viral load through day 7|proportion of participants experiencing any treatment-emergent adverse events|proportion of participants experiencing any treatment-emergent graded laboratory abnormalities|proportion of participants experiencing any treatment-emergent adverse events leading to study treatment discontinuation|proportion of participants progressing from early stage coronavirus disease 2019 (covid-19) to hospitalization or death by day 14|pharmacokinetic (pk) parameter: auc0-24h of remdesivir (rdv) and its metabolites (gs-441524 and gs-704277)|pk parameter: auclast of rdv and its metabolites (gs-441524 and gs-704277)|pk parameter: clss/f of rdv and its metabolites (gs-441524 and gs-704277)|pk parameter: t1/2 of rdv and its metabolites (gs-441524 and gs-704277)|pk parameter: vz/f of rdv and its metabolites (gs-441524 and gs-704277)|pk parameter: cmax of rdv and its metabolites (gs-441524 and gs-704277)|pk parameter: tmax of rdv and its metabolites (gs-441524 and gs-704277)|pk parameter: clast of rdv and its metabolites (gs-441524 and gs-704277)|pk parameter: tlast of rdv and its metabolites (gs-441524 and gs-704277)|pk parameter: auctau of rdv and its metabolites (gs-441524 and gs-704277)|pk parameter: œªz of rdv and its metabolites (gs-441524 and gs-704277)|pk parameter: ctau of rdv and its metabolites (gs-441524 and gs-704277)|change in sars-cov-2 viral load from baseline to day 4|change in sars-cov-2 viral load from baseline to day 7|change in sars-cov-2 viral load from baseline to day 14|time to negative sars-cov-2 polymerase chain reaction (pcr),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04312997,NCT04312997,severity of covid-19|sars-cov-2 infection|severity of covid-19 over 14 days|severity of covid-19 symptoms|icu admission|mechanical ventilation|mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19",nan,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04334980,NCT04334980,frequency of adverse events|immune response against sars-cov-2 spike protein|incidence of covid-19 infection|bactrl-spike in stool post-vaccination|immunity against sars-cov-2,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04377711,NCT04377711,"percentage of patients hospital admission or death by day 30|all-cause mortality by day 30|covid-19-related mortality by day 30|percentage of patients with subsequent emergency department visit or hospital admission for reasons attributable to covid 19 by day 30|time to hospital admission or death|time to alleviation of covid-19-related symptoms of cough, dyspnea, chills, and feeling feverish, defined as symptom-free for a continuous period of more than 24 hours (ie, > 3 am/pm assessments)|change from baseline in oxygen saturation levels|change from baseline in covid-19 viral load in nasopharyngel sample nasal secretions at day 30|safety will be assessed based on adverse events.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19,nan,recruiting,No Results Available,not applicable,Industry|Other,https://ClinicalTrials.gov/show/NCT04348409,NCT04348409,viral load|evolution of acute respiratory syndrome|change in clinical condition|hospital discharge|rate of mortality within 21-days|need of mechanical ventilation,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Establishment of a Biological Collection During COVID-19 Serological Screening in APHP Professionals (COVID-HOP),COVID-HOP,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04418375,NCT04418375,"identification of markers associated with asymptomatic covid + status (results of the serological test) versus symptomatic covid + status through a questionnaire (medical history, work environment, lifestyle) and a biological collection|identification of markers associated with a positive or a negative serology through a questionnaire (medical history, work environment, lifestyle) and a biological collection|description of the serological status according to the professional risk of exposure to the virus|description of the clinical manifestations of covid-19 infection in hospital professionals|identification of risk factors associated with the loss of anti sars-cov-2 immunity through a questionnaire (medical history, work environment, lifestyle) and a biological collection|identification of markers associated with symptomatic covid-19 infection during follow-up despite the presence of anti sars-cov-2 antibodies through a questionnaire (medical history, work environment, lifestyle) and a biological collection|correlation between the serology result and the pcr result (swabs) for people who have been tested as part of routine care.|identification of potential therapeutic targets to avoid developing a symptomatic form|identification of potential therapeutic targets to promote the maintenance of an anti sars-cov2 protective immunity|creation of covidneg and covid + asymptomatic control groups for other covid-19 biological collections.",observational,observational model: cohort|time perspective: prospective
Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19,nan,not yet recruiting,No Results Available,phase 3,Industry|Other,https://ClinicalTrials.gov/show/NCT04353518,NCT04353518,number of subject acquiring covid-19 infection|incidence of adverse event and serious adverse event (safety and tolerability)|number of subject developing upper respiratory tract infection (urti) symptoms|number of subject developing severe covid-19 infection based on ordinal scale,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04360551,NCT04360551,maximum clinical severity of disease|incidence of treatment emergent adverse events|renin angiotensin system peptides|plasma biomarkers,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04343989,NCT04343989,cumulative incidence of serious adverse events associated with clazakizumab or placebo|cumulative incidence of intubation|time to extubation|length of icu stay|number of patients who present a decrease in c-reactive protein|patient survival,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients,I-SPY_COVID,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04488081,NCT04488081,identify agents that will result in substantial improvements to the clinical condition of participants with covid-19|improvement in disease severity|health care utilization|frequency of serious aes|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients,CAPRI,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04421404,NCT04421404,mechanical ventilation or death endpoint|8-point ordinal scale endpoint,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19",nan,enrolling by invitation,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04348435,NCT04348435,incidence of hospitalization for covid-19|incidence of symptoms associated with covid-19|absence of upper/lower respiratory infection|leukocyte differential|c reactive protein|tnf alpha|il-6|il-10|glucose|calcium|albumin|total protein|sodium|total carbon dioxide|potassium|chloride|bun|creatinine|alkaline phosphatase|alanine aminotransferase|total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|lymphs|monocytes|eosinophils|basophils|absolute neutrophils|absolute lymphs|absolute monocytes|absolute eosinophils|absolute basophils|immature granulocytes|platelets|prothrombin time|inr|sf-36|phq-9,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19,nan,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04460183,NCT04460183,proportion of participants who progress to level >4 of modified who ordinal scale due to covid-19 by day 14|change in room air oxygen saturation (spo2) from baseline over time|change in national early warning score (news) 2 symptom score from baseline over time|change from baseline on the modified who ordinal scale at each visit up to day 28|time to improvement to a lower level (<4) of modified who ordinal scale|time to progression to a higher level (>4) of modified who ordinal scale|number of participants with adverse events and serious adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19,nan,suspended,No Results Available,early phase 1,Industry,https://ClinicalTrials.gov/show/NCT04329572,NCT04329572,"evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability|viral load|change in clinical condition|evolution of acute respiratory syndrome|hospital discharge|rate of mortality within 28-days",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Tetrandrine Tablets Used in the Treatment of COVID-19,TT-NPC,enrolling by invitation,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04308317,NCT04308317,survival rate|body temperature,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734‚Ñ¢) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)",CARAVAN,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04431453,NCT04431453,proportion of participants experiencing any treatment-emergent adverse events|proportion of participants experiencing any treatment-emergent graded laboratory abnormalities|plasma concentrations of remdesivir (rdv) and metabolites|change from baseline in oxygenation use|change from baseline in the use of mechanical ventilation or extracorporeal membrane oxygenation (ecmo)|clinical improvement on a 7-point ordinal scale|time (days) to discharge from hospital|days to first confirmed negative polymerase chain reaction (pcr) result|change from baseline in severe acute respiratory syndrome coronavirus (sars-cov-2) viral load|bilirubin concentrations in < 14-day-old participants|clinical improvement based on scoring using the pediatric early warning score (pews) improvement scale|plasma concentrations of sulfobutylether œ≤-cyclodextrin sodium (sbecd)|proportion of participants with concomitant use of medications other than rdv for treatment of coronavirus disease 2019 (covid-19),interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734‚Ñ¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,nan,completed,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04292730,NCT04292730,the odds of ratio for improvement on a 7-point ordinal scale on day 11|proportion of participants experiencing treatment-emergent adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial,nan,recruiting,No Results Available,phase 4,Industry,https://ClinicalTrials.gov/show/NCT04445935,NCT04445935,p/f ratio|kidney function,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: supportive care"
Flow Controlled Ventilation in ARDS Associated With COVID-19,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04399317,NCT04399317,arterial oxygen partial pressure (pao2),interventional,"allocation: randomized|intervention model: factorial assignment|masking: double (participant, outcomes assessor)|primary purpose: treatment"
Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic,PAPESCO-19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04421625,NCT04421625,"establishment of a clinical basis for to describe the number and severity of covid-19 infections in cancer centres staff and patients.|establishment of a biological basis for to describe the number and severity of covid-19 infections in cancer centres staff and patients.|dosage of igm and igg anti sars-cov2|evaluate the diagnostic performance of the minute test for igm|evaluate the quantification of igg in long term (m12) in the cancer centres populations|evaluate the frequency of reinfections among the persons who have developed igg|evaluate the threshold of protective igg among the subjects who have developed igg|evaluate the influence of polymorphisms of receptor of igg fc-gamma low-affinity (fcœ¥iia, fcœ¥iiia) on the humoral immune response|evaluate the severity of covid-19 infection (invisible, visible, prolonged, severe and fatal) by age group|evaluate the frequency of reinfection by covid-19 (recurrence of evocative clinical symptoms and positive viral pcr or positive igm serology) during follow-up|evaluate the risk factors (clinical and therapeutic) to develop severe forms of covid-19 infection in patients|evaluate the changes in health care practice|evaluate the resources associated with organizational changes|evaluate the allocated resources|evaluate the incidence of covid-19 infections|evaluate the distribution of risk factors for contamination in patients and in the general population|evaluate the anxiety state over time|evaluate the depression over time|evaluate the post-traumatic developments|evaluate the change in health care change frequency|evaluate the number of patients concerned by health care changes|evaluate the rate of morbidity|evaluate the rate of mortality",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: screening
Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure,PLACO-COVID,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04428021,NCT04428021,30-days survival|ventilator free survival|6-months survival|incidence of complications|days in intensive care units (icu)|positivity for immunoglobulin g to sars-cov-2|clearance of viral load|sequential organ failure assessment (sofa) score|any variation from standard therapy protocol,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, outcomes assessor)|primary purpose: treatment"
Testing for COVID-19 Infection in Asymptomatic Persons,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04345510,NCT04345510,covid-19 infection,observational,observational model: cohort|time perspective: prospective
Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19),nan,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04463264,NCT04463264,eradication of sars cov-2 from patients' respiratory tract secretions by treatment day 7th.|comparative decrease of the viral load|clinical improvement|pneumonia patients meeting severity criteria.|number of days with fever,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Predictors of COVID-19 Infection and Disease Progression,Portsaiduni,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04484597,NCT04484597,correlation of covid-19 antibody to pcr|correlation of ancillaey tests to pcr,observational,observational model: case-control|time perspective: cross-sectional
Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients,ConPlas-19,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04345523,NCT04345523,"category changes in ordinal scale|time to category 5, 6 or 7 of the ordinal scale|mortality of any cause at 15 days|mortality of any cause at 29 days|oxygenation free days|ventilator free days|incidence of treatment-emergent adverse events|antibodies levels in cp donors recovered from covid-19|viral load",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease,PC-COVID-HCM,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04542967,NCT04542967,disease progression|side effects|mortality|respiratory improvement|clinical improvement|acute adverse events (aae),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (care provider, outcomes assessor)|primary purpose: treatment"
Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04426084,NCT04426084,severe covid-19|severe covid-19 with pulmonary embolism|crrt(continuous renal replacement therapy)|ecmo (extracorporeal membrane oxygenation )|icu mortality,observational,observational model: case-control|time perspective: other
Home Usability Study of the SARS-CoV-2 (COVID-19) Test,nan,completed,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04395391,NCT04395391,valid sars-cov-2 test,observational,observational model: cohort|time perspective: prospective
Trial to Promote Recovery From COVID-19 With Endocrine Therapy,RECOVER,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04374279,NCT04374279,percentage of participants who have clinical improvement at day 7 after randomization|all-cause mortality|duration of hospitalization|percentage of patients needing upgrade to the intermediate care unit (imc)|duration of imc stay|percentage of patients needing upgrade to the intensive care unit (icu)|duration of icu stay|number of participants requiring mechanical ventilation|duration of mechanical ventilation|number of participants experiencing adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study of Hemostasis in Case of Severe COVID-19,THROMBOVID,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04359992,NCT04359992,platelet activation intensity with the occurrence of clinical thrombotic complications,observational,observational model: cohort|time perspective: prospective
Clinical Effect of Dialyzable Leukocyte Extract in Suspected or Confirmed Cases of COVID-19 (FUTURE-T),FUTURE-T,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04379479,NCT04379479,"change in the score of the ""contingency scale to assess the severity of acute respiratory disease in cases suspected/confirmed by covid-19""|clinical deterioration|duration of the clinical status",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19",KILLER,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04371965,NCT04371965,"change from baseline naso-pharyngeal viral load quantified by rt-pcr at day7|delay between inclusion and negativation of sars-cov-2 nasopharyngeal carriage|delay between inclusion and negativation of sars-cov-2 nasopharyngeal cell cultures|thyroid tests at day0 and day7|patient satisfaction at day7 using a numerical comfort scale, graduated from 0 (any discomfort) to 10 (maximum possible discomfort)|daily presence of clinical signs in favour of covid-19, including respiratory distress using nyha scale, chest pain, anosmia, agueusia, tiredness, cough, stiffness, nasal congestion, dysphagia and diarrhea|need for ward or intensive care hospitalization",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),ATOMIC2,recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04381962,NCT04381962,proportion progressing to respiratory failure or death (all clinically-diagnosed participants)|proportion progressing to respiratory failure or death (sars-cov-2 pcr positive)|all cause mortality|proportion progressing to pneumonia.|proportion progressing to severe pneumonia|peak severity of illness|safety and tolerability,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,SENTAD-COVID,completed,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04473170,NCT04473170,adverse reactions incidence.|rate of mortality within 28-days.|time to clinical improvement on a seven-category ordinal scale.|assessment of the immune response profile.|assessment of acute-phase serum markers.,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen,nan,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04346615,NCT04346615,"to compare the efficacy of zavegepant (bhv-3500) to placebo in subjects hospitalized with covid-19 infection requiring supplemental oxygen, using a six-point rating scale at day 15. .|proportion of subjects who have a 6-point severity rating of 5 or 6, are alive, and do not use supplemental oxygen as a procedure at day 29.|proportion of subjects who have a 6-point severity rating of 2 or 3, or use any ventilation or high-flow nasal cannula as procedures, on any day through day 29.|proportion of subjects admitted into an icu on any day through day 29 from ae ecrfs.|proportion of subjects who have a 6-point severity rating of 3, 4, 5, or 6, are alive, and do not use invasive mechanical ventilation as a procedure at day 15. the analogous definition is applied to day 29.|proportion of subjects who have a 6-point severity rating of 4, 5 or 6, or use a low- or high-flow nasal, are alive, and do not use any ventilation at day 15. the analogous definition is applied to day 29.|difference between treatment groups in the mean 6-point severity rating at day 29|number of days from baseline to the first day through day 29 with any 6-point severity rating greater than baseline.|number of days from baseline to the first of any 2 consecutive days through day 29 with all spo2/fio2 ratios > 400 on both days.|number of days from baseline to the first day through day 29 with ‚â• 1-point decrease in any news2 score from baseline.|number of days from baseline to the first day through day 29 with all news2 scores < 2 on that day.|mean change from baseline in news2 score at days 15 and 29 for subjects who are alive at these time points|proportion of subjects who have a 6-point severity rating of 5 or 6, are alive, and do not use supplemental oxygen as a procedure at day 15.|proportion of subjects who are discharged from the hospital, have a 6-point severity rating of 6 on any day after discharge, and use supplemental oxygen on any day after discharge.|mean number of days with respiratory rate > 24 breaths/minute through day 29 for subjects who are alive at day 29 and do not use invasive mechanical ventilation.|mean number of days with supplemental oxygen use through day 29 for subjects who are alive at day 29. a day in which any 6-point severity rating is 2, 3, or 4, or supplemental oxygen is used as a procedure counts.|number of days from baseline to the first day through day 29 on which any spo2 ‚â• 90%, any 6-point severity rating is 5 or 6, and no supplemental oxygen is used as a procedure.|mean number of ventilator-free days through day 29 for subjects who are alive at day 29.|mean sofa total scores at icu admission and day 29 (if still in icu), from sofa and ae ecrfs.|mean number of days of hospitalization through day 29 for subjects who are alive on day 29. all days on study on or before hospitalization discharge are days of hospitalization, from 6-point severity rating scale ecrfs|number of days from baseline to the first of any 2 consecutive days through day 29 in which all temperatures show lack of fever on both days and no antipyretics are used on either day.|number of subjects with deaths, saes, severe aes, and grade 3 or 4 laboratory test abnormalities at any time on study.|number and percentage of subjects with severe or life-threatening bacterial, invasive fungal, or opportunistic infections at any time through day 29 from ae/sae ecrfs.|number and percentage of subjects with intranasal administration reactions at any time through day 29 from ae/sae ecrfs.|proportion of subjects with ‚â• 50% reduction in egfr from baseline at any time on study from laboratory test ecrfs.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
RAPA-501-Allo Off-the-Shelf Therapy of COVID-19,nan,not yet recruiting,No Results Available,phase 1|phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04482699,NCT04482699,dose-limiting toxicity (dlt)|mortality rate|ventilation support|days of hospitalization|number of deaths|incidence of infection|gvhd incidence,interventional,"allocation: randomized|intervention model: sequential assignment|masking: double (participant, investigator)|primary purpose: treatment"
Control of COVID-19 Outbreaks in Long Term Care,nan,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04448119,NCT04448119,control of outbreak|mortality (residents)|covid-19 infection (residents)|covid-19 infection (staff)|hospitalization (residents)|medication discontinuation (residents)|medication discontinuation (staff)|covid-19 in new ltch units (a)|covid-19 in new ltch units (b)|covid-19 in new ltch units (c),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce,nan,recruiting,No Results Available,nan,Other|NIH,https://ClinicalTrials.gov/show/NCT04491292,NCT04491292,change in psychosocial outcomes|change in stress-related outcomes|demographic and occupational factors associated psychological and stress-related outcomes,observational,observational model: cohort|time perspective: cross-sectional
Pegylated Interferon Lambda Treatment for COVID-19,nan,enrolling by invitation,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04343976,NCT04343976,"undetectable covid pcr at day 7|undetectable covid pcr at day 3, 10 and 14|percentage of subjects on lambda vs placebo with symptomatic improvement|percentage of subjects on lambda vs placebo with improved clinical outcomes",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic,nan,recruiting,No Results Available,phase 1,Other|NIH,https://ClinicalTrials.gov/show/NCT04482647,NCT04482647,study recruitment|acceptability of study|adherence to the practice|change in resilience|perceive stress and psychological impact|breath holding time,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
"Knowledge, Attitudes and Clinical Practices of Pediatric Dentists Regarding Covid-19",nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04537117,NCT04537117,responses,observational,observational model: other|time perspective: cross-sectional
Myocardial Damage in COVID-19,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04312464,NCT04312464,the myocardial injury incidence|the risk factors analysis for the death|clinical characteristics|clinical course|cardiovascular comorbidity|analysis of causes of death,observational,observational model: case-control|time perspective: retrospective
Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04534790,NCT04534790,clinical improvement|improvement of laboratory and imaging parameters,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19),nan,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04363866,NCT04363866,clinical status at day 5 assessed by a 6-point ordinal scale|number of participants with detectable sars-cov-2 virus from day 0 to day 28 and at day 5|toxicity of study drug assessed by incidence of adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
CovidDB: The Covid-19 Inpatient Database,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04344171,NCT04344171,outcome comparison between different antiviral therapies|outcome comparisons between ventilation types|identification of risk factors|number of days in hospital vs. clinical classification,observational,observational model: cohort|time perspective: prospective
Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial,nan,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04382625,NCT04382625,change from baseline oxygenation on day 1 to day 5|change from baseline oxygenation at day 5|intensive care length of stay|required mechanical ventilation|required oxygen supplementation|hospitalization length of stay|mortality|cardiac arrhythmia - polymorphic ventricular tachycardia|cardiac arrhythmia - ventricular tachycardia|cardiac arrhythmia - lengthening qtc,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients,INHIXACOV19,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04427098,NCT04427098,to investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe covid-19.|to analyse the safety of enoxaparin in hospitalized patients with moderatesevere covid-19.|to describe the rates and the types of thromboembolic events among hospitalized patients with confirmed diagnosis of covid-19.,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
The COvid-19 Symptom MOntelukast Trial,COSMO,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04389411,NCT04389411,emergency room visits and hospitalizations|emergency room visit count|hospitalization admission count|time to er visit|time to hospitalization|all-cause mortality|inpatient length of stay|time to icu admission|time to intubation|time to other serious covid-19 complications,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04408209,NCT04408209,survival|clinical improvement ie percentage of patients not fulfilling the criteria for severe disease,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
COVID SAFE: COVID-19 Screening Assessment for Exposure,COVID SAFE,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04508777,NCT04508777,test compliance,observational,observational model: cohort|time perspective: prospective
A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04347369,NCT04347369,discrimination|calibration|net benefit,observational,observational model: case-only|time perspective: retrospective
Staff Absenteeism and Delivery of Healthcare Services During the COVID-19 Pandemic,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04521010,NCT04521010,number of days an individual person was absent,observational,observational model: other|time perspective: retrospective
Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04381858,NCT04381858,mean hospitalization time|mean oxigenation index evolution|rate of severe ards|rate and time to dead|mean time with invasive mechanical ventilation|time to viral pcr negativization,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: treatment"
Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients,SnPPIX,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04371822,NCT04371822,"lung injury score|serum ferritin|absolute lymphocyte counts|serum levels of crp, esr ,il-1,il-6,tnf and type i interferon|serum level of covid19 rna|all cause mortality rate|ventilation free days|icu free days|d-dimers|time to first negative sars-cov-2 pcr in np swap",interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs,nan,recruiting,No Results Available,phase 1|phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04461925,NCT04461925,"changes of oxygenation index pao2/fio2, most conveniently the p/f ratio.|changes in length of hospital stay|changes in mortality rate|changes of –°-reactive protein (crp, mg/l)|evaluation of pneumonia improvement|duration of respiratory symptoms (difficulty breathing, dry cough, fever, etc.)|peripheral blood count recovery time",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,nan,terminated,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04346355,NCT04346355,entry into intensive care with invasive mechanical ventilation or death from any cause or clinical aggravation|death from any cause|tocilizumab toxicity|levels of interleukin-6 and c-reactive protein (crp) and their correlation with the effectiveness of the treatment|evaluate the progress of the pao2 / fio2 ratio|evaluate the trend over time of the lymphocyte count,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Diagnostic Value of New COVID-19 Antibodies Testing Among Laboratory Healthcare Workers,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04445415,NCT04445415,diagnostic value of covid-19 antibodies testing|role of covid -19 antibodies testing in treatment of patients|assement of covid -19 prevalence among healthcare workers,observational,observational model: case-only|time perspective: retrospective
Stopping ACE-inhibitors in COVID-19,ACEI-COVID,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04353596,NCT04353596,"combination of maximum sequential organ failure assessment (sofa) score and death|composite of admission to an intensive care unit (icu), the use of mechanical ventilation, or all-cause death|maximum and median maximum sequential organ failure assessment (sofa) score|rates of non-invasive ventilation|rates of renal replacement therapies|change of viral burden|change of c-reactive protein (crp), interleukin 6 (il-6), d-dimer, il-6, hochsensitives troponin (hstn), nt-pro-brain natriuretic peptide (nt-pro bnp)|number of patients with systolic/diastolic blood pressure > 180/120 mmhg|hospitalisation due to cardiac decompensation|rates of mechanical ventilation|rates of clonal hematopoiesis of indeterminate potential (chip)",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease,CLARITY,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04394117,NCT04394117,7-point national institute of health clinical health score|mortality|intensive care unit admission|respiratory failure|dialysis requirement|hospitalisation days|ventilator-free days|dialysis days|acute kidney injury|hypotension requiring vasopressors,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT,BEST-RCT,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04305106,NCT04305106,the time from randomization to clinical improvement,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, outcomes assessor)|primary purpose: treatment"
NestaCell¬Æ Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia,HOPE,not yet recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04315987,NCT04315987,"change in clinical condition|rate of mortality within 10-days|change of clinical symptoms - respiratory rate|hypoxia|pao2 / fio2 ratio|cd4+ and cd8+ t cell count|changes of blood oxygen|side effects in the treatment group|complete blood count, cardiac, hepatic and renal profiles;",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia,nan,recruiting,No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04460105,NCT04460105,number of participants with treatment emergent adverse events (teaes)|pharmacokinetic (pk) plasma concentrations of lanadelumab|percentage change from baseline in plasma kallikrein activity (pkal)|percentage change from baseline in cleaved high molecular weight kininogen (chmwk)|percentage change from baseline in functional c1-inhibitor (c1-inh),interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
"To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)",nan,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04541485,NCT04541485,incidence of treatment-emergent adverse events|time to sars-cov-2 eradication (days) by nasopharyngeal specimen|rate of sars-cov-2 eradication by nasopharyngeal specimen,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination,nan,"active, not recruiting",No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04417335,NCT04417335,sars-cov-2 related hospital admission|the duration of hospital admission due to documented covid-19|the cumulative incidence of documented sars-cov-2 infection|the cumulative incidence of self-reported acute respiratory symptoms or fever|the cumulative incidence of death due to documented sars-cov-2 infection|the cumulative incidence of hospital admission for any reason|the cumulative incidence of intensive care admission due to documented sars-cov-2 infection,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,nan,completed,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04244591,NCT04244591,lower murray lung injury score|the difference of pao2/fio2 between two groups|lower sequential organ failure assessment (sofa) score|mechanical ventilation support|clearance of noval coronavirus|all-cause mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,COVACTA,completed,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04320615,NCT04320615,"clinical status assessed using a 7-category ordinal scale|time to clinical improvement (ttci), defined as a national early warning score 2 (news2) of </= 2 maintained for 24 hours|time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status|incidence of mechanical ventilation|ventilator-free days to day 28|incidence of intensive care unit (icu) stay|duration of icu stay|time to clinical failure|mortality rate|time to hospital discharge|time to recovery|duration of time on supplemental oxygen|percentage of participants with adverse events|covid-19 (sars-cov-2) viral load over time|time to reverse-transcriptase polymerase chain reaction (rt-pcr) virus negativity|proportion of participants with post-treatment infection|serum concentration of il-6|serum concentration of sil-6r|serum concentration of ferritin|serum concentration of c-reactive protein (crp)|serum concentration of tcz",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
"Influence of the COVId-19 Pandemic on STRESS, and Screening Procedures (COVISTRESS Screening)",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04538586,NCT04538586,stress measures|screening|sociodemographic characteristics,observational,observational model: cohort|time perspective: cross-sectional
Covid-19 Pediatric Observatory,PANDOR,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04336956,NCT04336956,percentage of children with severe or critical form.|percentage of children requiring intensive care support|clinical symptoms of children|biological results of children|ct chest of children|pulmonary echography|nasopharynx sarscov2 pcr|nasopharynx sarscov2 load|nasopharynx multiplex pcr|number of hospital days,observational,observational model: cohort|time perspective: other
Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.,nan,enrolling by invitation,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04407130,NCT04407130,virological clearance|remission of fever|remission of cough|patients requiring oxygen|patients failing to maintain spo2 >88% despite oxygenation|number of days on oxygen support|chest x-ray improvement|duration of hospitalization|all causes of mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,nan,"active, not recruiting",No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04372186,NCT04372186,"cumulative proportion of participants requiring mechanical ventilation by day 28|time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status|time to clinical failure, defined as the time to death, mechanical ventilation, icu admission, or withdrawal (whichever occurs first)|mortality rate by day 28|time to hospital discharge or ""ready for discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (l) supplemental oxygen)|percentage of participants with adverse events|percentage of participants with any post-treatment bacterial and/or fungal infection|incidence of post-treatment acute kidney injury (defined by 50% increase of creatinine from baseline)",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Implementation of Physiotherapy on COVID-19 Patients in ICU,PHYSIO-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04347070,NCT04347070,time of physiotherapy|type of physiotherapy implemented,observational,observational model: cohort|time perspective: retrospective
A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia,COVASTIL,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04386616,NCT04386616,"clinical status, assessed using a 7-category ordinal scale|time to clinical improvement, defined as a national early warning score 2 (news2) of ‚â§2 maintained for 24 hours|time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status|incidence of mechanical ventilation|incidence of extracorporeal membrane oxygenation (ecmo)|ventilator-free days|incidence of intensive care unit (icu) stay|duration of icu stay|time to clinical failure, defined as the time to death, mechanical ventilation, icu admission, or withdrawal of care (whichever occurs first)|mortality rate at days 7, 14, 21, 28, and 60|time to hospital discharge or ""ready for discharge""|duration of supplemental oxygen|percentage of participants alive and free of respiratory failure|incidence and severity of adverse events, with severity determined according to national cancer institute common terminology criteria for adverse events, version 5.0 (nci ctcae v5.0)|change from baseline in respiratory rate|change from baseline in pulse rate|change from baseline in systolic blood pressure|change from baseline in diastolic blood pressure|change from baseline in body temperature|change from baseline in oxygen saturation|change from baseline in rr, qrs, pr, qt, and qtcf intervals, as measured by electrocardiogram (ecg)|change from baseline in heart rate, as measured by electrocardiogram (ecg)|number of participants with clinical laboratory test abnormalities in hematology parameters|number of participants with clinical laboratory test abnormalities in blood chemistry parameters|serum concentration of uttr1147a at specified timepoints|serum concentration of mstt1041a at specified timepoints|prevalence of anti-drug antibodies (adas) at baseline and incidence of adas during the study",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
PEP Flute-selfcare in COVID-19,PEP-CoV,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04530435,NCT04530435,self-reported cat-score (copd assessment test)|hospital admissions|use of antibiotics,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19,NORCOVID,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04534478,NCT04534478,change in pulmonary diffusion.,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,MARIPOSA,completed,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04363736,NCT04363736,serum concentration of interleukin-6 (il-6) following administration of 8 mg/kg iv tcz|serum concentration of soluble interleukin-6 receptor (sil-6r) following administration of 8 mg/kg iv tcz|serum concentration of ferritin following administration of 8 mg/kg iv tcz|serum concentration of c-reactive protein (crp) following administration of 8 mg/kg iv tcz|serum concentration of il-6 following administration of 4 mg/kg iv tcz|serum concentration of sil-6r following administration of 4 mg/kg iv tcz|serum concentration of ferritin following administration of 4 mg/kg iv tcz|serum concentration of crp following administration of 4 mg/kg iv tcz|pecentage of participants with adverse events|severe acute respiratory syndrome corona virus 2 (sars-cov-2) (covid-19) viral load over time|time to real-time polymerase chain reaction (rt-pcr) virus negativity|proportion of participants with any post-treatment infection,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04472494,NCT04472494,proportion of participants with composite end point of mechanical ventilation or death prior to or on day 28|change from baseline in the ordinal 8-point outcome scale on day 28|all-cause mortality on day 28|proportion of participants alive and free of respiratory failure on day 28|proportion of participants returned to room air by day 28|proportion of participants alive and discharged home by day 28|proportion of participants with serious adverse events (saes)|proportion of participants with serious infections,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04329650,NCT04329650,"proportion of patients requiring icu admission at any time within the study period.|days of stay in the icu during the study period.|days until resolution of fever defined as body temperature (axillary ‚â§ 36.6 ¬∞ c, oral ‚â§ 37.2 ¬∞ c, or rectal or tympanic ‚â§ 37.8 ¬∞ c) for at least 48 hours, without administration of antipyretics or until hospital discharge.|proportion of patients with a worsening requirement of supplemental oxygen at 29 days. days.|days with hypoxemia (spo2 <93% in ambient air or requiring oxygen supplemental or mechanical ventilation support) at 29 days.|proportion of patients using mechanical ventilation at 29 days.|days with use of mechanical ventilation at 29 days.|days until the start of use of mechanical ventilation, non-invasive ventilation or use of high flow nasal cannula (if the patient have not previously required these interventions at the inclusion of the study) at 29 days.|days of hospitalization among survivors at 29 days.|mortality rate from any cause at 29 days.|proportion of patients with serious adverse events at 29 days.|proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic with grade 4 neutropenia (count neutrophil absolute <500 / mm3) at 29 days.|proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic at 29 days.|proportion of patients with grade 2 or higher adverse reactions related to the infusion of the sudy treatments at 29 days.|proportion of patients with hypersensitivity reactions of grade 2 or higher related to the administration of the study treatments at 29 days.|proportion of patients with gastrointestinal perforation at 29 days.|proportion of patients with secondary severe infections confirmed by laboratory or worsening of existing infections at 29 days.|changes from baseline in plasma leukocyte levels at days 1, 3, 5, 7 and 9.|changes from baseline in plasma hemoglobin levels at days 1, 3, 5, 7 and 9.|changes from baseline in plasma platelet at days 1, 3, 5, 7 and 9.|changes from baseline in plasma creatinine levels at days 1, 3, 5, 7 and 9.|changes from baseline in plasma total bilirubin levels at days 1, 3, 5, 7 and 9.|proportion of patients with alt‚â• 3 times uln (for patients with initial values normal) or> 3 times uln and at least 2 times more than the initial value (for patients with abnormal initial values) at days 1, 3, 5, 7 and 9.|changes from baseline in plasma biomarkers (pcr, lymphocytes, ferritin, d-dimer and ldh) at days 1, 3, 5, 7 and 9.|changes from baseline in chest rx at days 1, 3 and 5.",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 Recovered Volunteer Research Participant Pool Registry,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04359602,NCT04359602,serological testing of covid patients|immune response,observational,observational model: case-only|time perspective: prospective
Study of LAU-7b for the Treatment of COVID-19 Disease in Adults,RESOLUTION,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04417257,NCT04417257,"health status of the patient on the 7-point ordinal scale (world health organization) compared to placebo|the safety of lau-7b therapy will be assessed through the monitoring of treatment emergent adverse events, compared to placebo|rate of covid-19 disease-related aggravation, depicted by a change from baseline in the ordinal scale score of at least one category, compared to placebo|rate of covid-19 disease-related transfer to intensive care unit, depicted by a change from baseline in the ordinal scale score to categories 5 or 6, compared to placebo|rate of covid-19 disease-related transfer to mechanical ventilation, depicted by a change from baseline in the ordinal scale score to category 6, compared to placebo|rate of covid-19 disease-related death, depicted by a change from baseline in the ordinal scale score to category 7|health status of the patient on the 7-point ordinal scale (world health organization), compared to placebo|mean change from baseline of the ordinal scale patient health status as a function of assessment time, compared to placebo|time to an improvement of one category on the ordinal scale patient health status, compared to placebo|time to recovery, defined here as the time to reach categories 2 or 1 on the ordinal scale patient health status (first occurrence if more than once), compared to placebo|time to mechanical ventilation, defined here as time to reach category 6 on the ordinal scale patient health status, compared to placebo|time to death, defined here as a tim to reach category 7 on the ordinal scale patient health status, censored to day 29 if it happens later than day 29, compared to placebo|duration of hospitalization (days) within the study period days 1-29, compared to placebo|time to attain an undetectable viral load through oropharyngeal swabs done at specified times, compared to placebo|the change from baseline in the score obtained on the eq-5d-5l quality-of-life survey",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive But Are Able to Stay at Home,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04455815,NCT04455815,number of participants who require hospital admission and require supplemental oxygen.|rate of covid-19 related hospital admission in patients with sars-cov-2 infection.|number of supplementary oxygen-free days at 28 days (from randomisation).|number of ventilator-free days at 28 days (from randomisation).|to evaluate overall mortality.|time to worst point on the scale or deterioration of two points or more (from randomisation) on a 9-point category ordinal scale.,interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04331470,NCT04331470,clear chest ct-scan|pcr test|physical statues of patient,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: treatment"
COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells,MEMO-COV2,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04402892,NCT04402892,immunological memory: resolution of covid-19 after sars-cov2 infection.,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: basic science
Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic,PedCan-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04404244,NCT04404244,incidence of covid-19 among children with cancer|families training,observational,observational model: case-only|time perspective: prospective
Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in Coronavirus Disease 2019 (COVID19) Survivors,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04355884,NCT04355884,new-onset cardiac arrhythmia|elevation of nt-probnp|left ventricular dysfunction,observational,observational model: cohort|time perspective: prospective
Effect of COVID-19 Pandemic on Pediatric Cancer Care,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04374838,NCT04374838,pediatric cancer care pattern during covid 19 pandemic,observational,observational model: cohort|time perspective: cross-sectional
The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04273529,NCT04273529,time to clinical recoverytime to clinical recovery (ttcr)|all cause mortality|frequency of respiratory progression|time to defervescence,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Anti COVID-19 Convalescent Plasma Therapy,nan,not yet recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04345679,NCT04345679,changing of viral load of sars-cov2|changes in immunglobulin g covid-19 antibody titer|changes at the cytokine pattern|intensive care unit admission|length of hospital stay|duration of mechanical ventilation|clinical status|mortality,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04273581,NCT04273581,"time to clinical improvement (ttci)|clinical status|time to hospital discharge or news2 (national early warning score 2) of ‚â§ 2 maintained for 24 hours|all cause mortality|duration (days) of mechanical ventilation|duration (days) of extracorporeal membrane oxygenation|duration (days) of supplemental oxygenation|length of hospital stay (days)|time to 2019-ncov rt-pcr negativity in upper and lower respiratory tract specimens|change (reduction) in 2019-ncov viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|frequency of serious adverse drug events|serum tnf-œ±, il-1œ≤, il-2, il-6, il-7, il-10, gscf, ip10#mcp1, mip1œ± and other cytokine expression levels before and after treatment",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,REMDACTA,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04409262,NCT04409262,"clinical status as assessed by the investigator using a 7-category ordinal scale of clinical status on day 28|time to clinical improvement (ttci) defined as time from randomization to national early warning score 2 (news2) score of </= 2 maintained for 24 hours|time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status|clinical status as assessed by the investigator using a 7-category ordinal scale of clinical status on days 7, 14, and 21|proportion of participants requiring initiation of mechanical ventilation post-baseline|ventilator-free days from randomization to day 28|proportion of participants requiring initiation of intensive care unit (icu) care post-baseline|duration of icu stay in days|time to clinical failure, defined as the time from randomization to the first occurrence of death, mechanical ventilation, icu admission, or withdrawal (whichever occurs first)|mortality rate on days 7, 14, 21, 28, and 60|time to recovery, defined as time from randomization to the time when a category of 2, non-icu hospital ward (or ""ready for hospital ward"") not requiring supplemental oxygen, or better is observed|time from randomization to hospital discharge or ""ready for discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or </= 2l supplemental oxygen)|duration of supplemental oxygen use",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
"Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill",nan,not yet recruiting,No Results Available,phase 3,Industry|Other,https://ClinicalTrials.gov/show/NCT04358809,NCT04358809,number of patients with increased disease severity|incidence of adverse events and serious adverse events (safety)|number of covid-19 patients discharged from hospital|number of covid-19 patients transfer to icu|number of covid-19 patients with reduction in disease severity by 1 ordinal scale|number of of symptom free patients,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Convalescent Plasma for COVID-19 Close Contacts,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04390503,NCT04390503,rate of severe disease|rate of measurable anti-sars-cov-2 titers|rate of sars-cov-2 pcr positivity|duration of sars-cov-2 pcr positivity|levels of sars-cov-2 rna,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: treatment"
Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection,nan,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04374032,NCT04374032,time to onset of change in the patient's clinical condition|safety and tolerability evaluation - treatment-related adverse events will be assessed by ctcae|length of in-hospital stay|survival rate|intubation rate|proinflammatory markers levels,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 - Quality of Life After Infection,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04377464,NCT04377464,"six-month sf-12v2(hk) scores|six-month eq-5d-5l scores|one-month sf-12v2(hk)|one-month eq-5d-5l scores|three-month sf-12v2(hk) scores|three-month eq-5d-5l scores|one, three and six-month return to work status",observational,observational model: cohort|time perspective: prospective
Non Invasive Positive Pressure Ventilation to Minimize Aerosolization for COVID 19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04344925,NCT04344925,total leak volume of non invasive ventilation mask|glasgow coma scale(gcs)|respiratory rate|heart rate|metabolic data: blood gas measurements|metabolic data: bicarbonate (hc03)|metabolic data: partial pressure of carbon dioxide (pac02)|metabolic data: partial pressure of oxygen (pa02),observational,observational model: cohort|time perspective: prospective
PET/CT Imaging in COVID-19 Patients,nan,enrolling by invitation,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04376593,NCT04376593,administration of 18f-œ±vœ≤6-bp|determine whether 18f-œ±vœ≤6-bp demonstrates accumulation in lung damage,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,BCG-CORONA,"active, not recruiting",No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04328441,NCT04328441,"health care workers absenteeism|the cumulative incidence of documented covid-19|the cumulative incidence of hospital admission due to documented covid-19|the number of days of unplanned absenteeism, because of documented covid-19|the cumulative incidence of self-reported acute respiratory symptoms or fever|the cumulative incidence of death due to documented covid-19|the cumulative incidence of intensive care admission due to documented covid-19|the number of days of absenteeism, because of imposed quarantine as a result of exposure to covid-19|the number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented covid-19|the number of days of unplanned absenteeism because of self-reported acute respiratory symptoms|the number of days of self-reported fever (‚â•38 gr c)|the cumulative incidence of self-reported fever (‚â•38 gr c)|the number of days of self-reported acute respiratory symptoms|the cumulative incidence of self-reported acute respiratory symptoms|the cumulative incidence of death for any reason|the cumulative incidence of intensive care admission for any reason|the cumulative incidence of hospital admission for any reason|the cumulative incidence and magnitude of plasma/serum antibodies (iga,m,g) and sars-cov-2-specific antibodies at 12 weeks after vaccination and at the end of the study period",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
COVID-19 Among Healthcare Workers in Belgian Hospitals,COVHECBEHO,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04373889,NCT04373889,"change of prevalence of covid-19 infection among belgian active hospital healthcare workers (hcw)|change of seroprevalence of sars-cov-2 among belgian active hospital hcw|change in new cases (incidence) of covid-19 among belgian hospital hcw|change in sars-cov-2 seroconversion among belgian hospital hcw|sensitivity and specificity of serological tests|sensitivity and specificity of saliva sampling method (sampling with oracol or equivalent)|validate the nasal swab against the standard|potential risk factors for the infection|the proportion of asymptomatic cases among new cases that develop during a period of 5 months|the presence of virus shedding in urine, feces and sperm as well as cellular immune response",observational,observational model: cohort|time perspective: prospective
Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04542421,NCT04542421,"adoption of lung ultrasound by hospitalists caring for patients with covid|percentage of patients with covid who receive a lung ultrasound|chest x-ray utilization|adequacy of lung ultrasound images, interpretation and clinical decision-making as measured by a lung ultrasound expert|inpatient mortality",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19,nan,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04487210,NCT04487210,safety of mvc-cov1901|immunogenicity (neutralizing antibody titers and antigen specific binding antibody titers)|immunogenicity (antigen specific cellular immune responses),interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: prevention
"A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19",nan,not yet recruiting,No Results Available,phase 3,Industry|Other,https://ClinicalTrials.gov/show/NCT04425460,NCT04425460,time from randomization to clinical recovery|negativity in rt-pcr nucleic acid test|time from randomization to resolution of pyrexia|time from randomization to relief of cough|incidence of deterioration/aggravation of pneumonia|time from randomization to relief of dyspnoea|rate of auxiliary oxygen therapy or non-invasive ventilation|icu admission rate within 28 days of randomization|all-cause mortality within 28 days of randomization.,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
QT-Logs : Artificial Intelligence for QT Interval Analysis of ECG From Smartwatches in Patient Receiving Treatment for Covid-19,QT-Logs,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04371744,NCT04371744,corrected qt (qtc) interval measurement,observational,observational model: cohort|time perspective: prospective
Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),HYDRA,"active, not recruiting",No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04315896,NCT04315896,all-cause hospital mortality|length of hospital stay|need of mechanical ventilation|ventilator free days|grade 3-4 adverse reaction,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04428268,NCT04428268,overall mortality|clinical outcome assessment|number of participants with treatment-related adverse events as assessed by ctcae v4.0|time to negative sars-cov-2 test,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: treatment"
Neonatal Complications of Coronavirus Disease (COVID-19),nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04386109,NCT04386109,incidence of neonatal covid-19|incidence of vertically transmitted covid-19|presentation and natural history of neonatal covid-19|presentation of neonates with covid-19 positive mothers|outcomes for neonates with covid-19|clinical treatment of neonatal covid-19|neonatal secondary impacts of maternal covid-19,observational,observational model: cohort|time perspective: prospective
COVID-19 PrEP HCW HCQ Study,nan,"active, not recruiting",No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04354870,NCT04354870,frequency of seroconversion to sars-cov-2|incidence of covid-19 symptoms in the 4 weeks preceding seroconversion|hospital admission rate|icu admission rate|mortality rate|incidents of aes or saes related to hcq upon study termination time,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Hydroxychloroquine for COVID-19,COV-HCQ,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04342221,NCT04342221,effect of hcq on in vivo viral clearance,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Study of Sargramostim in Patients With COVID-19,iLeukPulm,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04411680,NCT04411680,change in oxygenation parameter of p(a-a)o2 gradient by day 6|percent of patients who have been intubated by day 14|change in ordinal scale|all cause 28-day mortality|number of patients with treatment-emergent serious adverse events or clinically significant adverse drug reactions (adrs),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Clinical Study for the Treatment With Interferon-√ü-1a (IFN√ü-1a) of COVID-19 Patients,INTERCOP,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04449380,NCT04449380,"time to negative conversion of sars-cov-2 nasopharyngeal swab|improvement in clinical severity score (a)|improvement in clinical severity score (b)|incidence of new oxygen use, non-invasive ventilation, or high flow oxygen devices during the trial|oxygenation free days in the first 28 days|ventilator free days in the first 28 days|incidence of new mechanical ventilation use during the trial|number of patients transferred to intensive care unit (icu)|mortality rate|changes from baseline in pulmonary computed tomography (ct) imaging severity score|duration of hospital stay expressed in days|viral load measured on plasma with rt-pcr",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,DEXA-COVID19,suspended,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04325061,NCT04325061,60-day mortality|ventilator-free days,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization,PAPR,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04368000,NCT04368000,change in imputed partial pressure of oxygen over fraction of inspired oxygen (pao2/fio2) from peripheral capillary oxygen saturation over fraction of inspired oxygen (spo2/fio2)|change in imputed pao2/fio2 from spo2/fio2|proportion of participants requiring endotracheal intubation|proportion of participants requiring mechanical ventilation|proportion of participants transferred to intensive care for worsening respiratory failure|proportion of participants who had escalated oxygen delivery needs|average number of days hospitalized|average number of ventilator-free days|proportion of participants discharged from hospital on hospice|proportion of participants with all-cause inpatient mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19,PED-COVID,recruiting,No Results Available,not applicable,Other|Industry,https://ClinicalTrials.gov/show/NCT04355533,NCT04355533,"seroconversion against sars-cov2 in children|protective immunity|measure of ab antin and ab anti-s1/2|neutralization activity|positive qpcr in children|correlation between different ab and qpcr and neutralization activity|duration of viral carriage in stool, saliva and or nasopharynx|correlation between antibody profile and viral clearance|ab profile and memory of immunity|transmission to other family members|presence of covid-19 symptom|seroconversion against sars-cov2 in parents|measure of ab antin and ab anti-s1 and neutralization activity|positive qpcr in parents|correlation between different ab and qpcr",interventional,allocation: non-randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
"Rapid, Onsite COVID-19 Detection",nan,enrolling by invitation,No Results Available,not applicable,Other|NIH,https://ClinicalTrials.gov/show/NCT04460690,NCT04460690,number of samples tested consistently and accurately per protocol|safety: covid-19 rates of investigators vs communities tested,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04528667,NCT04528667,"proportion of subjects discharged from hospital|incidence of adverse events (safety)|time to hospital admission, treatment, and discharge|number of days hospitalized|change in clinical status as assessed using a 0-8 ordinal scale|change in rt-pcr test results|change in c-reactive protein levels|auc of sti-5656 (pk)|cmax of sti-5656 (pk)|t¬ω of sti-5656 (pk)|change in cytokine levels|tmax of sti-5656 (pk)",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Ruxolitinib in the Treatment of Covid-19,nan,not yet recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04414098,NCT04414098,evaluate the efficacy of ruxolitinib in the treatment of covid-19 severe acute respiratory syndrome|evaluate the median duration of hospitalization.|evaluate the evolution of systemic inflammation parameters.|evaluate covid-19 mortality rate|evaluate the proportion of the requirement of mechanical ventilation.|evaluate ruxolitinib adverse reactions|evaluate the proportion of secondary infections during the treatment with ruxolitinib,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Immunoglobulin G Antibody Immune Response Profile Following Infection With SARS-CoV-2 in COVID-19 Egyptian Patients,COVID-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04483622,NCT04483622,rising titre of igg antibodies,observational,observational model: case-only|time perspective: prospective
Neuromuscular Electrical Stimulation in Patients With COVID19 Associated Pneumonia,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04382729,NCT04382729,short physical performance battery (sppb) score|functional independence measure (fim) scale score|fatigue severity scale score|muscle strength|two step test length|six minutes walking test distance|muscle thickness,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: supportive care
Convalescent Plasma Treatment in COVID-19,COLLATE,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04476888,NCT04476888,decrease length of stay|overall mortality|incidence of adverse events related to convalescent plasma transfusion|ordinal scale|improvement in laboratory parameters: serum ferritin|improvement in laboratory parameters: procalcitonin|improvement in laboratory parameters: c-reactive protein|improvement in laboratory parameters: d-dimer|improvement in laboratory parameters: complete blood count|chest x-ray findings,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Slovenian National COVID-19 Prevalence Study,SLO-COVID-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04376996,NCT04376996,prevalence of sars-cov-2 rna in nasopharyngeal samples|prevalence of anti-sars-cov-2 antibodies in blood samples,observational,observational model: cohort|time perspective: prospective
Max COVID19- Study,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04339608,NCT04339608,covid-19 positive case,observational,observational model: cohort|time perspective: prospective
COVID-FISETIN: Pilot in Covid-19 of Fisetin to Alleviate Dysfunction and Inflammation,nan,enrolling by invitation,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04476953,NCT04476953,serious adverse events|change in oxygenation status|covid-19 severity category,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Estrogen Therapy in Non-severe COVID-19 Patients,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04539626,NCT04539626,clinical improve to estrogen therapy in non-severe covid-19 patients clinical improve to estrogen therapy in non-severe covid-19 patients|clinical improve to estrogen therapy in non-severe covid-19 patients|symptomatic improve to estrogen therapy in non-severe covid-19 patients|biochemical improve to estrogen therapy in non-severe covid-19 patients,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,DAMPENCOVID,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04445285,NCT04445285,mortality at 28 days|systemic therapeutic response|respiratory response|legnth of icu stay|legnth of hospital stay|pulmonary function,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Defibrotide in COVID-19 Pneumonia,DEFI-VID19,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04335201,NCT04335201,to able to reduce the progression of acute respiratory failure|adverse events|duration of hospitalization|systemic inflammation|overall survival,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04356560,NCT04356560,incidence of healthcare workers with sars-cov-2|incidence of ent patients with sars-cov-2|development of sars-cov-2 antibodies among healthcare workers|sensitivity and specificity of a covid-19 screening symptom questionnaire among healthcare workers|sars cov-2 and bacterial super infections in upper respiratory airways,observational,observational model: cohort|time perspective: prospective
"Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)",nan,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04498325,NCT04498325,safe and tolerable dose of nt-i7 (phase i only)|percent change in absolute lymphocyte count (alc)|change in sars-cov-2 viral load|covid-19 symptom severity as measured by who ordinal scale for clinical improvement|time to resolution of covid-19 symptoms|incidence of treatment-emergent adverse events|number of participants by pcr result status (positive or negative),interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
COVID-19 Remote Monitoring,nan,withdrawn,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04350476,NCT04350476,number of different arrhythmias|temperature|oxygen saturation,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: screening
WORLD HEART FEDERATION (WHF) COVID-19 and Cardiovascular Disease Survey,WHF,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04475471,NCT04475471,"assessment of the patients for major adverse cardiovascular events (mace)|assessment of the patients for pulmonary outcomes including pulmonary embolism, pneumonia, acute respiratory distress syndrome, need of intensive care - number of days in icu or iccu, need of ventilator]|assessment of the patients for neurological outcomes including stroke and transient ischemic attack (tia)|all cause deaths",observational,observational model: cohort|time perspective: prospective
Neuroradiolological Analysis of COVID-19 Patients,COVID-19BRAIN,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04368390,NCT04368390,neuroradiological analysis of patients brain mri,observational,observational model: case-only|time perspective: other
Rehabilitation Needs and Functional Recovery in Covid-19 Acute and Post-acute Care,RECOVER-19,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04456036,NCT04456036,"change from pre-covid-19 condition in adl independence on the mod. rankin scale score at the enrolment (t0) assessment, at 3, 6 and 12 months|change from pre-covid-19 condition in walking performance on the walking handicap scale (whs) at 3, 6 and 12 months|patient-reported health-related well-being perception on the 36-item short form survey - sf-36 at 3, 6 12 months follow-up|change in global adl disability on modified barthel index (mbi), from the enrolment (t0), at 3, 6 12 months follow-up|change in walking capacity on functional ambulation category (fac), from the enrolment (t0) assessment, at 3, 6 12 months follow-up|change in cognitive abilities on the montreal cognitive assessment (moca) from the enrollment (t0) assessment, at 3, 6 12 months follow-up|change in patient-reported pain on numerical rating scale from the enrollment (t0) assessment, at 3, 6 12 months follow-up|change in swallow abilities on dysphagia outcome severity scale (doss) from the first functional assessment in acute care, at 3, 6 12 months follow-up|change in endurance on 6-minutes walking test (6mwt) from the enrolment (t0) assessment, at 3, 6 12 months follow-up|change in mood status on beck depression inventory (bdi) from the enrolment (t0) assessment, at 3, 6 and 12 month follow-up",observational,observational model: cohort|time perspective: prospective
Selective Estrogen Modulation and Melatonin in Early COVID-19,SENTINEL,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04531748,NCT04531748,peak increase in covid-19 sign and symptom score|nadir oxygen saturation|peak heart rate|time to covid-19 sign and symptom score resolution|time to who 7-point ordinal scale score of 3 or higher,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection,NIVISCO,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04413838,NCT04413838,patient's clinical state|readmission|mortality|oxygen flow needs|requirement of oxygen|discharge from hospital|adverse events|presence of nasopharyngeal sars-cov-2|nasopharyngeal sars-cov-2 viral charge|number of total lymphocytes t|number of cd3+ lymphocytes t(lymphocyte subpopulation of cd3+ t cells)|number of cd4+ lymphocytes t(lymphocyte subpopulation of cd4+ t cells)|number of cd8+ lymphocytes t(lymphocyte subpopulation of cd8+ t cells)|interleukin 6 (il-6)|interleukin 10 (il-10)|tumor necrosis factor alpha (tnfœ± )|interferon gamma (ifnœ≥)|type i interferon (type i ifn)|tim3 expression|pd1 expression|pd-l1 expression|human leukocyte antigen - dr isotype gene expression (hla-dr expression)|production of ifnœ≥ by lymphocytes t|production of granzyme b by lymphocytest|lipopolysaccharides (lps)|lbp(lps-binding protein)|scd14|high density lipoproteins|apolipoprotein,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults",nan,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04368728,NCT04368728,"percentage of participants in phase 1 reporting local reactions|percentage of participants in phase 1 reporting systemic events|percentage of participants in phase 1 reporting adverse events|percentage of participants in phase 1 reporting serious adverse events|percentage of phase 1 participants with abnormal hematology and chemistry laboratory values|percentage of phase 1 participants with grading shifts in hematology and chemistry laboratory assessments|in the first 360 participants randomized into phase 2/3, percentage of participants reporting local reactions|in the first 360 participants randomized into phase 2/3, percentage of participants reporting systemic events|in the first 360 participants randomized into phase 2/3, percentage of participants reporting adverse events|in the first 360 participants randomized into phase 2/3, percentage of participants reporting serious adverse events|in a subset of at least 6000 participants randomized in phase 2/3, percentage of participants reporting local reactions|in a subset of at least 6000 participants randomized in phase 2/3, percentage of participants reporting systemic events|percentage of participants in phase 2/3 reporting adverse events|percentage of participants in phase 2/3 reporting serious adverse events|confirmed covid-19 in phase 2/3 participants without evidence of infection before vaccination|confirmed covid-19 in phase 2/3 participants with and without evidence of infection before vaccination|in phase 1 participants, sars-cov-2 serum neutralizing antibody levels, expressed as gmts|in phase 1 participants, gmfr in sars-cov-2 serum neutralizing titers from before vaccination to each subsequent time point|proportion of participants in phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in sars-cov-2 serum neutralizing antibody levels|in phase 1 participants, sars-cov-2 anti-s1 binding antibody levels and anti-rbd binding antibody levels, expressed as gmcs|proportion of participants in phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in sars-cov-2 anti-s1 binding antibody levels and anti-rbd binding antibody levels|in phase 1 participants, gmfr in sars-cov-2 anti-s1 binding antibody levels and anti-rbd binding antibody levels from before vaccination to each subsequent time point|in phase 1 participants, gmr of the geometric mean of sars-cov-2 serum neutralizing titers to the geometric mean of sars cov 2 (anti-s1 and anti-rbd) binding antibody levels|confirmed severe covid-19 in phase 2/3 participants without evidence of infection before vaccination|confirmed severe covid-19 in phase 2/3 participants with and without evidence of infection before vaccination|confirmed covid-19 (according to the cdc-defined symptoms) in phase 2/3 participants without evidence of infection before vaccination|confirmed covid-19 (according to the cdc-defined symptoms) in phase 2/3 participants with and without evidence of infection before vaccination",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
How Routine Biomarkers and Blood Leucocytes Count Can Assist Diagnosis of COVID-19 in Emergency Department,MONACOVID,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04401241,NCT04401241,routine biomarkers and blood cell count are discriminant to diagnose covid-19|probability of covid-19 and crp|probability of covid-19 and pct|probability of covid-19 and ddimers|probability of covid-19 and ntprobnp|probability of covid-19 and ctnt-hs|probability of covid-19 and blood cell counts|performance of combined routine biomarkers|assess usual biomarkers and blood cell count,observational,observational model: other|time perspective: retrospective
Colchicine in Moderate Symptomatic COVID-19 Patients,COLCOVIDBD,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04527562,NCT04527562,"time to develop clinical deterioration, defined as the time from randomization to a deterioration of two points (from the status at randomization) on a seven-category ordinal scale.|length of hospital stay|number of participant requiring increased amount of supplemental oxygen|number of participants requiring mechanical ventilation|number of participants who die",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Psychological Intervention for Parent-child Relationship and Couple Relationship Under COVID-19 in China,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04463433,NCT04463433,parent-child conflict|parent-child communication|parent-child relationship|couple relationship quality|marital stability,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
COVID-19 Antibodies Among Healthcare Workers,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04425889,NCT04425889,presence of antibody,observational,observational model: cohort|time perspective: cross-sectional
Antioxidant Therapy for COVID-19 Study,GSHSOD-COVID,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04466657,NCT04466657,time to clinical improvement|time to sars-cov-2 negativity|clinical status on day 14|proportion of participants with sars-cov-2 pcr negative result at day 7|proportion of participants with sars-cov-2 pcr negative result at day 28|28 day mortality|duration of hospitalization in survivors|time from treatment initiation to death,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: supportive care
Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19,Explore,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04346056,NCT04346056,exploring the presence of covid-19,observational,observational model: cohort|time perspective: retrospective
Efficacy and Safety of Sirolimus in COVID-19 Infection,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04461340,NCT04461340,time to clinical recovery|viral clearance|radiological lung extension|drug adverse events|28 day mortality|intensive care unit (icu) admission rate|duration of hospital stay,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Host Response Mediators in Coronavirus (COVID-19) Infection,ARBS CORONA I,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04510623,NCT04510623,covid-19 who ordinal scale|organ dysfunction|28-day mortality|hospital/icu length of stay|icu admission,observational,observational model: cohort|time perspective: other
Data Analysis of the Cytokine Adsorption Treatment on Coronavirus Disease-19 (COVID-19) Patients With Respiratory Failure,CYTOAID,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04422626,NCT04422626,change in the partial pressure of oxygen/fraction of inspired oxygen (pao2/fio2) ratio after cytosorb therapy|change in inflammatory biomarker levels during treatment|change in organ function|length of stay in icu|length of hospital stay|duration of mechanical ventilation|duration of vasopressor therapy|duration of renal replacement therapy|occurrence of critical illness polyneuropathy and/or myopathy|need for extracorporeal membrane oxygenation (ecmo)|cost calculation|device-related adverse and serious adverse events|in-hospital mortality,observational,observational model: cohort|time perspective: prospective
Direct and Indirect Impact of COVID-19 In Older Populations,COVID-OLD,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04381312,NCT04381312,"mortality|risk factors for death|describe clinical symptoms specific to old population|describe specific and non-specific treatments used for covid 19|describe all acute complications|functional decline|rehospitalisation|medical complications|admission in nursing home|risk factors for 3-month functional decline, acute complication and admission to nursing home",observational,observational model: cohort|time perspective: prospective
Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,X-Covid 19,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04366960,NCT04366960,incidence of venous thromboembolism detected by imaging|in hospital major complications|number of deep venous thrombosis events|sequential organ failure assessment|c-reactive protein|interleukin-6|d-dimer|hs-troponin levels|acute respiratory distress syndrome|hospital stay|right ventricular function|number of pulmonary embolism events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Cardiac and Thoracic Imaging in Pediatric Patients With Evidence of Systemic Inflammation COVID19 Linked,CARDOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04455347,NCT04455347,imaging data at baseline|imagine data at follow-up,observational,observational model: cohort|time perspective: prospective
Seroprevalence and Immunoprotection Against COVID-19 in Parisian Children,AP-PEDCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04490811,NCT04490811,serological test|neutralizing ab|immuno phenotyping,observational,observational model: cohort|time perspective: retrospective
Role of Inflammasomes in COVID-19 Disease,CoVInnate,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04385017,NCT04385017,level of activation of inflammasomes in monocytes and polymorphonuclear neutrophils during covid-19|genes nucleoside polymorphism analysis,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Feasibility of Rapid COVID-19 Testing in Disadvantaged Populations,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04558307,NCT04558307,intervention feasibility measures - fqhc staff|2. uptake of rapid sars-cov-2 testing strategy at the fqhc- effectiveness of community-driven messaging to patients|uptake of rapid sars-cov-2 testing strategy at the fqhc|intervention satisfaction measures - participant satisfaction with covid-19 testing|5. intervention satisfaction measures - participant satisfaction with community-driven messaging,observational,observational model: ecologic or community|time perspective: prospective
Fingolimod in COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04280588,NCT04280588,the change of pneumonia severity on x-ray images,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04393558,NCT04393558,body temperature|cough frequency|respiratory frequency|heart rate instantaneous heart rate every 15 minutes.,observational,observational model: cohort|time perspective: prospective
NBT-NM108 as an Early Treatment of Suspected or Confirmed COVID-19 in Patients With Prediabetes or Type 2 Diabetes,nan,not yet recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04540406,NCT04540406,"gut microbiota composition|outcome of covid-19 related illnesses|proportion of participants who are ""alive and not admitted to the hospital""|proportion of participants who have complete resolution of all objective symptoms|proportion of participants who have complete resolution of subjective symptoms|illness severity based on the categorization from fda covid-19 guidance document|illness severity based the ordinal scale for clinical improvement from the world health organization|body temperature (f)|oxygen saturation spo2 level|pulse rate per minute|respiratory rate per minute|fasting blood glucose (mg/dl)",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF),nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04343248,NCT04343248,symptomatic laboratory-confirmed covid-19|symptomatic laboratory-confirmed vri,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
D-dimer Levels in Pregnant With COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04389554,NCT04389554,compare d-dimer values of covid-19 patients and healthy pregnant women,observational,observational model: case-control|time perspective: prospective
Study of Efficacy and Safety of MAS825 in Patients With COVID-19,MAS-COVID,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04382651,NCT04382651,apache ii severity of disease score on day 15 or on day of discharge (whichever is earlier)|serum c-reactive protein (crp levels)|ferritin levels|proportion of participants without the need for invasive mechanical ventilation|proportion of participants with at least one level improvement in clinical status|clinical status over time,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Catalysing the Containment of COVID-19,C3-RCT,recruiting,No Results Available,phase 2|phase 3,Other|NIH,https://ClinicalTrials.gov/show/NCT04523090,NCT04523090,"time specific disease severity|progression to severe disease|need for respiratory support (high flow nasal oxygen, non-invasive ventilation, or intubation) in those admitted to hospital because of disease progression.|in-hospital and 30- and 60-day all-cause mortality. available).|time-specific viral load as measured by rt-pcr using np swabs and sputum (where available).|cough aerosol sampling positivity",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
COVID-19 Infection in Patients With Hepatocellular Carcinoma,COVID19-CHIEF,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04367805,NCT04367805,incidence of covid-19 infection in patients with hepatocellular carcinoma in france,observational,observational model: case-only|time perspective: prospective
Role of Microparticles in Covid-19 Infection,MICO,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04448743,NCT04448743,western blot measurement of ace2 receptor expression in porcine cells,observational,observational model: cohort|time perspective: prospective
Health Professional Exposure Assessment to Covid-19,SERODRON,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04429724,NCT04429724,number of contaminated personnel|number of symptomatic staff by occupational category and service|number of contaminated personnel with effective protection|comparison of socio-demographic characteristics and co-morbidities between patients losing their antibodies and those maintaining their antibodies,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study,CIPOLLINI,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04359459,NCT04359459,nasal epithelial transcriptional response to sars-cov2|ace2-angii system,observational,observational model: cohort|time perspective: prospective
Implications of Covid-19 on the Lifestyle Changes,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04423978,NCT04423978,the ratio of individuals living in the province of reggio emilia who completed the survey|the ratio of individuals who changed the lifestyles during the lock-down|the number and the type of support services used the most by participants,observational,observational model: ecologic or community|time perspective: cross-sectional
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04359680,NCT04359680,the proportion of subjects with symptomatic laboratory-confirmed covid-19 identified after start of treatment and before the end of the 6-week treatment period.|the proportion of subjects with symptomatic laboratory-confirmed vri identified after the start of treatment and before the end of the 6-week treatment period.,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers,nan,not yet recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04473690,NCT04473690,"solicited administration site reactions|solicited systemic events|unsolicited adverse events and medically attended adverse events|serious adverse events, medically attended adverse events and new onset chronic diseae|vaccine elisa and neutralizing antibody titers for each treatment group|seroconversion rates",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04329559,NCT04329559,all-cause mortality of covid-19 patients with liver cirrhosis|liver-related mortality of covid-19 patients with liver cirrhosis|risk factors associated with specific outcomes of covid-19 patients with liver cirrhosis|baseline characteristics of covid-19 patients with liver cirrhosis,observational,observational model: cohort|time perspective: cross-sectional
A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04486482,NCT04486482,number of patients experiencing study-product related treatment-emergent adverse events (teaes)|relative abundance of microbial taxa in fecal samples as assessed by shotgun profiling based on shotgun sequencing.,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
Outpatient Use of Ivermectin in COVID-19,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04530474,NCT04530474,clinical improvement,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, outcomes assessor)|primary purpose: treatment"
Hypertension in Patients Hospitalized With COVID-19,HT-COVID19,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04318301,NCT04318301,rate of death|the severity of pneumonia,observational,observational model: case-control|time perspective: retrospective
Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04357535,NCT04357535,severity of covid-19 infection|degree of severity of respiratory disease|septic shock as defined by sepsis-3 criteria,observational,observational model: cohort|time perspective: prospective
Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19,nan,not yet recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04551547,NCT04551547,safety index-incidence of adverse reactions|immunogenicity index-seroconversion rates of neutralizing antibody|safety index-incidence of serious adverse events|immunogenicity index-seropositive rates of neutralizing antibody|immunogenicity index-geometric mean titer (gmt) of neutralizing antibody|immunogenicity index-geometric mean ratio (gmr) of neutralizing antibody,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19",nan,completed,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04436471,NCT04436471,changing ofantibody levels against the sars-cov-2 glycoprotein s in 42 days|number of participants with adverse events|changing of of virus neutralizing antibody titer|changing of antigen-specific cellular immunity level,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
SARS-CoV-2 (COVID-19) Detection Using the Breath Analizer TeraSystem,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04497610,NCT04497610,presence of disease,observational,observational model: cohort|time perspective: prospective
Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste,FORECAST,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04377815,NCT04377815,percentage of people reporting changes in smell/taste|mortality rate|percentage of people with change in smell/taste before other symptoms|proportion of other covid-19 linked symptoms in people with smell and/or taste change|percentage of people with persistent changes in smell and/or taste|percentage of hospitalisation|co-morbidities association|prevalence of changes in smell/taste|clinical outcomes,observational,observational model: cohort|time perspective: other
COVID-19 Virtual Care at Home,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04420182,NCT04420182,14 day patient satisfaction questionnaire|emergency department visits|14 day eq-5d-5l scores,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04412538,NCT04412538,"adverse reactions/events rate|seroconversion rate of neutralizing antibodies against sars-cov-2 phase iia (day 0, 14 schedule)|seroconversion rate of neutralizing antibodies against sars-cov-2 phase iia (day 0, 28 schedule)|seroconversion rate of igg antibodies against sars-cov-2 phase iia (day 0, 14 schedule)|seroconversion rate of igg antibodies against sars-cov-2 phase iia (day 0, 28 schedule)|serious adverse events|level of neutralizing antibodies against sars-cov-2 phase ia (day 0, 14 schedule)|level of neutralizing antibodies against sars-cov-2 phase iia (day 0, 14 schedule)|level of igg antibodies against sars-cov-2 phase ia (day 0, 14 schedule)|level of igg antibodies against sars-cov-2 phase iia (day 0, 14 schedule)|level of neutralizing antibodies against sars-cov-2 phase ia (day 0, 28 schedule)|level of neutralizing antibodies against sars-cov-2 phase iia (day 0, 28 schedule)|level of igg antibodies against sars-cov-2 phase ia (day 0, 28 schedule)|level of igg antibodies against sars-cov-2 phase iia (day 0, 28 schedule)|seroconversion rate of neutralizing antibodies against sars-cov-2 phase ia (day 0, 14 schedule)|seroconversion rate of igg antibodies against sars-cov-2 phase ia (day 0, 14 schedule)|seroconversion rate of neutralizing antibodies against sars-cov-2 phase ia (day 0, 28 schedule)|seroconversion rate of igg antibodies against sars-cov-2 phase ia (day 0, 28 schedule)",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Moxibustion Plus Cupping in Convalescent Patients With COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04374084,NCT04374084,"the change of the average vas score from baseline to week 4|the change of the average vas score from baseline to week 2, and week 8|the change of the severity vas score from baseline to week 2, week 4 and week 8|the change of the average insomnia vas score from baseline to week 2, week 4 and week 8|the change of the average vas score of sweating, mental fatigue, anorexia and nervousness from baseline to week 2, week 4 and week 8|the change of the average times of diarrhea and complete spontaneous bowel movement to week 2, week 4 and week 8|the proportion of patients with 50%/75% improvement of clinical symptoms to week 2, week 4 and week 8|the change of the walking distance of six-minute-walking test from baseline to week 2, week 4 and week 8|the change of the lowest oxygen saturation of six-minute-walking test from baseline to week 2, week 4 and week 8|the proportion of patients in recovery of pulmonary function on week 2 and week 4|the proportion of patients whose lung ct return to normal on week 4|the change of the who qol-bref score from baseline to week 4 and week 8|the change of the sas score from baseline to week 4 and week 8|the change of the sds score from baseline to week 4 and week 8|the change of the blood crp value from baseline to week 4|the change of the blood lymph# value from baseline to week 4|the change of the blood neut% value from baseline to week 4|the change of the average vas score from baseline to week 4 in different age groups.|the change of the average vas score from baseline to week 4 in different gender groups.|the change of the average vas score from baseline to week 4 in different clinical classification of covid-19.",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Core Warming of COVID-19 Patients,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04426344,NCT04426344,viral load measured in tracheal aspirate 72 hours after initiation of core warming|pao2/fio2 ratio 72 hours after initiation of core warming|duration of mechanical ventilation,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
COVID-19: Human Epidemiology and Response to SARS-CoV-2,HEROS,"active, not recruiting",No Results Available,nan,NIH|Other,https://ClinicalTrials.gov/show/NCT04375761,NCT04375761,"cumulative incidence of sars-cov-2 rna detection in nasal samples among index participants and their household contacts over the study/surveillance period|percent of index participants and their household contacts with detectable sars-cov-2-specific antibodies in serum over the study/surveillance period|cumulative incidence of sars-cov-2 detection in nasal samples among index participants with asthma and other atopic disease compared to index participants without atopic disease over the study/surveillance period|percent of index participants with asthma and other atopic disease with detectable sars-cov-2-specific antibodies in serum compared to index participants without atopic disease over the study/surveillance period|changes in the nasal transcriptome associated with detection of sars-cov-2 in nasal samples among index participants and their household contacts over the study/surveillance period|changes in the nasal transcriptome associated with detection of sars-cov-2 in nasal samples among index participants with asthma and other atopic disease compared to index participants without atopic disease over the study/surveillance period|symptoms associated with detection of sars-cov-2 in nasal samples among index participants and their household contacts over the study/surveillance period|cumulative incidence of sars-cov-2 detection in nasal samples among index participants using topical steroids compared to index participants that are not using topical steroids over the study/surveillance period|cumulative incidence of sars-cov-2 detection in nasal samples among index participants using topical, oral, or inhaled steroids compared to index participants that are not using topical, oral, or inhaled steroids during the study/surveillance period|analysis of factors, baseline and prior history, for possible association with the cumulative incidence of sars-cov-2 detection in nasal samples: index participants and their household contacts over the study/surveillance period",observational,observational model: family-based|time perspective: prospective
Enzalutamide Treatment in COVID-19,COVIDENZA,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04475601,NCT04475601,"time to worsening of disease|time to improvement of disease|adverse events|duration of supplemental oxygen (days)|admission to icu|laboratory assessment of hemoglobin concentration day 0, 2, 4 and 6|virus load assessment day 0, 2, 4 and 6|hospital stay (days)|re-admission to hospital due to rebound covid-19|mortality at 6 months|hormonal status at 6 months|serological immunity for covid-19|laboratory assessment of crp concentration day 0, 2, 4 and 6|laboratory assessment of liver function day 0, 2, 4 and 6|laboratory assessment of creatinine concentration day 0, 2, 4 and 6|laboratory assessment of d-dimer concentration day 0, 2, 4 and 6|laboratory assessment of platelets concentration day 0, 2, 4 and 6|laboratory assessment of il-6 concentration day 0, 2, 4 and 6|laboratory assessment of b- and t-lyphocytes concentration day 0, 2, 4 and 6",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Lung Function, Exercise Capacity and Health-Related Quality of Life After Severe COVID-19",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04410107,NCT04410107,forced expiratory volume in the first second/forced vital capacity|total lung capacity|lung diffusion capacity for carbon monoxide|6-minute walk test distance|short-form 36 questionnaire (sf-36)|forced vital capacity|residual volume/total lung capacity|inspiratory capacity/total lung capacity|airway resistance (raw)|resistance at 20hz and 5hz (r5-r20)|reactance at 5hz (x5)|resonant frequency (fres)|reactance area (a–•)|pulse oximetry (spo2) at rest|pulse oximetry (spo2) during exercise|respiratory symptoms adapted from american thoracic society questionnaire|oxygen uptake at peak exercise|minute-ventilation/carbon dioxide output during exercise|dyspnea during exercise|inspiratory capacity during exercise|beck anxiety inventory (bai)|beck depression inventory (bdi)|post-traumatic stress symptoms questionnaire,observational,observational model: cohort|time perspective: prospective
Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04435808,NCT04435808,sars-cov-2 infection|symptomatic vs. asymptomatic infection with sars-cov-2|occupational health exposure|impact of hydroxychloroquine use on need for hospitalization with sars-cov-2 infection|impact of hydroxychloroquine use on need for icu care with sars-cov-2 infection|adverse effect profile of hydroxychloroquine|seroconversion following sars-cov-2 infection|metagenomic next generation sequencing of sars-cov-2 isolates,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04273646,NCT04273646,"pneumonia severity index|oxygenation index (pao2/fio2)|side effects in the uc-mscs treatment group|28-days survival|sequential organ failure assessment|c-reactive protein|procalcitonin|lymphocyte count|cd3+, cd4+ and cd8+ t celll count|cd4+/cd8+ratio",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
The Nitazoxanide Plus Atazanavir for COVID-19 Study,NACOVID,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04459286,NCT04459286,time to clinical improvement|time to sars-cov-2 negativity|difference in sars-cov-2 auc|time to symptoms resolution|clinical status as assessed with the seven-category ordinal scale on days 7 and 14|duration of hospitalization in survivors|day 28 mortality|time from treatment initiation to death|proportion with viral rna detection over time,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04414124,NCT04414124,number of patients experiencing study-product related treatment-emergent adverse events (teaes)|change from baseline to end of intake in overall composite covid-19 symptom score|time to resolution of fever|proportion of patients with decreased oxygen saturation|effect of covid-19 symptoms on physical activities|proportion of patients requiring hospitalization,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
Chloroquine as Antiviral Treatment in Coronavirus Infection 2020,nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04331600,NCT04331600,covid-19-related hospitalization or all-cause death|decrease in covid-19 symptoms|development of pneumonia|development of coronavirus infection-related complications,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers",CHAMPS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04370821,NCT04370821,"sample size of enrolled champs study participants by demographic characteristics during the first two years of the study|exposure to sars-cov-2 based on models computed from participant baseline data and community variables, if available.|infectious disease and chronic disease incidence rates by demographic characteristics|completeness of data by demographic characteristics.|participation rates in ancillary and sub-studies within the champs registry.|number of participants enrolled in randomized trials based on the champs registry",observational,observational model: cohort|time perspective: prospective
Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ‚©æ60 Years,nan,enrolling by invitation,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04470609,NCT04470609,adverse reactions/events rate|seroconversion rate of neutralizing antibodies against sars-cov-2 phase iib|seroconversion rate of igg antibodies against sars-cov-2 phase iib|serious adverse events|seroconversion rate of neutralizing antibodies against sars-cov-2 phase ib|seroconversion rate of igg antibodies against sars-cov-2 phase ib|level of neutralizing antibodies against sars-cov-2 phase ib|level of igg antibodies against sars-cov-2 phase ib|level of neutralizing antibodies against sars-cov-2 phase iib|level of igg antibodies against sars-cov-2 phase iib,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04513158,NCT04513158,determine the therapeutic efficacy (response rate) of convalescent plasma infusion in patients at high risk for mortality when infected by sars-cov-2 (covid-19).|determine the immunologic effects of convalescent plasma infusion|absolute lymphocyte count (10*3/ul)|reatinine kinase (mg/dl)|c-reactive protein (mg/dl)|d-dimer (ng/ml feu)|interleukin-6 (pg/ml)|ferritin (ng/ml),interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19),nan,"active, not recruiting",No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04383574,NCT04383574,safety index-incidence of adverse reactions|immunogenicity index-seroconversion rates of neutralizing antibody|safety index-incidence of serious adverse events|immunogenicity index-seropositive rates of neutralizing antibody|immunogenicity index-geometric mean titer (gmt) of neutralizing antibody|immunogenicity index-geometric mean ratio (gmr) of neutralizing antibody,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),nan,"active, not recruiting",No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04352608,NCT04352608,"safety indexes of adverse reactions|immunogenicity indexes of neutralizing-antibody seroconversion rates for the emergency vaccination schedule ôºàday 0,14ôºâ|immunogenicity indexes of neutralizing-antibody seroconversion rates for the routine vaccination schedule (day 0,28)|occurrence of abnormal changes of laboratory safety examinations (hemoglobin,wbcs, platelets, alt, ast, total bilirubin, creatinine, creatine phosphokinase, urine protein, urine sugar, urinary erythrocyte)|safety indexes of serious adverse events (saesôºâ|immunogenicity indexes of neutralizing-antibody seroconversion rates|immunogenicity indexes of igg antibody seropositivity rates|immunogenicity indexes igm antibody seropositivity rates|immunogenicity indexes of gmt of neutralizing-antibody|immunogenicity indexes of gmr of neutralizing-antibody",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
TXA and Corona Virus 2019 (COVID19) in Outpatients,TCOutpatient,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04338074,NCT04338074,hospitalization,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness,nan,available,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04337359,NCT04337359,nan,expanded access:intermediate-size population,nan
Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain,COVID19@Spain,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04355871,NCT04355871,overall mortality|mechanical ventilation,observational,observational model: cohort|time perspective: retrospective
Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-COV-2 (COVID-19),VOC-COVID,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04379154,NCT04379154,profiles of volatile organic compounds (vocs) in exhaled air between 2 health conditions|profiles of volatile organic compounds (vocs) in exhaled air on 1 health condition|profiles of volatile organic compounds (vocs) in exhaled air between 2 periods,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Azithromycin for COVID-19 Treatment in Outpatients Nationwide,ACTION,recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04332107,NCT04332107,hospitalization|viral load|mortality|adverse events|positive sars-cov-2 test - nasal swab|positive sars-cov-2 test - saliva swab|positive sars-cov-2 test - rectal swab|genetic macrolide resistance determinants|covid-19 symptoms|number of emergency room visits|number of household members with covid-19 (confirmed or symptomatic)|death,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",COVID-19,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04344457,NCT04344457,improvement of clinical status|time of clinical recovery of fever|time of clinical recovery of cough|safety as determined by changes in qtc intervals measured by ecg|safety as determined by presence of side effects|time to improvement,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04346017,NCT04346017,il6 concentration|il6 concentration change from baseline value|complement parameters|complement parameters change from baseline values|inflammatory cytokines baseline concentrations|inflammatory cytokines change from baseline values|concentration of markers of macrophage activation|markers of macrophage activation change from baseline values,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: basic science
Early Use of Corticosteroids in Hospitalized Patients With Moderate COVID19 Pneumonia,PREDCOVID,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04451174,NCT04451174,"composite primary end-point: admission to icu, need for invasive mechanical ventilation or all-cause death by day 28",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort",CORIPLASM,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04345991,NCT04345991,survival without needs of ventilator utilization or use of immunomodulatory drugs|who progression scale ‚â•6|severe adverse events|who progression scale|overall survival|time from randomization to discharge|time to oxygen supply independency|survival without needs of ventilator utilization|survival without use of immunomodulatory drugs,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Convalescent Plasma Trial in COVID -19 Patients,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04356534,NCT04356534,requirement for invasive ventilation|change in viral clearance|radiological change|change in white cell count|c reactive protein measurement|lactate dehydrogenase measurement|procalcitonin measurement|d dimer measurement|ferritin measurement|troponin t measurement|brain naturetic peptide measurement|mortality rate,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04444596,NCT04444596,sars-cov2 positive conjunctival swabs|conjunctival swab vs nasopharyngeal swab,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Rehabilitation Needs After COVID-19 Hospital Treatment,REACT,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04438239,NCT04438239,"number of participants with considerable dyspnea: medical research council (mrc, 0-4, lower score better outcome)|number of participants with fatigue|number of participants with anxiety|number of participants with depression|level of independence in b-adl|level of participation in social|description of qualitative data about patients' experience",observational,observational model: other|time perspective: prospective
Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04458519,NCT04458519,change in severity of covid-19 infection|number of days with any symptom of anosmia|maximal intensity attained in overall assessment of symptoms of covid-19 infection as measured on visual analogue scale (vas).|number of days where rescue medication is required,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (care provider, outcomes assessor)|primary purpose: treatment"
Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04343742,NCT04343742,negative testing of covid19,observational,observational model: case-only|time perspective: prospective
Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital,CovidRegOUH,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04345536,NCT04345536,mortality|severe disease,observational,observational model: cohort|time perspective: prospective
Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study),ConCoVid-19,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04342182,NCT04342182,overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first|impact of 300ml convp therapy on hospital days|impact of 300ml convp on weaning from oxygen therapy|impact of 300ml convp on overall mortality in patients admitted to the icu within 24 hours after admission|difference in the effect of convp on mortality in patients with a duration of symptoms less or more the median duration of symptoms in the study population|impact of 300ml convp therapy on icu days in patients admitted to the icu within 24 hours after admission|impact of plasma therapy on the decrease in sars-cov2 shedding from airways|impact of ctl and nk cell immunity on the likelihood of being protected from immune serum transfer|safety of convp therapy|change of the 8-point who covid19 disease severity scale on day 15|change of the 8-point who covid19 disease severity scale on day 30|change of the 8-point who covid19 disease severity scale on day 15 in the subgroup of patients with a baseline neutralizing antibody titer (prnt50) <80.|impact of plasma therapy on risk of long-term structural lung damage and lung function,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Charit√© Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients,nan,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04500418,NCT04500418,subject¬¥s responder status (score on the 7-point ordinal scale on day 15)|evaluation of change in clinical condition based on the 7-point ordinal scale|evaluation of change in clinical condition based on the 7-point ordinal scale and responder status|hospital resource utilization comparison,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,nan,recruiting,No Results Available,not applicable,Industry|Other,https://ClinicalTrials.gov/show/NCT04347174,NCT04347174,sequential organ failure assessment (sofa) scores|7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)|all-cause mortality|incidence of ae / sae or event of clinical significance|sars-cov-2 detectable in nasal or oropharyngeal (op) sample|icu length of stay|duration of mechanical ventilation|duration of hospitalization|clinical improvement|time (in days) from treatment initiation to death,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04409522,NCT04409522,melatonin|inflammatory cytokines|c-reactive protein (crp)|cough|oxygen saturation of the blood|esr|radiological treatment response|inflammatory route,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: treatment"
The VOICE-COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04508972,NCT04508972,correlation between data captured using amazon alexa compared to manual (human) collected data.,observational,observational model: cohort|time perspective: prospective
The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04360980,NCT04360980,crpxn/r ratio change|clinical deterioration by the who definition|pcr viral load|ct severity involvement index|ldh change,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Hematology and Clinical Picture in Pediatric COVID-19 Infection,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04487119,NCT04487119,hematological findings|clinical presentations,observational,observational model: cohort|time perspective: retrospective
"A Study to Evaluate the Safety and Efficacy of Razuprotafib, a Novel Tie 2 Activator, in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19)",RESCUE,not yet recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04511650,NCT04511650,number of participants with any serious adverse event from baseline to day 7|number of participants with any serious adverse event from baseline to day 28|number of participants with any treatment emergent adverse event from baseline to day 7|number of participants with any treatment emergent adverse event from baseline to day 28|proportion of subjects alive and free of respiratory failure at day 7|proportion of subjects alive and free of respiratory failure at day 28|length hospitalized and free of respiratory failure from baseline to day 7|length hospitalized and free of respiratory failure from baseline to day 28|length of hospitalization from baseline to day 7|length of hospitalization from baseline to day 28|proportion of subjects who improve by at least 2 categories on the niaid 8-point ordinal scale from baseline to day 7|proportion of subjects who improve by at least 2 categories on the niaid 8-point ordinal scale from baseline to day 28|proportion of subjects who worsen by at least 2 categories on the niaid 8-point ordinal scale from baseline to day 7|proportion of subjects who worsen by at least 2 categories on the niaid 8-point ordinal scale from baseline to day 28|all-cause mortality at day 7|all-cause mortality at day 28|length of icu stay from baseline to day 28|number of subjects in each category of the niaid 8-point ordinal scale at day 7|number of subjects in each category of the niaid 8-point ordinal scale at day 28|time to return to prehospitalization oxygen requirement|proportion of subjects who were discharged and remained free of respiratory failure prior to day 7|proportion of subjects who were discharged and remained free of respiratory failure prior to day 28|change in pao2:fio2 ratio from baseline to day 7|change in pao2:fio2 ratio from baseline to day 28,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
The Heart Hive COVID-19 Study,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04468256,NCT04468256,"qualitative measures of exposure, perception of risk, behaviour, and experience during the covid-19 pandemic.|health outcomes",observational,observational model: case-control|time perspective: prospective
CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04512118,NCT04512118,visual analysis of pulmonary lobes|measurement of metabolic activity,observational,observational model: case-only|time perspective: retrospective
CAPTION AI to Minimize Risk of COVID Exposure,CAPTION AI,withdrawn,No Results Available,not applicable,Other|Industry,https://ClinicalTrials.gov/show/NCT04336774,NCT04336774,percent of patient echos that are not interpretable|percent of patient echos that provide an automated (ai) lvef (left ventricular ejection fraction)|time to acquire images as measured by time stamps|percent of agreement between ai calculate lvef and lvef read by physician,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04393246,NCT04393246,"time to incidence of the composite endpoint of: death, mechanical ventilation, ecmo, cardiovascular organ support, or renal failure|change in biomarkers thought to be associated with progression of covid-19 compared to baseline: il-6|change in biomarkers thought to be associated with progression of covid-19 compared to baseline: ferritin|change in biomarkers thought to be associated with progression of covid-19 compared to baseline: c-reactive protein (crp)|change in biomarkers thought to be associated with progression of covid-19 compared to baseline: d-dimer|change in biomarkers thought to be associated with progression of covid-19 compared to baseline: neutrophil/lymphocyte ratio|change in biomarkers thought to be associated with progression of covid-19 compared to baseline: lactate dehydrogenase (ldh)|change in clinical status as assessed on 7-point ordinal scale compared to baseline|time to each of the individual endpoints of the composite primary outcome measure|proportion of patients with adverse events of special interest in each treatment arm|time to sp02 >94% on room air|time to first negative sars-cov2 pcr|duration of oxygen therapy|duration of hospitalisation|all-cause mortality at day 28|time to clinical improvement",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure,COMBAT-COVID,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04420741,NCT04420741,mechanical ventilation free days|28 and 90-day mortality|modified sequential organ failure assessment (sofa)|vasopressor free days|renal replacement free days|serious adverse reactions (sars)|serious adverse events (saes),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Sitagliptin Treatment in Diabetic COVID-19 Positive Patients,SIDIACO-RETRO',completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04382794,NCT04382794,clinical parameter of acute lung disease|death|biochemical parameter of acute lung disease,observational,observational model: case-control|time perspective: retrospective
Treatment of SARS Caused by COVID-19 With Ruxolitinib,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04334044,NCT04334044,recovery of pneumonia|response of c-reactive protein|response of ferritin|response of d-dimer|rate of icu admission|rate of mechanical ventilation|overall survival|toxicity rate,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Predictive Factors COVID-19 Patients,MI-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04427345,NCT04427345,"identify risk factors for intra-hospital mortality.|identify risk factors to build a prognostic score.|predictive factors for the hospitalization duration.|predictive factors for clinical status patients based on ""ordinal scale for clinical improvement""|describe the anti-viral therapies used commonly in this emergency in terms of efficacy|describe the anti-viral therapies used commonly used in this emergency in terms of safety|monitor the clinical course of the disease in discharged patients.",observational,observational model: cohort|time perspective: retrospective
NutriCovid30 : Nutritional Evaluation for Covid-19 Infection at D30,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04365816,NCT04365816,evaluation of food intake at 1 month after discharge from hospital for covid|weight variation during the infection|clinical signs limiting food intake|factors limiting food intake|implemented nutritional strategy|pre-existing chronic disorders|covid-19 repercussions,observational,observational model: cohort|time perspective: prospective
Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling,Snowball,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04437706,NCT04437706,number of participants with active infection|number of participants with antibodies indicating past exposure,observational,observational model: ecologic or community|time perspective: prospective
Impact of COVID-19 on Personal Protection Among Dentist in Egypt,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04403828,NCT04403828,personal protection measures|impact of covid-19 pandemic on type of face masks used in dental clinic,observational,observational model: cohort|time perspective: cross-sectional
Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS),ANA-COVID-GEAS,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04443881,NCT04443881,"treatment success, defined as number of patients not requiring mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe covid-19 and css pneumonia.|number of patients not requiring mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe covid-19 and css pneumonia.|time to mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe covid-19 and css pneumonia.|time to oxygen saturation normalization to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe covid-19 and css pneumonia.|stay in icu and hospitalization to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe covid-19 and css pneumonia.|total mortality rate to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe covid-19 and css pneumonia.|mortality 48 hours, 7 days, in icu and hospital to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe covid-19 and css pneumonia.|viral clearance / viral shedding to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe covid-19 and css pneumonia.|to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe covid-19 and css pneumonia.",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit,AziA,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04363060,NCT04363060,rate of positive sars-cov-2 rt-pcr|clinical evolution on the world health organization ordinal scale for clinical improvement for covid-19|total duration of antibiotic treatment during the 30 days following inclusion|number of all-cause mortality during the 30 days following inclusion|number of in-hospital mortality during the 30 days following inclusion|number of patients transferred to intensive care unit during the 30-day follow-up|number of days without mechanical ventilation during the 30 days following inclusion|adverse events attributable to antibiotic treatment during the 30 days following inclusion|hospital length of stay during the 30 days following inclusion,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19,nan,"active, not recruiting",No Results Available,nan,U.S. Fed|Other,https://ClinicalTrials.gov/show/NCT04545047,NCT04545047,all-cause mortality|time to first intubation|time to hospital discharge|time to all-cause mortality,observational,observational model: other|time perspective: retrospective
Ivermectin Nasal Spray for COVID19 Patients,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04510233,NCT04510233,pcr of sars-cov2 rna,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Assessment of SARS-CoV-2 Seroprevalence in Detention,COVIDET,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04516512,NCT04516512,determination of the immunological parameters (immunoglobins g) of the sars-cov-2 infection|symptoms suggestive of covid-19|factors assumed to be related to infection with sars-cov-2 and the occurrence of moderate to severe forms of covid-19,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: screening
COVID - AirPollution,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04463862,NCT04463862,covid-19 related-mortality|covid-19 confirmed cases,observational,observational model: cohort|time perspective: other
Progesterone for the Treatment of COVID-19 in Hospitalized Men,nan,"active, not recruiting",No Results Available,phase 1,Other|Industry,https://ClinicalTrials.gov/show/NCT04365127,NCT04365127,"change in clinical status of subjects at day 7 based on the following 7-point ordinal scale|change in clinical status of subjects assessed daily while hospitalized and on day 15|duration of supplemental oxygen, mechanical ventilation (if applicable), and hospitalization",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
The Vietnam Chloroquine Treatment on COVID-19,VICO,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04328493,NCT04328493,viral clearance time|lengh of hospital stay|ventilator free days|oxygene free days|time to death|adverse events|fever clearance time|ordinal outcome scale|development of ards,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Genetics of COVID-19 Susceptibility and Manifestations,nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04371432,NCT04371432,molecular etiology of host susceptibility to severe covid-19|mechanisms of disease,observational,observational model: case-control|time perspective: prospective
Proctologic Practice and Covid-19,PROCTOLOCK,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04392245,NCT04392245,predictive power of respondents' and hospitals' demographics on the change of status of proctologic surgical and outpatient activities,observational,observational model: other|time perspective: prospective
Povidone-Iodine Rinses in the Management of COVID-19,nan,not yet recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04449965,NCT04449965,change in sars-cov-2 positivity in the saliva|change in the sar-cov-2 viral load in the saliva|change in wisconsin upper respiratory symptom survey (wurss-44)|change sino nasal outcome test (snot-22)|change in clinical condition,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Effect of COVID-19 on Platelet Aggregation,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04447131,NCT04447131,"platelet aggregation analyzed by multiplate-adp|platelet aggregation by multiplate-aspi and multiplate-trap in patients hospitalized for covid-19 versus healthy controls.|reticulated platelet fraction in patients hospitalized for covid-19 versus healthy controls.|platelet aggregation for covid-19 versus patients hospitalized for respiratory symptoms but negative for influenza and covid-19 research.|reticulated platelet fraction in patients hospitalized for covid-19 versus patients hospitalized for respiratory symptoms but negative for influenza or covid-19 research.|platelet aggregation in patients hospitalized for covid-19 versus patients hospitalized for influenza.|reticulated platelet fraction in patients hospitalized for covid-19 versus patients hospitalized for influenza.|platelete aggreggation versus composite outcome of death from any cause, thrombotic events, need for icu, need for intubation during hospitalization|reticulated platelet fraction versus composite outcome of death from any cause, thrombotic events, need for icu, need for intubation during hospitalization|platelet aggregation versus time (days) of total hospitalization and in the icu|reticulated platelet fraction versus time (days) of total hospitalization and in the icu|platelet aggregation versus who ordinal scale of outcomes for covid-19",observational,observational model: case-control|time perspective: prospective
Role of Famotidine in the Symptomatic Improvement of COVID-19 Patients,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04504240,NCT04504240,"symptomatic improvement|""clinical status (stable or deteriorate clinical state)""|adverse effects",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection,nan,"active, not recruiting",No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04372017,NCT04372017,cohort a: percentage of covid-19 exposed healthcare workers treated with hydroxychloroquine with a positive covid-19 test.|cohort b: percentage of covid-19 exposed high-risk individuals treated with hydroxychloroquine with a positive covid-19 test.,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
Registry of Seraph¬Æ-100 Microbind¬Æ Affinity Blood Filter for COVID-19 Under EUA,nan,recruiting,No Results Available,nan,Other|Industry,https://ClinicalTrials.gov/show/NCT04413955,NCT04413955,"rate of known, expected, or unanticipated adverse device effects|change in cardiovascular hemodynamic stability|change in cardiovascular hemodynamic support|change in pulmonary/respiratory status|change in laboratory measures of cytokine reactions and/or viral sepsis: il-6|change in laboratory measures of cytokine reactions and/or viral sepsis: crp|change in laboratory measures of cytokine reactions and/or viral sepsis: ferritin|change in laboratory measures of cytokine reactions and/or viral sepsis: d-dimer|change in laboratory measures of cytokine reactions and/or viral sepsis: alc",observational,observational model: cohort|time perspective: prospective
CSL324 in COVID-19,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04519424,NCT04519424,proportion of subjects progressing to endotracheal intubation or death prior to endotracheal intubation|proportion of deaths from all causes|proportion of subjects intubated|median length of stay in hospital|number and proportion of subjects with at least a 2-point improvement in the national institute of allergy and infectious diseases (niaid) ordinal scale|number and proportion of subjects within each of the categories of the niaid ordinal scale|proportion of subjects using continuous positive airway pressure (cpap) or bilevel positive airway pressure (bipap)|proportion of subjects using high-flow nasal cannula (hfnc)|proportion of subjects using extracorporeal membrane oxygenation (ecmo)|maximum change in sequential organ failure assessment (sofa) score|change in sofa score and in individual components of the sofa score|number and proportion of subjects experiencing adverse events (aes)|number and proportion of subjects experiencing serious adverse events (saes)|number and proportion of subjects experiencing adverse events of special interest (aesis)|presence of anti-csl324 antibodies|maximum concentration (cmax) of csl324|time to reach maximum concentration (tmax) of csl324|area under the concentration-time curve (auc0-last) of csl324|trough concentration (ctrough) of csl324,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Assess the Seroconversion Status of Health Care Workers Suspected or Confirmed Cases of COVID-19 Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04368884,NCT04368884,development of antibodies,observational,observational model: cohort|time perspective: prospective
"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19",nan,recruiting,No Results Available,phase 1,Industry|U.S. Fed|Other,https://ClinicalTrials.gov/show/NCT04469179,NCT04469179,number of participants having adverse events|number of participants having transfusion-related adverse events|assesment of the pd of sab-185 administered intravenously|immune response elicited by sab-185|concentration of subject anti-sab-185 antibodies elicited by sab-185|incidence of sars-cov-2 in oropharyngeal (op) or nasopharyngeal (np) swab specimens|level of sars-cov-2 in oropharyngeal (op) or nasopharyngeal (np) swab specimens,interventional,"allocation: randomized|intervention model: sequential assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Survey of the Anxiety Associated With the COVID-19 Pandemic,CORA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04331106,NCT04331106,characteristics of covid-19-related anxiety|covid-19-related anxiety symptoms|self-efficacy and coping with covid-19|consequences of covid-19 in the last three weeks.|general illness attitude|media reporting|ultra-brief screening scale for anxiety and depression|change in characteristics of covid-19-related anxiety|change in covid-19-related anxiety symptoms,observational,observational model: cohort|time perspective: prospective
VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL),VA-REACH,suspended,No Results Available,phase 3,U.S. Fed,https://ClinicalTrials.gov/show/NCT04363203,NCT04363203,"days to resolution of cough, fever and shortness of breath|days to resolution of all covid-19 symptoms|all cause hospitalization|all cause mortality|covid-19 specific mortality|covid-19 specific hospitalization",interventional,"allocation: randomized|intervention model: single group assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04521296,NCT04521296,time to sars-cov-2 eradication|rate of sars-cov-2 eradication|time to clinical improvement of subjective symptoms,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19,COVID19PUGG2,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04343781,NCT04343781,symptoms of covid-19 in older patients,observational,observational model: cohort|time perspective: cross-sectional
A Trial of Remdesivir in Adults With Mild and Moderate COVID-19,nan,suspended,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04252664,NCT04252664,"time to clinical recoverytime to clinical recovery (ttcr)|all cause mortality|frequency of respiratory progression|time to defervescence (in those with fever at enrolment)|time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)|frequency of requirement for supplemental oxygen or non-invasive ventilation|time to 2019-ncov rt-pcr negative in upper respiratory tract specimen|change (reduction) in 2019-ncov viral load in upper respiratory tract specimen as assessed by area under viral load curve.|frequency of requirement for mechanical ventilation|frequency of serious adverse events",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
The CEDiD Study (COVID-19 Early Diagnosis in Doctors and Healthcare Workers),CEDiD,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04363489,NCT04363489,covid-19 infection|symptoms|clinical observations,observational,observational model: cohort|time perspective: prospective
Efficacy and Safety of Favipiravir in Management of COVID-19,FAV-001,completed,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04349241,NCT04349241,viral clearance|clinical improvement|radiological improvement,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients,PredictCovid-D,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04371510,NCT04371510,predictive value of il-6 contents of whole blood samples after ex vivo stimulation,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
"Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19",ERap-COV,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04405492,NCT04405492,"clinical performance of several diagnostic tests : tests based either on detection of the virus sars-cov-2 or detection of human antibodies generated in response to infection|sensitivity and specificity of immunological, antigenic, molecular and proteomic tests according to symptom duration, stage of the disease: asymptomatic, ambulatory, hospitalized, ventilated|description of the incidence of infection among hospital caregivers, time to seroconversion according to clinical form, medium-term antibody persistence|sensitivity and specificity of immunodiagnostic tests according to the sample used (serum and capillary blood) and according to the duration of the symptoms|sensitivity and specificity of antigenic rapid tests, molecular tests, proteomic tests according to the sample used (salivary samples or nasopharyngeal swabs) and according to the duration of the symptoms|suitability of rapid tests in view of its intended purpose for self-testing",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: diagnostic
"COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients (COST ACTION)",COST ACTION,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04367402,NCT04367402,retrospective study on individuals with or without symptoms to verify the reliability of a prognostic/diagnostic test based on igm/igg analysis.|ace2 expression in patients with covid-19 infection,observational,observational model: case-control|time perspective: retrospective
Singapore COVID-19 Chemosensory Tracking (SCCT) Study,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04492904,NCT04492904,"taste and smell acuity|experienced symptoms, changes in appetite and food-related quality of life",observational,observational model: case-control|time perspective: other
Immunophenotyping Assessment in a COVID-19 Cohort,IMPACC,enrolling by invitation,No Results Available,nan,NIH|Other,https://ClinicalTrials.gov/show/NCT04378777,NCT04378777,"mortality rate among covid-19 patients|proportion of patients with covid-19 who require intensive care unit (icu)-level care, mechanical ventilatory support (mv), and/or extracorporeal membrane oxygenation (ecmo) over time to day 28|proportion of patients with covid-19 who develop shock, secondary organ failure, or secondary infection over time to day 28|mechanistic: longitudinal assessment of viral load by semi-quantitative polymerase chain reaction (pcr) over time to day 28|mechanistic: antibody isotype/subclass classification and functionality over time through day 28 and at follow-up through month 12|mechanistic: longitudinal assessment of inflammatory mediators as collected over time to day 28|mechanistic: longitudinal assessment of markers of myocardial injury over time to day 28|duration of mechanical ventilation in patients with covid-19 over time to day 28|proportion of patients with covid-19 with requirement for new (or increased from baseline if on home oxygen) supplemental oxygen over time to day 28|requirement for extracorporeal membrane oxygenation (ecmo) in covid-19 patients with covid-19 over time to day 28|mechanistic: immune cell frequencies and activation status (cytof) in blood and endotracheal aspirate over time through day 28 and in blood at select study visits through month 12|mechanistic: gene expression (transcriptomics) in blood|mechanistic: gene expression (transcriptomics) in respiratory epithelium|mechanistic: gene expression (transcriptomics) in plasma protein|mechanistic: gene expression (transcriptomics) in metabolic profiling|mechanistic: circulating immune mediators assessed by olink methodology",observational,observational model: cohort|time perspective: prospective
VIR-7831 for the Early Treatment of COVID-19 in Outpatients,COMET-ICE,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04545060,NCT04545060,"proportion of participants who have progression of covid-19 through day 29|occurence of of adverse events (aes)|occurrence of serious adverse events (saes)|occurrence of adverse events of special interest (aesi)|incidence and titers (if applicable) of serum ada to vir-7831|cmax|clast|tmax|tlast|aucinf|auclast|%aucextrap|t1/2|vz|vss|cl|proportion of participants who have progression of covid-19 as defined by hospitalization >24 hrs or death at day 8, day 15, or day 22|proportion of participants who progress to develop severe and/or critical respiratory covid-19 as manifest by requirement for and method of supplemental oxygen at day 8, day 15, day 22, or day 29|severity and duration of participant-reported symptoms of covid-19 related illness using the flu-pro patient-reported outcome instrument|detection of sars-cov-2 in nasal secretions by pcr at baseline and during follow-up period through day 29|29-day, 60-day, and 90-day all-cause mortality",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Saliva as Source of Detection for SARS-CoV-2,nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04424446,NCT04424446,saliva sars-cov-2 rt-pcr test results|saliva and midturbinate swab sars-cov-2 rt-pcr test results,observational,observational model: case-only|time perspective: cross-sectional
SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding,SHIELD,recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04478019,NCT04478019,number of participants with covid-19 diagnosis|sars-cov-2 viral load|fidelity of the treatment regimen|feasibility of the treatment regimen,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: prevention
Asunercept in Patients With Severe COVID-19,ASUNCTIS,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04535674,NCT04535674,time to sustained improvement of one category (i.e. two consecutive days) from randomisation|efficacy according to the national early warning score (news)|oxygenation|ventilation|hospitalisation - length|hospitalisation - proportion on icu|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Endoscopic Interventions in Patients With COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04423003,NCT04423003,death in time of observation,observational,observational model: cohort|time perspective: prospective
A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),CTII-nCoV,"active, not recruiting",No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04341389,NCT04341389,occurrence of adverse reactions|anti sars-cov-2 s igg antibody response(elisa)|neutralizing antibody response to sars-cov-2|occurrence of adverse events|occurrence of serious adverse reaction|neutralizing antibody response to ad5-vector|ifn-œ≥ elispot responses to sars-cov-2 spike protein,interventional,"allocation: randomized|intervention model: crossover assignment|masking: double (participant, investigator)|primary purpose: prevention"
Tableted COVID-19 Therapeutic Vaccine,COVID-19,"active, not recruiting",No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04380532,NCT04380532,effect on cbc as per ctcae v4.0|effect on biochemistry parameters as per ctcae v4.0|lack of adverse events as per ctcae v4.0,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"Identification of Genetic Factors Determining Disease Course in the New Type of Coronavirus Infection, COVID-19",nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04426253,NCT04426253,identification of genetic factors determining the course of the disease in case of covid-19,observational,observational model: case-only|time perspective: prospective
"A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19",nan,recruiting,No Results Available,phase 1,Industry|NIH,https://ClinicalTrials.gov/show/NCT03891420,NCT03891420,number of subjects with treatment emergent adverse events and serious adverse events|number of subjects with change in laboratory parameters|exposure of galidesivir as measured by plasma concentrations|yellow fever virus (yfv) titer (group a)|antiviral effect on sars-cov-2 in the respiratory tract - covid-19 (group b)|changes in clinical status using 8-point ordinal scale in covid-19 (group b)|changes from baseline and time to improvement using news in covid-19 (group b)|mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
"Egyptian Doctors Stresses, Knowledge and Attitude During COVID-19 Pandemic",nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04403581,NCT04403581,"cross-sectional descriptive study: egyptian doctors stresses, knowledge and attitude during covid-19 pandemic",observational,observational model: cohort|time perspective: cross-sectional
Surveillance of Individuals Following SARS-CoV-2 Exposure,nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04383444,NCT04383444,"results of sars-cov-2 rt- pcr testing, antibody assay, and culture|sars-cov-2 culture and rt-pcr results|symptom checklist",observational,observational model: cohort|time perspective: prospective
COVID-19 Follow up Intensive Care Studies,COFICS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04460170,NCT04460170,general health|anxiety and depression|long function|frailty|family functioning|effect of an icu admission on return to work|age|gender|social status|apache iv|comorbidity|body mass index|icu stay|mechanical ventilation|delerium|hospital stay|discharge locationn|mortality|relationship with the patient|educational level|readmission|health care consumption|weight|hypertensive|thrombosis|diabetes,observational,observational model: cohort|time perspective: prospective
Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19,CoronaStem1,not yet recruiting,No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04486001,NCT04486001,frequency of all adverse events|frequency of infusion related serious adverse events|frequency of serious adverse events|mortality|ventilator free days|icu free days|total hospital days|total icu days|improvement in oxygenation,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto,HETHICO,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04393805,NCT04393805,bleeding|thrombosis|mortality|worsening|los,observational,observational model: cohort|time perspective: retrospective
Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04412668,NCT04412668,"incidence of treatment-emergent adverse events (teaes)|time to normalization of oxygen saturation (spo2) (>93% on room air sustained for at least 24 hours)|duration of supplemental oxygen (o2) requirement|number of days with fever (temperature >100.4¬∫f [38.0¬∫c])|time to normalization of temperature (‚â§100.4¬∫f [38.0¬∫c])|change from baseline in world health organization (who) ordinal scale score on days 5, 7, 14, 28, and 60|time to improvement from inpatient hospital admission based on at least a 1 point reduction in who ordinal scale score",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Evaluating Clinical Parameters of COVID-19 in Pregnancy,COpregVID,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04470583,NCT04470583,"proportions of leukocyte subsets and thrombocytes in pregnant/postnatal and non-pregnant covid-19 positive women.|concentrations of other biochemical markers of severity in pregnant and non-pregnant covid-19 positive women.|profiling of clinical severity, determined by clinical symptoms and observations in pregnant and non-pregnant covid-19 positive women.",observational,observational model: cohort|time perspective: retrospective
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04555096,NCT04555096,28 day all-cause mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Clinical Improvement and COVID-19 Pneumonia,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04444531,NCT04444531,time to clinical improvement|clinical improvement at day 14|clinical improvement at day 28|time to a 2-fold decrease of c-protein reactive from baseline|time to a 2-fold decrease of ferritin from baseline|time to a 2-fold decrease of lactate dehydrogenase from baseline|time to a 2-fold decrease of d-dimer from baseline,observational,observational model: cohort|time perspective: prospective
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults,nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04537949,NCT04537949,"solicited local reactions at the injection site (pain/tenderness, erythema/redness, induration/swelling) recorded up to 7¬±1 days after each immunization.|solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) recorded up to 7¬±1 days after each immunization.|the proportion of subjects with at least 1 unsolicited treatment emergent adverse event (teae) occurring up to 21¬±2 days after the prime immunization.|the proportion of subjects with at least 1 unsolicited teae occurring up to 28¬±4 days after the boost immunization.|functional antibody responses.|fold increase in functional antibody titers.|number of subjects with seroconversion defined as a minimum of 4-fold increase of functional antibody titers as compared to baseline.",interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: prevention
Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19,nan,enrolling by invitation,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04346628,NCT04346628,time until cessation of oral shedding of sars-cov-2 virus|sars-cov-2 viral load|count of participants with clinical worsening of covid-19 disease|count of participants with development of sars-cov-2 antibodies|time until cessation of symptoms|count of participant with absence of development of any symptoms|cmax of favipiravir|cmin of favipiravir,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Role of Co-trimoxazole in Severe COVID-19 Patients,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04470531,NCT04470531,length of stay in hospital (in days)|in-patient mortality|spo2/fio2 ratio|respiratory rate|c-reactive protein|fever|ventilator support|proportion of drug adverse reaction,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Silymarin in COVID-19 Pneumonia,SCOPE,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04394208,NCT04394208,time to clinical improvement|clinical outcome|duration of mechanical ventilation|hospitalization|virologic response|adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Piclidenoson for Treatment of COVID-19,nan,not yet recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04333472,NCT04333472,proportion of subjects alive and free of respiratory failure|proportion of subjects discharged home alive|treatment-emergent adverse events (aes)|clinical status|time to improvement|incidence of mechanical ventilation|ventilator-free days|incidence of intensive care unit (icu) admission|duration of icu stay|time to hospital discharge|duration of need for supplemental oxygen|time to virus negativity|sars-cov-2 viral load|aes leading to withdrawal|treatment-emergent serious aes (saes)|treatment-emergent abnormalities in clinical laboratory parameters or electrocardiograms (ecgs)|incidence of meeting safety-related stopping rules|pharmacokinetics of piclidenoson in this patient population,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Genetic Basis of COVID-19 Infection,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04384250,NCT04384250,mutations leading to increase susceptibility to sars-cov-2 infection,observational,observational model: case-only|time perspective: prospective
Canakinumab MAP in COVID-19 Pneumonia With CRS,nan,available,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04476706,NCT04476706,nan,expanded access,nan
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,nan,completed,No Results Available,phase 2,NIH|Other,https://ClinicalTrials.gov/show/NCT04358068,NCT04358068,"proportion of participants who died from any cause or were hospitalized|proportion of participants who died from any cause|proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|proportion of participants who died from any cause or were hospitalized through the end of follow-up|proportion of participants who prematurely discontinue study treatment due to an adverse event|proportion of participants who had any cardiac adverse events|duration of fever|duration of symptoms associated with covid-19 disease|participant-specific area under the curve (auc) of the symptom score associated with covid-19 disease over time|time to self-reported return to usual (pre-covid) health.|sars-cov-2 rna detection status from self-collected nasal and site-collected np swabs among subset|sars-cov-2 rna level (continuous) from self-collected nasal and site-collected np swabs among subset",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Previfenon¬Æ as Chemoprophylaxis of COVID-19 in Health Workers,HERD,not yet recruiting,No Results Available,phase 2|phase 3,Industry|Other,https://ClinicalTrials.gov/show/NCT04446065,NCT04446065,event of clinical acute respiratory disease with a diagnosis of covid-19 confirmed with rtpcr|rate of positive cases for igm and igg anti-sars-cov-2|composite outcome considering symptomatic and asymptomatic cases with positive rtpcr test|hospitalization due to any acute respiratory infection|event of upper and lower airway respiratory infection,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Community Pharmacists Behaviour During Covid-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04374513,NCT04374513,community pharmacists facing covid-19,observational,observational model: other|time perspective: prospective
Long-term Characterization of Patients With Severe/Critical Infection by COVID-19 Virus,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04559100,NCT04559100,lung function|radiological alterations|quality of life alterations,observational,observational model: other|time perspective: prospective
"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19",nan,completed,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04437875,NCT04437875,the changing of antibody levels against the sars-cov-2 glycoprotein s at 42 days|number of participants with adverse events|the changing of virus neutralizing antibody titer|the changing of antigen-specific cellular immunity level,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04351152,NCT04351152,"time to recovery|incidence of invasive mechanical ventilation and/or death|incidence of severe acute respiratory distress syndrome (ards)|duration of intensive care unit (icu) stay|ventilator-free days|duration of hospitalization|time to improvement in 1 or 2 categories using 8-point ordinal scale|time to death|number of subjects alive and off oxygen|percentage of participants experiencing adverse events|percentage of participants experiencing serious adverse events|proportion of subjects discharged from hospital|all-cause mortality and proportion of subjects alive|time to improvement in oxygenation for > 48 hours|incidence of non-invasive ventilation (or use of high-flow oxygen device)|time to clinical improvement, defined as news2 < 2 maintained for 24 hours|change from baseline to day 28 in clinical status based on the 8-point ordinal scale|duration of time on low-flow or high-flow supplemental oxygen",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04471051,NCT04471051,inpatient mortality|requirement for mechanical ventilation|transfer to icu|icu mortality|icu length of stay (los)|hospital mortality|hospital length of stay (los),observational,observational model: cohort|time perspective: prospective
Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure,PRO-CARF,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04477655,NCT04477655,intubation rate|total hours of prone position at day|total number of prone sessions at day|hours of the longest prone session each day|change in oxygenation 1-hour after first prone session|change in the rox-index 1-hour after first prone session|total days of prone positioning therapy|adverse effects of prone positioning therapy|mechanical ventilation days|intensive care unit length of stay|hospital length of stay|hospital mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Prevalence Of COVID-19 Among Health-workers in a French General Hospital,POCAH-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04548908,NCT04548908,general prevalence of covid-19|number of asymptomatic healthcare workers|number of symptomatic healthcare workers|number of healthcare workers with a severe form of covid-19 which led to an hospitalization|number of healthcare workers infected with covid-19 and hospitalized in a critical care unit|influencing factors of the prevalence of the covid-19 among healthcare workers,observational,observational model: cohort|time perspective: prospective
Preventing COVID-19 in Healthcare Workers With HCQ: A RCT,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04347889,NCT04347889,covid-19 seroconversion rate|admission for covid-19,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
A Study of LY3819253 (LY-CoV555) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff,BLAZE-2,recruiting,No Results Available,phase 3,Industry|NIH|Other,https://ClinicalTrials.gov/show/NCT04497987,NCT04497987,"percentage of participants with sars-cov-2 infection|percentage of participants with moderate or worse severity covid-19|percentage of participants with mild or worse severity covid-19|percentage of participants who are hospitalized due to covid-19|percentage of participants who experience covid-19-related hospitalization, covid-19 related emergency room visit, or death|percentage of participants who die due to covid-19",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
Impact of the Coronavirus (COVID-19) on Patients With Cancer,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04330521,NCT04330521,number of participants who fill out the survey and participate in the semi-structured interviews.,observational,observational model: cohort|time perspective: retrospective
Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04366180,NCT04366180,incidence of sars cov-2 infection in healthcare workers|incidence of hospital admissions caused by sars-cov-2 infection|incidence of icu admissions caused by sars-cov-2 infection|incidence of pneumonia caused by sars-cov-2 infection|incidence of oxygen support requirement caused by sars-cov-2 infection|incidence of gastrointestinal symptoms caused by sars-cov-2 infection|days with body's temperature > 37.5 ¬∫c|days with cough|days with fatigue|medical treatment,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients,PIIPPI,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04364802,NCT04364802,percent of healthcare workers testing positive for covid-19.|percent of patients testing positive for covid-9.|pvp-i ease of use|pvp-i comfort,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),nan,"active, not recruiting",No Results Available,phase 1,NIH,https://ClinicalTrials.gov/show/NCT04283461,NCT04283461,frequency of solicited local reactogenicity adverse events (aes)|frequency of any medically-attended adverse events (maaes)|frequency of any new-onset chronic medical conditions (nocmcs)|frequency of any serious adverse events (saes)|frequency of any unsolicited adverse events (aes)|frequency of solicited systemic reactogenicity adverse events (aes)|grade of any unsolicited adverse events (aes)|grade of solicited local reactogenicity adverse events (aes)|grade of solicited systemic reactogenicity adverse events (aes)|geometric mean fold rise (gmfr) in igg titer from baseline|geometric mean titer (gmt) of antibody|percentage of subjects who seroconverted,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: prevention
Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04389944,NCT04389944,serious adverse events in convalescent plasma treated patients|virologic clearance in nasopharyngeal swab of convalescent plasma treated patients|transfer to icu|in-hospital death|virologic clearance in plasma of convalescent plasma treated patients|time to discharge from hospital after enrolment|humoral immune response,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,nan,completed,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04530422,NCT04530422,therapeutic success (cured)|28 days in hospital mortality|percentage of clinical failure of treatments|length of hospital stay|incidence of side effects,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Locally Produced Cloth Face Mask and COVID-19 Like Illness Prevention,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04471766,NCT04471766,reported covid-like illness|consultation|severe illness|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04420299,NCT04420299,proportion of patients that worsen|mortality from any cause at day 28|proportion of subjects that requires admission to the icu|proportion of subjects requiring non-invasive mechanical ventilation|proportion of subjects requiring invasive mechanical ventilation.|proportion of subjects with some organ failure|proportion of patients who have modified their oxygen therapy requirements between treatment assessment visit and baseline|proportion of subjects with pathological angiotac|proportion of subjects with improvement in chest radiography|proportion and median hospital discharge between patients in both groups.|titration score|ferritin score|d-dimer modification score|adverse events (total and serious).|related adverse events (total and serious).|clinically relevant major and non major hemorrhages.,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04411433,NCT04411433,"time to recovery (discharge)|decrease in viral load|adverse event (ae), serious adverse event (sae) and discontinuation of treatment|frequency of occurrence of lymphopenia from baseline|frequency of occurrence of thrombocytopenia from baseline|changes in alanine aminotransferase (alt) levels from baseline|changes in aspartate aminotransferase (ast) levels from baseline|changes in c-reactive protein (crp) levels from baseline|changes in level of d-dimer levels from baseline|changes in prothrombin time (pt) values from baseline|changes in partial thromboplastin time (ptt) values from baseline|changes in blood pressure from baseline|changes in respiratory rate from baseline|changes in pulse oxymetry from baseline|changes in fever from baseline",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Rapid Diagnostic Test for COVID-19 Based on Antibody Detection (YCOVID),YCOVID,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04490837,NCT04490837,igg anti-covid-19|igm anti-covid-19|iga anti-covid-19|time of onset symptoms|covid-19 pcr results|radiological studies,observational,observational model: case-control|time perspective: prospective
Acceptance of Telemedicine During the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04400448,NCT04400448,acceptance of telemedicine|patient satisfaction,observational,observational model: ecologic or community|time perspective: prospective
Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19),DAMPEN-CI,not yet recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04487886,NCT04487886,number of participants requiring mechanical ventilation or dying|days to recovery|duration of hospitalization|incidence of death|proportion of participants transferred to icu|change in eastern cooperative oncology group (ecog) performance status score|incidence of grade iii-v adverse events|incidence of secondary bacterial or viral infections|change in th1 t cell frequency|change in th17 t cell frequency|change in interleukin-2 (il-2)|change in interleukin-2 receptor (il-2r)|change in interleukin-6 (il-6)|change in interleukin-7 (il-7)|change in interleukin-8 (il-8)|change in interleukin-10 (il-10)|change in interferon gamma-induced protein 10 (ip-10)|change in macrophage inflammatory protein 1alpha (mip-1a)|change in monocyte chemoattractant protein-1 (mcp-1)|change in granulocyte colony-stimulating factor (g-csf)|change in tumor necrosis factor (tnf)-alpha|change in vasoactive intestinal peptide (vip)|change in gene expression profile of regulatory t cells (tregs)|change in gene expression profile of cluster of differentiation 8 (cd8)+interferon gamma (ifng)+ granulocyte-macrophage colony-stimulating factor (gm-csf)+|change in gene expression profile of cd8+ t cell immunoglobulin and mucin domain-containing protein 3 (tim3)+ programmed cell death protein 1 (pd-1)+|change in gene expression profile of cluster of differentiation 14 (cd14)+ cluster of differentiation (cd16)+ monocytes|change in sars-cov-2 viremia|change in immunoglobulin g (igg) antibodies|change in immunoglobulin m (igm) antibodies|overall survival,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04360122,NCT04360122,decrease the incidence of covid-19 infection or its severity,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,Bee-Covid,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04480593,NCT04480593,composite clinical outcome with oxygen therapy dependency time or hospitalization time|percentage of participants with adverse events during the use of propolis|rate and severity of acute kidney injury during the study|renal replacement therapy.|rate of need for vasopressor use|need for intensive care unit (icu)|intensive care unit (icu) readmission|invasive oxygenation time|variation of plasma c-reactive protein,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Australasian COVID-19 Trial (ASCOT),ASCOT,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04483960,NCT04483960,proportion of participants alive and not having required new intensive respiratory support (invasive or non-invasive ventilation) or vasopressors/inotropic support in the 28 days after randomisation.|world health organization (who) 7-point outcome scale (clinician assessed)|mortality|time to death|length of hospital stay|receipt of invasive or non-invasive ventilation|length of receipt of invasive or non-invasive ventilation|length of intensive care unit (icu) stay|presence of chest infiltrates on chest x-ray (cxr) or ct|time to defervescence from randomisation|biomarker levels|antibiotic use|adverse events|serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death in hospital|acute kidney injury (aki)|thrombotic events|viral clearance,interventional,allocation: randomized|intervention model: factorial assignment|masking: none (open label)|primary purpose: treatment
Smell and Taste Disorders in COVID-19 Patients,COVID-19 ORL,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04427332,NCT04427332,identification of demographic and clinical factors in covid19 patients.|description of the disturbances of smell and taste|description of factors that influence smell and taste,observational,observational model: cohort|time perspective: prospective
Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19),nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04341116,NCT04341116,proportion (%) of subjects experiencing deterioration in clinical status|treatment emergent adverse events|clinical status|improvement in clinical status|sequential organ failure assessment (sofa) score|change from baseline in pao2/ fio2|length of time to normalization of oxygen saturation|change from baseline in percentage of subjects requiring mechanical ventilation|change from baseline in glucocorticoid use|mortality rate from any cause|length of hospitalization|change from baseline in d-dimer|serum concentration of tj003234|incidence and titer of anti-drug antibodies (ada),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19),END CoV-2,recruiting,No Results Available,not applicable,Other|NIH,https://ClinicalTrials.gov/show/NCT04513990,NCT04513990,sensitivity of diagnostic test|specificity of diagnostic test|concordance of the novel point-of-care diagnostic test|positive predictive value (ppv) of the novel point-of-care diagnostic test|negative predictive value (npv) of the novel point-of-care diagnostic test|viral load metrics|disease progression,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
COVID-19 Detection Tests in Different Body Fluids,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04473352,NCT04473352,accuracy of covid19 detection,observational,observational model: other|time perspective: prospective
Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04360876,NCT04360876,ventilator free days (vfd) at day 28|clinical status at day 14 as measured by world health organization (who) 7-point ordinal scale.|clinical status at day 28 as measured by who 7-point ordinal scale|in-hospital mortality at day 28|in-hospital mortality at day 90|time to mortality to day 28|icu-free days to day 28|hospital length of stay among survivors to day 90|severity of ards to day 10|days to resolution of fever|change in c-reactive protein (crp) level from baseline to day 10|vasopressor-free days to day 28|renal replacement-free days to day 28|duration of mechanical ventilation to day 28|oxygenation-free days to day 28|incidence of new mechanical ventilation to day 28|change in sequential organ failure assessment (sofa) score from baseline to day 10|in-hospital adverse events to day 28|discontinuation of study drug infusion,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04336332,NCT04336332,changes in patients viral load|second evaluation of changes in patients viral load|symptom questionnaire|fever assessment|vital signs - body temperature|discharge|recovery|assessment of agent toxicity|oropharynx swab sample collections|blood sample collections|viral shedding assessment - nasopharyngeal secretions|viral shedding assessment - serology|cytokines in blood,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,VEP-COV,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04549376,NCT04549376,proportion of covid-19 positive cases following intervention|adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04386044,NCT04386044,covid-19 infection|oxygen therapy for covid-19|discharge following covid-19 hospitalisation|death due to covid-19,observational,observational model: other|time perspective: other
Effects of Cardiovascular and Pulmonary Optimization on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS,NIRS-COV,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04392089,NCT04392089,changes in cerebral oxygenation (sco2) during cardiovascular and pulmonary optimization|changes in peripheral oxygen saturation (sato2) during cardiovascular and pulmonary optimization|changes in systolic arterial pressure (sap) during cardiovascular and pulmonary optimization|changes in diastolic arterial pressure (dap) during cardiovascular and pulmonary optimization|changes in mean arterial pressure (map) during cardiovascular and pulmonary optimization|changes in heart rate (hr) during cardiovascular and pulmonary optimization|changes in stroke volume (sv) during cardiovascular and pulmonary optimization|changes in cardiac output (co) during cardiovascular and pulmonary optimization|changes in systemic vascular resistance (svr) during cardiovascular and pulmonary optimization|changes in peripheral perfussion index (ppi) during cardiovascular and pulmonary optimization|changes in ph during cardiovascular and pulmonary optimization|changes in pao2 during cardiovascular and pulmonary optimization|changes in paco2 during cardiovascular and pulmonary optimization|changes in arterial saturation (sao2) during cardiovascular and pulmonary optimization|changes in pvo2 during cardiovascular and pulmonary optimization|changes in pvco2 during cardiovascular and pulmonary optimization|changes in mixed venous saturation (svo2) during cardiovascular and pulmonary optimization|changes in lacatate during cardiovascular and pulmonary optimization|changes in hemoglobine concentration (hb) during cardiovascular and pulmonary optimization|changes in muscular oxygenation (smo2) during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and peripheral oxygen saturation (sato2) during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and systemic arterial pressure (sap) during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and diastolic arterial pressure (dap) during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and mean arterial pressure (map) during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and stroke volume (sv) during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and heart rate (hr) during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and cardiac output (co) during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and systemic vascular resistance (svr) during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and peripheral perfussion index (ppi) during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and ph during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and pao2 during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and paco2 during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and arterial saturation (sao2) during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and pvo2 during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and pvco2 during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and mixed venous saturation (svo2) during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and lactate during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and hemoglobine concentration (hb) during cardiovascular and pulmonary optimization|association between cerebral oxygenation (sco2) and muscular oxygenation (smo2) during cardiovascular and pulmonary optimization,observational,observational model: cohort|time perspective: prospective
Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19,LILIADE-COVID,not yet recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04357444,NCT04357444,"the pao2/fio2 ratio at d11|changes in tregs between baseline and day 7 (expressed in %)|number of days alive with oxygen therapy within 28 days|maximal oxygen rate within 28 days|number of days alive free of invasive or non-invasive ventilation within 28 days|number of days alive outside icu within 28 days|number of days alive outside hospital within 28 days|time (in days) from randomization to death|mortality rate at d28|difference between crp levels at randomization and at day 7 (or at the time of discharge if occurs before day 7)|use of antibiotics for respiratory (proved or suspected) infection within 28 days|number of prone positioning sessions|changes in tregs during the different visits between baseline and day 28|cytokines analysis on plasma samples at day 0, 7 and 14|tregs numbers during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first il-2 injection.|tregs percentages during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first il-2 injection.|deep immunophenotyping of cellular components in blood samples at day 0, 7, and 14|t cell repertoire on treg, after sorting from blood at day 7 and day 14 and compared to baseline|t cell repertoire on teff (cd4 and cd8) after sorting from blood at day 7 and day 14 and compared to baseline|single cells sequencing will be performed in bal at day 7 and day 14 and compared to baseline.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Almitrine and COVID-19 Related Hypoxemia,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04380727,NCT04380727,changes from baseline pao2 (mmhg)|changes from baseline scvo2 (%),observational,observational model: case-control|time perspective: prospective
Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04350931,NCT04350931,incidence of confirmed covid-19|effectiveness of bcg vaccine,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
Phase 2 Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild to Moderate COVID-19 Hospitalized Patients,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04523181,NCT04523181,recover ratio|time to 2-point improvement|duration of hospitalization|time to virological clearance,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04529499,NCT04529499,"primary efficacy endpoint: time to resolution of hypoxia (stage i)|time to alleviation of symptoms (stage i)|percentage of patients with score of 0 = absent or mild = 1 (stage i)|time to improvement in each of the symptoms (stage i)|percentage of patients reporting a 'clinical relapse' (stage i)|time to negative conversion of detectable sars-cov 2 (stage i)|percentage of patients showing negative conversion of detectable sars-cov 2 (stage i)|changes over time in patient's clinical status on the 10-point ordinal scale of clinical status (stage i)|changes over time in patient's clinical status on the 8-point ordinal scale of clinical status (stage i)|changes over time in findings on chest x-ray (stage i)|changes over time in the national early warning score-2 (stage i)|percentage of patients requiring icu management, high flow nasal oxygen and mechanical ventilation (stage i)|time (no. of days) from randomization to icu management, high flow nasal oxygen and mechanical ventilation (stage i)|duration (no. of days) the patient requires cu management, high flow nasal oxygen and mechanical ventilation (stage i)|percentage of patients dying (all cause and due to covid-19) (stage i)|percentage of 'clinical relapse' (stage i + stage ii)|incidence of treatment emergent adverse events (stage i + stage ii)",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database,Strain,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04346043,NCT04346043,dominant viral genome strain,observational,observational model: case-only|time perspective: other
Sildenafil in COVID-19,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04489446,NCT04489446,arterial oxygenation|alveolo-arterial gradient|intensive care unit admission|noninvasive mechanical ventilation or requirement of high-flow nasal cannula|invasive mechanical ventilation|survival,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04402840,NCT04402840,"adverse events related to sgb|all adverse events|death|pao2/fio2 or spo2/fio2(sf) ratio change from baseline|radiographic criteria|incidence of cardiac arrhythmia|resolution of cardiac arrhythmia|cardiac function|clinical relevant laboratory testing (d-dimer, ferritin, troponin t, ldh)",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04358081,NCT04358081,percentage of participants who achieve clinical response|percentage of participants with viral clearance|number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04362124,NCT04362124,primary outcome|secondary outcome,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: supportive care"
Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04432103,NCT04432103,incidence of critical pneumonia|mortality rate among critical pneumonia patients|incidence of mechanical ventilation|days of mechanical ventilation,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",nan,recruiting,No Results Available,phase 2,Other|NIH,https://ClinicalTrials.gov/show/NCT04373044,NCT04373044,proportion of patients requiring invasive mechanical ventilation or dying|identification of clinical features (vitals signs - body temperature)|identification of clinical features (vital signs - respiratory rate)|identification of clinical features (vital signs - heart rate)|identification of clinical features (vital signs - blood pressure)|identification of clinical features (imaging)|identification of clinical features (lab - white blood count)|identification of clinical features (lab - absolute lymphocyte count)|identification of clinical features (lab - hemoglobin)|identification of clinical features (lab - creatinine)|identification of biomarkers (c-reactive protein)|identification of biomarkers (interleukin-6)|identification of biomarkers (tumor necrosis factor-alpha)|identification of adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Association of the Neutrophil/Lymphocyte Ratio With Clinical Complications and Mortality in COVID-19 Patients,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04434157,NCT04434157,clinical complications and mortality|neutrophil-lymphocyte and lymphocyte-platelet ratio,observational,observational model: cohort|time perspective: cross-sectional
European Pathology Laboratories and COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04476823,NCT04476823,activity,observational,observational model: ecologic or community|time perspective: cross-sectional
Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04513184,NCT04513184,time of clinical improvement|time-to-death from all causes|time free from mechanical ventilation|viral load|length of hospital stay,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
TD-0903 for ALI Associated With COVID-19,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04402866,NCT04402866,part 2: sao2/fio2 ratio|part 2: ventilator-free days (vfds)|part 2: intensive care unit free days (icu-free)|part 2: auc in sao2/fio2 ratio|part 2: sao2/fio2 ratio > 315|part 2: subjects discharged|part 2: hospital discharge|part 2: mortality rate|part 2: modified borg dyspnea score|part 2: clinical status scale|part 2: vital status|part 2: subjects alive and free of ventilatory support,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Statistical and Epidemiological Study Based on the Use of Convalescent Plasma for the Management of Patients With COVID-19,PROMETEO,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04452812,NCT04452812,all-cause mortality|side effects|length of stay in intensive care unit (icu)|length of stay in hospitalization|days of mechanical ventilation|inflammatory biomarkers (d-dimer)|inflammatory biomarkers (c-reactive protein)|inflammatory biomarkers (lactate dehydrogenase)|inflammatory biomarkers (ferritin),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab,UHID-COVID19,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04359667,NCT04359667,serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease (covid-19) pneumonia treated with tocilizumab,observational,observational model: case-only|time perspective: prospective
"Clinical, Immunological, Genomic, Virological and Bioethical Actors of COVID-19",nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04505709,NCT04505709,identification of host genetic markers associated with the evolution of covid-19|analysis of bioethical aspects related to in-hospital management of the health crisis|analysis of the spectrum of mutants of sars-cov-2 and its possible association with the clinical evolution of covid-19,observational,observational model: cohort|time perspective: prospective
Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,PEP-CQ,completed,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04408456,NCT04408456,incidence confirmed case of covid-19|incidence of probable case of covid-19|incidence of adverse drug reaction (adr),interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
"Study of the Safety, Reactogenicity and Immunogenicity of ""EpiVacCorona"" Vaccine for the Prevention of COVID-19",EpiVacCorona,"active, not recruiting",No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04527575,NCT04527575,"the proportion of vaccinated volunteers with no laboratory confirmed symptoms caused by sars-cov-2 within 9 months post vaccination|the proportion of volunteers with increased levels of the immune response in terms of geometric mean titers of specific antibodies in elisa following the vaccination compared with a placebo.|the proportion of volunteers with increased levels of the immune response in terms of specific neutralizing antibody titers in elisa following the vaccination, compared with a placebo|the proportion of volunteers with an ex vivo cellular immune response following the vaccination, compared with a placebo|incidence and type of adverse events during the study|incidence of serious adverse events during the study|cases of early termination of the study due to the development of adverse events / sever adverse events",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
Computed Tomography for COVID-19 Diagnosis,STOIC,not yet recruiting,No Results Available,nan,Other|Industry,https://ClinicalTrials.gov/show/NCT04355507,NCT04355507,predictive values of ct criteria|accuracy of ct composite severity score|accuracy of deep-learning based score|predictive values of deep-learning based diagnostic algorithms|dice similarity coefficient between manual and automated segmentation of lung disease abnormalities,observational,observational model: cohort|time perspective: retrospective
Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-19,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04456049,NCT04456049,efficacy of enzalutamide|disease progression|tollerability of enzalutamide,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)",nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04498247,NCT04498247,"percentage of participants with at least 1 solicited injection site adverse event|percentage of participants with at least 1 solicited systemic adverse event|percentage of participants with at least 1 unsolicited adverse event|percentage of participants with at least 1 serious adverse event|percentage of participants who discontinued study treatment due to an adverse event|percentage of participants with at least 1 medically attended adverse event|geometric mean titers for serum neutralizing antibodies (nab) as measured by plaque reduction neutralization test (prnt): all panels|geometric mean concentration of total anti-spike immunoglobulin g (igg) antibodies as measured by enzyme-linked immunosorbent assay (elisa): all panels|geometric mean titers for serum neutralizing antibodies as measured by prnt: panels a,b, i and j|geometric mean concentration of total anti-spike igg antibodies as measured by elisa: panels a,b, i and j|geometric mean titers for serum neutralizing antibodies as measured by prnt: panels k and l|geometric mean concentration of total anti-spike igg antibodies as measured by elisa: panels k and l|geometric mean titers for serum nab as measured by prnt|geometric mean concentration of total anti-spike igg antibodies as measured by elisa",interventional,"allocation: randomized|intervention model: sequential assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: prevention"
Assessment of Thermal Condition of Health Workers Who Use Personal Protective Equipment From Biological Hazards During Their Work With COVID-19 Patients,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04427267,NCT04427267,skin thermometry|hygrometry under costume|heart rate|air thermometry|air hygrometry,observational,observational model: case-control|time perspective: prospective
COVID-19 Lessons Learned: the Outcome of TOMEKA¬Æ Project is to Teach,MD,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04424940,NCT04424940,number of participants with treatment-tomeka¬æ usage as assessed by education|change from baseline in nutraceuticals usage on the care of the covid-19 at 9 months,observational,observational model: cohort|time perspective: prospective
AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19,ARCADIA,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04516759,NCT04516759,"clinical improvement by day 14|*title: clinical improvement at day 7, 14 and 21|glycaemic control|occurrence of adverse events|occurrence of serious adverse events|duration of hospitalisation|time to intubation/ mechanical intervention|mortality rate",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04347876,NCT04347876,pneumonia severity index|need for icu admission|covid -19 test conversion|mortality,observational,observational model: case-control|time perspective: prospective
A Study of LY3127804 in Participants With COVID-19,nan,"active, not recruiting",No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04342897,NCT04342897,number of ventilator free days|number of participants reporting each severity rating on the national institute of allergy and infectious diseases (niaid) ordinal assessment|percentage of participants who are alive and respiratory failure free|mortality|length of hospitalization|number of participants with any serious adverse event (sae)|number of participants with any treatment emergent adverse event (teae),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Screening & Risk Assessment of Healthcare Workers & Infection Control in University & COVID-19 Quarantine Hospitals,SARAH,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04348214,NCT04348214,risk categorization of healthcare workers|covid-19 infection rate among health care workers|risk factors for covid-19 among health care workers|adherence of health care workers to infection prevention|validity of the available rapid serological test for detecting covid-19 virus infection|clinical spectrum of covid-19|effectiveness of infection prevention in the health care facility|emergency infection prevention and control needs|isolation rate and emergency health care worker replacement needs|rate of seroconversion,observational,observational model: cohort|time perspective: prospective
Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04279197,NCT04279197,hrct|the 6-minute walk test|blood oxygen saturation|clinical symptom score|sars-cov-2-specific igg and igm antibody detection|quality of life-bref (qol-bref)|patient health questionnaire-9(phq-9)|generalized anxiety disorder-7(gad-7),interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Therapeutics for Inpatients With COVID-19,TICO,recruiting,No Results Available,phase 3,NIH|Other|U.S. Fed,https://ClinicalTrials.gov/show/NCT04501978,NCT04501978,"pulmonary ordinal outcome (stage 1)|pulmonary+ ordinal outcome (stage 1)|time from randomization to sustained recovery (stage 2)|all-cause mortality|composite of time to sustained recovery and mortality|days alive outside short-term acute care hospital|pulmonary ordinal outcome|pulmonary+ ordinal outcome|change in new early warning (new) score|incidence of clinical organ failure|composite of death or serious clinical covid-19 related events|composite of cardiovascular events and thromboembolic events|composite of grade 3 and 4 clinical adverse events, serious adverse events (saes) or death|incidence of infusion reactions|composite of saes or death|change in sars-cov-2 neutralizing antibody levels|change in overall titers of antibodies|change in neutralizing antibody levels",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse,TRAPSAH,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04356417,NCT04356417,identification of serious covid-19 infections|pneumonia infections|icu stay|oro-tracheal intubation|death,observational,observational model: cohort|time perspective: other
Frailty in Elderly Patients With COVID-19,FRA-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04412265,NCT04412265,"development of a tool to measure frailty|a ""proxy"" variable of the fragility index can be built on the basis of regional administrative databases only.|give elements to focus the screening policies for covid19.|give the prevention of contagion at the elderly population level.",observational,observational model: case-only|time perspective: retrospective
COVID-19 Core Warming,nan,recruiting,No Results Available,not applicable,Industry|Other,https://ClinicalTrials.gov/show/NCT04494867,NCT04494867,pao2/fio2 ratio|viral load measurement|duration of mechanical ventilation|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Case Fatalities in Hospitalised COVID-19 Patients in the UK,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04527458,NCT04527458,case fatality,observational,observational model: cohort|time perspective: prospective
Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.,LIFESAVER,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04374526,NCT04374526,rate of covid-19 progression,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
COVID-19 (VA CURES-1),VA CURES-1,not yet recruiting,No Results Available,phase 3,U.S. Fed,https://ClinicalTrials.gov/show/NCT04539275,NCT04539275,"proportion of participants developing acute hypoxemic respiratory failure or all-cause death|time (in days) to recovery|time (in days) to death or respiratory failure|proportion of patients who died from any cause, had respiratory failure, or required humidified heated high-flow nasal cannula (hhhfnc) at 15 lpm|time (in days) to death or respiratory failure or hhhfnc at 15 lpm|subject 28-day all-cause mortality|time to an improvement of one category using an ordinal scale|time to an improvement of two categories using an ordinal scale|participant's clinical status by ordinal scale|mean change in the ordinal scale|time to discharge or to a national early warning score (news)-2 of = 2 and maintained for 24 hours, whichever occurs first|change in news-2 score from day 1 (baseline) to days 2, 4, 7, 11, 15, and 29|duration of hospitalization|number of hospitalizations related to covid-19|cumulative incidence of serious adverse events (saes)|cumulative incidence of grade 3 and 4 clinical and/or laboratory adverse events (aes)|incidence of discontinuation or temporary suspension of study product administrations (for any reason)|change from baseline in hemoglobin|change from baseline in platelets|change from baseline in creatinine|change from baseline in glucose|change from baseline in total bilirubin|change from baseline in alanine transaminase (alt)|change from baseline in aspartate transaminase (ast)|change from baseline in prothrombin time (pt)",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION,CROWN CORONA,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04333732,NCT04333732,symptomatic covid-19|severity of covid-19 over the study period|effectiveness of preventing/reducing sars-cov-2 infection,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma,nan,recruiting,No Results Available,nan,Other|NIH,https://ClinicalTrials.gov/show/NCT04497779,NCT04497779,convalescent plasma (ccp) units infused in coronavirus disease-2019 (covid-19) patients|all-cause mortality|donor antibody levels|incidence of adverse events|ccp recipient outcomes,observational,observational model: cohort|time perspective: prospective
"Favipiravir, Protease Inhibitors, Oseltamivir -Gpo, Hydroxychloroquine for Treatment of COVID-19",FIGHT-COVID-19,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04303299,NCT04303299,sars-cov-2 eradication time|number of patient with death|number of patient with recovery adjusted by initial severity in each arm|number of day with ventilator dependent adjusted by initial severity in each arm|number of patient developed acute respiratory distress syndrome after treatment,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 and Chilblains,ECCES,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04455308,NCT04455308,"level of viral exposure in ""case family"" compared to ""comparator family""|comparison of seropositivity rates in subjects with chilblains and their age-matched controls|comparison of sars-cov-2 seropositivity rates among members of case (subject with chilblains) and control (subject without chilblains) outbreaks|antibody avidity and differentiated igg and igm assay by subject in the homes",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
Non-invasive Ventilatory Support of Patients Affected by COVID-19,WARd-COVID,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04382235,NCT04382235,the number of patients treated with non-invasive ventilation devices.|incidence of patients requiring mechanical ventilation|incidence of organ failure|duration of hospitalization|clinical outcome at hospital discharge,observational,observational model: cohort|time perspective: prospective
Austrian COVID-19 Registry,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04351529,NCT04351529,documentation of natural course and the therapeutic landscape of patients with covid-19.,observational,observational model: other|time perspective: other
The Impact and Coping Strategy of COVID-19 Among Taiwan Society and Medical and Nursing Institutes,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04389476,NCT04389476,psychological impacts by coronavirus disease 2019(covid-19),observational,observational model: case-only|time perspective: prospective
"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above",COVID-19,recruiting,No Results Available,phase 3,Industry|Other,https://ClinicalTrials.gov/show/NCT04510207,NCT04510207,the incidence of covid-19 cases after two-doses of vaccination|the incidence of severe cases of sars-cov-2 pneumonia and deaths accompanied by covid-19 after two-doses of vaccination|the incidence of any adverse reactions/events|the incidence of serious adverse events (sae)|the geometric mean titer (gmt) of anti-sars-cov-2 neutralizing antibody|the four-fold increase rate of anti-sars-cov-2 neutralizing antibody|the geometric mean fold rise (gmfr) of anti-sars-cov-2 neutralizing antibody|the 4-fold increase rate of anti-sars-cov-2 neutralizing antibody,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19,Covid-19HUF,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04346147,NCT04346147,time to clinical improvement|safety of treatments|tolerability of treatments,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04526054,NCT04526054,"to compare the qualitative and quantitative morphological abnormalities of the olfactory bulb detected by mri on initial examination in covid-19 anosmic versus covid-19 normosmic patients.|to compare the result of the olfactometry (sniffin' test) on initial examination in covid-19 anosmic versus covid-19 normosmic patients.|longitudinal evaluation of qualitative and quantitative abnormalities of olfactory bulbs on mri in in covid-19 anosmic patient at initial examination, between 6 weeks and 2 months and between 6 and 9 months.",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial,HASCOPT,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04365231,NCT04365231,percentage of patients with a negative rt-pcr test result to covid-19|maternal outcomes: percentage of severe forms of the disease|newborn outcomes: rate of newborns hospitalized in intensive care or transferred to resuscitation unit,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
The McGill RAAS-COVID-19 Trial,RAAS-COVID,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04508985,NCT04508985,global rank score,interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04558463,NCT04558463,clinical radiologic changes|percentage of rt-pcr test convertion|adverse event|hospital length of stay (los)|case fatality rate (cfr),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19,LUSCOVIDPREG,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04432805,NCT04432805,description of the lesions,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS),nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04329507,NCT04329507,"to perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of covid-19 pneumonia in patients exposed to sars-cov-2, compared to unexposed patients or those without.|detection of markers of covid-19 pneumonia in non-invasive breath samples.|relationship of this biomarker signature to the presence of sars-cov-2 in nasal and throat swabs.|subsequently, the signature's relationship to other biomarkers of sars-cov-2 infection which are currently being explored|in a smaller group of participants, ideally daily non-invasive breath samples will be collected to determine if there are changes between sars-cov-2 positive patients and those that are negative until hospital discharge or undue participant burden .",observational,observational model: cohort|time perspective: prospective
Convalescent Plasma for COVID-19 Research Donor Study,CONCOR-Donor,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04555109,NCT04555109,seroprevalence and duration of protective immunity,observational,observational model: cohort|time perspective: prospective
COVID-19 and Deep Venous Thrombosis,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04338932,NCT04338932,"the prevalence of a dvt in patients at the icu.|oxygen partial pressure and carbon dioxide partial pressure levels in the blood|potassium, sodium, calcium, bicarbonate, base excess, lactate levels in the blood|glucose, haemoglobin, ureum, creatinine, total bilirubin levels in the blood|oxygen saturation, basophils, eosinophils, monocytes, neutrophils, haematocrit and prothrombine levels in the blood|white blood cells, red blood cells and platelets in the blood|pt (%)aptt (sec)fibrinogen (g/l)d-dimers (mg/l) pt (inr) (ratio) ast (u/l)alt (u/l)lactate dehydrogenase (u/l)troponin t (ng/l)crp (mg/l)ferritin (mg/l)in the blood|prevalence of co-morbidities|prevalence of vital signs at icu admission|prevalence of complications during icu stay|evaluation of treatment|evaluation of the oxygen therapy",observational,observational model: cohort|time perspective: retrospective
Tele-rehabilitation Versus Home Exercise Program in COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04482634,NCT04482634,6-minute walk test|short form - 36|chair- stand test|timed up and go test|st. george's respiratory questionnaire|the copd assessment test|medical research council dyspnea scale|hand grip strength,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study),CORONA,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04518735,NCT04518735,mortality|transfer to the intensive care unit (icu)|thromboembolic complications|major bleeding complications,observational,observational model: case-control|time perspective: retrospective
COVID-19 and Cancer Consortium Registry,CCC19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04354701,NCT04354701,web-based redcap survey,observational,observational model: case-only|time perspective: prospective
DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1),DISCONNECT-1,not yet recruiting,No Results Available,phase 1,Other|Industry,https://ClinicalTrials.gov/show/NCT04409925,NCT04409925,"safety of inhaled rhdnase1 in non-ventilated covid-19 patients by reporting of adverse events: rate of all adverse events, rate of serious adverse events, rate of grade 3/4/5 adverse events, drug-related adverse events.|time to first study participant enrolment|enrolment rate|eligible patient consent rate|completeness of drug delivery|completeness of study-specific tests or procedures|completeness of data collection|hypoxia rate|supplemental oxygen requirement type|progression to mechanical ventilation rate|duration of mechanical ventilation|radiological progression|renal dysfunction rate|renal dysfunction extent|time to hospital discharge or in-hospital mortality|overall safety of health care workers and study personnel|daily safety of health care workers and study",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04358939,NCT04358939,"therapeutic failure within 14 days of randomization|therapeutic failure within 28 days of randomization|timeframe of intubation or death|timeframe of therapeutic escalation (in case of non-invasive ventilation at two pressure levels)|evolution of oxygenation (pao2/fio2 ratio or spo2/fio2 surrogate) over the 14 days following randomization|evolution of the spo2/fio2 ratio during the first prone session|evolution of the rox index during the first prone session|evolution of the world health organization disease severity score of covid|patient comfort before, during and after the first prone position session|occurrence of skin lesions on the anterior surface of the body|displacement of invasive devices during reversals|days of nasal high-flow therapy use in the general population, in non-intubated patients and in intubated patients|days spent in the intensive care unit and in the hospital|mortality in the intensive care unit and in the hospital|ventilator-free-days within 28 days of randomization",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 and Mental Health,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407195,NCT04407195,emotional impact|depression|anxiety|insomnia|resilience|crisis support scale,observational,observational model: cohort|time perspective: prospective
Effect of Using Barrier Devices for Intubation in COVID-19 Patients,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04412226,NCT04412226,first pass success|time to endotracheal intubation|difficulty level of accessing the equipment|difficulty level of inserting the endotracheal tube into the glottis|clarity of the view of the patient's face,observational,observational model: other|time perspective: prospective
Glucocorticoids in COVID-19 (CORTIVID),CORTIVID,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04438980,NCT04438980,"proportion of patients developing treatment failure|mortality at day 28|proportion of patients requiring icu admission|proportion of patients requiring rescue-therapy with tocilizumab|length of hospital stay|proportion of severe adverse events|proportion of bacterial, fungal or opportunistic infections|evolution of inflammatory biomarkers related to covid-19|proportion of sars-cov-2 clearance.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients,MG-COVID,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04371406,NCT04371406,rate of patients with occurrence of an unfavorable outcome between randomization and day 14|primary outcome of ancillary virological study : evolution of viral load between day 0 and day 14|the all-cause mortality rate at day 14|the all-cause mortality rate at day 28|rate of patients with occurrence of an unfavorable outcome between randomization and day 28|the rate of use of mechanical ventilation at day 14|the rate of use of mechanical ventilation at day 28|the intensive care unit admission rate at day 14|the intensive care unit admission rate at day 28|number of days of hospitalization for any cause between day 0 and day 14|number of days of hospitalization for any cause between day 0 and day 28|the time to resolution of all covid symptoms at day 14|the time to resolution of all covid symptoms atday 28|the rate of use of oxygen therapy at day 14|the rate of use of oxygen therapy at day 28|the rate of use of secondary antibiotic therapy (after day 2) at day 14|the rate of use of secondary antibiotic therapy (after day 2) at day 28|clinical status at day 14|clinical status at day 28|number of serious adverse events at day 14|number serious adverse events at day 28|number of adverse events at day 14|number of adverse events at day 28|the rate of patients with treatment withdrawal|ancillary virological study : rate of patients with negative viral load at day 8|ancillary virological study : rate of patients with negative viral load at day 14,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 in Patients With Chronic Liver Diseases,COLD,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04439084,NCT04439084,all-cause mortality|liver-related mortality|overall survival|number of patients with hepatic decompensation|number of patients requiring hospitalization|duration of hospitalization|length of intensive care unit (icu) stay|number of participants requiring mechanical ventilation,observational,observational model: cohort|time perspective: prospective
Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19),nan,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04346368,NCT04346368,"changes of oxygenation index (pao2/fio2)|side effects in the bm-mscs treatment group|clinical outcome|hospital stay|ct scan|changes in viral load|changes of cd4+, cd8+ cells count and concentration of cytokines|rate of mortality within 28-days|changes of c-reactive protein",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
COVID-19 Saliva Test Research Study,nan,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04531501,NCT04531501,test result,observational,observational model: cohort|time perspective: cross-sectional
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS,AVM0703,not yet recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04366115,NCT04366115,dose-limiting toxicities|28 day all-cause mortality will be a primary end point for phase 1 and 2,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Niclosamide in COVID-19,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04542434,NCT04542434,mortality|teae|saes|safety laboratory|blood pressure|fecal rna virus clearance|body temperature|heart rate|sao2|ecg,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
COVID-19 and the Developement of Phobic Fears of Disease,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04359121,NCT04359121,development of phobias,observational,observational model: cohort|time perspective: prospective
Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients,nan,available,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04420988,NCT04420988,nan,expanded access:individual patients|intermediate-size population,nan
"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",nan,completed,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04350736,NCT04350736,safety and tolerability of sad of td-0903: adverse events|safety and tolerability of mad of td-0903: adverse events|pharmacokinetics (pk) of td-0903 when given as a single ascending dose (sad): auc|pharmacokinetics (pk) of td-0903 when given as a single ascending dose (sad): cmax|pharmacokinetics (pk) of td-0903 when given as a single ascending dose (sad): tmax|pharmacokinetics (pk) of td-0903 when given as a multiple ascending dose (mad): auc|pharmacokinetics (pk) of td-0903 when given as a multiple ascending dose (mad): cmax|pharmacokinetics (pk) of td-0903 when given as a multiple ascending dose (mad): tmax,interventional,"allocation: randomized|intervention model: sequential assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions,nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04348240,NCT04348240,to determine sars-cov-2 viral load and infectivity in saliva that may contribute to asymptomatic transmission,observational,observational model: cohort|time perspective: prospective
Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04425837,NCT04425837,mortality|adverse events|icu admission|mechanical ventilation|icu length|reduction of d dimer|ldh reduction|reduction of troponin level|decrease in ferritin level|decrease in procalcitonin level|decrease in crp|increase in lymphocyte count|increase in pao2 / fio2|decrease in sequential organ failure assessment (sofa ) score|extracorporeal membrane oxygenation (ecmo)|lung infiltration,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia,TOSCA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04332913,NCT04332913,"percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (spo2) after 14 days from the end of treatment with tocilizumab.|percentage of patients achieving a score <3 on the brescia-covid respiratory severity scale (bcrss) after the last tocilizumab administration.|percentage of patients with partial recovery defined as the disappearance of fever 14 days after the end of treatment with tocilizumab.|duration of hospitalization|time to the first negative sars-cov-2 negative rt-pcr test|changes from the baseline in the white blood cell count|changes from the baseline in the lymphocyte populations (cluster of differentiation (cd)3+cd4+, cd3+cd8+, cd19+, th17)|changes from the baseline of c-reactive protein (crp) values|changes from the baseline of ferritin values|changes from the baseline of bnp values|changes from the baseline of ck-mb values|changes from the baseline of troponin values|changes from the baseline of ldh values|changes from the baseline of myoglobulin values|changes in myocardial ischemia signs at the electrocardiographic trace (yes or no)|rate of adverse events report during and after tocilizumab|mortality (number of partecipants, cause and timing)|percentage of patients who develop autoimmune diseases",observational,observational model: cohort|time perspective: prospective
Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.,nan,not yet recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04395170,NCT04395170,admission to icu and/or mechanical ventilation|length of hospital stay|neutralizing antibody (igg) titers against covid-19|safety - adverse events|death,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
BCG Vaccination for Healthcare Workers in COVID-19 Pandemic,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04379336,NCT04379336,incidence of hcws hospitalized due to covid-19 per arm|incidence of sars-cov-2 infection per arm|incidence of upper respiratory tract infections per arm|days of unplanned absenteeism due to covid-19 or any reason per arm|incidence of hospitalization for any reason per arm|incidence of intensive care unit admission per arm|incidence of death per arm|prevalence of latent tb infection|incidence of active tb per arm|compare the effect of latent tb on morbidity and mortality due to covid-19 per arm|incidence of treatment related adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
COVID-19 IgG Antibodies in the Serum of Recovered Patients,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04470414,NCT04470414,levels of igg in the serum of recovered covid-19 patients|factors related to igg level,observational,observational model: cohort|time perspective: prospective
COVID-19 Project ECHO in Nursing Homes,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04499391,NCT04499391,infection rate|hospitalization|death,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04487951,NCT04487951,nt-pro-bnp and vitamin d|assessment of any possible correlation between nt-pro-bnp and vitamin d and the need for mechanical ventilation or mortality in covid-19 infection,observational,observational model: case-control|time perspective: cross-sectional
"Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection",nan,no longer available,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04366830,NCT04366830,nan,expanded access:intermediate-size population|treatment ind/protocol,nan
Oral 25-hydroxyvitamin D3 and COVID-19,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04386850,NCT04386850,covid-19 (sara-cov-2) infection|severity of covid-19 (sara-cov-2) infection|hospitalization|disease duration|death|oxygen support|type of oxygen support|symptoms of covid-19|serum levels of 25-hydroxyvitamin d3|serum levels of calcium|serum levels of phosphorus|serum levels of creatinine|serum levels of albumin|serum levels of the blood urea nitrogen (bun)|serum levels of the parathyroid hormone (pth),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
RT-PCR SARS-CoV-2 at 1 Month of COVID-19 Infection in the Geriatric Population,COVID-19GAOM,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04427358,NCT04427358,analysis of the rate of rt-pcr sars-cov-2 positive at 1 month of covid infection,observational,observational model: case-only|time perspective: retrospective
Efficacy and Safety of COVID-19 Convalescent Plasma,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04397523,NCT04397523,"duration of oxygenation and ventilation support|hospital length of stay (los)|icu admission|ventilator free days|incidence of serious adverse events|type of respiratory support|number of participants with different clinical outcomes including death, critical illness and recovery",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),SARCOVID,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04357808,NCT04357808,mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation|duration of hospitalisation (days)|death|time to become afebrile (days)|time to non-invasive mechanical ventilation (days)|time to invasive mechanical ventilation (days)|time to independence from supplementary oxygen therapy (days)|mean change in clinical status assessment using the 7-point ordinal scale at day 14 after randomisation,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study of the Sars-Cov2 Neuroinvasiveness - COVID19,CORONEVRAXE,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04427254,NCT04427254,percentage of patients with covid-19 positive samples/biopsies,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
The Clinical Study of Carrimycin on Treatment Patients With COVID-19,nan,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04286503,NCT04286503,fever to normal time (day)|pulmonary inflammation resolution time (hrct) (day)|negative conversion (%) of 2019-ncovrna in gargle (throat swabs) at the end of treatment,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Vitamin D on Prevention and Treatment of COVID-19,COVITD-19,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04334005,NCT04334005,"composite of cumulative death (i.e. mortality) for all causes and for specific causes.|necessity of invasive assisted ventilation|necessity of non-invasive assisted ventilation|intensive care unit admission|post-anesthesia care unit admission|hospital admission|medical consultation|home care and isolation time|bed rest time|symptoms' duration (i.e. cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, anosmia, ageusia, diarrhea or alternative signs of covid-19)|subjective perception of recovery",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: treatment"
CLBS119 for Repair of COVID-19 Induced Pulmonary Damage,nan,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04522817,NCT04522817,adverse events|change in oxygen saturation,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19,RASCOVID-19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04351581,NCT04351581,days alive and out of hospital within 14 days after recruitment|key-secondary composite endpoint: occurrence of worsening of covid-19|occurrence and time to occurrence of each of the components of the key-secondary composite endpoint|kidney function assessed by plasma creatinine|duration of index hospitalisation|30-day mortality|number of days alive during the intervention period|number of participants not yet discharged at day 30|number of readmissions after 30 days.|kidney function as assessed by egfr,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04349592,NCT04349592,proportion of virologically cured (pcr-negative status) as assessed on day six|virologic cure on other study days|virologic semiquantitative analysis of changing viral load|proportion of initially symtomatic subjects with disappearance of clinical symptoms|proportion of initially asymtomatic subjects with appearance of new clinical symptoms|proportions of subjects with potentially medication- related adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
COVID-19 PCR Test Results in Asymptomatic Pregnants,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04410939,NCT04410939,rate of positive covid-19 cases in asymptomatic pregnant women,observational,observational model: case-crossover|time perspective: retrospective
TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study),nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04405271,NCT04405271,covid-19 incident cases|number of asymptomatic sars-cov-2 (covid-19) infections confirmed by serology|severity of symptomatic covid-19|respiratory symptom duration in days|relation between treatments and symptoms duration|time course of specific igm/igg seroconversion,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),nan,completed,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04288102,NCT04288102,"change in lesion proportion (%) of full lung volume from baseline to day 28.|change in lesion proportion (%) of full lung volume from baseline to day 10 and 90|change in consolidation lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.|change in ground-glass lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.|pulmonary fibrosis - related morphological features in ct scan at day 90 a. cord-like shadow b. honeycomb-like shadows c. interlobular septal thickening d. intralobular interstitial thickening e. pleural thickening|lung densitometry: change in total voxel 'weight' in lesion area voxel 'weight'=voxel density (in hu) √ó voxel volume (in voxel)|lung densitometry: volumes histogram of lung density distribution (<-750, -750~-300, -300~50, >50) at day 10, 28 and 90.|time to clinical improvement in 28 days.|oxygenation index( pao2/fio2)|duration of oxygen therapy(days)|blood oxygen saturation|6-minute walk test|maximum vital capacity (vcmax)|diffusing capacity (dlco)|mmrc (modified medical research council) dyspnea scale|changes of absolute lymphocyte counts and subsets from baseline to day 6, 10, 28 and 90.|changes of cytokine/chemokine levels from baseline to day 6, 10, 28 and 90.|adverse events|serious adverse events|all-cause mortality",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Sodium Bicarbonate for Treatment of COVID-19 Pneumonia:A Preliminary Prospective Controlled Crossover Study,nan,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04374591,NCT04374591,time to clinical recovery|pulmonary recovery status,interventional,allocation: non-randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: treatment
Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19,VTE-COVID,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04359212,NCT04359212,the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism|the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism plus the asymptomatic incidentally detected pulmonary embolism,observational,observational model: cohort|time perspective: prospective
"COVID-19: Collecting Measurements of Renin-angiotensin-system Markers, Such as Angiotensin-2 and Angiotensin 1-7",Tomeka,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04537585,NCT04537585,number of participants with treatment-tomeka¬æ usage|change from baseline in herbs vernonia amygdalina usage,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,AZIQUINE-ICU,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04339816,NCT04339816,proportion of alive patients free off mechanical ventilation|proportion of patients who avoided the need of mechanical ventilation|icu los|mortality28|mortality90,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, outcomes assessor)|primary purpose: treatment"
"Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.",CORSA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04345315,NCT04345315,epidemiology|immunoglobulin g (igg) and immunoglobulin m (igm) antibodies evaluation|methods comparison|correlation between biochemical and coagulative factors with sars-cov-2 positivity.|phylogenetic map|interactions between the virus and host cells,observational,observational model: cohort|time perspective: other
The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04422678,NCT04422678,primary endpoint: disease progression|improvement in hypoxic index|hospital length of stay|days on invasive mechanical ventilation|inflammatory markers|viral clearance|radiological assessment|safety of imatinib,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Tigerase¬Æ Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04459325,NCT04459325,the proportion of patients with mechanical ventilation|category change on who ordinal scale for clinical improvement|proportion of patients surviving 28 days after inclusion in the study|number of days of oxygen therapy during the treatment period|change in c-reactive protein level|change in oxygenation index|change in spo2/fio2 index|change in ferritin level|change in d-dimer level|change in neutrophil-leucocyte ratio|change in leucocyte-c-reactive protein ratio|change in the level of relative (%) number of lymphocytes of the general blood test,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
CICERO- A Care Home Study of COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04453553,NCT04453553,cov-2 infection after 21 days|cov-2 infection after 14 days|cases of suspected or confirmed cov-2 infection|hospitalisation and death,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: diagnostic
Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19,DHYSCO,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04347980,NCT04347980,day-28 mortality|ventilator-free days|intensive care unit mortality|day-60 mortality|nosocomial pneumonia|bacteremia,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
"A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection",PREVENT-HD,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04508023,NCT04508023,"time to first occurrence of a composite endpoint of symptomatic vte, mi, ischemic stroke, acute limb ischemia, non-cns systemic embolization, all-cause hospitalization and all-cause mortality|time to first occurrence of a composite endpoint of symptomatic vte, mi, ischemic stroke, acute limb ischemia, non-cns systemic embolization, and all-cause mortality|time to first occurrence of all-cause hospitalization|time to first occurrence of symptomatic vte|time to first occurrence of an emergency room (er) visit|time to first occurrence of symptomatic vte, mi, ischemic stroke, acute limb ischemia, non-cns systemic embolization, and all-cause hospitalization|percentage of participants who are hospitalized or dead from any cause|time to all-cause mortality up to day 35|time to first occurrence of international society on thrombosis and hemostasis (isth) critical site and fatal bleeding|time to first occurrence of isth major bleeding events|time to first occurrence of clinically relevant non-major bleeding",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Longitudinal COVID-19 Cohort Study,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04393155,NCT04393155,six minute walk distance (6mwd)|hospital anxiety and depression scale (hads)|euroqol group standardized measure of health status (eq-5d-5l)|moca-blind|health care utilization survey (hus)|death|forced vital capacity (fvc)|forced expiratory volume in 1 second (fev1)|4-meter timed walk|peripheral blood mononuclear cell type: cd4+ t cells (#cells/ml)|peripheral blood mononuclear cell type: cd8+ t cells (#cells/ml)|peripheral blood mononuclear cell type: b cells (#cells/ml)|peripheral blood mononuclear cell type: nk cells (#cells/ml)|peripheral blood mononuclear cell type: monocytes (#cells/ml)|circulating markers of inflammation: c-reactive protein (crp) (mg/l)|circulating markers of inflammation: interleukin 6 (il-6) (pg/ml)|circulating markers of inflammation: interleukin 8 (il-8) (pg/ml)|circulating markers of inflammation: interferon gamma (ifng) (pg/ml)|circulating markers of inflammation: interferon alpha (ifna) (pg/ml)|circulating markers of inflammation: tumor necrosis factor alpha (tnfa) (pg/ml)|circulating markers of inflammation: interleukin 1 beta (il-1b) (pg/ml),observational,observational model: cohort|time perspective: prospective
COVID 19 Serology in Pulmonologists,Pneumoserocov,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04422574,NCT04422574,covid 19 serology|risk factors for positive serology testing,observational,observational model: ecologic or community|time perspective: cross-sectional
Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia,nan,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04459676,NCT04459676,"proportion of patients alive, without the need for mechanical ventilation and free of the need for rrt (on an ongoing basis) at day 28",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Nasal Irrigation to Reduce COVID-19 Morbidity,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04559035,NCT04559035,frequency|reduction,interventional,allocation: randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease,nan,not yet recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04533347,NCT04533347,proportion of patients with clinical recovery of covid-19 symptoms on day 12 [¬± 1 day]|proportion of patients with negative sars-cov-2 rt-pcr on day 12 [¬± 1 day]|hospitalization rates due to covid-19 symptoms (excluding admittance only for administrative or observations purposes)|number of covid-19-related medical follow up visits [doctor's office or emergency room (er) visit]|proportion of patients with covid-19 symptoms at day 12 by individual symptoms,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Passive Immunity Trial Of the Nation for COVID-19,PassItOnII,recruiting,No Results Available,phase 3,Other|NIH,https://ClinicalTrials.gov/show/NCT04362176,NCT04362176,"covid ordinal outcomes scale:day 15|all-location, all-cause 14-day mortality|all-location, all-cause 28-day mortality|covid ordinal outcomes scale day 3|covid ordinal outcomes scale day 8|covid ordinal outcomes scale day 29|composite of death or receipt of ecmo through day 28|oxygen-free days through day 28|vasopressor-free days through day 28|ventilator-free days through day 28|icu-free days through day 28|hospital-free days through day 28",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, outcomes assessor)|primary purpose: treatment"
COVID 19-Caregivers IGg Seroconversion,CoSigS,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04353323,NCT04353323,seroconversion,observational,observational model: cohort|time perspective: prospective
Early CPAP in COVID-19 Patients With Respiratory Failure. A Prospective Cohort Study.,EC-COVID-PCS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04323878,NCT04323878,death or need of intubation|30-day mortality,observational,observational model: cohort|time perspective: retrospective
Home Pulse Oximeter Use in Patients With COVID-19,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04373161,NCT04373161,hospitalization in covid-19 patients with low home spo2|trend in resting home pulse oximetry readings|timing of spo2 <92%|home pulse oximeter use effect on subsequent ed visits|reason for return to the emergency department|hospitalization outcome - morbidity|hospitalization outcome - mortality|median length of stay,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment,EPILOGUE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04343339,NCT04343339,evolution of consumption|health care access,observational,observational model: cohort|time perspective: prospective
Dietary and Lifestyle Habits During the Pandemic of COVID-19 in Greece,COV-EAT,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04437121,NCT04437121,change in weight (child)|behaviour (child)|behaviour (parents)|physical activity levels (child)|screen time (child)|sleep duration (child),observational,observational model: case-crossover|time perspective: cross-sectional
COVID-19 Risk From Attending Outpatient Appointments,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04544176,NCT04544176,a microbiological diagnosis of covid infection.,observational,observational model: cohort|time perspective: retrospective
EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA,TEACHCOVID,withdrawn,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04347512,NCT04347512,"rate of patients reaching a significant hypoxemia, in each arms.",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)",nan,available,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04456439,NCT04456439,nan,expanded access:intermediate-size population,nan
Elmo Respiratory Support Project - COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04470258,NCT04470258,usability tests of the elmo system using euristic usability principles|evaluation of the effectiveness of the elmo system using physiological parameters,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: device feasibility
Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia,COVID-Scan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04355715,NCT04355715,confirmed diagnosis of covid-19 infection|incidence of unexpected covid-19 positive patients admitted to the hospital|number of contaminating events avoided by the early detection of covid-19 patients|incidence of sars-cov-2 seroconversion,observational,observational model: cohort|time perspective: prospective
Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04451291,NCT04451291,number of ventilator free days following infusion of decidual stromal cells|mortality rate from covid-19|all-cause morality rate|average number of days in icu|average number of days of hospital admittance|average days not requiring vasopressors|overall survival rate|average viral clearance|average number of days of supplemental oxygenation|average number of day without supplemental oxygen|mean pao2/fio2 as compared to patient baseline,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"COVID-19 Vaccine Messaging, Part 1",nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04460703,NCT04460703,intention to get covid-19 vaccine|vaccine confidence scale|persuade others item|fear of those who have not been vaccinated|social judgment of those who do not vaccinate,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study,ATHLOS,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04368845,NCT04368845,physical performance|cardiorespiratory fitness|lower limb strength|health related quality of life|anxiety and depression|physical activity|fatigue|dyspnea,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
National Covid-19 Surveillance Physicians,NAT-COV-SURV,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04459312,NCT04459312,presence of antibodies against sars-cov2,observational,observational model: cohort|time perspective: prospective
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 (Randomized),Isotretinoin,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04353180,NCT04353180,"lung injury score|absolute lymphocyte counts|serum levels of crp, esr ,il-1,il-6,tnf and type i interferon|serum level of covid19 rna|all cause mortality rate|ventilation free days|icu free days|d-dimers|time to first negative sars-cov-2 pcr in np swap|angiotensin 1-7 (ang 1-7) changes over time|angiotensin 1-5 (ang 1-5) changes over time|renin changes over time|aldosterone changes over time|angiotensin-converting enzyme (ace) changes over time|frequency of adverse events and severe adverse events|angiotensin ii (ang ii) changes over time|sequential organ failure assessment score(sofa score) over time|transe membrane protease ,serine ii (tmprss2) changes over time|testosterone levels changes over time|dihydrotestosterone(dht) levels changes over time|cholesterol levels changes over time|thrombin time (tt)",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Extracorporeal Blood Purification as a Treatment Modality for COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04478539,NCT04478539,"changes in cytokine levels of interleukin (il) 6, il-8 and tumor necrosis factor-œ± (pg/ml)|changes in inflammatory markers; c-reactive protein (crp) (mg/l)|changes in thrombocyte counts (10^3 counts/microl)|changes in the coagulation marker fibrinogen (g/l)|icu length of stay after admission (days)|changes in neutrophil-to-lymphocyte ratio|changes in the coagulation marker d-dimers (ng/ml)|changes in the activation clotting time (seconds).",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
The Corona and COVID-19 Study in Telemark and Agder,COVITA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04514003,NCT04514003,sars-cov-2 igg antibody level|risk factors for covid-19,observational,observational model: case-control|time perspective: prospective
Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04386694,NCT04386694,time until discharge|survival rate|diaphragm muscle function|platelet count|leukogram|erythrogram|c-reactive protein|d-dimer|immunoglobulin g|immunoglobulin m|levels of positive end-expiratory pressure (peep)|fraction of inspired oxygen (fio2)|arterial partial pressure of oxygen (po2)|arterial partial pressure of oxygen (po2)/fraction of inspired oxygen (fio2) ratio|levels of tumor necrosis factor-œ± (tnf-œ±)|levels of vitamin d,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Swallowing Impairment After COVID-19 Infection,nan,not yet recruiting,No Results Available,nan,Other|NIH,https://ClinicalTrials.gov/show/NCT04537650,NCT04537650,swallowing safety|swallowing efficiency|time-to-laryngeal-vestibule-closure|laryngeal vestibule closure duration|pharyngeal constriction,observational,observational model: cohort|time perspective: prospective
Sex-Informed Data in the COVID-19 Pandemic.,G-COV,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04497402,NCT04497402,sex differences in platelet and immune function and covid19 severity|gut microbiome and covid19 severity,observational,observational model: cohort|time perspective: prospective
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04377750,NCT04377750,survival,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Predictors of Severe COVID-19 Outcomes,PRESCO,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04388813,NCT04388813,performance (discrimination / calibration) of models,observational,observational model: cohort|time perspective: prospective
COVID-19 in the Swedish ICU-cohort: Risk Factors of Critical Care Admission and Intensive Care Mortality,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04390074,NCT04390074,chronic medications as risk factor of intensive care for covid-19|comorbidities as risk factor of intensive care for covid-19|chronic medications as risk factor of death during intensive care for covid-19|comorbidities as risk factor of death during intensive care for covid-19,observational,observational model: case-control|time perspective: other
Nebulized PL for Post-COVID-19 Syndrome,nan,not yet recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04487691,NCT04487691,spirometry-fvc and fev1/fvc tests|6 minute walk distance test (6mwd)|distance-desaturation product from 6mwd|san diego shortness of breath questionnaire (sobq)|short form-36 (sf-36)|modified single assessment numeric evaluation (sane)|medications|incidence of adverse events|incidence of surgical/other treatment interventions,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Spartan COVID-19 System: Evaluation of Clinical Sample Collection,nan,recruiting,No Results Available,not applicable,Industry|Other,https://ClinicalTrials.gov/show/NCT04473248,NCT04473248,asses the % agreement between predicate results and spartan covid-19 results.,interventional,allocation: non-randomized|intervention model: single group assignment|masking: single (participant)|primary purpose: diagnostic
TREM-1 Pathway Activation in COVID-19,CoviTrem1,not yet recruiting,No Results Available,nan,Other|Industry,https://ClinicalTrials.gov/show/NCT04544891,NCT04544891,prognostic value of the trem-1 pathway activation on clinical worsening,observational,observational model: cohort|time perspective: prospective
Convalescent Plasma in Outpatients With COVID-19,C3PO,enrolling by invitation,No Results Available,phase 3,Other|NIH,https://ClinicalTrials.gov/show/NCT04355767,NCT04355767,number of patients with disease progression|worst severity rating on the who covid ordinal scale for clinical improvement during the 30 days following randomization|time to disease progression|number of hospital-free days during the 30 days following randomization|all-cause mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: treatment"
CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,CACOLAC,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04404426,NCT04404426,sofa|number and phenotype of lymphocytes|hla-dr|number of myeloid-derived suppressor cells|plasma cytokines / chemokines|repertoire t|lymphocyte t exhaustion|mitochondrial activity|plasma amino acids|duration of hospitalization in intensive care|duration of hospital stay in hospital|duration of mechanical ventilation|mortality in intensive care on day 28|hospital mortality on day 28|measurement of the presence of sars-cov2|nosocomial infections|number of days of exposure to each antibiotic per 1000 days of hospitalization,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
FREEDOM COVID-19 Anticoagulation Strategy,FREEDOM COVID,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04512079,NCT04512079,time to first event|number of in-hospital rate of barc 3 or 5|number of participants with myocardial infarction|number of participants with deep vein thrombosis|number of participants requiring ventilation|number of all death|cause of death|number of participants with stroke|number of participants with pulmonary emboli|number of participants with systemic thromboembolism,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study for Quantitative Analysis of the Recovered COVID-19 Patients by <Sup>18<Sup>F-FDG-PET/CT,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04519255,NCT04519255,"number of clinically cured patients with severe covid-19|number of clinically cured patients with mild covid-19|number of healthy people who are not infected with covid-19|ki comparison between the severe, the mild and the healthy|suvmax comparison between the severe, the mild and the healthy",observational,observational model: case-control|time perspective: cross-sectional
Healthy Volunteer COVID-19 Antibody Testing Study,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04529460,NCT04529460,sensitivity and specificity of the covid-19 antibody testing kit,observational,observational model: cohort|time perspective: prospective
Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure,nan,recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04353206,NCT04353206,proportion of subjects who consent to the study and receive at least one dose of convalescent plasma.|overall survival of patients in the icu receiving at least once dose of convalescent plasma for covid-19-induced respiratory failure.,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04395768,NCT04395768,symptoms|length of hospital stay|invasive mechanical ventilation or mortality|mortality|mechanical ventilation|oxygen|icu|days in hospital|days in icu|renal replacement therapy|extracorporeal support,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: treatment"
Coronavirus Studied by Metagenomics in ARDS COVID-19 Patients,COMETS,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04516486,NCT04516486,"identify two endotypes (hyper-inflammatory and co-infections) and quantify their prognostic value in terms of short-term mortality (day 28) in patients treated for ards infected with sars-cov2.|nature of viral, bacterial and fungal co-infections in the different clusters identified|comparison of sars cov-2 viral replication dynamics in the different clusters identified|4. characterization of the viral genetic determinants selected over time in the different clusters identified",observational,observational model: cohort|time perspective: retrospective
Forecast Number of Covid-19 Cases Worldwide,Covid19TmeSer,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04460274,NCT04460274,number of confirmed cases of covid-19,observational,observational model: cohort|time perspective: retrospective
Convalescent Plasma for COVID-19 Patients,CPCP,enrolling by invitation,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04516954,NCT04516954,evaluate the safety|change in requirement for mechanical ventilatory support,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Dysphagia Management During COVID-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04509752,NCT04509752,online survey,observational,observational model: cohort|time perspective: prospective
Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),OHB10cov,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04344431,NCT04344431,time to normalize the oxygen requirement (oxygeno-dependence)|days of hospitalization between the hbo group and the control group.|oxygen flow values to obtain a saturation by pulse oximetry greater than or equal to 92% values between the hbo group and the control group.|days on invasive mechanical ventilation|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia,MICOV,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04380376,NCT04380376,the changes of covid ordinal outcomes scale|percentage of the patients with clinical recovery|the changes of the borg's scale|crp level|lymphocyte count|d-dimer|il-6|percentage of patients without artificial lung ventilation,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
"ARB, ACEi, DRi in COVID-19",BIRCOV,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04364984,NCT04364984,bp (hypertensive efficacy)|covid-19 course,observational,observational model: cohort|time perspective: prospective
Hamburg Edoxaban for Anticoagulation in COVID-19 Study,HERO-19,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04542408,NCT04542408,combined endpoint: all-cause mortality and/ or venous thromboem-bolism and/ or arterial thromboembolism|all-cause mortality|mortality related to venous thromboembolism|mortality related to arterial thromboembolism|rate of venous and/ or arterial thromboembolism|rate and length of mechanical ventilation|length of initial stay at icu after application of imp|rehospitalisation|rate and length of renal replacement therapy|cardiac arrest/ cpr,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: treatment"
"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04412291,NCT04412291,"time to recovery|mortality|number of days on mechanical ventilation|number of days of supplemental oxygen use|number of patients requiring initiation of mechanical ventilation|time to improvement in oxygenation for at least 48 hours|mean change in the 8-point ordinal scale|proportion of patients on level e-h on the 8-point ordinal scale at day 15|time to improvement in one category from admission using the 8-point ordinal scale|mean change in sequential organ failure assessment score (sofa)|time to resolution of fever for at least 48 hours by clinical severity|time to change in national early warning score 2 (news2) scoring system|time to score of <2 maintained for 24 hours in news2 scoring system (national early warning score)|mean change in news2 scoring system (national early warning score)|number of days with fever|number of days of resting respiratory rate >24 breaths/min|time to saturation ‚â•94% on room air|incidence of serious adverse events|incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection|incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia|incidence of hypersensitivity reactions|incidence of infusion reactions|number of ventilator free days in the first 28 days|number of patients requiring non-invasive ventilation|number of patients requiring the use of high flow nasal cannula|number of patients requiring extracorporeal membrane oxygenation (ecmo)|number of patients that have been admitted into an intensive care unit (icu)|number of days of hospitalization in survivors|number of deaths due to any cause",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Convalescent Plasma for Severe COVID-19 Patients,PLACOVID,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04547660,NCT04547660,clinical improvement|6-point ordinal scale proportion at 14 days|6-point ordinal scale proportion at 28 days|overall mortality|days alive and free of respiratory support (dafor28)|mechanical ventilation|pao2/fio2 ratio|hospital stay|lactate dehydrogenase|troponin i|c reactive protein|d-dimers|fibrinogen|prothrombin time (pt)|activated partial thromboplastin time (aptt)|tumor necrosis factor alfa (tnf-alfa)|interleukin-6 (il-6)|rt-pcr|sequential organ failure assessment (sofa) score|national early warning score 2 (news) 2|safety and adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Modulation of Hyperinflammation in COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04353674,NCT04353674,efficacy of a l-mod against controls receiving supportive care in icu.|mortality|hospital discharge|leukocyte monitoring|sequential organ failure assessment (sofa) score|intubation length|markers of inflammation|leukocytes and macrophages|myocardial damage|renal recovery,interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Low Dose Radiotherapy for COVID-19 Pneumonitis,LOWRAD-Cov19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04420390,NCT04420390,radiological response|remission of respiratory symptoms|spo2 and pao2/fio2|adverse events|hospitalization|overall survival|ferritin value|blood cell count|c-reactive protein|d-dimer|ldh levels,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Kidney Injury Severity and COVID-19,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04386564,NCT04386564,the effect of covid-19 severity on the severity of renal failure|the expression of viral rna in the urine with the severity of renal failure|the severity of microalbuminuria in patients with covid-19 of different conditions and renal failure|assessment of the severity of renal impairment in patients who died from covid-19|estimation of the duration of urinary viral rna isolation in patients undergoing covid-19|expression of ace-2 receptors in the kidneys of patients with renal failure who died from covid-19,observational,observational model: cohort|time perspective: prospective
A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients,GARGLES,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04341688,NCT04341688,intraoral viral load|salivary cytokine profile,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: supportive care"
Chest Radiography in COVID-19 Patients,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04485338,NCT04485338,the prognostic capacity of the radiographic assessment of lung edema (rale) score of the first cxr under invasive ventilation in patients with severe covid-19.|the prognostic capacity of changes in the rale score of consecutive cxrs under invasive ventilation in patients with severe covid-19|number of ventilator-free day and alive at day 28 (vfd),observational,observational model: cohort|time perspective: retrospective
Covid-19: Possible Role of Neutrophil Extracellular Traps,NETSINCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04412382,NCT04412382,netosis and mortality|netosis and dcovid-19 severity|netosis and inflammation|netosis and venous thrombosis,observational,observational model: case-control|time perspective: prospective
ImmuneRACE - Immune Response Action to COVID-19 Events,nan,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04494893,NCT04494893,comparison of disease-specific tcr signatures in patients and controls|identify the immunodominant antigens that elicit a t-cell response to covid-19|risk stratification based on an individual's immune signature|determine whether an immune signature can be detected in individuals exposed to sars-cov-2 earlier than currently available tests|explore whether additional research assays could potential identify and/or confirm antigenic binding,observational,observational model: cohort|time perspective: prospective
Rapid Diagnostic Profiling of SARS-CoV-2 (COVID-19),Profile-Cov,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04473365,NCT04473365,proportion of patients identified as covid-19 by and monitoring virus clearance with covid-19 using algorithm of rdts.|proportion of non-covid-19 cases identified as negative by antibody assay,observational,observational model: cohort|time perspective: prospective
Compassionate Use of Hyperbaric Oxygen Therapy,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04386265,NCT04386265,gather information on patients treated with hyperbaric oxygen therapy|gather information on adverse events,observational,observational model: case-only|time perspective: prospective
Suloexide in the Treatment of Early Stages of COVID-19,SulES-COVID,completed,No Results Available,phase 2|phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04483830,NCT04483830,hospital care|days of hospital care|days of need suplemental oxigen|serum level of d-dimmer|serum level of creatinine|thromboembolic event|need for mechanical ventilation,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Helmet Non-Invasive Ventilation for COVID-19 Patients,Helmet-COVID,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04477668,NCT04477668,28-day all-cause mortality|requirement for endotracheal intubation within 28 days|icu mortality|hospital mortality|icu free days at day 28|ventilator free days at day 28|renal replacement therapy free days at day 28|vasopressor free days at day 28|skin pressure ulcers|tolerance of helmet (>1-hour use)|180-day mortality|180-day 5-level eq-5d version,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Western Kenya Integrated COVID-19 Response,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04501458,NCT04501458,mortality,interventional,allocation: non-randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: prevention
MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study,C3PI,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04424004,NCT04424004,"estimate the prevalence of covid-19 infection based on responses to questionnaire items on symptoms and practices using a biweekly electronic survey.|assess perceptions, concerns, and practices related to the covid-19 pandemic and mitigation strategies|estimate of the prevalence of active infection in cabarrus county.|estimate of the prevalence of exposure and potential immunity to covid-19.",observational,observational model: ecologic or community|time perspective: cross-sectional
COVIDIG (COVID-19 Hyper-ImmunoGlobulin),nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04555148,NCT04555148,ordinal scale outcome|viral negative|change in news|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Performance Evaluation of RealDetect‚Ñ¢ COVID-19 RT-PCR Kit for the Detection of SARS-CoV-2 Virus,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04403672,NCT04403672,performance evaluation of realdetect‚ñ¢ covid-19 rt-pcr kit|reduce the price of rt-pcr based covid-19 diagnostic test kits.,observational,observational model: case-control|time perspective: prospective
LLLT Treatment of Lung Inflammation in COVID-19,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04524715,NCT04524715,inflammation of the lungs - o2|inflammation of the lungs - crp|inflammation of the lungs - il6,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen,Opaganib-RHB,withdrawn,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04502069,NCT04502069,time to breathing room air|adverse event grading and coding,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Ivermectin to Prevent Hospitalizations in COVID-19,IVERCORCOVID19,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04529525,NCT04529525,percentage of hospitalization of medical cause in patients with covid-19 in each arm|time to hospitalization|percentage of use of invasive mechanical ventilation support in each arm|time to invasive mechanical ventilation support|percentage of dialysis in each arm|all-cause mortality|negative of the swab at 3¬±1 days and 12¬±2 days after entering the study|incidence of treatment-emergent adverse events [safety and tolerability]),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
COVID-19 Critically Ill Patients' Evolution After Medical Transport by Train From Paris Intensive Care Units to West of France Intensive Care Units,TOCCIP,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04433325,NCT04433325,number of death|number of infections|number of days of mechanical ventilation|number of days of sedation|number of days of use of neuromuscular blocking agents|number of days of vasopressor use|number of days in intensive care units|number of days in hospital,observational,observational model: case-control|time perspective: retrospective
Use of the Nasal Cannula During COVID-19,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04376580,NCT04376580,number of physician using los flow nasal cannula during covid 19 pandemia|number of physician getting sick during covid 19 pandemic,observational,observational model: ecologic or community|time perspective: prospective
Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04355247,NCT04355247,clinical complete response criteria|clinical partial response criteria|secondary response criteria,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell),nan,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04530656,NCT04530656,"occurrence of adverse reactions (ar) within 7 days after each dose of the recombinant sars-cov-2 vaccine (sf9 cell) or placebo.|occurrence of adverse events (ae) within 7 days after each dose of the recombinant sars-cov-2 vaccine (sf9 cell) or placebo.|occurrence of ae up to day 28 after prime and boost vaccination.|the proportion of saes up to day 28 after prime and boost vaccination.|the proportion of saes up to month 12 after prime and boost vaccination.|the proportion of abnormal markers of hematology, blood chemistry and urine analysis within 7 days before prime vaccination and at day 3 after each dose of recombinant sars-cov-2 vaccine (sf9 cell) or placebo.|gmt of anti-rbd specific antibody at day 7, day 14, day 28, month 3, month 6, and month 12 after boost vaccination.|four-fold increase in anti-rbd specific antibody titers, at day 7, day 14, day 28, month 3, month 6, and month 12 after boost vaccination.|gmfi of anti-rbd specific antibody at day 7, day 14, day 28, month 3, month 6, and month 12 after boost vaccination.|gmt of sars-cov-2 neutralizing antibody at day 7, day 14, day 28, month 3, month 6, and month 12 after boost vaccination.|four-fold increase in sars-cov-2 neutralizing antibody titers, at day 7, day 14, day 28, month 3, month 6, and month 12 after boost vaccination.|gmfi of sars-cov-2 neutralizing antibody at day 7, day 14, day 28, month 3, month 6, and month 12 after prime and boost vaccination.|seroconversion rates of ifn-œ≥ stimulated by the overlapping peptide library of s-rbd protein at day 14, day 28 after boost vaccination.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
Lung Recruitment Device for COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04361435,NCT04361435,spo2/fio2 ratio|blood pressures|heart rates|respiratory rate|body temperature|modified wood clinical asthma score (m-wcas)|expiratory tidal lung volume.|end-tidal co2|clinical respiratory severity scores.,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: supportive care
Oral Manifestations of Coronavirus Disease 2019(COVID-19) :a Multicentre Study,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04487665,NCT04487665,oral ulcer|hyposalivation,observational,observational model: ecologic or community|time perspective: cross-sectional
AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19,nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04507256,NCT04507256,"number of participants with adverse events (aes) and serious aes|observed maximum concentration (cmax) (iv infusion)|time to reach maximum concentration (tmax) (iv infusion)|terminal elimination half life, estimated as (ln2)/œªz (t¬ωœªz) (iv infusion)|area under the concentration curve from time zero to the time of last quantifiable concentration (auclast) (iv infusion)|area under the concentration time curve from time zero extrapolated to infinity (aucinf) (iv infusion)|volume of distribution at steady state (vss) (iv infusion)|volume of distribution at terminal phase (vz) (iv infusion)|systemic clearance (cl) (iv infusion)|cmax (im injection)|tmax (im injection)|t¬ωœªz (im injection)|auclast (im injection)|aucinf (im injection)|extravascular systemic clearance (cl/f) (im injection)|bioavailability (f) (im injection)|extravascular terminal-phase volume of distribution (vz/f) (im injection)|number and percentage of participants who are ada positive",interventional,"allocation: randomized|intervention model: sequential assignment|masking: double (participant, investigator)|primary purpose: treatment"
Maternal Morbidity and Mortality During the COVID-19 Pandemic,MFMU COVID-19,recruiting,No Results Available,nan,Other|NIH,https://ClinicalTrials.gov/show/NCT04519502,NCT04519502,maternal mortality and morbidity composite|cesarean delivery|severe maternal morbidity or mortality|adverse maternal outcomes|adverse neonatal outcomes|neonatal infection|maternal in-patient hospitalization days|maternal icu admission|duration of labor and delivery|neonatal length of stay|neonatal icu length of stay,observational,observational model: cohort|time perspective: retrospective
Convalescent Plasma for COVID-19 Patients (CPCP),CPCP,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04521036,NCT04521036,change in mortality|change in requirement for mechanical ventilation|change in the duration of mechanical ventilation|incidence of treatment-emergent adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),HBOTCOVID19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04358926,NCT04358926,pao2/fio2|spo2|news score|inflammation level -crp|inflammation level - esr|white blood cells number|cytokines - il1|cytokines - il2|cytokines - il6|cytokines - il10|cytokines - tnfalpha|inflammation level - procalcitonin|inflammation level - ferritin|symptoms level|average oxygen supply per day|viral load|chest xray changes|number of patients with igg seroconversion|number of patients with igm seroconversion|fev1/fvc|time to symptoms recovery|number of patients who required invasive ventilation|time to negative virus pcr|mortality rate|number of barotrauma events (safety),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: treatment"
Elderly Patients and COVID-19 Infection: a Cohort of Fifty Patients Over Ninety Years of Age,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04499300,NCT04499300,demographic data|comorbidities|cumulative illness rating scale-geriatric (cirs-g)|treatments|signs and symptoms|fever|hypoxemia|tachycardia|hypotension|gasometry|infectious data|blood count|ionogram|liver function|coagulation|renal function|albumin|crp|fibrinogen|d-dimers at hospital admission or first recorded|ntprobnp|ck|troponin|ferritin|procalcitonin|biology - highest rate|biology - lowest rate|percentage of pulmonary involvement on chest ct scan|number of pulmonary lobes affected|type of lesions|need for oxygenotherapy|means of ventilation|treatment received|length of icu stay|status at hospital exit|mortality,observational,observational model: cohort|time perspective: retrospective
COVID-19 Phase Ib Study of Safety and Tolerability of Alvelestat,COSTA,not yet recruiting,No Results Available,phase 1|phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04539795,NCT04539795,numbers and % of subjects who experience at least 1 treatment-emergent adverse event|mortality rate|adverse events of special interest|effect of alvelestat on blood pharmacodynamic biomarkers of inflammation,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above,nan,recruiting,No Results Available,phase 3,Industry|Other,https://ClinicalTrials.gov/show/NCT04526990,NCT04526990,incidence of covid-19 cases|incidence of sae|incidence of severe covid-19 cases|incidence of solicited adverse reactions|incidence of unsolicited adverse events|immunogencity of s-rbd igg antibody (elisa method)|immunogencity of neutralizing antibody|cell-mediated immune profile,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Cri Analog PG1 Effectiveness and Safety in Covid-19,PGE1-COVID19,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04536363,NCT04536363,mortality|hypoxemia resolution|days from admission to intensive care unit and administration of analog pge1|icu stay|days with high flow oxygen|days of invasive mechanical ventilation prior to administration of pge1 analog|evolution time of the disease,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Favipiravir vs Hydroxychloroquine in COVID -19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04387760,NCT04387760,"primary outcome measure will be time to viral clearance|requirement of escalation of respiratory support|adverse effects(cardiac, renal, hepatic, hypoglycaemia (defined as rbs <3.9 mmol/l))|requirement of icu admission|mortality rate|serum lactate measurement|serum ferritin measurement|serum d dimer measurement|ratio of lymphocyte to neutrophil, measurement|discharge and length of hospital stay|readmission rate|daily sequential organ failure assessment (sofa) score|daily national early warning score (news) 2 score|clinical improvement|qt prolongation|cardiac arrythmia (fatal and non fatal)",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID Screening Strategies in Homeless Shelters,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04438070,NCT04438070,covid-19 detection rate|number of outbreaks|enrollment over time,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: screening
Evaluation of Commercial SARS-CoV-2 Antibody Immunoassays for COVID-19,nan,"active, not recruiting",No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04496141,NCT04496141,the accuracy of the different commercial sars-cov-2 antibody immunoassays,observational,observational model: cohort|time perspective: retrospective
COVID-19 Convalescent Plasma for Mechanically Ventilated Population,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04388527,NCT04388527,"participants with serious adverse events.|time to clinical improvement.|clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration as compared to placebo recipients in dmid protocol number: 20-0006.|clinical status assessment using the national early warning score (news) of convalescent plasma administration as compared to placebo recipients in dmid protocol number: 20-0006.|incidence of new oxygenation use up to day 29 of convalescent plasma administration as compared to placebo recipients in dmid protocol number: 20-0006.|duration of new oxygen use up to day 29 of convalescent plasma administration as compared to placebo recipients in dmid protocol number: 20-0006.|oxygen-free days of convalescent plasma administration as compared to placebo recipients in dmid protocol number: 20-0006.|non-invasive ventilation/high flow oxygen days up to day 29 of convalescent plasma administration as compared to placebo recipients in dmid protocol number: 20-0006.|incidence of non-invasive ventilation/high flow oxygen up to day 29 of convalescent plasma administration as compared to placebo recipients in dmid protocol number: 20-0006.|duration of non-invasive ventilation/high flow oxygen up to day 29 of convalescent plasma administration as compared to placebo recipients in dmid protocol number: 20-0006.|ventilator/ecmo free days to day 29 of convalescent plasma administration as compared to placebo recipients in dmid protocol number: 20-0006.|incidence of new mechanical ventilation or ecmo use of convalescent plasma administration as compared to placebo recipients in dmid protocol number: 20-0006.|duration of new mechanical ventilation or ecmo use of convalescent plasma administration as compared to placebo recipients in dmid protocol number: 20-0006.|duration of hospitalization of convalescent plasma administration as compared to placebo recipients in dmid protocol number: 20-0006|mortality of convalescent plasma administration as compared to placebo recipients in dmid protocol number: 20-0006|cumulative incidence of saes through day 29 of convalescent plasma administration as compared to matched participants from the control arm of dmid protocol no. 20-0006.|cumulative incidence of grade 3 and grade 4 clinical and/or laboratory adverse events through day 29 of convalescent plasma administration as compared to matched participants from the control arm of dmid protocol no. 20-0006.|changes in wbc with differential through day 29 of convalescent plasma administration as compared to matched participants from the control arm of dmid protocol no. 20-0006.|changes in hemoglobin measurement through day 29 of convalescent plasma administration as compared to matched participants from the control arm of dmid protocol no. 20-0006.|changes in platelets measurement through day 29 of convalescent plasma administration as compared to matched participants from the control arm of dmid protocol no. 20-0006..|changes in creatinine measurement through day 29 of convalescent plasma administration as compared to matched participants from the control arm of dmid protocol no. 20-0006..|changes in glucose measurement through day 29 of convalescent plasma administration as compared to matched participants from the control arm of dmid protocol no. 20-0006.|changes in bilirubin measurement through day 29 of convalescent plasma administration as compared to matched participants form the control arm of dmid protocol no. 20-0006..|changes in alt measurement laboratory adverse events through day 29 of convalescent plasma administration as compared to matched participants from the control arm of dmid protocol no. 20-0006.|changes in ast measurement through day 29 of convalescent plasma administration as compared to matched participants from the control arm of dmid protocol no. 20-0006.|changes in pt measurement laboratory adverse events through day 29 of convalescent plasma administration as compared to matched participants from the control arm of dmid protocol no. 20-0006.",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Study on the Use of Sarilumab in Patients With COVID-19 Infection,nan,not yet recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04386239,NCT04386239,proportion of patients who show an improvement of the respiratory function|evaluation of the time to resolution of fever|evaluation of the viral load on blood and sputum for covid-19|evaluation of the plasma concentration of gm-csf|evaluation of the plasma concentration of il-6|evaluation of the plasma concentration of tnf-œ±|evaluation of the rate of progression of white blood cell (wbc) fraction,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Checkpoint Blockade in COVID-19 Pandemic,COPERNICO,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04335305,NCT04335305,"percentage of patients with normalization of spo2 ‚â•96% on room air (measured without any respiratory support for at least 15 minutes|proportion of patients discharged from the emergency department and classified as low risk|number of days of patient hospitalization|change from baseline in organ failure parameters|proportion of mortality rate|analysis of the remission of respiratory symptoms|evaluation of the radiological response|time to first negative in severe acute respiratory syndrome coronavirus 2 (sars-cov-2) rt-pcr test|change from baseline of absolute lymphocyte count (alc),white blood cell count and white blood cell differential count|change from baseline of hemoglobin|change from baseline of platelets|change from baseline of activated partial thromboplastin time (aptt)|change from baseline of alanine aminotransferase (alt) and aspartate aminotransferase (ast)|change from baseline of creatinine|change from baseline of glucose|change from baseline of total bilirubin|change from baseline of albumin|incidence of adverse events (aes), incidence of prespecified aes (safety and tolerability)",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Assesment of the Metabolomic Signature in COVID-19 Patients,SignCov,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04497272,NCT04497272,identifying the metabolomic signature|identification of the metabolomic profile according to clinical severity.,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Anxiety and Depression Among Pregnant Women During COVID-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04558749,NCT04558749,the mean scores anxiety and depression among pregnant women during covid-19 pandemic,observational,observational model: other|time perspective: cross-sectional
Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,nan,completed,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04523831,NCT04523831,early clinical improvement of the patients|late clinical recovery|percentage of patients having clinical deterioration.|persistently positive for rt-pcr of covid-19,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection,Ta1,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04487444,NCT04487444,"time to recovery (free of respiratory failure)|lymphopenia|survival|hospital length of stay|requirement for high flow oxygen supplementation|duration of high flow oxygen supplementation|icu admission|icu length of stay|mechanical ventilation|duration of mechanical ventilation|change in any existing comorbidities (e.g., worsening congestive heart failure) or occurrence of newly diagnosed disease|incidence of non-covid-19 infections (other respiratory, urinary tract, cellulitis, etc.)|aes/saes|changes to vital signs|changes in laboratory parameters",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Antibiotic Misuse During COVID-19 Pandemic: A Cross-sectional Survey Addressed to Community Pharmacists,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04553055,NCT04553055,antibiotic misuse,observational,observational model: ecologic or community|time perspective: cross-sectional
Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED,NO COV-ED,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04338828,NCT04338828,rates of return visits to the ed|inpatient hospitalizations required|rates of intubation|rates of mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia,COVIDICUS,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04344730,NCT04344730,"the time-to-death from all causes|the time to need for mechanical ventilation (mv)|the viral load in the respiratory tract|number of patient with at least one episode of healthcare-associated infections|number of days alive without mechanical ventilation|measure of sofa score|number of days alive without renal replacement therapy|lengths of icu-stay|lengths of hospital-stay|number of patients with severe hypoxemia,|number of patients with cardiac arrest within 1 hour after intubation",interventional,"allocation: randomized|intervention model: factorial assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Bucillamine in Treatment of Patients With COVID-19,nan,not yet recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04504734,NCT04504734,efficacy: frequency of hospitalization or death|safety: changes in adverse events from baseline to end of study,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Rehabilitation After Admission in Intensive Care Unit for COVID-19,RECOVER,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04523051,NCT04523051,functional independence measure (fim) at the admission|functional independence measure (fim) 1-month hospitalization|functional independence measure (fim) at the discharge|weight at admission|weight at the discharge|age|estimated functional independence measure score before covid-19|estimated dyspnea symptoms before covid-19|length of stay in icu unit|length of stay in acute care|length of stay in rehabilitation centers|length of invasive mechanical ventilation|presence of pressure ulcers|risk of bedsore|joint limitation|dominant side|presence of psychic disorders|muscle strength at the admission|muscle strength at the discharge|dyspnea symptoms at the admission|dyspnea symptoms at the discharge|functional exercise capacity|destination of patients at discharge|oxygen saturation of the blood at the admission|oxygen saturation of the blood at the discharge|presence of hoffman signs|presence of babinski signs|sex|neurological examination at the admission|neurological examination at the discharge,observational,observational model: cohort|time perspective: prospective
Ambulatory Management of Moderate to High Risk COVID-19 (SARS-CoV-2) Patients - The Coronavirus Related Outpatient Work Navigators (CROWN) Protocol,CROWN,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04476602,NCT04476602,hospital admission,observational,observational model: cohort|time perspective: retrospective
DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19),DYNAMIC,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04371952,NCT04371952,percentage of patients with clinical respiratory aggravation|percentage of patients hospitalized|percentage of patients requiring ventilatory assistance|positive sars-cov-2 pcr test|duration of symptoms|duration of hospitalization|hospitalization intensive care or reanimation|duration of mechanical ventilatory assistance|percentage of deaths related to sars-cov-2|ae / sae in both arms,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19),nan,not yet recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04391309,NCT04391309,acute respiratory failure|time to clinical improvement|invasive mechanical ventilation|hospitalization|sequential organ failure assessment|ordinal scale|time to clinical improvment|time to recovery|change in c-reactive protein|adverse events|serious adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC ),nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04372589,NCT04372589,intubation and mortality|all-cause mortality|intubation|hospital-free days|icu-free days|ventilator-free days|non-invasive ventilation|organ support-free|myocardial infarction|ischaemic stroke|venous thromboembolism|major bleeding|heparin-induced thrombocytopenia (hit),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Response of Korean Medicine Hospital to COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04529447,NCT04529447,satisfactory service regarding hospital response to covid-19|feelings of apprehension regarding hospital visits|medical staff wearing of facial masks and hand hygiene|cleanliness and sterilization of hospital facilities|convenience and accessibility of hand sanitizers|helpfulness and readability of posters and stand-up banners|satisfaction with hospital safety measures for covid-19|recommendation of hospital to friends and family,observational,observational model: other|time perspective: retrospective
Use of Convalescent Plasma for Treatment of Patients With COVID-19 Infection,CP IN COVID19,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04438694,NCT04438694,duration of hospitalization/recovery status,interventional,allocation: randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,nan,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04389840,NCT04389840,proportion of participants who are alive and free of invasive mechanical ventilation|all-cause mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Outcomes in Emergency Laparotomies During COVID-19 Pandemic,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04419571,NCT04419571,30-day mortality|7-day mortality|number of participants returning to theatre|length of stay|post-operative respiratory failure|post-operative ards|post-operative sepsis|itu/hdu admission,observational,observational model: cohort|time perspective: retrospective
Efficacy and Safety of Corticosteroids in COVID-19,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04273321,NCT04273321,the incidence of treatment failure in 14 days|clinical cure incidence in 14 days|the duration of virus change to negative|mortality at day 30|icu admission rate in 30 days,interventional,allocation: randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19,ASKCOV,not yet recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04549922,NCT04549922,days alive without respiratory support (any supplemental oxygen) after 15 days (dafor15)|sofa - sequential organ failure assessment score up to 15 days after randomization|need for mechanical ventilation|duration of mechanical ventilation,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
How Brazilian Chiropractors Are Facing the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04534621,NCT04534621,"what measures have been implemented to avoid sars-cov2 transmission when taking care of patients, during the covid-19 pandemic.|professionals sars-cov2 infection rates.|professional financial impact.",observational,observational model: other|time perspective: cross-sectional
Study to Evaluate the Effect of a Probiotic in COVID-19,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04390477,NCT04390477,cases with discharge to icu.|patients with home discharge.|mortality.|treatment safety assessed by number of adverse events.|new cases of sars-cov-2 infection among healthcare personnel caring for the patients.|patients with negative pcr result for sars-cov-2 infection.,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger,TRASCOV,withdrawn,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04409483,NCT04409483,hospitalization or death|all-cause mortality|time to hospitalization|length of hospitalization|admission to intensive care|adverse events|serious adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04500626,NCT04500626,"7-level covid ordinal outcome scale|length of hospital stay|days with oxygen supplementation|daily oxygen flow values required to obtain saturation values ‚â•90%,|icu admission|icu length of stay|days on invasive mechanical ventilation or high flow oxygenation|major arterial and venous thrombotic events|sleep quality|fatigue|mortality|incidence of any adverse events related to hbot",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Experience of an Emergency Intensive Care Unit During COVID-19 Pandemic,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04480060,NCT04480060,mortality of the covid-19 patients,observational,observational model: cohort|time perspective: retrospective
Protecting Health Care Workers During the COVID-19 Outbreak,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04387643,NCT04387643,physical health|psychological health|coping with distress|self-help,observational,observational model: other|time perspective: prospective
Decision Support System Algorithm for COVID-19 Diagnosis,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04479319,NCT04479319,diagnosing covid-19,observational,observational model: case-only|time perspective: retrospective
Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands,HOMECOMIN',recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04488562,NCT04488562,"vas|temperature|oxygen measurements|forced vital capacity (fvc) home spirometry in %|forced vital capacity (fvc) home spirometry in l|forced vital capacity (fvc) hospital spirometry in %|forced vital capacity (fvc) hospital spirometry in l|adherence to weekly home spirometry|eq5d|fas|groc|abc tool|correlation between fvc, hrct patterns, symptoms and quality of life|predictors for the course of recovery of covid-19 infection after hospital admission|satisfaction of patients and caregivers with the use of a home monitoring system",observational,observational model: cohort|time perspective: prospective
Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,CTCOVID-19,"active, not recruiting",No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04313127,NCT04313127,safety indexes of adverse reactions|safety indexes of adverse events|safety indexes of sae|safety indexes of lab measures|immunogencity indexes of gmt(elisa)|immunogencity indexes of gmt(pseudoviral neutralization test method)|immunogencity indexes of seropositivity rates(elisa)|immunogencity indexes of seropositivity rates(pseudoviral neutralization test method)|immunogencity indexes of gmi(elisa)|immunogencity indexes of gmi(pseudoviral neutralization test method)|immunogencity indexes of gmc(ad5 vector)|immunogencity indexes of gmi(ad5 vector)|immunogencity indexes of cellular immune,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: prevention
Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04347538,NCT04347538,change in sars-cov-2 mucosal immune response in the nasopharynx|change in microbial load in the nasopharynx|change in viral load in the nasopharynx over the course of covid-19 infection|symptom assessment|temperature assessment,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19,NOXCOVID,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04555213,NCT04555213,incidence of treatment-emergent adverse events|change of national early warning score 2 units from baseline|change in who-9 point ordinal scale,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04355026,NCT04355026,duration of hospitalization|duration of disease|hospital-aquired pneumonia|icu stay duration|oxygene therapy duration|mechanical ventilatory support duration,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection,nan,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04526717,NCT04526717,mtd|viral load|time to clinical improvement,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19,nan,approved for marketing,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04338360,NCT04338360,nan,expanded access:intermediate-size population,nan
Anti-thrombotics for Adults Hospitalized With COVID-19,nan,recruiting,No Results Available,phase 4,Other|NIH,https://ClinicalTrials.gov/show/NCT04505774,NCT04505774,21 day organ support (respiratory or vasopressor) free days|key platform secondary thrombotic endpoint|other platform secondary endpoints of morbidity and hospitalization|all cause mortality,interventional,allocation: randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04400058,NCT04400058,stabilization or improvement in clinical status|descriptive clinical status analysis|clinical status assessment|time to death|mechanical ventilation initiation|mechanical ventilation duration|sars-cov-2 test result|incidence of all aes|incidence of aes considered related to the imp|incidence of serious adverse events (saes)|radiological findings (chest ct/chest x-ray)|blood glucose|blood calcium|sodium|potassium|carbon dioxide|chloride|albumin|total protein|alkaline phosphatase|alanine transaminase|aspartate aminotransferase|bilirubin|blood urea nitrogen|d-dimer|fibrinogen|pt|ptt|inr|hscrp|ferritin|ldh|igg|igm|iga|ife|troponin|red blood cell count|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|white blood cell count|white blood cell differential|platelet count|mean platelet volume|platelet distribution width|spo2|a-a gradient|blood pressure|pulse|respiration rate|body temperature,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Delivery of Protocolised Emergency Surgical Care During COVID-19 Pandemic,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04450277,NCT04450277,surgical morbidity in patients with covid-19 infection and general surgical conditions,observational,observational model: cohort|time perspective: prospective
Changes in Cellular Immune Profile During COVID-19 Infection,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04470999,NCT04470999,cellular immune system profiling|innate immune system profiling|expansion of virus-specific innate immune cells,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: basic science
Local Thermotherapy for Patients With Moderate Symptoms of COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other|Industry,https://ClinicalTrials.gov/show/NCT04363541,NCT04363541,hospitalization time|patients needing intensive care|symptoms after hospitalization release,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia,nan,not yet recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04469114,NCT04469114,death or respiratory failure ate day 28|national institute of allergy and infectious diseases (niaid) ordinal scale of disease severity at day 14|status of alive and not on mechanical ventilation or ecmo at day 14 and 28 niaid ordinal scale of disease severity at day 14|status of requiring supplemental oxygen at day 28|status of being alive and not hospitalized at day 14 and 28|national institute of allergy and infectious diseases (niaid) ordinal scale of disease severity at day 14 niaid ordinal scale of disease severity at day 28|number of patients with cure|number of patients at the icu or on ventilatory support at day 28|number of days free from mechanical ventilation at 28 days|number of days in hospital|number of days in icu,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
A Study of N-acetylcysteine in Patients With COVID-19 Infection,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04374461,NCT04374461,arm a: number of patients who are successfully extubated and/or transferred out of critical care due to clinical improvement|arm b: number of patients who are discharged from the hospital due to clinical improvement,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Safe Return to Regular Clinical Operation After COVID-19 Pandemic,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04377802,NCT04377802,health care provider safe return to work,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04353336,NCT04353336,number of patients with cure or death,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Novel Face Mask Sampling for COVID-19: A Diagnostic and Public Health Tool,COVMASK,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04481646,NCT04481646,comparison with naso-pharyngeal swab|mask out over time|mask as a screening tool in asymptomatic people,observational,observational model: cohort|time perspective: prospective
IMU-838 and Oseltamivir in the Treatment of COVID-19,IONIC,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04516915,NCT04516915,"to evaluate whether time-to-improvement is significantly better in imu-838 plus oseltamivir (ionic intervention) vs. oseltamivir alone in adult subjects with covid-19|to evaluate safety (number of adverse events) and tolerability (laboratory abnormalities) of imu 838 + oseltamivir vs. oseltamivir alone in adult subjects with covid-19.|to determine the effects of ionic intervention on improvement of at least two points in clinical status scale (from 0 to 8; with 8 being no evidence of clinical infection and 8 being death)|to assess the effects of ionic intervention vs. oseltamivir on the need for invasive ventilation, renal replacement therapy or ecmo|to assess the effects of ionic intervention vs. oseltamivir on the length of hospital and intensive care unit (icu) stay|to assess the effects of ionic intervention vs. oseltamivir on the time from treatment initiation to death",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,SOCOVID,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04387292,NCT04387292,description of the ophthalmological problems observed,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19,EliSpot,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04418206,NCT04418206,iga specific cells of sars|oms progression scale,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04336657,NCT04336657,measure frequency of people suffered from unusual flu-like symptoms before december 2019|measure remote immunity for covid-19 in subject with past history of severe flu before who announcement date- if possible,observational,observational model: ecologic or community|time perspective: prospective
Dornase Alfa Administered to Patients With COVID-19 (DACOVID),DACOVID,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04387786,NCT04387786,number of participants discharged from the intensive care unit (icu)|number of participants who survived covid-19|mean change in fio2,observational,observational model: case-only|time perspective: retrospective
Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function,GenCov,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04506229,NCT04506229,genetic variants with vs without covid-19|cognitive function at baseline|change in cognitive function at 1 month|genetic analysis,observational,observational model: case-only|time perspective: prospective
CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment,SAC-COVID,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04317040,NCT04317040,improvement of covid-19 disease status|proportion of patients who died or had respiratory failure.|disease progression of covid-19|all cause of death|proportion of clinical relapse|conversion rate of clinical status at day 8|conversion rate of clinical status at day 15|hospital discharge time|duration of mechanical ventilation|duration of pressors|duration of ecmo|duration of high flow oxygen therapy|absolute lymphocyte count|change of d-dimers,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04334252,NCT04334252,prevalence of symptoms|prevalence of positive sars cov-2 pcr|prevalence of positive radiological findings|prediction of symptoms,observational,observational model: cohort|time perspective: prospective
COVID 19 Seroprevalence Amongst Healthcare Workers in JHAH,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04469647,NCT04469647,seroconversion status|the proportion of asymptomatic infections among staff who have seroconverted|the durability of covid 19 seroconversion in asymptomatic healthcare workers at jhah|identification of risk factors for covid 19 seroconversion in asymptomatic healthcare workers,observational,observational model: cohort|time perspective: cross-sectional
Oral Camostat Compared With Standard Supportive Care in Mild COVID-19 Patients,COPS-2002,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04524663,NCT04524663,time until cessation of shedding of sars-cov-2 virus|sars-cov-2 viral load (nucleic acid)|clinical worsening of covid-19 disease in symptomatic patients|development of antibodies to sars-cov-2|time until cessation of symptoms,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Pegylated Interferon - Œ±2b With SARSCoV- 2 (COVID-19),nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04480138,NCT04480138,change in clinical status of subject on a 7-point ordinal scale|pcr test|supplemental oxygen|mechanical ventilation|incidence of treatment-emergent adverse events|c-reactive protein (crp)|interleukin 6 (il-6)|d-dimer|interferon gamma|ferritin|tnf alpha|interleukin 1-œ≤,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04542876,NCT04542876,virologic clearance|hospital stay|clinically relevant adverse effects|laboratory tests,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
IL- 6 Gene (174G/C) Single Nucleotide Polymorphism as an Indicator of COVID-19 Severity in Egyptian Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04544033,NCT04544033,interleuken- 6 gene (174g/c) single nucleotide polymorphism|interleukin 6 level,observational,observational model: case-only|time perspective: prospective
Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04339426,NCT04339426,virology cure rate|incidence of gi adverse events|cardiac toxicity,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients,HCQ-COVID19,not yet recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04437693,NCT04437693,prevention of sars-cov-2 infection|presence of any adverse effects related to hcq|incidence of covid-19 related symptoms,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
CT Biomarkers Identification by Artificial Intelligence for COVID-19 Prognosis,COVID 19-IA,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04418245,NCT04418245,"vital status|patient requiring more than 3 liters of oxygen to maintain a saturation >95% (intensive care unit or resuscitation department)|percentage of lung affected on ct|percentage of lung affected by ground glass opacity on scan|percentage of lung affected by condensation on scan|length of hospitalization|rehospitalization|duration of intubation|software operating time|c-reactive protein levels|lactate dehydrogenase|lymphocytemia|d dimers level|time until onset of symptoms|time between rt-pcr positive results and first scan|age|bmi> 30|medical history of cardiovascular disease|diabetes|medical history of respiratory disease|medical history of immunosuppressed condition|current or previous history of smoking|calculate a prognostic score from clinical, biological and ct parameters|calculate a prognostic score from clinical and biological parameters only|compare receiver operating curves of prognostic scores with and without ct parameters",observational,observational model: case-only|time perspective: retrospective
AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience,Al-COVE,not yet recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04341103,NCT04341103,assessing the utility of allosure dd-cfdna to guide clinical immune-optimization for transplant patients with covid-19,observational,observational model: case-only|time perspective: prospective
Trial to Study the Benefit of Colchicine in Patients With COVID-19,COL-COVID,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04350320,NCT04350320,changes in the patients' clinical status through the 7 points ordinal scale who r&d blueprint expert group|changes in il-6 concentrations|improvement in the clinical status|changes in the score for the sequential organ failure assessment (sofa score)|changes in the punctuation in the national early warning score|number of days with invasive mechanical ventilation|number of days with high flow oxygen therapy|changes in other inflammatory markers|changes in severity markers|changes in myocardial damage|time until reaching a virus negative status|length of hospital stay|number of days in the intensive care unit.|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis,Predi-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04380987,NCT04380987,description of clinical manifestations|clinical aggravation of the infection|discharge of hospitalization|death|description of biological manifestations|patient-related prognostic factors|virus-related prognostic factors|vocal biomarker of covid-19 related respiratory complications,observational,observational model: cohort|time perspective: prospective
Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID),ECMO-VID,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04341285,NCT04341285,"28 day all cause mortality|90 day all cause mortality|sepsis-related organ failure assessment score at day 1-14, 28 and 90 days|duration of mechanical ventilation support|ventilator associated pneumonia|bleeding complications|acute renal failure|discharge location",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Compartmental Inflammation in Mechanically Ventilated Patients With COVID-19,COV2ICU-DK,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04354584,NCT04354584,white blood cell counts|lymphocyte populations|cytokines|lectin complement pathway|microorganisms|respiratory pathogens|ribosomal rna in the airways|levels of sars-cov-2 in the airways,observational,observational model: case-only|time perspective: prospective
Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04409509,NCT04409509,the incidence of tracheal intubation or death prior to tracheal intubation|proportion of subjects with death from all causes|proportion of subjects intubated|number and proportion of subjects with ‚â• 2-point improvement on national institute of allergy and infectious diseases (niaid) ordinal scale|number and proportion of subjects within each of the categories of the niaid|proportion of subjects requiring continuous positive airway pressure (cpap)|proportion of subjects requiring bilevel positive airway pressure (bipap)|proportion of subjects requiring high-flow nasal cannula (hfnc)|proportion of subjects requiring extracorporeal membrane oxygenation (ecmo)|maximum change from baseline in sequential organ failure assessment (sofa) score|change from baseline in sofa score and in the individual components of sofa score|length of hospital stay|number and proportion of subjects experiencing adverse events (aes)|number and proportion of subjects experiencing serious adverse events (saes)|number and proportion of subjects with adverse events of special interest (aesis)|number and proportion of subjects with csl312 induced anti-csl312 antibodies|maximum plasma concentration (cmax) of csl312|time to maximum plasma concentration (tmax) of csl312|area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (auc0-last) of csl312|terminal half-life (t1/2) of csl312,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Assessment of Long-term Impact Post COVID-19 for Patients and Health Care Professionals of the European Hospital,ALCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04525911,NCT04525911,"evaluation of post-traumatic stress symptoms (post traumatic stress disorder (ptsd) scale) at m3 for patients and caregivers|evaluation of post-traumatic stress symptoms (ptsd scale) at m12 and m24 for patients and caregivers|change from m3 in the score of the mental (mcs), physical (pcs) components and the scores of the individual domains of the questionnaire sf36 to m12 and m24 for the entire study population|% of patients presenting a positive result by elisa serology (= without distinction of igg, igm and iga)|comparison of m0 chest ct results at each follow-up for the entire study population",observational,observational model: cohort|time perspective: prospective
Vitamin D Status and Immune-inflammatory Status in Different UK Populations With COVID-19 Infection,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04519034,NCT04519034,"collecting vitamin d results in patients from the south-east london area together with age, sex, ethnicity and bmi and other relevant laboratory results.|collecting covid-19 screening results together with age, sex, ethnicity and bmi and other relevant laboratory results.",observational,observational model: other|time perspective: retrospective
Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU,MY-CO-VID,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04368221,NCT04368221,opportunistic fungal co-infections.|median time|time between diagnosis and targeted treatment|preventive strategies,observational,observational model: cohort|time perspective: other
Using Biovitals¬Æ Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04343794,NCT04343794,time to diagnosis of covid-19 by rt-pcr in subjects|compliance to complete the study|sensitivity and specificity of biovitals¬æ sentinel|cross infection rate within the family cluster|length of hospital stay of positive subjects|length of icu stay of positive patients|national early warning score 2 rating of positive patients|viral load of positive patients|worsening of comorbidities|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: diagnostic
COVID-19 SAFE Enrollment,COVID SAFE,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04506268,NCT04506268,proportion enrolled|participant age|participant sex|participant race/ethnicity|participant income|participant education|test completion,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: screening"
Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04331665,NCT04331665,proportion of patients with covid-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and/or fio2 of 60% of more)|number of adverse events|all cause mortality rate|average duration of hospital stay,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Effectiveness of Hydroxychloroquine in Covid-19 Patients,Covid,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04328272,NCT04328272,national early warning score equal to zero|c-reactive proteins|lymphocyte count|d-dimers,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04368260,NCT04368260,number of subjects for which the prototype swab and the control swab provide the same covid-19 pcr result,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
Enhanced Hood PPE to Minimize COVID-19 Transmission to Front-line Health Care Workers,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04373096,NCT04373096,incidence of contamination of any part of the base clothing or exposed skin of the upper body|1) number of body areas contaminated|2) number of discrete areas of contamination of <1 cm2 and >1 cm2|3) visibility during the simulated procedure|4) ease of intubation procedures when wearing ppe|5) ease of breathing while wearing ppe|6) thermal comfort while wearing the ppe|7) incidence of breaching of doffing procedures,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients,COVID-HO,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04371679,NCT04371679,death (all-cause mortality) or discharge from icu (limit of 4 months),observational,observational model: cohort|time perspective: retrospective
Workforce Serosurveillance to Track Long-term Modifications to COVID-19 Exposure Due to Factors in the Built Environment,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04542200,NCT04542200,covid-19 antibodies,observational,observational model: cohort|time perspective: prospective
Patients' Experiences in a Medicalized Hotel for COVID-19 Acute Care Support,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04503434,NCT04503434,the picker patient experience questionnaire|open questions,observational,observational model: cohort|time perspective: cross-sectional
A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19,nan,not yet recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04537806,NCT04537806,percentage of participants who are alive and free of respiratory failure at day 28|number of participants with at least one treatment-emergent adverse event (teae)|all-cause mortality through day 28,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Nudges to Improve Health Behaviors That Limit COVID-19 Spread,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04379375,NCT04379375,hand washing behavior|clinical outcomes - general/internal medicine|clinical outcomes - obstetrics & gynecology|clinical outcomes - surgery,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04352491,NCT04352491,assessment of the fear levels during the covid-19 disease pandemic among patients with liver disease (currently under treatment from ilbs)|assessment of the anxiety levels during the covid-19 disease pandemic among patients with liver disease (currently under treatment from ilbs)|assessment of the stress levels during the covid-19 disease pandemic among patients with liver disease (currently under treatment from ilbs)|association between presence of liver disease and fear levels|association between presence of liver disease and anxiety levels|association between presence of liver disease and stress levels|correlation between fear and child-turcotte-pugh score|correlation between anxiety and child-turcotte-pugh score|correlation between stress and child-turcotte-pugh score|correlation between fear and model for end stage liver disease score|correlation between anxiety and model for end stage liver disease score|correlation between stress and model for end stage liver disease score,observational,observational model: case-only|time perspective: cross-sectional
Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia,nan,not yet recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04527224,NCT04527224,"treatment related adverse events|number of subjects with treatment related abnormal variation of vital signs, physical examination and laboratory test values|oxygenation index (pao2 / fio2 ratio)|mortality rate|ventilator treatment status|improvement of pneumonia|sofa score (sequential organ failure assessment)|2019 ncov nucleic acid test|duration of total hospitalization and intensive care unit stay (days)",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
The Safety and Preliminary Efficacy of Lucinactant in Adults With COVID-19,nan,not yet recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04389671,NCT04389671,oxygenation index (oi) area under the curve (auc)0-12|fio2|pao2|oxygenation from pulse oximetry (spo2)|p/f ratio|ventilation index (vi)|lung compliance,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Virtual Reality Therapy Influence on Heart Rate Variability of Inpatients With COVID-19,nan,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04537858,NCT04537858,heart rate variability|motor skills|strength|perceived exertion|satisfaction using the technology|mood,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: treatment
Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04318444,NCT04318444,"number of participants with symptomatic, lab-confirmed covid-19.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Characteristics and Outcomes of Patients Admitted to Swedish Intensive Care Units for COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04462393,NCT04462393,30-day mortality|icu mortality,observational,observational model: cohort|time perspective: other
Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04402203,NCT04402203,number of participants negative by rt-pcr for the virus at 4-10 days after initiation of therapy.|number of participants with lung condition change assessed with x-ray.|number of participants with clinical recovery|number of participants with adverse effects of drug.|number of participants requiring icu admission|number of death,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
"Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study",nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04327531,NCT04327531,evaluation of covid-19 knowledge level of turkish physicians|what they think about the future,observational,observational model: ecologic or community|time perspective: prospective
Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01),COVITOZ-01,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04435717,NCT04435717,"change in il-12 values in the 3 study groups from the start of treatment (d0) and on days d + 1 and d + 3.|progression of pneumonia|pao2/fio2|cause mortality to 28 days after started treatment|length of hospital stay|patients requiring intensive care unit admission|evolution of inflammatory parameters il12|evolution of inflammatory parameters il-10, il-1, il-6, il-17 and ifn-gamma|evolution of inflammatory parameters procalcitonin (pct),|evolution of inflammatory parameters c-reactive protein (pcr),|evolution of inflammatory parameters d-dimer|evolution of inflammatory parameters and ferritin|pharmacokinetics of tocilizumab cmin|pharmacokinetics of tocilizumab cmax|pharmacokinetics of tocilizumab cmedia|pharmacokinetics of tocilizumab tmax|pharmacokinetics of tocilizumab auc|adverse event|adverse event to cause the treatment interruption.|adverse event abnormalities in laboratory",interventional,allocation: randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19,nan,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04454398,NCT04454398,"incidence of adverse events (safety)|incidence of treatment-emergent adverse events (safety)|incidence of serious adverse events (safety)|all-cause mortality at 29 and 60 days|incidence of dose-limiting toxicities (safety)|incidence of laboratory abnormalities (safety)|sars-cov-2 viral load as assessed using various sample types|time to hospitalization, treatment, icu admission, and discharge from icu and/or hospital|anti-drug antibodies|cytokine levels|auc of covi-guard (pk)|cmax of covi-guard (pk)|t¬ω of covi-guard (pk)|tmax of covi-guard (pk)",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19,CORONA-SHIELD,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04357574,NCT04357574,"radiation oncology providers perception of of telehealth for on treatment patients in lieu of in person on treatment visits during covid-19|number of missed telehealth clinical evaluation visits during covid-19|number of unplanned emergency department visits or hospital admissions during covid-19|number of acute care visits with listed reason as anemia, nutrition (including dehydration), diarrhea, emesis, infectious (including fever, pneumonia, and sepsis), nausea, neutropenia, pain category during covid-19",observational,observational model: other|time perspective: prospective
"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia",nan,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04467840,NCT04467840,intubation and mechanical ventilation|who ordinal scale for clinical improvement with a scale ranging from 8 down to 0|time to intubation and mechanical ventilation|time to low oxygen flow via nasal cannula|supplemental oxygen requirement|total daily oxygen requirement|time to negative swabs for sars-cov-2|negative swabs for sars-cov-2 at day 14|fever|mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04352751,NCT04352751,change in covid-19 severity status,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04498377,NCT04498377,niaid 8-point ordinal scale,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Epidemiological and Clinical Characteristics of Critically Ill Patients With COVID-19,2019nCoV_ICU,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04388670,NCT04388670,overall number and characteristics of patients with covid-19 in icu,observational,observational model: cohort|time perspective: other
Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04363502,NCT04363502,change in c-reactive protein (crp) level,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04435314,NCT04435314,the proportion of subjects with laboratory-confirmed covid-19 identified after start of treatment and before the end of the study|incidence of treatment-emergent adverse events|the proportion of subjects with symptomatic laboratory-confirmed covid-19 identified after start of treatment and before the end of the study|the proportion of subjects with asymptomatic laboratory-confirmed covid identified after the start of treatment and before the end of the study|treatment adherence|disease complication|incidence of subjects that underwent unscheduled visit,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment,Antibodies,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04396067,NCT04396067,"lung injury score|serum levels of crp, esr ,il-1,il-6,tnf and type i interferon|serum level of covid19 rna|d-dimers|absolute lymphocyte counts|the immune correlates of protection against future exposure to sars-cov-2|immunological profile|total duration of mechanical ventilation, ventilatory weaning and curarisation|occurrence of adverse event related to immunoglobulins|igg, iga and igm against covid-19|ace2 expression in patients with covid-19 infection|all cause mortality rate [|ventilation free days|icu free days",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Curosurf¬Æ in Adult Acute Respiratory Distress Syndrome Due to COVID-19,Caards-1,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04384731,NCT04384731,evolution of the pao2 / fio2 ratio between the measurements taken before (t0) and one hour after the end of the invasive procedure (h1).|oxygenation : pao2 / fio2 ratio.|oxygenation : area under the pao2 / fio2 curve.|oxygenation : area under the spo2 curve.|evolution of thoraco-pulmonary compliance (ml / mbar) between before and one hour after the procedure.|overall survival rate|mortality rate at discharge from the intensive care unit.|mortality rate at discharge from the hospital.|number of ventilator-free days|number of prone position sessions.|time between inclusion and the last prone position session.,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications,nan,"active, not recruiting",No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04374487,NCT04374487,"the primary outcome is a composite measure of the avoidance of - 1. progression to severe ards (p/f ratio 100) and 2. all-cause mortality at 28 days|time to symptom resolution-fever,shortness of breath,fatigue|hospital length of stay|change in sofa pre and post transfusion|duration of respiratory support required a. duration of invasive mechanical ventilation b. duration of non-invasive|radiological improvement|adverse events (ae) associated with transfusion|to measure the change in rna levels (ct values) of sars-cov-2 from rt-pcr [time frame: days 0, 1, 3, and 7 after transfusion]|levels of bio-markers pre and post transfusion|need of vasopressor use",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma,Inova-CCP,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04502472,NCT04502472,"change is clinical status|transfusion related events|sofa score at days 0, 7, 14, 21, 28|length of hospital stay|supplemental oxygen|mechanical ventilation|change in mechanical ventilation status|mortality|change in inflammatory markers",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"Study of the Spread of COVID-19 in Saint Petersburg, Russia",nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04406038,NCT04406038,"prevalence of the sars-cov-2 infection in saint petersburg, russia|prevalence odds ratios|immune response dynamics",observational,observational model: cohort|time perspective: prospective
SERO-EPIDEMIOLOGY OF SARS-COV2 INFECTION IN THE AUTONOMOUS CITY OF BUENOS AIRES,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04482361,NCT04482361,prevalence of igg for covid-19|changes in prevalence of igg for covid-19,observational,observational model: ecologic or community|time perspective: prospective
Virtual Assistant for COVID-19 PPE,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04435275,NCT04435275,performance of healthcare workers,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: other
Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04418128,NCT04418128,proportion of patients with clinical improvement|time to clinical improvement (ttci)|clinical status assessed by 7-category ordinal scale|change in national early warning score (news)|time to national early warning score (news) of ‚â§ 2 and maintained for 24 hours|duration of hospitalization|duration of new non-invasive ventilation or high flow oxygen use|incidence of new non-invasive ventilation or high flow oxygen use|duration of new supplement oxygen use|incidence of new supplement oxygen use|duration of new ventilator or extracorporeal membrane oxygenation (ecmo) use|incidence of new ventilator or extracorporeal membrane oxygenation (ecmo) use|mortality at day 28|time (days) from treatment initiation to death|proportions of patients with a negative nasopharyngeal swab and sputum sample for sars-cov-2 quantitative rt-pcr|viral load change (log10 viral load) of nasopharyngeal swab and sputum sample for sars-cov-2 quantitative rt-pcr|adverse events that occurred during treatment,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04412018,NCT04412018,change in hs-crp levels from the randomization visit (day 1) to the day 14 visit|change in d-dimer levels from the randomization visit (day 1) to the day 14 visit|change in erythrocyte sedimentation rate from the randomization visit (day 1) to the day 14 visit|change in complete blood count from the randomization visit (day 1) to the day 14 visit|change in differential count from the randomization visit (day 1) to the day 14 visit|change in serum albumin levels from the randomization visit (day 1) to the day 14 visit|change in neutrophil-to-lymphocyte ratio (nlr) from the randomization visit (day 1) to the day 14 visit|change in systemic immune-inflammation index from the randomization visit (day 1) to the day 14 visit,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers,COVIPACT,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04366154,NCT04366154,"to assess the impact of the covid-19 pandemic on the modifications of treatments administered in hospital (day units) to patients with cancer or malignant hemopathy|to assess the impact of the covid-19 pandemic on the change in the rate of treatment administration in hospital (day units) to patients with cancer or malignant hemopathy|to assess the impact of the covid-19 pandemic on the number of cures administeredin hospital (day units) to patients with cancer or malignant hemopathy|to assess the impact of the covid-19 pandemic on change of modality of administration in hospital (day units) to patients with cancer or malignant hemopathy|evaluate the perceived stress on cancer patients treated in unit day of hospital|evaluate the post-traumatic stress on cancer patients treated in unit day of hospital|evaluate the sleep disorders on cancer patients treated in unit day of hospital|evaluate the quality of life on cancer patients treated in unit day of hospital|evaluate the cognitive complaints on cancer patients treated in unit day of hospital|evaluate the perceived stress on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)|evaluate the post-traumatic stress on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)|evaluate the burnout on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)|evaluate the feeling of personal effectiveness on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)",observational,observational model: cohort|time perspective: prospective
"The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19",nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04468139,NCT04468139,"days of stay at hospital after treatment and discharge|serum zinc before and after treatment|questionnaire including parameters like bmi,,smoking , underling diseases, immunological treatment ,|day of negative conversion for nasopharyngeal swab for rt-pcr for covid-19",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19,NICLONEX,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04558021,NCT04558021,physician's judgment on clinical recovery from the time of admission|clinical improvement in news2|improvement in serum biomarkers|requirement for indotracheal intubation|occurrence of macrophage activation syndrome(mas)|occurrence of coagulopathy,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Prospective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acquired Pneumonia,TARGET-VIP,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04522076,NCT04522076,"overall survival|time to all-cause mortality or artificial pulmonary ventilation (apv)|time to all-cause mortality, nonfatal myocardial infarction, nonfatal cerebral stroke, and coronary or carotid revascularization|proportion of patients with severe pneumonia|proportion of patients with low oxygen saturation value|proportion of patients with hb <90 g/l (9.0 g/dl) at any point during hospitalization|proportion of patients hospitalized or transferred to intensive care unit (icu)|time to nonfatal myocardial infarction, nonfatal cerebral stroke, and coronary or carotid revascularization|time to pneumonia/recurrent pneumonia|time to primary or recurrent coronavirus infection disease (covid-19)",observational,observational model: cohort|time perspective: prospective
Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),PHYDRA,recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04318015,NCT04318015,symptomatic covid-19 infection rate|symptomatic non-covid viral infection rate|days of labor absenteeism|rate of labor absenteeism|rate of severe respiratory covid-19 disease in healthcare personnel,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Treatment for COVID-19 in High-Risk Adult Outpatients,nan,"active, not recruiting",No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04354428,NCT04354428,lower respiratory tract infection (lrti) rates|incidence of hospitalization or mortality|change in upper respiratory viral shedding|rate of participant-reported adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury,TACROVID,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04341038,NCT04341038,time to reach clinical stability|time to reach an afebrile state for 48 hours.|time to reach pao2 / fio2> 400 and / or sato2 / fio2> 300|time to reach fr ‚â§ 24 rpm for 48 hours|time to normalization of d-dimer (<250 ug / l)|time until pcr normalization (<5mg / l).|time until normalization of ferritin (<400ug / l)|study the impact of immunosuppressive treatment on viral load using quantitative pcr|time until hospital discharge|need for ventilatory support devices|duration that it is necessary to maintain ventilatory support.|covid-19 mortality|all-cause mortality|analyze the expanded cytokine profile before the start of treatment and their evolution every 7 days after admission|describe the side effects and their severity attributed to tacrolimus and / or methylprednisolone.,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Facilitating AcceLerated Clinical Validation Of Novel Diagnostics for COVID-19 (FALCON-C19),FALCON-C19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04408170,NCT04408170,if the participant has an active sars-cov-2 infection during admission|the participant has had a past sars-cov-2 infection,observational,observational model: cohort|time perspective: prospective
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04474340,NCT04474340,time to clinical improvement|all cause mortality,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID 19 Biomarkers,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04363008,NCT04363008,inflammation|oxygenation|chronic pulmonary outcomes|pulmonary artery pressure using transthoracic echocardiography|exertion|quality of life assessment,observational,observational model: cohort|time perspective: prospective
"RCT,Double Blind, Placebo to Evaluate the Effect of Zinc and Ascorbic Acid Supplementation in COVID-19 Positive Hospitalized Patients in BSMMU",nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04558424,NCT04558424,symptoms reduction time frame|symptom resolution: fever|symptom resolution: cough|symptom resolution: fatigue|symptom resolution: muscle/body aches|symptom resolution: headache|symptom resolution: new loss of taste|symptom resolution: new loss of smell|symptom resolution: congestion/ runny nose|symptom resolution: nausea|symptom resolution: vomiting|symptom resolution: diarrhea|day 5 symptoms|severity of symptoms|adjunctive medications|supplementation side effects,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: supportive care"
A Comparison of Sample Collection Methods for SARS-COV-2 Antibody Testing,nan,not yet recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04537572,NCT04537572,"laboratory determination of presence of anti-sars-cov2 antibodies (igm, iga, and igg)",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04366141,NCT04366141,"time to tracheal intubation (tti)|first pass success rate|total time of airway manipulation|number of intubation attempts|number of operators needed for intubation|number of alternative techniques used for intubation|cormack-lehane grade for the first attempt of intubation|lifting force applied on laryngoscope blade|laryngeal pressure application|vocal cord position|anesthesiologist perception of intubation difficulty|anesthesiologist perception of contributors to difficulty in intubation, if any|patient acceptability of the covid barrier box|patient comfort with the covid barrier box|patient comments on the covid barrier box",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Determination of the Hemoadsorption Impact as Adjunctive Treatment Upon the Support Therapy of COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04518969,NCT04518969,comparing % of change in cytokine's clearances of pro et anti -inflammatory types|evaluation of the impact upon the survival rate at 28 and 90 days.|chemokine kinetics|cytokine kinetics|complement pathway kinetics|pao2/fio2 ratio,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study to Evaluate the Safety and Efficacy of VIRAZOLE¬Æ in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19,nan,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04551768,NCT04551768,change in the clinical status severity (css) rating from the first dose date up to the completion of treatment|time to recover gas exchange to a pao2/fio2 ‚â•300 for at least 24 hours.|time to reach peripheral capillary oxygen saturation (sp02) >94% for at least 24 hours.,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Cardiac Arrest Incidence and Outcome Among Patients With COVID-19 in French ICUs,ACICOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04373759,NCT04373759,"incidence of unexpected cardiac arrest|charlson score|organ failure score at icu admission and/or before unexpected in-icu cardiac arrest|etiology retained to explain cardiac arrest occurrence|modified rankin score (mrs) at icu discharge, at hospital discharge and at 3 months",observational,observational model: cohort|time perspective: prospective
Clinical Application of Methylene Blue for Treatment of Covid-19 Patients,Covid-19,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04370288,NCT04370288,proportion of patients remaining free of need for mechanical ventilation in both groups|mortality rate in both groups|improvement in pa02/fi02 ratio in both groups|duration of hospital stay in both group.|duration of intensive care unit stay in both groups|days free of dialysis in both groups|c-reactive proteins|wbc count,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
"Psychological Impact, Mental Health and Sleep Disorder Among Patients Hospitalized and Health Care Workers During the 2019 Coronavirus Outbreak (COVID-19)",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04497246,NCT04497246,impact event scale-revised (ies-r)|generalised anxiety disorder-7 (gad-7)|patient health questionnaire-9 (phq-9)|insomnia severity index (isi)|demographic data|hospitalization duration|icu stay|medical history|alcohol consumption|tobacco consumption,observational,observational model: cohort|time perspective: prospective
Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,nan,completed,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04475120,NCT04475120,rate of viral clearance time to viral clearance|time to clinical improvement,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial,INTENSE-COV,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04466241,NCT04466241,"proportion of patients with undetectable nasopharyngeal swab sars-cov-2 pcr and c-reactive protein (crp) < 27 mg/l at day 11|proportion of patients with clinical improvement on the 7-point ordinal scale at day 11 and day 28|kinetics of sars-cov-2 viral load|death rate at day 11 and day 28|all causes of death and acute respiratory distress syndrome (ards) at day 28|time to hospital discharge|duration of oxygen supplementation|prevalence of grade iii or iv adverse events|residual concentration of lopinavir, telmisartan and atorvastatin|evolution of inflammatory and immunological markers (crp, fibrinogen, ferritin, d-dimer, dosing of igg, iga, igm; tcd4, cd8, b lymphocytes, nk lymphocytes; na√øve/memory t lymphocytes)|evolution of endothelial activation markers (vegf and soluble vegf receptor,ve-cadherin, pecam/cd31, cd42 and angiopoietin-2)|proportion of patients with good results according to hiv status|number of contact cases infected by covid-19 at day 28",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients,nan,not yet recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04441398,NCT04441398,change in signs and symptoms scale|incidence of treatment-emergent adverse events|the proportion of subjects hospitalized after start of treatment and before the end of the study|the proportion of subjects that need mechanical ventilation after start of treatment and before the end of the study|duration of symptoms|rate of mortality within 21-days,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
A Novel Nomogram to Predict Severity of COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04366024,NCT04366024,the consistency of predicted severe rate and observed severe rate of covid-19 patients|duration of severe illness,observational,observational model: case-only|time perspective: retrospective
Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With SOC Versus SOC in Subjects With COVID-19,SOC,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04440007,NCT04440007,proportion of subjects alive and free of respiratory failure at day 14|incidence of treatment-emergent adverse events (safety and tolerability of sti-5656)|proportion of subjects alive and free of respiratory failure at day 28|change in clinical status|discharge from icu|time to respiratory failure or death,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Characterising Transmission of SARS-CoV-2 in a Peri-urban Population in Mozambique,AfriCoVER,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04442165,NCT04442165,"covid-19 disease incidence rate (symptomatic infections per month)|covid-19 related hospitalization rate due to sars-cov-2|case (disease) fatality risk (percent) due to sars-cov-2|proportion asymptomatic infections, by age group|sars-cov-2 infection annual attack rate (percent)|sars-cov-2 infection fatality risk|infection fatality of sars-cov-2 infection.|serial interval number of sars-cov-2 infection|reproduction number of sars-cov-2 infection|correlation between anti-coronavirus (endemic coronavirus or sars-cov-2) antibody titers and reinfection|antibody titers against sars-cov-2 over time",observational,observational model: cohort|time perspective: prospective
Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,INSPIRATION,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04486508,NCT04486508,"composite of incident vte, undergoing ecmo, and all-cause mortality",interventional,allocation: randomized|intervention model: factorial assignment|masking: single (outcomes assessor)|primary purpose: treatment
Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04445610,NCT04445610,viral clearance,observational,observational model: case-only|time perspective: prospective
Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19,COVID-19,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04416139,NCT04416139,functional respiratory changes: pao2 / fio2 ratio|clinical cardiac changes: heart rate per minute|clinical respiratory changes: respiratory rate per minute|changes in body temperature|general biochemical changes in leukocytes|general biochemical changes on lymphocytes|general biochemical changes on platelets|general biochemical changes on fibrinogen|general biochemical changes on pocalcitonin|general biochemical changes on ferritin|general biochemical changes on d-dimer|changes on inflammatory c-reactive protein|cahnges on inflammatory cytokine tnfa|changes on inflammatory cytokine il10|changes on inflammatory cytokine il1|changes on inflammatory cytokine il6|changes on inflammatory cytokine il 17|changes on vegf|radiological changes|immunological changes on t cell|immunological changes on dendritic cells|immunological changes on cd4+ t|immunological changes on cd8+ t|immunological changes on nk cell|adverse events|rna detection by sars-cov2 pcr,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older,nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04537208,NCT04537208,neutralizing antibody titer at day 1|neutralizing antibody titer at day 22|neutralizing antibody titer at day 36|fold-rise of neutralizing antibody titer at day 22|fold-rise of neutralizing antibody titer at day 36|2-fold and 4-fold rise in neutralization antibody titer at day 22|2-fold and 4-fold rise in neutralization antibody titer at day 36|percentage of participants with neutralizing antibody seroconversion at day 22|percentage of participants with neutralizing antibody seroconversion at day 36|number of participants with immediate adverse events|number of participants with solicited injection site or systemic reactions|number of participants with unsolicited adverse events|number of participants with medically attended adverse events|number of participants with serious adverse events (saes)|number of participants with adverse events of special interest|number of participants with out-of-range biological test results|binding antibody concentration|binding antibody concentration ratio|fold rise in binding antibody concentration|neutralizing antibody titer|fold-rise in neutralization titer at day 181 and day 366 (cohort 1) and day 202 and day 387 (cohort 2)|2-fold and 4-fold rise in neutralization titer [post/pre] at day 181 and 366 (cohort 1) and day 202 and day 387 (cohort 2)|percentage of participants with neutralizing antibody seroconversion at day 181 and 366 (cohort 1) and day 202 and day 387 (cohort 2)|number of participants with virologically-confirmed covid-19-like illness|number of participants with serologically-confirmed sars-cov-2 infection|correlates of risk / protection based on antibody responses to sars-cov-2,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Efficacy and Safety of Nitazoxanide 600 mg TID for the Treatment of Hospitalized Patients With COVID-19,nan,not yet recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04423861,NCT04423861,viral load|evolution of acute respiratory syndrome|change in clinical condition|hospital discharge|rate of mortality within 21-days|need of mechanical ventilation,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Study to Evaluate the Safety and Efficacy of VIRAZOLE¬Æ in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19,nan,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04356677,NCT04356677,change in the clinical status severity (css) rating from the first dose date up to the completion of treatment|time to recover gas exchange to a pao2/fio2 ‚â•300 for at least 24 hours.|time to reach peripheral capillary oxygen saturation (sp02) >94% for at least 24 hours.,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Prediction of Clinical Course in COVID19 Patients,COVID-CTPRED,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04377685,NCT04377685,diagnostic of covid disease composite,observational,observational model: cohort|time perspective: retrospective
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort,ILIAD-7-FR,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04407689,NCT04407689,"improvement of the absolute lymphocyte count (alc) of lymphopenic (alc‚â§1000/mm3) covid-19 infected participants out to approximately 30 days following initial study drug administration or hospital discharge (hd), whichever occurs first|""clinical improvement"" as defined by a 2 points improvement in a 7-point ordinal scale for clinical assessment, through day 30 or hd.|a significant decline of sars-cov-2 viral load through day 30 or hd|frequency of secondary infections through day 45 compared tp placebo arm|length of hospitalization compared to placebo arm|length of stay in icu compared to placebo arm|number of readmissions to icu compared to placebo arm|organ support free days compared to placebo arm|frequency of re-hospitalization through day 45 compared to placebo arm|all-cause mortality through day 45 compared to placebo arm|cd4+ and cd8+ t cell counts compared to placebo arm|level of other known biomarkers of inflammation: ferritin compared to placebo arm|level of other known biomarkers of inflammation: crp compared to placebo arm|level of other known biomarkers of inflammation: d-dimer compared to placebo arm|physiological status through news2 evaluation compared to placebo arm",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort,ILIAD-7-UK,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04379076,NCT04379076,"improvement of the absolute lymphocyte count (alc) of lymphopenic (alc‚â§1000/mm3) covid-19 infected participants out to approximately 30 days following initial study drug administration or hospital discharge (hd), whicheve|to obtain ""clinical improvement"" as defined by a 2 points improvement in a 7-point ordinal scale for clinical assessment, through day 30 or hd.|determine if cyt107 will lead to a significant decline of sars-cov-2 viral load through day 30 or hd|to compare the effect of cyt107 versus placebo on the frequency of secondary infections through day 45|to compare the effect of cyt107 versus placebo on the length of hospitalization|to compare the effect of cyt107 versus placebo on the length of stay in icu|to compare the effect of cyt107 versus placebo on readmissions to icu|to compare the effect of cyt107 versus placebo on organ support free days|to compare the effect of cyt107 versus placebo on the frequency of re-hospitalization through day 45|to assess the impact of cyt107 on all-cause mortality through day 45|to determine the effect of cyt107 on cd4+ and cd8+ t cell counts|to track and evaluate other known biomarkers of inflammation: ferritin|to track and evaluate other known biomarkers of inflammation: crp|to track and evaluate other known biomarkers of inflammation: d-dimer|evaluation of physiological status through news2 score",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Risk Profiling of the Occupational Exposure of COVID-19 to Healthcare Workers.,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04477213,NCT04477213,rate of covid-19 in healthcare workers (hcws)|clinical severity of infection in hcws,observational,observational model: cohort|time perspective: retrospective
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19),nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04551898,NCT04551898,change from baseline to day 8 in sars-cov-2 viral shedding as measured by reverse transcription-quantitative polymerase chain reaction (rt-qpcr) in nasopharyngeal swab samples|time-weighted average change in viral shedding as measured by rt-qpcr in nasopharyngeal swab samples|change from baseline to day 15 in sars-cov-2 viral shedding as measured by rt-qpcr in nasopharyngeal swab samples|time to negative rt-qpcr in all tested samples with no subsequent positive rt-qpcr in any tested samples|number of participants requiring hospitalization due to worsened covid-19|time to resolution of all covid-19-related symptoms|all-cause mortality rate at day 29|number of participants experiencing adverse events (aes)|number of participants experiencing serious adverse events (saes),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04352764,NCT04352764,prevalence of covid-19 exposure|correlation between the test results with the presence or lack of covid-19 symptoms or illness|correlate pre-existing risk factors with test results and baseline symptoms|correlate subsequent healthcare utilization with test results and baseline symptoms,observational,observational model: case-control|time perspective: prospective
A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy,nan,not yet recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04445220,NCT04445220,safety and tolerability as measured by incidence of ip-related serious adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04377997,NCT04377997,"number of patients with the composite efficacy endpoint of death, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, or hemodynamic shock.|number of patients with a major bleeding event according to the international society on thrombosis and haemostasis (isth) definition.",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,SCOUT,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04338568,NCT04338568,accuracy of the diagnosis of interstitial syndrome by lung ultrasound|inter-observer variability,interventional,allocation: non-randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus,nan,withdrawn,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04293692,NCT04293692,"size of lesion area by chest imaging|blood oxygen saturation|rate of mortality within 28-days|sequential organ failure assessment|side effects in the uc-mscs treatment group|electrocardiogram, the changes of st-t interval mostly|concentration of c-reactive protein c-reactive protein, immunoglobulin|cd4+ and cd8+ t cells count|concentration of the blood cytokine (il-1œ≤, il-6, il-8,il-10,tnf-œ±)|concentration of the myocardial enzymes",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, outcomes assessor)|primary purpose: treatment"
EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic ( EPISODEPSCOVID ),EPISODE-PH-COV,not yet recruiting,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04445493,NCT04445493,prevalence of covid-19 infection in suspected stroke population|quality head pulse recordings,observational,observational model: cohort|time perspective: prospective
"Safety, Tolerability and Efficacy of Nangibotide in Mechanically Ventilated Patients With COVID-19 and Features of Systemic Inflammation",nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04429334,NCT04429334,adverse events|mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
The COVID-19 PUI Reality Check (CPRC) Study,CPRC,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04474288,NCT04474288,sars-cov-2 igg|host immune response|pathogen protein expression,observational,observational model: case-control|time perspective: other
Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04551781,NCT04551781,improved,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19,nan,suspended,No Results Available,early phase 1,Industry,https://ClinicalTrials.gov/show/NCT04348474,NCT04348474,change in clinical condition|hospitalization|rate of mortality within 28-days|change in clinical condition related to comorbidity,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Changes in the Consumption of Psychoactive Substances During Containment Linked to COVID-19,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04380714,NCT04380714,percentage changes in the consumption of psychoactive substances|assessment of the level of stress|assessment of depression|craving modification evaluation,observational,observational model: ecologic or community|time perspective: cross-sectional
Evaluation of Emergency Department (ED) Staff Stress Level During COVID-19 Pandemic,COVER-PRO,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04383886,NCT04383886,"change of emergency department staff's level of stress during the covid19 pandemic, measured using the chamoux et simard visual analogic scale",observational,observational model: cohort|time perspective: prospective
"Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center",nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04492358,NCT04492358,number of patients that a short cycle of steroids administered together with colchicine reduces mortality from covid-19|number and grade of adverse events at group of colchicine and glucocorticoids throughout the treatment and in the two weeks following treatment|percentage of patients who stop medication due to adverse events.|severity of symptoms by covid-19 in the two treatment arms,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Let It Out (LIO) and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic,LIO-C,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04386668,NCT04386668,kessler psychological distress scale (k10)|perceived stress scale (pss-10)|pittsburgh sleep quality index (psqi)|self-compassion scale (scs)|ucla loneliness scale (ucla ls)|uptake of existing mental health services (mhs)|mood and meaning|acceptability,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: other"
Follow NCT03305341 - Proof-of-Concept - COVID-19 AP TP Vaccine,AP-TP-V,"active, not recruiting",No Results Available,early phase 1,Industry,https://ClinicalTrials.gov/show/NCT03348670,NCT03348670,test macrophage migration inhibitory factor (mmif),interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Eosinophil and Anticoagulation in COVID-19 Patients,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04507282,NCT04507282,subprophylactic anticogulation level,observational,observational model: cohort|time perspective: prospective
Serologic Surveillance for SARS-CoV-2 (COVID-19) in a Prospective Cohort of Health Care Workers,nan,not yet recruiting,No Results Available,nan,Other|Industry,https://ClinicalTrials.gov/show/NCT04387890,NCT04387890,prevalence of anti sars-cov-2 antibodies (igm and igg) in health personnel|covid-19 incidence through serology-based screening and/or compatible symptoms in health personnel previously known to be unexposed to the virus|incidence of reactivation/reinfection for covid-19 in health personnel with a positive serology for sars-cov-2,observational,observational model: cohort|time perspective: prospective
Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,nan,completed,No Results Available,phase 4,Other|Industry,https://ClinicalTrials.gov/show/NCT04345276,NCT04345276,rate of composite adverse outcomes|time to recovery|rate of no fever|rate of no cough|rate of no dyspnea|rate of no requiring supplemental oxygen|rate of undetectable new coronavirus pathogen nucleic acid|rate of mechanical ventilation|rate of icu admission|rate of serious adverse event,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With Moderate to Severe COVID-19",nan,not yet recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04401475,NCT04401475,"an improvement of two points on the seven-point ordinal scale|time to clinical improvement by 2 points on the seven-point ordinal scale described in primary outcome.|ventilator-free days.|duration of ventilation|mortality rate|duration of hospitalization|time to independence from supplementary oxygen therapy|time to normalization of oxygen saturation, defined as sp02 > 94% sustained minimum 24 hours|change in four-point sequential organ failure assessment (sofa) score, daily while hospitalized|radiological response to treatment based on thoracic computerized tomography scan (ct-scan) or chest x-ray|change in cytokines, including il-6, and c-reactive protein (crp) levels|time to resolution of fever for at least 48 hours without antipyretics|decision by the attending physician to initiate treatment with another targeted immunomodulator (i.e. il-6 inhibitors)|change in the four-point berlin ards severity scale|change in three-point acute kidney injury network (akin) classification|change in troponin levels",interventional,"allocation: randomized|intervention model: sequential assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Evaluation of Ganovo ÔºàDanoprevir Ôºâ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,nan,completed,No Results Available,phase 4,Other|Industry,https://ClinicalTrials.gov/show/NCT04291729,NCT04291729,rate of composite adverse outcomes|time to recovery|rate of no fever|rate of no cough|rate of no dyspnea|rate of no requiring supplemental oxygen|rate of undetectable new coronavirus pathogen nucleic acid|rate of mechanical ventilation|rate of icu admission|rate of serious adverse event,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers,nan,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04405466,NCT04405466,immune responses to components of sars-cov-2|swabs for the presence of sarscov-2|difference between the study groups in anti-sars-cov 2 seropositivity status,observational,observational model: cohort|time perspective: prospective
Quality of Life and Physical Performance After Novel Coronavirus Infection (COVID-19);,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04375709,NCT04375709,health-related quality of life; euroqol (eq-5d-5l)|6-minute walk test|jamar dynamometer|hospital anxiety and depression scale (hads)|revised impact of event scale (ies-r)|mini-nutritional assessment (mna)|spirometry (bed-side)|post-covid functional scale (pcfs)|modified medical research council dyspnoea scale (mmrc dyspnoea),observational,observational model: cohort|time perspective: prospective
Physical Activity Following the Containment Period Imposed by the COVID-19 Pandemic in Patients,PhysiCOVID,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04451317,NCT04451317,physical activity measure|depression|sleep quality|food activity|activity level of chronic pathology,observational,observational model: case-control|time perspective: prospective
Study of seroPREvalence Vis-√†-vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital),PRESAGE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04528901,NCT04528901,"determine and compare the seroprevalence for sars-cov2 among patients with respiratory pathologies monitored in pneumology at the strasbourg university hospital, in the cluster zone of the grand est.",observational,observational model: cohort|time perspective: prospective
TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia,TOFACoV-2,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04390061,NCT04390061,prevention of severe respiratory failure requiring mechanical ventilation|prevention of need of icu admission|prevention of covid-19 related deaths|identification of predictors of outcome|incidence of treatment-emergent adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04535063,NCT04535063,28 days survival|efficacy of plasma infusion according to antibodies levels in the infuse bags|clinical efficacy of plasma infusion according to frame time from symptoms onset and hospitalization|change in clinical who ordinal scale from 1 to 10 points,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Nebulised Heparin in Patients With Severe COVID-19,CHARTER-MT,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04545541,NCT04545541,alive and ventilator free score,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: treatment"
Discovery Stage (Proof-of-concept) COVID-19 Antigen Presentation Therapeutic Vaccine,COVID-19--AP,"active, not recruiting",No Results Available,early phase 1,Industry,https://ClinicalTrials.gov/show/NCT03305341,NCT03305341,macrophage migration inhibitory factor (mmif),interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04361565,NCT04361565,anosmia|ageusia|duration of the loss of anosmia ageusia,observational,observational model: case-only|time perspective: retrospective
Lymphocyte - Monocyte Ratio As An Independent Predictor For Progression Of Illness In Patients With Covid-19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04534712,NCT04534712,progression|mortality,observational,observational model: cohort|time perspective: prospective
"A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)",nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04481685,NCT04481685,respiratory failure-free survival in participants with moderate-severe covid-19 who are treated with ati-450|change in 7 point-ordinal scale|change in oxygen saturation-normalization|need for advanced respiratory care|all-cause mortality|percentage of adverse events (aes)|percentage of serious adverse events (saes)|proportion of participants with normalization of fever for 24 hours|number of participants who develop new bacterial infection|number of participants who develop new fungal infection|incidence of adult respiratory distress syndrome (ards2)|change in serum cytokine interleukin (il)-6|change in serum cytokine il-8|change in serum cytokines il-1œ≤|change in serum cytokine tumor necrosis factor (tnf-œ±),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19,nan,recruiting,No Results Available,nan,Other|NIH,https://ClinicalTrials.gov/show/NCT04403880,NCT04403880,"humoral responses to peptide antigens derived from sars-cov-2 structural proteins and regions of the spike protein not present in vaccines|sars-cov-2-specific antibody binding response rate|sars-cov-2-specific antibody binding response magnitude|sars-cov-2-specific antibody binding response epitope specificity|sars-cov-2-specific antibody neutralization response rate|sars-cov-2-specific antibody neutralization response magnitude|sars-cov-2-specific antibody neutralization response epitope specificity|sars-cov-2-specific antibody-dependent cellular cytotoxicity (adcc) response rate|sars-cov-2-specific antibody-dependent cellular cytotoxicity (adcc) response magnitude|sars-cov-2-specific antibody-dependent cellular cytotoxicity (adcc) response epitope specificity|sars-cov-2-specific cd4+ and cd8+ t cell responses|sars-cov-2-specific cd4+ and cd8+ t cell response rate|sars-cov-2-specific cd4+ and cd8+ t cell response magnitude|sars-cov-2-specific cd4+ and cd8+ t cell response functional profiling|sars-cov-2-specific memory b cell characterization|sars-cov-2-specific infection presentation, including clinical course, along with demographics and corresponding medical history of participants|detection of viral rna in nasopharyngeal or nasal swab samples|response rate of sars-cov-2-specific binding antibodies in nasal samples|response magnitude of sars-cov-2-specific binding antibodies in nasal samples",observational,observational model: cohort|time perspective: other
Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,nan,recruiting,No Results Available,phase 1|phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04368988,NCT04368988,"participants with solicited adverse events (aes) - phase 1|safety laboratory values (serum chemistry, hematology) - phase 1|serum immunoglobulin g (igg) antibody levels expressed as geometric mean titers (gmts) - phase 1|serum igg antibody levels expressed as geometric mean fold rises (gmfrs) - phase 1|serum igg antibody levels expressed as seroconversion rates (scrs) - phase 1|serum igg antibody levels expressed as gmts - phase 2|serum igg antibody levels expressed as gmfrs - phase 2|serum igg antibody levels expressed as scrs - phase 2|participants with solicited adverse events (aes) - phase 2|participants with unsolicited aes - phase 2|participants with unsolicited aes - phase 1|participants with abnormal vital signs - phase 1|changes from baseline in body temperature - phase 1|changes from baseline in blood pressure - phase 1|changes from baseline in pulse rate - phase 1|participants with maaes - phase 1|participants with related maaes; serious adverse events (saes); and adverse events of special interest (aesi) - phase 1|assessment of serum igg antibody levels expressed as gmts at multiple time points - phase 1|assessment of serum igg antibody levels expressed as gmfrs at multiple time points - phase 1|assessment of serum igg antibody levels expressed as scrs at multiple time points - phase 1|assessment of serum igg antibody levels expressed by seroresponse rates (srrs) at multiple time points - phase 1|angiotensin-converting enzyme 2 (ace2) receptor binding inhibition assay expressed as gmts - phase 1|ace2 receptor binding inhibition assay expressed as gmfrs - phase 1|ace2 receptor binding inhibition assay expressed as scrs - phase 1|ace2 receptor binding inhibition assay expressed as srrs - phase 1|neutralizing antibody activity expressed as gmts - phase 1|neutralizing antibody activity expressed as gmfrs - phase 1|neutralizing antibody activity expressed as scrs - phase 1|neutralizing antibody activity expressed as srrs - phase 1|assessment of cell-mediated (t helper 1 [th1]/t helper 2 [th2]) pathways - phase 1|assessment of serum igg antibody levels expressed as gmts - phase 2|assessment of serum igg antibody levels expressed as gmfrs - phase 2|assessment of serum igg antibody levels expressed as scrs (‚â• 4-fold change) - phase 2|assessment of serum igg antibody levels expressed as gmts at multiple time points - phase 2|assessment of serum igg antibody levels expressed as gmfrs at multiple time points - phase 2|assessment of serum igg antibody levels expressed as scrs (‚â• 4-fold change) at multiple time points - phase 2|ace2 receptor binding inhibition assay expressed as gmts - phase 2|ace2 receptor binding inhibition assay expressed as gmfrs - phase 2|ace2 receptor binding inhibition assay expressed as scrs - phase 2|neutralizing antibody activity expressed as gmts - phase 2|neutralizing antibody activity expressed as gmfrs - phase 2|neutralizing antibody activity expressed as scrs (‚â• 4-fold change) - phase 2|assessment of serum igg antibody levels expressed as gmts - phase 2 boost|assessment of serum igg antibody levels expressed as gmfrs - phase 2 boost|participants with maaes - phase 2|participants with related maaes; saes; and aesis - phase 2|participants with abnormal vital signs - phase 2|changes from baseline in body temperature - phase 2|changes from baseline in blood pressure - phase 2|changes from baseline in pulse rate - phase 2|participants with sars-cov-2 positivity - phase 2|assessment of sars-cov-2 by qualitative pcr - phase 2|assessment of cell-mediated (th1/th2) pathways - phase 2",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",RUXCOVID,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04362137,NCT04362137,"proportion of patients who die, develop respiratory failure [require mechanical ventilation] or require intensive care unit (icu) care|clinical status|percentage of patients with at least two-point improvement from baseline in clinical status|percentage of patients with at least one-point improvement from baseline in clinical status|percentage of patients with at least one-point deterioration from baseline in clinical status|time to improvement in clinical status|mean change from baseline in the clinical status|mortality rate|proportion of patients requiring mechanical ventilation|duration of hospitalization|time to discharge or to a news2 score of ‚â§2|change from baseline in news2 score|change from baseline in spo2/fio2 ratio.|proportion of patients with no oxygen therapy",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19),nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04358029,NCT04358029,frequency of cardiac arrhythmias|mode of death,observational,observational model: case-only|time perspective: other
Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors,nan,recruiting,No Results Available,nan,Other|NIH,https://ClinicalTrials.gov/show/NCT04447222,NCT04447222,"coronavirus disease-2019 (covid19)-specific psychological distress|the extent to which covid-19 experiences are associated with covid-19 specific psychological distress, health, financial and social disruptions, perceived benefits and social support, and health-related quality of life (hrqol)|resiliency factors|group differences in the outcomes assessed in the protocol relative to prior group assignment in the behavioral clinical trials|health-related quality of life (hrqol)|general quality of life (qol)|sleep disturbances|depression|changes in anxiety|perceived availability of social support|elements of mindfulness|non-judgmental physical and emotional sensations associated with eating|the degree to which participants exercise compassion towards themselves under difficult circumstances and how this impacts their emotions|physical activity|intrusive thoughts, or the tendency to ruminate on or avoid thoughts about stressors|basic fruit/vegetable intake|usual intake of percentage energy from fat|engagement in the core mind-body practices that the patients learned",observational,observational model: cohort|time perspective: cross-sectional
Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04438837,NCT04438837,clinical covid-19|confirmed covid-19|time to virological recovery|time to symptoms onset|development of pneumonia|development of severe disease|need for hospitalization or icu|adverse events|mortality|time to de-isolation,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias,COVIM,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04416438,NCT04416438,rate of serious coronavirus infection in different mnp patient subgroups|proportion of mnp patients who had covid-19 infection during the 2020 epidemic.|rate of death of mnp patients who had covid-19|rate of passages in intensive care with need for mechanical ventilation,observational,observational model: cohort|time perspective: retrospective
Daily Regimen of Tenofovir/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04519125,NCT04519125,sars-cov-2 infection|serious and non-serious adverse events|discontinuation of using tdf/ftc for any reason|adherence to tdf/ftc|severity of sars-cov-2 infection,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ),ILIAD-7-US-I,not yet recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04442178,NCT04442178,"improvement of the absolute lymphocyte count (alc) of lymphopenic (alc‚â§1000/mm3) covid-19 infected participants out to approximately 30 days following initial study drug administration or hospital discharge (hd), whichever occurs first|""clinical improvement"" as defined by a 2 points improvement in a 7-point ordinal scale for clinical assessment, through day 30 or hd.|a significant decline of sars-cov-2 viral load through day 30 or hd|frequency of secondary infections through day 45 compared to placebo arm|length of hospitalization compared to placebo arm|length of stay in icu compared to placebo arm|number of readmissions to icu compared to placebo arm|organ support free days compared to placebo arm|frequency of re-hospitalization through day 45 compared to placebo arm|all-cause mortality through day 45 compared to placebo arm|cd4+ and cd8+ t cell counts compared to placebo arm|level of other known biomarkers of inflammation: ferritin compared to placebo a|level of other known biomarkers of inflammation: crp compared to placebo arm|level of other known biomarkers of inflammation: d-dimer compared to placebo arm|physiological status through news2 evaluation compared to placebo arm",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-O ),ILIAD-7-US-O,not yet recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04426201,NCT04426201,"improvement of the absolute lymphocyte count (alc) of lymphopenic (alc‚â§1000/mm3) covid-19 infected participants out to approximately 30 days following initial study drug administration or hospital discharge (hd), whichever occurs first|""clinical improvement"" as defined by a 2 points improvement in a 7-point ordinal scale for clinical assessment, through day 30 or hd.|a significant decline of sars-cov-2 viral load through day 30 or hd|frequency of secondary infections through day 45 compared to placebo arm|length of hospitalization compared to placebo arm|length of stay in icu compared to placebo arm|number of readmissions to icu compared to placebo arm|organ support free days compared to placebo arm|frequency of re-hospitalization through day 45 compared to placebo arm|all-cause mortality through day 45 compared to placebo arm|cd4+ and cd8+ t cell counts compared to placebo arm|level of other known biomarkers of inflammation: ferritin compared to placebo arm|level of other known biomarkers of inflammation: crp compared to placebo arm|level of other known biomarkers of inflammation: d-dimer compared to placebo arm|physiological status through news2 evaluation compared to placebo arm",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Polyvalent Immunoglobulin in COVID-19 Related ARds,ICAR,recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04350580,NCT04350580,"ventilator-free days|mortality|sequential organ failure assessment score|p/f ratio|lung compliance|radiological score|biological efficacy endpoints - c-reactive protein|biological efficacy endpoints - procalcitonin|immunological profile|number of patients using other treatments for covid-19 related ards|occurrence of deep vein thrombosis or pulmonary embolism|total duration of mechanical ventilation, ventilatory weaning and curarisation|kidney disease: improving global outcomes (kdigo) score and need for dialysis|occurrence of adverse event related to immunoglobulins|occurrence of critical illness neuromyopathy|occurrence of ventilator-acquired pneumonia",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival,SAVE-ICU,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04415060,NCT04415060,hospital mortality|ventilator-free days|icu-free days|participant quality of life at 3 and 12 months after discharge|median daily oxygenation|adjunctive ards therapies|hospital-free days|disability|cost utility analysis|cost effectiveness analysis,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.,Prolectin-M,not yet recruiting,No Results Available,not applicable,Industry|Other,https://ClinicalTrials.gov/show/NCT04512027,NCT04512027,sarscov2 viral copy number|b. disease progression will be measured on a 7-point scale at 28 days. a 2-point change will be considered disease progression.,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic,nan,recruiting,No Results Available,nan,Other|NIH,https://ClinicalTrials.gov/show/NCT04474301,NCT04474301,experiences during the covid-19 pandemic|covid-19-specific psychological distress|covid-19-specific health|covid-19-specific financial and social disruptions|covid-19-specific perceived benefits and social support|covid-19-specific health related quality of life (hrqol)|effects of covid-19 experiences on covid-19-specific psychological distress and hrqol|prior lifestyle data,observational,observational model: case-only|time perspective: cross-sectional
Beaumont Health Large-scale Automated Serologic Testing for COVID-19,BLAST COVID-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04349202,NCT04349202,prevalence covid antibodies in employees of beaumont health|covid-19 re-infection in participants positive for antibodies to sars-cov-2|correlation of dried blood spot and standard blood sampling positive for covid-19 igg antibodies|correlation of dried blood spot and standard blood sampling negative for covid-19 igg antibodies|correlation of dried blood spot and standard blood sampling positive for covid-19 iga antibodies|correlation of dried blood spot and standard blood sampling negative for covid-19 iga antibodies|reproducibility of sars-cov-2 igg antibody detection from dried blood spots|stability of dried blood spots for sars-cov-2 igg antibody detection|effect of shipping on dried blood spot samples for sars-cov-2 igg antibody detection|accuracy of participant-performed blood spot collection for sars-cov-2 igg antibody detection|ease of participant-performed blood spot collection|correlation of sars-cov-2 antibodies between immediate family members,observational,observational model: cohort|time perspective: prospective
Emergency Ventilator Splitting Between Two or More Patients (COVID-19),nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04381013,NCT04381013,completion of 1-minute test|completion of 24-hour test,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: device feasibility
Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease,CARR-COV-02,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04521322,NCT04521322,"diagnose of covid19 disease|progression to a more severe disease state, defined as need for oxygen therapy.|lasting of disease|incidence of covid-19 disease onset in the first week after treatment",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
"COVID19-OR (SARS-CoV-2): Observation,Risk & Recovery",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04524520,NCT04524520,physical|health related quality of life|psychological|risk stratification,observational,observational model: cohort|time perspective: prospective
"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine",nan,recruiting,No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04545749,NCT04545749,safety of ub-612 vaccine|safety|immunogenicity,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: prevention
New Treatment for COVID-19 Using Ethanol Vapor Inhalation .,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04554433,NCT04554433,disinfection of covid-19 in human respiratory tract .|improvement of general condition of mechanically ventilated patients confirmed covid-19 positive ..,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
The Critical Care Response to the COVID-19 Pandemic in Madrid,Tetrix,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04393324,NCT04393324,mortality|length of icu stay,observational,observational model: cohort|time perspective: other
Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04357327,NCT04357327,sensibility|specificity,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: diagnostic
Low Dose Radiation Therapy for Covid-19 Pneumonia,nan,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04394793,NCT04394793,symptomatic improvement by national early warning score (news)|length of hospital stay|number of icu admissions or deaths,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV),JAKINKOV,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04366232,NCT04366232,biological criteria|duration of oxygen therapy (days)|number of intensive care units admissions|number of days in intensive care units|mortality rate|total number of days in hospital|organ failure score modification (sepsis-related organ failure assessment (sofa) score)|number of bacterial and/or fungal sepsis,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19,nan,not yet recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04548895,NCT04548895,proportion of quality signals obtained out of all monitoring time for each device|predictive characteristics of the algorithm for respiratory tract infection,observational,observational model: ecologic or community|time perspective: prospective
"Development and Validation of ""Ready-to-Use"" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19",nan,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04477083,NCT04477083,time to clinical recovery defined as 3 days afebrile with improved cough and other clinical signs|time to achieve viral clearance state determined by two successive negative pcr results for two oropharyngeal swabs separated by 48 hours.|incidence of treatment-emergent adverse events,interventional,allocation: randomized|intervention model: crossover assignment|masking: single (outcomes assessor)|primary purpose: treatment
Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,PLASM-AR,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04383535,NCT04383535,clinical status during follow-up at 30th day|clinical status during follow-up at 7th day|clinical status during follow-up at 14th day|time until hospital discharge (days).|time until discharge from icu (days)|time to death|time until complete functional recovery|percentage of participants with adverse events / serious adverse events|percentage of patients with negative sars-cov-3 pcr at day 14th|d dimer plasma concentration at day 14th|ferritin plasma concentration at day 13th|plasma concentration of neutralizing antibodies at day 2nd|plasma concentration of neutralizing antibodies at day 7th|post-transfusion adverse reactions,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Over-the-counter Medications & COVID-19,OTC‚Ñû&COVID19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04500639,NCT04500639,ibuprofen exposure for symptom management|exposure to other drugs implicated in covid-19 severity,observational,observational model: case-control|time perspective: prospective
Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia,nan,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04540926,NCT04540926,number of days to clinical improvement until hospital discharge or death.,interventional,intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
S-Nitrosylation Therapy of COVID-19,nan,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04528771,NCT04528771,length of hospital stay|number of ventilator days|length of intensive care|all-cause mortality|treatment emergent adverse events|time to respiratory status improvement|clinical status|respiratory clinical status,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Covid-19 Rapid Diagnostic Tests on Blood Drop,COVID-TEST,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04467008,NCT04467008,positivity of the rapid diagnostic test,observational,observational model: cohort|time perspective: retrospective
Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome - Vanguard,CIRCA-19,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04400032,NCT04400032,number of participants with treatment-related adverse events as assessed by ctcae v4.0|number of participants alive by day 28|number of participants with ventilator-free days by day 28,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04470297,NCT04470297,time to resolution of symptoms [national early warning score 2 (news2) of 0]|clinical worsening to critical covid-19 illness|duration of supplemental oxygen therapy|duration of mechanical ventilation (if applicable)|duration of hospitalisation|proportion of participants with virologic clearance in nasopharyngeal swab rt-pcr|c-reactive protein (crp) level's reduction|incidence of new onset lymphopenia|direct bilirubin level's reduction|side effects,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19,MESCEL-COVID19,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04366271,NCT04366271,mortality due to lung involvement due to sars-cov-2 virus infection at 28 days of treatment|mortality due to lung involvement due to sars-cov-2 virus infection at 14 days of treatment|mortality from any cause at 28 days|days without mechanical respirator and without vasopressor treatment for 28 days|patients alive without mechanical ventilation and without vasopressors on day 28|patients alive and without mechanical ventilation on day 14|patients alive and without mechanical ventilation on day 28|patients alive and without vasopressors on day 28|days without vasopressors for 28 days|patients cured at 15 days|incidence of treatment-emergent adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Study on the Recovery of Pulmonary Function, Chest CT, Hematologic, and Immune & Inflammatory Conditions in COVID-19 Rehabilitation Patients",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04456101,NCT04456101,pulmonary function|chest ct|changes in hematology|changes in immune and inflammatory states|st. george's respiratory questionnaire(sgrq),observational,observational model: cohort|time perspective: prospective
Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial,nan,not yet recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04548557,NCT04548557,in hospital days|14 day mortality|d-dimers|c-reactive protein|oxygen saturation|tnf alpha|il-6|ferritin|number of participants with treatment-related adverse events as assessed by ctcae v4.0,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: treatment"
"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",STOP COVID,"active, not recruiting",No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04342663,NCT04342663,time to clinical worsening|clinical deterioration on a likert-type scale (1-6)|clinical deterioration measured by number of days|symptomatic severity on a likert scale (0-10 where 0= none and 10=very severe),interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Sirolimus in COVID-19 Phase 1,SirCO-1,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04371640,NCT04371640,change in sars-cov-2 viral burden from baseline to day 7 of treatment|change in sars-cov-2 viral burden at days 1-6|rate of treatment emergent adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
"NCI COVID-19 in Cancer Patients, NCCAPS Study",nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04387656,NCT04387656,patient variables (factors) associated with severe acute respiratory syndrome (sars) coronavirus 2 (covid-19) severity|effects of covid-19 on cancer therapy and association with clinical outcomes,observational,observational model: cohort|time perspective: prospective
Risks of COVID19 in the Pregnant Population,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04379284,NCT04379284,determine the prevalence of maternal fetal transmission of covid19|describe the outcomes of covid19 positive pregnancies|understand the placental impact of covid19 in pregnancy at various gestational ages,observational,observational model: case-only|time perspective: prospective
"Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)",nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04553705,NCT04553705,"clinical improvement|recovery rate from positive to negative swaps|fever to normal temperature in days|remission of lung inflammation in ct or x-ray|length of hospitalization|(pcr levels) polymerase chain reaction assay levels|respiratory indexes|c-reactive protein mg/l|serum ferritin ng/ml|lactic acid dehydrogenase u/l|leukocytes count œºl|lipid profile [ldl, hdl, total cholesterol ]|total plasma antioxidant capacity",interventional,"allocation: randomized|intervention model: sequential assignment|masking: double (participant, care provider)|primary purpose: treatment"
COVID-19 Breastfeeding Guideline for African-Americans,COVID-BF,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04476940,NCT04476940,covid-19 breastfeeding guidance adherence at birth.|covid-19 breastfeeding guidance adherence at 1-month postpartum.|covid-19 breastfeeding guidance adherence at 3-months postpartum.|exclusive breastfeeding at birth.|exclusive breastfeeding at 1-month.|exclusive breastfeeding at 3-months.|covid_status|covid-19 immunoglobulin g|covid-19 immunoglobulin m,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
"Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort",CORIMMUNO-COAG,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04344756,NCT04344756,"survival without ventilation (vni or mechanical ventilation)|ventilator free survival|world health organisation(who) progression scale ‚â§5|world health organisation(who) progression scale|overall survival|length of hospital stay|length of icu stay|time to oxygenation supply independency|time to ventilator (non invasive or invasive)|rate of acute kidney injury|time to renal replacement therapy (rrt) initiation|rate of clinically overt pulmonary embolism or proximal deep vein thrombosis|rate of clinically overt arterial thrombosis|rate of unscheduled central venous catheter replacement for catheter dysfunction|rate of central venous catheter-related deep vein thrombosis (cvc-dvt)|rate of unscheduled indwelling arterial catheter replacement for catheter dysfunction|rate of acute clotting leading to the replacement the renal replacement therapy circuit stratified by regional citrate anticoagulation or not|time to acute clot formation within the oxygenator (acute oxygenator thrombosis, aot) leading to the exchange of an extracorporeal membrane oxygenation (ecmo) system|time to acute clot formation within the pump head (pump head thrombosis, pht) leading to the exchange of an extracorporeal membrane oxygenation (ecmo) system|incidence of adverse events",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Photodynamic Therapy for the Treatment of COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04416113,NCT04416113,participants achieving either a major clinical response or partial clinical response (pcr) defined by who,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19,nan,enrolling by invitation,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04349631,NCT04349631,incidence of hospitalization for covid-19|incidence of symptoms for covid-19|absence of upper/lower respiratory infection|glucose|calcium|albumin|total protein|sodium|total carbon dioxide|potassium|chloride|bun|creatinine|alkaline phosphatase|alanine aminotransferase|aspartate aminotransferase|total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|lymphs|monocytes|eos|basophils|absolute neutrophils|absolute lymphs|absolute monocytes|absolute eosinophils|absolute basophils|immature granulocytes|absolute immature granulocytes|platelets|prothrombin time|inr|tnfalpha|interleukin-6|interleukin-10|c-reactive protein|sf-36|phq-9,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
"Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic",OBVIONCO,recruiting,No Results Available,not applicable,Other|Industry,https://ClinicalTrials.gov/show/NCT04437719,NCT04437719,covid-19 infection's symptoms|incidence and course of symptoms of covid-19 infection|correlation of the covid-19 infection with the biological and clinical data of patients,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04533399,NCT04533399,"cohort 1: hiv- participants with symptomatic mild, moderate, or severe covid-19|cohort 1: hiv- participants with symptomatic moderate or severe covid-19|cohort 1: hiv- participants with solicited adverse events (aes)|cohort 1: hiv- participants with unsolicited aes|cohort 2: hiv+ participants with solicited aes|cohort 2: hiv+ participants with unsolicited aes|cohort 2: serum immunoglobulin g (igg) antibody levels expressed as geometric mean titers (gmts)|cohort 2: serum igg antibody levels expressed as geometric mean fold rises (gmfrs)|cohort 2: serum igg antibody levels expressed as seroconversion rates (scrs)|cohort 1: hiv- participants with individual strata of symptomatic virologically confirmed, mild, moderate, or severe covid-19|cohort 1: hiv- participants with covid-19 requiring hospitalization|cohort 1: incidence, maximum severity score, and symptom duration of sars-cov-2 infection by severity classification|cohort 1: serum igg antibody levels at multiple time points expressed as gmts|cohort 1: serum igg antibody levels at multiple time points expressed as gmfrs|cohort 1: serum igg antibody levels at multiple time points expressed as scrs|cohort 1: serum igg antibody levels at multiple time points expressed as seroprotection rates (sprs)|cohort 1: angiotensin-converting enzyme 2 (ace2) receptor binding inhibition assay expressed as gmts|cohort 1: ace2 receptor binding inhibition assay expressed as gmfrs|cohort 1: ace2 receptor binding inhibition assay expressed as scrs|cohort 1: ace2 receptor binding inhibition assay expressed as seroresponse rates (srrs)|cohort 1: neutralizing antibody activity expressed as gmts|cohort 1: neutralizing antibody activity expressed as gmfrs|cohort 1: neutralizing antibody activity expressed as scrs|cohort 1: neutralizing antibody activity expressed as srrs|cohort 1: hiv- participants with medically attended adverse events (maaes), adverse events of special interest (aesis), and serious adverse events (saes)|cohort 2: serum igg antibody levels at multiple time points expressed as gmts|cohort 2: serum igg antibody levels at multiple time points expressed as gmfrs|cohort 2: serum igg antibody levels at multiple time points expressed as scrs|cohort 2: serum igg antibody levels at multiple time points expressed as sprs|cohort 2: ace2 receptor binding inhibition assay expressed as gmts|cohort 2: ace2 receptor binding inhibition assay expressed as gmfrs|cohort 2: ace2 receptor binding inhibition assay expressed as scrs|cohort 2: ace2 receptor binding inhibition assay expressed as srrs|cohort 2: neutralizing antibody activity expressed as gmts|cohort 2: neutralizing antibody activity expressed as gmfrs|cohort 2: neutralizing antibody activity expressed as scrs|cohort 2: neutralizing antibody activity expressed as srrs|cohort 2: hiv+ participants with maaes, aesis, and saes|cohort 2: hiv+ participants with symptomatic virologically confirmed, mild, moderate, or severe covid-19|cohort 2: incidence, maximum severity score, and symptom duration of sars-cov-2 infection by severity classification",interventional,"allocation: randomized|intervention model: sequential assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19,BRACE-CORONA,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04364893,NCT04364893,median days alive and out of the hospital|number of participants with adverse cardiovascular outcomes and new worsening heart failure|cardiovascular biomarkers related to covid-19,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Accuracy of Lung Ultrasound in the Diagnosis of covid19 Pneumonia,POCUSars-CoV-2,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04370275,NCT04370275,negative predictive value of lung ultrasound in the diagnosis of covid-19|positive predictive value of lung ultrasound in the diagnosis of covid-19|sensitivity and specificity of lung ultrasound in the diagnosis of covid-19,observational,observational model: cohort|time perspective: prospective
SARS-CoV-2 /COVID-19 Admission Screening in a University Hospital Setting,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04519372,NCT04519372,proportion of sars-cov-2 -infected patients,observational,observational model: other|time perspective: retrospective
COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE),CON-VINCE,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04379297,NCT04379297,prevalence and dynamics of the sars-cov 2 infection in luxemburg|collection of samples for research|psycho-social evaluation,observational,observational model: cohort|time perspective: prospective
Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04382053,NCT04382053,apache ii severity of disease score on day 15 or on the day of discharge (whichever is earlier)|serum c-reactive protein (crp) levels|clinical status over time|proportion of participants not requiring mechanical ventilation for survival.|proportion of participants with at least one-point improvement from baseline in clinical status,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.,PERSO-COVID,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04488484,NCT04488484,immune response description|evolution of the sars-cov2 overtime|clinical and immunological analysis|comparison of the occurrence of clinical events with other immunological data,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
CoVID-19 Plasma in Treatment of COVID-19 Patients,nan,recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04355897,NCT04355897,reduce mortality|reduce requirement for mechanical ventilation.|reduce the duration of mechanical ventilation.|review of treatment related adverse events.,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry,RegCOVID19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04347278,NCT04347278,"effectiveness of current drug treatments for hospitalized patients with sars-cov-2 infection (covid-19 patients) in routine clinical practice|risk factors or modifiers of pharmacological effect such as demographic characteristics, comorbidity or underlying pathology, concomitant medication.|information on the patterns of use of these drugs (dose, duration of treatment,|adverse events|time of hospital admission and/or stay in icu and maximum severity reached.|treatments for sars-cov-2 positive patients not described in the protocol|healthy survey for patients after their recovery/discharge from hospital.",observational,observational model: other|time perspective: other
COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities,CRC-COVID,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04363749,NCT04363749,intensity of the emotional response to hypoxic exposure (14.3 et 12.7% fio2)|perception of a hypoxic stimulus induced dyspnea (14.3 et 12.7% fio2)|perception of a hypercapnic stimulus induced dyspnea (7% co2)|perception of a inspiratory mechanical constraint induced dyspnea|brain mri,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: basic science
Plasma Rich Antibodies From Recovered Patients From COVID19,PRA-001,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04348877,NCT04348877,viral covid-19 clearance|decrease of radiological abnormalities|clinical improvement,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)",nan,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04379271,NCT04379271,"proportion of patients without any need* for inv until end-of-study (eos)|duration of icu treatment until eos|28-day all-cause mortality|time to clinical improvement|duration of hospitalization|proportion of patients both for all patients and surviving patients free of renal-replacement therapy (rrt)* until eos|proportion of patients both for all patients and surviving patients free from extracorporeal membrane oxygenation (ecmo)* until eos|proportion of patients free of inv until days 6 and 14*|proportion of patients free of rrt until days 6 and 14*|proportion of patients free ecmo until days 6 and 14*|proportion of patients with improvement of at least 2 points (from randomization) on the 9-category who ordinal scale1 on days 6, 14, and 28|proportion of patients with auxiliary oxygen therapy (including all types of oxygen therapy) on days 6, 14, and 28|proportion of patients with clinical recovery: axillary temperature ‚â§36.6 ‚ñé, or oral temperature ‚â§37.2 ‚ñé, or rectal or tympanic temperature ‚â§37.8 ‚ñé;|proportion of patients with clinical recovery: respiratory frequency ‚â§24 times/min without oxygen inhalation; and|proportion of patients with clinical recovery: oxygen saturation ‚â•98% without oxygen inhalation|proportion of patients with clinical improvement, defined as the time from first dose of imp to an improvement of at least 2 points on the who 9 category ordinal scale, or live discharge from hospital without oxygen supplementation, whichever comes first|clinical patient status on the 9-category who ordinal scale1 on days 6, 14, and 28|duration of inv|duration of ecmo|duration of rrt|duration of auxiliary oxygen therapy (including all types of oxygen therapy)|duration of hospitalization for survivors|the rate of icu* admission on days 6, 14, and 28|hospital-free days|time from imp treatment initiation to death|time to first prescription of inv|time to first prescription of rrt|time to first prescription of ecmo|time to first prescription of inv, rrt, and ecmo|time to icu admission|cumulative dose of vasoactive therapies and days with vasoactive therapies (daily until day 14)|time to clinical recovery|morning trough plasma levels of imu-838 on days 0, 1, 2, 3, 6, 14, and 28|correlation of trough levels (quartiles) to selected clinical outcomes (clinical improvement accoding to who criteria)|adverse events (aes) and serious aes|vital signs: height|vital signs: weight|vital signs: body temperature (¬∫c)|vital signs: pulse rates,|vital signs: systolic and diastolic blood pressures|clinical laboratory parameters: blood chemistry|clinical laboratory parameters: hematology|clinical laboratory parameters: urinalysis|12-lead electrocardiogram: heart rate|12-lead electrocardiogram: pq-interval|12-lead electrocardiogram: qrs-interval|12-lead electrocardiogram: qt interval|12-lead electrocardiogram: the heart rate-corrected qtc interval (according to bazett's formula)|temperature|d-dimer|lactate dehydrogenase (ldh)|c-reactive protein|troponin i|procalcitonin|correlation of disease markers to selected clinical outcomes (clinical improvement accoding to who criteria)|severe acute respiratory syndrome coronavirus virus (sars-cov-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples: decrease of sars-cov-2 viral load|severe acute respiratory syndrome coronavirus virus (sars-cov-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples: time course of sars-cov-2 viral load|qualitative virologic clearance in spontaneous sputum and nasopharyngeal swab samples (= 2 consecutive negative sars-cov-2 reverse transcriptase polymerase chain reaction tests at least 24 hours apart)|rate of conversion to a negative sars-cov-2 (qualitative) test on days 6, 14 and 28|time to conversion to a negative sars-cov-2 (qualitative) test|interleukin (il)-17|interleukin (il)-1√ü|interleukin (il)-6|interferon gamma (ifnœ≥)|tumor necrosis factor alpha|immunoglobulin (ig)a and igg antibodies against sars-cov-2: ‚ä¢ time to appearance of iga and/or igg antibodies|immunoglobulin (ig)a and igg antibodies against sars-cov-2: ‚ä¢ proportion of patients with iga and/or igg antibodies on days 6, 14, and 28",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients,nan,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04497389,NCT04497389,c-reactive protein,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +,eChoVid,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04335019,NCT04335019,"association of pulmonary lesions on ultrasound on d0 classified according to three stages of severity|assessment of the agreement between a newly trained operator and an experienced operator of classification in one of the three stages of ultrasound gravity, by cohen's kappa coefficient.|estimate in patients who had a ct-scan on d0, the agreement in the evaluation of the severity of lung lesions via ultrasound vs. ct-scan, by cohen's kappa coefficient|measurement of the cumulative incidence of invasive mechanical ventilation and measurement of survival",observational,observational model: other|time perspective: prospective
"Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin¬Æ/Zeribev¬Æ) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort",CORIMMUNO-BEVA,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04344782,NCT04344782,proportion of surviving patients without need for intubation for respiratory support|saturation of oxygen in the blood (sao2)|arterial oxygen partial pressure (pao2)|ratio of arterial oxygen partial pressure to fractional inspired oxygen (pao2/fio2)|ct-scan score|dyspnea|overall survival|admissionn to the intensive care unit (icu)|incidence of mechanical ventilation|hospital length of stay|incidence of adverse event|vegf plasma concentration,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Timing of Corticosteroids in COVID-19,nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04530409,NCT04530409,percentage of cases that will need hospitalization|percentage of cases that deteriorate to acute respiratory distress syndrome|percentage of cases with increased d-dimer|time to recovery of diarrhea|percentage reduction in crp|percentage reduction in ldh|percentage reduction in alt|percentage reduction in ferritin|time to recovery of lymphopenia|time to recovery of cough|time to recovery of fever|time to recovery of myalgia|time to recovery of anosmia|time to recovery of dyspnea,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
DISulfiram for COvid-19 (DISCO) Trial,DISCO,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04485130,NCT04485130,"number of participants with treatment-related adverse events as assessed by ctcae v4.0|change in covid-19 symptom severity score as assessed by a 5-point adapted somatic symptom severity score (sss-8)|virologic impact of 3 days of disulfiram, as measured by the fold-change in copies of sars-cov-2 virus per million cells between baseline and day 31.|immunologic impact of 3 days of disulfiram, as measured by the fold-change in plasma levels of pro-inflammatory cytokines (e.g, interleukin 6, interleukin 1-beta, etc.).",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Corticosteroid Nasal Spray in COVID-19 Anosmia,nan,completed,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04484493,NCT04484493,improvement of olfaction,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Hydroxychloroquine, Azithromycin in the Treatment of Covid-19",PACTT,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04405921,NCT04405921,"clinical recovery at day-14, from the start of treatment.|viral clearance via rt-pcr at day 5- 7-10 and day 14",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04557241,NCT04557241,change in trust in science|believability profiles|preventive behavioral intentions,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: prevention"
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19),nan,recruiting,No Results Available,phase 2|phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04494646,NCT04494646,incidence of serious adverse events in phase 2|proportion of participants who have recovered in phase 3|average number of renal replacement therapy (rrt)-free days|average number of mechanical ventilation-free days|incidence of all-cause mortality|proportion of participants who experienced deterioration from baseline,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Nigella Sativa in COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04401202,NCT04401202,proportion of patients who are clinically recovered|time to full clinical recovery or progression to pneumonia or hypoxia|normalization of chest radiograph|rate of complications|death,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen,COVIDOLIP,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04435223,NCT04435223,cholesterol concentration|ldl cholesterol / hdl cholesterol/ lipoprotein size and composition/ non esterified fatty acid/ triglyceridemia/ cetp and pltp activity/ apolipoprotein canceration/ lipid peroxidation/ pro and anti inflammatory profile.,observational,observational model: cohort|time perspective: prospective
Endovascular Thrombectomy in COVID-19 Infected Patients,ET-COVID-19,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04406090,NCT04406090,intrahospital mortality|short-term morbidity|angiographic success,observational,observational model: cohort|time perspective: retrospective
"Clinical Evaluation of Ventilador Innovation Product in Colombia in the SARS COVID 19 Pandemic, Unisabana Herons.",SabanaHerons,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04497623,NCT04497623,"improvement or maintenance of the oxygenation level measured by pao2|improvement or maintenance of the oxygenation level measured by o2 saturation|improvement or maintenance of adequate levels of carbon dioxide measured by paco2|improvement or maintenance of adequate levels of hco3|improvement or maintenance of adequate levels of excess base.|improvement or maintenance of adequate levels of blood ph|improvement or maintenance of pao2/fio2|improvement or maintenance of sato2/fio2|uninterrupted and faultless operation in the period of use of the ventilator|inspiratory peak pressure> 35 cm h2o that does not have a clinical explanation other than the ventilator (such as a mucus plug)|plateau airway pressure> 30 cm h2o that does not have a clinical explanation other than the ventilator|vt> 8 cc / kg of ideal weight that does not have a clinical explanation other than the ventilator|decrease or increase in respiratory rate, tidal volume, peep, peak inspiratory pressure, fio2, not due to a clinician order (changes not ordered by the clinical team but due to the ventilator variability)|pneumothorax (not having an explanation other than ventilatory support, such as the insertion of a central catheter)|pneumomediastinum (not having an explanation other than ventilatory support, such as the insertion of a central catheter)|subcutaneous emphysema (not having an explanation other than ventilatory support, such as the insertion of a central catheter)|hemodynamic deterioration in the hour following the start of the unisabana-herons ventilator that requires a 100% increase in the dose of vasopressors and that does not have a clinical explanation other than the ventilator|cardiac arrest without a clinical explanation other than the ventilator|death without a clinical explanation other than the ventilator|elevation of creatinine that does not have a clinical explanation other than the ventilator|elevation of bun that does not have a clinical explanation other than the ventilator|digestive bleeding without a clinical explanation other than ventilator|stress ulcers (upper gastrointestinal tract) without a clinical explanation other than ventilator|pneumonia associated with ventilator.|tracheobronchitis associated with ventilator.|critical care polyneuropathy that does not have a different explanation for the use of the ventilator and / or muscle relaxants necessary for mechanical ventilation|critical care myopathy that does not have a different explanation for the use of the ventilator and / or muscle relaxants necessary for mechanical ventilation",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: device feasibility
The PAWS-COVID-19 (Pediatric AirWay complicationS COVID-19) Registry,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04449042,NCT04449042,airway complications|airway device|ppe|first pass success|induction techniques|failed intubation|complication risk factors,observational,observational model: cohort|time perspective: prospective
Inhaled Ciclesonide for Outpatients With COVID19,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04435795,NCT04435795,improvement in dyspnea at day 7|hospitalization at day 14|oxygen use|mortality|clinical status|anxiety|sleep disturbance|exercise capacity,interventional,"allocation: randomized|intervention model: factorial assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,CAN-COVID,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04362813,NCT04362813,"number of patients with clinical response|covid-19-related death rate during the 4-week period after study treatment|ratio to baseline in the c-reactive protein (crp)|ratio to baseline in the serum ferritin|ratio to baseline in the d-dimer|number of participants with adverse event (ae), serious adverse events (sae), clinically significant changes in laboratory measures, and vital signs",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04501822,NCT04501822,echocardiographic assessment of cardiac function|–ú–ê–°–°–ï|quantitative analysis of parenchymal lung damage|functional exercises capacity assessment|evaluation of renal function|evaluation of inflammation|evaluation of coagulation abnormality|evaluation of quality of life in first year after discharge,observational,observational model: cohort|time perspective: prospective
Immunological Profiling of Patients With COVID-19 in Respiratory Distress,ACTICOV-2,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04351711,NCT04351711,membrane expression of human leukocyte antigen -dr isotype compared to normal values (based on 150 healthy volunteers previously sampled)|membrane expression of cluster of differentiation 38 compared to normal values (based on 150 healthy volunteers previously sampled)|membrane expression of programmed cell death 1 protein compared to normal values (based on 150 healthy volunteers previously sampled)|membrane expression of cluster of differentiation 45ra compared to normal values (based on 150 healthy volunteers previously sampled)|membrane expression of cluster of differentiation 27 (na√øve/central memory/effector memory) compared to normal values (based on 150 healthy volunteers previously sampled)|membrane expression of cd57 on t cd4+ and t cd8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)|membrane expression of cluster of differentiation 27 on t cd4+ and t cd8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)|membrane expression of cluster of differentiation 28 on t cd4+ and t cd8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)|membrane expression of human leukocyte antigen -dr isotype on naturel killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|membrane expression of cluster of differentiation 69 on naturel killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|membrane expression of cluster of differentiation 56 on naturel killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|membrane expression of cluster of differentiation 57 on naturel killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|membrane expression of cluster of differentiation 14 on naturel killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|membrane expression of cluster of differentiation 16 on naturel killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|number of regulatory t cells (cd4+cd25hicd127lofoxp3+).|percentage of regulatory t cells (cd4+cd25hicd127lofoxp3+).|rate of circulating immunoglobulin a compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating immunoglobulin g compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating immunoglobulin m compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating soluble cluster of differentiation 14 compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating soluble cluster of differentiation 163 compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating ultrasensitive c-reactive protein compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating soluble tumor necrosis factor alpha receptor type i compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating e-selectin (cluster of differentiation 62e) compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating granulocyte macrophage colony-stimulating factor compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating intercellular adhesion molecule-1 compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating interferon alpha compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating interferon beta compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating interferon gamma compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating interleukin-1 alpha compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating interleukin-1 beta compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating interleukin-4 compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating interleukin-6 compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating interleukin-8 compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating interleukin-10 compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating interleukin-12p70 compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating interleukin-13 compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating interleukin-17a compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating induced protein 10 (c-x-c motif chemokine 10) compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating monocyte chemoattractant protein-1 (c-c motif chemokine ligand 2) compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating macrophage inflammatory protein-1 alpha (c-c motif chemokine ligand 3) compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating macrophage inflammatory protein-1 beta (c-c motif chemokine ligand 4) compared to normal values (based on 150 healthy volunteers previously sampled)|rate of circulating p-selectin compared to normal values (based on 150 healthy volunteers previously sampled)|rate of tumor necrosis factor alpha compared to normal values (based on 150 healthy volunteers previously sampled)|rate of tissue plasminogen activator compared to normal values (based on 150 healthy volunteers previously sampled)|rate of soluble form of endothelial protein c receptor compared to normal values (based on 150 healthy volunteers previously sampled)|rate of d-dimers compared to normal values (based on 150 healthy volunteers previously sampled)|compare the immune activation phenotype (defined in primary outcome) of patients affected by covid-19 before any respiratory distress against that of 150 volunteers from the general population (data already existing).|compare the immune activation phenotype (defined in primary outcome) of patients affected by covid-19 with respiratory failure against versus those without respiratory failure|mortality rate|comparison of e-selectin levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of granulocyte macrophage colony-stimulating factor levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of intercellular adhesion molecule levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of interferon alpha levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of interferon gamma levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of interleukin-1alpha levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of interleukin-1beta levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of interleukin-4 levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of interleukin-6 levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of interleukin-8 (c-x-c motif ligand 8) levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of interleukin-10 levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of interleukin-12p70 levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of interleukin-13 levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of interleukin-17a levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of induced protein -10 (c-x-c motif chemokine 10) levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of monocyte chemoattractant protein-1 levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of macrophage inflammatory protein-1alpha levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of macrophage inflammatory protein -1beta levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of p-selectin levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|comparison of tumor necrosis factor alpha levels from plasma and the supernatant of pbmc activated or not by lipopolysaccharide and staphylococcal enterotoxin b against norms previously established from 16 healthy subjects|identify inflammatory mediators over-produced by the pbmc of patients with covid-19 before respiratory distress|compare the inflammatory mediators over-produced by the peripheral blood mononuclear cells of patients with covid-19 with versus without respiratory failure|comparison of transcriptome from peripheral blood mononuclear cells from 12 patients with respiratory failure (from intensive care ward) and 10 without (normal hospitalization),observational,observational model: case-control|time perspective: prospective
Exploring Brain Damages After COVID-19 Infection,BRAINCOV,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04405986,NCT04405986,latency of electrophysiological response|delay of muscle contraction|delay of silent period|duration of silent period|inhibition rate,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
COVID-19 Anosmia Study,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04495816,NCT04495816,brief smell identification test (bsit)|modified brief questionnaire of olfactory dysfunction (mqod-ns)|sinonasal outcomes test (snot-22),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Glycemic Control Among Children and Adolescents With Type 1 Diabetes During COVID-19 Pandemic in Egypt,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04531111,NCT04531111,impact of covid-19 pandemic and lockdown on glycemic control among a sample of egyptian children and adolescents with type 1 diabetes|impact of covid-19 pandemic and lockdown on insulin dosage among a sample of egyptian children and adolescents with type 1 diabetes,observational,observational model: case-only|time perspective: cross-sectional
COVID-19 Hyperinflammation Syndrome (COV-HI): Protocol for a Rapidly Executed Cohort Study,COV-HI,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04385069,NCT04385069,"to collect retrospective demographic information on 500 people admitted to selected hospital sites across the uk with a covid-19 diagnosis confirmed through positive laboratory pcr swab.|to record the results of each patient's measured medical observations, clinical investigations and outcomes during the course of their admission.|to conduct retrospective analysis of data collected to map each patient's clinical journey during their admission",observational,observational model: cohort|time perspective: retrospective
A Research Study to Evaluate the Benefits of a Self-management Booklet to Promote Wellbeing During the COVID-19 Pandemic,SWitCh,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04408157,NCT04408157,"warwick-edinburgh mental wellbeing scale (wemwbs): tennant et al., 2007|self-rated health status: bombak, 2013|brief resilience scale (brs): smith et al., 2008|intolerance of uncertainty scale (ius-12): carleton et al., 2007|positive affect subscale of the positive and negative affect scale-x (panas-x): watson & clark, 1999|ucla 3 item loneliness scale: russell, 1996|multidimensional scale of perceived social support (mspss): zimet et al., 1988|subjective health complaint scale (shc): eriksen, ihleb√¶k, & ursin, 1999|leeds sleep evaluation questionnaire (lseq): parrott & hindmarch, 1980|self-reported napping: stone et al., 2018|work and social adjustment scale (wsas): mundt et al., 2002|international physical activity questionnaire -short form (ipaq-sf): craig et al., 2003",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 Community Research Partnership,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04342884,NCT04342884,seroprevalence of sars-cov-2 infection in the general population of north carolina|seroprevalence of sars-cov-2 infection among health care workers of north carolina|cumulative incidence of sars-cov-2 infection|monthly incidence of sars-cov-2 infection|stratified incidence of sars-cov-2 infection by age group|stratified incidence of sars-cov-2 infection by sex|stratified incidence of sars-cov-2 by season|stratified incidence of sars-cov-2 infection by geographic area (zip code)|stratified incidence of sars-cov-2 infection by preexisting comorbidities|stratified incidence of sars-cov-2 infection by covid-2 contacts|stratified incidence of sars-cov-2 infection by use of personal protective equipment (ppe) by health workers|relative risk of sars-cov-2 infection by age group|relative risk of sars-cov-2 infection by sex|relative risk of sars-cov-2 infection by season|relative risk of sars-cov-2 infection by geographic area (zip code)|relative risk of sars-cov-2 infection by preexisting comorbidities|relative risk of sars-cov-2 infection by covid-2 contacts|relative risk of sars-cov-2 infection by use of ppe by health workers|incidence of sequelae,observational,observational model: cohort|time perspective: prospective
Ayurveda as Prophylaxis for Suspected COVID-19 Patients,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04395976,NCT04395976,clinical confirmation of covid-19,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
COVID-SErology in Rheumatoid Arthritis (COVID-19),COVID-SERA,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407559,NCT04407559,"evaluate the false positive results rate|characterize the rf isotype (igg, igm or iga) associated|determine the influence of ra on the false positivity rate in subjects|assess the influence of the presence of anti-ccp on the false positivity of the sars-cov-2 test|assess the relation between the rf plasma levels and the false positivity of the sars-cov-2 test",observational,observational model: cohort|time perspective: retrospective
COVID-19 Seroprevalence Study in ITM Staff,CovAb,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04503447,NCT04503447,"sars-cov-2 seroprevalence itm staff|sars-cov-2 seroprevalence in itm staff, stratified by variables",observational,observational model: other|time perspective: cross-sectional
Early CPAP in COVID-19 Confirmed or Suspected Patients,PAP-COVID,recruiting,No Results Available,not applicable,Other|Industry,https://ClinicalTrials.gov/show/NCT04390191,NCT04390191,efficacy endpoint composite score|time to icu admission|time to intubation and mechanical ventilation|14 day and 28 day mortality|conversion rate of covid household members in cpap vs control|clinical copd questionnaire (ccq)|percentage of patients electing to continue cpap for greater than 72 hours|degree of improvement in oxygen saturation|time to hospital admission or ed,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Gastrointestinal Manifestations Among Patients With COVID19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04544150,NCT04544150,frequency of git symptoms among patients with covid-19 infection,observational,observational model: case-only|time perspective: prospective
Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study,COV-NI,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04469491,NCT04469491,oxygen requirement score at day 0|oxygen requirement score at day 15|variation oxygen requirement score between day 0 and day15,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04397614,NCT04397614,percentage of ecological momentary assessments completed|percentage of satisfied mhealth app users|proportion of manifestation of severe disease|proportion of treatment-related toxicity|proportion of hospitalization|proportion of covid-19 related mortality,observational,observational model: cohort|time perspective: prospective
The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,COLCOVID,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04328480,NCT04328480,all-cause mortality|composite outcome:composite of intubation for mechanical ventilation or death.,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019),Covid-19,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04379310,NCT04379310,extend of lung involvement|oxygen saturation on admission,observational,observational model: cohort|time perspective: retrospective
Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID),ACROVID,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04387955,NCT04387955,"study of the link between sars-cov-2 infection and chilblains observed during covid-19 epidemics.|study of the sars-cov-2 virological profile of patients presenting chilblains during a covid-19 epidemic.|comparison of the clinical and biological profiles of patients presenting chilblains according to their sars-cov-2 virological status (in case of over-representation of sars-cov-2 positive patients, the results will be given without comparison).|comparison of the capillaroscopic profiles of patients with chilblains according to their sars-cov-2 virological status (in case of overrepresentation of sars-cov-2 positive patients, the results will be given without comparison).|comparison of the tcpo2 profiles of patients with chilblains according to their sars-cov-2 virological status (in case of overrepresentation of sars-cov-2 positive patients, the results will be given without comparison).|comparison of the toe or finger pressure index profiles of patients with chilblains according to their sars-cov-2 virological status (in case of overrepresentation of sars-cov-2 positive patients, the results will be given without comparison).|comparison of histo-pathological profiles of chilblains according to their sars-cov-2 virological status of patients with the disease (in case of overrepresentation of sars-cov-2 positive patients, results will be given without comparison).|comparison of the gene expression profiles of chilblains according to their sars-cov-2 virological status and in healthy subjects.|comparison of the immunostaining profiles of chilblains according to their sars-cov-2 virological status and in healthy subjects.|comparison of the elisa assays profiles of chilblains according to their sars-cov-2 virological status and in healthy subjects.",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Vocal Feature Analysis Algorithm,nan,recruiting,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04418544,NCT04418544,sensitivity and specificity,observational,observational model: cohort|time perspective: cross-sectional
Symptoms and Wellbeing of People Infected With Covid-19 Virus in Iceland,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04546191,NCT04546191,symptoms|wellbeing - hrql,observational,observational model: cohort|time perspective: cross-sectional
Performance Evaluation of LumiraDx SARS-CoV-2 Ag Test,ASPIRE,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04557046,NCT04557046,performance evaluation,interventional,allocation: non-randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
The United Kingdom Multiple Sclerosis Register Covid-19 Substudy,UKMSRCV19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04354519,NCT04354519,incidence of covid-19 infections within an ms cohort in the uk|hospitalisations in ms patients with covid-19|mortality|patient reported expanded disability status score|hospital anxiety and depression scale|multiple sclerosis impact scale 29 v2|multiple sclerosis walking scale 12 v2|fatigue severity scale|euroqol 5d (3l),observational,observational model: cohort|time perspective: prospective
COVID-19 Impact on Rheumatic Patients,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407299,NCT04407299,score of five-item brief symptom rating scale (bsrs-5),observational,observational model: other|time perspective: cross-sectional
A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers,COVID-Milit,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04377646,NCT04377646,sars cov2 infection|covid-19 symptoms description|adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
Registry on NEN Patients and COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04444401,NCT04444401,correlation between clinical parameters and sars-cov-2 infection|clinical outcome of sars-cov-2 infection|major demographic features|type of nen,observational,observational model: case-only|time perspective: other
"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19",RESIST,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04530396,NCT04530396,percentage of trial subjects with coronavirus disease 2019 (covid-19) developed within 6 months after the first dose|the severity of the clinical course of covid-19|changing of antibody levels against the sars-cov-2 glycoprotein s|changing of antigen-specific cellular immunity level|changing of of virus neutralizing antibody titer|incidence of adverse events in trial subjects|severity of adverse events in trial subjects,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
Qualitative Evaluation of Tear Fluid and Blood for Auto Antibodies Produced in Response to COVID-19,nan,not yet recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04542980,NCT04542980,qualitative assessment of igm and/or igg by indirect elisa assay.,observational,observational model: case-control|time perspective: retrospective
Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia,COVIDSTEROID2,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04509973,NCT04509973,days alive without life support at day 28|number of participants with one or more serious adverse reactions|all-cause mortality at day 28|all-cause mortality at day 90|days alive without life support at day 90|days alive and out of hospital at day 90|all-cause mortality at day 180|health-related quality of life at day 180,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
COVID-19 and HIV Patients,COCOVIH,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04523012,NCT04523012,measure of seroprevalence of covid-19 infection assessed by the level of anti-covid-19 igg antibodies in the population of people living with hiv monitored at the piti√©-salp√™tri√®re hospital,observational,observational model: cohort|time perspective: retrospective
COVID-19 Survivorship Registry,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04527315,NCT04527315,level of inflammatory markers|score on st. george's shortness of breath questionnaire (sgsq)|score on short form zarit burden interview (zbi-12),observational,observational model: case-control|time perspective: prospective
Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients,COVA,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04472728,NCT04472728,end-of-part 1 interim analysis: proportion of subjects with all cause mortality or with respiratory failure.|for part-2 sample size interim analysis: proportion of subjects with all cause mortality or with respiratory failure.|for the final analysis: proportion of subjects with all cause mortality or respiratory failure.|interim analysis; indication of activity of bio101: oxygen saturation by pulse oximetry (spo2) spo2 / fraction of inspired oxygen (fio2) ratio|interim analysis; indication of activity of bio101: inflammatory markers|interim analysis; indication of activity of bio101: renin angiotensin system biomarkers|key secondary endpoint for final analysis: proportion of participants with positive or negative events|additional secondary endpoints for final analysis: respiratory function|additional secondary endpoints for final analysis:proportion of patients who experienced positive event|additional secondary endpoints for final analysis:proportion of patients who experienced negative events|additional secondary endpoint for final analysis: the national early warning score 2 (news2):|additional secondary endpoint for final analysis: population pharmacokinetics study (pop-pk)|additional secondary endpoint : population pharmacokinetics study (pop-pk)|secondary endpoint: population pharmacokinetics study (pop-pk),interventional,"allocation: randomized|intervention model: sequential assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
EMPOWER - BAME vs COVID,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04399733,NCT04399733,"identify covid-19 specific host-defence (""protective"") or predisposing (""susceptibility"") genetic biomarkers|epidemiological profiles of covid-19 infections in different uk ethnic populations",observational,observational model: cohort|time perspective: prospective
Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19,ILIAD,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04354259,NCT04354259,cohort a (ambulatory) - proportion swab negative at day 7 (primary efficacy endpoint)|cohort a (ambulatory) - treatment-emergent and treatment related serious adverse events (primary safety endpoint)|cohort b (hospitalized) - time to viral negativity (primary efficacy endpoint)|cohort b (hospitalized) - treatment-emergent and treatment-related serious adverse events (primary safety endpoint)|cohort a (ambulatory) - symptom resolution (clinical outcome #1)|cohort a (ambulatory) - symptom severity scores (clinical outcome #2)|cohort a (ambulatory) - hospitalization (clinical outcome #3)|cohort a (ambulatory) - adverse and serious adverse events (clinical outcome #4)|cohort a (ambulatory) - swab negative at day 3 (virologic/immunological outcome #1)|cohort a (ambulatory) - time rna negativity (virologic/immunological outcome #2)|cohort a (ambulatory) - proportion viremic (virologic/immunological outcome #3)|cohort a (ambulatory) - proportion with antibodies (virologic/immunological outcome #4)|cohort a (ambulatory) - correlation with interferon lambda 4 genotype (virologic/immunological outcome #5)|cohort a (ambulatory) - symptoms in household contacts (transmission outcome #1)|cohort a (ambulatory) - covid-19 in household contacts (transmission outcome #2)|cohort b (hospitalized) - icu admission (clinical outcome #1)|cohort b (hospitalized) - need for intubation (clinical outcome #2)|cohort b (hospitalized) - length of hospital stay (clinical outcome #3)|cohort b (hospitalized) - change in respiratory symptom score (clinical outcome #4)|cohort b (hospitalized) - readmission to hospital (clinical outcome #5)|cohort b (hospitalized) - all-cause mortality (clinical outcome #6)|cohort b (hospitalized) - covid-19-related mortality (clinical outcome #7)|cohort b (hospitalized) - adverse (aes) and serious adverse events (saes) (clinical outcome #8)|cohort b (hospitalized) - dose reduction or dose omission (clinical outcome #9)|cohort b (hospitalized) - proportion negative swab. (virologic/immunological outcome #1)|cohort b (hospitalized) - proportion negative by day 14 (virologic/immunological outcome) #2)|cohort b (hospitalized) - time to negativity by rectal swab (virologic/immunological outcome #3)|cohort b (hospitalized) - correlation with interferon lambda 4 (ifnl4) genotype (virologic/immunological outcome #4)|cohort b (hospitalized) - proportion with antibody (virologic/immunological outcome #6)|cohort b (hospitalized) - proportion with viremia (virologic/immunological outcome #7),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg),CovidSurg,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04323644,NCT04323644,30-day mortality|7-day mortality|30-day reoperation|postoperative icu admission|postoperative respiratory failure|postoperative acute respiratory distress syndrome (ards)|postoperative sepsis,observational,observational model: cohort|time perspective: other
Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04457349,NCT04457349,mortality|the mean time with oxygen therapy|the mean time with non-invasive mechanical ventilation|the mean time of intubation|respiratory function parameters|radiological lung extension|mean duration of hospitalization and icu use|the requirement of additional organ support|the levels of il-6|incidence of adverse events|time to reverse-transcriptase polymerase chain reaction (rt-pcr) virus negativity|the levels of crp|the levels of procalcitonin (pct)|levels of d-dimer|levels of ferritin,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Post-traumatic Stress Disease in Health Workers During COVID-19 Pandemia,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04424771,NCT04424771,number of patients with diagnosis of ptsd.,observational,observational model: cohort|time perspective: prospective
COVidIVERmectin: Ivermectin for Treatment of Covid-19,COVER,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04438850,NCT04438850,sadr|viral load|trend viral load|clinical resolution|viral clearance|virological clearance|hospitalization rate|severity score,interventional,"allocation: randomized|intervention model: sequential assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Echocardiographic Manifestation in Patient With COVID-19 ÔºàEARLY-MYO COVID-19Ôºâ,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04352842,NCT04352842,death,observational,observational model: cohort|time perspective: prospective
Donated Antibodies Working Against nCoV,DAWN-Plasma,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04429854,NCT04429854,"patients requiring mechanical ventilation or death|clinical status of subject at day 15 and day 30 (on a 10-point ""who progression"" ordinal scale)",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.,nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04542447,NCT04542447,to evaluate safety and efficacy nuvastatic‚ñ¢ (c5osew5050esa)|il-6 reduction|serum c-reactive protein (crp)|igg|hb|total leucocyte count|f2-isoprostane|improvement in ards associated clinical symptoms cause,interventional,allocation: randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study,nan,recruiting,No Results Available,not applicable,Industry|Other,https://ClinicalTrials.gov/show/NCT04393961,NCT04393961,does participant accurately read result|acceptability and usability of tests|social distancing behavior change|covid-19 related anxiety,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: device feasibility
iNOPulse for COVID-19,NO-COVER,withdrawn,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04398290,NCT04398290,incidence of treatment emergent adverse events|incidence of adverse events|incidence of methemoglobinemia|number of participants with progression of respiratory failure|time until resolution of hypoxemia|incidence of mortality|duration of hospitalization,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Pulmonary Optical Coherence Tomography in COVID-19 Patients,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04410549,NCT04410549,"optical coherence tomography pulmonary microthrombosis assessment in covid-19 pneumonia patients|pulmonary artery vessel anatomy characterization|correlation between tte pulmonary hypertension and right ventricular disfunction|correlations with standard inflammatory, coagulation and tissue damage",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
London's Exogenous Surfactant Study for COVID19,LESSCOVID,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04375735,NCT04375735,adverse events (patient) - decrease in oxygenation|adverse events (patient) - decrease in hemodynamics|adverse event (healthcare worker) - circuit breach|adverse event (healthcare worker) - covid-19 symptoms|change in oxygenation|change in lung compliance|ventilated days|length of icu stay|length of hospital stay|mortality|g-csf levels (serum inflammatory biomarker)|gm-csf levels (serum inflammatory biomarker)|ifn gamma levels (serum inflammatory biomarker)|il-1 beta levels (serum inflammatory biomarker)|il-4 levels (serum inflammatory biomarker)|il-6 levels (serum inflammatory biomarker)|il-10 levels (serum inflammatory biomarker)|i levels (serum inflammatory biomarker)|mcp-1 levels (serum inflammatory biomarker)|tnf alpha levels (serum inflammatory biomarker),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04381988,NCT04381988,cumulative incidence of sars-cov-2 infection|cumulative incidence of severe covid-19 or death,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
IL-12RB and TNF-alpha Gene Polymorphism and Susceptibility and Progress of Covid-19 SARS-CoV-2: A Case Control Study,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04462120,NCT04462120,measure level of polymorphisms of interleukin (il)-12 receptor b1 (il-12rb1) and tnf- œ± alpha on covid-19 related severe acute respiratory syndrome (sars-cov-2).,observational,observational model: cohort|time perspective: prospective
FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals,FLARE,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04499677,NCT04499677,upper respiratory tract viral load at day 5|percentage of participants with undetectable upper respiratory tract viral load after 5 days of therapy|proportion of participants with undetectable stool viral load after 7 days of therapy and 14 days post-randomisation|rate of decrease in upper respiratory tract viral load during 7 days of therapy|duration of fever following commencement of medication|proportion of participants with hepatotoxicity after 7 days of therapy and 14 days post-randomisation|proportion of participants with other medication-related toxicity after 7 days of therapy and 14 days post-randomisation|proportion of participants admitted to hospital with covid-19 related illness|proportion of participants admitted to icu with covid-19 related illness|proportion of participants who have died with covid-19 related illness|pharmacokinetics of favipiravir as measured by clearance (cl)|pharmacokinetics of favipiravir as measured by volume of distribution (v)|pharmacokinetics of favipiravir as measured by absorption rate constant (ka)|pharmacokinetics of favipiravir as measured by maximum concentration (cmax)|pharmacokinetics of favipiravir as measured by time to maximum concentration (tmax)|pharmacokinetics of favipiravir as measured by elimination rate constant (ke)|pharmacokinetics of favipiravir as measured by area under the curve extrapolated to infinity (auc (0-inf)|pharmacodynamics of favipiravir as measured by rate of viral load decline (delta)|pharmacodynamics of favipiravir as measured by maximum increase in viral load under drug treatment (emax)|pharmacodynamics of favipiravir as measured by concentration to achieve half the maximum possible effect (ec50)|proportion of participants with deleterious or resistance-conferring mutations in sars-cov-2 by day 7 of treatment,interventional,"allocation: randomized|intervention model: factorial assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Fluoxetine to Reduce Intubation and Death After COVID19 Infection,nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04377308,NCT04377308,"hospitalizations|intubation|death|number of days of illness|phq-9 score for depressive symptoms,|generalized anxiety disorder-7 scale",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.,COVID AMBU 60,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04363099,NCT04363099,clinical description of covid 19 ambulatory cases.|biological and radiological description of ambulatory cases|prevalence of positive cases (pcr and/or serological positive),observational,observational model: cohort|time perspective: other
Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients,nan,"active, not recruiting",No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04458948,NCT04458948,duration of viral shedding|evaluation of fatality rate|evaluation of clinical response|evaluation of length of hospital stay,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04477954,NCT04477954,time to normalize the oxygen requirement (oxygen dependence)|need for invasive mechanical ventilation (imv) and / or respiratory distress syndrome acute (ards)|development of acute respiratory distress syndrome (ards)|30-day mortality|hypotension with vasopressor requirement|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Coronavirus Response - Active Support for Hospitalised Covid-19 Patients,CRASH-19,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04343001,NCT04343001,death|myocardial infarction|congestive cardiac failure|severe cardiac arrythmia|myocarditis|respiratory failure including ards|viral pneumonitis|acute renal failure|sepsis|stroke|gastrointestinal bleeding|receipt of non invasive or mechanical ventilation|ability to self care at hospital discharge,interventional,allocation: randomized|intervention model: factorial assignment|masking: none (open label)|primary purpose: treatment
Phase 3 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04409327,NCT04409327,"the percentage of subjects who develop laboratory-confirmed covid-19: - with protocol-defined progressive symptoms or - are hospitalized or - die|the percentage of subjects who develop symptomatic laboratory-confirmed covid-19 infection|mortality rate in subjects who develop laboratory-confirmed covid19|percent of subjects who are hospitalized due to having one or more predefined covid-19 symptoms and laboratory-confirmed sars-cov-2|percent of subjects who require mechanical ventilation, noninvasive ventilation, high flow nasal canula oxygen delivery or icu admission during the hospitalization for covid19|safety and tolerability will be assessed by report of ae/saes",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",CORIMUNO-VIRO,suspended,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04341870,NCT04341870,"need for ventilation (including invasive and non invasive ventilation), intensive care or death|early improvement: oms progression scale <= 5|oms progression scale|survival|icu-free days alive|ventilation-free days alive|hospital-free days alive|oxygen therapy-free days alive|time to negative viral excretion|immunophenotyping and multiplex cytokines",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Postpartum Sexual Function in Pregnant Women With COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04389489,NCT04389489,evaluation of pregnant women diagnosed with covid-19 using carol postpartum sexual function and dyspareunia scale,observational,observational model: ecologic or community|time perspective: prospective
"Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients",CANCOVID-19,enrolling by invitation,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04502342,NCT04502342,virological clearance of throat swabs or lower respiratory tract secretions|adverse effects|worsened conditions|covid-19 symptoms,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness,ECHO-vid,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04498299,NCT04498299,"‚ä¢ la volume index|‚ä¢ lv telediastolic diameter|‚ä¢ lv telesystolic diameter|‚ä¢ lv posterior wall|‚ä¢ ra area|‚ä¢ rv basal dimensi√≥n|‚ä¢ rv mid cavity dimension;|‚ä¢ rv longitudinal dimension|‚ä¢ distal, rv outflow tract dimension at the distal or pulmonic valve level|‚ä¢ proximal rv outflow tract dimension at the proximal subvalvular level|‚ä¢ tapse|‚ä¢ rv free wall strain|‚ä¢ inferior cava vein pw doppler|‚ä¢ e wave mitral|‚ä¢ a wave mitral|‚ä¢ e wave /a wave mitral|‚ä¢ e-wave at mitral annulus|‚ä¢ e-wave at mitral annulus / a-wave at the mitral annulus|‚ä¢ e wave/ e-wave at the mitral annulus|‚ä¢ e tricuspid (e)|‚ä¢ a tricuspid (a)|‚ä¢ e/a|‚ä¢ systolic pulmonary artery pressure|‚ä¢ e-wave at the tricuspid annulus|‚ä¢ mean pulmonary artery pressure|‚ä¢ stroke volume|‚ä¢ cardiac output",observational,observational model: cohort|time perspective: prospective
Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04323345,NCT04323345,rate of recovery from positive to negative swaps|fever to normal temperature in days|resolution of lung inflammation in ct or x ray|30 days mortality rate|number of days till reaching negative swab results,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (investigator)|primary purpose: treatment
Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04348500,NCT04348500,evaluate the safety of clazakizumab for the treatment of patients with covid-19 disease and signs of pulmonary involvement|patient survival at 28 days|patient survival at 60 days|number of patients requiring the dose of open-label clazakizumab|reduced duration of intensive care unit stay|reduced duration of hospital stay|reduced need for ventilation,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection,CORTI-Covid,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04344288,NCT04344288,number of patients with a theoretical respiratory indication for transfer to intensive care unit evaluated by a spo2 <90% stabilized at rest and under not more than 5 l / min of supplemental oxygen using medium concentration mask.|disease severity assessed on a 7-level ordinal scale|number of patients with a supplemental oxygen use|radiological signs on chest imaging|number of patients transferred to intensive care unit|number of patients requiring invasive ventilation|duration of oxygen therapy|number of adverse events induced by corticosteroid treatment|number of patients with infections other than sars-cov-2|number of deaths,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study of Immune Response During SARS-CoV-2 Infection - (COVID-19),CovImmune,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04355351,NCT04355351,level of ifn-gamma after a non-specific stimulation of t lymphocytes,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: basic science
Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection,VitD-COVID19,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04482673,NCT04482673,"change in total circulating 25(oh)d concentration|change in total circulating 25(oh)d concentration in covid-19 positives|change in sars-cov-2 antibody titers|change in inflammatory cytokine concentration (10 cytokine panel elisa: interferon (inf)-gamma, interleukin (il)-1beta, il-2, il-3, il-4, il-6, il-8, il-10, il-13, tumor necrosis factor (tnf)-alpha|respiratory symptoms|signs and symptoms of rhino/sinusitis|nci dietary intake|charlson comorbidity survey|paffenberger physical activity assessment|perceived stress|pandemic stress|neo-personality inventory|grassrootshealth monthly health assessment",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04488575,NCT04488575,change from baseline to the lowest s/f oxygen ratio|change in s/f ratio|percentage change in s/f ratio|percentage of participants at each level on the who osci score|percentage of participants with shifts from each level of the who osci score at baseline|percentage of participants remaining at their baseline score on the who osci (or lower)|percentage of participants reporting each level of the who osci score at their worst post-baseline day|the time in days spent at each participant's worst reported who osci score (excluding death).|intubation and mechanical-ventilation free survival|overall survival|number of days requiring oxygen therapy|number of days with pyrexia|maximum daily temperature|spo2 level|time to discharge|time to oxygen saturation (spo2) ‚â•94%|time to recovery|number of participants experiencing aes by seriousness and relationship to treatment|incidence of clinically significant abnormal lab parameters,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Testing the Accuracy of a Digital Test to Diagnose Covid-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407585,NCT04407585,sars-cov-2 infection,observational,observational model: cohort|time perspective: prospective
Results of Emotional Support Activities During Hospital Admission With a Diagnosis of COVID19,WW2COVID-19,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04481477,NCT04481477,the adequacy of nursing care to the needs of the patient|intervention effectiveness,observational,observational model: case-only|time perspective: cross-sectional
"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",HOPE,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04344951,NCT04344951,50% reduction in symptom score for patients with lower respiratory tract infection|lack of progression for patients with upper respiratory tract infection|comparison of the primary endpoint with respective patients not receiving the treatment|serious respiratory failure until day 14. this will be compared with respective patients not receiving the treatment.|frequency of aes and saes,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19,NEBUHEPA,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04530578,NCT04530578,percentage of patients requirement mechanical ventilation|percentage of patients with pao2 to fi02 ratio > 300|lengths of hospital-stay|mortality rate,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID19 Severity Prediction and Health Services Research Evaluation,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04463706,NCT04463706,clinical deterioration|relief of symptoms|mortality|complications at follow up|cost,observational,observational model: cohort|time perspective: retrospective
Therapeutic Plasma Exchange (TPE) for Covid-19 Cytokine Release Storm (CRS),Plexit,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04485169,NCT04485169,survival|duration of hospitalization|timing of pcr negativity|time to crs resolution|complications,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE),HYACINTHE,withdrawn,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04392128,NCT04392128,evaluation of the efficacy of hydroxychloroquine and azithromyncine on the viral load drop at day 5.|clinical evolution|proportion of patients progressing to a severe form|mortality|evaluation of viral load drop|tolerance of study treatment|evaluation of the seroconversion|nk immunological study|hospitalisation duration|impact of the study treatment on the treatment of the hematological disease|monitoring of the qt space|dosage of residual concentration of azithromycine and hydroxychloroquine.|t immunological study,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Acral Cutaneous Thrombotic Vasculopathy and Covid-19 Infection,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04361786,NCT04361786,biological acquired thrombophilia|overexpression of interferon type i,observational,observational model: case-only|time perspective: prospective
Predictors of Cardiovascular Risk in Covid-19 Patients During Acute Disease and at Short Term Follow-up,CARDICoVRISK,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04371289,NCT04371289,"predictive modeling of in-hospital outcome|clinical, pathophysiological and molecular mechanisms|short -term sequelae",observational,observational model: cohort|time perspective: prospective
COVID-19 Disease Duration and GIT Manifestations. A New Disease Severity Classification. An Egyptian Experience,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04554979,NCT04554979,covid-19 disease spectrum and duration|git manifestations among covid-19 patients|non-communicable disease and covid-19|seasonal change and covid-19|possible region specific classification for covid-19 disease,observational,observational model: cohort|time perspective: retrospective
"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults",nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04495933,NCT04495933,"frequency of solicited local reactogenicity adverse events (aes)|frequency of solicited systemic reactogenicity adverse events (aes)|grading of solicited local reactogenicity adverse events (aes)|grading of solicited systemic reactogenicity adverse events (aes)|unsolicited adverse events (aes)|serious adverse events (saes), medically attended adverse events (maaes) and any adverse events (aes) leading to study withdrawal at any time during the study|geometric mean titer (gmt) of the serum antibody response|geometric mean titer (gmt) of the serum neutralizing antibody (nab) response to sars-cov-2 virus|total serum antibody immune responses|proportion of participants with ‚â• 4 fold increase in titer above baseline|gmt of the serum neutralizing antibody (nab) titres",interventional,"allocation: randomized|intervention model: sequential assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
Hospitalized Children and Adolescent Patients With Type 1 Diabetes During the COVID-19 Pandemic in Egypt,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04536285,NCT04536285,clinical characteristic of pediatric and adolescent patients with type 1 diabetes hospitalized with covid -19.|laboratory characteristic of pediatric and adolescent patients with type 1 diabetes hospitalized with covid -19.|prognosis of pediatric and adolescent patients with type 1 diabetes hospitalized with covid -19.|incidence of new onset type 1 diabetes among confirmed cases of covid-19 infection among children and adolescents|presentation of diabetes and its acute complications among pediatric and adolescent patients with type 1 diabetes during covid-19 pandemic in egypt,observational,observational model: case-only|time perspective: cross-sectional
Reliability of a Pocket Sized Ultrasound Scanner in the Evaluation Covid-19 Pneumonia,USCovid,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04433000,NCT04433000,bland-altman estimate of bias and limits of agreement (loa) of patient mean scores obtained with the two instruments,observational,observational model: case-only|time perspective: retrospective
Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,nan,completed,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04261517,NCT04261517,"the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|the mortality rate of subjects at weeks 2|number of participants with treatment-related adverse events as assessed by ctcae v5.0|the critical illness rate of subjects at weeks 2",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Convalescent Plasma in Pediatric COVID-19,nan,recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04458363,NCT04458363,"number of grade 3-5 adverse events that are possible, probably or definitely related to the convalescent plasma (cp) infusion|change in percent of supplemental oxygen|number of patients that required change in level of respiratory support|mortality|mean length of icu stay (days)|mean length of hospital stay (days)|mean length of ventilation (days)|number of patients with progression to renal dysfunction and/or multisystem organ failure|il-6 level|number of anti-sars cov 2 specific t cells|diversity of circulating t cells|ars-cov-2 antibody titer|sars-cov-2 neutralizing titer",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04494204,NCT04494204,time (days) to clinical improvement from study enrollment|proportion of participants in each group with oxygen saturation more than 94% on room air for more than 24h|value of coagulation indicators|time to first negative sars-cov-2 pcr in np swab|duration of oxygen therapy|proportion of participants in each group with need for mechanical ventilation|duration of hospitalization,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.,DEFACOVID,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04348383,NCT04348383,1. mortality rate|clinical improvement by who|clinical improvement by news2 scales|biologic response|radiological response|collection and storage of biological samples,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Efficacy of Nafamostat in Covid-19 Patients (RACONA Study),RACONA,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04352400,NCT04352400,time-to-clinical improvement|responders|critical or dead patients|po2/fio2 ratio|sofa score over time|hospitalization|mechanical ventilation|mechanical ventilation duration|cardiovascular disease,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Fear Among Dentists During COVID-19 Pandemic,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04383626,NCT04383626,fear among dentist during covid 19 epidemic|practice modification among dentist during covid 19 epidemic,observational,observational model: other|time perspective: cross-sectional
Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,IMPROVE,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04367831,NCT04367831,total number of patients with clinically relevant venous or arterial thrombotic events in icu|total number of patients with in hospital clinically relevant venous or arterial thrombotic events|icu length of stay|total number of patients with the need for renal replacement therapy in the icu|total number of patients with major bleeding in the icu|hospital length of stay,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
"International COVID19 Clinical Evaluation Registry,",HOPE COVID 19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04334291,NCT04334291,death|in hospital stay.|heart failure|renal failure|respiratory insufficiency.|upper respiratory tract involvement|pneumonia|sepsis|systemic inflammatory response syndrome.|clinically relevant bleeding|other complications.,observational,observational model: cohort|time perspective: cross-sectional
Clinical Phenotype and Outcomes of Inpatients With COVID-19 and Diabetes,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04550403,NCT04550403,"prevalence of intensive care unit admission and/or in-hospital mortality among covid-19 inpatients|prevalence of death among covid-19 inpatients with and without diabetes|prevalence of intensive care unit admission among covid-19 inpatients with and without diabetes|demographic and clinical characteristics (age,gender, comorbidity status) and death and/or intensive care unit admission during hospitalization|laboratory parameters (glycated hemoglobin, glucose at admission, renal and liver function markers, blood count, inflammatory markers, hemostasis) and death and/or intensive care unit admission during hospitalization|pharmacological therapies and death and/or intensive care unit admission during hospitalization|number of days of hospitalization in patients with and without diabetes",observational,observational model: cohort|time perspective: retrospective
Tenecteplase in Patients With COVID-19,nan,not yet recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04505592,NCT04505592,number of participants free of respiratory failure|number of occurrences of bleeding|number of participants with in-hospital deaths at 14 days|number of participants with death at 28 days|number of ventilator-free days|number of respiratory failure-free days|number of vasopressor-free days|vasopressor doses at 24 hours|vasopressor doses at 72 hours|p/f ratio at 24 hours|p/f ratio at 72 hours|number of icu-free days|hospital length of stay|number of participants with new-onset renal failure|number of participants with need for renal replacement therapy,interventional,"allocation: randomized|intervention model: sequential assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
"Postoperative Recovery Index, Patient Expectations and Satisfaction With Prenatal Care Instrument in Pregnant Patients With COVID-19",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04389515,NCT04389515,"evaluation of pregnant women diagnosed with covid-19 with ""post-operative recovery index"" and ""prenatal care satisfaction and patient expectations scale""",observational,observational model: ecologic or community|time perspective: prospective
Post COVID-19 Functional Status in Egypt,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04479293,NCT04479293,number of functional limitations post covid-19|number of psychologic changes|sleep disturbance and quality|radiologic changes|laboratory changes,observational,observational model: cohort|time perspective: prospective
Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,nan,completed,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04346446,NCT04346446,proportion of patients remaining free of mechanical ventilation in both groups|mortality in both groups|improvement in pa02/fi02 ratio in both groups|improvement in sofa score in both groups|duration of hospital stay in both group.|duration of intensive care unit stay in both groups.|requirements of vasopressor in both groups.|days free of dialysis in both groups.,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Covid-19 Associated Coagulopathy,nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04360824,NCT04360824,"mortality|major bleeding|arterial thrombosis|venous thromboembolism|icu admission, intubation/ventilation|packed red blood cell transfusions|platelet transfusions|fresh frozen plasma transfusions|cryoprecipitate transfusions|prothrombin complex concentrate transfusions",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04499313,NCT04499313,mortality rate (in hospital)|clinical improvement|ventilator free days|changes in oxygen level,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation,nan,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04447469,NCT04447469,cohort 1: proportion of participants alive and without respiratory failure at day 15|cohort 2: mortality rate at day 15|cohort 1: time to return to room air by day 15|cohort 1: time to 2-point clinical improvement by day 15|cohort 1: mortality rate at day 29|cohort 1: time to 1-point clinical improvement by day 15|cohort 2: mortality rate at day 29|cohort 2: proportion of participants alive and without respiratory failure at day 15|cohorts 1 and 2: proportion of participants alive and without respiratory failure at day 29|cohorts 1 and 2: time to return to room air by day 29|cohort 2: time to 2-point clinical improvement by day 15|cohorts 1 and 2: time to 1-point clinical improvement by day 29|cohorts 1 and 2: time to 2-point clinical improvement by day 29|cohort 1: respiratory failure-free survival by day 15|cohort 1: respiratory failure-free survival by day 29|cohort 1: proportion of participants who return to room air by day 15|cohorts 1 and 2: proportion of participants who return to room air by day 29|cohort 1: mortality rate at day 15|cohorts 1 and 2: overall survival by day 29|cohorts 1 and 2: clinical status over time|cohorts 1 and 2: number of days alive and out of hospital through day 90,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Different PEEP Settings of COVID-19 Induced ARDS,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04359251,NCT04359251,respiratory system compliance improvement|gas echanges improvement,interventional,allocation: non-randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: treatment
Psychiatric Consultation for COVID-19 Patients,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04395872,NCT04395872,change of phq-9 (patient health questionnaire-9)|change of gad-7 (patient health questionnaire-9)|change of pc-ptsd-5 (primary care ptsd screen for dsm-5)|change of ais (athens insomnia scale)|change of p4 (p4 suicidality screener)|change of sf-36 (short form health survey questionnaire)|change of scl-90-r,observational,observational model: case-only|time perspective: retrospective
Extremely Premature Births During the Peak of the COVID-19 Pandemic: an International Study of the Active SafeBoosC III Departments,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04527601,NCT04527601,number of elgan admissions during peak three months of covid-19 compared to corresponding months in 2019|regional difference in elgan admissions during peak three months of covid-19 compared to corresponding months in 2019|correlation between the level of lockdown restrictions and number of elgan admissions during peak three months of covid-19 compared to corresponding months in 2019,observational,observational model: cohort|time perspective: retrospective
Protein Electrophoresis as a Tool for Complications Prediction in COVID-19 Hospitalised Patients,COVELEC,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04414059,NCT04414059,complications onset|risk value associated with each risk factor as identified at the end of the main study analysis|predictive performance and risk associated with each individual protein fraction|intra-patient kinetics evolution of the electrophoresis curves|intra-patient kinetics evolution of biological risk factors|inter-expert reproducibility analysis of electrophoretic inflammatory profiles centrally reviewed|contribution of urinary electrophoresis inflammation profiles in the interpretation of serum electrophoresis curves|exploratory biological objective: definition of a more detailed electrophoretic inflammatory profile,observational,observational model: case-only|time perspective: prospective
Interest of the Dosage of Ferritin / Glycosylated Ferritin in COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04469153,NCT04469153,assessment of the prognostic value of ferritin in sars-cov2 positiv patients,observational,observational model: cohort|time perspective: retrospective
Clinical Features of Severe Patients With COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04450017,NCT04450017,mechanical ventilation duration|non-invasive mechanical ventilation duration|mortality|–°omplete blood count|biochemistry analysis|–°omplete blood count dynamics|biochemistry analysis dynamics|computer tomography|high-sensitive troponin –¢|high-sensitive troponin –¢ dynamics|vitamin d level|vitamin d level dynamics|immunogram|immunogram dynamics,observational,observational model: case-only|time perspective: retrospective
Prevalence of COVID-19 Antibodies Kingman AZ,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04533360,NCT04533360,seroprevelence of sars-cov-2 antibodies among adults in kingman az|retention of sars-cov-2 antibodies among adults in kingman az,observational,observational model: ecologic or community|time perspective: prospective
A Study for Outpatients With COVID-19,nan,recruiting,No Results Available,phase 2|phase 3,NIH|Industry|Other,https://ClinicalTrials.gov/show/NCT04518410,NCT04518410,duration of covid-19 symptoms (phase 2)|post-treatment presence of sars-cov-2 rna at day 3 (phase 2)|post-treatment presence of sars-cov-2 rna at day 7 (phase 2)|post-treatment presence of sars-cov-2 rna at day 14 (phase 2)|post-treatment presence of sars-cov-2 rna at day 21 (phase 2)|post-treatment presence of sars-cov-2 rna at day 28 (phase 2)|incidence of new adverse event (ae) ‚â• grade 3 (phase 2)|cumulative incidence of death from any cause or hospitalization (phase 3)|proportion of participants with new adverse event (ae) ‚â• grade 3 (phase 3)|cumulative incidence of death from any cause or hospitalization (phase 2)|duration of covid-19 symptoms (phase 3)|presence of sars-cov-2 rna (phases 2 and 3)|level of sars-cov-2 rna (phases 2 and 3)|covid-19 severity ranking (phases 2 and 3)|incidence of ‚â•1 worsening symptom of covid-19 (phases 2 and 3)|duration of fever (phases 2 and 3)|time to self-report return to usual (pre-covid-19) health (phases 2 and 3)|cumulative incidence of death from any cause or hospitalization (phases 2 and 3)|oxygen saturation level (phase 2)|level of sars-cov-2 rna from site-collected np swabs (phase 2)|level of sars-cov-2 rna from saliva (phase 2)|level of sars-cov-2 rna from self-collected nasal swabs (phase 2)|level of sars-cov-2 rna (phase 2)|post-treatment presence of sars-cov-2 rna in saliva (phase 2)|post-treatment level of sars-cov-2 rna (phase 2)|incidence of new adverse event (ae) ‚â• grade 3 (phase 3)|concentration of investigational agent (phase 2 - ly3819253)|level of anti-drug antibodies (phase 2 - ly3819253)|auc (phase 2 - ly3819253)|total body clearance (cl) (phase 2 - ly3819253)|elimination half-life (phase 2 - ly3819253)|cmax (phase 2 - ly3819253)|cmin (phase 2 - ly3819253),interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19,nan,not yet recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04487574,NCT04487574,"patient rate with a transition to category 3 or lower according to the who scale by day 14 after the beginning of drug administration.|time till clinical improvement, which is described by presence of all of the following factors during 48 hours in a row.|patient rate with clinical improvement by day 2-28. presence of all of the following factors during 48 hours in a row.|patient rate with a negative test result for sars-cov-2 by day 7¬±1, 15¬±1, 21 ¬±1 and 28 ¬± 1.|duration of hospitalization.|patient rate transferred to the intensive care unit (icu) during hospitalization.|duration of icu stay.|patient rate with ards during hospitalization.|presence of a fatal outcome.|patient rate requiring oxygen therapy by day 2-28.|patient rate requiring high-flow oxygen therapy by day 2-28.|patient rate requiring non-invasive ventilation by day 2-28.|patient rate requiring invasive ventilation by day 2-28.|patient rate requiring extracorporeal membrane oxygenation (emo) by day 2-28.|the total duration of oxygen therapy by the last day of hospitalization.|the total duration of high-flow oxygen therapy by the last day of hospitalization.|the total duration of non-invasive ventilation by the last day of hospitalization.|the total duration of invasive ventilation of lungs by the last day of hospitalization.|the total duration of emo by the last day of hospitalization.|patient rate with sp02 > 95% by day 2-28.|average alteration of sp02 by day 2-28 from baseline.|average time to reach spo2 ‚â• 95%.|patient rate with rr < 22 / min by day 2-28.|average alteration in rr by day 2-28 from baseline.|average time to reach rr ‚â§ 22 / min.|patient rate with body temperature < 37.5¬∞c by day 2-28.|average alteration in body temperature by day 2-28 from baseline.|average time until the patient reaches a body temperature of ‚â§37.5¬∞c.|patient rate with ct-1 according to ct data by day 2-28.|average alteration in ct data by 1 point in terms of severity (ct-1, ct-2, ct-3, ct-4) by day 7, 10, 15, 18, 21 and 28 compared to the baseline value.|average time to reach ct-1 according to ct data.|patient rate with a score < 2 according to the daytime and nighttime cough scale by day 2-28.|mean change in daytime and nighttime cough scores by day 2-28 from baseline.|average time to reach < 2 points when assessed according to the daytime and nighttime cough scale.|patient rate with a score < 1 for each symptom (general fatigue, chest congestion, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale by day 2-28.|average change in score for each symptom (general fatigue, chest congestion, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale by day 2-28 from baseline.|average time to reach a score of < 1 for each symptom (general fatigue, feeling of congestion in the chest, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale.|patient rate with a transition decrease to category 3 or lower according to the who scale by day 2-13 and day 15-28.|mean who grade change by day 2-28 from baseline.|average time to reach the 3rd category or below according to the who scale.|patient rate with a news score < 2 by day 2-28.|average change in news score by day 2-28 from baseline.|average time to reach a news score ‚â§ 2.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Risk Factors Worsening COVID19 for Out-patient With Home Monitoring,COVIDADOMEVA,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04380662,NCT04380662,identify the factors associated with the worsening of the covid19|describe the clinical care pathway of patients from day 0 to day 14|describe the health status at day 30|describe the quality of life during the disease,observational,observational model: cohort|time perspective: prospective
Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,nan,completed,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04375098,NCT04375098,"percentage mechanical ventilation, hospitalization longer than 14 days or death during hospitalization|median duration of fever|median duration of mechanical ventilation|median length of icu stay|median length of admission|hospital mortality rate (percentage)|30-day mortality (percentage)|readmission rate (percentage)|median length of viral clearance",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Recovery of Patients From COVID-19 After Critical Illness,COVID-Recovery,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04401254,NCT04401254,physiotherapy intervention|disability-free survival|proportion of patients with covid-19 who received physiotherapy in icu|the reported barriers to delivering physiotherapy interventions|adverse events during physiotherapy interventions|health status|global function|cognitive function|anxiety and depression|screening for post-traumatic distress|work status|phenomenological data of the patient and family experience,observational,observational model: cohort|time perspective: prospective
Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection,nan,recruiting,No Results Available,phase 4,Other|Industry,https://ClinicalTrials.gov/show/NCT04411667,NCT04411667,mechanical ventilation|oxygen therapy|length of stay,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,ACHIEVE,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04398004,NCT04398004,"clinical outcome negative for two parameters(hospital admission/disease progression)|at least 50% change of the score of respiratory symptoms from the baseline|comparison of two parameters with historical comparators from hellenic sepsis study group database|comparison of the score of respiratory symptoms with historical comparators from hellenic sepsis study group database|clinical outcome negative for two parameters(hospital admission/disease progression) on day 4|at least 50% change of the score of respiratory symptoms from the baseline on day 4|range of development of severe respiratory failure|range of hospital readmission until day 14|change of viral load in respiratory secretions from baseline on day 8|change of function of monocytes at days 1 and 8|change of function of th1 cells at days 1 and 8|change of function of th2 cells at days 1 and 8|change of serum interleukin-6 (il-6) cytokine levels between days 1 and 8|change of serum interleukin-8 (il-8) cytokine levels between days 1 and 8|change of serum human beta defensin-2 (hbd-2) between days 1 and 8|change of cytokine levels interleukin-6 (il-6) at the rhinopharynx between days 1,4 and 8|change of interleukin-1 (il-1) cytokine levels at the rhinopharynx between days 1,4 and 8|change of the il-10/tnfœ± ratio between days 1 and 8",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France,FRENCH ICU,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04420286,NCT04420286,origin of the icu beds created during the covid-19 outbreak in france.|human resources,observational,observational model: other|time perspective: retrospective
Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04362345,NCT04362345,identification of risk factors for severity (death or transfer to resuscitation) of covid-19 infection,observational,observational model: case-only|time perspective: other
Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity),SARSCoV2CZImun,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04453280,NCT04453280,determination of the concentration of anti-sars-cov-2 antibodies in relation to the categories of cured patients.|determination of the concentration of anti-sars-cov-2 antibodies in relation to the age and to the severity of the disease.|the quantification of the dependence of the change in the concentration of anti-sars-cov-2 antibodies.,observational,observational model: cohort|time perspective: cross-sectional
Brazilian Registry for Clinical Presentation of Individuals With COVID-19 (SARS-Brazil),SARS-Brazil,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04479488,NCT04479488,all-cause mortality|incidence and course of symptoms of covid-19 infection|hospitalizations|oxygen supplementation|use of invasive mechanical ventilation|intensive care unit length of stay,observational,observational model: cohort|time perspective: prospective
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy,Reszinate,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04542993,NCT04542993,reduction in sars-cov-2 viral load|reduction in severity of covid-19 disease,interventional,allocation: randomized|intervention model: single group assignment|masking: single (participant)|primary purpose: supportive care
Complications and Mortality Following Emergency Digestive Surgery During the COVID-19 Pandemic,COVIDCIR,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04479150,NCT04479150,30-day mortality|90-day mortality|postoperative complications|severe complications|lenght of stay,observational,observational model: cohort|time perspective: cross-sectional
Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19,TOLD,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04424901,NCT04424901,coagulation system|viral detection,interventional,allocation: randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Effects of Early Use of Nitazoxanide in Patients With COVID-19,nan,completed,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04552483,NCT04552483,days with fever|days with cough|days with asthenia|sars-cov-2 viral load - absolute number|sars-cov-2 viral load - percentage|hospital admission rate - absolute number|hospital admission rate - percentage|serum interleukin-6|serum interleukin-1-beta|serum interleukin-8|serum tumor necrosis factor (tnf)-alfa|serum interferon-gamma|serum monocyte chemoattractant protein (mcp)-1|complete blood count|c-reactive protein - absolute number|c-reactive protein - percentage,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Perinatal Outcomes and Hematologic Parameters in COVID-19 Pregnancies,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04515108,NCT04515108,"complete blood count parameters (including the number of lymphocytes, leukocytes, monocytes, platelets and red blood cells).|apgar score|maternal and newborn length|maternal and newborn weight|body temperature",observational,observational model: cohort|time perspective: retrospective
Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04379037,NCT04379037,survival without need of mechanical ventilation|who progression scale ‚â§ 5 at day 4 since admission.|cumulative incidence of successful tracheal extubation at day 14 since symptom onset.|who progression scale ‚â§ 7 at day 4 since admission.|survival at day 14 of hospitalization|duration of hospitalization|time to hospital discharge,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Testing for Dysautonomia in Patients Hospitalized for SARS-CoV-2 Infection (COVID-19) : COVIDANS Study,COVIDANS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04374045,NCT04374045,"percentage of dysautonomia patients found within the first 24 hours of hospitalization (%)|analyse the other mathematical indices measuring autonomic balance, obtained by holter-ecg recording over the first 24 hours and throughout their hospitalisation, in search of possible dysautonomia|to investigate whether the autonomic balance of patients with cov-2 sars correlates with the severity of their clinical condition during their hospital stay.|to investigate whether the various autonomic parameters recorded are predictive of clinical worsening or improvement, by calculating a prediction threshold for each of the parameters.",observational,observational model: cohort|time perspective: prospective
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04516811,NCT04516811,clinical improvement|adverse events of special interest|serious adverse events|survival|invasive mechanical ventilation|disease severity|time to outcomes of interest|length of stay meausures|sars-cov pcr|inflammatory markers|radiography|fever & hypoxia|patients with hiv infection and other comorbidities|timing of ip & efficacy outcome|neutralising ab|sars cov antibody titre,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Cardiovascular Consequences After COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04452630,NCT04452630,"presence of at least one clinical, biological and/or imaging cardiovascular anomaly within 1 month of recovering",observational,observational model: cohort|time perspective: prospective
Covid-19 Messaging to Underserved Communities - 2nd Experiment,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04502056,NCT04502056,the number of participants with knowledge of covid related symptoms and transmission as assessed by a questionnaire we've developed specifically relevant to the intervention videos we are using for the project.|behavioral outcome 1: number of participants who report behavior change related to messages provided in the intervention videos; measured via a specific questionnaire instrument we've developed to correspond to the intervention.|behavioral outcome 2: willingness to pay (wtp) for masks|behavioral outcome 3: number of people who click on links for additional information on the covid-19 behaviors|behavioral outcome 4: the amount of money donated to a covid-19 relief fund.,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Study of a Possible Respiratory Degradation Prognosis Caused by Biomarkers in Severe Forms of COVID-19 Pneumonia,LPSARS2,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04505605,NCT04505605,evaluation of the dosage of biomarkers|link between the biomarkers,observational,observational model: other|time perspective: prospective
Safety and Immunity of Covid-19 aAPC Vaccine,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04299724,NCT04299724,frequency of vaccine events|frequency of serious vaccine events|proportion of subjects with positive t cell response|28-day mortality|duration of mechanical ventilation if applicable|proportion of patients in each category of the 7-point scale|proportion of patients with normalized inflammation factors|clinical improvement based on the 7-point scale if applicable|lower murray lung injury score if applicable,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Compensatory Reserve Index (CRI) for Management of COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04457817,NCT04457817,volume of iv fluid infused|quantity of blood pressure medication administered|resuscitation status|fio2 needs|days on oxygen|number of participants with hospital acquired pneumonia|number of patients with acute kidney injury (aki)|number of patients with hemodynamic collapse|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Cytokine Status of Covid-19 Patients,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04531345,NCT04531345,cytokine levels of patients,observational,observational model: case-control|time perspective: prospective
Halodine Nasal Antiseptic in Patients With COVID-19,nan,not yet recruiting,No Results Available,phase 4,Industry,https://ClinicalTrials.gov/show/NCT04517188,NCT04517188,nasopharyngeal sars-cov-2 viral load,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Thy-Support,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04348513,NCT04348513,assessment of weaning from cardiorespiratory support|assessment of hemodynamic status|assessment of pulmonary function|assessment of hepatic function|assessment of renal function|assessment of cardiac function|assessment of cardiac injury|assessment of the course of covid-19 infection|assessment of clinical outcome and safety,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Test and Treat COVID 65plus+,COVID65plus,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04351516,NCT04351516,‚óè rate of hospitalization or death at day 7 after study inclusion,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04559009,NCT04559009,covid-19 incidence and prevalence in the als population,observational,observational model: case-control|time perspective: prospective
Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome,nan,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04540120,NCT04540120,"proportion of subjects with complete resolution of fever symptoms and shortness of breath|cumulative incidence of saes|cumulative incidence of grade 3 and grade 4 adverse events|discontinuation or temporary suspension of participation|changes in white cell count|changes in hemoglobin|changes in platelets|changes in creatinine|changes in glucose|changes in total bilirubin|changes in alt|changes in ast|incidence of new infection that occurs during the study|incidence of opportunistic infections|complete resolution of fever symptoms and shortness of breath|time to clinical improvement|time to sustained absence of fever|clinical improvement in symptoms relevant to covid 19|incidence of composite endpoint of hospitalization, supplemental oxygen, mechanical ventilation, or death|clinical improvement in symptoms|improvement in oxygenation|change in alt|change in ast|change in blood glucose|change in erythrocyte sedimentation rate (esr)|change in hemoglobin a1c (hba1c)|change in lactate dehydrogenase (ldh)|change in lymphocyte, absolute count|change in monocyte, absolute count|change in neutrophils, absolute count|change in eosinophil, absolute count|change in crp|change in d-dimer|change in ferritin|change in fibrinogen|change in partial thromboplastin time (ptt) and international normalized ratio (inr)|change in il-1œ≤|change in il-6|change in il-18|change in granulocyte colony-stimulating factor (g-csf)|change in interferon-œ≥-induced protein 10 (ip-10)|change in c3a",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;,C-SMART,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04534725,NCT04534725,"incidence of covid-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with covid-19 (covid-19 confirmed by qpcr from respiratory swab)|incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing|incidence of covid-19 when interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with covid-19. covid-19 confirmed by qpcr from respiratory swab .|incidence of death and/or need for invasive or non-invasive ventilation. assessed using medical records|time to clinical improvement or discharge from hospital assessed using medical records|arm 1: duration of acute respiratory/ili symptoms in case of confirmed respiratory infection during the study period. assessed using patient symptom diary pro tool|arm 1: time to diagnosis of covid-19 in case of confirmed covid-19 diagnosed during the study period (days). assessed using patient medical records|arm 1: time to diagnosis of other respiratory viral infection in case of confirmed other respiratory viral infection diagnosed during the study period (days). assessed using patient medical records|arm 1: illness severity in case of confirmed covid-19 diagnosed during the study period using who clinical progression scale|arm 1: incidence of unplanned all-cause hospital admission during the study period. assessed using medical records|arm 1: incidence of unplanned infection-related hospital admission during the study period. assessed using medical records|arm 1: incidence of sero-conversion of sars-cov-2 at the end of the study period. assessed using qpcr|arm 1: incidence of death from any cause during the study period. assessed using patient medical records|arm 1: incidence of testing for covid-19 during the study period. assessed using medical records|arm 2 duration of acute respiratory symptoms in case of confirmed covid-19 diagnosed during the study period. assessed with pro and medical records.|arm 2: time to diagnosis of covid-19 in case of confirmed covid-19 diagnosed during the study period (days). assessed using medical records|arm 2: illness severity in case of confirmed covid-19 diagnosed during the study period. assessed using who clinical progression scale.|arm 2: incidence of unplanned all-cause hospital admission during the study period. assessed using medical records.|arm 2: incidence of unplanned infection-related hospital admission during the study period. assessed using medical records|arm 2: incidence of seroconversion of sars-cov-2 at the end of the study period. assessed using qpcr.|arm 2: incidence of testing for covid-19 during the study period assessed using medical records|arm 3: time to clinical improvement assessed using medical records.|arm 3: illness severity of covid-19, defined as the maximal score on the world health organization (who)'s clinical progression ordinal scale|arm 3: change to clinical condition assessed with karnofsky performance score|arm 3: time to progression to severe covid-19, defined by who ordinal scale|arm 3: time to all-cause mortality|arm 3:duration of hospitalisation assessed using medical records|arm 3: duration of covid-19 symptoms assessed using patient reported symptom diary.|arm 3: duration of oxygen supplementation (days). assessed using medical records.|arm 3: change in nasopharyngeal sars-cov-2 viral load shedding (assessed via qpcr)|arm 3: safety and tolerability of selinexor using relevant medical records|arm 3: incidence of changes in blood results relevant to clinical improvement assessed using medical records|arm 4: incidence of all cause death by day 28 and 60|arm 4: time to all-cause mortality|arm 4: illness severity of covid-19, defined as the maximal score on the world health organization (who)'s clinical progression ordinal scale|arm 4: incidence of ards assessed using medical records|arm 4: incidence of hlh. assessed using medical records|arm 4: duration of hospitalisation. assessed using hospital medical records.|arm 4: proportion discharged from hospital. assessed using medical records|arm 4: incidence of mechanical ventilation up to day 28. assessed using medical records|arm 4: ventilator-free days and proportion who did not receive invasive mechanical ventilation. assessed using medical records|arm 4: organ failure free days and proportion who did not develop organ failure. assessed using medical records.|arm 4: incidence and duration of icu admission. assessed using medical records|arm 4: incidence and duration of supplemental oxygen use. assessed using medical records|arm 4: time to clinical improvement defined as national early warning score 2 (news2) of <2 maintained for 24 hours.|arm 4: incidence of non-invasive ventilation. assessed using medical records|arm 4: number of participants alive and off oxygen at day 60. assessed using medical records.|arm 4: proportion of participants who had improved oxygenation for >48 hours. assessed using medical records|arm 4: incidence of adverse events based on the national cancer institute ctcae v5. assessed using medical records|arm 4: incidence of saes based on nci ctcae v5 assessed using medical records|arm 4: change in nasopharyngeal sars-cov-2 viral load shedding. assessed using qpcr.",interventional,"allocation: randomized|intervention model: sequential assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
"the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19",nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04521400,NCT04521400,time to clinical improvement|mortality|spo2 improvement|incidence of new mechanical ventilation use|duration of hospitalization|cumulative incidence of serious adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 Mortality Prediction Model,nan,completed,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04358510,NCT04358510,mortality outcome in covid-19 icu patients|mortality outcome in mechanically ventilated icu patients|mortality outcome in pneumonia icu patients,observational,observational model: cohort|time perspective: retrospective
Seroconversion in COVID 19 Recovered Population,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04558385,NCT04558385,igg sars cov2,observational,observational model: case-only|time perspective: retrospective
The A√ßa√≠ Berry COVID-19 Anti-Inflammation Trial,ACAI,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04404218,NCT04404218,7-point ordinal symptom scale|the composite of all-cause mortality and need for mechanical ventilation|the composite of all-cause mortality and hospitalization|all-cause mortality|need for mechanical ventilation|need for hospitalization,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Tannin Specific Natural Extract for COVID-19 Infection,TaCOVID,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04403646,NCT04403646,time to hospital discharge|28-day all-cause mortality|invasive ventilation on day 28|difference in pro and antiinflammatory citoquine levels|difference in fecal intestinal microbiota composition|negativization of covid-pcr at day 14,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
COVID-19 Related Health and Infection Control Practices Among Dentists,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04423770,NCT04423770,covid-19 probable or confirmed case|anxiety|depression|dental practice infection control efforts|dentists' use of personal protective equipment,observational,observational model: ecologic or community|time perspective: prospective
Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,COVID-19,completed,Has Results,phase 3,Other,https://ClinicalTrials.gov/show/NCT04491994,NCT04491994,number of participants with progression|viral clearance,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19,ECMO-SL-CoV-2,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04446286,NCT04446286,retrospective description of effect of the ecmo-vv or ecmo-va in the management of severe ards refractory in patients of the strasbourg and louvain centres with covid-19,observational,observational model: case-only|time perspective: other
Association of Comorbidities With COVID19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04459390,NCT04459390,rate of recovery/ icu admission/ need for mechanical ventilation|time to improvement,observational,observational model: case-control|time perspective: prospective
Home-Based Covid-19 Rehabilitation Program,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04406532,NCT04406532,change in pulmonary function (st george's respiratory questionnaire: sgrq)|change in physical function (activity measure for post-acute care: am-pac)|change in pulmonary function (sabrasez single breath count)|change in pulmonary function (peak flow tests)|change in physical function (5 times site to stand test)|health events (emergency room visits and hospitalizations)|change in psychological measures (beck anxiety inventory: bai)|change in psychological measures (center for epidemiologic studies depression scale: ces-d)|feasibility (adherence)|feasibility (acceptability),interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04347681,NCT04347681,icu length of stay|safety of convalescent plasma & serious adverse reactions.|number of days on mechanical ventilation|30 days of mortality|days to clinical recovery .,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children,CONCOR-KIDS,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04377568,NCT04377568,clinical recovery|combined mortality/intubation|respiratory status-1|respiratory status-2|respiratory status-3|respiratory status -4|respiratory status -5|respiratory status-6|mortality 1a|mortality 1b|mortality 2a|mortality 2b|care and critical care|organ systems: renal|organ systems: cardiac|transfusion-associated adverse events (ae)|safety of the intervention|organ systems: multi-system inflammatory disease,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04470648,NCT04470648,sars-cov-2 seroprevalence in 3 centers for homeless and people in social distress|morbidity rate|covid-19 related death rate in the 3 centers from march to may 2020|ratio of negative serology rate and positive serology rate in the 3 centers|ratio of sars-cov2 seroprevalence obtained in these centers to the estimated seroprevalence in the ile de france region,observational,observational model: other|time perspective: prospective
Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection,MARNEVO-Covid,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04361344,NCT04361344,change of neurodegeneration markers level,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial),nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04330144,NCT04330144,the rate of covid-19,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04342104,NCT04342104,hacor score efficacy|hacor score addaptation,observational,observational model: cohort|time perspective: prospective
"Trial Evaluating Efficacy and Safety of Nivolumab (Optivo¬Æ) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.",CORIMUNO-NIVO,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04343144,NCT04343144,time to clinical improvement|overall survival|cumulative incidence of icu admission|length of hospital stay|positive nasal pcr|incidence of adverse events|incidence of grade 3-4 adverse events|world health organisation (who) progression scale,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
AiM Covid Self Monitoring,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04425044,NCT04425044,fever|shortness of breath|cough|sore throat|headache|muscle/ joint pain|diarrhoea|vomiting/ nausea|runny nose|loss of smell/taste|other symptoms,observational,observational model: cohort|time perspective: prospective
Vienna Versus SARS-CoV-2 Virus Study,VIVI,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407429,NCT04407429,prevalence of antibody status in healthcare workers and in patients admitted for non-covid-19 related symptoms over time|incidence rate of sero-conversion|identification of risk markers/factors for sars-cov-2 infection,observational,observational model: cohort|time perspective: prospective
"CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort",CORIMUNO19-ECU,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04346797,NCT04346797,"survival without needs of intubation at day 14|change in organ failure at day 3|intubation free survival at day 14|who progression scale at days 4, 7 and 14|survival at 14, 28 and 90 days|time to discharge|time to oxygen supply independency|time to negative viral excretion|incidence of secondary infections|vasopressor-free survival|ventilator-free survival|28-day ventilator-free days|incidence of dialysis|pao2/fio2 ratio|rate of respiratory acidosis at day 4|time to icu discharge",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Washed Microbiota Transplantation for Patients With 2019-nCoV Infection,nan,withdrawn,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04251767,NCT04251767,number of participants with improvement from severe type to common type,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Nebulised Dornase Alfa for Treatment of COVID-19,COVASE,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04359654,NCT04359654,measuring the change in inflammation|number of patients that are alive at 28 days|amount of days that patient requires oxygen|average oxygenation index|days patient admitted to hospital|percentage of patients that need mechanical ventilation,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Does COVID-19 Pandemic Reduce In-hospital Mortality?,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04480515,NCT04480515,in-hospital mortality,observational,observational model: cohort|time perspective: other
Management of Covid-19 Patients During Home Isolation,nan,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04368923,NCT04368923,arterial blood gases (abg): partial pressure of oxygen and carbon dioxide|arterial blood gases (abg): acidity potential hydrogen (ph)|vital signs (temprature)|vital signs (respiratory rate)|vital signs (oxygen saturation)|vital signs (heart rate)|vital signs (blood pressure),interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Predicting Outcomes for Covid-19 Using Sonography,POCUS,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04384055,NCT04384055,"number of patients experiencing death, icu admission, mechanical ventilation, or use of high-flow nasal cannula|number of patients requiring mechanical ventilation|number of patients requiring supplemental oxygen usage|duration of supplemental oxygen usage|length of stay|characterization of ultrasound findings",observational,observational model: case-control|time perspective: prospective
Predict Adverse Events by Covid-19 Nephritis,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04347824,NCT04347824,time to disease-aggravation|complications|resources|blood-test,observational,observational model: case-only|time perspective: retrospective
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia,RESOLVE,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04468971,NCT04468971,"regimen related ‚â• grade 3 toxicity within 48 hours of first infusion|28-day treatment success, defined as s28|time to extubation|oxygenation improvement|ventilator free days|organ failure free days|icu free days|all-cause mortality",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
AiM COVID for Covid 19 Tracking and Prediction,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04354753,NCT04354753,physical symptoms|contact history|travel history|fever|headache|soar throat|runny nose|cough|shortness of breath|nausea|vomiting|muscle pain|joint pain|diarrhoea|other|hospitalisation history|co-morbid conditions,observational,observational model: case-only|time perspective: retrospective
Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19,PHYSIO-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04347928,NCT04347928,intrapulmonary shunt ratio|evolution of respiratory variables|evolution of hemodynamic stability variables,observational,observational model: cohort|time perspective: prospective
Immune Cell Subgroups in Covid 19 Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04531319,NCT04531319,t cell subtype ratios|monocyte ratio,observational,observational model: case-control|time perspective: prospective
Reduction of COVID 19 Transmission to Health Care Professionals,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04462627,NCT04462627,anti-a antibody concentration|anti-b antibody concentration|blood group,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19,nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04392531,NCT04392531,severity category|mortality rate|number of days in hospital|number of days in icu beds|fio2 needs|adverse events rate|change in crp|change in ferritin|change in ldh|change in cpk|change in d dimer|change in il-6|change in kl-6|change in viral load|change specific antibodies,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection,RESPIRE,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04361903,NCT04361903,number of patients who avoid mechanical assisted ventilation in acute respiratory distress syndrome in patients with sars-cov-2 covid-19|improvement of respiratory performance - arterial blood gas analisys - ph|improvement of respiratory performance - arterial blood gas analisys - po2|improvement of respiratory performance - arterial blood gas analisys - pco2|improvement of respiratory performance - ratio values|evaluation of known adverse events related to the use of the drug - d-dimer|evaluation of known adverse events related to the use of the drug - fibrinogen|evaluation of known adverse events related to the use of the drug - transaminases|evaluation of known adverse events related to the use of the drug - aptt|evaluation of known adverse events related to the use of the drug - inr|evaluation of known adverse events related to the use of the drug - glycemia|evaluation of known adverse events related to the use of the drug - creatinine|evaluation of known adverse events related to the use of the drug - leucocytes count|evaluation of known adverse events related to the use of the drug - leucocytes formula|evaluation of the epidemiological parameters: chest ct|evaluation of the epidemiological parameters: eco chest|evaluation of the epidemiological parameters: chest x-ray|monitoring of serum levels of cytokines before and every 48 h from start to to end of treatment|monitoring incidence of treatment emergent adverse events of ruxolitinib therapy,observational,observational model: cohort|time perspective: retrospective
A Trial of Remdesivir in Adults With Severe COVID-19,nan,terminated,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04257656,NCT04257656,time to clinical improvement (ttci) [censored at day 28]|clinical status|time to hospital discharge or news2 (national early warning score 2) of ‚â§ 2 maintained for 24 hours.|all cause mortality|duration (days) of mechanical ventilation|duration (days) of extracorporeal membrane oxygenation|duration (days) of supplemental oxygenation|length of hospital stay (days)|time to 2019-ncov rt-pcr negativity in upper and lower respiratory tract specimens|change (reduction) in 2019-ncov viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|frequency of serious adverse drug events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04385095,NCT04385095,"ordinal scale for clinical improvement|progression to pneumonia (hospital setting only)|time to clinical improvement (hospital setting only)|national early warning score 2 (news2) assessment of acute-illness severity (hospital setting only)|changes in daily breathlessness, cough and sputum scale (bcss)|safety and tolerability - blood pressure ii. viral load|safety and tolerability - heart rate ii. viral load|safety and tolerability - temperature ii. viral load|safety and tolerability - respiratory rate ii. viral load|safety and tolerability - oxygen saturation ii. viral load|safety and tolerability - adverse events ii. viral load|safety and tolerability - concomitant medications ii. viral load|time to clinical improvement (home setting only)|time to improvement of covid-19 symptoms (home setting only).|time to self-reported recovery (home setting only)|self-reported daily rating of overall feeling of wellness (home setting only).|quality of life measured using eq-5d-5l (home setting only).|virus clearance/load (if samples are available)|blood and sputum biomarkers (if samples are available).|contact with health services (home setting only|consumption of antibiotics (home setting only",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
COVID-19 Respiratory Distress and Antithrombotic Drugs in Subject's Habits,CRASH,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04412473,NCT04412473,analysis of respiratory distress and antithrombolytic therapy in patients with covid19,observational,observational model: case-only|time perspective: retrospective
Ivermectin In Treatment of COVID 19 Patients,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04425707,NCT04425707,to evaluate the role of ivermectin as a line of treatment for covid 19|to asses the rate of viral clearance in comparison to other treatment protocols.,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Aggrenox To Treat Acute Covid-19,ATTAC-19,not yet recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04410328,NCT04410328,covid (coronavirus disease-19) ordinal scale|mortality|supplemental oxygen|invasive-ventilator|icu stay|hospital stay|inflammatory markers|thromboembolic complications|covid ordinal scale,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Determinants of SARS-COV2 (COVID-19) Persistence After Convalescence,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04448145,NCT04448145,duration of sars-cov-2 viral persistence in naso/oropharyngeal samples|duration of sars-cov-2 viral persistence in stool or rectal swab samples|duration of sars-cov-2 viral persistence in semen samples|duration of sars-cov-2 viral persistence in breast milk samples|prevalence of cell immune responses|duration of covid-19 symptoms|prevalence of post-viral sequelae|prevalence of sars-cov-2 persistence and bacterial/viral community structures,observational,observational model: cohort|time perspective: prospective
COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04487873,NCT04487873,covid-19 phobia|qol|health anxiety|physical activity|quality of sleep,observational,observational model: case-control|time perspective: prospective
Growth Hormone in Obese Cases With Covid-19,nan,withdrawn,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04532554,NCT04532554,need for hospitalization|time to recovery|percentage of reduction in crp|percentage of reduction in ldh|percentage of reduction in ferritin|time to recovery from leucopenia,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19,nan,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04545008,NCT04545008,number of participants with treatment-related adverse events as assessed by ctcae v5.0|rate of hospitalization|time to symptom resolution,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Collection of Anti-SARS-CoV-2 Immune Plasma,NIAID,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04344977,NCT04344977,identification of eligible donors and collection of anti-sars-cov-2 immune plasma,observational,observational model: case-only|time perspective: prospective
Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19,ONCOVID-21,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04510454,NCT04510454,to determine the ddpcr ability to detect the sars-cov-2 in nasopharyngeal samples of symptomatic patients with suspected covid-19 infection|to determine the rt-qpcr ability to detect the sars-cov-2 in nasopharyngeal samples of symptomatic patients with suspected covid-19 infection|to determine the ddpcr and rt-qpcr abilities to detect the sars-cov-2 in oropharyngeal samples of symptomatic patients with suspected covid-19 infection|to determine the ability of a clinical diagnosis based both on patients' symptoms and chest ct-scan to detect the sars-cov-2 in symptomatic patients with suspected covid-19 infection|to determine the agreements between nasopharyngeal samples and oropharyngeal samples|to determine the agreements between a clinical diagnosis and ddpcr and rt-qpcr assays|to assess the 28-day mortality rate|to determine potential predictive factors of death among patients' characteristics|to evaluate the over risk of death of patients covid+ versus covid-,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Prevalence and Characteristics of Pulmonary Embolism on COVID-19 Patients Presenting Respiratory Symptoms,COVID-EP,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04420312,NCT04420312,impact of pe on covid-19 patients|clinical and radiological characteristics,observational,observational model: case-control|time perspective: retrospective
Characteristics of Critically Ill COVID 19 Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04465058,NCT04465058,clinical characteristics,observational,observational model: other|time perspective: prospective
Covid-19 Breath Test,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04459962,NCT04459962,to investigate/ examine the effectiveness of nanotechnology biomarker tagging (nbt) in detecting covid-19 infection using breath samples of patients with covid-19 symptoms|-to profile the unique pattern of volatile organic compounds (vocs) found in the expired breath of covid-19 patients using the nbt system (voc analysis and ml).|to differentiate this unique profile from the patients that are found to be negative for covid-19,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Echocardiography in Critically-ill Patients With COVID-19 Pneumonia,ECHO-COVID,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04414410,NCT04414410,incidence of left ventricular systolic dysfunction|incidence of rv failure|incidence of vasoplegia|incidence of hypovolemia|relation between plateau pressure and rv failure|relation between tidal volume and rv failure|relation between pao2 and rv failure|relation between paco2 and rv failure|relation between peep and rv failure,observational,observational model: cohort|time perspective: retrospective
COVID-19 in a Single Large UK Rheumatology Centre and Impact on QOL,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04542031,NCT04542031,prevalence of covid 19|mortality rates from covid 19|health related quality of life - short form 12,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19,COVCKD,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04367714,NCT04367714,aantibody response,observational,observational model: cohort|time perspective: prospective
"The Relationship Between COVID19 and Autoimmune Diseases, Lessons From Practice",nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04558203,NCT04558203,incidence of autoimmune conditions,observational,observational model: cohort|time perspective: cross-sectional
Sleep Quality in Healthcare Personnel During COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04395300,NCT04395300,measure sleep quality in healthcare worker|impact of covid-19 pandemic on general health|correlate between sleep quality and general health,observational,observational model: ecologic or community|time perspective: cross-sectional
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,nan,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04463004,NCT04463004,proportion of subjects alive and off of oxygen at day 14|proportion of subjects alive and without respiratory failure at 28 days,interventional,"allocation: randomized|intervention model: factorial assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),ABACCuS,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04432272,NCT04432272,avoidance of intubation at 28 days (group a)|mortality (group b)|cardio-circulatory arrest|patient outcome at 28 days|renal failure|liver failure|cytokine storm|respiratory support|vasopressor medication support|length of icu length of stay|intensive care unit (icu) mortality|hospital length of stay|ventilator free days|intubation duration|readmission|serum anti-sars-cov-2 igg|sars-cov-2 rna|mortality (group a)|time from transfusion to end of ventilator support (group b),interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment",nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04500067,NCT04500067,"period duration (in days) to clinical improvement|o2 saturation (spo2 percentage), with self-breathing|respiratory movements rate (amount per minute), with self-breathing|body temperature without antipyretics use|lymphocyte count|time from the onset of the disease to discharge, in days|duration of the need for ventilatory support, in days|duration of the need for intensive care, in days|duration of need for oxygenation in days (spo2 ‚â§ 93% with self-breathing)|the c-reactive protein (crp) level|the tumor necrozis factor alpha (tnf-œ±) level|the interleukin-1œ≤ (il-1œ≤) level|the interleukin-6 (il-6) level|the d-dimer level|the complement (c3 component) level|the circulating immune complexes level|the ferritin level|the procalcitonin level|igg subtypes|survival assessment for a 28-day follow-up period since the onset of severe pneumonia",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Comparison of the ID NOW and Accula Point-of-Care Assays for Detection of COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04403035,NCT04403035,test characteristics,observational,observational model: cohort|time perspective: prospective
Efficacy of Iodine Complex Against COVID-19 Patients,I-COVID-PK,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04473261,NCT04473261,qrt-pcr|severity of symptoms,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
CoVid-19 - Infection and Antibody Formation in the Viennese Population,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04346264,NCT04346264,prevalence of sars-cov-2 antibody titres|prevalence of sars-cov-2 antibody titres after 3 months,observational,observational model: cohort|time perspective: prospective
BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST),nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04534803,NCT04534803,"to assess the efficacy of bcg vaccination compared to placebo in reducing severe covid-19 disease among elderly residents of skilled nursing facilities.|to assess the efficacy of bcg vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of cases)|to assess the efficacy of bcg vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of cases), continued|to assess the efficacy of bcg vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of episodes)|to assess the efficacy of bcg vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of days)",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: prevention"
Covid-19 Pandemic: Patients' Experience in T1D,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04384471,NCT04384471,"self-reported acute diabetes complication|self-reported hypoglycemia|ability to get diabetes supplies and to access diabetes care|concern about not having access to diabetes supplies and to access diabetes care|impact of the pandemic situation on daily life activities|impact on stress, anxiety and depression for adults participants|impact on stress, anxiety and depression for children and adolescents",observational,observational model: case-only|time perspective: cross-sectional
Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04356586,NCT04356586,percentage of serological positive healthcare workers|percentage of hcw with positive saliva-sabs,observational,observational model: cohort|time perspective: prospective
Survival and 30-days Hospital Outcome in COVID-19 Patients in Upper Egypt,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04488588,NCT04488588,number of co-morbidities in hospitalized patients with covid-19|causes of icu admission,observational,observational model: cohort|time perspective: retrospective
IFN Beta-1b and Ribavirin for Covid-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04494399,NCT04494399,clinical symptoms alleviation|hospitalisation|time to negative viral load|inflammatory changes|mortality|adverse events and serious adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19,CONVINCE,not yet recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04516941,NCT04516941,edoxaban vs. no active treatment|colchicine vs no active treatment|number of patients with asymptomatic proximal deep-vein thrombosis|number of patients with symptomatic proximal or distal deep-vein thrombosis|number of patient with symptomatic pulmonary embolism or thrombosis|number of patients with myocardial infarction|number of patients with ischemic stroke|number of patients with non-cns systemic embolism|number of deaths|ventilation need,interventional,allocation: randomized|intervention model: factorial assignment|masking: none (open label)|primary purpose: treatment
Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2 (COVID-19),COVID-AKI,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04393428,NCT04393428,sensibility and specificity of urinary,observational,observational model: cohort|time perspective: retrospective
Incidence of COVID-19 Test Conversion in Post-surgical Patients,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04392323,NCT04392323,covid-19 test conversion|duration of hospitalization|rate of self-reported covid-19 exposure|rate of complications from covid-19,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04397939,NCT04397939,number of in-hospital death|length of stay|number of successful treatment,observational,observational model: cohort|time perspective: retrospective
ProAdrenomedullin Assessment of Multi-Organ Failure in COvid-19 Sepsis,PAMOCOS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04522310,NCT04522310,"association or correlation between mr-proadm at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation.|mortality at day 28 and day 90.|association between mr-proadm and mortality at day 28.|association or correlation between patient factor or treatment, and the onset or aggravation of visceral failures (day 3 and day 10), evolution until day 28.",observational,observational model: case-only|time perspective: prospective
Lactoferrin for Prevention of COVID-19 in Health Care Workers,LF-COVID,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04526821,NCT04526821,number of covid-19 infections during the 12 weeks of intervention|severity of the covid-19 infection|duration of symptoms of the covid-19 infection|frecuency of symptoms of the covid-19 infection,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19,PANCOLIN,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04543006,NCT04543006,anti-sars-cov-2 neutralizing antibody titers,interventional,intervention model: sequential assignment|masking: none (open label)|primary purpose: prevention
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),CORON-ACT,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04335071,NCT04335071,number of patients with icu admission|number of patients with intubation|number of patients with death|illness severity|number of patients with clinical improvement|time to clinical improvement (days)|duration of hospitalization (days)|time to icu admission (days)|duration of icu stay|time to intubation|duration of mechanical ventilation (days),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS,APRV-COVID19,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04386369,NCT04386369,proportion of patients improving pao2/fio2 ratio at 6 hours of aprv|number of interventions on ventilator settings|change in mean blood pressure|change in heart rate|changes in catecholamine doses|changes in static compliance at the end of 6 hours of aprv|variations of minute ventilation|changes in static compliance 4 hours after stopping aprv|proportion of patients with a decrease of the pao2/fio2 ratio,observational,observational model: cohort|time perspective: retrospective
"A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.",nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04494984,NCT04494984,clinical changes in covid-19 symptoms|pharmacokinetics evaluation of inm005|time to progression of disease|disease progression|discharge|intensive care unit (icu) hospitalization|mechanical ventilation assistance (mva)|mortality|changes in viral load,interventional,"allocation: randomized|intervention model: sequential assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients,PREAVIS,terminated,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04522466,NCT04522466,pharmacokinetics of hydroxychloroquine (hcq)|correlation between hydroxychloroquine (hcq) concentration and cardiac toxicity (qt interval)|correlation between pharmacokinetic (concentration) and pharmacodynamic (viral load) of hydroxychloroquine (hcq)|pharmacokinetic model,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel,Bacmune,not yet recruiting,No Results Available,phase 3,Industry|Other,https://ClinicalTrials.gov/show/NCT04452643,NCT04452643,incidence of subjects with covid-19|severity of covid-19|seroconversion to sars-cov-2|subjects with symptoms|hospital admission due to covid-19|admission to an intensive care unit due to covid-19|elapsed time until hospitalization|elapsed time until admission into an care unit for covid-19|elapsed time until death not related to covid-19,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
DIgital Online SuPport for COVID-19 StrEss,DISPOSE,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04324190,NCT04324190,change in short-form-36 (sf-36) health survey - mental health component summary score|short-form-36 (sf-36) health survey - mental health component summary score|chronic stress items (9 items)|generalized anxiety disorder scale (gad-7)|patient health questionnaire (phq8)|somatic symptom disorder (ssd-12)|somatic symptom scale (sss-8)|allgemeine selbstwirksamkeit kurzskala (asku)|screening tool for psychological distress (stop-d) - selected items,interventional,allocation: randomized|intervention model: sequential assignment|masking: single (care provider)|primary purpose: treatment
Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,RuxCoFlam,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04338958,NCT04338958,overall response rate in reversal of hyperinflammation,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"The Assessment of the Prevalence, Clinical Course and Treatment of COVID-19 Complications",nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04453748,NCT04453748,prevalence of covid-19 complications|assessment of risk factors of covid-19 complications,observational,observational model: cohort|time perspective: prospective
Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to COVID-19,DeCOPO,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04543760,NCT04543760,"[pao2 / fio2] ratio|œîpeso measured using an esophageal balloon catheter|concentration of co2 at the end of expiration (etco2, mmhg)|intensity of dyspnea|tolerance of the technique|the occurrence of side effects due to pp",interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: other
Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04497649,NCT04497649,number of patients with improvement or mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression,nan,enrolling by invitation,No Results Available,nan,Other|Industry,https://ClinicalTrials.gov/show/NCT04530500,NCT04530500,number of patients deceased|number of patients discharged,observational,observational model: cohort|time perspective: prospective
Clinical Trial to Evaluate the Efficacy of Food Supplement Manremyc¬Æ Against SARS- COV-2 Infection (COVID-19) in Healthcare Workers,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04452773,NCT04452773,documented cumulative incidence of sars-cov-2 infection|documented sick leave for sars-cov-2|days off work due to the quarantine|quarantine imposed by close contact outside the center with sars-cov-2 positive|fever|cumulative incidence of self-reported acute respiratory symptoms|number of days of self-reported acute respiratory symptoms|incidence of pneumonia|cumulative incidence of death from documented sars-cov-2 infection|incidence of admission to icu|days in iuc|incidence of mechanical ventilation|incidence of hospital admissions|days of hospitalization|levels of igg|levels of igm|levels of sars-cov-2 antibodies at the end of the study period,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia,MultiCov,recruiting,No Results Available,not applicable,Other|Industry,https://ClinicalTrials.gov/show/NCT04334850,NCT04334850,number of antibiotic free days|mortality rates|number of defined daily dose (ddd) per 100 patient-days of broad- and narrow-spectrum antibiotics.|antibiotics duration at d28|number of organ-failure free days (based on sofa)|incidence rates of bacterial super-infections|incidence rates of colonization/infection with multidrug resistant bacteria and clostridium difficile infections|icu and hospital lengths of stay|quality of life quality of life,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Optimising Resource Allocation Via Prediction of Outcomes for Covid-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04473105,NCT04473105,ventilation|death,observational,observational model: other|time perspective: prospective
Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19,CLOCC,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04338906,NCT04338906,"not hospitalized|time to improvement of 2 categories from admission on a 7-point ordinal scale|proportion of participants in each group with normalization of fever|proportion of participants in each group with oxygen saturation > 94% on room air for >24h|time to fever normalization (if febrile at baseline)|time to first negative sars-cov-2 pcr in np swap (if pos. at baseline)|time to first negative sars-cov-2 pcr in lower respiratory tract specimens (sputum, bronchoalveolar lavage, tracheal aspirate) (if positive at baseline)|duration of oxygen therapy|proportion of participants in each group with need for mechanical ventilation|duration of hospitalization|all cause mortality",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Baricitinib Therapy in COVID-19,nan,completed,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04358614,NCT04358614,"to assess the safety of baricitinib combined with antiviral (lopinavir-ritonavir) in terms of serious or non-serious adverse events incidence rate.|to evaluate the impact of baricitinib in terms of clinical, laboratory, respiratory parameters.|icu admission rate|discharge rate.",interventional,allocation: non-randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: treatment
Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak,DolPsyCOVID,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04353011,NCT04353011,hospital anxiety and depression scale questionnaire|quality of life (sf36)|self-reported questionnaire for painful|qualitive questionnaire,observational,observational model: family-based|time perspective: cross-sectional
Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak,OsPsyCOVID,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04351633,NCT04351633,percentage of patient with feeling of disabilities,observational,observational model: family-based|time perspective: cross-sectional
Efficacy of Ivermectin as Add on Therapy in COVID19 Patients,nan,completed,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04343092,NCT04343092,number of cured patients|mean time to cure of the covid 19 patients,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,OsCOVID19,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04386447,NCT04386447,proportion of cases who during 14 exhibit one of the following conditions|mortality 28 days after randomization,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Impact of COVID-19 on the Benefit of Cardiac Rehabilitation,REACARDIOCOVID,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04513964,NCT04513964,impact of covid-19 on exercise capacity gain after cardiovascular rehabilitation,observational,observational model: case-control|time perspective: cross-sectional
Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients,nan,recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04530370,NCT04530370,satisfactory outcome,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Early Cognitive Assessment and Evolutionary Monitoring of Patients With Severe ARDS on COVID-19 Pneumonia Requiring Mechanical Ventilation,CognitiVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04468035,NCT04468035,medium-term evolution between 3 and 6 months|cognitive impairment at m3|cognitive impairment at m6|memory scores at m3|memory scores at m6,observational,observational model: cohort|time perspective: cross-sectional
Incidence of Acute Pulmonary Embolism in Covid-19 Patients on CT Angiography and Relationship to D-dimer Levels,COVID-APE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04373486,NCT04373486,rate of positivity for acute pulmonary embolism,observational,observational model: case-only|time perspective: other
Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients,TCInpatient,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04338126,NCT04338126,admission to intensive care unit,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
COVID-19 in Pediatric Oncology and Hematology Centers in France,PEDONCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04433871,NCT04433871,oncologic data|covid-19 diagnosis|clinical signs|biological signs|radiological signs|covid-19 management|potent covid-19 sequelae,observational,observational model: cohort|time perspective: prospective
Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19,COVIDMES,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04390139,NCT04390139,"all-cause mortality at day 28|safety of wj-msc|need for treatment with rescue medication|need and duration of mechanical ventilation|ventilator free days|evolution of pao2 / fio2 ratio|evolution of the sofa index|evolution of the apache ii score|duration of hospitalization|evolution of markers of immune response (leucocyte count, neutrophils)|feasibility of wj-msc administration|evolution of disease biomarker: polymerase chain reaction (rt-pcr)|evolution of disease biomarker: lactate dehydrogenase (ldh)|evolution of disease biomarker: d-dimer|evolution of disease biomarker: ferritin",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
A Preventive Treatment for Migrant Workers at High-risk of Covid-19,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04446104,NCT04446104,"incidence of acute respiratory illness in treatment arms (hydroxycholorquine, ivermectin, zinc and povidone iodine)|incidence of febrile respiratory illness in treatment arms (hydroxycholorquine, ivermectin, zinc and povidone iodine)|rate of hospitalization for covid-19 and non-covid-19 related indications in treatment arms (hydroxycholorquine, ivermectin, zinc and povidone iodine)|rate of oxygen supplementation and mechanical ventilation in treatment arms (hydroxycholorquine, ivermectin, zinc and povidone iodine)|duration of oxygen supplementation and mechanical ventilation in treatment arms (hydroxycholorquine, ivermectin, zinc and povidone iodine)|length of hospital stay in treatment arms (hydroxycholorquine, ivermectin, zinc and povidone iodine)|rate of laboratory-confirmed covid-19 in treatment arms (hydroxycholorquine, ivermectin, zinc and povidone iodine)|incidence of adverse events and serious adverse events in control arm (vitamin c)|incidence of drug discontinuation due to adverse events in control arm (vitamin c)",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Changing Of Egyptian Population Behaviour Towards COVID 19 Outbreak,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04401098,NCT04401098,awareness of egyptian population,observational,observational model: other|time perspective: prospective
Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study,Covid-VAS,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04333693,NCT04333693,30-days mortality|7-days mortality|30-days reoperation|postoperative icu admission|postoperative respiratory failure|postoperative acute respiratory distress syndrome (ards)|postoperative sepsis,observational,observational model: cohort|time perspective: prospective
Neuropathology in Adults Intensive Care Unit Patients With COVID 19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04453670,NCT04453670,"detection of severe acute respiratory syndrome related to coronavirus-2 in brain tissues|quantification of inflammation, necrosis and hemorrhage in different brain areas",observational,observational model: case-only|time perspective: prospective
The Effect of Melatonin and Vitamin C on COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04530539,NCT04530539,symptom severity|symptom progression,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: supportive care"
Microbial Infection and AMR in Hospitalized Patients With Covid 19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04479982,NCT04479982,microbial infections and antimicrobial resistance (amr) patterns associated with hospitalized patients with 2019 novel coronavirus disease (covid 19),observational,observational model: other|time perspective: prospective
Attitude of Egyptian Population Toward COVID 19 in Ramadan,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04401072,NCT04401072,attitude of the egyptian population during the covid 19 pandemic in ramadan,observational,observational model: other|time perspective: prospective
Resting Energy Expenditure of the COronaVirus (COVID19) Patient in Reanimation Context,RECOVERY,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04391686,NCT04391686,the resting energy expenditure (in kcal / 24h) measured by indirect calorimetry during the stay in intensive care.,observational,observational model: cohort|time perspective: other
Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France,CORSER,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04325646,NCT04325646,presence of specific anti-sars-cov-2 antibodies in the different study groups.|percentage of asymptomatic forms in individuals with anti-sars-cov-2 antibodies,observational,observational model: cohort|time perspective: prospective
Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04519411,NCT04519411,transpulmonary pressure,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Collection of Biological Samples With Clinical Characterization of Covid-19 Patients,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04363385,NCT04363385,phenotype/genotype correlation research modulating the severity of covid-19 disease|phenotype/transcriptomic correlation research modulating the severity of covid-19 disease|phenotype/biomarker correlation research modulating the severity of covid-19 disease|development of clinical-biological scores in the severity of covid-19 disease|development of predictive imaging scores in the severity of covid-19 disease|identification of pathophysiological pathways to susceptibility to covid-19 disease|identification of genetic markers for treatment response|identification of transcriptomic markers for treatment response|identification of proteomic for treatment response,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Hydrocortisone for COVID-19 and Severe Hypoxia,COVID STEROID,"active, not recruiting",No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04348305,NCT04348305,days alive without life support at day 28|all-cause mortality at day 28|days alive without life support at day 90|all-cause mortality at day 90|number of participants with one or more serious adverse reactions|days alive and out of hospital at day 90|all-cause mortality at 1 year after randomisation|health-related quality of life at 1 year,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Functional and Respiratory Rehabilitation and Nutritional Care of COVID-19 Patients (RECOVER-19),RECOVER-19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04466800,NCT04466800,impact of a multidisciplinary and personalized rehabilitation program on covid patients's quality of life|impact of a multidisciplinary and personalized rehabilitation program in terms of physical capacities|impact of a multidisciplinary and personalized rehabilitation program in terms of respiratory capacities|impact of a multidisciplinary and personalized rehabilitation program in terms of functional capacities|impact of a multidisciplinary and personalized rehabilitation program in terms of malnutrition prevalence rate using glim malnutrition diagnostic criteria|impact of a multidisciplinary and personalized rehabilitation program in terms of mortality|impact of a multidisciplinary and personalized rehabilitation program in terms of quality of life|impact of a multidisciplinary and personalized rehabilitation program in terms of anxiety and depression|impact of a multidisciplinary and personalized rehabilitation program in terms of healthcare consumption|impact of a multidisciplinary and personalized rehabilitation program in terms of medico-economic evaluation|patient's opinion concerning the rehabilitation program,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications,CSSC-004,recruiting,No Results Available,phase 2,Other|U.S. Fed|NIH,https://ClinicalTrials.gov/show/NCT04373460,NCT04373460,cumulative incidence of hospitalization or death prior to hospitalization|cumulative incidence of treatment-related serious adverse events|cumulative incidence of treatment-related grade 3 or higher adverse events|change in serum sars-cov-2 antibody titers|time to sars-cov-2 polymerase chain reaction (pcr) negativity,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),TACTIC-R,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04390464,NCT04390464,"time to incidence of the composite endpoint of: death, mechanical ventilation, ecmo, cardiovascular organ support, or renal failure|change in clinical status as assessed on 7-point ordinal scale compared to baseline|proportion of patients with adverse events of special interest in each treatment arm|time to sp02 >94% on room air|time to first negative sars-cov2 pcr|duration of oxygen therapy|duration of hospitalisation|all cause mortality at day 28|time to clinical improvement",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Early Treatment of Cytokine Storm Syndrome in Covid-19,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04362111,NCT04362111,percentage of patients discharged from the hospital alive and without the need for mechanical ventilation.|percentage of subjects with 25% change (decrease) in cytokine storm markers at 48 hours|percentage of subjects without increase in oxygen requirement and no increase in oxygen delivery/respiratory support measures after 48 hours.|average time in days to achieve sustained ‚â•93% oxygen saturation without oxygen/respiratory support|percentage of subjects with resolution of laboratory markers of cytokine storm syndrome|percentage of subjects who develop bacterial or fungal or non-covid-19 viral infection|percentage of subjects who develop neutralizing antibody to covid-19,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Stellate Ganglion Blockade in COVID-19 Positive Patients,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04445337,NCT04445337,evaluate the safety of a new modified stellate ganglia block (sgb) in ards|evaluate the efficacy of a new modified stellate ganglia block (sgb) in ards,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease,nan,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04352803,NCT04352803,safety - incidence of unexpected adverse events|efficacy - frequency of progression to mechanical ventilation|efficacy - changes in length of mechanical ventilation|efficacy - changes in length of weaning of mechanical ventilation|efficacy - changes in length of hospital stay|efficacy - changes in mortality rate,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Senior-COVID-Rea Multicentric Survey,SeniorCOVIDRea,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04422340,NCT04422340,evaluation of the impact of age on mortality at 30 days after admission to intensive care,observational,observational model: cohort|time perspective: other
Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04551755,NCT04551755,time to outcome measure of fever (<100.40f)and cough|negative rt-pcr test on day 5 of treatment,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,SAVIOR,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04368156,NCT04368156,need for mechanical ventilation|supplemental oxygen requirements|mortality|delay onset of ventilation|cytokine levels,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Spread and Course of COVID-19 Infections,CoV-ETH,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04377724,NCT04377724,"seroprevalence as well as the titer of serum antibodies (igm, igg and iga) targeting sars-cov-2 antigens|the property of peripheral blood mononuclear cells before and after an infection with sars-cov-2 as opposed to other pathogens|the property of igm and iga antibody titers against the nucleocapsid protein of sars-cov-2 in symptomatic as well as asymptomatic covid-19 infections over the course of time following an infection|the immune response to common-cold (corona)virus and influenza virus infections in patients with covid-19 infections",observational,observational model: cohort|time perspective: prospective
"Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants",nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04532294,NCT04532294,number of participants experiencing treatment emergent adverse events (teaes)|number of participants experiencing serious adverse events (saes)|maximum observed plasma concentration (cmax) of bgb-dxp593|area under the plasma concentration-time curve (auc) from time zero to the time of the last quantifiable concentration (auct) of bgb-dxp593|auc from time zero to infinity (aucinf) of bgb-dxp593|auc from time zero to day 29 (auc0-29) of bgb-dxp593|time to maximum observed plasma concentration (tmax) of bgb-dxp593|terminal half life (t1/2) of bgb-dxp593|clearance (cl) of bgb-dxp593|volume of distribution (vz) of bgb-dxp593|immunogenic response to bgb-dxp593 as assessed by the detection of antidrug antibodies (ada),interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: basic science"
Back to School COVID-19 Simulation Study,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04531254,NCT04531254,total number of hand-to-face contacts per participant|total number of touches to another person per participant|total number of hand hygiene actions per participant|total number of glo germ transfers to another person|total number of glo germ transfers to a surface|teacher concerns measured using study-specific post-simulation questionnaire|teacher concerns measured using semi-structured group interviews|student concerns measured using study-specific post-simulation questionnaire|student concerns measured using semi-structured group interviews,observational,observational model: cohort|time perspective: prospective
Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04490824,NCT04490824,inhalation of kelea excellerated water in covid-19 infected individuals,interventional,allocation: randomized|intervention model: sequential assignment|masking: single (participant)|primary purpose: treatment
Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04445376,NCT04445376,6 minute walk test|modified borg dyspnea scale|sf-36 questionnaire,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04276896,NCT04276896,clinical improvement based on the 7-point scale|lower murray lung injury score|28-day mortality|duration of mechanical ventilation|duration of hospitalization|proportion of patients with negative rt-pcr results|proportion of patients in each category of the 7-point scale|proportion of patients with normalized inflammation factors|frequency of vaccine/ctl events|frequency of serious vaccine/ctl events,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,OUTCOV,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04365582,NCT04365582,hospital admission|effect of treatment on death at d20|effect of treatment on death at d60|effect of treatment on death due to covid at d20|effect of treatment on death due to covid at d60|effect of treatment on need for icu stay at d20|effect of treatment on need for icu stay at d60|effect of treatment on duration of icu stay at d20|effect of treatment on duration of icu stay at d60|effect of treatment on need of mechanical ventilation at d20|effect of treatment on need of mechanical ventilation at d60|effect of treatment on duration of mechanical ventilation at d20|effect of treatment on duration of mechanical ventilation at d60|effect of treatment on time to hospitalization at d20|effect of treatment on time to hospitalization at d60|effect of treatment on duration of hospital stay et d20|effect of treatment on duration of hospital stay et d60|effect of treatment on duration of symptoms at d20|effect of treatment on duration of symptoms at d60|incidence of treatment-emergent adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia,nan,withdrawn,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04298814,NCT04298814,success rate of intubation|infection rate of anesthesiologist|extubation time,observational,observational model: case-only|time perspective: prospective
CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04487990,NCT04487990,clotted dialyzers|time-free of clotting|number of dialyzers used|pressure variation|urea sieving|downtime of dialysis,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19,CHEER,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04359537,NCT04359537,covid-19-free survival in experimental arms compared to placebo|incidence of confirmed sars-cov-2 detection|incidence of possible covid-19 symptoms|incidence of all-cause study medicine discontinuation|ordinal scale of covid-19 disease maximum severity if covid-19 diagnosed at study end|incidence of hospitalization for covid-19 or death|incidence of study medication-related adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
Daily Home Spirometry for Early Detection of Pulmonary Complications in Patients With COVID19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04438863,NCT04438863,hospitalization,observational,observational model: cohort|time perspective: prospective
Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation,HSC19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04335097,NCT04335097,stop home isolation|news score|clinic at hospitalization|symptoms developed|relative/peers evaluation of the patient|serious of symptoms at admittance hospital,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
Home-based Kidney Care in Native Americans of New Mexico (HBKC) - Enhancement,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04520191,NCT04520191,disruption in health care,observational,observational model: cohort|time perspective: prospective
Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients,GA&COVID19,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04381871,NCT04381871,mean change from baseline score of immune response to end of the trial ( time frame: up to 4 weeks )|mortality rate|determine viral load in each patient,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection,nan,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04389801,NCT04389801,mortality rate|duration of severe symptoms,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Reliability of Standardized Protocol of Ultrasound of the Lungs in Prediction of Severity of Covid-19 Infection,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04513210,NCT04513210,relation of changes in ultrasound and progression to respiratory failure|impact of ultrasonographic pneumonia signs on the day of admission on severity of covid-19 infection|sensitivity of ultrasonographic pneumonia signs in detecting respiratory failure|sensitivity of ultrasound in detecting interstitial changes in the lungs|impact change in severity of ultrasonographic pneumonia signs on severity of covid-19 infection,observational,observational model: case-control|time perspective: prospective
CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients,nan,recruiting,No Results Available,phase 2,Other|NIH,https://ClinicalTrials.gov/show/NCT04364737,NCT04364737,score on the who 11-point ordinal scale for clinical improvement at 14 days|score on the who 11-point ordinal scale for clinical improvement at 28 days,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins,SARS-CoV-2,recruiting,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04465981,NCT04465981,detection test of covid-19,observational,observational model: cohort|time perspective: other
Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients,PHYTCOVID-19,enrolling by invitation,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04501965,NCT04501965,virologic clearance of throat swabs or lower respiratory tract secretions|covid-19 symptoms development|adverse effects|worsened condition,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04377503,NCT04377503,patient clinical status 15 days after randomization|improving oxygenation|thorax ct improvement|icu length of stay|duration of mechanical ventilation|incidence of acute kidney (aki) with necessity of renal replacement therapy,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: treatment
Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS),nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04377334,NCT04377334,lung injury score|d-dimers|phenotype|pro-resolving lipid mediators|cytokines|chemokines|survival|extubation|lymphocyte subpopulations|sars-cov-2-specific antibody titers|complement molecules (c5-c9),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection,Nancy-CovH-AKI,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04354610,NCT04354610,"worsening of renal function by at least kdigo grade 1 during hospitalization for covid-19 infection|troponin greater than 99th percentile during hospitalization for covid-19 infection|aki kdigo grade 1 or higher in hospitalisation (approach with and without a priori)|elevation of troponin> 99th percentile in hospitalisation (approach with and without a priori)|aki kdigo grade 1 or higher|association with troponin elevation >99th|association with elevation of serum creatinine >30%|with the onset of chronic renal failure (edfg <60 ml / min / 1.73m2)|the occurrence of cardiovascular events (stroke, myocardial infarction, hospitalisation for heart failure, cardiovascular death) during hospitalisation and three months after discharge from hospital|the occurrence of death from any cause during hospitalisation and three months after discharge from hospital",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study,CONNAITRE,withdrawn,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04384614,NCT04384614,differences related to epidemiological demographic characteristics,observational,observational model: other|time perspective: cross-sectional
"A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease",INFLAMMACOV,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04424056,NCT04424056,ventilation free days at d28,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS,CHILL-pilot,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT03376854,NCT03376854,targeted temperature compliance|adverse event|28-day icu-free days|survival|non neurologic sequential organ failure (sofa) scores|oxygen saturation (spo2)|plateau airway pressure|mean airway pressure|airway driving pressure|oxygen saturation index|core temperature|urine output|comprehensive metabolic panel|complete blood count with differential count and platelet count|biomarkers|serum electrolytes|blood glucose|28-day ventilator-free days,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation,nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04397796,NCT04397796,incidence of aes|mortality|death|number of ventilator-free days|improvement of one category|7-point ordinal scale|news|news of ‚â§ 2|sequential organ failure assessment (sofa)|oxygen|hospitalization|incidence of saes,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alfa Administration in Patients With COVID19-induced ARDS (COVIDORNASE),COVIDORNASE,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04355364,NCT04355364,efficacy of intratracheal administration: occurrence of at least one grade improvement,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT),COVIDPROIMPACT,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04375644,NCT04375644,"stress state score, during the confinement period",observational,observational model: cohort|time perspective: prospective
Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy,Covid-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04333862,NCT04333862,fraction of healthcare workers infected with sars-cov-2|fraction of healthcare workers with covid-19|number of patients infected in the hospital|development of sars-cov2 specific antibody repertoire,observational,observational model: cohort|time perspective: prospective
COVID-19 Survival - The COVIVA Study,COVIVA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04366765,NCT04366765,short-term prognosis|admission to the intensive care unit (icu)|invasive ventilation (intubation)|need for extracorporal membrane oxygenation (ecmo)|hemodynamic support|length of icu stay|acute respiratory distress syndrome (ards)|myocardial injury|st-segment elevation myocardial infarction|in-hospital resource use|eq-5d questionnaire,observational,observational model: case-control|time perspective: prospective
Patient-reported Outcomes and Lung Function After Hospitalization for COVID-19,PROLUN,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04535154,NCT04535154,forced vital capacity|gas diffusion capacity of carbon monoxide|modified medical respiratory council dyspnea scale|parenchymal opacities of the lungs|forced expiratory capacity during 1st second of expiration|fev1/fvc|gas diffusion capacity adjusted for alveolar ventilation (kco),observational,observational model: cohort|time perspective: prospective
Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,COVISLEEP,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04371029,NCT04371029,proportion of patients with altered spleep|sleep architecture at hospital discharge|sleep monitoring during hospital stay after icu discharge|sleep quality|sleep architecture at month-3|cost of icu hospitalization,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19,(COVID19_BMT),"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04349540,NCT04349540,comparison of inflammatory/immunological biomarkers <72 hours after development of oxygen requirement|overall survival at 30 and 100 days after development of oxygen requirement|comparison of 30 and 100 day survival in sct patients who are vs are not ongoing immunosuppression|proportion of patients requiring mechanical ventilation|incidence of secondary hlh (as defined by hs score),observational,observational model: case-only|time perspective: prospective
Cholecalciferol to Improve the Outcomes of COVID-19 Patients,CARED,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04411446,NCT04411446,"respiratory sofa.|need of a high dose of oxygen or mechanical ventilation.|change in oxygen saturation.|oxygen desaturation.|change in quick sofa score.|myocardial infarction.|stroke.|acute kidney injury.|pulmonary thromboembolism.|combined endpoint (stroke, myocardial infarction, acute kidney injury and pulmonary thromboembolism.|admission to icu.|invasive mechanical ventilation.|hospital length of stay.|icu length of stay.|death",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
MET-Covid Trial - METformin for Prevention and Outpatient Treatment of COVID-19,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04510194,NCT04510194,rate of death due to covid-19|rate of hospitalization due to covid-19|rate of emergency department utilization|rate of urgent care utilization|incidence of possible covid-19 symptoms|incidence of all-cause study medicine discontinuation|disease severity rating|dyspnea assessment (promis survey)|global health survey (promis survey)|seroconversion of sars-cov2 antibodies or sars-cov2 pcr positivity (prevention cohort only),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
A Phase 2 Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE),SAVE,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04395456,NCT04395456,"the proportion of patients who are alive, without evidence of ards (i.e. pao2/fio2 >300 mm hg), who do not require any oxygen support (in room air).|the proportion of patients assigned to each category, of a six-category ordinal scale.|proportion of patients surviving|proportion of respiratory failure-free survival|cumulative incidence of resolution of ards (defined as pao2/fio2 ‚â•200 in room air)|cumulative incidence of freedom from oxygen requirement|proportion of patients requiring invasive mechanical ventilation due to worsening of ards|proportion of patients requiring non-invasive mechanical ventilation (niv) due to worsening of ards|proportion of patients developing thrombotic microangiopathies|changes in pao2 and pao2/fio2|changes in quick sequential organ failure assessment score (qsofa: respiratory rate, systolic blood pressure, glasgow coma scale (gcs)|changes in maximal and minimal cardiovascular parameters: respiratory rate|changes in maximal and minimal cardiovascular parameters: heart rate|changes in levels of biomarkers of inflammation (cbc, crp, ferritin, procalcitonin, d-dimers, ldh)|length of stay in icu|cumulative incidence of discharge from hospital|number of adverse events|changes in levels of anti-drug antibodies|changes in levels of biomarkers of complement activity: c3, c3a, c5a, sc5b-9|changes in levels of biomarkers of cytokine release syndrome: il-1, il-6, il-12|changes in levels of club cell protein cc16 (biomarker of lung damage )|changes in levels of amy-101 plasma level",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
CORE Study COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04531202,NCT04531202,clinical characterization of coronavirus disease-2019 (covid-19),observational,observational model: cohort|time perspective: prospective
Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04547283,NCT04547283,average s/f ratio|time spent with s/f ratio < 315|highest oxygen support|number of patients requiring icu admission during study period|number of patients requiring icu admission during hospitalization|number of patients experiencing who die prior to discharge|number of patients requiring intubation|hospital length of stay,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Prediction Models for Diagnosis and Prognosis of Severe COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04525287,NCT04525287,chest ct and clinical features,observational,observational model: case-crossover|time perspective: cross-sectional
The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,BOIFIM,completed,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04479202,NCT04479202,changes in diarrhea frequency and bristol stool scale|il-6 (ng/ml)|il-10ôºàng/mlôºâ|il-1œ≤ (ng/ml)|tnf-œ± (pg/ml)|leukocyte count (10^9/l)|c reactive protein (mg/l)|procalcitonin (ng/ml),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: treatment"
Convalescent Plasma Therapy in Severe COVID-19 Infection,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04403477,NCT04403477,proportion of in-hospital mortality|time to death|fever|respiratory distress|saturation of oxygen|blood pressure|oxygen requirement|c-reactive protein|ferritin|sgpt|sgot|icu stay|ventilator support|hospital stay|proportion of transfusion reaction,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Barrier Measures to Limit Covid-19.Nosocomial Transmission: a Cross-sectional Evaluation,EMBELLIE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04376944,NCT04376944,proportion of caregivers and agents with a positive serodiagnosis|proportion of caregivers and agents with a positive rt-pcr,observational,observational model: case-control|time perspective: cross-sectional
Multi-modality Imaging & Immunophenotyping of COVID-19 Related Myocardial Injury,MIIC-MI,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04412369,NCT04412369,"number of participants with a diagnosis of covid-19 related myocarditis, type 1 or 2 myocardial infarction and/or other mechanism of cardiac injury confirmed by multi-modality imaging.|comparison of a panel of inflammatory cytokines and immune cell profiles in patients categorized by cardiac diagnosis after imaging|comparison of a panel of blood coagulation markers in patients categorized by cardiac diagnosis after imaging",observational,observational model: case-only|time perspective: prospective
Covid-19 Pandemic Triage Score,STC-19,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04371471,NCT04371471,stc-19 score,observational,observational model: cohort|time perspective: retrospective
COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes,COVID-FIS,not yet recruiting,No Results Available,phase 2,Other|NIH,https://ClinicalTrials.gov/show/NCT04537299,NCT04537299,change in covid-19 severity,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04525378,NCT04525378,intrahospital mortality|length of stay in the icu and hospital|days without mechanical ventilation in 28 days|pao2 / fio2 ratio|incidence of secondary infections|incidence of adverse events|quantification of inflammatory response markers,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Pulmozyme to Improve COVID-19 ARDS Outcomes,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04402944,NCT04402944,ventilator-free days at 28 days|change in airway resistance|change in lung compliance|oxygenation (pao2/fio2 ratio)|length of stay (icu and hospital)|rate of barotrauma|mortality.,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Comparison Between Positive and Negative COVID-19 Pneumonia,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04507893,NCT04507893,"evaluation of the clinical characteristics of patients with clinical presentation suggestive of covid-19 infection, classified according to the results of pcr assay as ""covid-19 patients"" and ""covid-19 negative controls"".|evaluation of the laboratory characteristics of patients with clinical presentation suggestive of covid-19 infection, classified according to the results of pcr assay as ""covid-19 patients"" and ""covid-19 negative controls"".|evaluation of the imaging characteristics of patients with clinical presentation suggestive of covid-19 infection, classified according to the results of pcr assay as ""covid-19 patients"" and ""covid-19 negative controls"".|evaluation of mortality of patients with clinical presentation suggestive of covid-19 infection, classified according to the results of pcr assay as ""covid-19 patients"" and ""covid-19 negative controls"".|evaluation of clinical severity of patients with clinical presentation suggestive of covid-19 infection, classified according to the results of pcr assay as ""covid-19 patients"" and ""covid-19 negative controls"".|evaluation of hospital stay length of patients with clinical presentation suggestive of covid-19 infection, classified according to the results of pcr assay as ""covid-19 patients"" and ""covid-19 negative controls"".",observational,observational model: case-only|time perspective: retrospective
Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected With COVID-19,ZnD3-CoVici,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04351490,NCT04351490,survival rate in asymptomatic subjects at inclusion|survival rate in symptomatic subjects at inclusion|survival rate in overall subjects|cumulative incidence of covid-19 infection in asymptomatic subjects at inclusion,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
SQuISH-COVID: A Pilot Study,nan,"active, not recruiting",No Results Available,nan,Industry|U.S. Fed,https://ClinicalTrials.gov/show/NCT04372472,NCT04372472,to demonstrate the performance of the septiscan system as a diagnostic marker of life-threatening organ dysfunction caused by a dysregulated host immune response to infection.,observational,observational model: cohort|time perspective: prospective
Pyridostigmine in Severe SARS-CoV-2 Infection,PISCO,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04343963,NCT04343963,critical condition or death|il-6,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Parental Attitude Toward Children Dental Treatment During COVID-19 Pandemic,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04512300,NCT04512300,assessment of parental attitude toward children dental visit during coronavirus crisis,observational,observational model: other|time perspective: cross-sectional
Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?,ImmCoV,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04469634,NCT04469634,antibody levels over time|antibody neutralizing capacity|memory b-cell function|antibody-dependent enhancement|re-infection with sars-cov2,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: basic science
The Prone Position in Covid-19 Affected Patients,PRON-COVID,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04365959,NCT04365959,number of patients in whom the prone position caused an increase in oxygenation|the feasibility of prone position,observational,observational model: case-only|time perspective: prospective
Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04411576,NCT04411576,sars-cov-2 infection,observational,observational model: cohort|time perspective: prospective
COVID-19 Registry Rhineland-Palatinate (Germany),nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04335188,NCT04335188,chest x-ray|chest ct|supportive care - icu|supportive care - oxygen therapy|supportive care - ventilation|medication|therapeutic strategies|lab parameters|intra-hospital complications|vital status at discharge,observational,observational model: other|time perspective: prospective
A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19,BTL-TML-COVID,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04522830,NCT04522830,mean duration and severity of disease|number of participants with treatment related adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Predictive Models for Intensive Care Admission and Death of COVID-19,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04401228,NCT04401228,admission to icu|death,observational,observational model: cohort|time perspective: retrospective
Colchicine vs Current Standard of Care in Hospitalized Patients With COVID-19 and Cardiac Injury,COLHEART-19,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04510038,NCT04510038,all cause mortality|mechanical ventilation|mechanical circulatory support|time to deterioration|adverse events|troponin|delta|bnp|changes in c reactive protein|los|re-hospitalization|changes in d dimer,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Can the Electronic Nose Smell COVID-19?,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04475562,NCT04475562,covid 19 positive vs negative,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Frequency of COVID-19 Antibodies in Patients With Hereditary Hematological Diseases,ThalaCoV,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04526405,NCT04526405,positive subjects,observational,observational model: cohort|time perspective: prospective
"Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19",nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04550325,NCT04550325,"adverse events, serious adverse events, and deaths|auc0-7 of anti sars cov-2 antibodies|neutralization activity",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"Maternal And Neonatal Outcome of Pregnant Patients With COVID-19 in Istanbul, Turkey: A Single-Center, Retrospective, Descriptive Study",nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04337320,NCT04337320,evaluation of apgar status of newborns from covid 19 positive mothers,observational,observational model: cohort|time perspective: retrospective
One-Year Quality of Life and Functional Prognosis of COVID-19 Patients in Post-ICU Setting,COVENTRY,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04373811,NCT04373811,mean in quality of life score at one year on the short form health survey (sf-36)|mean in quality of life score at six months on the short form health survey (sf-36)|mean in autonomy score on the activities daily living (adl) scale|survival rate|change from baseline in lung ultrasound aeration score|change from baseline in diaphragm ultrasound thickness and excursion|mean change from baseline in ultrasound muscle thickness|mean change from baseline in ultrasound muscle cross-sectionnal area|mean change from baseline in ultrasound muscle echogeneicity|mean change from baseline in ultrasound muscle pennation|mean change from baseline in medical research council (mrc) sum score|prevalence of adverse outcomes during early mobilization,observational,observational model: cohort|time perspective: prospective
Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020,Cova√©,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04514874,NCT04514874,prevalence of covid-19 infection among french military professional aircrew|predictive factors of covid-19 infection|techniques used for covid-19 screening|reasons for covid-19 screening|experienced symptoms of covid-19|medical care of covid-19|social consequences of the covid-19 pandemic|factors associated with pejorative consequences of the covid-19 pandemic,observational,observational model: cohort|time perspective: prospective
Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma Prepared by VIPS Mini-Pool IVIG Medical Devices in Prevention of SARS-CoV-2 Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04383548,NCT04383548,efficacy of covid19 hyper immunoglobulins for patients|efficacy of covid19 hyper immunoglobulins for high risk groups|safety of anti-sars-cov-2 hyper immunoglobulins assessed by percentage of adverse events,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19,nan,no longer available,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04358588,NCT04358588,nan,expanded access:intermediate-size population,nan
Is Thymus Size of Infants Who Born to COVID-19 Positive Mothers Associated With Neonatal Morbidities?,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04470739,NCT04470739,cardiothymic index|immune profile,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: diagnostic
Impact of an Intensified Thromboprofylaxis Protocol in COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04394000,NCT04394000,2 week mortality|incidence of venous thromboembolism|1 week mortality|3 week mortality|1 month mortality|incidence of kidney failure|incidence of continuous renal replacement therapy (crrt)|lowest pao2/fio2 (p/f) ratio|highest sequential organ failure assessment (sofa) score|length of stay|highest bilirubin|highest ( ast|highest aspartaat-amino-transferase (alt),observational,observational model: cohort|time perspective: other
Efficacy of Ivermectin in COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04392713,NCT04392713,negative pcr|need for mechanical ventilation,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite,nan,withdrawn,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04401527,NCT04401527,survival with unassisted breathing|survival without mechanical ventilation|survival without intensive care|survival without hospitalization|survival without ecmo|survival,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
COVID-19 Serology Screening and Strict Protocol in the Endoscopy Unit,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04374123,NCT04374123,rate of covid-19 nosocomial infection among the endoscopy staff at the end of the 30-days study.|numbers of patients evaluated and treated during the covid-19 outbreak in the endoscopy unit at the end of the 30-days study.|technical success rate of endoscopic procedures during the 30-days study period.|igg and igm against covid-19 in the endoscopy staff measured at the end of the study.|adverse events rate of endoscopic procedures during the 30-days,observational,observational model: cohort|time perspective: prospective
The Impact of COVID-19 Pandemic to Trauma Patients in Emergency Department: A Multicenter Experience of Istanbul,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04479124,NCT04479124,trauma admissions,observational,observational model: cohort|time perspective: retrospective
"Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects",nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04483375,NCT04483375,dose-limiting toxicity(dlt)|maximal tolerable dose(mtd)|auc0-t|auc0-‚àû|t1/2|tmax|anti-drug antibody(ada)|adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
"Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial",nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04395105,NCT04395105,ventilator-free days at 28 days|28-days mortality|frequency of nosocomila infections|viral shedding|serum c-reactive protein variation|sofa variation|use of prone position|delirium|muscle weakness|90-day mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Augmented CBGT for Perinatal Anxiety During a Global Pandemic (COVID-19),nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04495803,NCT04495803,state-trait inventory of cognitive and somatic anxiety (sticsa)|intolerance of uncertainty scale (ius)|penn state worry questionnaire (pswq)|edinburgh postnatal depression scale (epds)|covid-19 stress scales (css)|pregnancy-related anxiety questionnaire-revised (praq-r2)|postpartum specific anxiety scale (psas)|overall anxiety severity and impairment scale (oasis)|parenting sense of competence scale (psoc)|abbreviated dyadic adjustment scale (adas)|social provisions scale (sps)|maternal antenatal attachment scale (maas)|postpartum bonding questionnaire (pbq)|client satisfaction questionnaire (csq)|perceived stress scale (pss),interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia,PneumoCoV-Ambu,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04542044,NCT04542044,secondary hospitalization(s) or death covid-19 related|severity of covid-19 disease|patient satisfaction with management strategies|saved costs,observational,observational model: cohort|time perspective: prospective
Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia,ANOSIRM,withdrawn,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04408391,NCT04408391,brain regional homogeneity between covid-19 patients with and without anosmia|topography of supra- or sub-tentorial lesions between covid-19 patients with and without anosmia|fractional anisotropy between covid-19 patients with and without anosmia|mean diffusivity between covid-19 patients with and without anosmia|radial diffusivity between covid-19 patients with and without anosmia|self-assessed olfactory and gustatory test|ability to detect odor|ability to taste a pinch of sugar|presence of thrombotic and hemorrhagic lesions|presence of lesions with hyperintensity|projection network analysis of all patients|blinded independent component analysis of all patients|default mode network analysis of all patients|executive control network analysis of all patients,observational,observational model: case-only|time perspective: prospective
COVID-19 Among Egyptian Health Care Providers,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04357431,NCT04357431,the percentage of knowledge regarding covid-19 information,observational,observational model: other|time perspective: cross-sectional
Low Dose Radiotherapy in COVID-19 Pneumonia,nan,"active, not recruiting",No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04390412,NCT04390412,change from baseline blood oxygenation|number of hospital stay days|number of icu stay days|number of intubation events|wbc|platelets|crp|il-6,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,FMTVDM,completed,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04349410,NCT04349410,improvement in fmtvdm measurement with nuclear imaging.|ventilator status|survival status,interventional,allocation: randomized|intervention model: factorial assignment|masking: single (investigator)|primary purpose: treatment
Construction of a Composite Clinical-echo Score Predictive of a Risk of Short-term Aggravation of Respiratory Impairment in Patients Suspected of Covid-19,VIRUS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04370249,NCT04370249,"construction of a composite clinical-echo score (viruscore) predictive of risk of worsening respiratory impairment in covid-19 adult patients admitted to the emergency department|evaluate the prognostic performance of the viruscore on the risk of pulmonary aggravation|evaluate the prognostic performance of the viruscore on the risk of severe pulmonary aggravation defined by resuscitation admission and/or death at d14 (sensitivity, specificity, positive predictive value, negative predictive value).|construction of a decisional algorithm for triage and management of covid-19 patients.|search for ""ultrasound signature"" (lung fields and/or severity of involvement) associated with mild (return home) vs. moderate (oxygen therapy) vs. severe (resuscitation/death) clinical forms.|evaluate the analytical concordance between the pulmonary ultrasound (luscore) and the gold-standard ct-scan (ct score)|construction of a score predictive of aggravation in the sub-population of patients returned home",observational,observational model: case-only|time perspective: retrospective
Clinical Scores for Outcome Prediction in Patients With Severe COVID-19 Pneumonia Requiring ECMO,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04405973,NCT04405973,overall survival|duration of ecmo treatment|duration of ventilation treatment|duration of initiation of ecmo treatment to icu discharge,observational,observational model: cohort|time perspective: retrospective
Human Ab Response & immunoMONItoring of COVID-19 Patients,HARMONICOV,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04373200,NCT04373200,"number of increased immune population|number of decreased immune population|number of statically different phenotypes compared to control patients|gain or loss of functional phenotypic markers between d1 and d14|gain or loss of functional phenotypic markers between between acute and mild infections|gain or loss of functional phenotypic markers between d1 and month 4|evaluation of v, d, j gene usage alterations in the immunoglobulin and t cell receptor (tcr) repertoires during ards linked to covid-19|identification of the ig classes and of v, d, j sequences of anti-cov-2 antibodies|characterization of a new set of human antibodies from patients who have recovered of covid-19",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
Ivermectin in Treatment of COVID-19,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04445311,NCT04445311,time to be symptoms free|hospitalization|mechanical ventilation|length of stay|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Phase I/II Trial of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects,nan,not yet recruiting,No Results Available,phase 1|phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04510402,NCT04510402,"number of participants with treatment-related adverse events as assessed by self reporting, metabolic and endocrine metrics|number of participants with dose dependent side effects determined by self reporting diaries, thyroid and metabolic testing",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Prognosis in Pregnant With COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04409249,NCT04409249,the factors affecting prognosis in pregnant women diagnosed with covid-19,observational,observational model: other|time perspective: retrospective
A Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Disease (LEAF-4L7520/4L6715),LEAF-4L6715,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04378920,NCT04378920,proportion of patients showing an increase of at least 25% of pao2/fio2 ratio|proportion of patients with a pao2/fio2 ratio above 200 mm hg|all cause mortality,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Can the Electronic Nose Smell COVID-19 Antibodies?,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04475575,NCT04475575,covid-19 antibodies vs covid-19 negative,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome,SOS-COVID19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04341415,NCT04341415,comparison of the percentage of clinically improved inpatients between d0 and d14,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Niclosamide In Moderate COVID-19,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04436458,NCT04436458,"the primary endpoint is the rate of faecal sars-cov-2 virus clearance (rectal swab or stool sample) assessed by rt-pcr in the niclosamide group, compared to the placebo group",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy,COVID-Preg,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04410562,NCT04410562,number of pcr confirmed cases among pregnant women|incidence of covid-19 disease during pregnancy|incidence of covid-19-related admissions|incidence of all-cause admissions|incidence of all-cause outpatient attendances|mean duration of symptoms-signs of covid-19|frequency and severity of adverse events|incidence of preeclampsia|incidence of gestational diabetes|incidence of sars-cov-2 infections during pregnancy|prevalence of intrauterine growth restriction|maternal mortality rate|proportion of neonates with sars-cov-2- intrauterine infection by pcr-confirmed sars-cov-2-infection in nasopharyngeal aspirate.|proportion of neonates with clinical signs/symptoms of covid-19|prevalence of low birth weight (<10th centile according to local standards)|prevalence of preterm birth (<37 weeks of gestational age)|prevalence of embryo and foetal losses (miscarriages and stillbirths)|frequency of congenital malformations|proportion of adverse perinatal outcome|neonatal morbidity|neonatal mortality rate,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
The MEseNchymal coviD-19 Trial: a Pilot Study to Investigate Early Efficacy of MSCs in Adults With COVID-19,MEND,recruiting,No Results Available,phase 1|phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04537351,NCT04537351,trend in trajectory of pao2/fio2 ratio (p/f ratio) between groups|incidence and severity of treatment-emergent adverse events|change in c-reactive protein (crp) levels|proportional differences between groups on the clinical improvement scale|changes in p/f ratio|changes in respiratory rate|changes in oxygenation index|changes in respiratory compliance (the change in lung volume per unit change in transmural pressure gradient)|changes in positive end-expiratory pressure|ventilator-free days|proportional differences between groups on the sf-36|proportional differences between groups on the mini mental state examination,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Convalescent Plasma for Patients With COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04385199,NCT04385199,improvement in respiratory disease|icu length of stay|length of stay|ventilator days|tolerability of convalescent plasma|radiographic improvement,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Identification of Predictors for the Evolution of COVID-19 Related Pneumonia by Transcriptomic and Seroproteomic,COVID_OMICS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04441502,NCT04441502,circulating markers for covid-19 signature|covid-19 signature and adverse cardiovascular events|covid-19 related coagulation pattern,observational,observational model: cohort|time perspective: prospective
COVID-19 in Patients With HIV,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04333953,NCT04333953,mortality|frequency of patients requiring hospital admissions|frequency of patients requiring icu admissions|frequency of respiratory support use|frequency of kidney injury|frequency of liver injury,observational,observational model: case-only|time perspective: prospective
Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,COVID-HEP,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04345848,NCT04345848,"composite outcome of arterial or venous thrombosis, disseminated intravascular coagulation and all-cause mortality|arterial thrombosis|venous thromboembolism|disseminated intravascular coagulation|all-cause mortality|sepsis-induced coagulopathy|acute respiratory distress syndrome|durations of hospital stay, icu stay, ventilation|sequential organ failure assessment score|clinical deterioration",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel,SeroCovEms,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04516928,NCT04516928,proportion of anti-sars-cov2 seropositive participants|proportion of asymptomatic participants (among anti-sars-cov2 seropositive participants)|correlation coefficient between medical risk factors and a positive serology|correlation coefficient between epidemiological risk factors and a positive serology|correlation coefficient between social risk factors and a positive serology,observational,observational model: cohort|time perspective: prospective
Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04383587,NCT04383587,prevalence of covid19 antibody positivity|ability to predict immune status/antibody positivity,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
COVID-19 Child Health Investigation of Latent Disease in Hamburg,C19CHILD,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04534608,NCT04534608,acute infection by sars-cov-2|seroconversion for sars-cov-2|immune phenotyping|hla typing|matabolomics,observational,observational model: family-based|time perspective: prospective
Possible Predictors of Mortality Based on COVID-19 for Patients Under 50 Years Old: A Multi-Center Experience of Istanbul,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04479137,NCT04479137,mortality based on covid-19,observational,observational model: cohort|time perspective: retrospective
Emotional Burden of Healthcare Professionals and Covid Infection 19,Emocovid,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04350099,NCT04350099,anxiety,observational,observational model: cohort|time perspective: prospective
An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications,SISCO,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04322188,NCT04322188,mortality in siltuximab treated patients|the need of invasive ventilation in siltuximab patients reduction of the need of time of ventilatory support|clinical course of patients treated with siltuximab percentage of patients that undergo to tracheostomy|safety improvement of the lung function assessed by radiologic findings|the effect on inflammatory parameters|correlation of outcomes with il-6 levels,observational,observational model: cohort|time perspective: retrospective
PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial,PREPARE-IT,not yet recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04460651,NCT04460651,"percentage of sars-cov-2 positive subjects|highest mean who descriptive score of covid-19 in the active treatment group compared to the placebo group.|highest mean who score up to day 60 for the active treatment group as compared to placebo among subjects with a positive test received at any moment during the study after the first visit|total cholesterol, ldl, hdl, triglycerides (mg/dl) at baseline and at day 60|ultrasensitive c-reactive protein (mg/dl) at baseline and at day 60|difference in hospital length of stay between groups|difference in duration of mechanical ventilation in both groups|rate of hospital admissions due to sars (severe acute respiratory syndrome) in patients who were negative for sars cov-2 upon admission|mean highest who descriptive score in active treatment versus placebo groups up to day 60 among hospitalized patients (who grades 3 or more) without serum evidence / pcr detecting sars-cov-2 infection|rate of total events, non-fatal myocardial infarction or non-fatal stroke or death (initial and subsequent), up to day 60",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Lung Irradiation for COVID-19 Pneumonia,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04393948,NCT04393948,phase 1: feasibility and safety of treating hospitalized patients with sars-cov-2 pneumonia with single or bilateral whole lung irradiation|phase 2: proportion with clinical improvement on a 7-point ordinal scale on day 4 after randomization|improvement or worsening on the 7-point ordinal scale over additional intervals|rate and duration of use of supplemental oxygen|rate and duration of fever > 38¬∫c|rate and duration of invasive mechanical ventilation|duration of hospitalization|proportion of participants with overall survival up to 30 days after randomization|improvement in radiographic findings related to infection/inflammation; comparisons include on study versus baseline scans and irradiated vs. unirradiated lung in subjects randomized to receive single lung irradiation|treatment-emergent adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19,nan,"active, not recruiting",No Results Available,early phase 1,Industry,https://ClinicalTrials.gov/show/NCT04456361,NCT04456361,oxygen saturation|oxygen pressure in inspiration|ground-glass opacity|pneumonia infiltration|lactate dehydrogenase|c-reactive protein|d-dimer|ferritine,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Post Covid-19 Cardiopulmonary and Immunological Changes,covid-19,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04388436,NCT04388436,measurement of pulmonary function changes either obstructive or restrictive also lung diffusion and if there is remaining interstitial fibrosis|measurement for cardiac function and ejection fraction changes and if there is changes in pulmonary artery pressure|assessment of igm and igg level and if there is immunological changes,observational,observational model: cohort|time perspective: prospective
Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis,COVRTE-19,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04414293,NCT04414293,blood oxygen saturation level|torax x-ray|hospitalization|days free of assisted mechanical respiration|mortality,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
PSYCHIATRIC Disorders and Covid-19,PSYCHIC,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04358042,NCT04358042,impact of the covid-19 pandemic on psychiatric symptomatology,observational,observational model: cohort|time perspective: prospective
"Safety of TY027, a Treatment for COVID-19, in Humans",nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04429529,NCT04429529,number of participants with treatment-related adverse events as assessed by ctcae v4.0|maximum concentration (cmax) - pharmacokinetic assessment|time to maximum concentration (tmax) - pharmacokinetic assessment|area under the curve extrapolated to infinity (auc0-‚àû) - pharmacokinetic assessment|auc calculated from time of administration to the last measurable concentration (auc0-last) - pharmacokinetic assessment|half-life (t1/2) - pharmacokinetic assessment|volume of distribution (vd) - pharmacokinetic assessment|clearance [cl] - pharmacokinetic assessment,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Prophylactic Ivermectin in COVID-19 Contacts,nan,completed,Has Results,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04422561,NCT04422561,"development of symptoms ( fever ,cough, sore throat, myalgia,diarrhea, shortness of breath)|development of covid",interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: prevention
COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04354155,NCT04354155,safety of in-hospital thromboprophylaxis|median twice-daily enoxaparin dose,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Ivermectin and Doxycycine in COVID-19 Treatment,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04403555,NCT04403555,the number of patients with improvement or mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19,nan,available,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04445207,NCT04445207,nan,expanded access:treatment ind/protocol,nan
A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19,COViNOX,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04421508,NCT04421508,"the proportion of subjects who died or had respiratory failure|clinical status using national institute of allergy and infectious diseases (niaid) 8-point ordinal scale|proportion of subject to recover, defined as return to room air or baseline o2, or discharged alive|proportion of subjects discharged alive from hospital|duration of hospitalization|mortality - all cause and cardiopulmonary|proportion of subjects with a negative conversion of reverse transcription polymerase chain reaction (rt-pcr) from a nasopharyngeal swab",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
New Antiviral Drugs for Treatment of COVID-19,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04392427,NCT04392427,negative test result for covid-19,interventional,allocation: randomized|intervention model: sequential assignment|masking: single (outcomes assessor)|primary purpose: treatment
Efficacy of Faviprevir in COVID-19 Treatment,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04351295,NCT04351295,number of patients with viral cure,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Saved From COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04349371,NCT04349371,number of symptomatic illness in at risk healthcare workers|number of healthcare workers with symptomatic covid infections|number of severe illness in at risk healthcare workers|number of sero-conversions in at risk healthcare workers|percentage of patients with adverse events grade 3 or higher|percentage of patients with gi intolerance,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales,COSiN,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04383652,NCT04383652,coronavirus sequencing|coronavirus culturing,observational,observational model: cohort|time perspective: prospective
Asymptomatic COVID-19 Trial,ACT,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04374552,NCT04374552,the primary outcome is the rate of decline in viral load over the 10 days after randomization,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
COVID-19 Staff Testing of Antibody Responses Study (Co-Stars),Co-Stars,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04380896,NCT04380896,change in serial monthly log-transformed antibody titre levels as measured|proportion of completely asymptomatic healthcare workers with evidence of sars-cov-2 antibodies|the attack rate of sars-cov-2 in healthcare workers who have antibodies compared to those who do not|the immune correlates of protection against future exposure to sars-cov-2,observational,observational model: cohort|time perspective: prospective
Use of Ascorbic Acid in Patients With COVID 19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04323514,NCT04323514,in-hospital mortality|pcr levels|lactate clearance|hospital stay|symptoms|positive swab|tomography imaging,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04356508,NCT04356508,viral clearance kinetics|treatment-related adverse events of nivolumab (intervention arm only)|lymphocyte kinetics|cytokine kinetics|length of inpatient stay due to covid-19,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Use of Remote Monitoring for COVID-19 Patient,RPM,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04425720,NCT04425720,monitored versus non-monitored in-patient admission|emergency department visits|length of stay|patient satisfaction|the incidence of mechanical ventilation and ecmo|serious adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19,Covid19DPP4i,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04542213,NCT04542213,glucose levels|number of patients who achieve metabolic control|number of patients who die or need mechanical ventilation|c reactive protein levels,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (care provider, investigator, outcomes assessor)|primary purpose: treatment"
Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04387240,NCT04387240,length of stay in hospital|number of icu admission|resolution of symptoms,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children,CiaoCorona,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04448717,NCT04448717,"seroprevalence of sars-cov-2 igg, igm and/or iga antibodies|presence of self-reported symptoms|proportion of seropositive children reporting covid-19 related symptoms from january 2020|incidence of symptoms in initially seropositive participants|proportion of participants, seronegative at inclusion, with symptoms in the follow-up|presence of risk factors for infection at inclusion (assessment via custom questionnaire)|presence of risk factors for infection during follow-up (assessment via custom questionnaire)|self-reported lifestyle changes of participants at inclusion|self-reported lifestyle changes of participants during follow-up|self-reported mental well-being (kindl questionnaire)|self-reported mental well-being (hbsc questionnaire)|self-reported quality of life (kindl questionnaire)|prevalence of seropositive sars-cov-2 clusters in schools at inclusion|incidence of seropositive sars-cov-2 clusters in schools during the follow-up|change in seropositive participants within school or class, depending on the initial proportion of seropositive participants|effect of risk factors and preventive measures on sars-cov-2 infection incidence within schools",observational,observational model: cohort|time perspective: prospective
Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04401293,NCT04401293,"composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at day 30 ¬± 2 days.|major bleeding|composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at hospital day 10 + 4|sepsis-induced coagulopathy (sic) score|progression to acute respiratory distress syndrome (ards)|need for intubation|re-hospitalization",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04366206,NCT04366206,composite of death and mechanical ventilation|need for mechanical ventilation|death|acute kidney injury|acute respiratory distress syndrome|cardiac arrhythmia and conduction disorder|60-days mortality|60-days mechanical ventilation,observational,observational model: cohort|time perspective: prospective
"Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia",THINC,withdrawn,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04528927,NCT04528927,evaluate the rate of patients cured at the end of the study.|evaluate the rate of patients are pauci-symptomatic at the end of the study.|evaluate the rate of patients with worsening clinical signs,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,nan,"active, not recruiting",No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04374149,NCT04374149,overall response rate,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
"Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms",SILVERBULLET,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04407507,NCT04407507,participants with a disease control status defined as no disease progression to severe.,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (care provider)|primary purpose: treatment
Lung Ultrasound to Diagnose COVID-19,COVILUS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04368338,NCT04368338,lung ultrasound/biological correlation research modulating the severity of covid-19 disease,observational,observational model: case-only|time perspective: prospective
Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury,iNSPIRE,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04375397,NCT04375397,percentage of participants alive and without respiratory failure|change in the world health organization (who)-8 point ordinal scale from baseline|median reduction in days spent on supplemental oxygen|all-cause mortality|percentage of participants experiencing respiratory failure or death|mechanical ventilation-free survival|days on mechanical ventilation|duration of hospitalization|time to discharge|partial pressure of oxygen in arterial blood (pao2) to fraction of inspired oxygen (fio2) ratio|oxygenation index|number of participants with adverse events|number of participants with abnormal laboratory findings,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH,COVIDHLH,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04347460,NCT04347460,presence of shlh as determined by expert chart review by two independent reviewers|determine the incidence of patients fulfilling hlh criteria in covid 19 viral infection|determine the incidence of patients fulfilling modified 2004 hlh diagnostic criteria (ferritin > 10000 œºg/l) in covid 19 viral infection|characterization and incidence of the hyper-inflammatory state in covid-19|all cause mortality assesed on day 15|all cause mortality assesed on day 29|immunophenotpye,observational,observational model: cohort|time perspective: prospective
Cardiac Imaging in SARS-CoV-2 (COVID-19),CISCO-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04403607,NCT04403607,the primary cardiac outcome is the proportion of patients with a diagnosis of myocardial inflammation (myocarditis).|the primary cardio-pulmonary outcome is the proportion of patients with thrombosis|myocardial injury|myocardial stress|systemic inflammation|vascular injury|endothelial activation and haemostasis|fibrin lysis|coagulation|platelet count|renal function|quantify myocardial perfusion as a measure of coronary microvascular function|association of the primary outcome according to a prior history of cardiovascular disease or no history of prior cardiovascular disease.|patient reported outcome measures (proms) - health status|proms - functional capacity,observational,observational model: cohort|time perspective: prospective
Tocilizumab Treatment in Patients With COVID-19,nan,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04363853,NCT04363853,hematic biometry|blood chemistry|blood gas|blood gas|thorax radiography,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
EuRopean Study of MAjor Infectious Disease Syndromes Related to COVID-19,MERMAIDS 2,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04364711,NCT04364711,"pneumonia severity indexes|need for supplemental oxygen; non-invasive or invasive mechanical ventilation; extra-corporeal life support|hospital - and icu/hcu length of stay|in-hospital mortality|activities of daily life, quality of life, variations in home living status and employment status|proportion of sars-cov2 positive patients",observational,observational model: cohort|time perspective: prospective
Novel Agents for Treatment of High-risk COVID-19 Positive Patients,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04374019,NCT04374019,clinical deterioration|change in viral load|rate of organ failure|progression to icu care or ventilation|change in clinical status|mortality|rate of severe adverse events|oxygen-free days|ventilator-free days|vasopressor-free days|icu-free days|hospital-free days|patients meeting hy's law criteria|liver function|heart function,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Assessment of Lung Inflammation With FDG PET/CT in COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04441489,NCT04441489,primary endpoint,observational,observational model: case-only|time perspective: prospective
Rapid Detection of COVID-19 by Portable and Connected Biosensor,COR-DIAL-1,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04367142,NCT04367142,sensitivity and specificity of the cor-dial based on nasopharyngeal swabs taken on admission of the patient compared to the final diagnosis of covid-19 made by the medical team|cohen's kappa coefficient for concordance for the diagnosis of cov-2-sars between pcr and cor-dial based on nasopharyngeal swabs taken on patient admission,observational,observational model: case-control|time perspective: prospective
"COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic",SEROCOV,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04304690,NCT04304690,"quantify the proportion of patients with documented sars-cov2 infection among medical and paramedical staff|identification of risk factors for seroconversion|quantify the proportion of asymptomatic infections among staff who have seroconverted|"" describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome """,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Inhaled Iloprost for Suspected COVID-19 Respiratory Failure,ILOCOVID,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04445246,NCT04445246,change in oxygenation parameters|rates of endotracheal intubation|invasive ventilation duration|icu length of stay|hospital length of stay|rates of proning therapy|rates of ecmo cannulation|mortality,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19),HALT,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04381364,NCT04381364,duration of received supplemental oxygen therapy|invasive mechanical ventilation or all-cause death (key secondary outcome)|all cause death|invasive mechanical ventilation|remaining dyspnea symptoms,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers,COVID-19,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04535791,NCT04535791,number of participants with covid-19|number of participants with hospitalization for covid-19|serum concentration of 25 (oh) vitamin d,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Adolescents and Health Professionals Faced With the Necessity for Changing to Remote Care During the COVID-19 Outbreak Quarantine (AdoPro-Cov19),AdoPro-Cov19,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04363671,NCT04363671,exploration of themes emerging from analysis of the content of the interview with the adolescents and therapists,observational,observational model: other|time perspective: prospective
Use of Convalescent Plasma for COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04408040,NCT04408040,arms 1 & 2: number of critical and severe covid-19 infected patients who are transfused with convalescent plasma result in lower death rates than the reported fatality rate|arms 1 & 2: number of critical and severe covid-19 infected patients who survive the infection|arm 3: number of high risk covid-19 infected patients who are transfused with convalescent plasma result in lower incidence of progression to severe or critical disease than the reported case rate|arm 4: number of health care providers who are at risk to exposure to covid-19 who are transfused with convalescent plasma result in lower incidence of developing covid-19 infection than the reported case rate,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Sarilumab for Patients With Moderate COVID-19 Disease,nan,recruiting,No Results Available,phase 2,U.S. Fed,https://ClinicalTrials.gov/show/NCT04359901,NCT04359901,intubation or death,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Emergency Department (ED) Self-Monitoring Pilot COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04462783,NCT04462783,change in the percent of participants using the covidx web application (app) on 50% or greater of days|average compliance rate with daily symptom tracking by day 30|recruitment rate|change in patient-reported outcomes measurement information system (promis) anxiety short form 4a|change in coronavirus anxiety scale|covidx web application usability and utility measured adapted by mhealth app usability questionnaire|differences in covidx web application engagement between patients who do and do not receive a pulse oximeter,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection,nan,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04428073,NCT04428073,to evaluate the safety of a therapeutic covid-19 vaccine in participants by measuring the severity of local and systemic adverse events and laboratory abnormalities.|to evaluate the immunogenicity of a therapeutic covid-19 vaccine in participants by measuring cd8+ t cells immune response|virologic response after vaccination|clinical outcome and progression after vaccinations,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
An Adaptive Clinical Trial of Antivirals for COVID-19 Infection,VIRCO,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04445467,NCT04445467,time to virological cure|safety|clinical improvement|clinical symptoms|biomarkers,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04338945,NCT04338945,measure of the impact of covid emergency on surgical specialist training programs|measure of impact of covid emergency on wellness of residents,observational,observational model: cohort|time perspective: prospective
"Short Term, High Dose Vitamin D Supplementation for COVID-19",SHADE,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04459247,NCT04459247,virus negativity|inflammatory marker|inflammatory marker 2,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Acquiring Convalescent Specimens for COVID-19 Antibodies,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04342195,NCT04342195,number of antibodies against coronaviruses isolated and identified from patient samples,observational,observational model: case-only|time perspective: cross-sectional
Efficacy of Convalescent Plasma Therapy in Patients With COVID-19,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04425915,NCT04425915,"efficacy of convalescent plasma in severe covid 19 patients in time to clinical improvement (clinical improvement: reduction of two points in ordinal scale or live discharge from the intensive care unit, whichever is earlier)|proportion of patients in each category according to the ordinal scale|duration of oxygen therapy in both groups|duration of hospital stay in both groups|proportion of patients on mechanical ventilation at day 7 in both groups|mortality in both groups|duration of intensive care unit stay|incidence of adverse effects in both groups|presence of antibodies against sars-cov-2 in serum after plasma administration|change in cytokines in both groups|change in acute phase reactants in both groups|correlation of the titers in covid-19 convalescent plasma donors with duration of illness, the severity of symptoms, duration of hospital stay, drugs used in therapy, duration between recovery, and donation.",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
SARS-CoV2 (COVID-19) Diagnosis in Human Saliva by MALDI-TOF MS Profiling,CoviDiagMS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04460638,NCT04460638,development of a test based on the maldi-tof profiling method to detect individuals infected with sars-cov2 from saliva sample.|rate of correct classification by the test (maldi-tof ms profiling) from saliva sample|rate of correct classification by rt-pcr from saliva sample|identification of proteins specific to the sars-cov2 infection|presence of a positive anti-sars-cov2 antibody response by rt-pcr|correlation between the identified protein markers and the clinical course of the participants.,observational,observational model: cohort|time perspective: prospective
Unraveling the Mechanisms of Olfactory Dysfunction in COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04445597,NCT04445597,prevalence of sars-cov-2 in the sampled tissue,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: basic science
COVID-19 Progression in End-Stage Kidney Disease,COPE,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04495907,NCT04495907,sars-cov-2 igg|anti-sars-cov-2 igg,observational,observational model: cohort|time perspective: other
The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04351347,NCT04351347,number of patients with improvement or died,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04346186,NCT04346186,positive igm/igg tests|comparison of the point of care test and elisa|re-infection rate|igm/igg positive participants on follow-up test,observational,observational model: cohort|time perspective: prospective
Clinical Trial to Evaluate the Efficacy of RUTI¬Æ Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04453488,NCT04453488,documented cumulative incidence of sars-cov-2 infection|sick leave for sars-cov-2|days off work due to the quarantine|quarantine imposed by close contact outside the center with sars-cov-2 positive|professional category|fever|incidence of self-reported acute respiratory symptoms|days of self-reported acute respiratory symptoms|incidence of pneumonia|incidence of death from sars-cov-2 infection|incidence of admissions to intensive care unit (icu)|days in icu|incidence of mechanical ventilation|incidence of hospital admissions|days of hospitalization|incidence of sars-cov-2 antibodies|types of antibodies detected|levels of sars-cov-2 antibodies,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Part 2 on the Study Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children (COVILLE2 ),COVILLE2,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04416893,NCT04416893,proportion of asymptomatic children or children with mild respiratory symptoms|cov2-sars cases by age|cov2-sars cases by symptoms|viral load|presence of anti-sars-cov-2 antibodies (igm and igg) by the rapid serological test,observational,observational model: cohort|time perspective: prospective
Do Vitamin D Levels Really Correlated With Disease Severity in COVID-19 Patients?,COVIDVIT,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04394390,NCT04394390,laboratory measured vitamin d levels,observational,observational model: case-control|time perspective: prospective
A Study of Immune Responses to the Virus That Causes COVID-19,CoVPN 5001,recruiting,No Results Available,nan,Other|NIH,https://ClinicalTrials.gov/show/NCT04431414,NCT04431414,"response rate of sars-cov-2-specific b cells in peripheral blood samples|magnitude of sars-cov-2-specific b cells in peripheral blood samples|phenotypic characterization of sars-cov-2-specific b cells in peripheral blood samples|response rate of sars-cov-2-specific antibody binding in serum samples|response rate of sars-cov-2-specific neutralizing antibodies in serum samples|magnitude of sars-cov-2-specific antibody binding antibodies in serum samples|magnitude of sars-cov-2-specific neutralizing antibodies in serum samples|response rate of sars-cov-2-specific binding antibodies in nasal wash samples|magnitude of sars-cov-2-specific binding antibodies in nasal wash samples|frequency of leukocyte populations in peripheral blood|transcriptional profiles of peripheral blood leukocytes|concentration of serum cytokines and other soluble factors|response rate of sars-cov-2-specific cd4+ and cd8+ t cells|magnitude of sars-cov-2-specific cd4+ and cd8+ t cells|functional profiling, including intracellular cytokine staining, of sars-cov-2-specific cd4+ and cd8+ t cells|quantitation of viral rna in nasal swabs",observational,observational model: cohort|time perspective: prospective
Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04447534,NCT04447534,number of patients with improvement or mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Maternal-foetal Transmission of SARS-Cov-2,TMF-COVID-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04395924,NCT04395924,covid-19 by positive pcr in cord blood and / or positive serologies|covid-19 by positive pcr in amniotic fluid and placenta|new born infected by covid-19,observational,observational model: cohort|time perspective: prospective
Follow-up of Respiratory Sequelae of Hospitalized Patients With COVID-19,SISCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04505631,NCT04505631,"presence of respiratory sequelae|presence of respiratory sequelae on low dose thoracic tomodensitometry|forced vital capacity (fvc, %)|forced expiratory volume in 1 second (fev1, %)|tiffeneau-pinelli index (fev1/fvc, %)|total lung capacity (tlc, %)|residual volume (rv, %)|rv/tlc ratio (%)|maximal inspiratory pressure (mip, %)|maximal expiratory pressure (mep, %)|diffusion capacity of the lungs for carbon monoxide (dlco, %)|ph|arterial oxygen partial pressure (pao2, mmhg)|arterial carbon dioxide partial pressure (paco2, mmhg)|bicarbonate concentration (mmol/l)|arterial oxygen saturation (sao2, %)|six-minute walk test",observational,observational model: cohort|time perspective: prospective
Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04383678,NCT04383678,in-hospital mortality|death on ecmo|stroke|blood stream infection|lung complications requiring surgical treatment|blood transfusion|acute kidney injury|duration of mechanical ventilation|deep vein thrombosis|pulmonary embolism|length of icu stay|length of hospital stay|death after hospital discharge,observational,observational model: cohort|time perspective: retrospective
Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,nan,"active, not recruiting",No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04345653,NCT04345653,recruitment feasibility|recourse utilization|safety as reflected on the number and severity of adverse events and serious adverse events|early feasibility as reflected on the number of participants contracting covid-19 (10% or less) in comparison to the expected 30% as per cdc.|effect of basic inflammatory regulation,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection,PROTECT,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04344600,NCT04344600,proportion of participants with no evidence of sars-cov-2 infection|time (days) to no detection of sars-cov-2 in two upper respiratory samples,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories,WAVE,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04357834,NCT04357834,diagnostic accuracy of smartwatch data in predicting icu requirement in covid-19 contracted inpatients quantified as the area under the receiver operator characteristics curve (auc roc > 0.85).|diagnostic accuracy of routine physiological data in predicting icu requirement in covid-19 contracted in-patients quantified as the area under the receiver operator characteristics curve (auc roc > 0.85).|diagnostic accuracy of predicting hospital discharge without icu admission in covid-19 contracted in-patients quantified as area under the receiver operator characteristics curve|change of heart rate from baseline (hospitalization) to icu admission|change of heart rate variability from baseline (hospitalization) to icu admission|change of skin temperature from baseline (hospitalization) to icu admission|change of blood oxygen saturation from baseline (hospitalization) to icu admission|change of respiration rate from baseline (hospitalization) to icu admission|change of physical activity from baseline (hospitalization) to icu admission|change of stress level from baseline (hospitalization) to icu admission|change of sleep pattern from baseline (hospitalization) to icu admission|change of steps per day from baseline (hospitalization) to icu admission|change of systolic blood pressure from baseline (hospitalization) to icu admission|change of diastolic blood pressure from baseline (hospitalization) to icu admission|change of body temperature from baseline (hospitalization) to icu admission|change of oxygen partial pressure (po2) from baseline (hospitalization) to icu admission|change of co2 partial pressure (pco2) from baseline (hospitalization) to icu admission|change of blood ph from baseline (hospitalization) to icu admission|change of bicarbonate from baseline (hospitalization) to icu admission|change of base excess from baseline (hospitalization) to icu admission|change of oxygen flow rate from baseline (hospitalization) to icu admission,observational,observational model: other|time perspective: prospective
Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,IvAzCol,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04399746,NCT04399746,viral clearance|symptoms duration|spo2|spo2/fio2,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic,COVID-19,"active, not recruiting",No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04416061,NCT04416061,proportion of asymptomatic subjects|proportion of subjects with recent contact history|proportion of subjects with recent travel history,observational,observational model: cohort|time perspective: retrospective
Primary Prevention of Infection by COVID-19 in Health Providers,PI-Covid-19,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04420260,NCT04420260,seroconversion of igm for covid-19.|seroconversion of igg for covid-19.,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04498936,NCT04498936,change of pcr from positive to negative|clinical improvement|adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04402814,NCT04402814,igg/igm antibodies,observational,observational model: cohort|time perspective: prospective
Mother-infant Bonding During COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04531618,NCT04531618,change in welch emotional connection score|change in maternal caregiving behavior score (acceptance versus rejection)|change in maternal caregiving behavior score (sensitivity versus insensitivity)|change in maternal caregiving behavior score (consideration versus intrusiveness)|change in maternal caregiving behavior score (quality of physical contact)|change in maternal caregiving behavior score (quality of vocal contact)|change in maternal caregiving behavior score (effectiveness of response to baby's crying)|right and left frontal mother & infant eeg synchrony|heart rate variability (hrv),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency,COVIT-D,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04403932,NCT04403932,severe covid-19,observational,observational model: cohort|time perspective: prospective
HYPONATREMIA IN COVID-19 PATIENTS,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04493268,NCT04493268,mortality|icu hospitalization,observational,observational model: cohort|time perspective: prospective
Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial,COLSTAT,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04472611,NCT04472611,covid 19 severity,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Efficacy of Tocilizumab on Patients With COVID-19,nan,"active, not recruiting",No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04356937,NCT04356937,"the primary endpoint is the time from administration of the investigational agent (or placebo) to requiring mechanical ventilation and intubation, or death for subjects who die prior to intubation|time from investigational medication (or placebo) to at least one point worsening on clinical improvement scale for subjects requiring supplemental oxygen (score >= 3) at baseline, or at least two point worsening otherwise (score = 2 at baseline|time from administration of the investigational agent (or placebo) to absence of the need for supplemental oxygen among those who require at least supplemental oxygen at baseline",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
"COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador",nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04362969,NCT04362969,"clinical characteristics of patients with covid-19|prognosis of patients, in terms of need for admission to intensive care, use of mechanical ventilation or death|clinical characteristics of the patients with the worst prognosis|relationship between the different treatments and the prognosis",observational,observational model: cohort|time perspective: retrospective
Acute Kidney Injury in Patients Hospitalized With COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04316299,NCT04316299,rate of acute kidney injury|rate of death|the length of hospital stay,observational,observational model: case-control|time perspective: retrospective
Tele-based Psychological Emotional Support for Informal CARegivers of COVID-19 Patients in Intensive Care,CO-CarES,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04409821,NCT04409821,recruitment rate|completion rate|peri-traumatic distress inventory (negative emotions)|impact of events scale (6 item)|prolonged grief-13-scale|promis depression (8 item scale)|promis anxiety (8 item scale)|perceived stress scale (4 item),interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,DOCOV,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04385810,NCT04385810,describe ophthalmologic damage to the cornea with direct exam at day 0|describe ophthalmologic damage to the cornea with direct exam at day 7|describe ophthalmologic damage to the cornea with direct exam at day 14|describe ophthalmologic damage to the cornea with direct exam at discharge of hospital|describe ophthalmologic damage to the cornea with slit lamp exam at day 0|describe ophthalmologic damage to the cornea with slit lamp exam at day 7|describe ophthalmologic damage to the cornea with slit lamp exam at day 14|describe ophthalmologic damage to the cornea with slit lamp exam at discharge of hospital|describe tear film anomalies at day 0|describe tear film anomalies at day 7|describe tear film anomalies at day 14|describe tear film anomalies at discharge of hospital|describe ophthalmologic damage to the retina at day 0|describe ophthalmologic damage to the retina at day 7|describe ophthalmologic damage to the retina at day 14|describe ophthalmologic damage to the retina at discharge of hospital|describe ophthalmologic damage to the optic nerve at day 0|describe ophthalmologic damage to the optic nerve at day 7|describe ophthalmologic damage to the optic nerve at day 14|describe ophthalmologic damage to the optic nerve at discharge of hospital,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS,RAPA-CARDS,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04482712,NCT04482712,survival rate|change in clinical status assessed by the world health organization (who) scale|change in clinical status assessed by the national institute of allergy and infectious disease (niaid) scale,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Trial of Hydroxychloroquine In Covid-19 Kinetics,THICK,terminated,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04353271,NCT04353271,percentage of virus free subjects|disease severity|incidence of hospitalization|incidence of death|incidence of confirmed sars-cov-2 detection|incidence of all-cause study medication discontinuation or withdrawal|immunity to covid-19,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Complicated Grief in ICU in the Aftermath of COVID-19,DEPARTS,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04554264,NCT04554264,proportion of complicated grief 4 month after death in relative from patients who died in icu after covid-19 infection evaluate with icg score.|proportion of complicated grief 6 month after death in relative from patients who died in icu after covid-19 infection evaluate with icg score.|proportion of complicated grief 12 month after death in relative from patients who died in icu after covid-19 infection evaluate with icg score.,interventional,allocation: non-randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
"Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia",TRONCHER,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04361032,NCT04361032,the mortality rate,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04480580,NCT04480580,seroprevalence of sars-cov-2,observational,observational model: cohort|time perspective: retrospective
The Impact of COVID-19 on the Health Care Utilization of Inflammatory Bowel Disease,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04387279,NCT04387279,patient's perception of covid-19 and medical use patterns|exacerbation of symptoms,observational,observational model: cohort|time perspective: cross-sectional
COVID-19 Search in Conjunctival Cells,COVID-T,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04364594,NCT04364594,conjunctival swab results based on rt-pcr|conjunctival swab positivity in relation to pulmonary and blood abnormalities,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04379661,NCT04379661,rate of completion|rate of adherence|score on the state trait anxiety inventory (stai)|score on the personal health questionnaire depression scale (phq-8),interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
Outcomes of Patients With COVID-19 in the Intensive Care Unit,MexCOVID-19,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04336345,NCT04336345,hospital mortality|length of stay in the intensive care unit,observational,observational model: cohort|time perspective: cross-sectional
EARSATS-19: In-ear Measurement of Blood Oxygen Saturation in COVID-19 Follow up,EARSATS-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04529408,NCT04529408,in-ear vs finger spo2,observational,observational model: cohort|time perspective: prospective
COVID-19 Pandemic and Parents of Disabled Children,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04525742,NCT04525742,a questionnaire that we created will be used to determine the difficulties experienced by disabled children's parents during covid 19 pandemic related to their medical follow-up|the fear of covid-19 scale,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: screening
Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff,SEROSARSCOV,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04387838,NCT04387838,anti-sars-cov2 seroconversion between day 0 and day 60.|anti-sars-cov2 seroconversion between day 0 and day 30.|anti-sars-cov2 seroconversion between day 30 and day 60.|anti-sars-cov2 seroprevalence at day 0.|correlation between seroconversion and socio-demographic factors - sex|correlation between seroconversion and socio-demographic factors - age|correlation between seroconversion and professional factors - job type|correlation between seroconversion and professional factors - personal protective equipment type|correlation between seroconversion and non-professional factors - contact with infected individuals|correlation between seroconversion and non-professional factors - wearing of professional equipment|correlation between seroconversion and non-professional factors - respect of barrier gestures,observational,observational model: cohort|time perspective: prospective
Radiographic Findings and Their Temporal Changes in COVID-19 Positive Changes Patients: A Prospective Study,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04368871,NCT04368871,radiographic findings and their temporal changes in covid-19 positive patient: a prospective study,observational,observational model: cohort|time perspective: prospective
BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04475302,NCT04475302,"mortality due to covid-19 disease|hospital admission and icu admission due to covid-19, severity of covid-19 (mild, moderate or severe), hospital admission due to other respiratory febrile illness, immunological outcomes in the sub study",interventional,allocation: non-randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Convalescent Plasma vs. Standard Plasma for COVID-19,nan,enrolling by invitation,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04344535,NCT04344535,28 day ventilator free days|90 day all-cause mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )",FORCE,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04371367,NCT04371367,number of patients alive and no longer hospitalized at d14|number of ventilator-free days at day 28 (vfd28)|number of participants with treatment-related adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff,IMMUNO-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04408001,NCT04408001,induced sars-cov2 immunity|long-term protection of induced sars-cov2 immunity at 6 months|long-term protection of induced sars-cov2 immunity at 1 year|anti-sars-cov2 antibodies kinetics in blood throughout the study|anti-sars-cov2 antibodies kinetics in saliva throughout the study|kinetics of serum neutralization in blood throughout the study|anti-sars-cov2 seroprevalence in asymptomatic individuals at day 0|anti-sars-cov2 seroprevalence in asymptomatic individuals at day 21,observational,observational model: cohort|time perspective: prospective
Prediction of Acute Kidney Injury in Patients With COVID-19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04406688,NCT04406688,occurence of acute kidney injury (aki)|occurence of transient and persistent aki|occurence of renal replacement therapy during hospital stay|duration of renal replacement therapy|mortality|duration of mechanical ventilation|duration of vasopressor administration|icu length of stay|hospital length of stay,observational,observational model: cohort|time perspective: prospective
Anakinra for COVID-19 Respiratory Symptoms,ANACONDA,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04364009,NCT04364009,"treatment success|oms progression scale (on a 7 point ordinal scale)|overall survival|time to icu admission|time to ventilatory support|change in national early warning score (new)from baseline to day 3, day 10, day 14 and day 28|change in inflammatory parameter|hospital length of stay|icu parameter|number of participants with treatment-related adverse events as assessed by ctcae v4.0|predictors of efficacy of anakinra",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Baricitinib Compared to Standard Therapy in Patients With COVID-19,BARICIVID-19,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04393051,NCT04393051,need of invasive mechanical ventilation|mortality|time to invasive mechanical ventilation|time to independence from non-invasive mechanical ventilation|time to independence from oxygen therapy|time to improvement in oxygenation for at least 48 hours|length of hospital stay|length of icu stay|instrumental response|proportion of adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID),FALP-COVID,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04384588,NCT04384588,"in-hospital mortality secondary to covid-19 among patients treated with convalescent plasma|safety of the use of convalescent plasma drom covid 19 donors|mortality at 30 days, 90 days, 6 months and 1 year|in-hospital mortality covid-19 related compared with non-treated population according to chilean official reports|number of days of hospitalization in high complexity facilities after convalescent plasma use|number of days of hospitalization in intensive care unit after convalescent plasma use|number of days of mechanical ventilatory support in patients after convalescent plasma use|total number of days of mechanical ventilatory support|total number of hospitalization days in patients treated with convalescent plasma|number of hospitalization days in patients after treatment with convalescent plasma|viral load measuring|immunological response in treated patients (covid19-immunoglobulin m and immunoglobulin g, neutralizing antibodies)|negativization of covid 19 load since convalescent plasma use|negativization of covid 19 load since hospitalization|negativization of covid 19 load since first reported symptoms covid-19 related|donor interferon gamma profile characterization|donor granulocyte macrophage colony stimulating factor characterization|donor tumor necrosis factor alfa characterization|donor interleukin -1 beta characterization|donor interleukin-2 characterization|donor interleukin-4 characterization|donor interleukin-6 characterization|donor interleukin-8 characterization|donor interleukin-10 characterization|receptor interferon gamma profile characterization|receptor granulocyte macrophage colony stimulating factor characterization|receptor tumor necrosis factor alfa characterization|receptor interleukin -1 beta characterization|receptor interleukin-2 characterization|receptor interleukin-4 characterization|receptor interleukin-6 characterization|receptor interleukin-8 characterization|receptor interleukin-10 characterization",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Registry of Sustained Immunity to COVID-19 Among ESKD Patients,RePAiR,"active, not recruiting",No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04495764,NCT04495764,anti-sars-cov-2 antibodies|incidence and severity of covid-19,observational,observational model: cohort|time perspective: prospective
Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients,ONCOVID,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04341207,NCT04341207,prevalence and the 3-months incidence of sars-cov-2 in cancer patients|covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects",nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04441918,NCT04441918,correlation of adverse events with the investigational product|primary pharmacokinetic variables,interventional,"allocation: randomized|intervention model: sequential assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Study of SARS-CoV2 Virus (COVID-19) Seroprevalence in the Population of Creil Air Force Base (BA110),EpiCovCreil,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04404270,NCT04404270,proportion anti-sars-cov2 seropositive|proportion of asymptomatic anti-sars-cov2 seropositive participants|agreement between the anti-sars-cov2 serological results obtained using two different techniques (detecting the presence of different antibodies)|proportion of serum neutralization positive|change of antibody level over time,observational,observational model: cohort|time perspective: prospective
Evaluation of Antibody Tests for COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04360954,NCT04360954,test sensitivity|test specificity,observational,observational model: case-only|time perspective: retrospective
Lessening Organ Dysfunction With VITamin C - COVID-19,LOVIT-COVID,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04401150,NCT04401150,death or persistent organ dysfunction|number of intensive care unit-free days|persistent organ dysfunction-free days in icu|number of patients deceased at 6 months|health related quality of life in 6-month survivors|organ function|global tissue dysoxia|rate of inflammation|rate of infection|rate of endothelial injury|occurrence of stage 3 acute kidney injury|acute hemolysis|hypoglycemia,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS,nan,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04452097,NCT04452097,incidence of infusion-related adverse events|incidence of any treatment-emergent adverse events (teaes) and treatment emergent serious adverse events (tesaes)|selection of an appropriate dose of the huc-msc product for the following phase 2 study,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Understanding COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04329546,NCT04329546,immunogenicity primary outcome: geometric mean antibody concentration of total igg antibodies to sars-cov-2 assessed by elisa at 28 days|virologic primary outcome: peak viral load in the 56 days following diagnosis/suspected diagnosis,observational,observational model: cohort|time perspective: prospective
Lung CT Scan Analysis of SARS-CoV2 Induced Lung Injury,TAC-COVID19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04395482,NCT04395482,a qualitative analysis of parenchymal lung damage induced by covid-19|a quantitative analysis of parenchymal lung damage induced by covid-19|the potential impact of parenchymal morphological ct scans in patients with severe moderate respiratory failure.|automated segmentation of lung scans of patients with covid-19 and ards.|knowledge of chest ct features in covid-19 patients and their detail through the use of machine learning and other quantitative techniques.|the ability within which the analysis of artificial intelligence that uses deep learning models can be used to predict clinical outcomes,observational,observational model: cohort|time perspective: retrospective
Surgical Telemedicine in the COVID-19 Pandemic Era,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04376710,NCT04376710,evaluate surgeon perceptions to telemedicine and perceived barriers to implementation|evaluate patient perceptions to telemedicine and perceived barriers to implementation,observational,observational model: other|time perspective: prospective
PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04404361,NCT04404361,proportion of patients who progress to imv and/or ecmo or death during the 28 days following randomization,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04390217,NCT04390217,effect of lb1148 on disease progression via measurement of the proportion of patients who are alive and free of respiratory failure.|clinical status at fixed time points|duration of hospital stay|measurement of the number and proportion of patients requiring admission to the intensive care unit (icu) during hospitalization|duration of icu stay|invasive mechanical ventilation requirements|duration of invasive mechanical ventilation|all-cause 28-day mortality|safety and tolerability of lb1148,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
QuadraMune(TM) for Prevention of COVID-19,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04421391,NCT04421391,prevention of covid-19|safety as determined by presence or absence of adverse events and serious adverse events,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,COVILLE,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04318431,NCT04318431,proportion of asymptomatic children or children with mild respiratory symptoms|confirmed cov2-sars cases by age|confirmed cov2-sars cases by symptoms|viral load|other respiratory viruses|sars-cov2 igm|sars-cov2 igg,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Predicting Death and ICU Admission in COVID-19 Patients in ED,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04371562,NCT04371562,7-day death|7-day icu,observational,observational model: cohort|time perspective: retrospective
Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease),nan,not yet recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04345601,NCT04345601,treatment-related serious adverse events (tsaes)|change in clinical status at day 14,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Correlation Fear of COVID-19 & Dental Treatment Anxiety,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04497818,NCT04497818,fear of covid-19 infection|dental anxiety|correlation of fear of covid-19 infection & dental anxiety|correlation of the nearest dental treatment seeking time and fear of covid-19 infection.|correlation of the nearest dental treatment seeking time and dental anxiety|correlation of the age and fear of covid-19 infection|correlation of the age and dental anxiety.,observational,observational model: other|time perspective: prospective
Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04527354,NCT04527354,"rate of clinically significant change in fvc and/or dlco at week 4 relative to the baseline value|change in distance covered for 6 minutes (6mwd) at weeks 2 and 4 from the baseline value (based on 6-minute walk test)|change in the score of the borg scale at weeks 2 and 4 from the baseline value (based on the 6-minute walk test)|change in forced expiratory volume for the first second (fev1) according to spirometry data at weeks 1, 2, 3 and 4 relative to the baseline values|change in fvc according to spirometry data at weeks 1, 2, 3 and 4 relative to the baseline values|change in fev1/fvc according to spirometry data at weeks 1, 2, 3 and 4 relative to the baseline values|change in dlco according to bodyplethysmography at week 2 and week 4 relative to baseline values|change in total lung capacity (tlc) according to bodyplethysmography at week 2 and week 4 relative to baseline values|change in functional residual capacity (frc) according to bodyplethysmography at week 2 and week 4 relative to baseline values|the rate of reduction in the lung damage degree based on the computed tomography (ct) at week 4 relative to the baseline value|change in mmrc dyspnea score in week 1, week 2, week 3, and week 4 from the baseline value|change in the overall score of the kbild questionnaire at week 2 and week 4 relative to the baseline value",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
To Study the Clinical Characteristics and Treatment Outcome of COVID-19 Patients Admitted in Hospitals of Max Healthcare (SCOPe Study),SCOPe,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04367064,NCT04367064,we will compare the clinical outcome of the covid 19 patients with their age and gender|we will compare the effect of different treatments given to the covid 19 patients at max hospital,observational,observational model: cohort|time perspective: prospective
Use of UC-MSCs for COVID-19 Patients,nan,"active, not recruiting",No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04355728,NCT04355728,incidence of pre-specified infusion associated adverse events|incidence of severe adverse events|survival rate after 90 days post first infusion|ventilator-free days|change in oxygenation index (oi)|plat-peep|sequential organ failure assessment (sofa) scores|small identification test (sit) scores|troponin i levels|c-reactive protein levels|arachidonic acid (aa)/eicosapentaenoic acid (epa) ratio|d-dimer levels|25-hydroxy vitamin d levels|alloantibodies levels|blood white cell count|platelets count,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
LunG and Melanoma canceR pAtients coVId19 Disease (GRAVID),GRAVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04344002,NCT04344002,clinical data of lung cancer patients with covid-19 diagnoses|diagnosis data|treatments received|prognostic factors,observational,observational model: cohort|time perspective: other
Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning,IDENTIFY,completed,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04423991,NCT04423991,mortality outcome,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: diagnostic
Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,nan,recruiting,No Results Available,phase 2|phase 3,Industry|Other,https://ClinicalTrials.gov/show/NCT04382924,NCT04382924,"patient clinical status (on the who 7-point ordinal scale) at day 15 in ip versus soc control group patients:|status on an ordinal scale assessed daily while hospitalized and on days 15 and 28 in ip versus control group patients|news assessed days 3, 5, 8 ,11 daily while hospitalized and on days 15 and 29 in ip versus control group patients|rate of mechanical ventilation in ip versus control group patients|duration of mechanical ventilation (if applicable) in ip versus control group patients|duration of supplemental oxygen in ip versus control group patients|time to return to room pressure (spo2 > 94%) on room air|duration in icu (if applicable) in ip versus control group patients|rate of mortality in ip versus control group patients|duration of hospitalization in ip versus control group patients|time to discharge in ip versus control group patients|effect on the rate of change of partial pressure of oxygen (pao2) and pao2/fio2 ratio taken at baseline and measured once daily up to 2 weeks of treatment in ip versus control group patients",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Cardiovascular Risk Stratification in Covid-19,CaVaR-Co19,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04555187,NCT04555187,number and rate of persons with cardiovascular composite outcome|rate of all-cause death outcome|rate of cardiac arrhythmia,observational,observational model: cohort|time perspective: retrospective
Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury,nan,enrolling by invitation,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04397510,NCT04397510,mean daily pao2 to fio2 ratio|duration of mechanical ventilation|icu length of stay|mortality rate|incidence of adverse drug events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Muscle Mass and Strength as Predictors of Time to Discharge in Patients With COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04406233,NCT04406233,time to medical discharge|all-cause mortality|hospital readmission,observational,observational model: cohort|time perspective: prospective
"Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198",nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04479644,NCT04479644,incidence of adverse events (aes) by ctcae v5.0|proportion of subjects with saes|proportion of subjects with infusion-related reactions|proportion of subjects with hypersensitivity reactions|serum concentration of brii-198,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
"Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196",nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04479631,NCT04479631,incidence of adverse events (aes) by ctcae v5.0|proportion of subjects with saes|proportion of subjects with infusion-related reactions|proportion of subjects with hypersensitivity reactions|serum concentration of brii-196,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Oral Manifestation of COVID 19 Patient: A Cross Sectional Study on Egyptian Population,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04391881,NCT04391881,oral manifestation,observational,observational model: other|time perspective: cross-sectional
A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19),FITE19,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04439071,NCT04439071,time from randomization to respiratory improvement|percentage of participants requiring invasive ventilation|percentage of participants requiring supplemental oxygen or non-invasive ventilation in participants who did not require supplemental oxygen at baseline|time from randomization to defervescence|time from randomization to respiratory rate ‚â§ 24 breaths per minute on room air|time from randomization to cough reported as mild or absent|time from randomization to dyspnea reported as mild or absent|reduction of immune responses|reduction in viral load|duration of hospitalization|number of fatalities|number of participants with treatment-emergent adverse events (teaes),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04360837,NCT04360837,changes in lung compliance|change in global impedance|change in recruitability|gas exchange|plateau pressure|end expiratory lung impedance (eeli)|antero-to-posterior ventilation ratio|center of ventilation|global inhomogeneity index,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19,SWITCH-COVID,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04493359,NCT04493359,need for icu or mortality|high sensitivity troponin levels and covid-19 severity|ace-2 activity and disease severity|ace-2 activity with different renin-angiotensin system inhibitors|blood control and acute renal failure,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,DW-MSC,not yet recruiting,No Results Available,phase 1,Other|Industry,https://ClinicalTrials.gov/show/NCT04535856,NCT04535856,incidence of teae* in treatment group|survival rate|duration of hospitalization|clinical improvement ordinal scale|clinical improvement national ews|clinical improvement oxygenation index|clinical improvement lung involvement change|clinical improvement inflammation markers change,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community (ReCOVER),ReCOVER,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04399109,NCT04399109,"rate of avoidable emergency department presentations per diagnosed covid-19 case|all cause mortality per diagnosed covid-19 case all-cause mortality rate at 30 days per diagnosed covid-19 case|rate of hospital admission per diagnosed covid case|rate of mbs claims for un-referred visits to general practitioners and analogous covid-19 mbs telehealth items per diagnosed covid case|average length of stay (los) for admitted patients per diagnosed covid case|rate of admission to intensive care unit (icu) for admitted patients per diagnosed covid case|time from presentation to admission to icu for patients admitted to icu per diagnosed covid case|rate of intubation in admitted patients per diagnosed covid case|rate of readmission within 30 days of discharge in admitted patients per diagnosed covid case|all-cause mortality at 90 days per diagnosed covid case|rate of avoidable emergency department presentations with covid-19 diagnosis per 100,000 population, during trial period|rate of hospital admission with covid-19 diagnosis per 100,000 population, during trial period|rate of admission to icu with covid-19 diagnosis per 100,000 population during trial period|rate of mortality with covid-19 cause of death per 100,000 population, during trial period|qualitative assessment of tcc-covid app usability via a subjective feedback questionnaire provided to all patients enrolled in the study.|cost-effectiveness of tcc-covid by measuring the incremental cost per death averted, per icu admission averted and per length of stay in icu|rate of hospital bed days with covid-19 diagnosis per 100,000 population, during trial period|rate of icu bed days with covid-19 diagnosis per 100,000 population, during trial period|qualitative assessment of kiola physician portal usability via a subjective feedback questionnaire",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
MIND/COVID-19: Mental Health Impact and NeeDs Associated With COVID-19: a Comprehensive National Evaluation in Spain,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04556565,NCT04556565,post-traumatic stress disorder|depression|generalized anxiety disorder|suicidal thoughts and behaviors|alcohol and drug use problems|panic attacks|health-related quality of life|overall perceived health|role limitation,observational,observational model: cohort|time perspective: prospective
Cross-sectional Study of COVID-19 Infection in Hospital Health Personnel,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04466462,NCT04466462,number of participants with past sars-cov-2 infection|number of infections in health personnel who have taken voluntary hydroxychloroquine as a prevention strategy for covid-19 infection|number of infections in health personnel based on the degree of exposure to patients infected with covid-19.|number of infected participants who are active smokers and/or have chronic lung disease and/ or have history of hypertension.relationship of degree of exposure to participants infected with sars-cov-2 admitted to the hospital.professional category.|number of participants infected with sars-cov-2 that presented symptoms and their grade. number of participants infected with sars-cov-2 who required hospitalization. number of participants infected with sars-cov-2 who received treatment.|number of family members infected from each participant with sars-cov-2 infection,observational,observational model: case-crossover|time perspective: other
Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia,nan,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04344548,NCT04344548,adverse effects and safety|nk transfer immunogenicity,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial,COVID-PACT,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04409834,NCT04409834,primary endpoint: venous or arterial thrombotic events|key secondary endpoint: clinically evident venous or arterial thrombotic events,interventional,allocation: randomized|intervention model: factorial assignment|masking: none (open label)|primary purpose: prevention
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04334460,NCT04334460,time to recovery|change in oxygenation|safety & tolerability: incidence of teaes and serious adverse events (saes),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure,COV-IMMUNO,recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04442048,NCT04442048,"the rate of ""flu-like illness"" which includes:|the incidence of documented covid-19 infection (confirmed by any health canada approved covid-19 test. both symptomatic and asymptomatic infections will be documented|the rate of severe respiratory and covid-19 infection defined as a confirmed covid-19 infection leading to hospitalization, icu admission or death|the number of events that meet the definition of the primary endpoint, as measured within the one-year follow-up (patients may meet the primary endpoint more than once and be counted multiple times).|the incidence of covid-19 seroconverted patients between baseline, 3 months, 6 months and 12 months|the incremental cost-effectiveness ratio (in the unit of cad$ per life-years gained) measured with eq-5d-5l|failure-free survival, as time from enrollment to recurrence or progression declared by the investigator on the basis of objective standard evaluation consistent with the disease site or death|overall survival (os), as time from enrollment to death from any cause|incidence, frequency, and severity of aes considered possibly, probably or definitely related to receipt of imm-101|incidence and frequency of local injection site reactions subsequent to imm-101 administration|incidence and duration of icu admission related to documented covid-19 infection",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04378712,NCT04378712,the proportion of patients with improved disease severity at day 2|the proportion of patients with improved disease severity at day 3|the proportion of patients with improved disease severity at the day before hospital discharge|the change from baseline in oxygen saturation at day 2.|the change from baseline in oxygen saturation at day 3.|the change from baseline in oxygen saturation at the day before hospital discharge|the change from baseline in dyspnea scale at day 2.|the change from baseline in dyspnea scale at day 3.|the change from baseline in dyspnea scale at the day before hospital discharge.|the change from baseline in cough scale at day 2|the change from baseline in cough scale at day 3|the change from baseline in cough scale at the day before hospital discharge|the change from baseline in chest pain scale at day 2.|the change from baseline in chest pain scale at day 3.|the change from baseline in chest pain scale at the day before hospital discharge.|the change from baseline in chest distress scale at day 2.|the change from baseline in chest distress scale at day 3.|the change from baseline in chest distress scale at the day before hospital discharge.,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,SAINT,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04390022,NCT04390022,"proportion of patients with a positive sars-cov-2 pcr|mean viral load|fever and cough progression|seroconversion at day 21|proportion of drug-related adverse events|levels of igg, igm and iga|frequency of innate immune cells|frequency sars-cov-2-specific cd4+ t and and cd8+ t cells|results from cytokine human magnetic 30-plex panel",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak,COVEMUZ,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04426292,NCT04426292,seroprevalence|seroconversions|incidence of definite cases|incidence of probable cases|antibody kinetics|potential work-related risk factors|proportion of asymptomatic seroconversions|concerns for safety for infection with covid-19,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
Analysis of the Inflammatory Response and the Development of Humoral and Cellular Immunity in Patients With COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04423640,NCT04423640,"serum levels of cytokines and chemokines|viral load|immunophenotype of myeloid cells|rbd-sars-cov protein s- antibodies|analysis of cellular immune response|hematopoietic stem cells and progenitor cells populations in peripheral blood|questionnaire of sociodemographic, labor, pathological and personal characteristics|sofa (secuential organ failure assessment score)|fibrinogen|c-reactive protein",observational,observational model: cohort|time perspective: prospective
Will Hydroxychloroquine Impede or Prevent COVID-19,WHIP COVID-19,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04341441,NCT04341441,"to determine if the use of hydroxychloroquine as preventive therapy decreases the rate of acquisition of sars-cov 2 infections and clinical covid-19 disease in study participants for each randomized treatment arm as compared to placebo.|determine the effect of hydroxychloroquine dose in the prevention of covid-19 viremia and disease.|assess the impact of chronic weight-based dosing of hcq for covid-19 prevention.|comparison of the rate of sars-cov 2 infections as measured by igm/igg seroconversion in study participants receiving randomized hcq versus placebo.|compare the seroprevalence of sars-cov 2 igm/igg positive samples at study entry and study conclusion in all participants receiving hcq compared to those receiving placebo.|comparison of the emergence of clinical symptoms or covid-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm.|to examine the level of care needed by participants in each arm developing covid19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care.|determine the safety and tolerability of hcq dosing for preventive strategy against covid-19 as measured by adverse events and serious adverse events.|to examine other clinical determinants contributing to the risk of sars-cov 2 infection in healthcare workers and first responders.|examine the association between hcq drug levels and development of covid-19 symptoms or positive test results.|identify immunologic, serological and inflammatory markers associated with acquisition and response to covid-19 in both hcq and placebo participants developing laboratory or clinical confirmed disease.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
"NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE",GERONIMO 19,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04403269,NCT04403269,mortality|total number of days of full hospitalization|duration of oxygen therapy|ferritin level in the blood|crp level in the blood|ldh level in the blood|lymphocyte level in the blood|pnn level in the blood|platelet level in the blood|who performance index|whoqol-old questionnaire|lung function by pulmonary computed tomography|lung function by efr|readmission rates,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04555005,NCT04555005,perceived helpfulness to reduce current stress,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults",nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04445389,NCT04445389,incidence of solicited adverse events|incidence of unsolicited adverse events|incidence of serious adverse events|geometric mean titer (gmt) of antigen-specific binding antibody titers|percentage of subjects who seroconverted after vaccination|geometric mean titer (gmt) of neutralizing antibody level|geometric mean fold rise (gmfr) of antigen-specific binding antibody titers,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19,nan,not yet recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04537975,NCT04537975,pulmonary oxygenation function|pulmonary compliance of respiratory system (crs)|survival|hospital costs 1|cardiovascular vasoactive-inotropic score (vis)|hospital costs 2|hospital costs 3|hospital costs 4|hospital costs 5,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 and Obstetric Transmission,COVIDOB,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04418557,NCT04418557,presence of covid-19 virus|presence of antibodies to covid-19 virus,observational,observational model: case-control|time perspective: prospective
Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+),COVID+PA,withdrawn,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04351919,NCT04351919,improvment or healing of clinical signs|evolution of clinical signs,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"A Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19",nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04405570,NCT04405570,"virologic efficacy|number of participants with any adverse events (aes) as assessed by kaplan meier approach|number of participants with any adverse events (aes), grade 2 or higher as assessed by kaplan meier approach",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia,AIRVM-COVID,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04357457,NCT04357457,rate of endotracheal intubation|28-day mortality|in-hospital mortality|number of ventilator-free days|number of days in the icu|number of days in the hospital|discontinuation rate of the treatment,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Extracellular Vesicle Infusion Therapy for Severe COVID-19,EXIT COVID-19,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04493242,NCT04493242,all-cause mortality|median days to recovery,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (investigator)|primary purpose: treatment
The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors,nan,recruiting,No Results Available,nan,Other|NIH,https://ClinicalTrials.gov/show/NCT04551378,NCT04551378,coronavirus disease 2019 (covid-19) specific psychological stress|survey responses|patient reported outcomes|changes of survey responses|changes in discrete responses|incidence of survey question non-response,observational,observational model: cohort|time perspective: prospective
Indirect Endovenous Systemic Ozone for New Coronavirus Disease (COVID19) in Non-intubated Patients,OzonoCOVID19,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04359303,NCT04359303,covid19 clinical scale|number of died patients|oro/nasopharynx virus|thorax imaging (0=none; 1=unilateral; 2=bilateral; 3=ground-glass opacification; 4=consolidation)|days in hospital|venous gas blood analysis,interventional,"allocation: randomized|intervention model: crossover assignment|masking: double (participant, investigator)|primary purpose: treatment"
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2,nan,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04382950,NCT04382950,time course of body temperature (fever)|viral load over time|p/f ratio over time|sequential organ failure assessment score(sofa score) over time|pulmonary severity index (psi)|image examination of chest over time|proportion of subjects who progressed to critical illness or death|time from first dose to conversion to normal or mild pneumonia|t-lymphocyte counts over time|c-reactive protein levels over time|angiotensin ii (ang ii) changes over time|angiotensin 1-7 (ang 1-7) changes over time|angiotensin 1-5 (ang 1-5) changes over time|renin changes over time|aldosterone changes over time|angiotensin-converting enzyme (ace) changes over time|interleukin 6 (il-6) changes over time|soluble tumor necrosis factor receptor type ii (stnfrii) changes over time|plasminogen activator inhibitor type-1 (pai-1) changes over time|von willebrand factor (vwf) changes over time|tumor necrosis factor-œ± (tnf-œ±) changes over time|soluble receptor for advanced glycation end products (srage) changes over time|surfactant protein-d (sp-d) changes over time|frequency of adverse events and severe adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04366245,NCT04366245,"safety: incidence of adverse events and serious adverse events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (ctcae).|efficacy: death from any cause|efficacy: need for mechanical ventilation|efficacy: any of the following analytical data after 72h of randomization.|efficacy: sofa scale ‚â• 3 after 72 hours of randomization or an increase of 2 points or more from the basal level|efficacy. mortality on days 14 and 28.|efficacy: proportion of patients who required mechanical ventilation|efficacy: proportion of patients who develop analytical alterations.|efficacy: cure / clinical improvement (disappearance or improvement of signs and symptoms of covid-19) in the cure test.|efficacy: pcr negative for sars-cov-2|efficacy: proportion of patients requiring treatment.|efficacy: duration of hospitalization (days)|virology and immunological variables: qualitative pcr for sars-cov-2 in naso-oropharyngeal exudate sample|virology and immunological variables: total antibody quantification|virology and immunological variables: quantification of total antibodies in pc donors recovered from covid-19.",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications,nan,not yet recruiting,No Results Available,phase 1|phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04435015,NCT04435015,percent change in plasma d-dimer|overall safety and adverse event|change in plasma fibrinogen levels|change in plasma troponin|new onset cardiomyopathy|duration of intubation|length of stay in the intensive care unit|time to discharge from hospital|occurrence of major adverse cardiovascular events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis).,CoVIHDis,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04526977,NCT04526977,changes in immune cellular response,observational,observational model: case-control|time perspective: cross-sectional
Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19,COVID-19,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04490486,NCT04490486,percent of participants with treatment related serious adverse events (sae)|change in inflammatory marker levels|change in systemic inflammatory marker levels|covid-19 viral load|change in sofa score|change in electrolytes levels|change in ldh levels|number of subjects discharged from the icu|percentage of participants with less requirement for vasoactive agents|rate of mortality|percentage of participants with changes in immune marker expression|percentage of participants with changes in radiologic findings|percentage of participants with less pneumonia symptoms,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Impact of Covid-19 in Congenital Heart Disease,COVID-CHD,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04336384,NCT04336384,prevalence of covid-19 infection in the overall chd population|prevalence of covid-19 infection per chd sub-group|cardiovascular complications|other complications|number of deaths,observational,observational model: cohort|time perspective: prospective
Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic,nan,recruiting,No Results Available,nan,Other|NIH,https://ClinicalTrials.gov/show/NCT04500600,NCT04500600,experiences during the coronavirus disease 2019 (covid-19) pandemic|covid-19-specific psychological distress|covid-19-specific health|covid-19-specific financial and social disruptions|covid-19-specific perceived benefits and social support|covid-19-specific health related quality of life (hrqol)|effects of covid-19 experiences on covid-19-specific psychological distress and hrqol,observational,observational model: case-only|time perspective: cross-sectional
SOLIRIS¬Æ (Eculizumab) Treatment of Participants With COVID-19,nan,available,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04355494,NCT04355494,nan,expanded access:intermediate-size population,nan
"A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic",nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04369365,NCT04369365,cumulative number of severe acute respiratory syndrome corona virus 2 (sars-cov-2) infections|number of severe covid-19 cases|severity of covid-19 cases|incidence of treatment-emergent adverse events [safety and tolerability]|number of viral and bacterial infections|number of participants with azithromycin-resistant bacterial strains in nasal swabs test,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
COVID-19 in Patients With Anosmia in Egypt,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04473157,NCT04473157,recovery from anosmia|seroconversion|covid 19,observational,observational model: case-only|time perspective: prospective
Preeclampsia-like Syndrome Induced by COVID-19: Is it a Real Public Health Issue in Pregnancy During the Pandemic?,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04443140,NCT04443140,pcr positivity,observational,observational model: cohort|time perspective: prospective
Place of Circulating Biomarkers and Respiratory Eicosanoids in the Prognosis of Severe Forms of Covid-19 Pneumonia,BIOCOVID,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04485364,NCT04485364,inflammatory response in the evolution of respiratory diseases|impact of the respiratory disease during mechanical ventilation,observational,observational model: other|time perspective: prospective
Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients,POCUSCO,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04338100,NCT04338100,risk of unfavourable outcome at d14|risk of unfavourable outcome over time|risk-stratification threshold values|adding value of pocus score to previous risk-stratification clinical rules|pocus score and patient clinical status at d14|pocus and ct scan correlation|pocus versus ct scan risk-stratification performances|pocus score evolution performances,observational,observational model: case-only|time perspective: prospective
Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04341766,NCT04341766,characteristics of pulmonary ultrasound for covid-19 patients|charateristics of pulmonary ct-scan for covid-19 patients,observational,observational model: cohort|time perspective: prospective
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation,nan,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04492514,NCT04492514,primary outcome measure:|secondary outcome measures:,interventional,"allocation: randomized|intervention model: factorial assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
"A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects",nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04516564,NCT04516564,incidence of treatment-emergent aes|maximum serum concentration (cmax) of ak119|area under the concentration-time curve (auc) of serum concentration of ak119|percentage of subjects who develop detectable anti-drug antibodies (adas),interventional,"allocation: randomized|intervention model: sequential assignment|masking: triple (participant, care provider, investigator)|primary purpose: other"
Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients,HBOT,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04409886,NCT04409886,oxygenation index|spo2|symptoms level|chest xray,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
GLS-1200Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04408183,NCT04408183,"evaluate the number of gls-1200 topical nasal spray adverse events as assessed by ctcae v5.0|incidence of sars-cov-2 infection, confirmed by pcr relative to treatment group|symptom score of documented sars-cov-2 infection relative to treatment group with a higher score being a worse outcome.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
COVID19 Clinical Predictors and Outcome,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04416347,NCT04416347,sars-cov-2 hospital mortality|sars-cov-2 mortality in critical care unit,observational,observational model: cohort|time perspective: retrospective
Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection,PRODEX,withdrawn,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04350086,NCT04350086,efficacy of mild to moderate palliative sedation induced by dexmedetomidine.|overall survival of patients on dexmedetomidine|daily analgesic effect of dexmedetomidine|other sedative pharmacological agents|average dosage required for dexmedetomidine to achieve mild to moderate sedation,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Eucaloric Ketogenic Diet in COVID-19 Cytokine Storm Syndrome,ketocovidiet,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04492228,NCT04492228,"mortality rate in the ketogenic group diet vs standard one|access in intensive care unit in the ketogenic group diet vs standard one|need of non invasive ventilation in the ketogenic group diet vs standard one|combined endpoint ""mortality, icu transfer or need for cpap or intubation"" in the ketogenic group diet vs standard one",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines",nan,not yet recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04391400,NCT04391400,"identification of nucleic acid sequencing, antibodies and antigens to be used in detection methods or treatments and/or vaccines",observational,observational model: case-only|time perspective: prospective
Dissemination of SARS-COV-2 (COVID-19) in the Environment of Infected Patients Admitted to Intensive Care Unit,ENVIROREA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04355481,NCT04355481,estimate the proportion of patients hospitalized in intensive care for a sars-cov-2 viral lung infection and contaminating their environment at 1 meter.,observational,observational model: cohort|time perspective: prospective
LILLE COVID RESEARCH NETWORK (Covid-19),LICORNE,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04475211,NCT04475211,"number of patients ""confirmed cases"" of sars-cov-2 infection who died at d28 of inclusion|correlation between infection characteristics of patients at inclusion and all predictors for covid-19|correlation between evolution infection characteristics of patients during stay of hospitalisation and all predictors for covid-19|positivity for covid-19 patients performed and all predictors for covid-19|correlation between hospitalisation and all predictors for covid-19|correlation between risk factors measured at d0 for severe cov-2 sars infection and all predictors for covid-19|correlation between overall survival at day 28 and all predictors for covid-19|cumulative incidence of at least one complication related to covid 19|cumulative incidence of the thrombosis complication related to covid 19|all type of co-infections|alteration of microbiota|biobanking for further analyses such as sars-cov2 studies",observational,observational model: cohort|time perspective: retrospective
Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19,JOCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04320017,NCT04320017,incidence of acute myocardial events in covid-19 population at baseline and during hospital stay|description of cardiovascular outcomes in the cohort|prognosis role of baseline cardio-vascular caracteristics on patients survival|prediction of cardio-vascular events with baseline characteristics|characterization of inflammation on cardio-vascular outcomes|prognosis role of baseline clinico-biological caracteristics on patients transfer to icu and survival,observational,observational model: cohort|time perspective: prospective
COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,BBCovid,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04352959,NCT04352959,change from baseline amount of sars-cov-2 in salivary samples at 7 days|change from baseline amount of sars-cov-2 virus in nasal samples at 7 days,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04366323,NCT04366323,safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by adverse event rate|efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by survival rate,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Perceptions of Undergraduate Students and Teaching Staff on Online Teaching,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04466371,NCT04466371,satisfaction with online learning|knowledge about covid-19 crisis|perception of covid-19 crisis,observational,observational model: case-only|time perspective: cross-sectional
Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity,COBRA,recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04439045,NCT04439045,covid-19 infection|incidence of hospitalization for covid-19|incidence of icu admission for covid-19|incidence of ards|mechanical ventilation for covid-19|secondary infection in covid-19|covid-19-related mortality|incidence of dvt,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: prevention"
Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04457609,NCT04457609,clinical improvement: presence of dyspnea|clinical improvement: presence of sputum|clinical improvement: fever|clinical improvement: ventilation status|clinical improvement: blood pressure|clinical improvement: heart rate|clinical improvement: respiratory rate|clinical improvement: oxygen saturation|general laboratory outcome from leukocyte level|general laboratory outcome from lymphocytes level|general laboratory outcome from blood ph|general laboratory outcome from blood level of co2|general laboratory outcome from blood base excess level|general laboratory outcome from blood oxygen partial pressure|general laboratory outcome from blood level of hco3|general laboratory outcome from blood level of o2 saturation|general laboratory outcome from level of crp|general laboratory outcome from level of sgot/sgpt (ast/alt)|general laboratory outcome from the level of ureum/creatinine level|general laboratory outcome from the level of egfr|general laboratory outcome from the level of sodium|general laboratory outcome from the level of potassium|general laboratory outcome from the level of chloride|changes in procalcitonin level|general laboratory outcome from albumin level|general laboratory outcome from total bilirubin level|changes in d-dimer level|changes in fibrinogen level|cardiac changes from troponin level|cardiac changes from nt probnp level|changes in leukemia inhibiting factor|changes in level of il-6|changes in level of il-10|changes in level of vascular endothelial growth factor (vegf)|changes in level of ferritin|changes in level of cxcr3|changes in level of cd4|changes in level of cd8|changes in level of cd56|radiologic improvement from chest x-ray/ct scan,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19,RESCUE1-19,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04433949,NCT04433949,time to clinical recovery|freedom from icu admission|temperature|heart rate|systolic blood pressure|oxygen saturation|supplemental oxygenation need|respiratory rate|glasgow comma scale from minimum of 3 to maximum of 15.|performance status|survival|serial chest x-rays severe acute respiratory syndrome (sars) scoring|changes on computed tomography (ct) scans pre and post rt|crp|serum chemistry + complete blood cell (cbc) with differential|blood gases ph(when available)|albumin|procalcitonin|aspartate aminotransferase (ast)|creatine kinase|prothrombin time (pt)/partial thromboplastin time (ptt)|troponin|lactate|nt-pbnp (cardiac injury)|gamma-glutamyl transferase (ggt)|triglycerides|fibrinogen|changes in cd8 t cells|changes in cd4 t cells|changes in serum antibodies against covid-19 epitope|ldh|d-dimer|il-6|myoglobin|potassium|ferritin|alt,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,nan,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04399980,NCT04399980,proportion of subjects alive and off of oxygen at day 14|proportion of subjects alive at 28 days|proportion of subjects alive and without respiratory failure at 28 days,interventional,"allocation: randomized|intervention model: factorial assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Covid 19 Pandemic. Emerging Legal and Ehical Disputes Over Patient Confidentiality,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04344938,NCT04344938,evaluate the ethical requirement of controlled disrupts of patients in case of infectious disease pandemic,observational,observational model: ecologic or community|time perspective: cross-sectional
Is Adipose Tissue a Reservoir for SARS-Cov2 Spread in Covid-19 Patients?,TA/SARS-Cov2,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04427878,NCT04427878,the presence of sars-cov2 in adipose tissue of covid19 patients|the expression of inflammatory cytokines in adipose tissue of covid19 patients,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Anti Infective Agents Impact in COVID-19 Pneumonia,AZITHROVID,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04453501,NCT04453501,favorable outcome|risk factors 1|risk factors 2|interest of anti-infective agents,observational,observational model: cohort|time perspective: retrospective
Telmisartan in Respiratory Failure Due to COVID-19,STAR-COVID,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04510662,NCT04510662,death|mechanical ventilation|occurrence of acute kidney injury|incidence of hypotension|incidence of hypotension requiring vasopressors|incidence of sepsis|hospital length of stay,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP),nan,available,No Results Available,nan,U.S. Fed,https://ClinicalTrials.gov/show/NCT04360486,NCT04360486,nan,expanded access:treatment ind/protocol,nan
Impact of COVID-19 Infection During Pregnancy on Newborns and Young Children,ELIKYA COVID,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04432779,NCT04432779,outcome of pregnancy|prevalence of positive serology to sars-cov-2 at delivery|transplacental transfer of antibodies to sars-cov-2|to characterize placental alterations related to sars-cov-2 infection|presence of maternal antibodies to sars-cov-2 in breast milk in breastfeeding mothers|to characterize the immunity transmitted to the newborn to cord blood and its persistence at the age of 1 month of life|clinical evolution of the children,observational,observational model: cohort|time perspective: prospective
Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04527471,NCT04527471,proportion of patients with recovery|time to recovery|proportion of patients with improvement (from day 1) of one category using the 7-point ordinal scale|proportion of patients with improvement (from day 1) of two categories using the 7-point ordinal scale|mortality rate|proportion of patients alive and not in respiratory failure|proportion of patients needing re-hospitalization|duration of hospitalization from day 1|mean change from baseline in 7-point ordinal scale|total time on supplemental oxygen|incidence of new non-invasive ventilation or high flow oxygen use|duration of new non-invasive ventilation or high flow oxygen use|incidence of new oxygen use|duration of new oxygen use|incidence of new mechanical ventilator use|duration of new mechanical ventilator use|proportion of patients receiving invasive mechanical ventilation or ecmo,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Impact of COVID-19 Pandemic on Perceived Exercise Benefits and Barriers,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04412278,NCT04412278,exercise benefits and barriers scale|sociodemographic information|international physical activity questionairre,observational,observational model: ecologic or community|time perspective: cross-sectional
CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19,CORONA,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04378244,NCT04378244,maximum tolerated dose|survival|hospital stay|ventilator therapy|intensive care unit stay|cytokine pattern,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Canine COVID-19 Detection,nan,recruiting,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04509713,NCT04509713,sensitivity and specificity precision of dogs to detect people with covid-19 by their odour.|identification of the volatile profile that is specific to asymptomatic or mild symptomatic participants with sars-cov-2 compared with uninfected individuals.,observational,observational model: cohort|time perspective: other
Hydroxy Chloroquine and Covid in RA Patients,Covid-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04471649,NCT04471649,number of patients in need for hospitalization|length of hospitalization and icu admission|the need for mechanical ventilation|severity of covid-19 disease,observational,observational model: case-control|time perspective: retrospective
hCT-MSCs for COVID19 ARDS,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04399889,NCT04399889,safety of the investigational product|describe the potential for msc therapy to favorably alter the course of covid-ards,interventional,"allocation: randomized|intervention model: single group assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04525417,NCT04525417,to assess the predictive value of covid-19 rapid test|compare the results of rapid tests on serum and capillary samples|a posteriori diagnosis of a covid-19 recent infection with suggestive symptomatology|analysis of factors associated with negativity of pcr test on oropharyngeal swabs and positive serology,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: diagnostic
USZ BioResource COVID,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04414657,NCT04414657,blood sampling for biobank,observational,observational model: cohort|time perspective: prospective
COVID-19 in PID Survey,COPID19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04459689,NCT04459689,survival of patients with pid affected by covid-19|rate of admission to icu of patients with pid affected by covid-19|rate of oxygen therapy of patients with pid affected by covid-19|sequelae of patients with pid affected by covid-19,observational,observational model: case-only|time perspective: prospective
PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds,PRECISE,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04351191,NCT04351191,rt-pcr result|progression of symptoms|mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Estrogen Patch for COVID-19 Symptoms,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04359329,NCT04359329,rate of hospitalization|rate of transfer to intensive care unit|rate of intubation|rate of death,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Excess Risk of Morbi-mortality Due to COVID-19 in Patients With Cancer,ONCOVID-AURA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04457570,NCT04457570,mortality for sars-cov-2 infection,observational,observational model: case-control|time perspective: retrospective
Telemedicine in Outpatient Covid-19 Patients,MR SPOC,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04471636,NCT04471636,rate of participants with a combination of hospitalization and unplanned use of hospital emergency department or emergency medical service|rate of participants hospitalized|rate of participants with unplanned use of hospital emergency department or emergency medical service|rate of participants experiencing death of any cause|rate of participants experiencing death of covid-19,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,IMMUNONCOVID,suspended,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04333914,NCT04333914,28-day survival rate|time to clinical improvement|clinical status|mean change in clinical status from baseline to days|overall survival|length of stay in intensive care unit|duration of mechanical ventilation or high flow oxygen devices|duration of hospitalization|rate of throat swab negativation|quantitative sars-cov-2 virus in throat swab and blood samples|rate of secondary infection by other documented pathogens|biological parameters|number of participants with treatment-related adverse events as assessed by ctcae v5.0|cost-effectiveness analyses (cea),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.,CONEC,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04347694,NCT04347694,status of immunization,observational,observational model: other|time perspective: prospective
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel,IveprofCovid19,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04527211,NCT04527211,clinical development of covid-19 disease during the intervention period|seroconversion|hospitalization requirement|intensive care unit requirement|safety of the intervention,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
"Nutritional Habits, and Coronavirus Disease 2019 (COVID-19) Outcome",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04447144,NCT04447144,western versus mediterranean diet in covid-19 outcome|gut- lung axis in covid-19|protective role of minerals and vitamins in covid-19 patients|non-communicable diseases and covid-19,observational,observational model: cohort|time perspective: prospective
Perceived Impact of the COVID-19 Pandemic on Medical Management and Symptoms in a High Risk Group,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04477473,NCT04477473,questionnaire,observational,observational model: other|time perspective: prospective
Outcomes and Prognostic Factors in COVID-19,COVIP,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04321265,NCT04321265,survival|fragilty,observational,observational model: cohort|time perspective: prospective
Investigation of Safety and Efficacy of CARDIO Softgels in Former Smokers and Asthma Patients With COVID-19 Infection,nan,not yet recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04465513,NCT04465513,oxygenation requirements during hospital stay (oxygen saturation rates)|oxygenation requirements during hospital stay (supplemental oxygen)|oxygenation requirements during hospital stay (ventilator support)|clinical improvement|clinical status|serial chest ct or x-ray findings|time to clinical recovery|time to improvement in oxygenation for at least 48 hours|hospitalization period|amount of time on ventilator|intensive care stay|quality of life (qol)|all-cause mortality|temperature measurements|oxygen saturation measurements|covid-19 qol measurements,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Interferon Lambda Therapy for COVID-19,nan,not yet recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04388709,NCT04388709,number of participants with resolution of hypoxia|number of adverse events.|days with fever|time to resolution of fever|rate of progression to requiring critical care|overall survival|time to discharge,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID19 Versus H1N1: Radiological Challenge During Next Influenza Season Rising,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04433039,NCT04433039,covid19 versus h1n1; radiological comparative study,observational,observational model: case-crossover|time perspective: retrospective
Effects of a N95 Respirator vs Cloth Mask on Exercise Capacity During Treadmill Exercise.,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04415879,NCT04415879,exercise capacity,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: health services research
COVID-19 Seroprevalence Study in French Guiana,EPI-COVID-POP,recruiting,No Results Available,not applicable,Industry|Other,https://ClinicalTrials.gov/show/NCT04490850,NCT04490850,measure of the covid-19 immunity of the population|evaluation of the level of asymptomatic and pauci-symptomatic infections,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Coronavirus (COVID-19) ACEi/ARB Investigation,CORONACION,suspended,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04330300,NCT04330300,"number of covid-19 positive participants who die, require intubation in icu, or require hospitalization for non-invasive ventilation (niv)|number of covid-19 positive participants who die|number of covid-19 positive participants who require intubation in intensive care unit (icu)|number of covid-19 positive participants who require hospitalization for non-invasive ventilation (niv)|number of sars-cov-2 positive participants|maximum troponin t value (ng/l) among covid-19 positive participants who require acute hospitalization|24 hour mean systolic bp (mmhg) on ambulatory bp monitoring|all-cause mortality",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
COVID-19: Herd Immunity Study in the Czech Republic,SARSCoV2CZPrev,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04401085,NCT04401085,"estimation of the actual prevalence of sars-cov-2 positive persons in the czech republic.|estimation of the proportion of people with a subclinical course of the disease|estimation of the cumulative prevalence of the disease and the proportion of people with a subclinical course differences between subcohorts according to demographic, social and clinically relevant stratifications.|estimation of the proportion of persons suitable for the donation of convalescent plasma",observational,observational model: cohort|time perspective: cross-sectional
Using GM-CSF as a Host Directed Therapeutic Against COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04400929,NCT04400929,measuring oxygenation,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
COVID-19 Blood Pressure Endothelium Interaction Study (OBELIX),OBELIX,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04409847,NCT04409847,abpm systolic blood pressure|24-hr abpm dbp|day abpm sbp|day abpm dbp|night abpm sbp|night abpm dbp|dipping status|morning surge|24 hour abpm hr|day abpm hr|night abpm hr,observational,observational model: cohort|time perspective: prospective
COVID-19 Infection and Multiple Myeloma,EMN-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04492371,NCT04492371,nature of covid19|costs related to covid-19|systemic anti-cancer therapy subgroup|laboratory values collected at hospitalization|covid-19 infection in myeloma patient subgroups|incidence of covid-19 infection in frail patients|infection outcome in different countries,observational,observational model: cohort|time perspective: other
Outcomes of Covid-19 Protective Measures in Endoscopy,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04371354,NCT04371354,rate of new covid infection of patients and staff members|covid disease prevalence in the patients referred to endoscopy|categorization by clinical triage and covid test|influence of the fype of endoscopy procedure and staff protective equipment,observational,observational model: other|time perspective: prospective
Immune Status SARS-CoV-2 in a Sample of a Tertiary Eye Health Centre,CovidImmunEye,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04446338,NCT04446338,seroprevalence|agreement of the test results and questionnaire|positive predictive / negative values of the tests applied,observational,observational model: cohort|time perspective: prospective
"Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)",SeroCoV-HUS,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04441684,NCT04441684,"presence of specific sars-cov2 antibodies in the serum in the 3 groups of subjects studied, at the inclusion visit (d0).|detection and titration of neutralizing antibodies anti-sars-cov-2|kinetics of antibodies and their persistence over a period of 1 year|number of asymptomatic subjects in the pcr - and -pcr groups|number of people with positive sars-cov-2 serology|questionnaire (type of health care personnel, contact history, medical operation and respect of hygiene standards)",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: screening
COVID-19 in Liver Transplant Recipients,COVID19-SETH,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04361591,NCT04361591,incidence of covid19 in lt recipients|clinical characteristics of covid19 in lt recipients|survival and mechanical ventilation / respiratory support|observed treatments and immunosuppression management,observational,observational model: cohort|time perspective: prospective
Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic,TeleCoviDiab,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04370171,NCT04370171,"comparison of metabolic control (hba1c) between diabetic patients followed by teleconsultation and patients with a conventional follow-up during covid-19 infection.|hba1c measured at 6 months post-telemedicine consultation for the tc group / post-cancellation of the face-to-face consultation for the p group.|total number of patients inaccessible to teleconsultation and number of patients inaccessible by type of associated reason.|number of complications: severe hypoglycemia, ketoacidosis, myocardial infarction, stroke, foot ulcer.|results of patient satisfaction questionnaire.|results of doctor satisfaction questionnaire.|number of patients infected with covid-19 (positive smear by rt-pcr for sars-cov-2 virus).|number of conventional hospitalizations, in intensive care and deaths.",observational,observational model: cohort|time perspective: prospective
Canakinumab in Covid-19 Cardiac Injury (The Three C Study),nan,"active, not recruiting",No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04365153,NCT04365153,"time to clinical improvement up to day 14, defined as the time in days from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever occurs first.|mortality at day 28",interventional,"allocation: randomized|intervention model: factorial assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Rhu-pGSN for Severe Covid-19 Pneumonia,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04358406,NCT04358406,"efficacy: proportion of subjects alive not on vasopressors, mechanical ventilator, and dialysis|safety and tolerability: proportion of subjects with serious adverse events (saes)|efficacy: daily change in the who 9-point severity score|efficacy: all cause mortality rate at days 28 and 90|efficacy: proportion of subjects alive without the ongoing use of vasopressors, ongoing intubation/mechanical ventilation, ongoing residence in an intensive care unit (icu), new ongoing need for dialysis/renal replacement therapy|efficacy: proportion of subjects discharged to home or immediate prior residence|efficacy: length of stay (los) of surviving subjects in the hospital and in icu|efficacy: proportion of subjects readmitted to the hospital|safety and tolerability: proportion of subjects with adverse events (aes)|safety and tolerability: proportion of subjects with new or worsening clinically significant laboratory abnormalities|immunogenicity: proportion of subjects with rhu-pgsn antibodies|pharmacokinetics: maximum concentration (c max) of added rhu-pgsn|pharmacokinetics: time to maximum concentration (t max) of added rhu-pgsn|pharmacokinetics: half-life (t 1/2) of added rhu-pgsn|pharmacokinetics: area under the curve from time 0 to 8 hours (auc 0-8) of added rhu-pgsn|pharmacokinetics: area under the curve from time 0 to infinity (auc 0-inf) of added rhu-pgsn",interventional,"allocation: randomized|intervention model: single group assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Renin-Angiotensin System Inhibitors and COVID-19,SARS-RAS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04331574,NCT04331574,"numbers of covid-19 patients enrolled that use ace inhibitors and/or angiotensin receptor blockers (arb) as antihypertensive agents|numbers of covid-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the who specification for ards that also used ace inhibitors and/or angiotensin receptor blockers (arb) as antihypertensive agents|number and type of anthropometric and clinical parameters that associate with covid19 and covid-19 severity",observational,observational model: case-only|time perspective: cross-sectional
COVID 19 Preventive Measures Among Mansoura Nursing Students,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04473547,NCT04473547,"adherence level to coronavirus disease 19 preventive measures among nursing students during written exams.|number of students who develop possible covid-19 symptoms during written exams|eye,nose,mouth,face and mask touch frequency during written exams|nursing students knowledge level of covid 19|covid 19 risk perception level among nursing students undergoing written exams",observational,observational model: cohort|time perspective: prospective
BCG Vaccination to Protect Healthcare Workers Against COVID-19,BRACE,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04327206,NCT04327206,covid-19 disease incidence|severe covid-19 disease incidence|covid-19 incidence by 12 months|severe covid-19 incidence by 12 months|time to first symptom of covid-19|episodes of covid-19|asymptomatic sars-cov-2 infection|work absenteeism due to covid-19|bed confinement due to covid-19|symptom duration of covid-19|sars-cov-2 pneumonia|oxygen therapy with sars-cov-2|critical care admissions with sars-cov-2|critical care admission duration with sars-cov-2|mechanical ventilation with sars-cov-2|mechanical ventilation duration with sars-cov-2|hospitalisation duration with covid-19|mortality with sars-cov-2|fever or respiratory illness|episodes of fever or respiratory illness|work absenteeism due to fever or respiratory illness|bed confinement due to fever or respiratory illness|symptom duration of fever or respiratory illness|pneumonia|oxygen therapy|critical care admissions|mechanical ventilation|mortality|hospitalisation duration with fever or respiratory illness|unplanned work absenteeism|hospitalisation cost to treat covid-19|local and systemic adverse events to bcg vaccination in healthcare workers,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: prevention"
Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy,THROMBCOVID2,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04377490,NCT04377490,variation of thrombin time (in secondes) in hospitalized covid-19 patients|variation of factor v concentration (u/dl) in hospitalized covid-19 patients.|variation of factor ii concentration (u/dl) in hospitalized covid-19 patients|variation of concentration of fibrin and fibrinogen degradation products (‚â• 10 ¬µgm/ml) in hospitalized covid-19 patients.,observational,observational model: case-only|time perspective: prospective
RAS and Coagulopathy in COVID19,nan,not yet recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04419610,NCT04419610,coagulopathy associated with covid-19|markers of dysregulation of coagulation system|markers of dysregulation of ras|markers of haemolysis/inflammation|markers of haemolysis/inflammation|markers of inflammation (bacterial sepsis)|markers of organ dysregulation - kidney|markers of dysregulation of cardiovascular system|marker of dysregulation of endocrine system,interventional,"allocation: randomized|intervention model: single group assignment|masking: double (participant, investigator)|primary purpose: health services research"
Honey & Nigella Sativa Trial Against COVID-19,HNS-COVID-PK,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04347382,NCT04347382,days required to get a positive covid-19 pcr to negative|hrct/ x-ray findings of disease progression|severity of symptoms progression|duration of hospital saty|30 day mortality|oxygen saturation at room air|incidence of viral myocarditis|incidence of acute respiratory distress syndrome,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04389294,NCT04389294,correlation between serology testing and clinical suspicion of covid-19|prevalence of sars-cov2 exposure|correlation of pre-existing risk factors with results of serology testing|number of asymptomatic participants with positive antibody serology|proportion of antibody- positive participants who subsequently develop covid-19|proportion of participants who are eligible for in plasma donation,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
The Natural History of Hospitalized COVID-19 Patients,STORM,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04424992,NCT04424992,covid19 infection clinical evolution|risk factors for intra-hospital mortality|the impact of a fragility index (if)|prognostic score|the lung sequelae of sars-cov-2 pneumonia|the accuracy of if in elderly patients|coagulation system anomalies|the impact of the prone position on the oxygenation,observational,observational model: cohort|time perspective: prospective
Bacteriotherapy in the Treatment of COVID-19,BACT-ovid,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04368351,NCT04368351,delta of time of disappearance of acute diarrhea|delta in the number of patients requiring orotracheal intubation despite treatment|delta of crude mortality|delta of length of stay for patients in hospital,observational,observational model: case-control|time perspective: retrospective
Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergoni√© in the Context of the COVID-19 Pandemic - PRO-SERO-COV,PRO-SERO-COV,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04426006,NCT04426006,"serological immune status to an infection by the sars-cov-2 virus|the serological immune status to infection with the sars-cov-2 virus will also be determined from the different antibody isotypes (igg and igm), from a rapid diagnostic unit test (rdt).|kinetics of antibody production (igg) against the sars-cov-2 virus|kinetics of antibody production (igm) against the sars-cov-2 virus|kinetics of antibody production (iga) against the sars-cov-2 virus|active covid-19 infection|symptoms of anxiety",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04345406,NCT04345406,number of patients with virological cure,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,COVIDSPERM,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04391829,NCT04391829,detection of sars-cov-2 in the semen|duration of sars-cov-2 presence in semen|semen viscosity|semen volume|semen ph|sperm motility|sperm morphology|sperm density,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
COVID-19 Pandemic and Female Sexual Behavior,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04374422,NCT04374422,fsfi (female sexual function index)score difference,observational,observational model: cohort|time perspective: prospective
Coagulation Changes Associated With COVID-19 Infection,nan,enrolling by invitation,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04460664,NCT04460664,quantra clot time results|quantra clot stiffness results,observational,observational model: cohort|time perspective: prospective
Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19),nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04391101,NCT04391101,"intrahospital mortality from any cause|length of hospital stay|free time for ventilatory support on day 60|overall survival at day 60 since hospitalization|cumulative incidence of adverse events: transfusion reactions (fever, flare), trali (transfusion-associated lung injury), taco (transfusion-related circulatory overload), transfusion- related infections",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Screening for Patients Admitted to Ain-Shams University Hospitals for SARS-COV-2 (COVID19),nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04443712,NCT04443712,the incidence of the new covid19 among hospitalized patients|cost of screening hospitalized patients,observational,observational model: cohort|time perspective: cross-sectional
Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19,DEXDO-COVID,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04413864,NCT04413864,change of inflammatory cytokines concentration (mmol / l) in covid19 + patients from baseline at 6 months|change of interrelationship between inflammation (cytokines levels) and icu delirium in covid19 + patient from baseline at 6 months|modification in inflammatory genes expressed (expressed / non expressed) in pbmc between baseline and m6|change in quantity of chromatine's openings (chromatin accessibility profiles) in icu patient recovering from covid19 infection|change in genes expression in covid-19 patient with delirium in icu between day2 and month6,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID),nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04346342,NCT04346342,ventilation mode|tidal volume set|expiratory tidal volume|positive end-expiratory pressure|maximum airway pressure or plateau pressure (p plateau) or peak pressure (p peak) (cm h2o);|level of pressure support above positive end-expiratory pressure (peep)|inspired fraction of oxygen|set and measured respiratory rate|inspiration to expiration ratio|number of ventilation-free days and alive at day 28|duration of ventilation in survivors;|use of prone positioning|use of recruitment maneuvers|incidence of acute kidney injury|duration of icu stay|duration of hospital stay|icu mortality|hospital mortality|28-day mortality|90-day mortality,observational,observational model: cohort|time perspective: retrospective
Novel Regimens in COVID-19 Treatment,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04382846,NCT04382846,number of patients with virological cure,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Influence of COVID-19 on Vascular Endothelial Function,COVAS,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04468412,NCT04468412,endothelial dysfunction|major adverse cardiovascular events (mace),observational,observational model: cohort|time perspective: prospective
Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19,HYdILIC,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04372082,NCT04372082,"death|clinical worsening (composite criteria)|assisted-ventilation and/or hospitalization (composite criteria)|national early warning score (news)|cumulative incidence of hospitalizations|cumulative incidence of the use of oxygen therapy, non-invasive ventilation or invasive ventilation ( composite criteria)|mortality|cumulative incidence of viral shedding on sars-cov-2 rt-pcr on nasopharyngeal swab;|adverse drug reactions",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (investigator)|primary purpose: treatment
Prasugrel in Severe COVID-19 Pneumonia,PARTISAN,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04445623,NCT04445623,p/f ratio at day 7|daily p/f ratio|daily need for oxygen supply|need for icu|death|mof|discharge|clinical progression of the disease sofa score|clinical progression of the disease apache ii|venous thrombosis/ pulmonary embolism/thrombosis|need for ct imaging|daily temperature|daily blood pressure|daily total blood count hemoglobin|daily total blood count red blood cells|daily total blood count leukocytes|daily total blood count platelets|daily indices of organ damage liver|indices of inflammation c-reactive protein|indices of haemostasis pt|daily progression at imaging (chest-x-ray)|major bleeding|total bleeding|unexpected clinical or laboratory findings|indices of inflammation d-dimer|indices of inflammation fibrinogen|indices of inflammation il-6|indices of inflammation il-1|daily indices of organ damage kidney|daily indices of organ damage heart|haemostasis aptt|haemostasis vasp pri|haemostasis platelet-leukocytes aggregates,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Characteristics of Neonatal Covid-19 in Turkey,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04401540,NCT04401540,vertical transmission|hospital stay|early neonatal sepsis rate,observational,observational model: cohort|time perspective: prospective
Performance Assessment of SARS-CoV-2 Detection Breath Biopsy - SARS-CoV-2 Study,COVID,not yet recruiting,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04508556,NCT04508556,positive control for technical validation|evaluation of test performance,observational,observational model: cohort|time perspective: cross-sectional
The Utility of Enhanced Pre and Post-surgical Work-out to Prevent the Spread of COVID-19 in a Large Urology Department,UroCovid,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04409899,NCT04409899,rate of sars-cov-2/covid-19 in a selected cohort of urological patients undergoing surgery|post-operative covid-19 related complication rates|association between post-surgery inflammatory indexes and covid-19 diagnosis during hospitalization,observational,observational model: cohort|time perspective: prospective
The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,GRECCO-19,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04326790,NCT04326790,clinical deterioration in the semiquantitative ordinal scale suggested by the who r&d committee|maximal concentration of cardiac troponin,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Burden for STaff Working in the NHS,COST-NHS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04506632,NCT04506632,changes in depression|changes in anxiety|changes in feelings of paranoia|traumatic stress|conspiracy mentality and social interactions,observational,observational model: ecologic or community|time perspective: prospective
Use of PCR-Sars-CoV-2 in Children,VIGIL,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04412317,NCT04412317,percentage of children screened with a positive pcr result|percentage of pcr-sars-cov-2 positive in the sick child in the presence of a covid contagion in the family environment or not,observational,observational model: cohort|time perspective: prospective
"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04382040,NCT04382040,"time to clinical improvement, defined as a national early warning score 2 (news2) of </= 2 maintained for 24 hours in comparison to routine treatment|percentage of participants with definite or probable drug related adverse events|time to negative covid-19 pcr|proportion of participants with normalization of fever and oxygen saturation through day 14 since onset of symptoms|covid-19 related survival|incidence and duration of mechanical ventilation|incidence of intensive care init (icu) stay|duration of icu stay|duration of time on supplemental oxygen",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,COVID-19EXO,enrolling by invitation,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04491240,NCT04491240,number of participants with non-serious and serious adverse events during trial|number of participants with non-serious and serious adverse during inhalation procedure|time to clinical recovery (ttcr)|blood gases changes|spo2 concentration changes|chest imaging changes,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: other"
COVID-19 Thales Thermography Triage : Thermal Camera Feasibility Study,COVID3T,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04397380,NCT04397380,temperature,observational,observational model: cohort|time perspective: prospective
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,ESCAPE,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04339712,NCT04339712,change of baseline total sequential organ failure assessment (sofa) score|improvement of lung involvement measurements|increase of po2/fio2 ratio|comparison of change of baseline total sequential organ failure assessment (sofa) score in enrolled subjects towards historical comparators|comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|comparison of po2/fio2 ratio in enrolled subjects towards historical comparators|change of sequential organ failure assessment (sofa) score|rate of mortality|cytokine stimulation|gene expression|serum/plasma proteins|classification of the immune function,interventional,allocation: non-randomized|intervention model: factorial assignment|masking: none (open label)|primary purpose: treatment
Transpulmonary Driving Pressure in ARDS COVID19 Patients,TRANSPULMONARY,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04381286,NCT04381286,duration of mechanical ventilation|number of participants with during of acute respiratory distress syndrom (sdra)|length of stay in intensive care unit|mortality|number of patients with pulmonary complications|number of participants with pulmonary stress and strain,observational,observational model: cohort|time perspective: prospective
Monocytes and NK Cells Activity in Covid-19 Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04375176,NCT04375176,immune cells activity|protective factors and new therapeutic strategies,observational,observational model: case-only|time perspective: prospective
PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort,PROSAIC-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04444609,NCT04444609,anti-viral cytokine levels in blood samples in chronic respiratory disease associated with susceptibility to severe covid-19 infection|anti-viral cytokines profiles within sputum samples in chronic respiratory disease associated with susceptibility to severe covid-19 infection|anti-viral cytokine profiles within nasal lavage samples in chronic respiratory disease associated with susceptibility to severe covid-19 infection associated with susceptibility to severe covid-19 infection|expression of inflammatory gene expression in upper respiratory epithelial airway cells using nasal brush specimens in chronic respiratory disease associated with susceptibility to severe covid-19 infection|identify the t cell antigens and b cell epitopes in chronic respiratory disease associated with susceptibility to severe covid-19 infection|peripheral blood mononuclear cell (pbmc) interferon mediated immune responses to pathogen recognition receptor agonists in chronic respiratory disease associated with susceptibility to severe covid-19 infection|identify endothelial function in chronic respiratory disease associated with susceptibility to severe covid-19 infection using endopat testing|endothelial cell inflammation biomarkers in chronic respiratory disease associated with susceptibility to severe covid-19 infection|identify sputum 16s rrna and its sequences in chronic respiratory disease associated with susceptibility to severe covid-19 infection|identify nasal lavage 16s rrna and its sequences in chronic respiratory disease associated with susceptibility to severe covid-19 infection|identify quality of life markers in chronic respiratory disease associated with susceptibility to severe covid-19 infection,observational,observational model: cohort|time perspective: prospective
Convalescent Plasma for COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04365439,NCT04365439,"titers of anti-sars-cov-2 antibodies in the plasma derived from convalescent donors|change in titers of anti-sars-cov-2 antibodies in patients' plasma|change in inflammatory cytokines concentration (e.g. il-6, hmgb1)|viral load decay in the recipient after plasma transfusion with semiquantitative assessment of nasopharyngeal swabs|number of patients with improvement in the 7-points ordinal scale|proportion of patients with adverse events, severity of adverse events",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04351503,NCT04351503,"identification of factors associated with (i) infection (binary, yes/no), (ii) hospitalization (binary, yes/no), (iii) requirement for icu treatment (binary, yes/no)|duration of hospitalization (in days)|duration of intensive care unit (icu) stay (in days)|in-hospital mortality (binary, yes/no)|number of infected cases within the city of basel|whole genome sequencing to study pathogen evolution (number, type, and complexity of viral genome)|identification which treatment modality is associated with adverse events (binary, yes/no)|identification which treatment modality is associated with pulmonary recovery (binary, yes/no)",observational,observational model: other|time perspective: retrospective
To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04468646,NCT04468646,time to improvement on a 7-point ordinal scale as compared to baseline|total in-hospital days and the total duration|treatment and prevention of inflammatory lung injury as measured by change in baseline of interleukin-6 (il-6)|rate of decline of covid-19 viral load assessed by rt-pcr from nasopharyngeal samples|reduction from baseline of nrs for cough|reduction from baseline of nrs for nausea|time to normalization of fever for at least 48 hours|time to improvement in oxygenation for at least 48 hours,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
A Study of Quintuple Therapy to Treat COVID-19 Infection,HAZDpaC,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04334512,NCT04334512,the rate of recovery of mild or moderate covid-19 in patients using quintuple therapy|reduction or progression of symptomatic days|assess the safety of quintuple therapy|assess the safety of quintuple therapy via pulse|assess the safety of quintuple therapy via oxygen saturation|assess the safety of quintuple therapy via ekg|assess tolerability of quintuple therapy,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Detecting SARS-CoV-2 in Tears,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04526769,NCT04526769,covid-19 virus detection in tears|covid-19 virus detection in nasopharyngeal swabs|expression of ace2 in lacrimal gland samples|expression of ace2 in ocular surface samples,observational,observational model: case-only|time perspective: prospective
Protective Role of Inhaled Steroids for Covid-19 Infection,INHASCO,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04331054,NCT04331054,"time (in days) to clinical improvement within 30 days after randomization|mortality rate at d30|time (in days) from randomization to death|number of days alive outside icu within 30 days|number of days alive free of invasive or non-invasive ventilation within 30 days|number of days alive with oxygen therapy within 30 days|maximal oxygen rate within 30 days|difference between pao2/fio2 ratio at randomization and at day 7 (or at the time of stopping oxygen therapy or discharge if occurs before day 7)|number of days alive outside hospital within 30 days|use of antibiotics for respiratory (proved or suspected) infection within 30 days|difference between crp levels at randomization and at day 7 (or at the time of discharge if occurs before day 7)|safety outcomes included events that occurred during treatment, serious adverse events, and premature discontinuation of treatment.",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 IgG Formation in Physicians at ALGH and Their Household Members,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04540484,NCT04540484,identifying positive covid-19 igg formation|physician prevalence of covid-19 serum igg|household member prevalence of covid-19 serum igg|physician risk of exposure|physician and household member transmission|asymptomatic infection|ppe use and positivity|antibody persistence,observational,observational model: cohort|time perspective: prospective
Frequency of Perforated Appendicitis in Times of COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04472052,NCT04472052,rate of perforated appendicitis,observational,observational model: cohort|time perspective: other
"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",nan,terminated,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04335552,NCT04335552,world health organization (who) ordinal scale measured at 14 days after enrollment|rates of death during the index hospitalization|number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|who ordinal scale measured at 28 days after enrollment|hospital length of stay in days for the index hospitalization|rates of all-cause study medication discontinuation|rates of severe adverse events,interventional,allocation: randomized|intervention model: factorial assignment|masking: none (open label)|primary purpose: treatment
PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 70 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS,COLCHI-COVID,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04416334,NCT04416334,number of participants who die due to covid-19 infection|number of participants who require hospitalization due to covid-19 infection,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
St. Jude Tracking of Viral and Host Factors Associated With COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04362995,NCT04362995,proportion of asymptomatic subjects|positive cd4 and cd8 cell epitope positive response|proportion of seroprevalence|t-cell response,observational,observational model: cohort|time perspective: prospective
Covid-19 in Lupus Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04355702,NCT04355702,prevalence and severity of covid-19 infection in patients with sle|prevalence and severity of covid-19 infection in patients treated by hydroxychloroquine,observational,observational model: cohort|time perspective: retrospective
Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients,COBETOX,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04463849,NCT04463849,serum œ≤ - cellular function index insulin levels|serum œ≤ - cellular function index c-peptide levels|serum œ≤ - cellular function homa-œ≤ index|serum œ≤ - cellular function pro-insulin/insulin ratio|evaluation of the secretory response of insulin to the arginine stimulation test|viral sars-cov-2 particles in œ≤ cells|percentage of patients with preserved œ≤ cells function|glucose values|values of continuous glucose monitoring|changes in the inflammatory marker interleukin 1-œ≤|changes in the inflammatory marker interleukin il-2|changes in the inflammatory marker interleukin il-6|changes in the inflammatory marker interleukin il-7|changes in the inflammatory marker interleukin il-10|changes in the inflammatory marker tumor necrosis factor-œ±|changes in the inflammatory marker interferon gamma|changes in the inflammatory marker macrophage inflammatory protein-1œ≤|changes in the inflammatory marker monocyte chemoattractant protein-1|changes in the inflammatory marker granulocyte-macrophage colony-stimulating factor|changes in the inflammatory marker granulocyte colony-stimulating factor,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: diagnostic
Ultrasonography in Norwegian Emergency Department Patients With Suspected Covid-19 Infection,COVIDUS-NOR,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04422691,NCT04422691,mortality|level-of-care|in-hospital length of stay|oxygen usage in the emergency department|emergency department length of stay|antibiotics usage,observational,observational model: cohort|time perspective: cross-sectional
Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),nan,"active, not recruiting",No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04328961,NCT04328961,polymerase chain reaction (pcr) confirmed sars-cov-2 infection|rate of participant-reported adverse events|incidence rates of covid-19 through study completion,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
Efficacy of Subcutaneous Ivermectin With or Without Zinc and Nigella Sativa in COVID-19 Patients,SINZ-COVID-PK,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04472585,NCT04472585,qrt-pcr|severity of symptoms,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
"Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers",nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04461379,NCT04461379,demonstrate covid- 19 disease incidence among health care workers:|demonstrate cumulative incidence of hospitalization for covid-19 among health care workers:|demonstrate the incidence of specific antibodies against sars-cov-2 at 3 and 6 months in health care workers|hospitalization of severe disease covid-19|oxygen supplementation in severe disease covid-19|need for intubation or non-invasive ventilation for the patient.|critical care admission with sars-cov2|mortality associated to progressive pulmonary disease|evaluate the safety of the vaccine by measuring the incidence rates of local and systemic adverse effects that occur after one month its application.|calculate the incidence of covid-19 complications|determine the mean days of hospitalization and days in intensive care unit by coivd-19|calculate the cost associated with in-hospital medical care|determine the scores of the clinical prediction rules associated with mortality using sequential organ failure assessment (sofa score) at the patient's hospital admission:|determine the scores of the clinical prediction rules associated with mortality using acute physiology and chronic health disease classification system (apache) at the patient's hospital admission:|evaluate and determine the alteration profile in laboratory studies at the patient's hospital admission|registration of chronic medications|need for vasopressors,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, outcomes assessor)|primary purpose: prevention"
FAvipiravir and HydroxyChloroquine Combination Therapy,FACCT,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04392973,NCT04392973,clinical improvement|viral shedding,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,AVoCaDO,"active, not recruiting",No Results Available,phase 1|phase 2,U.S. Fed|Other,https://ClinicalTrials.gov/show/NCT04357782,NCT04357782,incidence of adverse events|incidence of serious adverse reactions|incidence of adverse reactions|ventilator-free days|icu-free days|hospital-free days|all-cause mortality|change in s/f ratio during hdivc infusion|c-reactive protein (crp)|lactate dehydrogenase (ldh)|d-dimer|lymphocyte count|neutrophil to lymphocyte ratio (nlr)|serum ferritin,interventional,allocation: non-randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Oropharyngeal Dysphagia in Patients With COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04346212,NCT04346212,prevalence of oropharyngeal dysphagia|swallowing screening|swallowing status.|nutritonal status of study patient's.|needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation).|needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation).|clinical complications at 6 months follow up from patient's medical history (incidence of readmissions).|clinical complications at 6 months follow up from patient's medical history (prevalence of readmissions).|clinical complications at 6 months follow up from patient's medical history (number of visits to emergency department).|clinical complications at 6 months follow up from patient's medical history (percentage of visits to emergency department).|clinical complications at 6 months follow up from patient's medical history (respiratory complications).|clinical complications at 6 months follow up from patient's medical history (mortality).,observational,observational model: cohort|time perspective: prospective
HSD3B1 Gene Polymorphisms With Outcomes in SARS-CoV-2 Infected Patients,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04516850,NCT04516850,expression of receptors and activating proteases|prevalencen of olymorphisms of the hsd3b1|association of polymorphisms of the hsd3b1,observational,observational model: other|time perspective: retrospective
Identification of Differences in Breath Components Detected With IMS in Patients Tested on SARS-CoV-2,nan,not yet recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04556318,NCT04556318,sars-cov-2 related volatile organic compounds (voc)|to compare the sars-cov-2 specific voc with the clinical symptoms of covid-19 and diagnostic findings,observational,observational model: cohort|time perspective: prospective
Prognostic Factors of Patients With COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04292964,NCT04292964,all-cause mortality|severe state,observational,observational model: cohort|time perspective: retrospective
SEVERITY SCORE FOR COVID-19 PNEUMONIA,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04372199,NCT04372199,"to identify the best predictors of critical coronavirus pneumonia and to realize a simple severity score able to early classify high-risk individuals admitted to internal medicine department for covid-19 disease, needing an intensive approach",observational,observational model: cohort|time perspective: prospective
Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy,nan,not yet recruiting,No Results Available,phase 1|phase 2,Other|NIH,https://ClinicalTrials.gov/show/NCT04532372,NCT04532372,"incidence of toxicity, graded according to the nci ctcae version 5|maximum tolerated dose (mtd) (phase 1)|clinical activity (response)(phase 2)|time to clinical activity (response)|overall survival|oxygen saturation improvement|sars-cov-2 resolution|hospitalization|mechanical ventilation required|mechanical ventilation duration|vital status (alive/dead)|vital status (cause of death)",interventional,"allocation: randomized|intervention model: sequential assignment|masking: double (participant, investigator)|primary purpose: treatment"
Lung Ultrasound in COVID-19 Patients,LUS-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04487769,NCT04487769,liberation from invasive ventilation|mortality,observational,observational model: cohort|time perspective: retrospective
MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009),nan,withdrawn,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04425733,NCT04425733,number of participants who experience an adverse event (ae)|number of participants who discontinued study drug due to an adverse event (ae)|change from baseline to day 1 in the time-weighted average from 0 through 24 hours (twa0-24hrs) for the ratio of blood oxygen saturation to the fraction of inspired oxygen (spo2/fio2)|change from baseline to day 2 in the time-weighted average from 0 through 24 hours (twa0-24hrs) for the ratio of blood oxygen saturation to the fraction of inspired oxygen (spo2/fio2)|change from baseline to day 3 in the time-weighted average from 0 through 24 hours (twa0-24hrs) for the ratio of blood oxygen saturation to the fraction of inspired oxygen (spo2/fio2)|change from baseline to day 4 in the time-weighted average from 0 through 24 hours (twa0-24hrs) for the ratio of blood oxygen saturation to the fraction of inspired oxygen (spo2/fio2)|change from baseline to day 5 in the time-weighted average from 0 through 24 hours (twa0-24hrs) for the ratio of blood oxygen saturation to the fraction of inspired oxygen (spo2/fio2)|change from baseline to day 6 in the time-weighted average from 0 through 24 hours (twa0-24hrs) for the ratio of blood oxygen saturation to the fraction of inspired oxygen (spo2/fio2)|change from baseline to day 7 in the time-weighted average from 0 through 24 hours (twa0-24hrs) for the ratio of blood oxygen saturation to the fraction of inspired oxygen (spo2/fio2),interventional,"allocation: randomized|intervention model: sequential assignment|masking: double (participant, investigator)|primary purpose: treatment"
Blood Volume Assessment in COVID-19 ICU Patients - BVAC19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04517695,NCT04517695,total blood volume (absolute and relative to ideal body weight)|red blood cell volume (absolute and relative to ideal body weight)|plasma volume (absolute and relative to ideal body weight)|transudation rate of the 131i albumin tracer|incidence of new onset renal injury (failure) and requirement for renal replacement therapy,observational,observational model: cohort|time perspective: prospective
"Epidemiologic, Clinical and Molecular Characteristics of Patients With Acute Respiratory Failure Affected by 2019-NCOV.",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04552340,NCT04552340,"mortality predictors in patients with respiratory failure who require oxygen therapy in the intensive care unit or ventilatory support.|molecular profile of cell populations present in the bal at early timepoint during sars-cov2 infection to predict severity of disease progression.|type of possible complications such as aki (acute kidney injury) , infection, shock|sars-cov2 mechanisms of infection in alveolar macrophages|sars-cov2 genotypes in a cohort of patients representative of the lombardy population|number of successful respiratory weaning",observational,observational model: cohort|time perspective: prospective
Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19),COVERAGE,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04356495,NCT04356495,"proportion of participants with an occurrence of hospitalization|death|proportion of hospitalizations, overall and by cause, in each group|death and causes of death|proportion of intensive care hospitalizations, overall and by cause, in each group|proportion of participants with negative nasopharyngeal sars-cov-2 rt-pcr|proportion of participants with a loss of autonomy evaluated by the adl and iadl scale|haematological markers evolution|biochemical markers evolution|inflammatory markers evolution|immunological markers evolution|adverse events|adverse reactions|plasma concentration|acceptability of the treatment",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04410510,NCT04410510,"evaluate the efficacy of p2et in reducing the length of hospital stay of patients with clinical suspicion or confirmed case of covid-19|efficacy of p2et in reducing the time to clinically significant improvement in patients with clinical suspicion or confirmed case of covid-19|proportion of patients with clinical suspicion or confirmed case of covid-19, who achieve clinical improvement after 14 days of treatment|proportion of patients with clinical suspicion or confirmed case of covid-19, who achieve clinical improvement after 28 days of treatment|efficacy of p2et in reducing the proportion of hospitalized patients with clinical suspicion or confirmed case of covid-19 who require admission to the icu due to worsening clinical symptoms.|efficacy of p2et in reducing the proportion of patients with clinical suspicion or confirmed case of covid-19 who die from the disease.|incidence of treatment-emergent adverse events (safety and tolerability) of the p2et in patients with covid-19",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: supportive care"
Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic,IBD-COVID-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04344249,NCT04344249,igg and igm anti sars-cov-2|clinical factors and severity of covid-19 infection|demographic factors and severity of covid-19 infection|pharmacologic factors and severity of covid-19 infection,observational,observational model: cohort|time perspective: prospective
Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore,nan,withdrawn,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04350450,NCT04350450,time to resolution of symptoms|number of days from onset of illness to symptom resolution|number of days to return to work|rate of hospital admission in treated and untreated healthcare workers|adverse effect of hcq during treatment,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Evaluation of Covid 19 Anxiety in Endometriosis Patients,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04337346,NCT04337346,covid 19 anxiety levels in endometriosis patients,observational,observational model: case-control|time perspective: prospective
COVID19-FOIE National Observatory,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04375670,NCT04375670,"mortality rate related to covid-19 in patients with a chronic liver disease|mortality rate according the stage of fibrosis and the cirrhotic status|mortality related to covid-19 according an history of hepatocellular carcinoma, an immunosuppressive treatment and this type the etiology-ies of liver disease at the infection and comorbidities.|incidence of liver complications",observational,observational model: cohort|time perspective: other
Contribution of a Prone Team in Intensive Care During the Covid-19 Epidemic,COVID-PRONE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04438941,NCT04438941,analysis of the effect of prone position in patients with covid-19 in intensive care,observational,observational model: case-only|time perspective: other
The C3I COVID-19 Project,nan,recruiting,No Results Available,nan,Other|NIH,https://ClinicalTrials.gov/show/NCT04506528,NCT04506528,mortality due to covid-19|covid-19 severity,observational,observational model: cohort|time perspective: other
Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,nan,completed,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04405999,NCT04405999,polymerase chain reaction (pcr)|time to symptoms|time to positive pcr|number of cases|case severity|drug tolerance,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Convalescent Plasma for the Treatment of COVID-19,nan,"active, not recruiting",No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04554992,NCT04554992,cumulative incidence of serious adverse events related to the treatment intervention.|mortality at day 28 post-hospital admission.|legnth of hospital stay|length of supplemental oxygen requirement.|length of mechanical ventilation requirement.|length of icu stay,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Early Short Course Corticosteroids in COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04374071,NCT04374071,transfer to intensive care unit (icu)|need for mechanical ventilation|mortality|development and severity of ards|length of hospital stay (los).,observational,observational model: cohort|time perspective: retrospective
"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.",nan,"active, not recruiting",No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04450004,NCT04450004,"immediate adverse event (aes)|solicited local and systemic adverse events (aes)|unsolicited adverse events (aes)|serious adverse events (saes), adverse events (aes) leading to withdrawal, adverse event of special interest (aesi) (including vaccine-enhanced disease) and deaths|safety labs|neutralizing antibody (nab assay) response|specific th1 cell-mediated immunity (cmi) response|specific th2 cell-mediated immunity (cmi) response|specific antibody response induced by the vaccine against the sars-cov-2 virus measured by total igg and/or igm levels|neutralizing antibody (nab assay) response induced by the treatment groups against the sars-cov-2 virus|specific th1 cell-mediated immunity (cmi) response induced by the vaccine against the sars-cov-2 virus|specific th2 cell-mediated immunity (cmi) response induced by the vaccine against the sars-cov-2 virus",interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: prevention
"A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls",nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04498442,NCT04498442,change in perceived stress levels|changes in resilience levels|changes in covid-19 prevalence|changes in self-reported duration of fever and respiratory symptoms in covid-19 positive participants|changes in self-reported readiness to return to work in covid-19 positive participants,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
FEnofibRate as a Metabolic INtervention for COVID-19,FERMIN,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04517396,NCT04517396,"hierarchical composite endpoint|number of days alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support in the 30 days following randomization|seven-category ordinal scale",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients,CODYS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04522037,NCT04522037,title : reduction of respiratory rate between hour 0 and hour 12 at initiation of morphine treatment,observational,observational model: cohort|time perspective: retrospective
COVID-19 Outbreak Consequences for Outpatients Followed in PRM,Handicall,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04384406,NCT04384406,proportion of patients necessitating the scheduling of a medical consultation|the reason for this urgent need of a medical consultation|the access to other medical services during the quarantine period|the interruption of home-based rehabilitation services,observational,observational model: cohort|time perspective: retrospective
Myeloproliferative Neoplasms (MPN) and COVID-19,MPN-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04385160,NCT04385160,pulmonary embolism (pe)|fatal or non fatal thrombotic event|continuous positive airway pressure (cpap)|invasive ventilation|admission in intensive care unit (icu)|death|treatments and interventions applied for mpn|treatments and interventions applied for covid-19|thrombotic events association to patients characteristic and treatments,observational,observational model: cohort|time perspective: other
Pediatric Acute and Critical Care COVID-19 Registry of Asia,PACCOVRA,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04395781,NCT04395781,overall severity of illness|respiratory complications|other complications|mortality,observational,observational model: cohort|time perspective: other
Atrium COVID-19 Syndromic and Serologic Surveillance,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04361123,NCT04361123,seroprevalence of sars-cov-2 infection in the general population of north carolina|seroprevalence of sars-cov-2 infection among health care workers of north carolina|cumulative incidence of sars-cov-2 infection|monthly incidence of sars-cov-2 infection|stratified incidence of sars-cov-2 infection by age group|stratified incidence of sars-cov-2 infection by sex|stratified incidence of sars-cov-2 by season|stratified incidence of sars-cov-2 infection by geographic area (zip code)|stratified incidence of sars-cov-2 infection by preexisting comorbidities|stratified incidence of sars-cov-2 infection by covid-2 contacts|‚ä¢stratified incidence of sars-cov-2 infection by use of personal protective equipment (ppe) by health workers|relative risk of sars-cov-2 infection by age group|relative risk of sars-cov-2 infection by sex|relative risk of sars-cov-2 infection by season|relative risk of sars-cov-2 infection by geographic area (zip code)|relative risk of sars-cov-2 infection by preexisting comorbidities|relative risk of sars-cov-2 infection by covid-2 contacts|relative risk of sars-cov-2 infection by use of ppe by health workers|incidence of sequelae,observational,observational model: cohort|time perspective: prospective
COVID-19 in Cancer Patients: Evaluation of Clinical Course and Impact on Oncological Care Including Biobanking,COVIDHELP,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04408339,NCT04408339,"rate of hospitalization|duration of hospitalization|rate of admission to intensive care unit|length of stay in intensive care unit|need of mechanical ventilation|duration of mechanical ventilation|disease-specific mortality rate|rate of patients, whose oncologic treatment had to be modified due to covid-19|cellular and humoral immune response to covid-19 infection",observational,observational model: cohort|time perspective: prospective
Global Impact of COVID-19 on Pulmonology Special Units,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04554251,NCT04554251,global impact of covid-19 on baseline patients number|measure the changes in practice in each unit|frequency of sars-cov-2 infection in healthcare workers,observational,observational model: cohort|time perspective: prospective
Clinical Characterisation Protocol for COVID-19 in People Living With HIV,COVIDHIV,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04361604,NCT04361604,"describe the course of covid-19 disease in patients infected with hiv,",observational,observational model: cohort|time perspective: other
Helmet CPAP Versus HFNC in COVID-19,COVID HELMET,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04395807,NCT04395807,ventilator-free days (vfd)|spo2/fio2-ratio|patient comfort|frequency of endotracheal intubation|frequency of carbon dioxide rebreathing|days alive within,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Kidney Involvement in COVID-19 Disease (COVKID),COVKID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04355624,NCT04355624,kidney involvement in covid-19 disease|physiopathologic mechanism of kidney involvement in sars-cov-2 infection|to identify risk factors for kidney involvement in in sars-cov-2 infection|to evaluate the impact of kidney involvement in sars-cov-2 infection|to assess the long-term health effect of kidney injury on survivors of sars-cov-2 infection in case of aki kdigo 2 or 3,observational,observational model: cohort|time perspective: prospective
Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04406493,NCT04406493,correlation between impudence deterioration to clinical conditions and hospitalization period,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes,nan,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04397900,NCT04397900,identify the viral epitopes of memory cd8+ t cells from individuals that have recovered from sars-cov-2 infection.|determine which sars-cov-2 proteins are frequently recognized by t cells in patients with varying hla types.,observational,observational model: other|time perspective: retrospective
The COVID-19 Disease and CARdiac Events Study,COVICARE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04438993,NCT04438993,cardiac abnormalities in covid-19 disease in-patients|biomarkers,observational,observational model: cohort|time perspective: prospective
COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2,COVIDMED,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04328012,NCT04328012,national institute of allergy and infectious diseases covid-19 ordinal severity scale (ncoss)|hospital length of stay (los)|intensive care unit level los|mechanical ventilation|survival,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
The Effect of Aromatherapy on COVID-19-induced Anxiety,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04495842,NCT04495842,change from baseline in state anxiety on the state portion of the state trait anxiety scale (stai-s) at 15 minutes,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: supportive care
Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System: CV COVID-19 Registry,CV-COVID-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04359927,NCT04359927,cardiovascular mortality|acute myocardial infarction|stroke,observational,observational model: case-control|time perspective: cross-sectional
Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection,IDRA-COVID19,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04435587,NCT04435587,adverse event rates|efficacy for shortening duration of sar-cov2 detection by pcr|antibody detection rates,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19,RESCUE 1-19,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04366791,NCT04366791,rate of extubation (for intubated patients)|clinical outcome - temperature|clinical outcome - heart rate|clinical outcome - systolic blood pressure|clinical outcome - oxygenation|clinical outcome - respirations|clinical outcome - fio2|clinical outcome - peep|clinical outcome - tidal volume|clinical outcome - intubation/extubation events|clinical outcome - overall survival|radiographic outcome - chest xray|radiographic outcome - ct can|serologic outcome - wbc|serologic outcome - hgb|serologic outcome - procalcitonin|serologic outcome - anc|serologic outcome - creatine kinase|serologic outcome - myoglobin|serologic outcome - albumin|serologic outcome - pt/ptt|serologic outcome - d-dimer|serologic outcome - ggt|serologic outcome -triglycerides|serologic outcome -ferritin|serologic outcome -fibrinogen|serologic immune markers flow cytometry|serologic outcome -bilirubin|serologic outcome - ldh|serologic outcome - creatinine|serologic outcome - egfr|serologic outcome - crp|serologic outcome - alt|serologic outcome - ast|serologic outcome - troponin-i|serologic outcome - bnp|serologic outcome - blood gases ph|serologic outcome - blood gases po2|serologic outcome - blood gases pco2|serologic outcome - lactic acid|serologic outcome - il-6|serologic outcome - potassium,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04384042,NCT04384042,presence or absence of olfactory and taste disturbances in study participants|adjusted odds ratio of olfactory & taste disturbances in covid-19 infection|clinical manifestations of study participants|other pre-existing health conditions|positive predictive value (ppv) of olfactory and taste disturbances in predicting diagnosis of covid-19 infection|negative predictive value (npv) of olfactory and taste disturbances in predicting absence of covid-19 infection|sensitivity of olfactory and taste disturbances in predicting covid-19 infection|specificity of olfactory and taste disturbances in predicting covid-19 infection,observational,observational model: case-control|time perspective: retrospective
Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04390165,NCT04390165,presence or absence of olfactory and taste disturbances in covid-19 patients|prevalence of olfactory disturbances in covid-19 patients|prevalence of taste disturbances in covid-19 patients|clinical manifestations of study participants|other pre-existing health conditions|rating of baseline sense of smell & taste in covid-19 patients prior to diagnosis of their infection|rating of sense of smell & taste in covid-19 patients at time of diagnosis of their infection|rating of sense of smell & taste in covid-19 patients at time of answering questionnaire survey,observational,observational model: case-only|time perspective: cross-sectional
"COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur",Curie-O-SA,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04369066,NCT04369066,antibodies against the sars-cov-2 virus in serum at inclusion|antibodies against the sars-cov-2 virus in serum at 1 month|antibodies against the sars-cov-2 virus in serum at 3 months|antibodies against the sars-cov-2 virus in serum at 6 months|comparative performance of anti-sars-cov-2 antibody detection techniques|prevalence of immune subjects for sars-cov-2|nature and quantity of anti-sars-cov-2 antibodies|evolution of the different antibodies against the sars-cov-2 virus over time.|prevalence of anti-covid iga response in the nasal mucosa,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
International Registry of Coronavirus (COVID-19) Exposure in Pregnancy,IRCEP,recruiting,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04366986,NCT04366986,pregnancy outcomes|birth outcomes,observational,observational model: cohort|time perspective: prospective
Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04455958,NCT04455958,severity of symptoms|clinical benefit rate of lopinavir/ritonavir|time to symptom progression|time to improvement of participants|time to hospital admission for those who develop severe of critical symptoms|intensive care unit (icu) admission: yes or no|receiving ventilator support: yes or no|overall survival,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19",nan,recruiting,No Results Available,phase 3,Industry|U.S. Fed|NIH,https://ClinicalTrials.gov/show/NCT04470427,NCT04470427,number of participants with a first occurrence of covid-19 starting 14 days after second dose of mrna-1273|number of participants with adverse events (aes) or medically attended aes (maaes) leading to withdrawal|number of participants with solicited local and systemic adverse reactions (ars)|number of participants with unsolicited aes|number of participants with a first occurrence of severe covid-19 starting 14 days after second dose of mrna-1273|number of participants with a first occurrence of either covid-19 or sars-cov-2 infection regardless of symptomatology or severity starting 14 days after second dose of mrna-1273 or placebo|number of participants with a secondary case definition of covid-19 starting 14 days after second dose of mrna-1273 or placebo|number of participants with a first occurrence of covid-19 starting 14 days after first dose of mrna-1273 or placebo|number of participants with a first occurrence of covid-19 starting 14 days after second dose of mrna-1273 or placebo regardless of evidence of prior sars-cov-2 infection|number of participants with a first occurrence of sars-cov-2 infection in the absence of symptoms defining covid-19 starting 14 days after second dose of mrna-1273 or placebo|geometric mean titer (gmt) of sars-cov-2 specific neutralizing antibody (nab)|geometric mean fold rise (gmfr) of sars-cov-2 specific nab|quantified levels or gmt of s protein-specific binding antibody (bab)|gmfr of s protein specific bab,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE),SAVE,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04357366,NCT04357366,the ratio of patients who will not develop serious respiratory failure (srf)|comparison of the rate of patients who will not develop serious respiratory failure (srf) until day 14 with historical comparators from hellenic sepsis study group database|change of scoring for respiratory symptoms in enrolled subjects between days 1 and 7|change of scoring for respiratory symptoms in enrolled subjects between days 1 and 14|change of sofa score in enrolled subjects between days 1 and 7|change of sequential organ failure assessment (sofa) score in enrolled subjects between days 1 and 14|change of cytokine production between days 1 and 7|change of plasma inflammatory mediators levels between days 1 and 7,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
The Impact of COVID-19 Pandemic on Critical Limb Threatening Ischemia and Emergency Vascular Practice,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04452682,NCT04452682,the icu admission with associated pneumonia|impact of covid-19 on the different presentation of vascular surgery at the emergency|mortality rates,observational,observational model: case-only|time perspective: retrospective
WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound,INVICTUS,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04372680,NCT04372680,delay from the start of mechanical ventilation weaning process to extubation|delay from intubation to extubation|successful of extubation|mortality rate,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: diagnostic
Prediction of Unfavourable Outcome in Newly Covid-19 Hospitalized Patient,PredictCovid19,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04412031,NCT04412031,"need of mechanical ventilation, transfer to an intensive care unit or death within 21 days of admission.",observational,observational model: cohort|time perspective: retrospective
Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04400799,NCT04400799,hospitalizations|all-cause death|number of cardiovascular events|any hospitalizations|net clinical benefit|disseminated intravascular coagulation,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04346420,NCT04346420,change in o2 output|comfort with the interfaces|changes in pao2|changes in paco2|changes in ph|changes in respiratory rate,interventional,allocation: non-randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: supportive care
Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient,BIOCOVU,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04341792,NCT04341792,rate of secondary aggravation|change of standart biological parameters|change of von willebrand factor (vwf) changes over time|change of the factor viii (fviii)|prevalence of positivity of covid-19 virus measured by pcr or serology,observational,observational model: cohort|time perspective: prospective
Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04424017,NCT04424017,describe the serological status of individuals in the study by presence of specific anti-sars-cov-2 antibodies,observational,observational model: other|time perspective: cross-sectional
Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19,RUXO-COVID,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04477993,NCT04477993,a composite outcome of death or icu admission or mechanical ventilation at day 14.|a composite outcome of death or icu admission or mechanical ventilation at day 28|time to treatment failure|overall survival at days 14 and 28|cumulative incidence of icu admission rate at days 14 and 28|cumulative incidence of mechanical ventilation at days 14 and 28|duration of hospital stay|duration of icu stay|duration of mechanical ventilation|duration of non-invasive ventilation|secondary hemophagocytic syndrome rate|cumulative incidence nosocomial infection rate at days 14 and 28|incidence of discontinuation of oxygen supplementation at days 14 and 28|rate of grade 1-2 and 3-5 emerging adverse events at day 28|cumulative dose of methylprednisolone at days 14 and 28|change in pao2/fio2 ratio from baseline to days 14 and 28|change in interleukin 6 levels [pg/ml] from baseline to days 14 and 28|change in d-dimer levels [ng/ml] from baseline to days 14 and 28|change in fibrinogen levels [mg/dl] from baseline to days 14 and 28|change in ferritin levels [ng/ml] from baseline to days 14 and 28|change in c reactive protein levels [mg/l] from baseline to days 14 and 28|change in alanine aminotransferase [u/l] from baseline to days 14 and 28|change in aspartate aminotransferase [u/l] from baseline to days 14 and 28|change in creatinine levels [mg/dl] from baseline to days 14 and 28|change in glucose levels [mg/dl] from baseline to days 14 and 28|change in hemoglobin levels [g/dl] from baseline to days 14 and 28|change in platelet count [x10àü3/mmàü3] from baseline to days 14 and 28|change in absolute neutrophil count [x10àü3/mmàü3] from baseline to days 14 and 28|change in absolute neutrophil count [/mmàü3] from baseline to days 14 and 28|change in absolute lymphocyte count [/mmàü3] from baseline to days 14 and 28|change in prothrombin time ratio from baseline to days 14 and 28|change in partial thromboplastin time ratio from baseline to days 14 and 28|change in bilirubin [mg/dl] from baseline to days 14 and 28|change in lactate dehydrogenase [u/l] from baseline to days 14 and 28|change in cpk-mb [ng/ml] from baseline to days 14 and 28|change in troponin [ng/ml] from baseline to days 14 and 28|change in von willebrand factor antigen level (vwf:ag) [%] from baseline to days 14 and 28|change in von willebrand factor activity (ristocetin cofactor) [%] from baseline to days 14 and 28|change in adamts-13 [%] from baseline to days 14 and 28|change in von willebrand multimeters from baseline to days 14 and 28|change in plasminogen activator inhibitor-1 levels [ng/ml] from baseline to days 14 and 28|change in e-selectin levels [ng/ml] from baseline to days 14 and 28|change in p-selectin levels [ng/ml] from baseline to days 14 and 28|change in endothelin [fmol/ml] from baseline to days 14 and 28|change in circulating microparticles from baseline to days 14 and 28|change in thromboelastography from baseline to days 14 and 28,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04540419,NCT04540419,"superiority of the vaccine ad5-ncov to placebo by the level of seroconversion|immunogenicity of the vaccine ad5-ncov compared with placebo (titer of sars-cov-2 antibodies)|immunogenicity of the vaccine ad5-ncov compared with placebo (level of seroconversion)|immunogenicity of the vaccine ad5-ncov compared with placebo (rise of sars-cov-2 antibodies)|immunogenicity of the vaccine ad5-ncov compared with placebo (t-cell response)|frequency of confirmed covid-19|frequency of confirmed cases of covid-19, requiring hospitalization|frequency of cases with severe course of covid-19|frequency of death due to covid-19.|reactogenicity of the vaccine ad5-ncov compared with placebo|frequency and character of adverse events and serious adverse events.|to evaluate safety of the vaccine ad5-ncov by its effect on vital parameters (blood pressure)|to evaluate safety of the vaccine ad5-ncov by its effect on vital parameters (heart rate)|to evaluate safety of the vaccine ad5-ncov by its effect on vital parameters (respiratory rate)|to evaluate safety of the vaccine ad5-ncov by its effect on results of physical examination|to evaluate safety of the vaccine ad5-ncov by its effect on results of electrocardiography (heart rate)|to evaluate safety of the vaccine ad5-ncov by its effect on results of electrocardiography|to evaluate safety of the vaccine ad5-ncov by its effect on results of serum chemistry (enzymes)|to evaluate safety of the vaccine ad5-ncov by its effect on results of serum chemistry|to evaluate safety of the vaccine ad5-ncov by its effect on results of complete blood count (hemoglobin)|to evaluate safety of the vaccine ad5-ncov by its effect on results of complete blood count (hematocrit)|to evaluate safety of the vaccine ad5-ncov by its effect on results of complete blood count (erythrocytes)|to evaluate safety of the vaccine ad5-ncov by its effect on results of complete blood count|to evaluate safety of the vaccine ad5-ncov by its effect on results of complete blood count (erythrocyte sedimentation rate)|to evaluate safety of the vaccine ad5-ncov by its effect on results of coagulogram|to evaluate safety of the vaccine ad5-ncov by its effect on results of coagulogram (fibrinogen)|to evaluate safety of the vaccine ad5-ncov by its effect on results of clinical urinalysis (relative density)|to evaluate safety of the vaccine ad5-ncov by its effect on results of clinical urinalysis (ph)|to evaluate safety of the vaccine ad5-ncov by its effect on results of clinical urinalysis|to evaluate safety of the vaccine ad5-ncov by its effect on results of clinical urinalysis (protein)|to evaluate safety of the vaccine ad5-ncov by its effect on results of clinical urinalysis (glucose)|to evaluate safety of the vaccine ad5-ncov by its effect on results of determination of immunoglobulin e serum concentrations.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Anti-SARS Cov-2 T Cell Infusions for COVID 19,BATIT,not yet recruiting,No Results Available,phase 1,Other|Industry,https://ClinicalTrials.gov/show/NCT04401410,NCT04401410,graft versus host disease (gvhd)|cytokine release syndrome (crs)|immune effector cell-associated neurotoxicity syndrome (icans)|adverse events|clinical response assessment: world health organization (who) ordinal scale,interventional,allocation: randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Vitamin D Testing and Treatment for COVID 19,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04407286,NCT04407286,vitamin d levels|severity of covid 19 symptoms,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Early CPAP in COVID-19 Patients With Respiratory Failure.,EC-COVID-RCT,suspended,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04326075,NCT04326075,death or need of intubation|30-day mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation,UPSAT,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04344561,NCT04344561,incidence of mechanical ventilation|number of participants with supplemental oxygen requirements|mean oxyhemoglobin saturation|mean nocturnal oxyhemoglobin saturation|heart rate|respiratory rate|percentage of time in the assigned position,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Immune Changes in Severe COVID-19 Pulmonary Infections,COVIDIMM,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04386395,NCT04386395,changes in monocytes hla-dr expression|changes in lymphocytes subpopulations numbers|changes in monocytes number|tnfalpha level|infgamma level|il1beta level|sofa score|number of recorded deaths|presence of pneumonia|presence of bacteremia|presence of urinary tract infection|c reactive protein|d dimers,observational,observational model: cohort|time perspective: prospective
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19,nan,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04347226,NCT04347226,time to improvement in the 7-point ordinal scale|time to death|time to intubation|proportion of patients requiring icu admission|percentage rate of mortality at 1 month,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04399681,NCT04399681,presence of viral pneumonia caused by covid 19,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients,SIDIACO,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04365517,NCT04365517,time for clinical improvement|clinical parameter of acute lung disease|biochemical parameter of acute lung disease|clinical parameters of acute lung disease|dipeptilpeptidase 4 expression in biological samples|cytokine-inflammatory profile|glycemic variability,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Endothelial Function, Inflammation and Organ Dysfunction in COVID-19",nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04408365,NCT04408365,"plasma bio-adrenomedullin, proenkephalin, dipeptidyl peptidase-3, renin and angiotensin ii|duration of vasodilatory shock|acute kidney injury|need for renal replacement therapy|duration of ventilation|duration of extracorporeal membrane oxygenation|mortality",observational,observational model: cohort|time perspective: prospective
Characterizing the Immune Response and Neuronal Damage in COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04510012,NCT04510012,cytokine response to sars-cov-2|innate immune response to sars-cov-2|humoral immune response|cell mediated immune response|neurological damage|complement activation,observational,observational model: cohort|time perspective: prospective
Prognostication of Recovery in Early Disorders of Consciousness After COVID-19,PREDICT-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04476589,NCT04476589,disability rating scale score,observational,observational model: cohort|time perspective: prospective
Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19),CovILD,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04416100,NCT04416100,pattern of pulmonary abnormalities in sars-cov2 infected patients after 1 month|pattern of pulmonary abnormalities in sars-cov2 infected patients after 3 months|pattern of pulmonary abnormalities in sars-cov2 infected patients after 6 months,observational,observational model: cohort|time perspective: prospective
African Covid-19 Critical Care Outcomes Study,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04367207,NCT04367207,"in-hospital mortality|risk factors (resources, comorbidities and interventions) associated with mortality",observational,observational model: cohort|time perspective: prospective
BAttLe Against COVID-19 Using MesenchYmal Stromal Cells,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04348461,NCT04348461,efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by survival rate)|safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by adverse event rate,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
"Perceptions, Representations and Experiences of Septic Isolation of Hospitalized Patients for COVID-19 Infection",nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04432922,NCT04432922,"to highlight the perceptions, representations and experiences of septic isolation of patients hospitalized for covid-19 infection|to identify key elements to improve the medical discourse on septic isolation among patients",observational,observational model: other|time perspective: prospective
Clinical Trial of Sarilumab in Adults With COVID-19,SARICOR,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04357860,NCT04357860,"ventilation requirements|crude mortality|time to clinical improvement|time until improvement in oxygenation|proportion of patients requiring invasive mechanical ventilation|proportion of patients having negative covid-19 crp at each visit|mean of serum cytokine levels|adverse events related to medication and its administration|incidence in the appearance of serious bacterial, fungal or opportunistic infections|incidence of perforation of the gastrointestinal tract|leukocyte and neutrophil count|hemoglobin levels|platelet count|levels of creatinemia|bilirubin levels|alt and ast levels",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04412057,NCT04412057,proportion of patient alive and free of respiratory failure|proportion of subjects who are alive,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
MOIST Study: Multi-Organ Imaging With Serial Testing in COVID-19 Infected Patients,MOIST,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04525404,NCT04525404,"native myocardial t1 relaxation time|flair imaging|compare 12-week cognitive testing to the corresponding findings on mri of brain, heart and lung at baseline|compare 12-week spirometry to the corresponding findings on mri of brain, heart and lung at baseline|compare 12-week walk test results to the corresponding findings on mri of brain, heart and lung at baseline|compare 12-week cognitive testing in patients with normal smell and/or normal appearing brainstem on mri to patients with no or impaired smell and/or injury to brainstem on mri|compare mri measures of organ dysfunction at 12-24 weeks in survivors according to severity of prior covid-19 illness: (i) hospitalized, (ii) symptomatic, not hospitalized and (iii) asymptomatic",observational,observational model: cohort|time perspective: prospective
Post Intensive Care Syndrome in COVID19 Patients,PICS-COVID19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04422444,NCT04422444,change from baseline short form 12 health survey (sf12) at 12 month|change from baseline lawton & brody instrumental activities of daily living scale at 12 months|change from baseline perceived deficits questionnaire (pdq) at 12 months|change from baseline hospital anxiety and depression scale (hads) at 12 months|change from baseline davidson trauma scale (dts) at 12 months,observational,observational model: cohort|time perspective: prospective
Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury (EVICT-CORONA-ALI),nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04344184,NCT04344184,number of ventilator-free days|all-cause-mortality|acute-inflammation-free days|organ-failure-free days,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",PROTECT,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04338698,NCT04338698,laboratory result|clinical outcome,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: treatment"
Determination of Acute Encephalopathy Predictors in Patients With COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04405544,NCT04405544,the percentage of patients who have developed encephalopathy,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: diagnostic
Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04420247,NCT04420247,world health organization (who) 9-levels scale (from 0-8)|who 9-levels scale (from 0-8)|mortality|ventilation free days|duration of mechanical ventilation|national early warning score (news)|icu lenght of stay|hospital lenght of stay|acute kidney disease incidence|percentage of patients needing dialysis|mean of c reactive protein levels|mean of leucocytes levels|mean of lymphocyte levels,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,COVID-AIV,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04311697,NCT04311697,mortality|pao2:fio2 ratio|tnf alpha|multi-system organ failure free days|days free of respiratory failure,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Psychological Impact of COVID-19 Outbreak on Caregivers,PSY-CO-ICU,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04511780,NCT04511780,post-traumatic stress disorder|anxiety and depression|burn out,observational,observational model: cohort|time perspective: prospective
Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women,HyPreC,withdrawn,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04354441,NCT04354441,covid-19-related hospital admissions|symptoms related to covid-19 infection|adverse events|maternal outcomes|newborn outcomes,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2,ANTI-COV-2,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04354766,NCT04354766,production of several human monoclonal antibodies capable of neutralizing the infection of a target cell by sars-cov-2.,observational,observational model: cohort|time perspective: prospective
Oral Health and Psychosocial Factors During the Covid-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04381273,NCT04381273,how do people assess their oral health-related quality of life in times of the covid-19 pandemic?|does the periodontitis risk have an influence on the severety of the covid-19 disease and its' treatment?|do psychosocial stress factors in times of the covid-19 pandemic have an impact on their oral health related quality of life?|have people changed their oral hygiene practices in times of the covid-19 pandemic?,observational,observational model: other|time perspective: prospective
Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19,COVID-19,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04502667,NCT04502667,"interleukins (il-2,6,7,10) (pg/ml)|ferritin (ng/ml)|dimer-d|vitamin d (ng/ml)",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
ACEI or ARB and COVID-19 Severity and Mortality in US Veterans,nan,"active, not recruiting",No Results Available,nan,Other|U.S. Fed,https://ClinicalTrials.gov/show/NCT04467931,NCT04467931,all-cause-hospitalization or all-cause mortality|all-cause mortality|icu admission|duration of hospitalization|mechanical ventilation|dialysis,observational,observational model: cohort|time perspective: retrospective
The Impact of COVID-19 on Dialysis Users,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04422873,NCT04422873,"qualitative assessment of the effect of covid-19 restrictions on patients' well-being, quality of life and physical activity and sedentary behaviours|thematic analysis of qualitative interview exploring patients' experiences of telemedicine during the covid-19 restrictions in the uk",observational,observational model: cohort|time perspective: cross-sectional
COVID-19 in Pain Perspective,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04454333,NCT04454333,numeric rating scale for pain|hospital anxiety and depression scale (hads)|sf-12 health assesment questionaire,observational,observational model: cohort|time perspective: retrospective
"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older",nan,"active, not recruiting",No Results Available,phase 2,Industry|U.S. Fed,https://ClinicalTrials.gov/show/NCT04405076,NCT04405076,"solicited local and systemic adverse reactions (ars)|unsolicited adverse events (aes)|medically-attended adverse events (maaes)|serious adverse events (saes)|change in the measure of clinical safety laboratory values in cohort 2 from baseline|the number and percentage of participants with abnormalities in blood pressure, temperature, hr or respiratory rate will be assessed.|the number and percentage of participants with abnormalities in physical examinations will be assessed|evaluate immunogenicity of mrna-1273 by titer of sars-cov-2-specific binding antibody (bab) measured by enzyme-linked immunosorbent assay (elisa)|titer of sars-cov-2-specific neutralizing antibody (nab)|seroconversion as measured by an increase of sars-cov-2-specific neutralizing antibody (nab) titer",interventional,"allocation: randomized|intervention model: sequential assignment|masking: double (participant, investigator)|primary purpose: prevention"
Seroconversion Among Staff at a Large Acute Care Hospital in Denmark During the COVID-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04431310,NCT04431310,serology testing for specific covid-19|sars-cov-2 infection,observational,observational model: cohort|time perspective: prospective
Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection,SOLID,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407143,NCT04407143,description of the characteristics of patients,observational,observational model: cohort|time perspective: prospective
The Effect of Covid-19 on Patient Outcomes Among Operated Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04525716,NCT04525716,death|length of stay|complications,observational,observational model: cohort|time perspective: prospective
ICU Trial in Critical Ill COVID-19 Patients,POINT-C,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04349982,NCT04349982,icu cv risk and biomarker (e.g. troponin)|cv risk and outcome during icu stay,observational,observational model: cohort|time perspective: prospective
Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04480398,NCT04480398,virologic clearance|change in the number of patients going from asymptomatic to moderately disease|hospital stay|clinically relevant adverse effects,observational,observational model: cohort|time perspective: retrospective
"Platelet Count, Platelet, Mean Platelet Volume and Platelet Distribution Width in COVID-19",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04378829,NCT04378829,change in pdw and mpv parameters,observational,observational model: case-only|time perspective: retrospective
Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04366063,NCT04366063,adverse events assessment|blood oxygen saturation|intensive care unit-free days|clinical symptoms|respiratory efficacy|biomarkers concentrations in plasma,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q Vest for COVID-19,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04369599,NCT04369599,change in arterial oxygenation levels|number of participants requiring advanced therapy|number of participants avoiding proning ventilation|number of participants delaying proning ventilation,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds,PEACE,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04346667,NCT04346667,rt-pcr negative status|progression of symptoms|development of symptoms|adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: treatment"
Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04530617,NCT04530617,rate of hospitalizations and oxygen use,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04385901,NCT04385901,change in 6 minute walk test|change in short form 35 (sf-36) questionnaire|change in strength testing|change in peak flow meter test,interventional,"allocation: non-randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: treatment"
"Knowledge, Attitudes, and Practices Towards COVID-19 Among Health Care Professionals Among Healthcare Professionals",nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04492202,NCT04492202,"questionnaire for the evaluation of knowledge, attitude and practise levels of healthcare professionals for covid-19|support approach survey for patients in recovery stage after covid-19 diagnosis",observational,observational model: other|time perspective: other
"Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04342806,NCT04342806,"number and percent of participants who enroll in the hero registry study by geographic region, age, covid-19 risk factors, and past covid-19 diagnosis|distribution of covid-19 risk factors by participant characteristics|proportion of participants undergoing changes in health status (e.g. new diagnosis of covid-19, er visits, hospitalization)|proportion of all participants enrolled in the hero registry who participate in an ancillary research study|proportion of participants who continue to supple information about their health to the hero registry at various time points after their enrollment",observational,observational model: cohort|time perspective: prospective
Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy,(ESCAPE),recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04361253,NCT04361253,modified who ordinal scale (mos) score,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04379492,NCT04379492,clinical improvement on the ordinal scale for clinical improvement (osci)|number of participants requiring mechanical ventilation for respiratory failure,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04365764,NCT04365764,composite of death and mechanical ventilation|death|mechanical ventilation|world health organization score,observational,observational model: case-control|time perspective: cross-sectional
Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,MolCOVID,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04367545,NCT04367545,number of positive patient using saliva method compared to number of positive patient using standard method|number of negative patient using saliva method compared to number of negative patient using standard method,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04434118,NCT04434118,the risk of covid-19 infection among ra patients|the incidence of hospitalization for covid-19 patients.,observational,observational model: case-control|time perspective: retrospective
Endotracheal Tube Obstruction in Covid-19 Patients Requiring Mechanical Ventilation,TubeObs-Covid,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04394429,NCT04394429,analysis of risk factors for intubation tube obstruction,observational,observational model: case-only|time perspective: other
Prone Positioning for Patients on General Medical Wards With COVID19,COVID-PRONE,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04383613,NCT04383613,"composite outcome of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, or need for fio2 of 60% or more|length of hospitalization|adverse events of prone positioning (i.e., venous thromboembolism, pneumonia)|in-hospital all-cause mortality|invasive or non-invasive mechanical ventilation|need for fio2 of 60% or more|ventilator-free days (i.e., the number of days in hospital the patient was not on a ventilator)|composite outcome of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, or need for fio2 of 60% or more assessed at 30 days, 90 days and 1 year|time spent in prone positioning among patients achieving the composite outcome of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, or need for fio2 of 60% or more",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (investigator)|primary purpose: other
Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status,RECOVIDS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04556513,NCT04556513,respiratory sequelae 6 months after resuscitation.,observational,observational model: cohort|time perspective: prospective
"Reactogenicity, Safety and Immunogenicity of QazCovid-in¬Æ COVID-19 Vaccine",nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04530357,NCT04530357,"frequency of adverse events up to seven days after immunization|frequency of adverse events up to 21 days after immunization|the proportion of volunteers with increased levels of the immune response of specific neutralizing antibody titers in elisa following the vaccination, compared with a placebo|incidence of serious adverse events during the study|cell-mediated immune profile",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF),nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04534569,NCT04534569,consensus using participating experts opinions.,observational,observational model: other|time perspective: prospective
Efficacy and Safety of Itolizumab in COVID-19 Complications,nan,completed,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04475588,NCT04475588,"one-month mortality rate between the two arms|biomarkers (il-6, tnf-a, il1, il17, etc‚ä¶)|lymphocyte count|crp (c-reactive protein) level|pao2 (partial pressure of oxygen) / fio2 (fraction of inspired oxygen, fio2) ratio (or p/f ratio)|radiological response|duration of hospitalization|remission of respiratory symptoms",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium,nan,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04513314,NCT04513314,change from baseline rass score of +3 or greater|total dose of dexmedetomidine administered|incidence of treatment emergent adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: treatment"
Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19,BONSAI,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04504877,NCT04504877,ambi-hss: abbreviated maslach burnout inventory - human services survey|posttraumatic stress disorder checklist for dsm-5 (pcl-5)|brief measure for assessing generalized anxiety disorder: the gad-7|phq-9: patient¬¥s health questionnaire-9|change in proinflammatory cytokine concentration|number of participants with treatment-related adverse events as assessed by ctcae v5.0,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19,CQOTE,withdrawn,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04360759,NCT04360759,"event-free survival at 28 days post-randomization between experimental group and standard of care group|incidence of serious adverse events|incidence of adverse events of special interest related to investigational product at time of hospitalisation|premature discontinuation of treatment|time from treatment initiation to death, ards (pf/sf ratio < 300), or mechanical ventilation|proportion with moderate and severe ards|duration of hospitalisation and icu stay in survivors|incidence of covid-19 in household contacts",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19,nan,suspended,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04278963,NCT04278963,"mean clinical recovery time (hours)|time to covid-19 rt-pcr negative in upper respiratory tract specimen|change (reduction) in covid-19 viral load in upper respiratory tract specimen as assessed by area under viral load curve.|time to defervescence (in those with fever at enrolment)|time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)|frequency of requirement for supplemental oxygen or non-invasive ventilation|frequency of respiratory progression|severe case incidence|proportion of re-hospitalization or admission to icu|all-cause mortality|frequency of serious adverse events",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: treatment"
Use of Technology and Telemedicine to Improve Quality of Care in COVID 19 Patients,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04480411,NCT04480411,hospital admission rate|hospital re-admission rate|hospital length of stay|patient provider experience survey score|provider experience survey score|use of personal protective improvement|number of in-patient encounters with covid patients as a measure of provider exposure to high risk illness,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04380935,NCT04380935,all-cause mortality|length of stay in intensive care unit|duration of mechanical ventilation|body temperature (degree in celsius)|the sequential organ failure assessment (sofa) score|pao2/fio2 ratio|c-reactive protein (crp) in mg/l|d-dimer in ng/ml|procalcitonin in ng/ml|interleukin 6 (il-6) in pg/ml|allergic/ anaphylaxis transfusion reaction|hemolytic transfusion reaction|transfusion related acute lung injury|transfusion associated circulatory overload,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
SPI-1005 Treatment in Severe COVID-19 Patients,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04483973,NCT04483973,number of participants with treatment-related adverse events|who ordinal scale|degree of supplemental oxygen|peripheral oxygen saturation (spo2),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room,ReCovER,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04351854,NCT04351854,"identification of risk factors present at the earliest stage of hospital care (i.e. in the ed) that warrant hospital admission.|determination of the course of the disease (days since onset of symptoms, nature of symptoms, e.g. fever, chills, headache) and the state at which patients present to the ed|identification of the ratio of patients with mild or moderate to severe disease",observational,observational model: case-control|time perspective: retrospective
SPI-1005 Treatment in Moderate COVID-19 Patients,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04484025,NCT04484025,number of participants with treatment-related adverse events|who ordinal scale|degree of supplemental oxygen|peripheral oxygen saturation (spo2),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19,COPLASCOV19,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04356482,NCT04356482,clinical improvement|improvement in tomographic image|test positivity for covid-19|early and late complications associated to convalescent plasma|days at icu,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04412304,NCT04412304,28-days icu mortality|incidence of thromboembolic events|incidence of bleeding events|icu-free days alive from icu-admission.,observational,observational model: cohort|time perspective: retrospective
"Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19",nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04389450,NCT04389450,number of ventilator free days|all-cause mortality|duration of mechanical ventilation,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,COPCOV,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04303507,NCT04303507,number of symptomatic covid-19 infections|symptoms severity of covid-19|number of asymptomatic cases of covid-19|number of symptomatic acute respiratory illnesses|severity of symptomatic acute respiratory illnesses,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
Remdesivir vs Chloroquine in Covid 19,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04345419,NCT04345419,number of patients with improvement or mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Postural Recruitment Maneuver in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Infection,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04475068,NCT04475068,effects of a postural recruitment maneuver in lung aeration|effects of a postural recruitment maneuver in distribution of ventilation|effects of a postural recruitment maneuver in gas exchange|effects of a postural recruitment maneuver in respiratory mechanics|effects of a postural recruitment maneuver in hemodynamic|feasibility of a postural recruitment maneuver,observational,observational model: cohort|time perspective: prospective
Prospective Observational Cohort Study of Critically Ill Patients With Covid-19 in Sweden,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04382417,NCT04382417,demographic characteristics of patients with covid-19 receiving intensive care|survival rate in patients with covid-19 receiving intensive care|clinical course characteristics of patients with covid-19 receiving intensive care|number of days on mechanical ventilation,observational,observational model: cohort|time perspective: prospective
Pilot Study on Cytokine Filtration in COVID-19 ARDS,CytokCOVID19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04361526,NCT04361526,mechanical ventilation-free days|30-day mortality|length of icu stay (days)|length of hospital stay|duration of renal replacement and cathecolamines therapies|need for extracorporeal membrane oxygenation (ecmo) support|multi-organ failure measured by the sequential organ failure assessment (sofa) score,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Awake Prone Positioning and Oxygen Therapy in Patients With COVID-19,APRONOX,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407468,NCT04407468,to analyze the relationship between the prone position and the need for orotracheal intubation.|the impact of the prone position on the partial oxygen saturation / inspired oxygen fraction index (sao2 / fio2).,observational,observational model: cohort|time perspective: retrospective
Mechanisms of Multi-organ Failure in COVID-19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04399603,NCT04399603,variation in inflammatory mediators in patients with multi-organ failure suffering from covid-19|correlation of inflammatory mediators in the bronchoalveolar lavage fluid with extent of lung injury (e.g. based upon oxygen requirement)|correlation of circulating inflammatory mediators with renal and cardiovascular markers|assess the role of inflammatory mediators obtained from patients in the development of renal injury using in vitro models (i.e. applying these inflammatory mediators isolated from these clinical samples on kidneys cells in a petri dish),observational,observational model: other|time perspective: prospective
Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,APPROVE-CARE,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04347941,NCT04347941,the effect of prone positioning on requirement for invasive mechanical ventilation in patients with covid 19 induced respiratory failure.|length of time tolerating prone positioning|pao2/fio2 measured before prone positioning|pao2/fio2 ratio after 1 hours of prone positioning|spo2/fio2 ratio measured before prone positioning|spo2/fio2 ratio after 1 hours of prone positioning|number requiring increase in ventilatory assistance (cpap+bipap+imv etc)|work of breathing assessment (respiratory distress scale)|changes in bioimpedance measures of lung edema in patients in pp|use of awake prone positioning as a rescue intervention in control patients,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: treatment"
Rehabilitation for People With COVID-19 in ICU,COVID_REHAB,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04381338,NCT04381338,length of icu stay|length of hospital stay,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID19 Neurological Manifestation,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04496128,NCT04496128,prevalence of neurological manifestations|hospital mortality|global functional outcomes using modified rankin score|length of icu stay|length of hospital stay (in days)|30-day mortality|90-day mortality,observational,observational model: cohort|time perspective: prospective
Association Between BMI and COVID-19,BMI-SARS-CoV-2,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04391738,NCT04391738,relationship between body mass index (bmi) and sars-cov-2|associations between bmi and outcomes is independent of the known cardiometabolic risk factors|investigate the modifying effects of age and sex on the associations between bmi and outcome: invasive mechanical ventilation|investigate the modifying effects of age and sex on the associations between bmi and outcome: mortality,observational,observational model: cohort|time perspective: retrospective
SARS-CoV-2 Associated Respiratory Failure Recovery (COVID-19 CAir),nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04365595,NCT04365595,health-related quality-of-life|anxiety and depression|symptom burden|spirometry,observational,observational model: case-only|time perspective: prospective
Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1b,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04453982,NCT04453982,sars-cov-2 in breastmilk|sars-cov-2 antibody in breastmilk,observational,observational model: cohort|time perspective: prospective
Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1a,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04453969,NCT04453969,sars-cov-2 in breastmilk|sars-cov-2 antibody in breastmilk,observational,observational model: cohort|time perspective: prospective
Prevalence of COVID-19 Infection Among HCW in a French University Hospital,EXPOCOVIA,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04371692,NCT04371692,the prevalence of sars- cov2 infection health care worker with or without symptoms suggestive of a covid-19 infection|occupational exposures associated with the sars-cov2 infection|environmental exposures associated with the sars-cov2 infection|immunologic status of health care worker|inflammatory biomarkers status of health care worker,observational,observational model: cohort|time perspective: prospective
Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly,NR-COVID19,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04407390,NCT04407390,hypoxic respiratory failure|mortality|sepsis|circulatory failure|days in hospital|nad levels,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19),nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04466098,NCT04466098,incidence of grade 3-5 infusional toxicities and predefined hemodynamic or respiratory adverse events related to the infusion of msc|incidence of a reduction in one or more biomarkers of inflammation by day 7|trend changes in pao2:fio2 ratio|trend changes in mean airway pressure|trend changes in peak pressure|trend changes in plateau pressure|trend changes in positive end-expiratory airway pressure (peep)|incidence of mortality|number of icu-free days|number of days alive and ventilator free composite score 3|change in acute lung injury (ali) score 2|incidence of serious adverse events|number of days alive off supplemental oxygen,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85,COVIDRASP,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04496245,NCT04496245,acute respiratory infection necessitating workforce removal|time to ari necessitating workforce removal.|the proportion of health care workers contracting an acute respiratory infection necessitating workforce removal|the proportion of hcw with documented cov infection.|time to lower respiratory infection (lri) necessitating workforce removal.|the proportion of health care workers contracting a lri necessitating workforce removal|the proportion of hcw with documented cov lri.,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04411602,NCT04411602,transfusion of patients in the icu with convalescent plasma for covid-19-induced respiratory failure.|ventilatory free days|patient mortality (including death from any cause),interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Tomographic Findings in COVID-19 and Influenza,TOMOCOVIDMX,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04497311,NCT04497311,radiological findings|survival,observational,observational model: cohort|time perspective: prospective
"Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis",SAPRIS-SERO,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04392388,NCT04392388,"cumulative incidence of sars-cov2 infection in the general population.|maintenance over time of the acquisition of anti-sars-cov2 antibodies|rate of use of care (medical care, hospitalization, center 15) linked to the occurrence of symptoms suggestive of a sars-cov2 infection, and share attributable to the infection|proportion of infections without reported or pauci-symptomatic symptoms and their epidemiological and social determinants|proportion of tests proposed, accepted, performed, based on social and demographic characteristics|proportion and intensity of use of barrier measures (hydroalcoholic gel, mask, social distancing, description of outings / reasons, duration, frequency) and association with the level of seroprevalence|strengths of associations between socio-behavioral factors and level of seroprevalence",observational,observational model: cohort|time perspective: prospective
Maraviroc in Patients With Moderate and Severe COVID-19,nan,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04435522,NCT04435522,rate of completion|clinical improvement at day 7|change in chitinase 3-like 1(chi3l1) (ng/ml)|change in interleukin-6 (il-6) (pg/ml)|change in ccl5 (rantes) (ng/ml)|mortality|time to discharge|days on mechanical ventilation,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Detection of COVID-19 (SARS-CoV-2) in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),COVISPERM,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04460534,NCT04460534,testing for the presence of covid-19 (sars-cov-2 virus) in the semen|kinetics of sars-cov-2 virus presence in the semen,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Stroke Rehabilitation Outcome During COVID-19 Lockdown,SROCL,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04373109,NCT04373109,rehabilitation data|motor activity log - 14 item version|international physical activity questionnaire|patient-reported outcomes measurement information system - 29 version|global rating of perceived changes (physical activity engagement and upper limb use)|fatigue severity scale|hospital anxiety and depression scale|montreal cognitive assessment|functional ambulation categories|ten-meter walk test|rivermead mobility index|activities-specific balance confidence scale|fugl-meyer motor assessment|action research arm test|modified rankin scale|national institutes of health stroke scale,observational,observational model: cohort|time perspective: prospective
Impact of COVID-19 Infection on the Incidence of Ventilator-acquired Infections,COVAPID,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04359693,NCT04359693,cumulative incidence of ventilator-associated lower respiratory tract infection|cumulative incidence of ventilator-associated tracheobronchitis|cumulative incidence of ventilator-associated pneumonia|the cumulative incidence of icu acquired bacteremia diagnosed|icu mortality|mortality|the duration of mechanical ventilation|length of stay in intensive care unit,observational,observational model: cohort|time perspective: prospective
Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada,nan,not yet recruiting,No Results Available,phase 1|phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04398147,NCT04398147,incidence of the solicited ae in all groups|incidence of unsolicited ae in all groups|incidence of serious adverse events (sae) in all groups|geometric mean titer (gmt) of the igg antibody against sars-cov-2 (elisa method);|seroconversion rate of the igg antibody against sars-cov-2(elisa method )|geometric mean increase ratio (gmi) of the specific antibody against sars-cov-2(elisa method);|geometric mean titer (gmt) of the neutralizing antibody against sars-cov-2(pseudo-viral neutralization assay)|seroconversion rate of the neutralizing antibody against sars-cov-2(pseudo-viral neutralization assay)|geometric mean increase ratio (gmi) of neutralizing antibody against sars-cov-2 (pseudo-viral neutralization assay)|geometric mean titer (gmt) of the neutralizing antibody against adenovirus type 5 vector|geometric mean increase ratio (gmi) of the neutralizing antibody against adenovirus type 5 vector|cellular immune response by elispot|cellular immune response by ics,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04340479,NCT04340479,correlation of fast+ pulmonary findings with active covid infection|description of additional ancillary findings of the fast+ examination among infected and non-infected patients,observational,observational model: cohort|time perspective: prospective
Evaluation of Physical Activity and Quality of Life of Patients With Type 1 Diabetes Mellitus During the Covid-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04558645,NCT04558645,physical activity level|general quality of life|depression|anxiety|self-reported hypoglycemia|loneliness|hypoglisemia fear|dyspnea,observational,observational model: case-control|time perspective: prospective
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults,BCG-PRIME,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04537663,NCT04537663,"the trial has an adaptive primary endpoint. based on predefined objective and quantitative criteria the primary endpoint will be either a clinically relevant respiratory tract infection, or covid-19.|cumulative incidence of sars-cov-2 infection (irrespective the presence of symptoms)|cumulative incidence of asymptomatic, mild/moderate, and severe (requiring hospitalization) sars-cov-2 infection.|influenza infection|an acute respiratory tract infection|medically attended acute respiratory tract infection|acute respiratory tract infection related hospital admission|pneumonia diagnosed by a gp or medical specialist|functioning in daily activities|serious adverse events and adverse events.|major cardiovascular events|all cause 6-month mortality|history of falls|quality of life using the eq5d quality of life instrument|activities in daily living",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
NORPLASMA Covid-19 Convalescent Plasma Treatment Monitoring Study,MONITOR,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04463823,NCT04463823,observation,observational,observational model: case-only|time perspective: prospective
Bacillus Calmette-gu√©rin Vaccination to Prevent COVID-19,ACTIVATEII,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04414267,NCT04414267,"positive for the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to covid-19 on visit 3.|positive respiratory questionnaire endpoint consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to covid-19 on visit 4|positive respiratory questionnaire endpoint consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to covid-19 on visit 5|prevalence of igg/igm against sars-cov-2|analysis of each of the components of the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to covid-19.|the impact of new cardiovascular events between the two study groups|differences in repeated measurements of angiometric parameters (arterial hardness) between the two sub-study groups in visit 3|differences in repeated measurements of angiometric parameters (central arterial pressures and reflected waves) between the two sub-study groups in visit 3|differences in repeated measurements of angiometric parameters (endothelial function) between the two sub-study groups in visit 3|differences in repeated measurements of angiometric parameters (thickness of the medial carotid sheath) between the two sub-study groups in visit 3|differences in repeated measurements of angiometric parameters (arterial hardness) between the two sub-study groups in visit 5|differences in repeated measurements of angiometric parameters (central arterial pressures and reflected waves) between the two sub-study groups in visit 5|differences in repeated measurements of angiometric parameters (thickness of the medial carotid sheath) between the two sub-study groups in visit 5|differences in repeated measurements of angiometric parameters (endothelial function) between the two sub-study groups in visit 5|differences in cardiac ultrasound at visit 5 between the two sub-study groups|changes in the release of cytokines from blood mononuclear cells at visit 3 between the two sub-study groups",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of S√£o Paulo,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04408014,NCT04408014,prevalence of antibodies against sars-cov-2 through serological testing|frequency of participants with a positive rt-pcr test result for sars-cov-2,observational,observational model: other|time perspective: cross-sectional
Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined Hospitalized Patients,CGM-ISO,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04430608,NCT04430608,time in range (tir) for blood glucose|saved patient-personnel contacts related to blood glucose measurements.|glucose variations during hospitalization|blood glucose lowering interventions|cgm sensor performance|course of hospital stay.,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
Precision Immunology to Determine the Immune Response in Patients With COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04360733,NCT04360733,immune response,observational,observational model: other|time perspective: prospective
Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,DICER,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04391179,NCT04391179,change in d-dimer|global composite rank score,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Acute Encephalopathy in Critically Ill Patients With COVID-19,NeuroCOVID19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04320472,NCT04320472,prevalence|favorable outcome,observational,observational model: cohort|time perspective: prospective
"COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications",CORONA-VTE NET,recruiting,No Results Available,nan,Other|Industry,https://ClinicalTrials.gov/show/NCT04535128,NCT04535128,"frequency of arterial or venous thromboembolism over 30 days|frequency of arterial or venous thromboembolism over 90 days|frequency of all-cause death, bleeding, and thromboembolic outcomes at 30 days|frequency of all-cause death, bleeding, and thromboembolic outcomes at 90 days",observational,observational model: cohort|time perspective: cross-sectional
Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences),CoCo-Neuro,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04362930,NCT04362930,central or peripheral neurological symptoms or psychiatric symptoms observed in patients with covid-19|progression of pre-existing neurological or psychiatric pathologies,observational,observational model: cohort|time perspective: retrospective
Oncological Surgery in Times of COVID-19: Effectiveness of Preoperative Screening for Sars-Cov-2,ASTANA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04434261,NCT04434261,"incidence of patients with a positive test for sars-cov-2, detected in the preoperative screening program|incidence of sars-cov-2 infection in the postoperative period in patients with negative screening test;|postoperative complications|mortality|delay in the cancer treatment",observational,observational model: cohort|time perspective: prospective
Covid-19 at the Regional Medical Center Metz-Thionville: a Descriptive Study,COMETE-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04430322,NCT04430322,icu admission|hospitalization|length of stay at the icu|death|ct scan result|c reactive protein|blood count|sodium|urea|troponine|liver function|coagulation test|creatinine|clearance|potassium|calcium|gamma-glutamyl transpeptidase|bilirubine|alcaline phosphatase|prothrombine,observational,observational model: other|time perspective: retrospective
Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,SINK COVID-19,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04365985,NCT04365985,progression of oxygenation needs|renal failure|liver failure|cytokine storm|mortality|length of hospital stay|intensive care unit (icu) admission|intensive care unit (icu) duration|intubation|intubation duration|time until recovery,interventional,"allocation: randomized|intervention model: factorial assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
COVID-19 and Cancer Patients,OnCovid,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04393974,NCT04393974,describe presenting characteristics and severity or sars-cov-2 infection in patients with cancer|assessing what factors are involved in prognosis of cancer patients with covid-19,observational,observational model: case-only|time perspective: retrospective
Prognostic Factors of COVID19,Covid-HUS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04405726,NCT04405726,clinical presentation and incidence of covid-19 infection in patients hospitalised in strasbourg hospital,observational,observational model: case-only|time perspective: other
Impact of the Covid-19 Pandemic on Gastrointestinal and Liver Diseases,RetroCov,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04420637,NCT04420637,liver disease|covid infection in patients with chronic liver disease|decompensation of cirrhosis|effect of antiviral drugs on covid-19 infection,observational,observational model: cohort|time perspective: retrospective
Evaluation of Vaginal Fluid for Covid-19 Positivity in Women With Positive Nasofarengeal Covid-19 Test,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04437940,NCT04437940,vaginal fluid covid-19 pcr test result|becoming negative from positive,observational,observational model: cohort|time perspective: prospective
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04369469,NCT04369469,survival (based on all-cause mortality) at day 29|number of days free of mechanical ventilation at day 29|duration of intensive care unit stay at day 29|change from baseline in sequential organ failure assessment at day 29|change from baseline in spo2/fio2 at day 29|duration of hospitalization at day 29|survival (based on all-cause mortality) at day 60 and day 90,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Prognositc Factors in COVID-19 Patients Complicated With Hypertension,nan,withdrawn,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04272710,NCT04272710,occupancy rate in the intensive care unit (icu)|mechanical ventilation|death|all cause mortality|time from onset of symptoms to main outcome and its components|time to clinical recovery,observational,observational model: cohort|time perspective: retrospective
Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS),nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04339998,NCT04339998,pocus score - lungs|pocus score - heart,observational,observational model: cohort|time perspective: prospective
Emergence of the COVID 19 Epidemic in the City of Nice,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04449094,NCT04449094,attack rate,observational,observational model: ecologic or community|time perspective: retrospective
Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04396197,NCT04396197,mobility level|time taken to first mobilise|discharge location,observational,observational model: cohort|time perspective: prospective
Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives,ICOS,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04357418,NCT04357418,state anxiety assessed by the state-trait anxiety inventory (stai)|visual numeric scales assessing anger and stress the ongoing week.|beck depression inventory,observational,observational model: other|time perspective: retrospective
Long-term Pulmonary Outcomes After Infection With Sars-CoV-2,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04401163,NCT04401163,imaging of the lungs|pulmonary function tests|six-minute walk test|short form-36 (sf-36) questionnaire|fatigue assessment score|cognitive sore (moca)|hospital anxiety and depression score (hads)|comorbidities|blood sample at routine follow up.|biobanking of blood,observational,observational model: cohort|time perspective: prospective
Measles Vaccine in HCW,MV-COVID19,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04357028,NCT04357028,covid-19 disease incidence|sars-cov-2 pneumonia|critical care admission duration with sars-cov-2|oxygen therapy with sars-cov-2,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04388618,NCT04388618,correlation of anosmia and ageusia to covid19 positive patients|objective assessment of severity of smell and taste senses alterations in covid19 patients,observational,observational model: case-control|time perspective: prospective
National Survey on the Lockdown of Children With Disabilities,ECHO,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04395833,NCT04395833,experience during lockdown|health risk during lockdown|impact on medical and rehabilitation follow up|impact on daily living,observational,observational model: family-based|time perspective: cross-sectional
Physical Rehabilitation in ICU in ARDS Patients With COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04435080,NCT04435080,hand grip strength|short form - 36|length of stay in intensive care unit|length of stay in hospital|duration of invasive mechanical ventilation|manual muscle strength|range of joint motion,observational,observational model: cohort|time perspective: retrospective
Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19,MICROVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04359706,NCT04359706,composition of the fecal bacterial and fungal microbiota|analysis of the faecal microbiota from rectal swab|analysis of the respiratory microbiota from the bronchoalveolar lavage liquid|serum inflammatory markers changes|inflammatory markers changes|mortality|mechanical ventilation free days,observational,observational model: cohort|time perspective: prospective
Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients,nan,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04433988,NCT04433988,primary outcome|respiratory infection|serious adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients,ERCO-Park,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04466839,NCT04466839,impact of containment related to the covid-19 pandemic.|conditions of containment during the covid-19 pandemic.|the number of patients infected or possibly infected with covid-19|symptoms modifications,observational,observational model: case-only|time perspective: prospective
Assessment of Safety and Efficacy of CCP,COVIDIT,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04542941,NCT04542941,time to viral clearance (rt-pcr negativity)|time to symptom resolution|number of participants reporting an adverse event as evidenced by clinical manifestations,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19,Chloroquine UN,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04346329,NCT04346329,adverse effects|immune-score|covid-19 prevention|clinical response,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: prevention"
EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2),nan,not yet recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04335032,NCT04335032,evaluation of epa-ffa efficacy compared to standard of care|increase in oxygen saturation|pao2/fio2 >300mmhg increase|reduction of il-6|mortality rate reduction|reduction in icu stays|reducing hospitalisation days|reduction in need for mechanical ventilation|fever reduction,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Sofosbuvir With and Without Ribavirin in Treatment of COVID 19,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04460443,NCT04460443,number of patients with response to treatment,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care (LUS-COVID19),LUS-COVID19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04393402,NCT04393402,lus applicability with covid 19|radiographic correlation (chest xray and tomodensitometry)|lus mortality prediction|prediction of prone position response,observational,observational model: cohort|time perspective: prospective
Pediatrics HOT COVID-19 Database in NY Tristate,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04445402,NCT04445402,number of tristate area pediatric hot patients tested for covid-19 that completed 1 year follow-up|change in promis t-score|number of collected and analyzed stool samples,observational,observational model: other|time perspective: prospective
Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),nan,"active, not recruiting",No Results Available,not applicable,Other|Industry,https://ClinicalTrials.gov/show/NCT04273763,NCT04273763,time to clinical recovery after treatment|rate of aggravation|clinical remission rate|dynamic changes of oxygenation index|time to cure|rate to cure|time to defervescence|time to cough remission|time to dyspnea remission|days of supplemental oxygenation|rate of patients with requring supplemental oxygen|rate of patients with mechanical ventilation|time of negative covid-19 nucleic acid results|rate of negative covid-19 nucleic acid results|rate of icu admission|28-day mortality,interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Consequences of the QUARANTINE Relating to the COvid-19 Epidemic on the Mental Health of the Patients Followed in PSYchiatry,QUARCOPSY,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04405362,NCT04405362,number of patients with post-traumatic stress disorder (ptsd) defined by a total score on pcl-5 ‚â• 31 at the time of quarantine|ies-r (impact of events scale revised)|presence of suicidal ideation during the past month at the different times of the study|total score at ghq-28 (general health questionnaire)|total score at bdi (beck depression inventory)|total score at isi (insomnia severity index)|changes in alcohol and/or cannabis consumption during and at the end of the quarantine period|total score warwick-edinburgh mental well-being scale (wemwbs)|socio-demographic factors significantly associated with all scores,observational,observational model: cohort|time perspective: prospective
Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19,CROWNLESS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04456075,NCT04456075,tlco|d5-20|fev1/fvc|comorbidities|clinical symptoms|st. george's respiratory questionnaire total score,observational,observational model: cohort|time perspective: prospective
Impact of COVID-19 on Psychological Status in Case of IVF Interrupted or Postponed,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04395755,NCT04395755,severity of anxiety|severity of depression,observational,observational model: cohort|time perspective: prospective
Proactive Care of Ambulatory COVID19 Patients,AMBU-COVID,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04371107,NCT04371107,length of symptom duration (in days) with azithromycin treatment,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Prospective Assay for SARS-CoV-2 (COVID-19) Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method,IIF,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04429620,NCT04429620,sensitivity of the method by sars-cov2 elisa compared|detectability of the antibodies iga type against sars-cov2 virus,observational,observational model: case-control|time perspective: other
Neurologic Manifestations of COVID 19 in Children,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04379089,NCT04379089,frequency of neurologic manifestations of covid 19 among pediatric patients requiring hospital admission for confirmed or presumed covid 19|associations between prescription of empiric covid-19 directed therapies and patient characteristics and outcomes among children with or without neurologic manifestations and confirmed or presumed covid-19,observational,observational model: cohort|time perspective: prospective
Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection,TITAN,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04447235,NCT04447235,incidence of severe complications due covid-19 infection|incidence of severe acute respiratory syndrome|adverse events|overall survival,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement",BATTLE,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04369794,NCT04369794,clinical evolution of covid-19|sars-cov-2 elimination|seroconversion rate and titration|local and systemic adverse events to bcg vaccination,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial,HERO,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04352946,NCT04352946,cumulative incidence of covid-19 infection|adverse events incidence|duration of symptomatic covid-19 disease|days hospitalized attributed to covid-19|number or respiratory failure attributable to covid-19 disease|mortality incidence|days of work lost,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Thrombosis and Covid-19,COVBIO,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04366778,NCT04366778,coagulability|venous thrombotic event (vte) or arterial thrombosis,observational,observational model: cohort|time perspective: prospective
Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis,CovidSurg-Can,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04384926,NCT04384926,30-day postoperative covid-19 infection rate|30-day postoperative mortality rate|postoperative critical care utilisation rate in high-risk cancer surgery patients.|proportion of patients with delay of greater than 4 weeks from decision for surgery to date of surgery|proportion of non-operated patients with progression to incurable disease by 3-months after decision for surgery,observational,observational model: cohort|time perspective: other
Analysis of Mortality of Critically Ill Patients With COVID-19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04379258,NCT04379258,icu mortality|hospital mortality|28-day mortality|effectiveness of treatment|length of icu stay|length of hospital stay|ventilator-associated pneumonia|bacteriemia|barotrauma|duration of mechanical ventilation,observational,observational model: cohort|time perspective: prospective
Epidemiological Characteristics of COVID-19 in Patients With MS or NMO,COVISEP,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04355611,NCT04355611,clinical severity|edss (expanded disability status scale),observational,observational model: cohort|time perspective: retrospective
Prevalence of COVID-19 (Coronavirus Disease 19) in Pregnant Women on Labor in a Public Hospital in Chile (COroNavirus diSease Covid-19 pandEmic iN ChilE),CONSCIENCE,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04551690,NCT04551690,prevalence of sars-cov-2 in pregnant patients on labor|characterization of clinical features of patients who tested positive for covid 19.|characterization of living conditions of pregnant women with covid 19|neonatal hospitalization|neonatal weight|perinatal outcomes,observational,observational model: case-control|time perspective: cross-sectional
Imaging Feature of SARS-CoV2 Infection,COVID19IF,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04394026,NCT04394026,describe qualitative and quantitative variables|ability of imaging to predict disease progression|ability of imaging to predict disease evolution|imaging findings and demographic data|imaging findings and laboratory exams,observational,observational model: cohort|time perspective: other
Medium and Long Term Follow-up of COVID-19 Infected Patients: Research and Characterization of Pulmonary Sequelae,COV-RECUP,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04519320,NCT04519320,"proportion of patients with an alteration of the capillary alveolus barrier at 12 months of follow-up, characterized by a decreased of the diffusing capacity for carbon monoxide (dlco) below the lower limit of normal",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04344210,NCT04344210,variation in hba1c levels|covid-19 infection|variation in lipid profile|variation in blood pressure levels|comparison of emotional distress associated with the routine of living with diabetes after intervention between groups|comparison of eating disorders between groups|comparison of adherence to the proposed clinical treatment between groups|comparison of minor psychiatric disorders between groups|comparison of sleep pattern changes between groups,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
Extra Vascular Lung Water and Pulmonary Permeability in Critically Ill Patients With SARS-CoV-2 (COVID-19),PiCCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04376905,NCT04376905,changes of extra vascular lung water|changes of pulmonary vascular permeability index|changes of pulmonary compliance,observational,observational model: cohort|time perspective: prospective
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19,PROTECT-Surg,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04386070,NCT04386070,pneumonia free survival; acute respiratory distress syndrome (ards) free survival; or death|rate of pneumonia|rate of ards|death rate|rate of unexpected ventilation|covid-19 pulmonary complications|overall sars-cov-2 infected rate|duration of hospital stay|pulmonary function,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
"Seroprevalence of Coronavirus Disease 2019 (COVID-19) Antibodies in a Vulnerable Neighbourhood, Buenos Aries Argentina",nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04472078,NCT04472078,to establish the seroprevalence of sars-cov-2,observational,observational model: cohort|time perspective: cross-sectional
The RAPID COVID TRIAGE Algorithm,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04353154,NCT04353154,sensitivity,observational,observational model: cohort|time perspective: prospective
Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04397172,NCT04397172,short form (36) health survey (sf-36)|mortality|modified rankin scale (mrs)|duration of mechanical ventilation in days|barthel index|beck's depression inventory ii (bdi-ii)|essener questionnaire for coping with a disease (efk)|number of patients with critical illness myopathy,observational,observational model: cohort|time perspective: prospective
Impact of COVID-19 Pandemic on Depression and Quality of Life,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04394078,NCT04394078,sociodemographic information form|zung depression scale|world health organization quality of life - bref,observational,observational model: ecologic or community|time perspective: cross-sectional
Psychological Impact of COVID-19 Quarantine and Worsening of Cardiovascular Risk in the French General Population,PSYCOV-CV,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04397835,NCT04397835,worsening of cardiovascular risk (treatments)|worsening of cardiovascular risk (smoking consumption)|worsening of cardiovascular risk (food balance)|worsening of cardiovascular risk (weight gain)|worsening of cardiovascular risk (physical activity)|psychological impact of the quarantine on anxiety|psychological impact of the quarantine on health|psychological impact of the quarantine on stress,observational,observational model: cohort|time perspective: prospective
Zofin (Organicell Flow) for Patients With COVID-19,nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04384445,NCT04384445,incidence of any infusion associated adverse events|incidence of severe adverse events|all cause mortality|survival rate|cytokine levels|d-dimer levels|c-reactive protein levels|quantification of the covid-19|improved organ failure|chest imaging changes,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Netizens' Perception of COVID-19 Information & Information Sources.,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04497441,NCT04497441,netizens' perception of the sources of covid-19 information|netizens' perception on covid-19 information|correlation of age and the frequency of checking covid-19 information updates|correlation of gender and the frequency of checking covid-19 information updates|correlation of age and the perception of newly infected covid-19 cases information update|correlation of age and the perception of covid-19 deaths information update|correlation of age and the perception of covid-19 vaccine information update|correlation of age and the perception of covid-19 treatment medicines/drugs information update,observational,observational model: other|time perspective: prospective
High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy,COVID-19 HD,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04408235,NCT04408235,"clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first:|any of the following events occurring within the hospital stay|mortality at 30 days",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (investigator)|primary purpose: treatment
Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons,nan,enrolling by invitation,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04401449,NCT04401449,inflammatory responses of cells in lung and circulation,observational,observational model: cohort|time perspective: prospective
COG-UK Project Hospital-Onset COVID-19 Infections Study,COG-UK HOCI,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04405934,NCT04405934,incidence rates of ipc-defined hospital-onset covid-19 infection (hocis)|change in incidence rates of ipc-defined hocis with rapid vs standard sequencing|incidence rates of ipc-defined hospital outbreaks|incidence rates of ipc+sequencing-defined hospital outbreaks|changes to ipc actions following viral sequence reports|recommended changes to ipc actions following viral sequence report - not implemented|health economic benefit to ipc of standard vs rapid sequencing reports|impact of both standard and rapid sequencing reports on number of hcw days off work,interventional,intervention model: sequential assignment|masking: none (open label)|primary purpose: health services research
Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease,nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04335786,NCT04335786,"first occurrence of intensive care unit admission, mechanical ventilation or death|death|mechanical ventilation|intensive care unit admission|occurrence of acute kidney injury",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy,TRANSCOVID,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04402918,NCT04402918,vrological profile of newborns.|immunological profile of newborns.,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak,PRPsyCOVID,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04351399,NCT04351399,frequency of ra patients with emotional impact (feeling of isolation)|self-reported questionnaire for painful,observational,observational model: family-based|time perspective: cross-sectional
Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04331613,NCT04331613,adverse reaction (ae) and severe adverse reaction (sae)|changes of lung imaging examinations|time to sars-cov-2 rt-pcr negative|duration of fever (celsius)|changes of blood oxygen (%)|rate of all-cause mortality within 28 days|lymphocyte count (*10^9/l)|alanine aminotransferase (u/l)|creatinine (umol/l)|creatine kinase (u/l)|c-reactive protein (mg/l)|procalcitonin (ng/l)|lactate (mmol/l)|il-1beta (pg/ml)|il-2 (pg/ml)|il-6 (pg/ml)|il-8 (pg/ml),interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease,CRITICoVid,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407169,NCT04407169,"percentage of patients who reached, during their hospitalization, a value greater than or equal to 6 on the who covid-19 infection progression scale|determined potential predictive factors of critic form in patients with chronic lung diseases|determined percentage of death|determined duration of oxygen therapy|determined duration of hospitalization|determine mean values of the who covid-19 infection progression scale measured",observational,observational model: cohort|time perspective: retrospective
Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection,SynCov,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04420676,NCT04420676,diarrhea|stool frequency|stool consistency|gastrointestinal symptoms|duration of covid-19 disease|severity of covid-19 disease|stool calprotectin|stool zonulin|microbiome composition,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04479163,NCT04479163,"development of severe respiratory disease defined as a respiratory rate (rr)>30 and/or an o2 sat<93%|life threatening respiratory disease|critical systemic illness, defined as respiratory failure|death|combination of secondary outcomes #2 (life threatening respiratory disease) and/or #3 (critical systemic illness, defined as respiratory failure) and//or #4 (death)|duration of oxygen support requirement in patients with covid-19 due to saturation in ambient air <93%.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Northeast COVID-19 and Pregnancy Study Group,NCOVIP,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04462367,NCT04462367,"near miss maternal:|maternal death|near miss neonate|neonatal death|early neonatal death|fetal death|perinatal death|maternal age|maternal pre-pregnancy weight|maternal height|pre-gestational nutritional classification|pre-gestational body mass index (bmi)|maternal color|number of people living in the household|family income per capita|maternal education|maternal occupation|maternal occupation with financial income|maternal marital status|maternal origin|maternal religion|maternal smoking|maternal alcoholism|maternal use of illicit drugs|number of pregnancies|parity|number of previous cesarean sections|number of previous vaginal births|number of previous abortions|number of children alive|number of prenatal consultations|gestational age of the onset of flu-like signs and symptoms|number of puerperium days of onset of flu-like signs and symptoms|duration of maternal symptoms|social isolation during the signs and symptoms of flu-like syndrome|social distance before the signs and symptoms of flu-like syndrome|quarantine|need for hospitalization due to flu-like syndrome and/or complications|day of hospitalization due to flu syndrome and/or complications|length of hospital stay due to flu-like syndrome and/or complications|maternal signs and symptoms of flu-like syndrome at diagnosis, at 6 months, 12 months and 24 months|result of polymerase chain reaction - real time (rt-pcr) for maternal covid19 in diagnosis, at 6 months, 12 months and 24 months|result of polymerase chain reaction - real time (rt-pcr) for the differential diagnosis of maternal respiratory syndrome (viral panel)|maternal viral panel in the diagnosis, at 6 months, 12 months and 24 months|rapid test for maternal covid-19 at diagnosis, at 6 months, 12 months and 24 months|serial maternal igm covid-19|serial maternal iga covid-19|serial maternal igg covid-19|serial maternal serology day|maternal reinfection|cytokines in maternal diagnosis|day of the first cytokine dosage from the beginning of the flu syndrome or covid-19|day of the first blood count from the beginning of the flu syndrome or covid-19|hemoglobin of maternal diagnosis|leukocytes from maternal diagnosis|deviation to the left of the maternal diagnosis|platelets of maternal diagnosis|typical lymphocytes of maternal diagnosis|atypical lymphocytes of maternal diagnosis|day of the first coagulogram from the beginning of the flu syndrome or covid-19|maternal diagnosis bleeding time (tb)|maternal diagnosis clotting time (ct)|maternal prothrombin time of diagnosis (td)|maternal active partial thromboplastin time of diagnosis (aptt)|international normalized ratio (inr)|day of the first urea from the beginning of the flu syndrome or covid-19|urea from maternal diagnosis|day of the first creatinine from the beginning of the flu syndrome or covid-19|creatinine of maternal diagnosis|transaminases in maternal diagnosis|day of the first erythrocyte sedimentation rate (vsh) of maternal diagnosis from the beginning of the flu syndrome or covid-19:|vsh of maternal diagnosis|day of the first c-reactive protein (crp) from the beginning of the flu syndrome or covid-19|crp of maternal diagnosis|day of the first d-dimer from the beginning of the flu syndrome or covid-19|d-dimer of maternal diagnosis|day of the first lactic dehydrogenase (dhl) from the beginning of the flu syndrome or covid-19|dhl of maternal diagnosis|day of the first alkaline phosphatase from the beginning of the flu syndrome or covid-19|alkaline phosphatase in maternal diagnosis|day of the first troponin from the beginning of the flu syndrome or covid-19|troponin in maternal diagnosis|day of the first ferritin from the beginning of the flu syndrome or covid-19|ferritin in maternal diagnosis|bilirubins in maternal diagnosis|day of the first blood culture from the beginning of the flu syndrome or covid-19|blood culture of maternal diagnosis|blood culture microorganism in maternal diagnosis|day of the first uroculture from the beginning of the flu syndrome or covid-19|uroculture of maternal diagnosis|uroculture microorganism in maternal diagnosis|igm covid-19 worst maternal result|iga covid-19 worst maternal result|maternal igg covid-19 - worst serial result|cytokines worst maternal outcome|day of the worst urea result from the beginning of the flu syndrome or covid-19|urea worst maternal result|day of the worst creatinine result from the beginning of the flu syndrome or covid-19|creatinine worst maternal result|transaminases worst maternal outcome|day of the worst result of the erythrocyte sedimentation rate of maternal diagnosis (vsh) from the beginning of the flu syndrome or covid-19|vsh worst maternal result|day of the worst c-reactive protein (crp) result from the onset of the flu syndrome or covid-19|crp worst maternal result|day of the worst d-dimer result from the onset of the flu syndrome or covid-19|d-dimer worst maternal result|day of the worst result of lactic dehydrogenase (dhl) from the beginning of the flu syndrome or covid-19|dhl worst maternal result|alkaline phosphatase worst maternal result|troponin worst maternal result|ferritin worst maternal result|bilirubins worst maternal result|blood culture worst maternal result|blood culture microorganism worst maternal result|uroculture worse maternal result|uroculture microorganism worst maternal result|presence of changes in maternal chest radiography|result of maternal chest radiography|presence of changes in the mother's chest tomography|day of normalization of the alteration of the tomography of the maternal chest|result of maternal chest tomography|use of maternal nasal catheter|use of maternal venturi mask|prone maternal position on spontaneous ventilation|use of therapeutic antibiotics|use of azithromycin|use of maternal hydroxychloroquine/chloroquine|use of antiparasitic drugs|use of anticoagulant|use of antiretroviral|use of pulse therapy|use of convalescent plasma|assisted mechanical ventilation (amv)|use of neuromuscular blocker|use of extracorporeal circulation (ecmo)|renal replacement therapy (dialysis)|blood products|other therapeutic modalities|amniotic fluid in the last ultrasound examination|fetal growth restriction|small fetus for gestational age (sga)|presence of fetal morphological changes|fetal morphological changes|frequency of fetal tachycardia (fft)|doppler velocimetry parameters in the last ultrasound examination|gestational age of amniocentesis|amniocentesis indications|result of amniocentesis for covid19|amniocentesis cytokines|need for hospitalization due to obstetric causes|maternal hospital stay|obesity|chronic arterial hypertension (cah)|superimposed preeclampsia|gestational hypertension|pre-eclampsia|eclampsia|hellp syndrome|clinical diabetes|gestational diabetes|premature rupture of membranes|premature labor|placenta previa|abortion|normally inserted placental abruption|maternal urinary tract infection|maternal heart disease|bronchial asthma|chronic obstructive pulmonary disease (copd)|cerebrovascular disease|chronic kidney injury|immunosuppression|maternal pneumonia|maternal sepsis|septic shock|severe acute respiratory syndrome (sars)|postpartum hemorrhage|infection of the operative site|endometritis|peritonitis|need for postpartum hysterectomy|type of delivery|indication of cesarean section|gestational age at birth|use of labor analgesia|type of anesthesia for cesarean section|antenatal corticosteroid therapy (pulmonary maturity)|use of maternal magnesium sulphate (prophylaxis of the newborn and / or prevention of eclampsia)|maternal prophylactic antibiotic therapy (prophylaxis of neonatal sepsis)|hospital discharge when pregnant|hospital discharge when puerperal|maternal death when pregnant|maternal death when puerperal|birth weight|adequacy of birth weight|apgar scores in the first minute|apgar scores in the fifth minute|neonatal icu admission|need for neonatal resuscitation|need for neonatal mechanical ventilation|neonatal nasal catheter|neonatal continuous positive airway pressure (cpap) mask|neonatal hypothermia|neonatal hypoglycemia|neonatal infection|chorioamnionitis|neonatal respiratory distress modality|neonatal congenital infection (torchs)|congenital malformation|breastfeeding|cord ligation|skin-to-skin contact|breastfeeding in the delivery room|days of life of the newborn's diagnostic suspicion|result of the polymerase chain reaction - real time (rt-pcr) for neonatal covid-19 in diagnosis, at 6 months, 12 months and 24 months|result of polymerase chain reaction - real time (rt-pcr) for the differential diagnosis of neonatal respiratory syndrome (viral panel)|neonatal viral panel in the diagnosis, at 6 months, 12 months and 24 months|neonatal cytokines|neonatal igm covid-19|iga covid-19 neonatal serial|serial neonatal igg covid-19|neonatal reinfection|hemoglobin from neonatal diagnosis|diagnostic neonatal bleeding time (bt)|diagnostic neonatal clotting time (ct)|urea from neonatal diagnosis|creatinine from neonatal diagnosis|transaminases of the neonatal diagnosis|blood culture of the neonatal diagnosis|uroculture of neonatal diagnosis|igm covid-19 - worst neonatal result|neonatal igg covid-19 - worst serial result|cytokines - worst neonatal result|day of the worst blood count result from the beginning of the suspected diagnosis by covid-19|day of the worst value of the neonatal coagulogram from the suspicion of the diagnosis by covid-19|bleeding time - worst neonatal result (bt)|urea - worst neonatal result|creatinine - worst neonatal result|transaminases - worst neonatal result|blood culture - worst neonatal result|uroculture - worst neonatal result|gasometry - worst neonatal result|result of rt-pcr of the placenta|placental viral panel|histopathological of the placenta|result of rt-pcr in breast milk at diagnosis, at birth and with and at hospital discharge|viral panel in breast milk|presence of alteration of the neonatal chest radiography|result of neonatal chest radiography|presence of alteration of the neonatal chest tomography|result of neonatal chest tomography|parameters for monitoring the growth of the newborn at 6, 12 and 24 months - head circumference|parameters for monitoring the growth of the newborn at 6, 12 and 24 months - weight|parameters for monitoring the growth of the newborn at 6, 12 and 24 months - height|development of the newborn up to 6 months|development of the newborn up to 12 months|development of the newborn up to 24 months",observational,observational model: cohort|time perspective: other
"Effect of COVID-19 Pandemic on Perceived Stress, Anxiety, Mood, and Training Quality in Elite Athletes.",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04453566,NCT04453566,sociodemographic information and training characteristics|the beck anxiety inventory (bai)|the visual analogue scale (vas)|perceived stress scale (pss)|satisfaction with life scale|brunel mood scale (brums),observational,observational model: other|time perspective: retrospective
Whole Blood Collection From Individuals in the Convalescent Phase of SARS-CoV-2 Infection,nan,withdrawn,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04409184,NCT04409184,characterization of specific t cell responses in peripheral blood isolated from patients that have been exposed to sars-cov-2.,observational,observational model: cohort|time perspective: retrospective
Burnout Among Caregivers Facing COVID-19 Health Crisis at a Non-conventional Intensive Care Unit Compared to a Conventional Intensive Care Unit,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04346810,NCT04346810,stress in a recovery room transformed into an intensive care unit versus a conventional intensive care unit,observational,observational model: ecologic or community|time perspective: prospective
Long-Term Experience and Health Effects of COVID-19,nan,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04477902,NCT04477902,longitudinal survey,observational,observational model: ecologic or community|time perspective: prospective
COVID-19 in ART: Perception and Experience,COVAPEX,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04456010,NCT04456010,personal experience of the covid19 pandemic and the discontinuation of their fertility treatment pandemic and the discontinuation|risk assessment|patients'expectations regarding the management of an abrupt closure of the fertility center,observational,observational model: other|time perspective: prospective
Yinhu Qingwen Granula for the Treatment of Severe CoVID-19,nan,suspended,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04310865,NCT04310865,changes in the ratio of pao2 to fio2 from baseline|pao2|blood oxygen saturation (spo2)|clinical status rating on the 7-point ordinal scale|time to clinical improvement (ttci)|duration (hours) of non-invasive mechanical ventilation or high-flow nasal catheter oxygen inhalation use|duration (hours) of invasive mechanical ventilation use|duration (hours) of extracorporeal membrane oxygenation (ecmo) use|duration (days) of oxygen use|the proportion of the patients reporting 2019-ncov rt-pcr negativity at day 10 after treatment|the counts/percentage of lymphocyte|time to hospital discharge with clinical recovery from the randomisation|the incidence of critical status conversion in 30 days|all-cause mortality within 30 days|frequency of severe adverse drug events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection,SEVO-COVID19,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04359862,NCT04359862,pao2/fio2|tnfœ±|il-1b|il-6|il-8|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS,nan,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04536350,NCT04536350,time to clinical improvement|frequency of mechanical ventilation|time requiring oxygen supplementation|slope in sao2|slope in fio2|slope in c-reactive protein|neutrophile ratio|lymphocyte ratio|interleukine 6 level|procalcitonin level|frequency of multi organ dysfunction syndrome (mods),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark,PISCA,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04351789,NCT04351789,anxiety 1 month|anxiety 3 months|depression 3 months|post traumatic stress disorder (ptsd) symptoms 3 months|anxiety 12 months|post traumatic stress disorder (ptsd) symptoms 12 months|depression 12 months,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
"Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19",nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04476667,NCT04476667,"change in stress|change in resilience|change in quality of life assessment|change in symptom severity - 1|change in symptom severity - 2|change in symptom severity - 3|qualitative information: healthcare providers|qualitative information: personal, social, and cultural factors",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04392232,NCT04392232,survival rate,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"Epidemiologic, Clinical, Molecular Characteristics of Hospital Employees With or Without Covid-19 Infection",UNICODE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04451577,NCT04451577,clinical response to covid-19|immunological response to covid-19|genetic predisposition to covid-19|microbiome-related response to covid-19,observational,observational model: case-control|time perspective: other
Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic,COVIE-19/20,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04487171,NCT04487171,variation of prevalence of clinically-significant post-partum depressive symptoms,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Long-term Impact of Infection With Novel Coronavirus (COVID-19),LIINC,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04362150,NCT04362150,participant age|participant sex|participant race/ethnicity|proportion of participants previously hospitalized.,observational,observational model: cohort|time perspective: prospective
Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia,PREVENT,not yet recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04466683,NCT04466683,step 1 dose selection|clinical benefit of step 2 radiation dose|changes of the cost of care for the control arm versus the radiation arms,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Lung Ultrasound for COVID-19 Initial Triage and Monitoring,QUICK,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04474236,NCT04474236,"area under the curve (auc) of a predictive model built on lus and clinical (q-sofa, spio2/fio2) data|area under the curve (auc) of a predictive model built on ct scan and clinical (q-sofa, spio2/fio2) data|mortality",observational,observational model: cohort|time perspective: prospective
COVID-19 and ICU-acquired MDR Bacteria,COVID-BMR,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04378842,NCT04378842,cumulative incidence of icu-acquired colonization related multidrug resistant bacteria|cumulative incidence of icu-acquired infection related to multidrug resistant bacteria|mechanical ventilation duration|mortality|length of stay in intensive care unit,observational,observational model: cohort|time perspective: prospective
Mindfulness During COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04319445,NCT04319445,helpfulness of the session|platform effectiveness|change in anxiety level|change in stress level|value of the session|satisfaction with the session|percentage of participants that showed interest in a future session|percentage of participants that would recommend this session to a family member|percentage of participants by session frequency preference,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04361448,NCT04361448,sensitivity,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
COVID-19 in Immunosuppressed Children,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04511429,NCT04511429,"serology (igm, igg) for covid-19.|hospital admission|intensive care admission|death|positive pcr for covid-19|clinical characteristics of patients with covid-19|proportion of patients with viral excretion in respiratory secretion and faeces on days 3, 7, 14, 21 and 30 after confirmation of covid 19.",observational,observational model: cohort|time perspective: prospective
COVID-19 Epidemic Response Study,COVeR,not yet recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04357496,NCT04357496,identification of prognostic parameters for sars-cov-2 infected participants.|investigation of the kinetics of immune activation and antibody production against sars-cov-2 and correlation with clinical course,observational,observational model: cohort|time perspective: prospective
PHenotyping patiENts Admitted to Hospital With cOvid-19 Infection and idenTifYing Prognostic markErs,PHENOTYPE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04459351,NCT04459351,identification of baseline characteristics which correlate with disease severity|identification of blood biomarkers which correlate with disease severity|genomic analysis of blood samples to look for genetic susceptibility to severe disease presentations|incidence|change in respiratory symptom scores|change in frailty and quality of life scores|relationship between serum markers and clinical outcomes,observational,observational model: cohort|time perspective: other
Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04374656,NCT04374656,proportion of conjunctival samples tested positive for sars-cov-2|proportion of nasal samples tested positive for sars-cov-2 among patients with positive conjunctival samples|proportion of nasopharyngeal samples tested positive for sars-cov-2 among patients with positive conjunctival samples|rate of development of covid-19 in the study patient population|positive conjunctival sample rate in patient developed covid-19,observational,observational model: cohort|time perspective: prospective
The McMaster Multi-Regional COVID-19 Hospital Case Registry,COREG,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04508959,NCT04508959,serious covid-19 infection|severe infection (requiring admission)|covid-19 related death|length of stay|complications|intensive interventions,observational,observational model: cohort|time perspective: prospective
Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.,nan,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04324021,NCT04324021,treatment success|time to mechanical ventilation|change from baseline in modified early warning system score|change from baseline in resting peripheral capillary oxygen saturation (spo2)|change from baseline in partial pressure of oxygen/fraction of inspired oxygen (pao2/fio2)|change of ph in hemogasanalysis from baseline|change of carbon dioxide tension (pco2) in hemogasanalysis from baseline|change of oxygen tension (po2) in hemogasanalysis from baseline|change of potassium in hemogasanalysis from baseline|change of sodium in hemogasanalysis from baseline|change of chloride in hemogasanalysis from baseline|change of lactic acid in hemogasanalysis from baseline|change of hemoglobin in hemogasanalysis from baseline|change from baseline in oxygen supplementation|change of findings of high-resolution computed tomography (ct) scan of the chest|change from baseline in ferritin|change from baseline in lactate dehydrogenase (ldh)|change from baseline in d-dimers|change from baseline in white blood cells with differential counts|change from baseline in red blood counts|change from baseline in hemoglobin|change from baseline in platelet count|change from baseline in fibrinogen|change from baseline in complement factors c3/c4|change from baseline in prothrombin time|change from baseline in cardiac troponin|change from baseline in aspartate aminotransferase (ast)|change from baseline in alanine aminotransferase (alt)|change from baseline in total bilirubin levels|change from baseline in c-reactive protein|change from baseline in creatinine|overall survival|time to hospital discharge,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City,COVIDGHPSJCite,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04365530,NCT04365530,clinical consequences of a covid-19 infection in the care population|risk factors at m6|risk factors at year 1|risk factors at year 2|impact of hospital reorganization on medical care at m6|impact of hospital reorganization on medical care at year 1|impact of hospital reorganization on medical care at year 2,observational,observational model: cohort|time perspective: other
"Prone Position and Respiratory Outcomes in Non-Intubated COVID PatiEnts The ""PRONE"" Study",PRONE,not yet recruiting,No Results Available,not applicable,Other|Industry,https://ClinicalTrials.gov/show/NCT04517123,NCT04517123,occurrence of an escalation in respiratory related care (yes vs no)|oxygen saturation|respiratory effort as assessed by respiratory rate,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Convalescent Plasma in the Treatment of COVID 19,nan,completed,Has Results,phase 2,Other,https://ClinicalTrials.gov/show/NCT04343261,NCT04343261,mortality|viral load|serum antibody titers,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
STATIN THERAPY AND COVID-19 INFECTION,STACOV,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407273,NCT04407273,sars-cov-2 scale of severity (9 steps) in covid-19 infected patients with statin therapy,observational,observational model: case-only|time perspective: prospective
Mechanisms for Covid-19 Disease Complications,COVID MECH,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04314232,NCT04314232,number of participants with icu admission or death|number of participants with icu admission|number of participants with death from all causes|total duration of icu stay|total duration of hospital stay,observational,observational model: cohort|time perspective: prospective
Egyptian Initial Experience About 2019 Novel Corona Virus: Study of 48 Patients in Alexandria-Egypt Using Chest CT,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04382469,NCT04382469,"radiological pattern of initial presentation, disease progress, healing and recovery|survey of co-morbid lung diseases",observational,observational model: case-crossover|time perspective: retrospective
Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19),COV-CREM,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04365322,NCT04365322,specific immune responses,observational,observational model: cohort|time perspective: prospective
Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04468009,NCT04468009,"mortality at icu at 30 days|mortality at icu at 90 days|sofa score of study days 1, 3, 5, 7, 14 and 28|need for supportive therapy after enrollment|lenght of stay in icu|lenght of mechanical ventilation|lenght of hospitalization",interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
MSCs in COVID-19 ARDS,nan,recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04371393,NCT04371393,number of all-cause mortality|number of days alive off mechanical ventilatory support|number of adverse events|number of participants alive at day 7|number of participants alive at day 14|number of participants alive at day 60|number of participants alive at day 90|number of participants with resolution and/or improvement of ards|change from baseline of the severity of ards|length of stay|clinical improvement scale|change in serum hs-crp concentration|change in il-6 inflammatory marker level|change in il-8 inflammatory marker level|change in tnf-alpha inflammatory marker level,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04508439,NCT04508439,low molecular weight heparin (enoxaparin) and ventilatory support time|thrombotic complications and rivaroxaban|low molecular weight heparin (enoxaparin) and length of hospital stay|low molecular weight heparin (enoxaparin) and mortality rate,interventional,"allocation: randomized|intervention model: crossover assignment|masking: double (participant, care provider)|primary purpose: treatment"
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04551911,NCT04551911,severity and duration of disease as evidenced by covid-19 symptoms using the flu-pro¬© questionnaire.|concentration of serum total 25-hydroxyvitamin d maintained at or above 50 ng/ml.,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04492501,NCT04492501,survival|duration of hospitalization|time to resolution of cytokine release storm|time of viral clearance|complications,interventional,allocation: non-randomized|intervention model: factorial assignment|masking: none (open label)|primary purpose: treatment
Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses (COVID-19),SERO-MARES,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04425759,NCT04425759,"antibodies to sars-cov2: iga, igm, igg|pcr of nasopharyngeal smears on all igm +",observational,observational model: cohort|time perspective: prospective
Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection,PICOV,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04527614,NCT04527614,"time to occurrence of ili and ari both in participants previously exposed to sars-cov-2 and controls|number of patients with ili or ari, diagnosed with covid-19, influenza, rsv|validation of (simplyspiro) to replace nasopharyngeal swabs|identify the antibody characteristics in participants with reinfection with sars-cov-2|correlation of the pre-existing antibody characteristics for covid-19 with disease severity.|correlation of the level of neutralization antibodies against influenza subtypes with protection against influenza reinfection",interventional,"intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: diagnostic"
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease,nan,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04419025,NCT04419025,decrease in respiratory rate|hospital length of stay (los)|need for mechanical ventilation|length of time intubated|need for hospitalization|recovery disposition,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to COVID-19,nan,not yet recruiting,No Results Available,nan,Other|Industry,https://ClinicalTrials.gov/show/NCT04556864,NCT04556864,"total amount of hypotension|minimally invasive hemodynamic monitoring and related variables obteined from hemosphere platform with acumen iq sensor (stroke volume)|minimally invasive hemodynamic monitoring and related variables obteined from hemosphere platform with acumen iq sensor (stroke volume variation)|minimally invasive hemodynamic monitoring and related variables obteined from hemosphere platform with acumen iq sensor (cardiac index)|minimally invasive hemodynamic monitoring and related variables obteined from hemosphere platform with acumen iq sensor ( hpi)|minimally invasive hemodynamic monitoring and related variables obteined from hemosphere platform with acumen iq sensor (eadyn)|minimally invasive hemodynamic monitoring and related variables obteined from hemosphere platform with acumen iq sensor (dp/dt max,)|presence of treatment with noradrenaline; presence of treatment with dobutamine, presence of treatment with other vasoactive/ionotropic/hypotensive drugs|furosemide treatment|daily diuresis, daily water balance, accumulated water balance since icu admission, daily parenteral nutrition volume, and daily enteral nutrition volume.|atrial fibrillation|acute kidney injury|continuous renal replacement therapies|need for hemadsorption|specific treatment for sars-cov2 (presence of tocilizumab, antimalarial drugs, antivirals)|corticoid treatment.",observational,observational model: cohort|time perspective: prospective
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),nan,available,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04323761,NCT04323761,nan,expanded access:treatment ind/protocol,nan
ACCESS A Master Digital Surveillance Protocol for COVID-19,ACCESS,recruiting,No Results Available,nan,Other|Industry,https://ClinicalTrials.gov/show/NCT04363268,NCT04363268,development of population-based models of disease risk|relation between disease burden and geolocation|effect of medications on symptoms of covid19|effect of medications on disease severity of covid19|rate of covid19 infection and disease outcomes|effect of covid19 on health outcomes|long-term follow up and recontact,observational,observational model: cohort|time perspective: prospective
"COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04335773,NCT04335773,risk factors for severe infection|immunulogical mechanisms|long term outcome,observational,observational model: case-control|time perspective: prospective
Study of the Pathogenesis of Olfactory Disorders in COVID-19,COVIDSMELL,recruiting,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04366934,NCT04366934,molecular and cellular defects in olfactory epithelium|biological mechanisms involved in the pathogenesis of the disease|epidemiological characteristics|olfactory and taste dysfunction,observational,observational model: case-control|time perspective: cross-sectional
COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2,COVID-pO2-RAAS,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04524156,NCT04524156,"transcutaneous po2 and pco2 as predictive factors for respiratory deterioration|pneumoproteins cc16 and sdp as predictive factors for respiratory deterioration|diagnostic and prognostic utility of plasma concentration of ace2, ang ii, ang 1-7, ang 1-9 in covid-19",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: basic science
Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04373824,NCT04373824,effect of ivermectin on eradication of virus.,interventional,allocation: non-randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: treatment
Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation,CONFIDENT,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04558476,NCT04558476,"vital status|day 90 mortality|number of ventilator-free days at day 28|number of renal replacement therapy free days at day 28|number of vasopressors free-days at day 28|use of ecmo before day 28|value of the sofa score at days 7, 14 and 28|changes in sofa scores (delta sofa) over 7, 14 and 28 days|assessment of the sars-cov-2 viral load|blood c reactive protein (crp) concentration|ferritin concentration|lymphocyte count|length of stay in the acute care hospital|location of the patient|katz index of independence in activity day living functional score|hospital anxiety and depression scale (hads)|quality of life scale eq-5d-5l|transfusion related adverse events",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 Related Lung Ventilation and Perfusion Injury,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04549636,NCT04549636,short-term difference in ventilation defect percent assessed by ventilation spect-ct - healthy|short-term difference in perfusion defect percent assessed by perfusion spect-ct - healthy|short-term difference in lung ventilation/perfusion mismatch assessed by ventilation/perfusion spect-ct - healthy|long-term difference in ventilation defect percent assessed by ventilation spect-ct - healthy|long-term difference in perfusion defect percent assessed by perfusion spect-ct - healthy|long-term difference in ventilation/perfusion mismatch assessed by ventilation/perfusion spect-ct - healthy|short-term difference in ventilation defect percent assessed by ventilation spect-ct - asthmatic|short-term difference in perfusion defect percent assessed by perfusion spect-ct - asthmatic|short-term difference in ventilation/perfusion mismatch assessed by ventilation/perfusion spect-ct - asthmatic|long-term difference in ventilation defect percent assessed by ventilation spect-ct - asthmatic|long-term difference in perfusion defect percent assessed by perfusion spect-ct - asthmatic|long-term difference in ventilation/perfusion mismatch assessed by ventilation/perfusion spect-ct - asthmatic|longitudinal change in ventilation defect percent assessed by ventilation spect-ct - healthy|longitudinal change in perfusion defect percent assessed by perfusion spect-ct - healthy|longitudinal change in ventilation/perfusion mismatch assessed by ventilation/perfusion spect-ct - healthy|longitudinal change in ventilation defect percent assessed by ventilation spect-ct - asthmatic|longitudinal change in perfusion defect percent assessed by perfusion spect-ct - asthmatic|longitudinal change in ventilation/perfusion mismatch assessed by ventilation/perfusion spect-ct - asthmatic|correlation of lung ventilation with the st. george's respiratory questionnaire (sgrq) score ‚â§4-weeks post covid-19 recovery|correlation of lung ventilation with six-minute walk distance (6mwd) ‚â§4-weeks post covid-19 recovery|correlation of lung ventilation with the forced expiratory volume in one second (fev1) ‚â§4-weeks post covid-19 recovery|correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (dlco) ‚â§4-weeks post covid-19 recovery|correlation of lung ventilation with the st. george's respiratory questionnaire (sgrq) score 6-months post covid-19 recovery|correlation of lung ventilation with six-minute walk distance (6mwd) 6-months post covid-19 recovery|correlation of lung ventilation with the forced expiratory volume in one second (fev1) 6-months post covid-19 recovery|correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (dlco) 6-months post covid-19 recovery,observational,observational model: cohort|time perspective: prospective
Evolution of Facial Trauma During COVID Containment Measures,Traumax,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04355442,NCT04355442,evolution of number of maxillofacial trauma|variability in terms of type of trauma|comparative assessment of types of trauma by the inter-regional variability,observational,observational model: cohort|time perspective: retrospective
COVID 19: Is SARS-CoV-2 Contaminating Surgical Aerosols From Laparoscopy and Open Abdominal Surgery?,LapCoVIDSurg,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04444687,NCT04444687,sars-cov-2 rna detection|viral contamination of peritoneal cavity and fluid|viral contamination of peritoneal cavity and fluid in open cases|viral infection of members of the surgical team,observational,observational model: case-control|time perspective: prospective
Antibodies Responses to COVID-19 Infection in Hospitalized Patients,No-SARS,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04520880,NCT04520880,changes in the levels of s specific antibodies in severely ill patients compared to mild cases.|changes in the levels of n specific antibodies in severely ill patients compared to mild cases.|s specific binding antibodies of sars-cov-2|n specific binding antibodies of sars-cov-2|neutralizing antibodies directed against s protein of sars-cov-2|the severity category of critically ill|length of icu|length of hospital stays|alive status at 28-days|alive status at 90-day|correlation between the levels of s neutralizing antibodies and disease severity|correlation between the levels of n neutralizing antibodies and disease severity,observational,observational model: other|time perspective: prospective
Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection,PRIORITISE,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04441372,NCT04441372,clinical and biochemical prognostic markers|evaluate field-based performance of poc,observational,observational model: cohort|time perspective: prospective
Repeated Employee Testing for Understanding Our Recovery to Normal,RETURN,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04472793,NCT04472793,the 6-month cumulative incidence of acquired covid infection in the study cohort.,observational,observational model: case-control|time perspective: prospective
A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,nan,recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04319731,NCT04319731,ventilator free days|duration of supplemental oxygen use|all cause mortality|systemic inflammation,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus,Combination,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04389580,NCT04389580,"lung injury score|absolute lymphocyte counts|serum levels of crp, esr ,il-1,il-6,tnf and type i interferon|serum level of covid19 rna|all cause mortality rate|ventilation free days|icu free days|d-dimers|time to first negative sars-cov-2 pcr in np swap",interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,COPLA,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04357106,NCT04357106,lung injury|overall survival|adverse reactions to plasma,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,REPLACECOVID,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04338009,NCT04338009,"hierarchical composite endpoint|all-cause death|length of hospital stay|length of icu stay, invasive mechanical ventilation or extracorporeal membrane oxygenation|auc sofa",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04334265,NCT04334265,changes in high-resolution computer tomography of the lung|change in 6-minute walking distance|changes in compound physiological index|changes in the scores of the st. george's hospital respiratory questionnaire|changes in modified british medical research council dyspnea scale (mmrc) scores|changes in vital capacity of the lung,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine,HERO-HCQ,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04334148,NCT04334148,number of participants with clinical infection with covid-19 infection|number of participants with covid-19 viral shedding|safety as measured by number of adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04333589,NCT04333589,viral nucleic acid test negative conversion rate|clinical cure rate,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care,nan,suspended,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04334967,NCT04334967,total hospitalization|total mechanical ventilation|fever intensity measure|shortness of breath measure|changes in daytime cough measure|changes in nighttime cough measure|total mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04311398,NCT04311398,sensitivityôºå spectivity turnaround time of the new qiastat-dx fully automatic multiple pcr detection platform,observational,observational model: cohort|time perspective: retrospective
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04310228,NCT04310228,clinical cure rate|viral nucleic acid test negative conversion rate and days from positive to negative|duration of fever|lung imaging improvement time|mortality rate because of corona virus disease 2019|rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|mean in-hospital time,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells,nan,not yet recruiting,No Results Available,early phase 1,Industry,https://ClinicalTrials.gov/show/NCT04302519,NCT04302519,disppear time of ground-glass shadow in the lungs|absorption of lung shadow absorption by ct scan-chest|changes of blood oxygen,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe),nan,not yet recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04295551,NCT04295551,clinical recovery time,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,PROACTIVE-19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04321928,NCT04321928,"primary composite rate of intensive care unit (icu) admission, 48 hours of hospital admission, death in covid-19 positive cases|the number of general practitioner visits|the number of emergency, hospital admission and intensive care admission|length of hospitalization and intensive care unit stay|organ dysfunction|lifestyle changes|the cost of care",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: prevention"
Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,BBV152,recruiting,No Results Available,phase 1|phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04471519,NCT04471519,phase 1: occurrence of adverse events and serious adverse events|phase 2: evaluation of neutralizing antibody titers|phase 1: evaluation of neutralizing antibody titers|phase 2: occurrence of adverse events and serious adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: prevention"
Vaccination of Ex-acute COVID Patied-19 Patients With Fibrosing Lung Syndrome at Discharge,COVINVAC,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04537130,NCT04537130,safety assessment|oxygen saturation|quality of life (qol)|fibrotic pulmonary extension (measured as the size of the lesions),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial),nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04456088,NCT04456088,time to deterioration|time to stable oxygen saturation,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID),CAPTOCOVID,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04355429,NCT04355429,efficacy of captopril nebulization addition to standard of care compared to standard of care.,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus,CoVid3S,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04441710,NCT04441710,establishment of a reliable prediction model for the effectiveness of virus control,observational,observational model: cohort|time perspective: prospective
Advanced Endoscopy During COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04385147,NCT04385147,"age, gender, nationality|indication for procedure, status of sars-cov-2 infection|complete blood count and liver functions tests|procedure related complications|effect of covid-19 precautions on procedure time|effect of covid-19 precautions on staff number",observational,observational model: cohort|time perspective: prospective
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,TOCIBRAS,terminated,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04403685,NCT04403685,evaluation of clinical status|all-cause mortality|hospital mortality|improvement of sequential sepsis-related organ failure assessment (sofa) scale|ventilator free days|time until oxygen support independence|need of mechanical ventilation support|days to mechanical ventilation support.|duration of hospitalization|other infections|incidence of thromboembolic events|incidence of adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),HCQPreP,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04363450,NCT04363450,incidence of symptomatic covid-19 infection in healthcare workers|absenteeism from work due to covid-19|severity of covid-19 infection,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Maternal Psychological Implications of Covid-19 Pandemic and Possible Effect on Anaesthetic Management.,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04432948,NCT04432948,"association between covid-19 pandemic and maternal psychological distress|association between covid-19 pandemic, maternal psychological distress and anaesthetic practice",observational,observational model: other|time perspective: prospective
COVID-19 Pandemic Burden in Severe Mental Disease Patients,PsyCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04357769,NCT04357769,perceived stress scale (pss) outcome|generalized anxiety disorder (gad-7) scale outcome|patient health questionnaire (phq-9) scale outcome|specific psychotic experiences questionnaire (speq) - paranoia subscale outcome|specific psychotic experiences questionnaire (speq) - grandiosity subscale outcome|caregiver burden,observational,observational model: case-control|time perspective: cross-sectional
Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection,STAUNCH-19,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04528888,NCT04528888,"all-cause mortality at day 28|all-cause mortality at icu discharge|all-cause mortality at hospital discharge|need of rescue administration of high-dose steroids or immune-modulatory drugs|new organ dysfunction during icu stay|grade of organ dysfunction during icu stay|icu free days at day 28|occurrence of new infections|ventilation free days at day 28|vasopressors free-days at day 28|switch from non-invasive to invasive mechanical ventilation|delay from start of non-invasive ventilation to switch to invasive ventilation|occurrence of protocol related adverse events|occurrence of venous thromboembolism, stroke or myocardial infarction|occurrence of major bleeding (safety end point)|occurrence of clinically relevant non-major bleeding (safety end point)",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
RISK FACTORS FOR NECROTIC CHOLECYSTITIS DURING COVID-19 PANDEMIC: THE ChoCO WSES PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY,ChoCO,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04542512,NCT04542512,risk factors for necrotic cholecystitis in covid-19 patients,observational,observational model: case-only|time perspective: prospective
Patient Recovery From Heart Surgery During the Covid-19 Pandemic,CardiacCovid,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04366167,NCT04366167,change in impact of events scores|survival|morbidity|change in health-related quality of life scores|change in depression scores,observational,observational model: cohort|time perspective: prospective
"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection",NATADEX,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04452565,NCT04452565,1. time (hours) to recovery|time fever resolution,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (care provider, investigator, outcomes assessor)|primary purpose: prevention"
Hydroxychloroquine to Prevent SARS-CoV-2 Infection,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04414241,NCT04414241,efficacy: proportion of participants with positive molecular or serologic testing for sars-cov-2|safety: proportion of participants with grade 3 or more adverse events|tolerability: proportion of participants that discontinue prophylactic treatment due to grade 1 or 2 adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Clinical Epidemiology and Characteristics Of Covid-19 Cases Occurred In A Lymphoma Setting In The First Epidemic Phase (LymphoCov1),LymphoCov1,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04386512,NCT04386512,mortality|transfer to icu,observational,observational model: case-only|time perspective: retrospective
COVID-19 Immune Repertoire Sequencing,IMSEQ,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04368143,NCT04368143,provide proof-of-concept that (longitudinal) b cell repertoire mining allows identification of emerging virus specific b cell receptor variable regions.|study evolutions in b and t cell repertoires to understand covid-19 specific immune responses fundamentally.|clinical and epidemiological description of uza hospitalized covid-19 patients,observational,observational model: cohort|time perspective: prospective
Increased Risk of SARS-CoronaVirus-2 (SARS-CoV-2) Infection Associated With Endoscopy (DECORE Study),DECORE,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04401033,NCT04401033,sars-cov-2 infection in patients|sars-cov-2 infection in hcw,observational,observational model: cohort|time perspective: prospective
Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04370015,NCT04370015,prevention of sars-cov-2 as determined by negative rt-pcr at the end of 12 week study period|safety as determined by presence or absence of any adverse event related with hydroxychloroquine treatment|confirmed sars-cov-2 infection based on symptoms and confirmed by rt-pcr|clinical disease severity in confirmed sars-cov-2 participants|incidence of any acute respiratory infection,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Covid-19 in Pregnancy: a French Population-based Cohort of Women and Newborns,Coropreg,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04463758,NCT04463758,joint evaluation of morbi-mortality for mother and child up to 12 weeks postpartum|number of women infection covid-19|severe forms of covid-19 infection in the mother|severe neonatal morbidity,observational,observational model: cohort|time perspective: prospective
Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS),nan,not yet recruiting,No Results Available,phase 1,Other|Industry,https://ClinicalTrials.gov/show/NCT04530604,NCT04530604,number of major hemorrhagic complications within 14 days of initiation of treatment|overall survival|ventilator free survival|number of ventilator free days within 14 days of study entry|the time to improvement in oxygenation|mean change in the who covid-19 ordinal scale during therapy,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04400877,NCT04400877,is there an increased prevalence of venous thromboembolism in a regional healthcare system in sweden during the sars-cov-2 pandemic?|is a sars-cov-2-infection an isolated risk factor for thromboembolism?|are there geographic differences in the prevalence of venous thromboembolism within the healthcare system?|is venous thromboembolism associated with increased mortality adjusted for relevant comorbidities?|how long is the time between symptom onset of the sars-cov-2-infection and any subsequent venous thromboembolism?|is treatment with prophylactic antithrombotic or anticoagulant treatment associated with increased survival?,observational,observational model: cohort|time perspective: retrospective
"A Study to Assess the Virus RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease",nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04346160,NCT04346160,virus molecular analysis|host molecular analysis|epidemiologic data,observational,observational model: case-control|time perspective: prospective
Mental Health Outcomes in Healthcare Workers During COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04397848,NCT04397848,impact of event scale - revised (ies-r)|general anxiety disorder (gad-7)|patient health questionnaire (phq-9)|qualitative data,observational,observational model: cohort|time perspective: prospective
Cardiovascular Implications of COVID-19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04435457,NCT04435457,prevalence of myocarditis|prevalence of cardiac abnormalities by cardiac magnetic resonance imaging|prevalence of molecular and genetic immune system abnormalities,observational,observational model: cohort|time perspective: cross-sectional
Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19,COVID-19-HBO,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04327505,NCT04327505,icu admission|30-day mortality|time-to-intubation|time-to-icu|inflammatory response|overall survival,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Impact of COVID-19 on Lung Cancer Patients,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04538456,NCT04538456,physical and social impact|psychological impact|prevalence and impact of frailty,observational,observational model: cohort|time perspective: prospective
Investigation of the Relationship Between New Coronary Virus Disease (COVID-19) and Anxiety and Depressive Symptoms in Pregnant Women,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04384887,NCT04384887,evaluation of depression and anxiety score changes of covid-19 positive pregnants,observational,observational model: case-control|time perspective: prospective
Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19),COMBAT-19,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04397497,NCT04397497,reduction in the dependency on oxygen supplementation|proportion of responders (using the who 7-point ordinal scale)|time to response (using the who 7-point ordinal scale)|proportion of improving patients (using the who 7-point ordinal scale)|time to resolution of fever|reduction in case fatality|proportion of patient requiring mechanical ventilation/deaths|change in biochemical markers|median changes in the national early warning score 2 (news2)|time to clinical improvement as evaluated with the national early warning score 2 (news2)|variations in radiological findings|incidence of treatment-emergent adverse events [safety and tolerability],interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Long Term Outcomes of Patients With COVID-19,COVID19 LTFU,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04360538,NCT04360538,quality of life score|cognitive dysfunction|functional status score|physical disability|psychological sequelae,observational,observational model: cohort|time perspective: prospective
Home Management of Adult Egyptian Mild COVID-19 Cases,COVID-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04515199,NCT04515199,percent of adherence to isolation measures|the incidence of symptoms and their duration|change in short form 35 (sf-36) questionnaire|cost- effectiveness of home isolation vs hospital admission in mild covid-19 cases|identifying the duration of post-covid-19 symptoms|long-term respiratory complications,observational,observational model: cohort|time perspective: prospective
The Impact of COVID-19 Outbreak on Trans-population's Health in Italy,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04448418,NCT04448418,assessment of the specific health need of the transpopulation during the covid-19 pandemic in italy|assessment of risk factors for covid-19 infection in the traspopulation|evaluation of the satisfaction of this population with telemedicine for hormonal treatment monitoring|evaluation of the psychological wellbeing of the trans-population during covid-19 outbreak in italy|evaluation of the psychological and physical wellbeing of the trans-population during covid-19 outbreak in italy,observational,observational model: cohort|time perspective: cross-sectional
Post ICU Follow up in Patients With Severe SARS-CoV-2 Infection (Covid-19),nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04491214,NCT04491214,assess quality of life after severe covid infection|quality of life and clinical status,observational,observational model: cohort|time perspective: prospective
Cardiac Dysfunction in Critically Ill Patients Infected With COVID-19,CARDY-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04524234,NCT04524234,mortality|left ventricular dysfunction|right ventricular dysfunction,observational,observational model: cohort|time perspective: prospective
The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04340921,NCT04340921,t-cell immunophenotype|mortality|itu admission|myocardial injury,observational,observational model: cohort|time perspective: prospective
Detection of COVID-19 in Saliva Collection,SALICOV,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04386551,NCT04386551,detection of sars-cov-2 rna in the saliva sample|concordance between the saliva sample and the nasonasopharyngeal sample sars-cov-2 rt-pcr results,observational,observational model: case-only|time perspective: prospective
One-year Outcomes in Survivors of the Severe COVID-19 Pneumonia (CO-Qo-ICU),CO-Qo-ICU,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04401111,NCT04401111,evaluation of recovery of quality of life in first year after icu discharged in patients hospitalised for severe pneumonia at sars-cov2|evaluation of respiratory function during first year after icu discharged in population studied|evaluation at 1 year of evolution of functional exercises capacity in population studied|evaluation of evolution of renal function during first year after icu discharged in population studied|evaluation of evolution of right and left myocardic function during first year after icu discharged in population studied|evaluation at 1 year of incidence of psychiatric pathology|evaluation at 1 year of consequences in professional activity in population studied,observational,observational model: cohort|time perspective: prospective
Risk of Air Contamination During Visceral Surgery in COVID19 Patients,COELIOCOVID,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04395599,NCT04395599,air contamination|environment contamination|surgical approach|opening of the digestive tract|biological fluids|pneumoperitoneum,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Host-pathogen Interactions During SARS-CoV-2 Infection,HPI-COVID-19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04376476,NCT04376476,initial biological profile of children and adults with covid-19 infection|initial immunological profile of children and adults with covid-19 infection|clinical worsening|evolution of the immunological profile of children and adults with covid-19|nasopharyngeal swabs sars-cov-2 viral loads of children and adults with covid-19|titers in specific immunoglobulin g (igg) antibodies of children and adults with covid-19|titers in specific immunoglobulin m (igm) antibodies of children and adults with covid-19|titers in specific immunoglobulin g (igm) antibodies of children and adults with covid-19|genetic profile of adults with covid-19 infection,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
Assessment of the Psycho-social Impact of COVID-19 Outbreak,COM-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04378452,NCT04378452,"psychological impact of the outbreak, total score|psychological impact of the outbreak: depression questions score|psychological impact of the outbreak: anxiety questions score|psychological impact of the outbreak: stress questions score|psychological impact of the outbreak: pstd questions score|descriptive statistics for the non-psychological questions",observational,observational model: cohort|time perspective: cross-sectional
Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04270383,NCT04270383,"the cure rate of 2019-ncov.|the improvement rate of 2019-ncov.|the incidence of long-term adverse outcomes.|duration of fever|duration of respiratory symptoms|duration of hospitalization|number of participant(s) need intensive care|number of participant(s) with acute respiratory distress syndrome|number of participant(s) with extra-pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al.|number of participant(s) who died during the trial",observational,observational model: cohort|time perspective: prospective
Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04411459,NCT04411459,duration of mechanical ventilation and 28 days ventilator free days|icu mortality|30 days survival after icu discharge|90 days survival after icu discharge|quality of life at 90 days after icu discharge measured with 15d instrument|radiologic aspects - structured description of ct and rx data,observational,observational model: cohort|time perspective: prospective
Psychological Impact of the Covid-19 Pandemic on Student Nurses,StudentCov,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04402229,NCT04402229,prevalence of ptsd-related symptoms assessed by the ies-r|ptsd-related symptoms assessed by the ies-r in the total population of students nurses|ptsd-related symptoms assessed by the ies-r according to student's years of school,observational,observational model: other|time perspective: prospective
SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04494776,NCT04494776,death|graft loss|hospitalization,observational,observational model: cohort|time perspective: retrospective
Rutgers COVID-19 Cohort Study,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04336215,NCT04336215,prevalence|incidence,observational,observational model: cohort|time perspective: prospective
Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar,DOLCI,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04425382,NCT04425382,time to clinical improvement and/or virological clearance (composite endpoint)|percentage of virological clearance|percentage of clinical deterioration|incidence of adverse events|length of hospital stay|all-cause mortality,observational,observational model: other|time perspective: retrospective
A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04434144,NCT04434144,"number of participants with ""treatment success"" determine by a negative rt pcr for covid19.|number of participants with ""adverse effects"" determined by the existence of the pharmacological side effects of the particular drug during treatment.",observational,observational model: case-only|time perspective: prospective
Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19 and High Risk of Acute Kidney Injury,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04445259,NCT04445259,incidence of any stage of acute kidney injury|mortality|renal recovery|percentage of patients who receive renal replacement therapy|percentage of participants who are dialysis dependent|free-days of vasoactive medications and mechanical ventilation|length of intensive care unit and hospital stay|number of participants with consequences following aki|time from illness onset to need for mechanical ventilator support,observational,observational model: cohort|time perspective: retrospective
A Cross-sectional and Cohort Study of COVID-19 Patients With Post - Discharge Dysfunction,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04382534,NCT04382534,symptoms and signs|respiratory function|the body function|adl,observational,observational model: cohort|time perspective: prospective
Respiratory Decompensation and Model for the Triage of COVID-19 Patients,READY,completed,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04390516,NCT04390516,mechanically ventilated patient outcome|mortality or mechanically ventilated patient outcome,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Maintenance Versus Reduction of Immunosuppression for Renal Transplant Patients Hospitalized With COVID-19 Disease,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04420364,NCT04420364,change in il-6 concentration from baseline to day 7|change in il-6 concentration from baseline to day 28|change in t cell response to sars-cov-2|change in titer of serum anti-sars-cov-2 antibodies|change in covid-19 disease severity score (range 1 to 8; higher worse)|proportion of patients needing non-invasive ventilation or intubation|proportion of patients developing anc < 500 cells per microliter|proportion of patients developing lymphopenia < 400 cells per microliter|length of hospital stay|proportion of patients developing biopsy-proven acute rejection|in-hospital and 28-day mortality|adverse and serious adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals,CORONA,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04402879,NCT04402879,hospital mortality or discharge to hospice|adverse events and serious adverse events|change in spo2|hospital free days|admission to icu|intubation and mechanical ventilation|initiation of non-invasive ventilation (niv) or high-flow nasal oxygen (hfno).|oxygen-free days|in-hospital death (time)|death at 90 days,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital,PRECOVIA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04362267,NCT04362267,the incidence of sars- cov2 infection heath care worker diagnosed by the positivity of sars-cov2 rt-pct and serological testing|occupational exposures associated with the sars-cov2 infection|environmental exposures associated with the sars-cov2 infection,observational,observational model: cohort|time perspective: cross-sectional
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations,nan,"active, not recruiting",No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04378881,NCT04378881,calculate the medication risk score of de-identified participants from medicare/medicaid and commercial health insurance plans using their current drug regimen via our proprietary risk stratification process.|simulate the medication risk score following the addition of different repurposed drugs against covid-19 to their current drug regimen via our proprietary risk stratification process.|compare the impact (change) on the medication risk score using the calculate before score and simulated after score following the addition of repurposed drugs for covid-19 to the drug regimens of patients enrolled in the study.|measure the effects of various repurposed drugs for covid-19 on each of the five factors computed by algorithms to derive the medication risk score will be calculated via our proprietary risk stratification process.|comparison of the medication risk score and the effects of the addition of repurposed drugs on the drug regimen between participants with medicare/medicaid vs. commercial health insurance plans will be assessed.|measure the effects on medication risk score of various repurposed drugs for covid-19 within subgroups of patients classified by specific diseases or drugs used and the impact of various covariables.,observational,observational model: cohort|time perspective: retrospective
Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19,TSUNAMI,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04393727,NCT04393727,need of invasive mechanical ventilation|mortality rates|time to invasive mechanical ventilation|time to virologic cure|length of hospital stay|adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19),nan,available,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04346277,NCT04346277,nan,expanded access:intermediate-size population,nan
Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19,COVLA,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04452604,NCT04452604,clinical prognostic factors for infection with covid-19|biological prognostic factors for infection with covid-19|medical care of coronavirus infection,observational,observational model: cohort|time perspective: retrospective
Psychosocial Outcomes in Families of COVID-19 ICU Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04498507,NCT04498507,occurence of anxiety and depression|occurence of acute stress|occurence of post-traumatic stress disorder|quality of life,observational,observational model: cohort|time perspective: prospective
Anti-Androgen Treatment for COVID-19,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04446429,NCT04446429,covid-19 hospitalization|covid-19 ordinal outcomes scale|symptoms severity of covid-19,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Electrolyte State in Patients With COVID-19,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04539834,NCT04539834,electrolytes disturbances in patients with covid-19|to asses the relation of the electrolyte disturbances with the severity of covid-19 infection.,observational,observational model: case-only|time perspective: retrospective
A Study to Explore the Role of Gut Flora in COVID-19 Infection,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04359836,NCT04359836,correlation of microbiome to disease via relative abundance found in microbiome sequencing|validation of sequencing methods,observational,observational model: other|time perspective: other
Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF,CCF,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04344327,NCT04344327,death rate|transfer to intensive care unit|ventilation analysis|construction of a predictive score for covid-19 severe form,observational,observational model: cohort|time perspective: retrospective
Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04320511,NCT04320511,"predictive association between ct-v, pbm score and disease progression",observational,observational model: cohort|time perspective: prospective
The Prevalence of Pulmonary Hypertension in Patients With COVID-19.,nan,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04459364,NCT04459364,prevalence,observational,observational model: cohort|time perspective: other
Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients,COVID_OFF,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04425317,NCT04425317,"presence or absence of sars-cov-2 in follicular fluid, cumulus cells, immature oocytes and endometrium|presence of ace2, tmprss and bsg receptors in cumulus cells, immature oocytes and endometrium",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Anxiety Level and Oral Hygiene Practice in Dental Students During Covid-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04460469,NCT04460469,correlate between the level of anxiety and the practice of oral hygiene during covid-19 pandemic in dental students of cairo university,observational,observational model: other|time perspective: cross-sectional
PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),PROVID,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04366856,NCT04366856,"proportion of patients who meet one or both following criteria: need for intubation (for mechanical ventilation), occurrence of death during hospital stay.|proportion of patients admitted to icu (for patients included out of icu)|days alive and free from non invasive ventilation (niv) or high flow nasal canula oxygen delivery (hfnc) (for those neither under niv or hfnc at the time of study inclusion)|days alive and out of icu|days alive and out of hospital|maximum oxygenotherapy rate during hospital stay [time frame: at day28]",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS,RuXoCoil,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04359290,NCT04359290,overall survival|assessment of the duration of ventilation support|cytokine storm|time on icu|number of participants with treatment-related adverse events as assessed by ctcae v4.0|time frame for seroconversion under ruxolitinib treatment (sars-co-19- igg)|pulmonary function assessed by a ct scan|overall survival,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,ORCHID,completed,No Results Available,phase 3,Other|NIH,https://ClinicalTrials.gov/show/NCT04332991,NCT04332991,"covid ordinal outcomes scale on day 15|all-location, all-cause mortality assessed on day 15|all-location, all-cause mortality assessed on day 29|covid ordinal outcomes scale on study day 3|covid ordinal outcomes scale on study day 8|covid ordinal outcomes scale on study day 29|number of patients dead or with receipt of ecmo between enrollment and day 28|oxygen-free days through day 28|ventilator-free days through day 28|vasopressor-free days through day 28|icu-free days to day 28|hospital-free days to day 28",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
SARS-COV2 Pandemic Serosurvey and Blood Sampling,nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04334954,NCT04334954,number of people with detectable antibodies to sars-cov2,observational,observational model: case-only|time perspective: cross-sectional
COPE - COVID-19 in Pregnancy and Early Childhood,COPE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04433364,NCT04433364,biobank with linkage to registers|experiences of pregnancy during a pandemic,observational,observational model: cohort|time perspective: prospective
Drug Safety and the Occurrence of Complications During Hospitalization in Patients With COVID-19,COR-CARDIO,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04374110,NCT04374110,"adverse events|number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke|ventilation during hospitalization",observational,observational model: case-control|time perspective: prospective
COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia,COVIDNOCHE,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04381923,NCT04381923,ventilator-free days (vfd)|icu and hospital length of stay|intubation|renal replacement therapy (rrt)|mortality,interventional,allocation: randomized|intervention model: crossover assignment|masking: single (outcomes assessor)|primary purpose: supportive care
Pediatric Acute Kidney Injury in COVID-19,SPARC-1,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04466306,NCT04466306,acute kidney injury (aki)|survival|rate of extracorporeal therapy requirement|fluid overload|rate of nephrotoxic medication exposure,observational,observational model: cohort|time perspective: prospective
Pathogens Involved in Secondary Infections During Severe Forms of Covid-19 Pneumonia:,COVAP,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04488510,NCT04488510,research of the bacteria responsible for nosocomial pneumonia|additional evaluations to the study,observational,observational model: other|time perspective: prospective
Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions,COVID-TRUST,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04517136,NCT04517136,professional burnout|mindfulness level|perceived stress level following the emotional stimulation|parasympathetic flexibility evolution during emotional recall|sympathetic tone at rest|corticotropic activation at rest|mood disorders (anxiety / depression)|post-traumatic stress disorder|sleep quality,observational,observational model: cohort|time perspective: prospective
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04395911,NCT04395911,mortality at day 60|dialysis dependency|ventilation at day 28|mortality at day 28|urinary output change|p02/fio2 change|safety assessments|scd integrity,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
EXercise TRAining and Sedentary Lifestyle on Clinical Outcomes in Patients With COVID-19,WHO,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04396353,NCT04396353,number of hospitalizations|percentage of symptoms of the disease|length of hospital stay|percentage of mechanical ventilation,observational,observational model: cohort|time perspective: cross-sectional
Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia,CCAP,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04345289,NCT04345289,all-cause mortality or need of invasive mechanical ventilation|frequency of adverse events|frequency of severe adverse events|time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status|ventilator-free days|organ failure-free days|duration of icu stay|mortality rate|length of hospital stay|duration of supplemental oxygen,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,PROBIOZOVID,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04366089,NCT04366089,delta in the number of patients requiring orotracheal intubation despite treatment|delta of crude mortality|delta of length of stay for patients in hospital|delta in the value of interleukin (il)-1|delta in the value of il-6|delta in the value of il-10|delta in the value of tumor necrosis factor (tnf)-alpha|delta in the value of cluster of differentiation (cd)4+ cd38/ human leukocyte antigen-dr isotype (hla-dr)|delta in the value of cd8+ cd38/ hla-dr|delta in the value of fecal calprotectin|delta in the value of lipopolysaccharide (lps)|delta in the value of zonulin|delta in the value of alpha1-antitrypsin,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19),STOP-Flu,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04298060,NCT04298060,percent of subjects who have returned to room air|percent change of subjects return to baseline oxygen requirement,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
COVID-19 Diagnostic Self-testing Using Virtual Point-of-care,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04348864,NCT04348864,clinical accuracy of the antibody and antigen rapid tests compared to lamp/pcr-based test result|clinical accuracy of the antibody and antigen rapid tests based on clinical diagnosis|self-test interpretation of result vs expert clinical image interpretation of result|ease of self-testing procedure,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: diagnostic
"Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients",NSpectroCovid,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04546737,NCT04546737,variation from baseline of mri radiological semiology in covid-19 patients,interventional,allocation: non-randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Influence Physical Activity Psychological Responses COVID-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04352517,NCT04352517,"impact of international physical activity questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on avoidance impact of covid-19 through ies-r|impact of international physical activity questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on intrusion impact of covid-19 through ies-r|impact of international physical activity questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on hyperarousal impact of covid-19 through ies-r|impact of international physical activity questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on depression health status through dass-21|iimpact of international physical activity questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on anxiety health status through dass-21|impact of international physical activity questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on stress health status through dass-21",observational,observational model: ecologic or community|time perspective: cross-sectional
Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease,COVID-19_LF,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04412395,NCT04412395,survival rate.|rate of disease remission.|the number of patients with pcr negative results.|mean change in the disease severity (clinical assessment).|mean change in blood pressure.|mean change in heart beats.|mean change in body temperature.|mean change in body respiratory rate.|mean change in oxygen saturation.|mean change in the ratio in arterial oxygen partial pressure to fractional inspired oxygen (pf ratio).|mean change in complete blood picture (cbc).|mean change in c reactive protein (crp).|mean change in erythrocyte sedimentation rate (esr).|mean change in d-dimer.|mean change in ferritin.|mean change in liver albumin.|mean change in total and direct bilirubin.|mean change in prothrombin time (pt) and partial thromboplastin time (ptt ).|mean change in aspartate aminotransferase (ast).|mean change in alanine aminotransferase (alt).|mean change in blood urea nitrogen (bun).|mean change in serum creatinine.|mean change in serum creatinine clearance.|mean change in glomerular filtration rate (gfr ).|the mean change in serum interleukin-1 (il-1).|the mean change in serum interleukin-6 (il-6).|the mean change in serum interleukin-10 (il-10).|the mean change in serum tumor necrosis factor-alpha (tnf alpha).|mean changes in immunoglobulin g (igg).|mean changes in immunoglobulin m (igm).|the mean change in pcr viral load.|mean change in lung ct manifestation.|nature and severity of adverse events.|time for lung recovery.|the number of missed drug doses among each treatment group.,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
COVID-19 Convalescent Plasma,nan,"active, not recruiting",No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04340050,NCT04340050,"feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for fda eind and administering convalescent plasma to the patients|type of respiratory support|cardiac arrest|transfer to icu|icu mortality|icu length of stay|hospital mortality|hospital length of stay|ventilator-free days|overall survival (28-day mortality)",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Acceptability of Telehealth Triage Using Robotic Systems in COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04452695,NCT04452695,acceptance of robotic telehealth system|willingness to interact with robotic telehealth system|satisfaction of interacting with a robotic telehealth system|use of robotic system versus in-person triage,observational,observational model: cohort|time perspective: prospective
ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04367857,NCT04367857,proportion seropositive,observational,observational model: cohort|time perspective: prospective
Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP,FamilyPEDCOVID,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04442087,NCT04442087,seroprevalence of antibodies anti- sars cov2 in children of hospital workers|number of asymptomatic children with a positive seroloy|number of severely symptomatic children with a positive serology|prevalence of different clinical symptoms in children with a positive serology|serological result of each member of the family|number of spouses of hospital workers with a positive serology|number of asymptomatic spouses of hospital workers with a positive serology|number of severely symptomatic spouses of hospital workers with a positive serology,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: basic science
COVID-19 Associated Coagulopathy in Egypt,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04507230,NCT04507230,"coagulation screen|thrombophilia screen|vwf, fviii",observational,observational model: cohort|time perspective: cross-sectional
The RIsk Stratification in COVID-19 Patients in the ICU Registry,RISC-19-ICU,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04357275,NCT04357275,icu mortality|hospital mortality|icu length of stay,observational,observational model: cohort|time perspective: prospective
Outcomes of Urological Surgery During Periods of Social COVID-19 Containemnt: is it Reasonable to Limit Access to Surgical Care for All?,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04352699,NCT04352699,rate of uci admission for surgery-related complication|rate of surgery-specific death|rate of coronaviruse positive serologies,observational,observational model: cohort|time perspective: retrospective
"Impact of Covid-19 Restrictive Measure on Anxiety, Depression and PTSD for Relatives of ICU Patients",HAD-Covid,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04430049,NCT04430049,anxiety|depression|post-traumatic stress disorder,observational,observational model: case-control|time perspective: prospective
Neurocognitive Impairment in Patients With COVID-19,NCoV,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04359914,NCT04359914,incidence of delirium/neurocognitive impairment in adult and pediatric patients with covid-19 compared to patients without covid-19|change in neuroaxonal injury biomarker levels in patients with covid-19 compared to patients without covid-19|neurocognitive 3-months outcome in patients with covid-19 compared to patients without covid-19|quality of life in patients with covid-19 compared to patients without covid-19 after hospital discharge|length of hospital stay in patients with covid-19 compared to patients without covid-19|90-day survival in patients with covid-19 compared to patients without covid-19,observational,observational model: case-control|time perspective: prospective
Double Therapy With IFN-beta 1b and Hydroxychloroquine,nan,completed,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04350281,NCT04350281,time to negative nps viral load|time to news 0|length of hospitalisation|time to negative viral load in all clinical samples|adverse events|mortality|inflammatory markers changes,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19),PROTECT,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04363827,NCT04363827,the proportion of subjects of group 1 who become symptomatic and/or swab positive in each arm within 1 month from randomization.|the proportion of subjects of group 2 who become swab negative in each arm within 14 days from randomization.|the proportion of subjects with positive swabs in group 1 within 1 month from randomization in both arms|the proportion of subjects of group 1 who become symptomatic in each arm within 1 month from randomization|the proportion of subjects of group 2 who become swab negative in each arm within 14 days from randomization.|the proportion of subjects of group 2 who become swab negative in each arm within 1 month from randomization in overall population and in subgroup population|absolute and relative frequencies of serious adverse events|variation in quality of life scores in different time points,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19),nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04402957,NCT04402957,development of acute respiratory distress syndrome (ards) and other organ injuries|ventilation-free days|time on nasal cannula or oxygen masks|28 day mortality - all cause and attributable|icu and hospitalization length of stay (days)|sars-cov2 testing|need and duration for extracorporeal membrane oxygenation (ecmo)|vasopressor free days|radiographic pulmonary assessments|change in modified medical research council (mmrc) dyspnea and sequential organ failure assessment (sofa) scores|incidence of non-lung disorders|measures of liver dysfunction|measures of kidney dysfunction|measures of cardiac dysfunction|measures of coagulopathies|changes in immunogenic responses|healthcare outcomes|molecular changes in pro-inflammatory pathways|pharmacokinetics of lsalt peptide,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP),nan,available,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04374370,NCT04374370,nan,expanded access:intermediate-size population,nan
Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,nan,"active, not recruiting",No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04343651,NCT04343651,"clinical improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough)|time to clinical resolution (ttcr)|change from baseline in national early warning score 2 (news2)|change from baseline in pulse oxygen saturation (spo2)|change from baseline in the patient's health status on a 7-category ordinal scale|incidence of hospitalization|duration (days) of hospitalization|incidence of mechanical ventilation supply|duration (days) of mechanical ventilation supply|incidence of oxygen use|duration (days) of oxygen use|mortality rate|time to return to normal activity",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
"Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine",nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04336787,NCT04336787,international physical activity questionnaire|pittsburgh sleep quality index|perceived stress scale|numerical pain rating scale,observational,observational model: ecologic or community|time perspective: prospective
A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04398277,NCT04398277,patient health questionnaire - 4|world health organization well being questionnaire|affective experience|treatment acceptability questionnaire,interventional,"allocation: randomized|intervention model: single group assignment|masking: double (participant, investigator)|primary purpose: supportive care"
The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19,nan,withdrawn,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04285190,NCT04285190,"the time to oxygen saturation recovery to normal level (‚â•97%)|the proportion of patients with normal level of oxygen saturation(‚â•97%)|the degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, etc.|the time to the myocardial enzyme spectrum recovery to normal after treatment|the proportion of the patients with normal myocardial enzyme spectrum after treatment|the time to the electrocardiogram recovery to normal level after treatment|the proportion of the patients with normal electrocardiogram after treatment|the time to the hemodynamics recovery to normal after treatment|the proportion of the patients with normal hemodynamics after treatment|the time to exacerbation or remission of the disease after treatment;|the proportion of the patients with exacerbation or remission of disease after treatment|the proportion of patients who need other treatment (e.g. heparin, anticoagulants) due to microcirculation disorders|the all-cause mortality rate|the proportion of patients with acidosis|the total duration of the patients in-hospital|the total duration of oxygen inhalation during treatment|the oxygen flow rate during treatment|the oxygen concentration during treatment",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Glycine Supplement for Severe COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04443673,NCT04443673,mortality|days under mechanical ventilation|pao2/fio2 ratio|arterial plasma lactate|serum il-1œ≤|serum il-2|serum il-4|serum il-5|serum il-6|serum il-7|serum il-8|serum il-10|serum il-12|serum il-13|serum il-17|serum g-csf|serum gm-csf|serum ifn-œ≥|serum mcp-1|serum mip-1œ≤|serum tnf-œ±|serum creatinine|serum alanine aminotransferase|serum aspartate aminotransferase|serum alkaline phosphatase|serum total bilirubin|serum unconjugated bilirubin|serum conjugated bilirubin|serum c reactive protein|hemoglobin|total leukocytes|neutrophils|lymphocytes|monocytes|eosinophils|basophils|platelets|prothrombin time|serum pai-1|sofa score|apache ii score,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Characteristics of Patients and Healthcare Workers With COVID-19 in Meta State, Colombia",nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04456426,NCT04456426,mortality|icu admission|mechanical ventilation|icu length of stay|hospital length of stay|days of mechanical ventilation,observational,observational model: ecologic or community|time perspective: retrospective
Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04517162,NCT04517162,clinical primary outcome measure|immunological secondary outcome measure,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Monovalent Recombinant COVID19 Vaccine,COVAX19,recruiting,No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04453852,NCT04453852,incidence of adverse events|covid19 neutralizing antibody titers|covid19 t cell immunogenicity|durability of antibody response,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: prevention"
Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,CYCOV,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04324528,NCT04324528,interleukin-6 (il-6) level after 72 hours|30-day-survival|vasopressor dosage|fluid balance|lactate,interventional,allocation: randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04384380,NCT04384380,time to negatively rt-pcr|virologic assessment|number of participants with treatment-related adverse events as assessed by ctcae v4.0,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Comparison of Extra Vascular Lung Water Index in Covid-19 ARDS and ""Typical""ARDS Patients",nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04508933,NCT04508933,extravascular lung water index|pulmonary vascular permeability index,observational,observational model: case-control|time perspective: prospective
Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients,nan,not yet recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04325048,NCT04325048,voice anaysis,observational,observational model: cohort|time perspective: prospective
A Study of a Candidate COVID-19 Vaccine (COV001),nan,"active, not recruiting",No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04324606,NCT04324606,"assess efficacy of the candidate chadox1 ncov-19 against covid-19: number of virologically confirmed (pcr positive) symptomatic cases|assess the safety of the candidate vaccine chadox1 ncov: occurrence of serious adverse events (saes)|assess the safety, tolerability and reactogenicity profile of the candidate vaccine chadox1 ncov: occurrence of solicited local reactogenicity signs and symptoms|assess the safety, tolerability and reactogenicity profile of the candidate vaccine chadox1 ncov: occurrence of solicited systemic reactogenicity signs and symptoms|assess the safety, tolerability and reactogenicity profile of the candidate vaccine chadox1 ncov: occurrence of unsolicited adverse events (aes)|assess the safety, tolerability and reactogenicity profile of the candidate vaccine chadox1 ncov through standard blood tests|assess the safety, tolerability and reactogenicity profile of the candidate vaccine chadox1 ncov by measuring the number of disease enhancement episodes|assess efficacy of the candidate chadox1 ncov-19 against severe and non-severe covid-19|assess efficacy of the candidate chadox1 ncov-19 against severe and non-severe covid-19 by measuring seroconversion rates|assess cellular and humoral immunogenicity of chadox1 ncov-19 through elispot assays|assess cellular and humoral immunogenicity of chadox1 ncov-19",interventional,allocation: randomized|intervention model: sequential assignment|masking: single (participant)|primary purpose: treatment
Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019,nan,"active, not recruiting",No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04371601,NCT04371601,"changes of oxygenation index (pao2/fio2) ,blood gas test|detection of tnf-œ± levels, il-10 levels|detection of immune cells that secret cytokines, including cxcr3+, cd4+, cd8+, nk+ cells, and regulatory t cells (cd4 + cd25 + foxp3 + treg cells).|changes of c-reactive protein and calcitonin",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
MYocardial DOmmages Related to COVID-19,DOMY COVID,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04498065,NCT04498065,characterize the myocardial damage associated with cov-2 sars infection,observational,observational model: cohort|time perspective: prospective
Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial),nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04397692,NCT04397692,time to deterioration|time to niv|time to hfnc|time to intubation|time to patient having stable oxygen saturation (spo2) of greater than or equal to 93%,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: device feasibility
Echocardiography in Patients With Covid-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04412460,NCT04412460,icu mortality|icu length-of stay|icu ventilator free days|hospital length-of-stay,observational,observational model: cohort|time perspective: prospective
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,PREP-COVID,suspended,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04344379,NCT04344379,to assess the impact of hydroxychloroquine and azithromycin on the prevention of sars-cov-2 contamination in hospital workers exposed to 40 days of treatment.|reducing clinical episodes due to suspected sars-2 cov infection confirmed by pcr|reducing seroconversion for sars-cov-2 without any clinical sign|evaluation of drug tolerance in the study|evaluation on work stopping of hospital workers|observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|incidence of cardiologic events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia,VT4COVID,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04349618,NCT04349618,a composite score based on all-cause mortality and the number of ventilator free-days (vfd)|all-cause mortality (intention to treat)|ventilator-free days (vfd)|all-cause mortality with per protocol analysis|time to successful extubation|length of hospital stay|respiratory parameters assessed daily from inclusion to weaning of deep sedation or 14 days whichever comes first|daily sedation dose during the first 14 days of the study|rate of use of rescue therapies|incidence density rate of severe mixed acidosis|incidence density rate of ventilator associated pneumonia|incidence density rate of acute cor pulmonale|incidence density rate of barotrauma|incidence density rate of any serious adverse events|cognitive impairment assessed by phone call using the telephone montreal cognitive assessment (t-moca) test|quality of life assessed by the rand 36-item health survey (sf-36) score|post-traumatic stress disorder assessed by the impact of event scale - revised (ies-r) score by phone call|cost-efficacy ratio of the innovative strategy compared to the reference strategy,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Psychological Impact of the Hospitalization of a Family Member in Intensive Care for Covid-19 Infection,Familles-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04385121,NCT04385121,existence of a post-intensive care syndrome-family ((combined score of the had ( hospital anxiety and d√©pression scale) and ies-r ( impact of event scale-revised) questionnaires)),observational,observational model: cohort|time perspective: prospective
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome,COVIDIOL,not yet recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04366908,NCT04366908,admission to intensive care unit|death|time from onset of symptoms to discharge of patients in conventional hospitalization|icu - time until admission|icu - time mechanical ventilation is removed|evaluation of the inflammatory markers related with the disease|vitamin d metabolites|evolution in sato2|evolution in the sat o2/fio2 ratio.|evolution in the degree of dyspnea|evolution of the improvement of radiological findings by simple radiology|incidence of adverse events|appearance of hemorrhagic or thrombotic phenomena,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Serological Testing for COVID-19 (SARS-CoV-2) in ESKD,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04378686,NCT04378686,antibodies against sars-cov-2,observational,observational model: cohort|time perspective: prospective
Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04347239,NCT04347239,all-cause mortality at day 28|all-cause mortality at day 14|change in clinical status of subject at day 14 (on a 7 point ordinal scale)|change in clinical status of subject at day 28 (on a 7 point ordinal scale)|change from baseline in sequential organ failure assessment (sofa) score at day 14.,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Impact of COVID19 Outbreak in Cardiac Acute Care,CCU-COVID19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04344912,NCT04344912,incidence of recurrent major cardiovascular events (mace) and urgent rehospitalization,observational,observational model: cohort|time perspective: other
Efficacy and Safety of Polyoxidonium¬Æ in Hospitalized Patients With Coronavirus Disease COVID-19,nan,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04381377,NCT04381377,clinical status of the patient (according to 7-point ordinal scale)|news|oxygenation|mechanical ventilation|mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04522128,NCT04522128,change in world health organisation quality of life combination|change in the lubben social network scale|change in 6-item loneliness scale|quality of life importance ratings,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: other"
In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity,nan,recruiting,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04368897,NCT04368897,hospital-free days to day 28 [ time frame: 28 days]|1. severity of disease,observational,observational model: case-control|time perspective: prospective
Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04362956,NCT04362956,vertical transmission|neonatal protection due to maternal antibodies|increase risk of neonatal morbidity|increase risk of obstetric complications,observational,observational model: case-control|time perspective: prospective
Community Health Workers Against COVID19,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04426305,NCT04426305,change in patient-reported emotional support (based on the promis¬æ emotional support instrument)|change in patient-reported social isolation (based on the promis¬æ emotional support instrument)|change in patient-reported ability to participate in social roles and activities (based on the promis¬æ ability to participate in social roles and activities instrument)|change in patient-reported anxiety (based on the promis¬æ anxiety instrument),interventional,allocation: randomized|intervention model: parallel assignment|masking: single (care provider)|primary purpose: supportive care
Obesity and Mortality of Critically Ill Patients With COVID-19,COV-OB-ICU,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04425213,NCT04425213,icu mortality|invasive mechanical ventilation|in-hospital mortality,observational,observational model: cohort|time perspective: prospective
Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe,Euro-COVIMID,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04397237,NCT04397237,covid-19 seroconversion|covid-19 infection|seroconversion rate by disease|penetration across europe|covid-19 severity|covid-19 mortality rate|covid-19 impact on immunomodulatory treatment|patient-reported flares|patient's fears towards covid-19|patient's beliefs in their medicines towards covid-19,observational,observational model: case-control|time perspective: cross-sectional
REassessement After Hospitalization for Sars-COV-2 disordER,REHCOVER,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04443257,NCT04443257,"development or worsening of a ventilatory disorder and/or chronic respiratory failure assessed by spirometry|assessment of dyspnea|description of pulmonary lesions as assessed by lung ct scan|development of pulmonary fibrosis as assessed by lung ct scan|incidence or worsening of cardiovascular diseases|incidence or worsening of renal disease|incidence or worsening of liver disease|incidence or worsening of psychological pathology : anxiety|incidence or worsening of psychological pathology: depression|incidence or worsening of psychological pathology: post-traumatic stress|incidence or worsening of psychological pathology: insomnia|assessment of the health-related quality of life|assessment of the fatigue|assessment of the socioeconomic deprivation|development or worsening of metabolic disorders: diabetes, thyroid diseases, dyslipidemia, adrenal disorders, malnutrition|development of auto-immune disorders|assessment of the evolution of the humoral anti-sars-cov-2 immunization profile|patients' self-reported level of physical activity|determination of risk factors associated with sequelae or comorbidities",observational,observational model: cohort|time perspective: prospective
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19),AMPoL,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04409873,NCT04409873,change in sars-cov-2 viral load|change in self-reported clinical symptom onset|change in healthcare utilization and hospitalization,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: supportive care"
The Geneva Covid-19 CVD Study,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04384029,NCT04384029,"mobidity discharge|mobidity at 30 days|mobidity 1 year after hospitalization|mortality discharge|mortality 30 days after hospitalization|mortality 1 year after hospitalization|clinical outcomes according to medication at admission|clinical outcomes related to preexisting cardiovascular risk factors at admission|new onset of cvd induced by covid-19 disease|cost of hospital stay|clinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).|clinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).",observational,observational model: cohort|time perspective: other
Sevoflurane in COVID-19 ARDS (SevCov),nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04355962,NCT04355962,composite outcome of death rate (rate of patients that did not survive) and organ failure rate (rate of patients surviving with persistent organ dysfunction) at day 28|length of stay icu|plasma inflammatory markers|length of stay at hospital|sex-related differences in complications,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: treatment"
Low-Dose Tenecteplase in Covid-19,nan,"active, not recruiting",No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04558125,NCT04558125,percent improvement in shock index (hr/sbp) 6 hours after the tnk/placebo bolus.|1. clinical status at 24 hours after administration of tnk / placebo based upon 7-point scale.,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy,nan,"active, not recruiting",No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04339634,NCT04339634,to determine the medication risk score of de-identified pace's participants using their current drug regimen.|to simulate the medication risk score following the addition of different repurposed drugs against covid-19 to their current drug regimen.|to compare the impact on medication risk score before and after the addition of repurposed drugs for covid-19.|to assess and compare the effects of various repurposed drugs for covid-19 on each of the 5 factors computed by algorithms to derive the medication risk score.|to investigate the effects of various covariables on the medication risk score in the presence of repurposed drugs for covid-19.|to explore the effects on medication risk score of various repurposed drugs for covid-19 within subgroups of patients classified by specific diseases or drugs used.,observational,observational model: cohort|time perspective: retrospective
Analysis of the Coagulopathy Developed by COVID-19 Infected Patients,COVID-TGT,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04356950,NCT04356950,28-day survival rate|absolute thrombin generation test latent period|relative thrombin generation test latent period compared to reference plasma|absolute thrombin generation test initial velocity|relative thrombin generation test initial velocity compared to reference plasma|relative thrombin generation test peak thrombin compared to reference plasma|absolute thrombin generation test peak thrombin|absolute thrombin generation test peak thrombin time|relative thrombin generation test peak thrombin time compared to reference plasma|absolute thrombin generation test total thrombin generation time|relative thrombin generation test total thrombin generation time compared to reference plasma|absolute thrombin generation test endogenous thrombin potential|relative thrombin generation test endogenous thrombin potential compared to reference plasma|3-month survival rate|transfer to intensive care unit during hospitalization|thrombotic complication during hospitalization|plasma concentrations of d-dimers|plasma concentrations of soluble fibrin monomers,observational,observational model: other|time perspective: prospective
Intensive Care Therapy of Covid-19 Disease in Germany,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04455451,NCT04455451,mortality|icu length of stay,observational,observational model: cohort|time perspective: other
Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04356443,NCT04356443,"endotracheal intubation during present hospitalization, recorded through chart review|improvement in hypoxemia as indicated by oxygen saturation and requirement for supplemental oxygen, recorded through chart review|premature need for removal of the band, recorded through investigator report|in-hospital mortality, recorded through chart review",observational,observational model: cohort|time perspective: prospective
COVID-19 (SARS-CoV-2) in Urine and Semen,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04446169,NCT04446169,sars-cov 2 presence in semen|sars-cov 2 presence in urine|inflammation in semen|semen quantitative and qualitative analysis|erectile function|sexual habits|urinary function|sexual and ejaculatory function,observational,observational model: cohort|time perspective: prospective
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,CYCOV-II,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04385771,NCT04385771,il-6 reduction by 75% or more after 72 hours as compared to the baseline measurement|time to successful ecmo-explantation|ventilator free days (vfd)|time to extubation from ventilation and explantation from ecmo|overall survival time|days on intensive care unit (icu)|vasopressor dosage|fluid substitution and fluid balance|serum lactate|urine output|willebrand factor|d-dimers|interleukin-6 levels|sofa-score|serious adverse device effects|adverse event of special interest: air in the ecmo system|adverse event of special interest: blood-clotting in the ecmo system|adverse event of special interest: bleeding complications,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine",COVID-19,recruiting,No Results Available,phase 3,Industry|Other,https://ClinicalTrials.gov/show/NCT04508075,NCT04508075,"incidence of laboratory-confirmed covid-19 after the second dose|incidence of suspected covid-19 cases|incidence of laboratory-confirmed cases (severe, critical and death)|seroconversion rate anti-s antibody igg titer (elisa)|seropositive rate of neutralizing antibodies",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19),COVEN,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04497454,NCT04497454,average daily modified lung injury score until day 28|high oxygen dependence free days until day 28|mechanical ventilation free days until day 28|incidence of shock or barotrauma|incidence of acute renal failure requiring renal replacement therapy|28-day mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: ""The Hope Coalition - 1""",nan,recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04403100,NCT04403100,"proportion of participants who were hospitalized for progression of covid-19 disease|proportion of participants who died due to covid-19 progression and/ or complications|proportion of participants with viral load change on 03, 07, 10 and 14 after randomization|time to clinical improvement|time to clinical failure|hospitalization for any cause|proportion of participants who died due to pulmonary complications|proportion of participants who died due to cardiovascular complications|proportion of participants who presented with adverse events|time to improvement on respiratory scale symptoms|proportion of non-adherent participants to any of study drugs",interventional,"allocation: randomized|intervention model: factorial assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
The Impact of Camostat Mesilate on COVID-19 Infection,CamoCO-19,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04321096,NCT04321096,"cohort 1: days to clinical improvement from study enrolment|cohort 2: days to clinical improvement from study enrolment|safety evaluation, as measured by aes, adverse reactions (ars), saes, serious ars (sars)|cohort 1: clinical status as assessed by the 7-point ordinal scale at day 7, 14 and 30|cohort 1: day 30 mortality|cohort 1: change in new(2) score from baseline to day 30|cohort 1: admission to icu|cohort 1: use of invasive mechanical ventilation or ecmo|cohort 1: duration of supplemental oxygen (days)|cohort 1+2: days to self-reported recovery (e.g. limitations in daily life activities) during telephone interviews conducted at day 30|cohort 2: number participant-reported secondary infection of housemates|cohort 2: time to hospital admission related to covid-19 infection",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress,PROVID-19,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04363463,NCT04363463,"percent age of patients who will have endotracheal intubation or non-invasive ventilation at two pressure levels and/or die, in each of the 2 randomization groups.|duration in days for the change of 2 points on the who ordinal scale|rate (%) of intubation and invasive ventilation in the 2 randomization groups.|rate (%) of non-invasive ventilation at two pressure levels in the 2 randomization groups|duration of oxygen therapy in the 2 randomization groups.|duration of hospitalization in the 2 randomization groups.|hospital mortality and mortality at d28 in the 2 randomization groups|rate (%) of need for transfer to intensive care unit|rate (%) of use of non-invasive ventilation at two pressure levels, intubation throughout the entire stay when the stay is longer than 28 days.",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by COVID-19 in OECD Countries?,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04468802,NCT04468802,case fatality rate,observational,observational model: case-only|time perspective: prospective
Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA),CORIA,recruiting,No Results Available,nan,Other|Industry,https://ClinicalTrials.gov/show/NCT04354818,NCT04354818,"percentage of patients who required hospitalisation, developed severe illness (icu admission) or died",observational,observational model: cohort|time perspective: prospective
Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04376814,NCT04376814,mortality|long of hospitalization|laboratory treatment response (blood cell count)|laboratory treatment response (crp )|dyspnea|oxygen saturation without supplemental oxygen.|oxygen therapy,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
The Impact of COVID-19 Pandemic on Cancer Care,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04382495,NCT04382495,patients' and survivors' perspective of their cancer care during covid-19 pandemic,observational,observational model: other|time perspective: cross-sectional
COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study,RICO,recruiting,No Results Available,nan,Other|Industry,https://ClinicalTrials.gov/show/NCT04392401,NCT04392401,kinetics over time of hla-dr expression on the surface of monocytes,observational,observational model: cohort|time perspective: prospective
Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407156,NCT04407156,incidence of acute kidney injury in covid-19|all-cause mortality in aki patients,observational,observational model: case-control|time perspective: retrospective
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects,nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04523571,NCT04523571,"occurrence of solicited local reactions in the subjects (e.g., vaccination sites: pain/tenderness, erythema/redness, induration/swelling) during the 14-days after each dose of bnt162b1 or placebo.|occurrence of solicited systematic reactions (e.g., nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) during 14-day after each dose of bnt162b1 or placebo.|occurrence of adverse event (ae) associated with vaccination in subjects during the 21-day period after prime vaccination of bnt162b1 or placebo.|occurrence of ae associated with vaccination in subjects during the 28-day period after boost dose of bnt162b1 or placebo.|the proportion of subjects experiencing serious adverse events (saes), occurring up to day 21 after prime vaccination and day 28 after boost vaccination, up to month 3, 6 and 12.|the proportion of subjects experiencing ae associated with bnt162b1, occurring up to month 3, 6 and 12.|the proportion of subjects experiencing abnormal markers of hematology, blood chemistry and urine analysis, occurring at hour 24 and day 7 after prime vaccination and day 7 period after boost dose of bnt162b1 or placebo.|geometric mean titer (gmt) of anti-s1 igg antibody at day 7, day 21 after prime vaccination, at day 7, day 21 after boost vaccination, and at month 3, 6 and 12.|gmt of anti-receptor binding domain (rbd) immunoglobulin g (igg) antibody at day 7, day 21 after prime vaccination, at day 7, day 21 after boost vaccination, and at month 3, 6 and 12.|gmt of sars-cov-2 neutralizing antibody (including true virus-based sars-cov-2 neutralizing test) at day 7, day 21 after prime vaccination, at day 7, day 21 after boost vaccination, and at month 3, 6 and 12.|fold increase in antibody anti-s1 igg antibody titers, as compared to baseline, at day 7, day 21 after prime vaccination, at day 7, day 21 after boost vaccination, and at month 3, 6 and 12.|fold increase in antibody anti-rbd igg antibody titers, as compared to baseline, at day 7, day 21 after prime vaccination, at day 7, day 21 after boost vaccination, and at month 3, 6 and 12.|fold increase in sars-cov-2 neutralizing antibody titers (virus neutralizing test), as compared to baseline, at day 7, day 21 after prime vaccination, at day 7, day 21 after boost vaccination, and at month 3, 6 and 12.|seroconversion rates (scr) defined as a minimum of 4-fold increase of antibody titers, as compared to baseline, at day 7, day 21 after prime vaccination, and at day 7, day 21 after boost vaccination.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: prevention"
Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04373291,NCT04373291,"number of days of unplanned absenteeism for any reason|the cumulative incidence of documented covid|the cumulative incidence of hospital admission for any reason|the number of days of unplanned absenteeism, because of documented covid|the number of days of absenteeism, because of imposed quarantine as a result of exposure to sars-cov-2|the number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented sars- cov-2 infection|the number of days of unplanned absenteeism because of self-reported acute respiratory symptoms|the number of days of self-reported fever (‚â•38 ¬∞c)|the number of days of self-reported acute respiratory symptoms|the cumulative incidence of self-reported acute respiratory symptoms|the cumulative incidence of death for any reason|the cumulative incidence of death due to documented covid|the cumulative incidence of intensive care admission for any reason|the cumulative incidence of intensive care admission due to documented covid|the cumulative incidence of hospital admission due to documented covid",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: prevention"
A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04346602,NCT04346602,fever|cough|diarrhea|anxiety|insomnia|depression,observational,observational model: cohort|time perspective: prospective
Respiratory Mechanics and Gas Exchange Characteristics in Patient With SARS-CoV-2,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04486729,NCT04486729,driving transpulmonary pressure (cmh2o)|bohr dead space fraction (%)|shunt fraction (%),observational,observational model: case-crossover|time perspective: cross-sectional
Observational Study of COVID-19 Treatment Efficacy,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04369989,NCT04369989,mortality during the covid-19 treatment hospital encounter|icu admission during the covid-19 treatment hospital encounter|ventilator use during the covid-19 treatment hospital encounter,observational,observational model: cohort|time perspective: other
International SARS-CoV-2 (COVID-19) Infection Observational Study,ICOS,recruiting,No Results Available,nan,Other|NIH,https://ClinicalTrials.gov/show/NCT04385251,NCT04385251,time to hospitalization|time to expiration|rate of death at 7 days|rate of death at 14 days|rate of death at 28 days|rate of hospitalization at 7 days|rate of hospitalization at 14 days|rate of hospitalization at 28 days|participant health at 7 days|participant health at 14 days|participant health at 28 days|modified borg dyspnea scale at 7 days|modified borg dyspnea scale at 14 days|modified borg dyspnea scale at 28 days,observational,observational model: cohort|time perspective: prospective
Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04491227,NCT04491227,aki incidence|dialysis requirement|hospital mortality|renal functional recovery|functional status|resource utilization,observational,observational model: cohort|time perspective: retrospective
Solid Organ Transplant Recipients With SARS-CoV-2 French Registry,TX-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04360707,NCT04360707,clinical presentation and incidence of covid-19 infection in different cohorts of solid organ transplant patients,observational,observational model: case-only|time perspective: prospective
The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04402983,NCT04402983,modified medical research council dyspnea score|timed up and go test|visual analog scale to assess the pain severity|the short physical performance battery (sppb)|visual analog scale to assess the fatigue severity|beck depression inventory|saint george respiratory questionnaire,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Validation of an Immunochromatographic Assay for IgG/IgM Antibodies to 2019- nCoV,I-GLOBAL,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04434417,NCT04434417,evaluation of the rate of sars-cov-2 positive cancer patients and health professionals in a comprehensive cancer center or in a cancer setting.|evaluation of test accuracy|interleukin-6 quantification|interleukin-2 quantification|interleukin-1 quantification|tumor necrosis factor (tnf) quantification|interferon gamma quantification,observational,observational model: cohort|time perspective: prospective
Impact of the COVID-19 Pandemic in Gynecological Oncology,COVID-GYN,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04351139,NCT04351139,"percentage of patients with a change in the planned therapeutic management (surgery, chemotherapy, radiotherapy, hormone therapy)",observational,observational model: case-control|time perspective: other
CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,Co-PARENT,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04431856,NCT04431856,measure of anxiety as assessed by the oasis|measure of depression as assessed by the odsis|measure of ptsd as assessed by the pcl-5|measure of parenting overprotection/overcontrol as assessed by the s-embu|measure of parenting rejection as assessed by the s-embu|measure of parenting emotional warmth as assessed by the s-embu|measure of parent accommodation for child anxiety as assessed by the fasa,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
SARS-CoV-2 Disguise Study,Disguise,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04395794,NCT04395794,sars-cov-2 positive test|transformation|predictors (asymptomatic)|predictors (symptomatic)|percentage from different departments,observational,observational model: cohort|time perspective: prospective
The Containing Coronavirus Disease 19 (COVID-19) Trial,ConCorD-19,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04552379,NCT04552379,"the proportion of index cases shedding sars-cov-2, at day 11, in the active arm compared to the standard of care arm.|the proportion of household contacts shedding sars-cov-2, at day 11, in the active arm compared to the standard of care arm.|duration (in days) of sars-cov-2 by pcr of samples taken on study days 1, 6, 11, 16, 21, and 29.|number of household contacts of participants in the ifn arm with positive upper airway pcr compared to that in the standard of care arm at day 1 & 11, and seroconversion (ig) over the study period, up to day 29.|the proportion of infected cases in the active arm that are hospitalised or die due to covid-19, as compared to the proportion in the standard of care arm.|incidence and severity of reported adverse events in the interferon arm compared to the standard of care arm.",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Convalescent Plasma for Patients With COVID-19: A Pilot Study,CP-COVID-19,completed,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04332380,NCT04332380,change in viral load|change in immunoglobulin m covid-19 antibodies titers|change in immunoglobulin g covid-19 antibodies titers|intensive care unit admission|length of intensive care unit stay|length of hospital stay (days)|requirement of mechanical ventilation|duration (days) of mechanical ventilation|clinical status assessed according to the world health organization guideline|mortality,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
TARGet Kids! COVID-19 Study of Children and Families,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04449978,NCT04449978,cumulative incidence of covid-19|risk factors for covid-19|parent-reported probable case definition of covid-19|dynamics of covid-19|risk to family members|severity of covid-19|longer term effects of covid-19 on physical health|longer term effects of covid-19 on mental health|longer term effects of covid-19 on child development|longer term effects of covid-19 on family functioning|longer term effects of covid-19 on health behaviours|longer term effects of covid-19 on healthcare utilization|effects of preventive measures on infection|effects of preventive measures on physical health|effects of preventive measures on mental health|effects of preventive measures on child development|effects of preventive measures on family functioning|effects of preventive measures on health behaviours|effects of preventive measures on healthcare utilization,observational,observational model: cohort|time perspective: prospective
Liver Injury in Patients With COVID-19,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04358380,NCT04358380,liver injury in patients with covid-19|prognostic factors associated with death|clinical characteristics of patients who developed liver injury,observational,observational model: cohort|time perspective: prospective
Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE),VADER,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04375774,NCT04375774,evaluation of airtightness (fit test)|user comfort|breathing easiness|field of view quality|ease of use,interventional,allocation: non-randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19),nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04442230,NCT04442230,proportion of patients with clinical worsening|maximal severity of covid-19 after treatment|all-cause mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04380961,NCT04380961,"time to improvement of at least 2 categories relative to baseline on the 6-point ordinal clinical recovery scale|percentage of participants with an improvement of at least 2 categories relative to baseline on the 6-point ordinal clinical recovery scale on day 28|percentage of participants with all-cause mortality|percentage of participants with serious adverse events (saes)|percentage of participants with related adverse events|percentage of participants with severe or life threatening bacterial, invasive fungal, viral or opportunistic infections|percentage of participants with grade 3 and 4 neutropenia|percentage of participants with grade 3 and 4 lymphocytopenia|percentage of participants with increased alanine aminotransferase (alt) greater than or equal to 3 times upper limit of normal (uln) combined with increased bilirubin > 2 times uln|time to improvement of at least 1 category relative to baseline on the 6-point ordinal clinical recovery scale|percentage of participants with an improvement of at least 1 category relative to baseline on the 6-point ordinal clinical recovery scale on day 28|time from study intervention to end of oxygen supplementation|time from study intervention to hospital discharge among the surviving participants|total length of hospitalization|number of ventilation free days|participant's clinical status at day 7, 14, 21, 28 as assessed by 6-point ordinal clinical recovery scale|total time on invasive mechanical ventilation|percentage of participants with a worse category relative to baseline on the 6-point ordinal clinical recovery scale over time|percentage of participants on extracorporeal membrane oxygenation (ecmo) over time|total time on ecmo|percentage of alive participants at day 28, week 8 and week 16|percentage of alive participants that required readmission at week 8 and week 16",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Immunoregulatory Therapy for 2019-nCoV,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04268537,NCT04268537,"lung injury score|absolute lymphocyte counts|serum level of crp, pct and il-6|sofa score|all cause mortality rate|ventilation free days|icu free days",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
"The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations",LEAD COVID-19,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04363840,NCT04363840,hospitalization,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
M5049 Study in Participants With Coronavirus Disease 2019 (COVID-19) Pneumonia,ANEMONE,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04448756,NCT04448756,"percentage of participants alive and not requiring supplemental oxygenation|occurrence of treatment-emergent adverse events (teaes), adverse events of special interests (aesis), teaes leading to treatment discontinuation and serious aes (saes)|number of participants with clinically significant changes in laboratory parameters and electrocardiogram findings|clinical status of participants on a 9-point ordinal scale|time to reach peripheral capillary oxygen saturation (spo2) greater than or equal to 94 percent for at least 24 hours on room air|percentage of participants with all-cause mortality|clinical deterioration: time to intensive care unit (icu) admission|clinical deterioration: time to invasive mechanical ventilation|clinical deterioration: time to non-invasive mechanical ventilation|total length of stay in intensive care unit (icu)|total length of hospitalization stay|percentage change from baseline in inflammatory biomarkers|percentage change from baseline in cytokine biomarkers|percentage of participants with relapse|percentage of participants who are re-hospitalized|maximum observed concentration (cmax) of m5049|time to reach the maximum observed concentration (tmax) of m5049|terminal rate constant (lambda z) of m5049|apparent elimination half-life (t1/2) of m5049|area under the plasma concentration-time curve from time of dosing to the time of the last observation (auc0-t) of m5049|area under plasma concentration-time curve from time of dosing to 12 hours post-dose (auc0-12h) of m5049|area under the plasma concentration-time curve from time of dosing to infinity (auc0-infinity) of m5049|apparent total body clearance (cl/f) of m5049|apparent volume of distribution during the terminal phase following extravascular administration (vz/f) of m5049|dose-normalized maximum observed concentration (cmax/dose) of m5049|dose-normalized area under the plasma concentration-time curve from time of dosing to the time of the last observation (auc0-t/dose) of m5049|dose-normalized area under plasma concentration-time curve from time of dosing to 12 hours post-dose (auc0-12h/dose) of m5049|dose-normalized area under the plasma concentration-time curve from time of dosing to infinity (auc0-infinity/dose) of m5049|accumulation ratio for area under plasma concentration-time curve from time of dosing to 12 hours post-dose [racc(auc0- 12h)] of m5049|accumulation ratio for maximum observed concentration [racc(cmax)] of m5049",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Pediatric Intensive Care and COVID-19,CLOVIS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04544878,NCT04544878,number of patient with secondary infection|number of patients dying|description of clinical phenotypes|description of immunological phenotypes,observational,observational model: cohort|time perspective: prospective
Nutritional Assessment of Hospitalized Patients With COVID-19,DenutCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04503525,NCT04503525,nutritional status of covid infected patients|correlation between the nutritional status and the supplemental oxygen requirement|correlation between the nutritional status and the prognostic after hospitalization,observational,observational model: other|time perspective: prospective
Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,Coronavirus,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04349098,NCT04349098,percentage of participants with at least a 2 point improvement in the ordinal scale|time to clinical improvement (ttci)|overall death rate|rate of mechanical ventilation|time to mechanical ventilation|overall survival|time to improvement (2 points) in clinical measures using the ordinal scale|time to intensive care unit (icu) admission|rate of intensive care unit (icu) admission|length of stay in hospital|percentage of participants discharged from hospital|length of stay in intensive care unit (icu)|duration of oxygen supplementation|duration of mechanical ventilation|time to clinical improvement in participants ‚â§ 70 years old|time to clinical improvement in participants > 70 years old|time to clinical improvement in participants with pre-existing diseases|change in oxygenation index|time to improvement of one point using who ordinal scale improvement|percentage of participants experiencing who ordinal scale improvement of >1 point|change from baseline in c-reactive protein (crp) levels|change from baseline in ferritin levels|change from baseline in lactate dehydrogenase (ldh) levels|changes from baseline in blood plasma cytokines levels|number of participants with adverse events (ae),interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Tomographic Findings in COVID-19 and Influenza H1N1,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04499378,NCT04499378,oral intubation|survival,observational,observational model: cohort|time perspective: prospective
COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID),NEOSCREENCOVID,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04492410,NCT04492410,to evaluate the prevalence of covid-19|to evaluate patient's and health care professional's perception about the rapid serological test.|to evaluate the concordance of covid-19 positivity by the rapid serological test compared to the gold-standard rt-pcr on nasal swab for eligible patients|to evaluate the concordance of covid-19 positivity by the rapid serological test compared to a classic serological test (elisa method) from whole blood|to evaluate the proportion of the patients who will have at least one positive testing among all the methods applied.|to evaluate the number of patients who will get at least one new testing after the rapid serological test has been performed.|to compare the clinical and biological characteristics between positive and negative tested covid-19 patients|to describe the outcome of covid-19 positive patients|to evaluate the impact of covid-19 rapid serological test on the anti-cancer treatment schedule,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: screening
Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04407182,NCT04407182,symptom resolution|cumulative incidence of disease severity|complementary drugs required|side effects of supplementation|duration of sars-cov-2 pcr positivity|concentration of reactive protein c in peripheral blood|incidence of hospitalization|duration (days) of hospitalization|incidence of mechanical ventilation supply|duration (days) of mechanical ventilation supply|incidence of oxygen use|duration (days) of oxygen use|mortality rate|time to return to normal activity,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: supportive care"
Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation,RHUMACOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04393233,NCT04393233,reduction or discontinuation of the dmard therapy in relation to the covid-19 sanitary crisis,observational,observational model: cohort|time perspective: prospective
Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment,RHUMAJICOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407923,NCT04407923,reduction or discontinuation of the dmard therapy in relation to the covid-19 sanitary crisis,observational,observational model: cohort|time perspective: prospective
Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome,ACES,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04408326,NCT04408326,proportions of patients with mean arterial pressure ‚â• 65 mmhg or an increase of mean arterial pressure ‚â•10 mmhg at 3 hours|noradrenaline dose|sequential organ failure assessment (sofa) score|rrt-free days|rrt discontinuation|serum creatinine|pao2/fio2 ratio|mortality|adverse events|change in serum c-reactive protein|change in serum ferritin,observational,observational model: case-control|time perspective: retrospective
Glycaemia and Cardiac Function in Patients With COVID-19,GLYCOVID-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04410718,NCT04410718,"plasma glucose levels and left ventricular ejection fraction|key secondary outcome: hba1c, plasma glucose levels and left ventricular systolic function|plasma glucose levels and strain analysis|plasma glucose levels and mitral annular systolic velocity|plasma glucose levels and left ventricular ejection fraction (sub-group analysis)|plasma glucose levels and strain analysis (sub-group analysis)|plasma glucose levels and mitral annular systolic velocity (sub-group analysis)|hba1c, plasma glucose levels and strain analysis|hba1c, plasma glucose levels and mitral annular systolic velocity|diabetes status and whole blood coagulability and fibrinolysis|diabetes status and change in whole blood coagulability and fibrinolysis during icu stay|prognostic value of teg analysis|prognostic value of cardiac function|diabetes status and high-sensitivity troponins|diabetes status and change high-sensitivity troponins",observational,observational model: cohort|time perspective: prospective
"Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in SARS CoV 2 Virus",COSTA,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04355052,NCT04355052,clinical state as reflected by news scoring|positive pcr|prevention of icu|prevention of assisted ventilation|prevention of ecmo|death,interventional,allocation: randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
COVID-19 Research in Organ Transplant Recipients,CORONA,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407221,NCT04407221,seroprevalence of sars-cov-2 antibodies (positive antibody test)|change in levels of sars-cov-2 antibodies (antibody titers)|cellular response to sars-cov-2 (th4 and th8 levels)|change in cellular response to sars-cov-2 (th4 and th8 levels)|symptoms and hospitalisations (electronic questionnaire),observational,observational model: cohort|time perspective: prospective
CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms,CANDIDATE,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04467918,NCT04467918,reduction in viral load|number of participants with negative clinical covid19 symptoms as assessed by ctcae v5.0|change in proinflammatory cytokine concentration|describe the parenchymal lung damage induced by covid-19 through a qualitative analysis with chest ct|number of participants with treatment-related adverse events as assessed by ctcae v5.0|time to clinical improvement with ctcae v5.0 covid19 symptoms to 0|number of participants that need hospitalisation|28-day mortality|time to negative saliva 2019-n-cov rt-pcr,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
"Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial",ATCO,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04332666,NCT04332666,ventilator free days|icu free days|hospital length of stay|time to wean from mechanical ventilation|pao2/fio2 changes during drug administration|deep vein thrombosis incidence|changes in inflammatory markers|ras effectors levels|radiological findings,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Screening of Cancer Patients to Assess Impact of COVID-19,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04373005,NCT04373005,rate of asymptomatic covid-19 infection among cancer patients receiving cancer therapy|rate of sero-conversion in cancer patients|describe the clinical course of covid-19 infection in cancer patients,observational,observational model: cohort|time perspective: prospective
Early Intervention in COVID-19: Favipiravir Verses Standard Care,PIONEER,recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04373733,NCT04373733,"time to improvement by two points on a seven-category ordinal scale|clinical status on a seven-category ordinal scale (day 7)|clinical status on a seven-category ordinal scale (day 14)|overall survival|time to improvement by two points on the news score|time to improvement by two points on the news element score for temperature|time to improvement by two points on the news element score for heartrate|time to improvement by two points on the news element score for respiratory rate|time to improvement by two points on the news element score for oxygen saturation.|admission to intensive care|requirement for mechanical ventilation|requirement for non-invasive ventilation, continuous positive airways pressure or high-flow oxygen|incidence of bacterial or fungal infection|incidence of adverse events not directly caused by covid-19 infection.",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
In-Utero Vascular Accidents in Neonates From COVID-19 Infected Mothers,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04431869,NCT04431869,"rates of intestinal atresias and limb abnormalities|rates of preterm labor, fetal growth restriction and spontaneous abortions|rates of maternal sars-cov-2 infection among mothers to infants born with intestinal atresias or limb anomalies",observational,observational model: cohort|time perspective: prospective
Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,EPICOS,recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04334928,NCT04334928,number of confirmed symptomatic infections of sars-cov-2 (covid-19)|severity of disease in confirmed infected participants of sars-cov-2 (covid-19)|duration of symptoms in confirmed infected participants of sars-cov-2 (covid-19) measured in days,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04355676,NCT04355676,percentage of participants with at least a 2 point improvement in the ordinal scale|time to clinical improvement (ttci)|overall death rate|rate of mechanical ventilation|time to mechanical ventilation|overall survival|time to improvement (2 points) in clinical measures using the ordinal scale|time to intensive care unit (icu) admission|rate of intensive care unit (icu) admission|length of stay in hospital|percentage of participants discharged from hospital|length of stay in intensive care unit (icu)|duration of oxygen supplementation|duration of mechanical ventilation|time to clinical improvement in participants ‚â§ 70 years old|time to clinical improvement in participants > 70 years old|time to clinical improvement in participants with pre-existing diseases|change in oxygenation index|time to improvement of one point using who ordinal scale improvement|percentage of participants experiencing who ordinal scale improvement of >1 point|change from baseline in c-reactive protein (crp) levels|change from baseline in ferritin levels|change from baseline in lactate dehydrogenase (ldh) levels|number of participants with adverse events (ae),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
SARS Cov-2 in Conjunctival Secretion,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04402853,NCT04402853,virus presence in covid 19 patients tears|concordance to naso-pharingeal swab,observational,observational model: case-crossover|time perspective: prospective
Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04437823,NCT04437823,safety and efficacy assessment of infusion associated adverse events|chest radiograph or chest ct scan|covid-19 quantitative real time pcr|sequential organ failure assessment (sofa) score|rate of mortality|clinical respiratory changes,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU,EpiCoV-Brazil,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04378582,NCT04378582,icu survival at 28 days|hospital survival at 60 days|duration of mechanical ventilation|need for renal replacement therapy|complications during the icu stay,observational,observational model: case-only|time perspective: other
Renal Biomarkers in AKI and COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04517630,NCT04517630,urinary levels of renal biomarkers|incidence of aki|urinary levels of renal biomarkers and mortality|urinary levels of renal biomarkers and severity of the disease.|risk factors for aki in severe covid-19|evolution renal biomarkers|evolution of viral load|evolution of complement pathway|metabolomic profile|respiratory changes,observational,observational model: cohort|time perspective: prospective
Obstructive Sleep Apnea & Covid-19 Outcomes,OSACOVID-19,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04363333,NCT04363333,the rate of clinical improvement|clinical status - improvement|clinical status - worsening,observational,observational model: cohort|time perspective: prospective
"Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19",nan,recruiting,No Results Available,phase 1|phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04447781,NCT04447781,primary outcome measures,interventional,"allocation: randomized|intervention model: sequential assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: prevention"
Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,CORMOR,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04388514,NCT04388514,time of respiratory improvement and earlier weaning from oxygen support|the time of respiratory improvement and earlier weaning from oxygen support|assessment of the length of hospitalization|assessment of the length of intensive care unit (icu) stay|improvment in chest imaging finding|improvment in cytokine release syndrome,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (investigator)|primary purpose: treatment
"The Use of Oxygen Hoods as Compared to Conventional High-flow Oxygen Delivery Systems, the Effects on Oxygenation, Mechanical Ventilation and Mortality Rates in Hypoxic Patients With COVID-19. A Prospective Controlled Cohort Study.",nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407260,NCT04407260,oxygen saturation|in-hospital intubation/mechanical ventilation status|in-hospital mortality|length of hospitalization,observational,observational model: cohort|time perspective: prospective
"Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection",nan,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04330495,NCT04330495,incidence rate of new covid-19 cases in both arms|prevalence of covid-19 cases in both arms|mortality rate secondary to covid-19 cases in both groups|intensive care unit (cu) admission rate secondary to covid-19 cases in both groups|adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 ( COVIP ),nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04357639,NCT04357639,comparison of the incidence of covid-19 infection in plwhiv treated with long-term antiretroviral drugs including a protease inhibitor and those without a protease inhibitor|determination of the seroprevalence of covid-19 infection in both groups of the study|comparison of the severity of covid-19 infection symptoms in both groups of the study.|identification of potential risk factors for covid-19 infection in hiv patients treated with protease inhibitor or without protease inhibitor,observational,observational model: cohort|time perspective: prospective
Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04399252,NCT04399252,change in shannon diversity|change in shannon diversity in patients that develop covid-19,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: basic science"
Loneliness During the NPIs for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04365881,NCT04365881,ucla loneliness scale-8 (uls-8)|patient health questionnaire-9 (phq-9)|generalized anxiety disorder-7 (gad-7),observational,observational model: other|time perspective: cross-sectional
Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.,MeCOVID,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04353128,NCT04353128,sars-cov 2 infection rate,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
A Study of Combination Therapies to Treat COVID-19 Infection,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04459702,NCT04459702,efficacy of treatment by reduced symptoms news (national early warning system) scores|efficacy of treatment by time to non-infectivity|safety of dual therapy as measured by symptoms rated on the news (national early warning system) sores|safety of quadruple therapy as measured by symptoms rated on the news (national early warning system) scores.|safety of dual therapy as measured by complete blood count|safety of quadruple therapy as measured by complete blood count|safety of dual therapy as measured by metabolic panel -albumin|safety of quadruple therapy as measured by metabolic panel - albumin|safety of quadruple therapy as measured by metabolic panel - a/g ratio|safety of dual therapy as measured by metabolic panel a/g ratio|safety of quadruple therapy as measured by metabolic panel - alkaline phosphatase|safety of dual therapy as measured by metabolic panel alkaline phosphatase|safety of dual therapy as measured by metabolic panel - ast|safety of quadruple therapy as measured by metabolic panel - ast|safety of quadruple therapy as measured by metabolic panel - alt|safety of dual therapy as measured by metabolic panel alt|safety of dual therapy as measured by metabolic panel bun/creatinine ratio|safety of quadruple therapy as measured by metabolic panel bun/creatinine ratio|safety of quadruple therapy as measured by metabolic panel - bun|safety of dual therapy as measured by metabolic panel - bun|safety of dual therapy as measured by metabolic panel - calcium|safety of quadruple therapy as measured by metabolic panel - calcium|safety of quadruple therapy as measured by metabolic panel - carbon dioxide|safety of dual therapy as measured by metabolic panel - carbon dioxide|safety of dual therapy as measured by metabolic panel - chloride|safety of quadruple therapy as measured by metabolic panel - chloride|safety of quadruple therapy as measured by metabolic panel - creatinine|safety of dual therapy as measured by metabolic panel - creatinine|safety of dual therapy as measured by metabolic panel - globulin|safety of quadruple therapy as measured by metabolic panel - globulin|safety of quadruple therapy as measured by metabolic panel - glucose|safety of dual therapy as measured by metabolic panel - glucose|safety of dual therapy as measured by metabolic panel - potassium|safety of quadruple therapy as measured by metabolic panel - potassium|safety of quadruple therapy as measured by metabolic panel - total bilirubin|safety of dual therapy as measured by metabolic panel - total bilirubin|safety of dual therapy as measured by metabolic panel - total protein|safety of quadruple therapy as measured by metabolic panel - total protein|safety of dual therapy as measured by treatment related sae|safety of quadruple therapy as measured by treatment related sae,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
NOsocomial Dissemination Risk of SARS-Cov2,NODS-Cov2,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04339881,NCT04339881,understanding the dissemination of sars cov2 in hospital|optimizing hospital strategies to prevent transmission to caregivers and not infected hospitalized patients with sarscov2,observational,observational model: other|time perspective: prospective
"High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study",VitCov,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04525820,NCT04525820,length of hospitalization|need of intensive care|lenght of the intensive care treatment|overall mortality|development of vitamin d levels|development of sepsis,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04329533,NCT04329533,perceived stress scale|hospital anxiety and depression scale|promis sleep disturbance short form survey|adherence|participant satisfaction|coronavirus questionnaire,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry,COVID-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04323787,NCT04323787,icu and hospital mortality of covid-19 patients|30 days mortality,observational,observational model: cohort|time perspective: other
Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04374786,NCT04374786,perceived stress scale|hospital anxiety and depression scale|promis sleep disturbance short form survey|impact of event scale-6|maslach burnout inventory|adherence|coronavirus questionnaire|participant satisfaction,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS,ULSC,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04494386,NCT04494386,"incidence of dose limiting toxicity (dlt)|incidence of dose limiting toxicity (dlt), suspected adverse reaction (sar), or serious adverse event (sae)|treatment-emergent adverse events (ae) and serious adverse events (sae)|levels of covid-19 related ards as defined by the berlin definition of ards|changes from baseline pulse oximetric saturation spo2/fio2 ratio or arterial oxygen pressure pao2/fio2 ratio|number of ventilator-free days (vfd)|changes in complete blood count (cbc) with differential from baseline|changes in levels of blood glucose (mg/dl) from baseline|changes in levels of sodium (meq/l) from baseline|changes in levels of potassium (meq/l) from baseline|changes in levels of blood urea nitrogen (bun; mg/dl) from baseline|changes in levels of alanine transaminase (alt; u/l) from baseline|change in urinalysis (ua) from baseline",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04473183,NCT04473183,prevalence of symptomatic infection|prevalence of subclinical infection,observational,observational model: cohort|time perspective: prospective
Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19,ECMO-SARS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04397588,NCT04397588,hospital mortality|mortality day 28|mortality day 90|ventilator-free days|intensive care unit-free days|hospital-free days,observational,observational model: cohort|time perspective: prospective
"Feasibility, of Tele-rehabilitation Following COVID-19",nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04511962,NCT04511962,recruitment - contact to consent ratio|recruitment - screen failure rate|recruitment rate|recruitment retention|the modified medical research council (mmrc) dyspnoea scale|numerical rating scale (nrs) of breathlessness|cough visual analogue scale (vas)|eq-5d-5l questionnaire|hospital anxiety and depression scale|sit to stand test,observational,observational model: ecologic or community|time perspective: prospective
COVID-19 Pandemic Impact on Patients With Cancer - a Danish Survey,COPICADS,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04389996,NCT04389996,overall quality of life,observational,observational model: cohort|time perspective: cross-sectional
"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study",CP-COVID-19,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04332835,NCT04332835,change in viral load|change in immunoglobulin g covid-19 titers|intensive care unit admission|length of intensive care unit stay|length of hospital stay (days)|requirement of mechanical ventilation|duration (days) of mechanical ventilation|clinical status assessed according to the world health organization guideline|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04419623,NCT04419623,part 1 - recommended dose of tl-895|part 2 - change in the need for artificial ventilation or death|part 2 - change in respiratory failure events that require invasive ventilation or death,interventional,"allocation: randomized|intervention model: single group assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Consequences of Intensified Handwash and Hand Disinfection Among Children During the COVID19 Pandemic,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04375410,NCT04375410,dermal reaction to frequent hand wash and disinfection in children,observational,observational model: cohort|time perspective: cross-sectional
Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04396210,NCT04396210,patients perspectives on the abruptly discontinuation of their fertility treatment by using a questionnaire|patients reproductive behaviour by using a questionnaire|patients views on resuming fertility treatment by using a questionnaire,observational,observational model: other|time perspective: prospective
"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants",COVIDOCRECHE,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04413968,NCT04413968,assess the serological status/rate of past infections in the children of priority staff in the nursery during the containment period,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
COVID19-hematological Malignancies: the Italian Hematology Alliance,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04352556,NCT04352556,to evaluate mortality.|to evaluate potential predictive biochemical parameters of mortality.|to evaluate potential predictive hm-related parameters of mortality.|to evaluate covid severity as predictive parameter of mortality.|epidemiology of patients with hm infected by sars-cov-2with any spectrum of illness severity|definition of complete clinical picture of covid-19 in hm|evolution of hm|to evaluate admission to icu requiring mechanical ventilation or death per characteristics|viral dynamics in infected hm patients,observational,observational model: cohort|time perspective: other
COVID-19 Testing Sample Acquisition Throughput and Efficiency,HexapodBooth,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04532411,NCT04532411,change in testing throughput after hexapod implementation|change in isolation gowns utilized after hexapod utilization|change in cost per test after hexapod implementation|return on investment|change in testing personnel cost per test|change in cost of isolation gowns utilized,observational,observational model: other|time perspective: other
Psychological Impact of COVID-19 Pandemic in Healthcare Workers,PSIMCOV,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04506515,NCT04506515,psas (psychological stress and adaptation at work score) during the crisis|psas (psychological stress and adaptation at work score) in basal conditions,observational,observational model: ecologic or community|time perspective: cross-sectional
Social Media and COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04367363,NCT04367363,change in dass scores across 9 days|changes in fear with regards the covid-19 situation across 1 week|changes in amount of thinking about the covid-19 situation across 1 week,observational,observational model: cohort|time perspective: prospective
FOUND - Ancillary Study to Smile Protocol NCT03654105,FOUND,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04441814,NCT04441814,temporal variations in the frequency and morphology of ssns according to the covid-19 epidemic|geographical variations in the frequency and morphology of ssns according to the covid-19 epidemic|correlation between sub-solid lesions and individual risk|correlation between sub-solid lesions and incidence of acute events,observational,observational model: cohort|time perspective: retrospective
"First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19.",nan,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04535167,NCT04535167,"frequency of treatment-emergent adverse events (teaes)|number of participants who withdraw due to treatment-emergent adverse events (teaes)|frequency of treatment-emergent adverse events (teaes), causally related to study intervention|frequency of treatment-emergent serious adverse events|frequency of treatment-emergent infusion site reactions|magnitude of abnormal hematologic laboratory findings|frequency of abnormal chemistry values|frequency of abnormal hematologic laboratory findings|magnitude of abnormal urinalysis findings|change from baseline in pr values|change from baseline in rr values|change from baseline in qtc values|change from baseline in qtcf values|change from baseline in qrs values|change from baseline in pulse rate measurements|change from baseline in temperature values|change from baseline in respiratory rate values|change from baseline in systolic blood pressure|change from baseline in diastolic blood pressure|change from baseline in pulse oximetry/spo2 measurement|change in concentration at 24 hours (c24[end of infusion]) of pf-07304814 and pf-00835231|change in concentration, dose normalised, at 24 hours (c24 (dn) [end of infusion]) of pf-07304814 and pf-00835231|change in concentration at 120 hours (c120[end of infusion]) of pf-07304814 and pf-00835231|change in maximum observed concentration (cmax) of pf-07304814 and pf-00835231|change in maximum observed concentration, dose normalised (cmax [dn]) of pf-07304814 and pf-00835231|change in concentration at steady state (css) of pf-07304814 and pf-00835231|change in concentration at steady state, dose normalised (css [dn]) of pf-07304814 and pf-00835231|change in terminal half life (t1/2) of pf-07304814 and pf-00835231|change in clearance (cl) of pf-07304814|change in area-under-the-curve plasma concentration from 0 to time extrapolated to infinity (aucinf) of pf-07304814 and pf-00835231|change in area-under-the-curve plasma concentration from 0 to last quantifiable concentration (auclast) of pf-07304814 and pf-00835231|change in area-under-the-curve plasma concentration from 0 to time extrapolated to infinity, dose normalised (aucinf [dn]) of pf-07304814 and pf-00835231|change in steady state volume of distribution (vss) of pf-00835231|cumulative amount of unchanged drug excreted into urine (ae)|percent of dose excreted as unchanged drug (ae%) over dosing period",interventional,"allocation: randomized|intervention model: sequential assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04376840,NCT04376840,medium-term respiratory complications|long-term respiratory complications,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Severe Acute Respiratory Syndrome-Coronavirus-2 and Loss of Autonomy in the Elderly,CovAged,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04414319,NCT04414319,loss of autonomy|hospital readmission|nursing home admission|all-cause mortality|change in self-rated health,observational,observational model: other|time perspective: prospective
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia,nan,"active, not recruiting",No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04374565,NCT04374565,transfer to icu|28 day mortality|cumulative incidence of serious adverse events|rates and duration of sars-cov-2|serum of plasma antibody titer to sars-cov-2|cellular and humoral immune response|supplemental oxygen free days|ventilator free days|icu free days|sequential organ failure assessment score|need for vasopressors|need for renal replacement therapy|need for extracorporeal membrane oxygenation (ecmo)|hospital length of stay (los)|icu los|grade 3 or 4 adverse events (aes),interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers,COVID-Antibody,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04334876,NCT04334876,validation of sars-cov-2 igg antibody test|incidence of seroconversion|identify candidacy,observational,observational model: ecologic or community|time perspective: prospective
"PB1046, a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).",VANGARD,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04433546,NCT04433546,"days alive and free of respiratory failure from initiation of pb1046|time to clinical recovery (being well enough for hospital discharge or returning to normal baseline activity level prior to discharge)|development of ards (pao2:fio2 ratio < 300 mm hg) during hospitalization|all-cause mortality|reduction in hospital resource utilization defined as a composite of:total days: in hospital, in icu, on ventilator, on ecmo, with invasive hemodynamic monitoring, with mechanical circulatory support, and with inotropic or vasopressor therapy|time to clinical improvement as defined by reduction of at least 2 points on an 8-category ordinal scale of clinical improvement or discharge from hospital, whichever comes first.|change from baseline in cardiac marker high sensitivity troponin i (hstni)|change from baseline in cardiac marker nt-probnp|change from baseline in tnf alpha|change from baseline in il-1|change from baseline in il-6|incidence and severity of any treatment emergent adverse events (teaes) or serious adverse events (saes) as determined by clinical adverse events (aes) and their relationship to pb1046|incidence and severity of any treatment emergent adverse events (teaes) or serious adverse events (saes) as determined by vital signs and their relationship to pb1046|incidence and severity of any treatment emergent adverse events (teaes) or serious adverse events (saes) as determined by laboratory results and their relationship to pb1046|incidence and severity of any treatment emergent adverse events (teaes) or serious adverse events (saes) as determined by electrocardiogram (ecg) abnormalities and their relationship to pb1046|incidence and severity of any treatment emergent adverse events (teaes) or serious adverse events (saes) as determined by incidence of anti-drug antibodies and their relationship to pb1046",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04354779,NCT04354779,antibody status in hcw|active virus carriers in hcw|incubation time|background incidence rate|occupation associated infection risk,observational,observational model: cohort|time perspective: cross-sectional
"Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels",nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04438954,NCT04438954,fatigue|physical activity|sleep quality|anxiety,observational,observational model: case-only|time perspective: prospective
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19),nan,withdrawn,No Results Available,phase 3,Industry|Other,https://ClinicalTrials.gov/show/NCT04361461,NCT04361461,individual response rate|all-cause mortality|duration of mechanical ventilation|proportion of patients which needed mechanical ventilation during study|world health organization (who) ordinal scale|duration of hospitalization|rates of drug discontinuation,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04374617,NCT04374617,venous thromboembolisms|deaths,observational,observational model: cohort|time perspective: prospective
Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19,TACOS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04306705,NCT04306705,"proportion of participants with normalization of fever and oxygen saturation through day 14|duration of hospitalization|proportion of participants with normalization of fever through day 14|change from baseline in white blood cell and differential count|time to first negative in 2019 novel corona virus rt-pcr test|all-cause mortality|change from baseline in hscrp|change from baseline in cytokines il-1œ≤, il-10, sil-2r, il-6, il-8 and tnf-œ±|change from baseline in proportion of cd4+cd3/cd8+cd3 t cells",observational,observational model: cohort|time perspective: retrospective
The COVID-ICU Healthcare Professional Study,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04372056,NCT04372056,views and experiences of health care professionals working in intensive care units during the covid-19 pandemic,observational,observational model: cohort|time perspective: prospective
STerOids in COVID-19 Study,STOIC,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04416399,NCT04416399,emergency department attendance of hospitalisation related to covid-19|body temperature|blood oxygen saturation level|symptoms as assessed by common cold questionnaire|symptoms as assessed by flupro questionnaire|nasal/throat swab sars-cov-2 viral load,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Sequential Oxygen Therapy Strategy for Patients With COVID-19,SOTSPC,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04312100,NCT04312100,incidence of respiratory failure|28 day mortality rate,observational,observational model: cohort|time perspective: prospective
Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04478071,NCT04478071,"number of participants who are classified 8 (dead), 7 (hospitalized, on invasive mechanical ventilation or ecmo), or 6 (hospitalized, on non-invasive ventilation or high flow oxygen devices) on the niaid ordinal scale|number of participants with a total score of 0 on the modified sequential organ failure assessment (msofa) scale",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Awake Proning in COVID-19 Patients With Hypoxemic Respiratory Failure,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04408222,NCT04408222,change in spo2|mean risk difference in intubation rates,observational,observational model: cohort|time perspective: retrospective
Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2,EasyCoV,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04337424,NCT04337424,specific detection of sars-cov-2 specific rna|analytical sensitivity of the lamp test.|the correlation between the measurement of the assayed viral load (ct value) by the standard method and by the lamp developed by sys2diag / skillcell.|evaluation of the use of saliva samples compared to nasopharyngeal samples,observational,observational model: case-control|time perspective: prospective
National Survey of the Impact of COVID-19 Pandemics,CMDA-SURVEY2,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04491201,NCT04491201,the changes of workload of physicians during covid-19 pandemics compared with 2019 year|the changes of education activities during covid-19 pandemics compared with 2019 year|the changes of research activities during covid-19 pandemics compared with 2019 year,observational,observational model: cohort|time perspective: cross-sectional
A Study of ResCure‚Ñ¢ to Treat COVID-19 Infection,nan,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04395716,NCT04395716,the rate of recovery of mild or moderate covid-19 in patients using rescure‚ñ¢|reduction or progression of symptomatic days|assess the safety of rescure‚ñ¢ via pulse|assess the safety of rescure‚ñ¢ via oxygen saturation|assess the safety of rescure‚ñ¢ via ekg|assess tolerability of rescure‚ñ¢,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"Covid-19, Acute Myocardial Infarctions and Strokes in France",COVUSI,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04542083,NCT04542083,daily number of admissions for acute cardio- and neurivascular conditions in france.|specific mortality rate.,observational,observational model: other|time perspective: retrospective
Losartan for Patients With COVID-19 Requiring Hospitalization,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04312009,NCT04312009,difference in estimated (peep adjusted) p/f ratio at 7 days|daily hypotensive episodes|hypotension requiring vasopressors|acute kidney injury|sequential organ failure assessment (sofa) total score|oxygen saturation / fractional inhaled oxygen (f/s)|28-day mortality|90-day mortality|icu admission|number of ventilator-free days|number of therapeutic oxygen-free days|number of vasopressor-free days|length of icu stay|length of hospital stay|incidence of respiratory failure|change in promis dyspnea functional limitations|change in promis dyspnea severity|disease severity rating|viral load by nasopharyngeal swab day 9|viral load by nasopharyngeal swab day 15|viral load by blood day 9|viral load by blood day 15,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Clinical Effects of Internet Assisted Pulmonary Rehabilitation of COVID-2019 Pneumonia Patients After Discharge,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04368793,NCT04368793,six-minute walking distance (6mwd)|pulmonary function|respiratory muscle strength|physical fitness assessment|symptom|psychological evaluation|quality of life|physical activity|proportion of returning to society,observational,observational model: cohort|time perspective: prospective
Screening for SARS-CoV-2-Infections and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers,SeCo,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04370119,NCT04370119,number of people with detectable antibodies to sars-cov2|number of people with detectable sars-cov2 nucleic acid,observational,observational model: cohort|time perspective: prospective
Randomised Evaluation of COVID-19 Therapy,RECOVERY,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04381936,NCT04381936,all-cause mortality|duration of hospital stay|composite endpoint of death or need for mechanical ventilation or ecmo,interventional,allocation: randomized|intervention model: factorial assignment|masking: none (open label)|primary purpose: treatment
"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection",HELPCOVID-19,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04335084,NCT04335084,prevention of covid-19 symptoms as recorded in a daily diary|safety as determined by presence or absence of adverse events and serious adverse events,interventional,"allocation: randomized|intervention model: single group assignment|masking: double (participant, investigator)|primary purpose: prevention"
"COVID-19, Obesity and Lifestyle in Children",COLC,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04411511,NCT04411511,change in weight child|change in weight parents|eating behaviour|symptoms|day structure|physical activity|screentime|online possibilities|quality of life in children|parenting practices,observational,observational model: cohort|time perspective: prospective
"Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases",covid19 fai2r,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04353609,NCT04353609,proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death|proportion of patients who die from a severe form of covid-19|proportion of patients who present an history of diabetes according to medical records|proportion of patients who present obesity (validated by body mass index value > 30 kg/cm2)|proportion of patients who present an history of chronic pulmonary obstructive disease according to medical records|proportion of patients who present an history of asthma according to medical records|proportion of patients who present an history of hypertension according to medical records|proportion of patients who present an history of cardiac disease according to medical records|proportion of patients who present an history of pulmonary interstitial disease according to medical records|proportion of patients who present an history of stroke according to medical records|proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records|proportion of patients who present an history of cancer according to medical records,observational,observational model: cohort|time perspective: retrospective
Impact of COVID-19 on Family Dynamics on Bandebereho Study Participants,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04442152,NCT04442152,gender division of caregiving/domestic tasks|couple communication|couple conflict|men's alcohol use|household economic situation|stress and frustration,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
Trial of Treatments for COVID-19 in Hospitalized Adults,DisCoVeRy,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04315948,NCT04315948,"percentage of subjects reporting each severity rating on a 7-point ordinal scale|percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|the time to discharge or to a news of ‚â§ 2 and maintained for 24 hours, whichever occurs first.|number of oxygenation free days in the first 28 days|incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|ventilator free days in the first 28 days|incidence of new mechanical ventilation use during the trial.|hospitalization|mortality|cumulative incidence of serious adverse events (saes)|cumulative incidence of grade 3 and 4 adverse events (aes)|number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|changes from baseline in blood white cell count|changes from baseline in haemoglobin|changes from baseline in platelets|changes from baseline in creatinine|changes from baseline in blood electrolytes (including kaliemia)|changes from baseline in prothrombine time|changes from baseline in international normalized ratio (inr)|changes from baseline in glucose|changes from baseline in total bilirubin|changes from baseline in alanine aminotransferase (alt)|changes from baseline in aspartate aminotransferase (ast)",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Losartan for Patients With COVID-19 Not Requiring Hospitalization,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04311177,NCT04311177,hospital admission|change in promis dyspnea functional limitations|change in promis dyspnea severity|daily maximum temperature|emergency department/clinic presentations|disease severity rating day 7|disease severity rating day 15|disease severity rating day 28|viral load by oropharyngeal swab day 9|viral load by oropharyngeal swab day 15|ventilator-free days|therapeutic oxygen-free days|need for hospital admission at 15 days|need for oxygen therapy at 15 days,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID),nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04405739,NCT04405739,number of participants that achieve virologic clearance after oral administration of eidd-2801|number of participants with any serious adverse events(saes) as assessed by daids|number of participants with any adverse events(aes) as assessed by daids,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Psychiatric Disturbances and COVID-19 Infection,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04459403,NCT04459403,"psychiatric well-being, level of anxiety, symptoms of depression and coping strategies questionnaire|prevalence and types of psychiatric disturbances in patients with covid-19 infection",observational,observational model: case-only|time perspective: cross-sectional
Serological Study of the Exposure of Personnel to Sars-cov-2,SEROPHUGAC,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04422977,NCT04422977,measurement of overall seroprevalence of sars-cov-2 in an hospital staff,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays,AI-COVID-Xr,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04313946,NCT04313946,covid-19 positive x-rays|covid-19 negative x-rays,observational,observational model: ecologic or community|time perspective: prospective
Nebulised Rt-PA for ARDS Due to COVID-19,PACA,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04356833,NCT04356833,treatment efficacy - percentage change in pao2/fio2 ratio|safety as measured by bleeds|safety as measured by other (non-bleed related) adverse events|safety as measured by fibrinogen levels|absolute change in pao2/fio2 ratio|changes in respiratory compliance|clinical status as determined by a 7 point ordinal scale|sequential organ failure assessment (sofa) score|follow up period - oxygen free days|follow up period - ventilator free days|follow up period - intensive care stay|new oxygen via ventilation use - incidence|new oxygen via ventilation use - duration|incidence of new mechanical ventilation use|duration of new mechanical ventilation use|in hospital mortality,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Methylprednisolone in COVID-19 Patients (Methyl19LGH),Methyl19LGH,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04559113,NCT04559113,clinical response after administration|clinical response to treatment|duration of hospitalization,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,COVIDORL,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04361474,NCT04361474,patient with more than 2 points on the odoratest,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19,OMNI-Can,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT03944447,NCT03944447,prevention of covid-19|treatment of covid-19|treatment of symptoms|cannabis impact on quality of life|cannabis route and dosing|monitoring adverse events,interventional,allocation: non-randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease,COVIDeHPAD,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04337788,NCT04337788,impact of gerontological telemonitoring on healthcare management for older adults living in nursing homes with symptoms of confirmed or probable covid-19 disease (death within 30 days).,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
DUR-928 in Subjects With SARS-CoV-2 With Acute Liver or Kidney Injury,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04447404,NCT04447404,composite endpoint of alive and free of organ failure|occurrence of serious adverse events following treatment|alive at days 28 and 60|alive and out of icu|alive and out of hospital,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
"COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior",nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04377581,NCT04377581,"knowledge and confidence in knowledge of covid-19|beliefs about the effectiveness of public health recommendations|intent to comply with public health recommendations|perception of risk of covid-19 and other health threats|perceptions of trust in common health information sources|single most trusted news source|intention to change consumption of news because of covid-19 (yes/no)|for participants who will change their news consumption, in what way will they change?|secondary information sources|concerns about covid-19",observational,observational model: ecologic or community|time perspective: cross-sectional
RECHARGE: A Brief Psychological Intervention to Build Resilience in Healthcare Workers During COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04531774,NCT04531774,change from baseline in psychological distress kessler psychological distress scale (k10) at week 5 and week 13|fewer worries in intervention group than in active control group|less anxiety symptoms in intervention group than in active control group|fewer depression symptoms in intervention group than in active control group|lower level of burnout in intervention group than in active control group|less traumatic stress in intervention group than in active control group|lower level of distress due to perceived moral injury in intervention group than in active control group|higher work performance in intervention group than in active control group,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
"PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis",PROTECT-ASUC,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04411784,NCT04411784,primary outcome measure: the need for in-hospital colectomy or rescue therapy|2.1: duration and type/route of steroid use|2.2: 30 day colectomy free survival rates|2.3: covid-19 infection rates|2.4: rate of rescue therapy use|2.5: duration of hospital stay|2.6: admission severity scoring|2.7: readmission rates,observational,observational model: case-control|time perspective: retrospective
Follow-up of Critical COVID-19 Patients,FUP-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04474249,NCT04474249,mortality|renal recovery|respiratory recovery|working capacity|quality of life score|cognitive recovery|frailty|activities of daily life|anxiety|depression|neurological recovery,observational,observational model: cohort|time perspective: prospective
COVID-19 Brain Injury,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04496076,NCT04496076,in-hospital mortality|30-day mortality|limitations of patient care- frequency of care not being provided|limitations of patient care- conversion of dnr/dni/cmo status,observational,observational model: cohort|time perspective: prospective
The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia,nan,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04261426,NCT04261426,clinical improvement based on the 7-point scale|lower murray lung injury score|28-day mortality|duration of mechanical ventilation|duration of hospitalization|proportion of patients with negative rt-pcr results|proportion of patients in each category of the 7-point scale|proportion of patients with normalized inflammation factors|frequency of adverse drug events|frequency of serious adverse drug events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Trial of Combination Therapy to Treat COVID-19 Infection,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04482686,NCT04482686,time to non-infectivity by rt-pcr|time to symptom progression in days as measured by news scoring system (national early warning score)|time to symptom improvement as measured by news scoring system (national early warning score)|efficacy of treatment as measured by titer|efficacy of treatment as measured by rt-pcr|safety of treatment as measured by d-dimer|safety of treatment as measured by pro-calcitonin|safety of treatment as measured by c-reactive protein|safety of treatment as measured by ferritin|safety of treatment as measured by liver enzymes|safety of treatment as measured by complete blood count|safety of treatment as measured by electrolyte levels|safety of treatment as measured by treatment related adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY),PRIORITY,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04323839,NCT04323839,clinical presentation|disease prognosis outcomes|pregnancy outcomes|obstetric outcomes|neonatal outcomes|modes of transmission of covid-19,observational,observational model: cohort|time perspective: prospective
Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches,MICRO-COV,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04410263,NCT04410263,"change of pro-inflammatory response over the icu stay as a causative for primary endothelial dysfunction|time-to-event ""pulmonary bacterial superinfection or death""|positive bacteria and/ or sars-cov-2 cultures on handheld devices used in clinical routine and correlation to the adherence to disinfection protocols|life quality after covid-19 infection",observational,observational model: cohort|time perspective: prospective
COVID-19 Persistence in Stool,CoPS,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04546776,NCT04546776,"prevalence and persistence of the sars-cov-2 virus in the faeces, and change in associated health status|viral strain-specific prevalence, associated with change in health status|biogeographical viral strain identification, associated with change in health status|create a sars-cov-2 biological sample repository",observational,observational model: cohort|time perspective: prospective
French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study,FRENCH CORONA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04340466,NCT04340466,mortality at day 28|severe complications|imaging|delay in microbiological diagnosis|antiviral therapy|antibiotic therapy|covid-19 treatments|patients receiving renal replacement therapy|patients receiving mechanical ventilation|vital status,observational,observational model: cohort|time perspective: prospective
"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia",nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04255017,NCT04255017,"rate of disease remission|time for lung recovery|rate of no fever|rate of respiratory symptom remission|rate of lung imaging recovery|rate of crp,es,biochemical criterion(ck,alt,mb) recovery|rate of undetectable viral rna",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects,nan,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04547114,NCT04547114,correct classification of sars-cov-2 infected and not infected subjects,observational,observational model: case-control|time perspective: prospective
COVID-19 Detection Test in Oncology,EVIDENCE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04367870,NCT04367870,"to evaluate the ability of sars-cov-2 immunoassays, following a positive result, to identify patients with very low risk of recurrence of covid-19 within 3 months.|to estimate the prevalence of patients immunized to the sars-cov-2 virus in an oncology population over the whole study duration and within one-month periods.|to estimate the discordance rate between local immunoassay and a centralized elisa in patients with a positive immunoassay, whatever the immunoassay.|to identify patients with very low risk of recurrence of covid-19 within 6 months following a positive immunoassay result.|to characterize the evolution over time of the serologic response against sars-cov-2 (in a subgroup of patients).",observational,observational model: cohort|time perspective: prospective
Colchicine Counteracting Inflammation in COVID-19 Pneumonia,ColCOVID-19,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04322565,NCT04322565,clinical improvement|hospital discharge|death|clinical status|mechanical ventilhation|hospitalization|time from treatment initiation to death|time to negativization covid 19|fever,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia",nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04254874,NCT04254874,"rate of disease remission|time for lung recovery|rate of no fever|rate of respiratory symptom remission|rate of lung imaging recovery|rate of crp,es,biochemical criterion (ck,alt,mb)recovery|rate of undetectable viral rna",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
COVID-19 Biological Samples Collection,COLCOV19-BX,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04332016,NCT04332016,covid-19 desease description,observational,observational model: case-only|time perspective: prospective
Investigating the Involvement of ACE and Angiotensinogen Genes' Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events,iGenes-COVID19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04519398,NCT04519398,number of patients with thrombophilic profile alterations|number of patients with raas components alterations,observational,observational model: ecologic or community|time perspective: prospective
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04402060,NCT04402060,cumulative incidence of treatment-emergent serious adverse events and treatment-emergent adverse events.|hospital length of stay|any cause of mortality|sequential organ failure assessment|total duration of mechanical ventilation|total duration of oxygen therapy,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
COPD in the Time of COVID-19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407598,NCT04407598,"change in copd exacerbation rate|change in number of severe aecopd events during period of interest in 2020 from same period in 2019.|change in moderate aecopd events during period of interest in 2020 from same period in 2019.|social contact changes during i) pre-lockdown and ii) lockdown period|household contacts during i) pre-lockdown and ii) lockdown period|household visitors during i) pre-lockdown and ii) lockdown period|regular shopping behaviour during i) pre-lockdown and ii) lockdown period|medication changes during i) pre-lockdown and ii) lockdown period|reported change in regular medication usage during i) pre-lockdown and ii) lockdown period|change in physical activity levels during i) pre-lockdown and ii) lockdown period|change in anxiety levels during i) pre-lockdown and ii) lockdown period|perceived fear of hospitalisation during covid-19 period|patient reported changes in perception of symptoms, need for hospitalisation and availability and safety of healthcare resources thought semi-structured interviews in 20 patients (nested qualitative study)|association between changes in aecopd event rate and changes in local air pollution during the covid-19 lockdown",observational,observational model: cohort|time perspective: cross-sectional
A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19,OPV-NA831,enrolling by invitation,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04540185,NCT04540185,number of participants with a first occurrence of covid-19 starting 14 days after second dose of opv with or without na-831|number of participants with adverse events (aes) or medically attended aes (maaes) leading to withdrawal|number of participants with a first occurrence of severe covid-19 starting 14 days after second dose of opv with or without na-831|number of participants with a first occurrence of covid-19 starting 14 days after second dose of opv with or without na-831 or placebo regardless of evidence of prior sars-cov-2 infection,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Neurologic Manifestations of COVID-19,CORONA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04386083,NCT04386083,mortality (binary outcome)|respiratory failure (binary outcome)|duration of ventilator dependence (continuous outcome)|intensive care unit (icu) admission (binary outcome),observational,observational model: cohort|time perspective: retrospective
"COVID-19, bLOod Coagulation and Thrombosis",CLOT,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04388657,NCT04388657,percentage of patients with one or more dvts.,observational,observational model: cohort|time perspective: prospective
Engaging Patients in Colon Cancer Screening Decisions During COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04548531,NCT04548531,shared decision making (sdm) process scale score|decisional conflict (sure scale)|patient's preferred approach to screening|intention to screen|colon cancer screening rate,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: health services research
Effects of the COVID-19 Health Emergency on Biopsychosocial Health,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04409535,NCT04409535,world health organization quality of life-brief scale|open-ended interview,observational,observational model: ecologic or community|time perspective: other
OPV as Potential Protection Against COVID-19,nan,enrolling by invitation,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04445428,NCT04445428,mortality or infectious disease causing consultation or admission (composite outcome)|self-reported morbidity|suspected covid-19 infection|mortality|hospital admission for infectious disease|consultations for infectious disease,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (care provider, outcomes assessor)|primary purpose: prevention"
Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY,CAPACITY-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04325412,NCT04325412,the incidence of cardiovascular complications in patients with covid-19,observational,observational model: cohort|time perspective: prospective
Inhaled Aviptadil for the Treatment of Moderate and Severe COVID-19,AVICOVID-2,not yet recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04360096,NCT04360096,progression to ards|blood oxygenation|rdp dsypnea scale|distance walked in six minutes,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04371978,NCT04371978,"time to clinical change|percent of serious adverse events and premature discontinuation of treatment.|percent of patients with clinical improvement.|length of hospitalization.|all-cause mortality.|percent of supplemental oxygen use.|supplemental oxygen-free days.|percent of mechanical ventilation use.|ventilator-free days.|percent of icu admissions.|icu-free days.|percent of 50% decrease in c-reactive protein (crp) levels|time to virologic response, defined as no detection of sars-cov-2 in a pcr test.",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Evaluation of the COVID-19 Infection Response in Patients Admitted to the Emergency Department for Dyspnea,EPRICOD,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04422587,NCT04422587,develop a predictive model of the risk of being covid-19 for patients admitted to the emergency room for dyspnea|describe the characteristics of patients admitted to recop units according to their virological status|virological status|mortality status,observational,observational model: cohort|time perspective: other
The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04357340,NCT04357340,mixed venous o2 pressure (pvo2)|mixed venous co2 pressure (pvco2)|ph|hco3|oxygen saturation (o2 sat) from vbg|three minute walk test|o2 sat after one minute walking|o2 sat after two minutes use of partial rebreather|o2 sat after two minutes free air breathing|o2 sat/ fio2|mortality rate|number of participants with rehospitalization|the health-related quality of life (hrqol)|breathlessness,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04410471,NCT04410471,incidence of igg against sars-cov-2|titration and evolution of humoral response (igg) along first 12 months after having covid-19|reinfection of covid-19,observational,observational model: case-control|time perspective: prospective
Predictors of Respiratory Failure in SARS-Cov-2 Infection,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04316949,NCT04316949,respiratory failure|occurence of bacterial superinfection,observational,observational model: cohort|time perspective: retrospective
Emergency Management in a Dedicated Respiratory Unit of Patients With a Possible COVID-19 Infection,RECOP,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04371328,NCT04371328,describe the characteristics of patients admitted to recop units according to their virological status vis-√†-vis covid-19|develop a predictive model of the risk of being covid for patients admitted to the emergency room for dyspnea,observational,observational model: cohort|time perspective: prospective
Preoperative Shielding and N/T RT-PCR Swabbing for Elective Cancer Surgery,CHICANE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04449783,NCT04449783,diagnosis of covid before surgery|diagnosis of covid after surgery,observational,observational model: cohort|time perspective: prospective
Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,nan,completed,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04385238,NCT04385238,post-traumatic stress disorder|anxiety and depression,observational,observational model: case-only|time perspective: cross-sectional
Psychological Effects of the COVID-19 Pandemic on the Hungarian Adult Population,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04426266,NCT04426266,sociodemopraphic factors|perceived stress|level of anxiety|self-reported health state|number of complaints|strategies in coping with stressful situations|psychological effects of the coronavirus pandemic on the participants' mood and ways of coping with difficulties arising from the pandemic|level of depression,observational,observational model: cohort|time perspective: cross-sectional
Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection,ONCOVID-19,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04363632,NCT04363632,mortality of cancer patients under active anticancer treatment|overall survival|hospitalizations|death|complications|patients' characteristics,observational,observational model: cohort|time perspective: other
Menstrual Cycle Characteristics of Healthcare Professionals,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04413058,NCT04413058,rate of irregular menstrual cycle|length of cycle|rate of prolonged bleeding|amount of flow|rate of dysmenorrhea|the number of difference in menstrual cycle length|the number of difference in bleeding days|the number of difference in amount of flow,observational,observational model: case-crossover|time perspective: prospective
Tocilizumab for Patients With Cancer and COVID-19 Disease,nan,suspended,No Results Available,phase 2,NIH,https://ClinicalTrials.gov/show/NCT04370834,NCT04370834,clinical outcome as evaluated by the 7-category clinical status ordinal scale,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Arrhythmic Manifestations and Management in Hospitalized COVID-19 Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04465552,NCT04465552,"to better characterize arrhythmic manifestations, employed treatment strategies and long- term outcomes in hospitalized covid-19 patients in the us through a multicenter retrospective chart review.",observational,observational model: case-control|time perspective: retrospective
Appendicitis During the National Lockdown During the COVID-19 Pandemic,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407117,NCT04407117,appendectomy|postoperative length of stay|mortality|incidence of complicated appendicitis,observational,observational model: cohort|time perspective: retrospective
Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04378595,NCT04378595,food insecurity score,observational,observational model: cohort|time perspective: prospective
Effects of DPP4 Inhibition on COVID-19,nan,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04341935,NCT04341935,changes in glucose llevels|changes in spo2 levels|changes in interleukin 6 (il6)|changes in chest structures,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Birth Experience During COVID-19 Confinement,CONFINE,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04348929,NCT04348929,"labor agentry scale questionnaire score in immediate post-partum (duration of hospital stay)|""labor agentry scale questionnaire"" score at two months after birth|edinburg postnatale depression scale questionnaire"" score at two months after birth|""impact of event scale - revised questionnaire"" score at two months after birth|breastfeeding statement at two months after birth|""sf-12 quality of life questionnaire"" score at two months after birth|""sf-12 quality of life questionnaire"" score in immediate post-partum",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: screening
Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients,ACTIV,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04492384,NCT04492384,rate of non-infectious diseases|severity of covid-19 depending on pre-existing diseases|disability registration / change of disability status|rate of letal outcomes|rate of letal outcomes depending on pre-existing disease,observational,observational model: cohort|time perspective: other
"COVID-19 Brief Advice and Chat-based Support for Smoking Cessation Via ""Quit to Win"" Contest 2020",QTW2020,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04399967,NCT04399967,biochemical validated quit rate|smoking quit rate change from baseline at 3-month follow-up|smoking quit rate change from baseline at 6-month follow-up|smoking reduction rate change from baseline at 3-month follow-up|smoking reduction rate change from baseline at 6-month follow-up|smoking quit attempt change from baseline at 3-month follow-up|smoking quit attempt change from baseline at 6-month follow-up|use of smoking cessation service|engagement in chat-based support,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: health services research
Tools for Wellbeing COVID-19 National Study of Undergraduate Students,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04414371,NCT04414371,stress|wellbeing|anxiety|depression|resilience|positive affect|negative affect,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: supportive care
Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,ATTAC-Co,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04343053,NCT04343053,on-treatment platelet reactivity|apoptosis rate in human umbilical vein endothelial cells (huvec)|nitric oxide (no) intracellular levels|reactive oxygen species (ros) levels|coagulation factors levels|respiratory function|cardiac function|clinical outcome,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04391140,NCT04391140,therapeutic failure death or intubation|feasibility and safety of prone position in hfnc patients|efficacy of prone position in hfnc patients,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
WGS ANALYSIS OF SARS-COV-2 POSITIVE PATIENTS,CALYPSO,enrolling by invitation,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04353401,NCT04353401,associations with severity and outcomes,observational,observational model: cohort|time perspective: prospective
An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,COVID-19,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04522986,NCT04522986,safety: adverse event,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic,ACORES-2,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04329195,NCT04329195,"time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)|primary safety endpoint: major adverse cardiac events defined as the composite of cardiovascular death, myocardial infarction, stroke or acute heart failure at day 28|clinical status as assessed with the seven-category ordinal scale on days 7, 14 and 28.|number of days alive free of oxygen.|number of days alive outside hospital until day28|number of days alive free of intensive-care unit (icu) admission or mechanical ventilation (invasive or non-invasive) until day28|number of days alive free of mechanical ventilation (invasive or non-invasive) until day28|number of days alive free of icu admission until day28|rate of all-cause mortality at day 28|rate of cardiovascular death at day 28|number of days alive free of acute kidney injury until hospital discharge",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Taiwan ""Aerosol Box"" Versus UMMC ""Intubation Box""",nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04385576,NCT04385576,time to successful intubation|number of intubation attempts|evaluation of the intubator's experience using both boxes,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: basic science
Brain Health in the Time of COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04438967,NCT04438967,test the hypothesis that covid-19 infection will lead to increased risk of neurological impairment|determine cognitive and behavioral functional patterns that predict susceptibility to neurological impairment due to covid-19,observational,observational model: cohort|time perspective: other
"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia",nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04261270,NCT04261270,"rate of comprehensive adverse outcome|time of clinical remission|rate of no fever|rate of no cough|rate of no dyspnea|rate of no need for oxygen inhalation|rate of undetectable viral rna|rate of mechanical ventilation|rate of icu admission|rate and time of crp,es,biochemical criterion(ck,alt,mb)recovery",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
COVID-19 Pandemic Short Interval National Survey Gauging Psychological Distress,COPING,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04379063,NCT04379063,burnout|psychological distress|post-traumatic stress symptoms|post-traumatic growth,observational,observational model: cohort|time perspective: prospective
Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections,SCout,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04357938,NCT04357938,sensitivity and specificity of chest ct in detecting pneumonia in unspecific symptomatic patients who are to be admitted to hospital and who are rt-pcr negative for sars-cov-2.|sensitivity and specificity of chest ct in patients with pulmonary comorbidities|sensitivity and specificity of chest ct in patients with cardiovascular comorbidities|sensitivity and specificity of chest ct in patients with malignancy|sensitivity and specificity of chest ct in patients with immunodeficiency,observational,observational model: cohort|time perspective: prospective
Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada),nan,terminated,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04421664,NCT04421664,ordinal scale of covid19 disease severity at 14 days|incidence of hospitalization|incidence of covid-19 related death|incidence of all-cause death|incidence of all-cause study medicine discontinuation or withdrawal|overall symptom severity at 5 and 14 days|overall change in disease severity over 14 days among those who are symptomatic at baseline,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Study on Incidence of Elective Surgery Postponed During COVID-19 Pandemic in Geriatric Population,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04547218,NCT04547218,incidence of elective surgeries has postponed during covid-19 pandemic in geriatric population|incidence of cancer surgeries postponed during covid-19 pandemic in geriatric population|physical and psychological impact of postponed elective surgery in geriatric population during covid-19 pandemic,observational,observational model: case-only|time perspective: cross-sectional
Assessment of Olfactory Dysfunction in SARS CoV-2 (COVID-19) Infection,ODYSSI,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04466982,NCT04466982,upsit scores|eqod scores|snot 22 scores,observational,observational model: cohort|time perspective: prospective
Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN),CARTESIAN,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04558450,NCT04558450,pwv|pwv change|arterial distensibility|arterial distensibility change|brachial artery fmd|brachial artery fmd change|central blood pressure|central blood pressure (bp) change|wave separation/wave intensity analysis (wsa/wia)|wsa/wia change|cardiac diastolic dysfunction|cardiac diastolic dysfunction change|myocardial stiffness|myocardial stiffness change,interventional,allocation: non-randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
The Impact of COVID-19 Pandemic on the Smoking Behaviour of Young Smokers and the Youth Quitline Service in Hong Kong,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04360863,NCT04360863,smoking behaviors|knowledge|readiness to quit,observational,observational model: other|time perspective: cross-sectional
TOFAcitinib in SARS-CoV2 Pneumonia,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04332042,NCT04332042,need of mechanical ventilation|need of admission in intensive care unit|death|rate of adverse events,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Acute Cardiovascular Events Triggered by COVID-19-Related Stress,JoCORE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04368637,NCT04368637,acute cardiovascular event triggered by covid-19 stress|ventricular tachycardia|acute stroke|implantable cardioverter defibrillator (icd) shock,observational,observational model: cohort|time perspective: cross-sectional
University of Utah COVID-19 Hydrochloroquine Trial,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04342169,NCT04342169,duration of viral shedding|duration of covid-19-attributable symptoms|hospitalization|adult household contact viral acquisition,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
The New Silicone N99 Half-Piece Respirator,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04454606,NCT04454606,fit test,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2),COVID-ARA2,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04337190,NCT04337190,"ace2 level change over time|ace2 activity over time|mortality at day 28|ards severity|duration of mechanical ventilation|need for prone positionning|need for extracorporeal membran oxygenation|use of paralytic agents|need for renal replacement therapy|need for vasoactive drugs (norepinephrine, dobutamine,epinephrine)|sequential organ failure assessment (sofa) score|number of session(s) of prone positionning|duration of extracorporeal membran oxygenation treatment|type of vasoactive drugs|duration of vasoactive treatment",observational,observational model: cohort|time perspective: prospective
Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19),CARDS,recruiting,No Results Available,nan,Other|Industry,https://ClinicalTrials.gov/show/NCT04427280,NCT04427280,"proportion of patients, at each sample timepoint, with a positive detection of igm and igg specific antibodies to sars-cov-2.|clinical course of sars-cov-2 infection in cancer patients.|proportion of patients, at each sample timepoint, with sars-cov-2 viral clearance by throat/nose swab by rt-pcr.|time from start of symptoms to day 0 testing in the study.|feasibility of sars-cov-2 testing with a lateral flow assay.",observational,observational model: cohort|time perspective: prospective
Plasma Therapy of COVID-19 in Critically Ill Patients,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04359810,NCT04359810,time to improvement|rate of sars-cov-2 pcr positivity|duration of sars-cov-2 pcr positivity|duration of need for supplemental oxygen|duration of hospitalization|in-hospital 28-day mortality rate,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: treatment"
Impact of COVID-19 on Mental Health of Health Care Workers,COVID-Impact,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04382196,NCT04382196,depressive symptoms at baseline|change in depressive symptoms|anxiety levels at baseline|change in anxiety levels|stress levels at baseline|change in stress levels|quality of life at baseline|change in quality of life|covid-19 related psychological distress|change in covid-19 related psychological distress|post traumatic stress symptoms|change in post traumatic stress symptoms|perceived social support at baseline|change in perceived social support,observational,observational model: cohort|time perspective: prospective
The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04321616,NCT04321616,in-hospital mortality|occurrence and duration of mechanical ventilation|occurrence and duration of intensive care unit (icu) treatment|duration of hospital admittance|28 day mortality|viral clearance as assessed by sars-cov-2 pcr in peripheral blood and nasopharyngeal airway speciemen|occurrence of co-infections|occurrence of organ dysfunction,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Clinical Performance of the VivaDiag ‚Ñ¢ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04316728,NCT04316728,number of patients with constant negative results|number of patients with positive test with a positive pcr for covid-19|overall number of patients positive for covid-19|overall number of patients negative for covid-19|number of patients with contrasting results|reliability of the test|positive hcw|number of chronic patients,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Evaluation of Immune Response in COVID-19 Patients,IMMUNOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04438629,NCT04438629,covid-19 associated immune disorder|covid-19 associated inflammation|oxygenation|diagnostic of covid disease composite|changes at the cytokine pattern|changes at circulating immune cell composition|intensive care unit admission|length of hospital stay|clinical status|mortality,observational,observational model: cohort|time perspective: prospective
Clinical Use of Stem Cells for the Treatment of Covid-19,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04392778,NCT04392778,clinical improvement|lung damage improvement|sars-cov-2 viral infection laboratory test|blood test,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Immune Response and Risk of Serious Infection to SARS-Cov2,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04410432,NCT04410432,"percentage of circulating th1 lymphocytes|serum ifn concentrations-œ≥, cxcl9, cxcl10, cxcl11",observational,observational model: cohort|time perspective: prospective
Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,nan,enrolling by invitation,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04382547,NCT04382547,number of cured patients|number of patients with treatment-related adverse events,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04327349,NCT04327349,mortality changes in day 10|mortality changes in day 30|changes of c-reactive protein|changes of interleukin 6|changes of tumor necrosis factor-œ±|changes of pao2/fio2 ratio|changes of cd3|changes of cd4|changes of cd8|changes of cd4/cd8 ratio|changes of lymphocyte count|changes of leukocyte count|changes of alanine transaminase (alt)|changes of aspartate transaminase (ast)|changes of alkaline phosphatase (alp)|changes of lactate dehydrogenase (ldh)|changes of creatine phosphokinase (cpk)|changes of creatine kinase-mb (ck-mb)|changes of specific igg|radiological findings|number of days ventilated|length of hospitalization,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19",UC-COVID,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04373135,NCT04373135,improvement in knowledge surrounding sra policy|improvement in anxiety surrounding sra policy|improvement in trust surrounding sra policy,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: health services research
COVID-19 Risk Stratification,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04339387,NCT04339387,suitable for discharge,observational,observational model: cohort|time perspective: other
Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey,PSY_CO_CHU,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04358640,NCT04358640,anxiety|insomnia|catastrophism,observational,observational model: other|time perspective: prospective
Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,nan,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04357730,NCT04357730,pao2/fio2 improvement from pre-to-post intervention|achievement of pao2/fio2 ‚â• 200 or 50% increase in pao2/fio2|national early warning score 2 (news2)|national institute of allergy and infectious diseases (niaid) ordinal scale|48 hour in-hospital mortality|14 days in-hospital mortality|28 days in-hospital mortality|icu-free days|in-hospital coagulation-related event-free (arterial and venous) days|ventilator-free days|successful extubation|successful weaning from paralysis|survival to discharge,interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Telerehabilitation After Coronavirus,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04473898,NCT04473898,dyspnoea|anxiety and depression|sleep quality|health related quality of life|kinesiophobia|patient satisfaction|fatigue,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: supportive care
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNK-001-COVID-19),CYNK001COVID,recruiting,No Results Available,phase 1|phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04365101,NCT04365101,phase 1: frequency and severity of adverse events (ae)|phase 1: rate of clearance of sars-cov-2|phase 1: rate of clinical improvement|phase 2: time to clearance of sars-cov-2|phase 2: time to clinical improvement by news2 score|rate of clearance of sars-cov-2|phase 2: frequency and severity of adverse events (ae)|overall clinical benefit by time to medical discharge|overall clinical benefit by hospital utilization|overall clinical benefit by measuring mortality rate|impact of cynk-001 on sequential organ failure assessment (sofa) score|time to pulmonary clearance|supplemental oxygen-free days|proportion of subjects requiring ventilation,interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Respiratory Syncytial Virus Infection May be More Dangerous in Neonate,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04531735,NCT04531735,oxygen status and evaluation of neonatal intensive care stay,observational,observational model: case-control|time perspective: prospective
Household Transmission Investigation Study for COVID-19 in French Guiana,EPI-COVID-19,recruiting,No Results Available,not applicable,Industry|Other,https://ClinicalTrials.gov/show/NCT04328129,NCT04328129,evaluation of the extent of the virus transmission within households|characterization of the secondary cases,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: screening
The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04263402,NCT04263402,rate of disease remission|rate and time of entering the critical stage|rate of normal tempreture|rate of respiratory symptom remission|rate of lung imaging recovery|rate of laboratory indicator recovery|rate of undetectable viral rna,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Convalescent Plasma Therapy in Patients With COVID-19,nan,completed,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04407208,NCT04407208,plaque reduction neutralization test (pnrt)|d-dimer|c-reactive protein (crp)|international normalized ratio (inr)|oxygenation index|chest x-ray|severe adverse event,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
Effect of Tele-consultation in Addition With Psychiatric Follow-up During COVID-19 in Women Who Have Medical History of Post-partum Depression,COVIDDEPERINAT,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04516668,NCT04516668,evaluation of hospital anxiety and depression scale (had)|evaluation of edinburgh postpartum depression scale (epds)|evaluation of had score in fathers|evaluation of epds in fathers|study of the relationship between maternals and paternals symptoms|study of difficuties in child during the quarantine|risk and protection factors,observational,observational model: cohort|time perspective: retrospective
"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants",nan,recruiting,No Results Available,phase 1,Industry|U.S. Fed|Other,https://ClinicalTrials.gov/show/NCT04468958,NCT04468958,number of participants having adverse events|number of participants having transfusion-related adverse events|pharmacokinetics from screening to day 90,interventional,"allocation: randomized|intervention model: sequential assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19),AtTAC,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04453371,NCT04453371,p/f (pao2/fio2) change during the first 72hrs after the end of the procedure in adult patients with severe atypical ards caused by sars-2-cov.|ventilator-free time (days free from mv) for 28 days of observation.,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic,RAPID-BRAZIL,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04444700,NCT04444700,"composite main outcome|all-cause death|composite outcome of icu admission or all-cause death|major bleeding|number of participants who received red blood cell transfusion|number of participants with transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate.|number of hospital-free days alive up to day 28|number of icu-free days alive up to day 28|number of ventilator-free days alive up to day 28|number of participants with venous thromboembolism|number of participants with arterial thromboembolism|number of participants with heparin induced thrombocytopenia",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Thrombo Embolic Events in Critical Care Patients With Covid-19 Serious Acute Pneumopathy,THROMBOCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04366752,NCT04366752,variation of thrombin time (in secondes) in covid-19 patients with pneumonia admitted in icu.|variation of factor v concentration (u/dl) in covid-19 patients with pneumonia admitted in icu.|variation of factor ii concentration (u/dl) in covid-19 patients with pneumonia admitted in icu.|variation of concentration of fibrin and fibrinogen degradation products (‚â• 10 ¬µgm/ml) in covid-19 patients with pneumonia admitted in icu.,observational,observational model: case-only|time perspective: prospective
Using BCG to Protect Senior Citizens During the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04542330,NCT04542330,acute infection|sars-cov-2 infection|self-reported respiratory illness,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: prevention"
Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19),nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04382131,NCT04382131,"time to resolution of symptoms as defined by the single question 'how unwell do you feel today'.|severity of all symptoms|the length of time for individual symptoms to resolve|severity of individual symptoms|contacting healthcare (nhs 24, ooh, gp)|participants needing gp appointments|participants attending hospital|length of stay in hospital if admitted|number of participants reporting over the counter medication use|reduction in transmission to household contacts|number of participants reporting side effects of nasal irrigation|types and severity of side effects reported|cost of over the counter medication used",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVIDAR - Arrhythmias in COVID-19,COVIDAR,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04437901,NCT04437901,arrhythmia|electrocardiographic changes - underlying rhythm|electrocardiographic changes - atrioventricular conduction|electrocardiographic changes - qrs duration|electrocardiographic changes - presence of brugada qrs pattern|electrocardiographic changes - qtc duration|laboratory abnormalities - electrolyte misbalance|laboratory abnormalities - cardiac biomarkers|laboratory abnormalities - renal function|laboratory abnormalities - liver function,observational,observational model: cohort|time perspective: other
Psychological Impact of the Lockdown on Patients Giving Birth During the COVID-19 Epidemic Short Title : Isolement and Childbirth: Psychological Impact,COVMUM,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04366817,NCT04366817,"proportion of patients with postpartum depression defined by an epds score >12|socio-demographic data|occurrence of a maternal or fetal pathology in a previous pregnancy|pregnant maternal pathology (hypertension, diabetes, threat of premature delivery)|presence of psycological maternal risk factor|dyadic adjustment scale 16 (das-16)|perinatal post traumatic stress disorder questionnaire (ppq scale)|mother to infant bonding scale (mibs) autoquestionnaire|measure qualitative interviews by grounded theory",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Evaluation of an Alternative Method of Obtaining Viral RNA for the Detection of SARS-CoV-2 Virus Using PCR,nan,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04468217,NCT04468217,"evaluation of an alternative method of obtaining viral rna for the detection of sars-cov-2 virus in nasopharyngeal samples.|evaluation of an alternative method of obtaining viral rna for the detection of sars-cov-2 virus in oropharyngeal, nasal, buccal and saliva samples|establish a sample bank of nasopharyngeal, oropharyngeal, nasal, buccal and saliva mucosa for future analytical validations of new solutions associated with the detection of the sars-cov-2 virus.",observational,observational model: case-control|time perspective: prospective
"Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS",nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04429555,NCT04429555,"proportion of subjects free from respiratory failure|mean change from baseline in clinical status using the niaid 8-point ordinal scale at day 7|percentage of patients with improvement in clinical status|change in cytokine levels from baseline|adverse event incidence, severity, relationship to study drug, and study discontinuations|changes in laboratory values from baseline|proportion of subjects free from respiratory failure as defined by the need for decreased oxygen requirement (invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen, or ecmo, cpap, bipap, nasal cannula) at day 14|mean change from baseline in clinical status|incidence of mechanical ventilation or intubation|intensive care unit admission|plasma concentrations of ibudilast|all cause mortality",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury,CHARTER-Irl,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04511923,NCT04511923,d-dimer profile|frequenccy of severe adverse outcomes|oxygenation index|indices of inflammation|ratios of indices of inflammation|indices of coagulation|quasi-static lung compliance|time to separation from invasive ventilation|number treated with neuromuscular blockers|number treated with prone positioning|number treated with extra-corporeal membrane oxygenation|number requiring tracheostomy|time to separation from invasive ventilation among survivors|discharge to ward|discharge to ward in survivors|patient survival|number of patients residing at home or in a community setting at day 60|number of surviving patients residing at home or in a community,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Investigating a Vaccine Against COVID-19,nan,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04400838,NCT04400838,"assess the efficacy of the candidate chadox1 ncov-19 against covid-19 in adults aged 18 years and older.|assess the safety of the candidate vaccine chadox1 ncov-19 in adults and children|assess the safety, tolerability and reactogenicity profile of the candidate vaccine chadox1 ncov-19: occurrence of solicited local reactogenicity signs and symptoms for 7 days following|assess the safety, tolerability and reactogenicity profile of the candidate vaccine chadox1 ncov-19: occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following|assess the safety, tolerability and reactogenicity profile of the candidate vaccine chadox1 ncov-19: occurrence of unsolicited adverse events (aes) for 28 days following vaccination|assess the safety, tolerability and reactogenicity profile of the candidate vaccine chadox1 ncov-19 through standard blood tests (full blood count, liver and kidney function tests)|assess the safety, tolerability and reactogenicity profile of the candidate vaccine chadox1 ncov-19 by measuring the number of disease enhancement episodes|assess efficacy of the candidate chadox1 ncov-19 against severe and non-severe covid-19: hospital admissions|assess efficacy of the candidate chadox1 ncov-19 against severe and non-severe covid-19|assess efficacy of the candidate chadox1 ncov-19 against severe and non-severe covid-19: number of deaths|assess efficacy of the candidate chadox1 ncov-19 against severe and non-severe covid-19 by measuring seroconversion rates|assess humoral immunogenicity of chadox1 ncov-19: antibody quantification|assess humoral immunogenicity of chadox1 ncov-19: seroconversion|assess cellular and humoral immunogenicity of chadox1 ncov-19 through elispot assays (groups 1, 2 and 3 only)|assess the safety and immunogenicity of a booster dose of chadox1 ncov-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only): local reactogenicity|assess the safety and immunogenicity of a booster dose of chadox1 ncov-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only): systemic reactogenicity|assess the safety and immunogenicity of a booster dose of chadox1 ncov-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only)|assess the safety and immunogenicity of a booster dose of chadox1 ncov-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) through standard blood tests (full blood count, liver and kidney function tests)|assess the safety and immunogenicity of a booster dose of chadox1 ncov-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) via seroconversion",interventional,allocation: randomized|intervention model: sequential assignment|masking: single (participant)|primary purpose: prevention
Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04379453,NCT04379453,successful cardiovascular intervention|performed with the professional team positioned at> 2 meters from the patient for at least 50% of the duration of the intervention|absence of fatal complications caused by the procedure or acute non-fatal vessel occlusion during index admission,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis,NINTECOR,not yet recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04541680,NCT04541680,"the primary objective is to assess whether nintedanib slows the progression of lung fibrosis in covid-19 survivors as assessed by the decline in the forced vital capacity (fvc) over 12 months compared to placebo.|compare the rate of decline of dlco over 12 months|compare exercise capacity at 12 months|compare high resolution ct (hrct) lung opacities extension at 12 months|compare change in health-related quality of life|compare the evolution of dyspnea over time|compare change in depression and anxiety over time|compare change in lung injury, pulmonary hypertension and inflammation biomarkers|pulmonary hypertension prevalence at inclusion and 12 months|association between genetic susceptibility (muc5b polymorphism) and lung fibrosis in covid-19 survivors|safety of nintedanib",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
MultiStem Administration for COVID-19 Induced ARDS (MACoVIA),MACoVIA,recruiting,No Results Available,phase 2|phase 3,Industry,https://ClinicalTrials.gov/show/NCT04367077,NCT04367077,ventilator-free days|safety and tolerability as measured by the incidence of treatment-emergent adverse events as assessed by ctcae v5.0.|all-cause mortality|ranked hierarchical composite outcome of alive and ventilator-free|ventilator-free days,interventional,"allocation: randomized|intervention model: sequential assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,ACTION,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04394377,NCT04394377,"hierarchical composite endpoint composed of mortality, number of days alive, number of days in the hospital and number of days with oxygen therapy at the end of 30 days.|incidence of venous thromboembolism|incidence of acute myocardial infarction|incidence of stroke|number of days using oxygen therapy|peak of troponin|peak of d-dimer|incidence of major bleeding and clinically relevant non-major bleeding by the isth criteria",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Patients With Respiratory Involvement Secondary to COVID-19,nan,suspended,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04415073,NCT04415073,proportion of subjects alive and free of respiratory failure|secondary clinical improvement outcomes|time to clinical improvement (ttci)|to evaluate improvement in oxygenation in hospitalized adults with respiratory signs and symptoms secondary to covid 19 treated with axatilimab|to evaluate changes in biomarkers following treatment with axatilimab|to evaluate the safety and tolerability of axatilimab in the same population|ventilation outcomes|to evaluate antiviral effect of axatilimab in hospitalized adults with recently diagnosed sars cov-2 infection|to characterize exposure to axatilimab,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,STROMA-CoV2,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04333368,NCT04333368,"respiratory efficacy evaluated by the increase in pao2/fio2 ratio from baseline to day 7 in the experimental group compared with the placebo group|lung injury score|oxygenation index|in-hospital mortality|mortality|ventilator-free days|number of days between randomization and the first day the patient meets weaning criteria o number of days between randomization and the first day the patient meets pao2/fio2 > 200 (out of a prone positioning session)|cumulative use of sedatives|cumulative duration of use of sedatives|cumulative duration of use of neuromuscular blocking agents (other than used for intubation)|cumulative use of neuromuscular blocking agents (other than used for intubation)|icu-acquired weakness and delirium|treatment-induced toxicity rate and adverse events up to day 28|quality of life at one year (eq5d-3l quality of life questionnaire)|measurements of plasmatic cytokines (il1, il6, il8, tnf-alpha, il10, tgf-beta, srage, ang2) level|anti-hla antibodies plasmatic dosage",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization,nan,recruiting,No Results Available,phase 2,Other|NIH|Industry,https://ClinicalTrials.gov/show/NCT04439006,NCT04439006,"proportion of patients with diminished respiratory failure and death|death|time from study initiation to 48 hours fever-free|duration of hospitalization|time in intensive care unit (icu)|time to icu admission|number of days requiring supplemental oxygen|total days of mechanical ventilation|time to mechanical ventilation|shock and need for pressure support|incidence of any infection (viral, fungal, bacterial)|time to clinical resolution|incidence of grade 3 or higher adverse events|at the end of therapy (day 14)|time to viral clearance|survival",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04341480,NCT04341480,sars-cov-2 infection|tumor response|safety and tolerability|patient-reported outcomes,observational,observational model: cohort|time perspective: prospective
Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19),REALIST,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT03042143,NCT03042143,oxygenation index (oi)|incidence of serious adverse events (saes)|oxygenation index|sequential organ failure assessment (sofa) score|respiratory compliance (crs)|partial pressure of arterial oxygen to the fraction of inspired oxygen ratio (p/f ratio)|driving pressure|extubation and reintubation|ventilation free days at day 28|length of icu and hospital stay|28-day and 90-day mortality,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Survey on COVID-19 Airway Management,ISAM-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04487977,NCT04487977,preferred device,observational,observational model: other|time perspective: cross-sectional
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04380818,NCT04380818,efficacy of low-dose pulmonary irradiation assessed by change in pafi o2 by 20%|number of participants with treatment-related adverse events as assessed by ctcae v5.0|change of the radiological image|overall mortality|measure of pro-inflammatory interleukins|measure of trasforming growth factor (tgf-b)|measure of tumor necrosis factor alpha (tnf-a)|determining overexpression of pro-inflammatory selectin|determining cell adhesion molecules (cams)|measure of marker of oxidative stress pon-1,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
In-depth Immunological Investigation of COVID-19.,COntAGIouS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04327570,NCT04327570,clinical features|immune host response at systemic level|immune host response at local level|host genetic variation|comparison severe and non-severe covid-19 hospitalised patients|correlation of findings with outcome|correlation of immune profiling - microbiome,observational,observational model: other|time perspective: prospective
Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19,COVID-19,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04256395,NCT04256395,positive number diagnosed by national guideline in the evaluated population|distribution map of evaluated people|effect of medical guidance by designated feedback questionnaire|mental scale of relief the mental anxiety and avoid unnecessary outpatient,observational,observational model: other|time perspective: prospective
Immunogenetics Predictors With COVID-19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04390269,NCT04390269,for the patients,observational,observational model: case-control|time perspective: cross-sectional
Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,ELEVATE,enrolling by invitation,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04340349,NCT04340349,polymerase chain reaction assay (pcr) negative at day 0 plus negative serological panel for covid-19 antibodies at enrolment.|polymerase chain reaction assay (pcr) negative at day 30.|polymerase chain reaction assay (pcr) negative at day 60.,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
BromhexIne And Spironolactone For Coron–∞VirUs Infection Requiring HospiTalization,BISCUIT,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04424134,NCT04424134,change from baseline in clinical assessment score covid 19 (cas covid 19)|- combine endpoint -|c-reactive protein|d-dimer|euroqol group. eq-5d‚ñ¢|euroqol group. eq vas|hads|hospital length of stay,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,DC-COVID-19,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04252274,NCT04252274,"the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|number of participants with treatment-related adverse events as assessed by ctcae v5.0|the critical illness rate of subjects at weeks 2|the mortality rate of subjects at weeks 2",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants,CORhum,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04426279,NCT04426279,"the number of patients with severe covid-19 who were admitted to a conventional unit and/or an icu and/or deceased, during the covid-19 epidemic wave (from march to august 2020) among patients with irc under is.|diagnosis of covid-19 either confirmed by diagnostic test (rt-pcr), or by a physician, or by serology.|the number of patients admitted to conventional unit and/or icu and/or deceased among patients with irc under is between the covid-19 epidemic wave (march to august 2020) and the six-month period preceding it (september to february 2020).|the number of patients who maintained, modified, or discontinued their treatment.",observational,observational model: cohort|time perspective: retrospective
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO),nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04401436,NCT04401436,"evaluation of lymphocyte subsets in patients with covid-19 at various stages of disease, including recovery.|evaluation of inflammatory pathways that may contribute to covid-19 disease pathogenesis.",observational,observational model: cohort|time perspective: prospective
Assessment of the Impact of COVID-19 on Transplant Patients and on Patients Awaiting Transplantation,COWAIT,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04376775,NCT04376775,compliance precautions with covid-19|clinical impact of covid-19,observational,observational model: cohort|time perspective: prospective
Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04325919,NCT04325919,clinical|virological|microbiological,observational,observational model: case-control|time perspective: prospective
RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM,STORM,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04433078,NCT04433078,"time free of either hospitalization, hypoxemia, icu admission or death|np sars-cov-2 pcr|sars-cov-2 serum quantitative viral load|sars-cov-2 igm/igg antibodies|white blood cell count (wbc)|absolute lymphocyte count (alc)|c-reactive protein (crp)|n-terminal pro-b-type natriuretic peptide (pro-bnp)|high sensitivity troponin i (hstnt)|tumor necrosis factor alpha (tnf-a)|il-1|il-1b|il-6",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
RLF-100 (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE),SAMICARE,available,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04453839,NCT04453839,nan,expanded access:intermediate-size population,nan
Remote Monitoring of Cancer Patients With Suspected Covid-19,RECAP,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04397705,NCT04397705,device tolerability (attrition)|correlation of physiological data with clinical events|device tolerability (questionnaire)|device tolerability (semi-structured interviews)|reliability of data transmission,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement,NICOR,"active, not recruiting",No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04476992,NCT04476992,"change in methemoglobin level at 48 hours|change in methemoglobin level at 96 hours|improvement in oxygenation between the groups at 48 hours or at discharge if before 48 hours|improvement in oxygenation between the groups at 96 hours or at discharge if before 96 hours|rate of positive rt-pcr for sars-cov-2 between groups in 5 days, discharge, and 28 days|time to clinical recovery among groups, defined as time to interruption of oxygen administration for 24 hours or discharge|reduction in the inflammatory markers among groups|rate of acute kidney disease (aki) between groups during hospitalization|difference in katz score between groups",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Combined Endophthalmitis and Orbital Cellulitis in Patients With Novel Coronavirus Disease (COVID-19),nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04456556,NCT04456556,combined endophthalmitis and orbital cellulitis in patients with novel coronavirus disease (covid-19),observational,observational model: case-only|time perspective: retrospective
COVID-19 and Lactating Mothers,nan,recruiting,No Results Available,nan,Other|NIH,https://ClinicalTrials.gov/show/NCT04558320,NCT04558320,mean change in sars-cov-2 viral load in breast milk,observational,observational model: cohort|time perspective: prospective
The Use of Lung Ultrasonography in COVID-19 Patients,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04432051,NCT04432051,change in po2 values|change in pco2 values,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, outcomes assessor)|primary purpose: other"
Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04324866,NCT04324866,point prevalence of covid-19 infection|incidence of covid-19 infection|percentage of subjects presenting fever or respiratory symptoms|evaluate the relationship between covid-19 infection and chronic pharmacological treatments|evaluate the relationship between covid-19 infection and comorbid medical conditions,observational,observational model: cohort|time perspective: prospective
Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease,COVCALL,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04345159,NCT04345159,adjusted odds ratio,observational,observational model: cohort|time perspective: retrospective
Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France,INCOVPED,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04336761,NCT04336761,prevalence of positivity of covid-19 virus measured by rt-pcr|prevalence of positivity of covid-19 virus measured by rt-pcr in the following subpopulations of emergency patients|respiratory signs of children tested within 28 day|percentage of children hospitalized tested within 28 day|contact frequency|prevalence of positivity of other respiratory viruses measured by rt-pcr,observational,observational model: cohort|time perspective: prospective
Description of Respiratory Mechanics in Patients With SARS-CoV-2 Associated ARDS,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04350710,NCT04350710,recruitment-to inflation ratio (r/i ratio)|pao2/fio2 (mmhg)|lung volume recruited (vrec)|plateau pressure (cm h2o)|oesophagal pressure (cm h2o)|weight (kg)|urine output (ml)|serum creatinine (umo/l)|mean arterial pressure (mmhg)|peak pressure (cm h2o)|peep total (cm h2o)|pep set (cm h2o)|height (cm)|airway pening pressure (cm h2o)|expired volume in peep setted at 15 cmh2o (ml)|expired volume in peep setted at 5 cmh2o (ml),observational,observational model: cohort|time perspective: prospective
Serologic Testing of Household Contacts of Confirmed Cases of COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04393142,NCT04393142,identify antibodies|determine antibody sensitivity|igm determination|igg determination,observational,observational model: other|time perspective: cross-sectional
Electrocardiogram Analysis in COVID-19 Patients,ELCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04367129,NCT04367129,phase 1: ecg characteristics in patients presenting with severe form of sars-cov-2 infection|phase 2: correlation between ecg signs and needs for invasive mechanical ventilation and/or mortality in the acute phase|phase 3: correlation between ecg signs and cardiac involvement and mortality in the chronic phase,observational,observational model: cohort|time perspective: prospective
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,NoCovid,"active, not recruiting",No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04305457,NCT04305457,reduction in the incidence of patients with mild/moderate covid-19 requiring intubation and mechanical ventilation|mortality|time to clinical recovery,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Registry of Patients With Hematologic Disease and COVID-19 in Russia,CHRONOS19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04422470,NCT04422470,30-day all-cause mortality|covid-19 complications|icu admission|mechanical ventilation / o2 requirement|relapse or progression of hematologic disease|overall survival|risk factors,observational,observational model: cohort|time perspective: prospective
Assessment of Chilbains Occuring During Covid-19 Infection,ChilblainCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04344119,NCT04344119,clinical skin manifestations|histology and biological data|non invasive vascular examination,observational,observational model: case-only|time perspective: prospective
AKI Biomarkers in Coronavirus(COVID)-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04408248,NCT04408248,any stage of acute kidney injury|need for rrt in first 7 days|mortality|duration of mechanical ventilation|duration of vasopressor support,observational,observational model: cohort|time perspective: prospective
Evaluation of the Relationship Between Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407572,NCT04407572,"serum zinc, vitamin d vitamin b12 deficiency levels",observational,observational model: case-control|time perspective: prospective
Cardiovascular Complications and COVID-19 (CovCardioVasc),CovCardioVasc,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04335162,NCT04335162,determine the incidence of cardiomyopathies and venous thromboembolism|mortality|duration of mechanical ventilation|shock at day 28|length of stay in the intensive care unit,observational,observational model: cohort|time perspective: prospective
HFNC and NIV for COVID-19 Complicated by Respiratory Failure,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04452708,NCT04452708,detection of viral rna from one or more participants' air samples|the nasopharyngeal flocked swab and throat swab viral load (log10 copies/ml),observational,observational model: cohort|time perspective: prospective
COVID-19 and Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder,COVID-TRAUMA,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04401046,NCT04401046,score of the impact of event scale revisited scale|factors associated with post-traumatic stress disorder|measure of the patient's anxiety|proportion of patients perceiving poorer management of their cancer care since the start of the covid-19 epidemic.|proportion of patients perceiving the implementation of all necessary measures to reduce the risk of exposure to covid-19|proportion of patients stating that remote consultation is as useful as a face-to-face consultation|proportion of patients with access to a clinical psychology consultation (at the hospital or on the phone)|score on the cancer recurrence scale,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
COVID-19 Ad Intervention,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04555122,NCT04555122,mobility,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: other"
COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04371835,NCT04371835,clinical features of symptomatic covid-19 in people living with hiv (plwh)|clinical outcomes of symptomatic covid-19 in plwh|seroprevalence of covid-19 in all parent study participants,observational,observational model: cohort|time perspective: prospective
Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents,COVIDIV,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04395859,NCT04395859,change of visual acuity in patients treated with repeated ivt anti-angiogens during the covid-19 epidemic,observational,observational model: cohort|time perspective: prospective
Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention,COV-ENOX,withdrawn,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04520620,NCT04520620,measure of anti-xa activity|analysis of hemorrhagic risk|venous thromboembolic events|analysis individual patient characteristics by the biomarker of kidney function|analysis individual patient characteristics by the biomarker of inflammation|analysis individual patient characteristics by the biomarker of coagulation|demographic characteristics,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Ruxo-Sim-20,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04348695,NCT04348695,percentage of patients who develop severe respiratory failure.|length of icu stay.|length of hospital stay|survival rate at 6 months|survival rate at 12 months|survival rate at 28 days|percentage of patients with each ae by grade|percentage of patients who discontinued due to aes,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
The Covid-19 HEalth caRe wOrkErS (HEROES) Study,HEROES,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04352634,NCT04352634,"anxiety and depressive symptoms|experiences, fears and concerns about the covid-19|training and resource prioritization|suicide ideation (presence)|suicide ideation (frequency)|acute stress symptoms|psycho/social support and network|resilience",observational,observational model: cohort|time perspective: prospective
Mental Health Consequences of COVID19 Infection in the French RMD Cohort,MentCovid19RMD,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04510467,NCT04510467,frequency of ptsd depending on whether or not autoimmune patients have experienced covid|severity of ptsd depending on whether or not autoimmune patients have experienced covid,observational,observational model: case-control|time perspective: cross-sectional
"Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.",BARI-COVID,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04320277,NCT04320277,"the percentage of patients requiring transfer to icu as compared with the rate of transfers observed in controls.|the percentage of patients achieving the remission; crp, il-6 and tnfœ± values at baseline and during the treatment course; the number of aes.",interventional,allocation: non-randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: treatment
Stress Induced by the COVID-19 Pandemic and Nonconfinement: Study of Anxiety Factors and Potential Effects on Immunity.,SCEI,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04491071,NCT04491071,results of the generalized anxiety disorder (gad-7)|results of the mental health questionnaire|results of the patient health questionnaire (phq-9)|results of the post traumatic stress disorder (ptsd-8)|results of the experiences in close relationship scale questionnaire (ecr-s),observational,observational model: cohort|time perspective: prospective
Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04409743,NCT04409743,change in insomnia clinical diagnosis|change in beck depression inventory-ii (bdi) scale score|change in beck anxiety inventory (bai) scale score|change in quality of life (sf-36) scale score|change in sheehan suicidality tracking scale (s-sts) score|change in ford insomnia response to stress test (first) scale score|change in ucla loneliness scale score|change in social network index (sni) scale score|change in perceived stress scale score|change in screen time- self report|change in international physical activity questionnaire (ipaq) scale score|change in sleep onset latency (sol) as a measure of sleep continuity|change in number of arousals as a measure of sleep continuity|change in wake after sleep onset (waso) as a measure of sleep continuity|change in total sleep time (tst) as a measure of sleep continuity|change in sleep efficiency (se) as a measure of sleep continuity|change in insomnia severity index (isi) scale score|change in patient health questionnaire-9 (phq-9) scale score as a measure of depression symptoms|change in generalized anxiety disorder-7 (gad-7) scale score,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
Assessing the Impact of the COVID-19 Lockdown on Metabolic Control and Access to Health Care in Patients With Diabetes,CONFI-DIAB,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04485351,NCT04485351,"compare glycated hemoglobin levels of patients with diabetes from the university hospital of nancy between the period preceding and following the lockdown related to the covid-19 pandemic.|describe the clinical and biological characteristics of patients with diabetes followed in routine care at the university hospital of nancy|describe the change from baseline of biological and clinical parameters of patients with diabetes followed in routine care at the university hospital of nancy between the period preceding and following the lockdown.|describe the proportion of patients who presented with one or more significant clinical event during the lockdown.|describe the proportion of patients who forgot and/or discontinued one or several medication(s) during the lockdown.|describe the proportion of patients who changed their lifestyle's habits during the lockdown.|describe healthcare consumption of patients with diabetes during the lockdown.|describe the proportion of patients who (1) was tested for sars-cov-2 by pcr, (2) developped covid-19 confirmed by pcr and (3) was hospitalized due to the severity of covid-19.",observational,observational model: cohort|time perspective: cross-sectional
COVID-19 Wellness Survey,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04394104,NCT04394104,health behavior change regression questionnaire,observational,observational model: other|time perspective: retrospective
Patients' Preferences About Rescheduling Colonoscopies Delayed Due to COVID-19: Cross Sectional Study,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04432870,NCT04432870,interest in colon cancer screening|preference for stool testing|preference for postponing colonoscopy for one year|worry about delay|risk perception on covid-19,observational,observational model: other|time perspective: cross-sectional
Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,COVIDAtoZ,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04342728,NCT04342728,symptom reduction|symptom resolution: fever|symptom resolution: cough|symptom resolution: shortness of breath|symptom resolution: fatigue|symptom resolution: muscle/body aches|symptom resolution: headache|symptom resolution: new loss of taste|symptom resolution: new loss of smell|symptom resolution: congestion/ runny nose|symptom resolution: nausea|symptom resolution: vomiting|symptom resolution: diarrhea|day 5 symptoms|hospitalizations|severity of symptoms|adjunctive medications|supplementation side effects,interventional,allocation: randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals,COVID_2Pro,withdrawn,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04349228,NCT04349228,symptomatic covid(+) infection rate,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
Artificial Intelligence-assisted Diagnosis and Prognostication in COVID-19 Using Electrocardiograms,AI-COV-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04510441,NCT04510441,accuracy of machine learning to be able to predict outcome of coronavirus (covid-19) infection|accuracy of machine learning to be able to predict prognosis of coronavirus (covid-19) infection|accuracy of machine learning to be able to predict cardiac involvement of coronavirus (covid-19) infection|accuracy of machine learning vs human assessment to diagnose coronavirus (covid-19) infection,observational,observational model: cohort|time perspective: retrospective
Thromboembolic Events in Severe COVID-19 Patients,COVICLOT,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04405869,NCT04405869,analysis of incidence of thromboembolic events in patients with sars-cov-2,observational,observational model: cohort|time perspective: other
Psychological Well-being of Patients Awaiting for Cardiac Surgery During the COVID-19 Pandemic,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04406181,NCT04406181,anxiety/depression by means of hospital anxiety and depression scale (hads)|medical problems induced by deferred elective surgery or delayed postoperative ambulatory visit|reduced access to medical and psychological help,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
Cardiac COVID-19 Health Care Workers,CCC,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04413071,NCT04413071,myocarditis|pericarditis|atrial fibrillation|ischemic heart disease|dilatation of right heart chambers|valvular hear disease|rhythm disorders,observational,observational model: cohort|time perspective: cross-sectional
Characteristics of COVID-19 Infection Among PREGnant Women,CCOVID-PREG,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04398264,NCT04398264,asymptomatic covid-19 positive pregnant women|asymptomatic hispanic covid-19 positive pregnant women|follow up of asymptomatic covid-19 positive pregnant women|covid-19 positive newborns|severe covid-19 disease in pregnant women,observational,observational model: cohort|time perspective: other
Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt,COVID-19,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04339322,NCT04339322,demographics of coronavirus disease 2019 (covid-19) in the cohort group|clinical manifestations of coronavirus disease 2019 (covid-19)|laboratory data of included coronavirus disease 2019 (covid-19) cohort|radiological features of coronavirus disease 2019 (covid-19) cohort|outcomes of coronavirus disease 2019 (covid-19) infection in the cohort group,observational,observational model: cohort|time perspective: prospective
"Knowledge, Attitude and Practice of Dental Students About COVID-19",nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04449081,NCT04449081,"knowledge, attitude, practice of dental students towards covid-19|awareness level about infection control to prevent covid-19 transmission in clinics|preference towards online learning.",observational,observational model: cohort|time perspective: cross-sectional
"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04367883,NCT04367883,hospital output|hospital stay,observational,observational model: other|time perspective: other
Patient Outcome of Cardiac Surgery During the COVID-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04389463,NCT04389463,highest vis (vasoactive-inotropic score) in the first 12 hours postoperatively.|post-operative organ failure|post-operative outcome,observational,observational model: cohort|time perspective: prospective
COVID-19 Prevalence and Cognitive Deficits in Neurological Patients,Neuro-Covid,withdrawn,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04377425,NCT04377425,prevalence of covid-19 infection in consecutive patients with neurological symptoms|three months cognitive function of covid-19 positive patients|clinical presentation of neurological symptoms in covid-19 positive patients|prevalence of pre- and asymptomatic covid-19 positive patients in acutely admitted neurological patients|anosmia in covid-19 positive patients|exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of covid-19 infection|exploratory analysis of the coagulation profile of covid-19 positive patients compared to covid-19neg patients,observational,observational model: cohort|time perspective: prospective
COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study,nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04391816,NCT04391816,audit score|ads score|life events questionnaire (leq) score|ucla loneliness scale (uclals) score|perceived stress scale (pss) score,observational,observational model: other|time perspective: prospective
Short-term Impact of COVID-19 Lockdown on Metabolic Control of Type 2 Diabetes,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04501991,NCT04501991,glucose|hba1c|lipid profile,observational,observational model: cohort|time perspective: retrospective
Timing of Tracheotomy in Covid-19 Patients,TTCOV19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04412356,NCT04412356,mechanical ventilation|icu stay|oxygen support|sedation|adverse events|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19,SHARP COVID-19,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04342156,NCT04342156,positive serology or reverse transcriptase (rt-pcr) for covid-19 up until day 28.|positive serology at day 28.|symptoms of covid-19.,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Familial Mediterranean Fever and Beh√ßet: Analysis Before and After Covid19 Pandemic,nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04403438,NCT04403438,ipaq-sf|numeric rating scale|short-form 36 health survey (sf-36)|exercise stage of change questionnaire|exercise self-efficacy questionnaire|decisional balance questionnaire,observational,observational model: cohort|time perspective: prospective
Ultra-brief Online Mindfulness-based Intervention During COVID-19 Movement Control Order,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04536441,NCT04536441,changes of subjective unit of distress|changes of anxiety scores|changes of psychological insecurity|changes of general well-being|fear of covid-19,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
Effect of a Nss to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04507867,NCT04507867,"oxygen saturation|body temperature|blood pressure|heart rate|breathing frequency|death|awareness|hospital stay|qsofa score|progression to ventilation|progression to intensive care unit|cephalea|activity level|anatomic position|hair hydration|hair loss|decalvary patches|scalp lesions|itching scalp|loss of eyelashes|drooping of eyebrows|eyelid edema|vascularity of the sclera|ocular hydration|sclera color|sense of smell|irritation in the nostrils|nasal secretions|cheilitis|taste buds|saw edge of the tongue|changes in the body of the tongue|thickness of the tongue|salivation|taste|gums|skin sensitivity|skin lesions|skin hydration|skin texture|absence of body hair|cervical pain points|forearm pain points|odynophagia|cough|sneezing|respiration rhythm|abdominal breathing|use of accessory muscles when breathing|xiphoid retraction when breathing|dyspnea|abdomino-cutaneous reflexes|rebound sensitivity|right hypochondrium|epigastrium|left hypochondrium|right flank|mesogastrium|left flank|right iliac fossa.|hypogastrium|left iliac fossa.|vomiting|appetite|reflux|burps|bristol scale|hair loss on legs|sensitivity of the tibial tract|nail strength|fungus in the nails of the hands|white stripes on the nails|white spots on the nails|ridges on the nails|height|weight|bmi|erythrocytes|hemoglobin|hematocrit|mean corpuscular volume|mean hemoglobin concentration|mean corpuscular hemoglobin concentration|erythrocyte distribution width|hemoglobin distribution index|leukocytes|neutrophils (%)|neutrophils (#)|lymphocytes (%)|lymphocytes (#)|monocytes (%)|monocytes (#)|eosinophils (%)|eosinophils (#)|basophils (%)|basophils (#)|prothrombin time|inr|control blood sample (100-50) 1|partial thromboplastin time|control blood sample (100-50) 2|platelets|mean platelet volume|d-dimer|homocysteine|vitamin d|calcium|phosphorus|magnesium|sodium|potassium|chlorine|blood glucose|total cholesterol|triglycerides|ldl cholesterol|hdl cholesterol|aspartate aminotransferase|alanine aminotransferase|total bilirubin|direct bilirubin|indirect bilirubin|alkaline phosphatase|total proteins|albumin level|globulin level|a / g ratio|urea nitrogen|urea|creatitine|uric acid|ferritin|fibrinogen|c-reactive protein|adherence to the nutritional support system (nss)|intake time|amount of prepared ""nss"" he drink|taking of the ""floratil"" pill|neurobion injection|diet calories|trans fat in the diet|saturated fat in the diet.|monounsaturated fats in the diet|polyunsaturated fat in the diet|protein of animal origin in the diet|plant-based protein in the diet|fluid balance (income)|fluid balance (outcome)|hungry|abdominal circumference|arm circumference.|tricipital fold|arm area|biological sex|age|ab0 system|rh factor|use of proton pump inhibitors|obesity medications|use of antiepileptic drugs|use of oral contraceptives|use of antimitotics|antibiotics|analgesics|corticosteroids|diuretics|antihypertensive|anticoagulants|other medications|acute alterations in the absorption of nutrients.|drug interactions and adverse effects|oxygen therapy|mood",interventional,allocation: randomized|intervention model: sequential assignment|masking: single (investigator)|primary purpose: supportive care
Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,CloroCOVID19II,completed,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04342650,NCT04342650,proportion of patients with onset of severe acute respiratory syndrome (sars)|mortality rate|number of participants in need of intensive care support|viral concentration|cumulative incidence of serious adverse events|cumulative incidence of grade 3 and 4 adverse events|proportion of patients with discontinued treatment|incidence of cardiac lesions|incidence of cardiac disfunctions|change in respiratory capacity,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Characteristics and Outcomes of Gastrointestinal Manifestations of COVID-19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04490772,NCT04490772,clinical data questionnaire|tests such as cbc|liver function test,observational,observational model: cohort|time perspective: prospective
Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19,eCardioCovid19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04325867,NCT04325867,providing a special electronic platform (e-health) for remote managing cardiovascular outpatients|number of patients included in this platform|number of consultations/sessions given,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
"ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19",nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04367740,NCT04367740,percentage of asymptomatic patients with an igg response from sars-cov-2 infection.|percentage of asymptomatic patients with viral presence of sars-cov-2 infection.,observational,observational model: case-only|time perspective: cross-sectional
SURgical Outcomes in COvid Patients - the SUROCO Multicenter Cohort Study (COVID-19),SUROCO,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04458337,NCT04458337,survival up to 30 days|occurrence of postoperative respiratory complications|occurrence of postoperative non-pulmonary infectious complications|occurrence of acute kidney injury (aki)|occurrence of postoperative thromboembolic complications|the need for a new postoperative icu admission|hospital length of stay|30-day mechanical ventilation free-days|30-day organ dysfunction free days|surgical reinterventions|any icu admission during the index hospital stay|time of room cleaning|6-month survival,observational,observational model: cohort|time perspective: prospective
Cardiovascular Prevention During COVID-19 Pandemic Lockdown in Young Adults (COLA Trial),nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04361877,NCT04361877,change of physical activity|change of nutrition behaviour|semiquantitative change of alcohol intake|change of smoking behaviour|change of stress level|step count,observational,observational model: cohort|time perspective: prospective
Experience of Orthopaedic and Spine Center Pakistan During COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04516824,NCT04516824,clinical and functional characteristics|patient's journey,observational,observational model: other|time perspective: retrospective
"COVID-Impact ""Psychological IMPACT of Covid-19 on AP-HP Staff""",Covid-Impact,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04558437,NCT04558437,"prevalence of ptsd among aphp staff during the covid-19 epidemic and at a distance (inclusion, 3 months or 6 months).|prevalence of anxiety disorder among aphp staff during the covid-19 epidemic and at a distance (inclusion, 3 months and 6 months).|prevalence of depressive disorder among aphp staff during the covid-19 epidemic and at a distance (inclusion, m3 and m6).",observational,observational model: cohort|time perspective: prospective
Careful Ventilation in COVID-19 -Induced Acute Respiratory Distress Syndrome,CAVIARDS-19,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT03963622,NCT03963622,"all-cause 60-day mortality|duration of ventilation|duration of icu and hospital stay|number of patients with organ dysfunction|number of patients with barotrauma|mortality at icu discharge, 28 days, and hospital discharge",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",REMAP-CAP,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT02735707,NCT02735707,all-cause mortality|days alive and not receiving organ support in icu|icu mortality|icu length of stay|hospital length of stay|ventilator free days|organ failure free days|health-related quality of life assessment|proportion of intubated patients who receive a tracheostomy|destination at time of hospital discharge|readmission to the index icu during the index hospitalization|world health organisation 8-point ordinal scale outcome,interventional,allocation: randomized|intervention model: factorial assignment|masking: none (open label)|primary purpose: treatment
Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation,CAPACoV19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04356378,NCT04356378,physical functional limitations,observational,observational model: cohort|time perspective: prospective
Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19,OPTIMAL,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04412330,NCT04412330,"adverse events (safety)|feasibility (success of consent process, adherence, and attrition)|six minute walk test|short performance physical battery|quality of life (eq-5dl)|cognitive function|anxiety and depression|ptsd and distress|return to work|secondary complication",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Yoga Pranayama Adjuvant to Treat Burden COVID-19,YOCO,not yet recruiting,No Results Available,not applicable,Industry|Other,https://ClinicalTrials.gov/show/NCT04413747,NCT04413747,mortality|mortality-suicide|incidence of hospitalization for respiratory failure of covid-19's patients-|incidence of al home professional psychiatric-psychological interventions for mental disorder.|incidence of mental disorder: beck depression inventory-second edition (bdi-ii).|incidence od spleep disorder:pittsburgh sleep quality index (psqi).,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
CT Scores Predict Mortality in 2019-nCoV Pneumonia,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04284046,NCT04284046,7-day mortality,observational,observational model: cohort|time perspective: retrospective
Spanish Registry of Pregnant Women With COVID-19,OBS COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04558996,NCT04558996,maternal complications|neonatal infection,observational,observational model: cohort|time perspective: prospective
Plasma Adsorption in Patients With Confirmed COVID-19,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04358003,NCT04358003,all-cause mortality|change in sequential organ failure assessment [sofa] scores,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Intravascular Access of COVID-19 Patient Under Personal Protective Equipment,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04366297,NCT04366297,successful rate of first intravascular access attempt|time to successful access|number of attempts to successful access|time to infusion|complication rates|ease of use|preferred intravascular access method,interventional,allocation: randomized|intervention model: crossover assignment|masking: single (outcomes assessor)|primary purpose: treatment
Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers,nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04339790,NCT04339790,nimh covid study survey - adult responses|dsm xc and ks survey,observational,observational model: cohort|time perspective: prospective
"Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey",nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04344197,NCT04344197,"overview of surgical management on preventive measures of hospital infection spread during covid 19|testing policies and preventive measures for covid-19, and their association with asymptomatic cases.",observational,observational model: other|time perspective: cross-sectional
Burnout and Medical Errors in the Anaesthesiology Fraternity During Covid-19 Pandemic,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04362319,NCT04362319,"prevalence of burnout among anaesthesiology clinicians during covid-19|prevalence of depression risk among anaesthesiology clinicians during covid-19|prevalence of self-perceived medical errors among anaesthesiology clinicians during covid-19|association of burnout, depression and medical errors among anaesthesiology clinicians during covid-19",observational,observational model: cohort|time perspective: cross-sectional
COVID-19 and Pregnancy Outcomes,COVID&PREG,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04416373,NCT04416373,sars-cov-2 neonatal infection|perinatal mortality|icu maternal admission|5 minute apgar score < 7|preterm labour|pprom|miscarriage,observational,observational model: cohort|time perspective: prospective
COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo),nan,"active, not recruiting",No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04389385,NCT04389385,adverse reaction (ae) and severe ae (sae)|efficacy assessment|the rate of recovery without mechanical ventilator,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Stress Related Disorders in Family Members of COVID-19 Patients Admitted to the ICU,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04476914,NCT04476914,symptoms of post-traumatic stress disorder (ptsd)|symptoms of anxiety|symptoms of depression|family satisfaction with communication and decision making,observational,observational model: cohort|time perspective: retrospective
Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,ULTRA-COVID,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04394182,NCT04394182,oxygen therapy status at day 2|oxygen saturation (sat02; pulse oximeter measurement) at day 2|blood gas analysis at day 2|blood test at day 2|oxygen therapy status at day 5|oxygen saturation (sat02; pulse oximeter measurement) at day 5|blood test at day 5|oxygen therapy status at day 7|oxygen saturation (sat02; pulse oximeter measurement) at day 7|blood test at day 7|change from baseline total severity score (tss) analyzed in a thoracic ct scan at day 7|recovery time|covid-19 status|change from baseline total severity score (tss) analyzed in a thoracic ct scan al month 1|acute toxicity,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Mental Health Impact of the COVID-19 Pandemic Among Migrants in Chile,STRING-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04497636,NCT04497636,"depressive symptoms|symptoms of anxiety|symptoms of post-traumatic stress disorder|change in mental health symptoms, well-being from last 2 weeks before the pandemic to last 2 weeks during covid-19 pandemic|loneliness|change in general physical health|change in general mental health",observational,observational model: cohort|time perspective: prospective
COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial,COLORIT,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04403243,NCT04403243,change from baseline in clinical assessment score covid 19 (cas covid 19) frame: baseline|combine endpoint: time to death or mechanical ventilation|c-reactive protein|d-dimer|euroqol group. eq-5d‚ñ¢|exposure area on lung ct,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia,PULCO-19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04422613,NCT04422613,alteration of the dlco|mechanism of the alteration of gas exchanges|measurement on lung volumes|mechanism of the alteration of gas exchanges by chest scan|mechanism of the alteration of gas exchanges by scintigraphy|respiratory symptom|bronchial or ventilatory anomalies|persistent respiratory anomalies,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Health Behavior Change During COVID-19 Pandemic,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04367337,NCT04367337,handwashing adherence|frequency of handwashing|self-efficacy|risk perception|outcome expectancy|intention|planning|action control|perceived effectiveness of hand hygiene|anxiety|country-level covid-19 morbidity and mortality rates,observational,observational model: ecologic or community|time perspective: prospective
Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04373382,NCT04373382,change in instances of burnout for hospital staff due to the peer resilience champion intervention|change in instances of burnout for hospital staff due to the enriched feedback survey intervention,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: prevention
COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III,CoDEX,terminated,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04327401,NCT04327401,ventilator-free days|evaluation of the clinical status|all-cause mortality|mechanical ventilation duration|sequential organ failure assessment (sofa) score,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients,LAPTRANSCOV,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04361396,NCT04361396,assessment of the presence of the sars-cov-2 virus at t4|assessment of the presence of the sars-cov-2 virus at t1|assessment of the presence of the sars-cov-2 virus in the peritoneal effusion at t2 or t4|assessment of the presence of the sars-cov-2 virus at t3|assessment of the presence of the sars-cov-2 virus at t5,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
A Study of Outcomes in Patients With Fractured Neck of Femur During the COVID-19 Pandemic,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04375501,NCT04375501,mortality|morbidity|discharge,observational,observational model: cohort|time perspective: prospective
Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),COVIDOC,terminated,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04345861,NCT04345861,time to clinical improvement of at least 1 level on the ordinal scale between day 1 (day of the first administration of study drug) to day 11 (day after last day of treatment).|clinical status assessed by ordinal scale|transfer to icu|length of hospital day|hospital mortality|need to mechanical ventilation|occurence of grade 3-4 adverse event|qtc lengthening|evolution of pulmonary ct scan images,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Psychological Impact of Admission With Covid-19 During the SARS-CoV-2 Pandemic: Naturalistic Cohort Study With a Digital Intervention,FeelGood,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04449627,NCT04449627,anxiety as measured by generalised anxiety disorder score (gad-7) scale|depression as measured by the patient health questionnaire 9 (phq-9)|trauma as measured by trauma screening questionnaire (tsq),observational,observational model: cohort|time perspective: retrospective
Canakinumab in Patients With COVID-19 and Type 2 Diabetes,CanCovDia,not yet recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04510493,NCT04510493,unmatched win ratio after treatment with canakinumab compared to placebo (composite endpoint)|time to clinical improvement|death rate|admission to intensive care unit (icu)|secondary worsening of disease|prolonged hospital stay|change in ratio to baseline in the glycated hemoglobin|change in ratio to baseline in the fasting glucose|change in ratio to baseline in the fasting insulin|change in ratio to baseline in the fasting c-peptide|ratio to baseline in the c-reactive protein (crp)|change in ratio to baseline in the d-dimer|change in ratio to baseline in the natriuretic peptide (ntprobnp)|change in ratio to baseline in the glomerular filtration rate renal (egfr)|type of antidiabetic treatment at day 29|number of antidiabetic treatment at day 29|type of antidiabetic treatment at three months|number of antidiabetic treatment at three months,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia,POLYCOR,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04453384,NCT04453384,phase 2a: xav-19 antibody titers|phase 2a: adverse events of xav-19|phase 2b: time to weaning of supplemental oxygen.|phase 2a: pharmacokinetic analysis|phase 2a: antibody titer between the two groups|phase 2a: supplemental oxygen|phase 2a: evaluation of transfer to intensive care|phase 2a: normalization of fever|phase 2a: biomarkers|phase 2a: hospital length of stay|phase 2b: national early warning score (news)|phase 2b: clinical status|phase 2b: time to improvement|phase 2b: fever normalization|phase 2b: oxygen therapy|phase 2b: oxygen requirement|phase 2b: time to weaning|phase 2b: ventilation|phase 2b: hospital length of stay|phase 2b: mortality|phase 2b: safety,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04338802,NCT04338802,changes in forced vital capacity (fvc)|changes in carbon monoxide dispersion (dlco%)|changes in the six-minute walk test (6mwt)|changes in high resolution ct score,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Seroprevalence of SARS-Cov-2 Antibodies in Children,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04347408,NCT04347408,immunoglobulins (g and m) to sars-cov2 in plasma,observational,observational model: cohort|time perspective: prospective
COVID-19 Quarantine on Musculoskeletal Status in Hemophilia,HemoCov,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04491318,NCT04491318,change from baseline frequency of hemarthrosis after confinement period|change from baseline joint health after confinement period|change from baseline joint pain after confinement period|change from baseline range of motion after confinement period,observational,observational model: cohort|time perspective: prospective
Collaborative Outcomes Study on Health and Functioning During Infection Times During COVID-19 Pandemic,COH-FIT,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04383470,NCT04383470,"mental health symptoms, well-being change from last 2 weeks before the pandemic to last 2 weeks during covid-19 pandemic|mental health symptoms, well-being change from last 2 weeks before the pandemic to last 2 weeks 6 months after who declares pandemic over covid-19 pandemic|mental health symptoms change, well-being change from last 2 weeks before the pandemic to last 2 weeks 12 months after who declares pandemic over covid-19 pandemic|change in alcohol abuse, as change in units used from last 2 weeks before the pandemic to last 2 weeks during pandemic|change in cigarettes use, as change in number of cigarettes per day from last 2 weeks before the pandemic to last 2 weeks during pandemic|change in grams of cannabinoids smoked from last 2 weeks before the pandemic to last 2 weeks during pandemic|change in general physical health, self-rated, on a vas scale from 0 to 100.|change in general mental health, self-rated, on a vas scale from 0 to 100.|change in easiness of access to care, self-rated a on a vas scale from 0 to 100.|change in medication adherence, self-rated a on a vas scale from 0 to 100.|change in functioning in self-care, school/work, social, and family, self-rated a on a vas scale from 0 to 100.",observational,observational model: ecologic or community|time perspective: cross-sectional
"Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic",COroFet,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04360811,NCT04360811,number of positive covid-19 women,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,BEST-CP,completed,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04275414,NCT04275414,partial arterial oxygen pressure (pao2) to fraction of inspiration o2 (fio2) ratio|rate of improvement of oxygen-support status|the change of areas of pulmonary lesions shown on chest radiological imaging (chest ct or x-ray)|blood lymphocyte counts|level of crp|level of hs-crp|all-cause mortality|discharge rate,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"Imaging SARS-CoV-2 Involvement of Leptomeninges, Olfactory and Limbic Areas",ICILOLA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04448054,NCT04448054,"percentage of patients included with at least one sign of neuromeningeal, neurosensory or neurovascular involvement on mri imaging with the specific sequences used.",observational,observational model: case-only|time perspective: prospective
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease,OSCAR,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04376684,NCT04376684,"proportion of participants alive and free of respiratory failure at day 28|number of deaths due to all causes at day 60|time to number of deaths due to all causes up to day 60|proportion of participants alive and free of respiratory failure at days 7, 14, 42 and 60|time to recovery from respiratory failure|proportion of participants alive and independent of supplementary oxygen at days 7, 14, 28, 42, and 60|time to last dependence on supplementary oxygen|proportion of participants admitted to intensive care unit (icu)|time to final icu discharge|time to final hospital discharge|number of participants with adverse events (aes) and serious adverse events (saes)",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
"Bariatric Surgery During Lockdown, Impact of COVID-19 on Physical and Mental Health",nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04453579,NCT04453579,psychological conditions,observational,observational model: case-only|time perspective: prospective
Measuring Outcomes of Maternal COVID-19-related Prenatal Exposure,MOM-COPE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04540029,NCT04540029,infant negative emotionality|infants' target gene methylation status,observational,observational model: case-control|time perspective: prospective
COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,COVAYDE,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04395144,NCT04395144,"rate of therapeutic failure, defined as a combined outcome of rate of intubation or death|intubation rate|mortality|days spent on mechanical ventilation|days spent in the icu|hospital stay (in days)",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology,VT-Covid-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04452422,NCT04452422,number of cumulated deep venous thrombosis among the hospitalization,observational,observational model: case-only|time perspective: other
A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment,COVIQuest,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04359875,NCT04359875,hospitalization(s) at 1 month|phone-call from the general practitioner (in the experimental group only)|mortality at 1 month|use of primary care|use of secondary care|number of prescriptions related to the chronic disease dispensed by the pharmacy|number of hospitalization(s)|time to hospitalization(s)|hospitalization(s)' durations|reasons for hospitalization(s)|mortality at 6 months|cardiovascular events (mace)|psychotropic drugs,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: health services research
Tele-health Enabled Clinical Trial for COVID-19,nan,not yet recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04489628,NCT04489628,patients requiring admission to the hospital or experiencing death,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
COVID-19 Health Messaging to Underserved Communities,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04371419,NCT04371419,knowledge beliefs and practices related to covid-19|video ratings,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
"SARS-CoV2 (COVID-19) Seroepidemiological Transplanted Subjects (Kidney, Kidney-pancreas, Pancreas, Langerhans Islets)",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04487197,NCT04487197,"serum-prevalence of covid-19 tx|serum-prevalence of covid-19 / age, gender, type of transplantation, comorbities, italian regions-proviences transplanted patients|asymptomatic or subclinical infections in transplanted patients|risk factors for infection covid-19 transplanted patients|hospitalization rate covid-19 transplanted patients|mortality rate covid-19 transplanted patients",observational,observational model: cohort|time perspective: other
Respiratory Mechanics and Gas Exchange in Patients With COVID-19 and Hypoxemic Acute Respiratory Failure,COVID-VENT,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04445961,NCT04445961,optimum positive end-expiratory pressure (peep) level|number of patients with recruitable lung|change in alveolar dead space|change in plethysmogram variability during recruitment maneuver|change in arterial partial oxygen tension to inspiratory oxygen fraction (pao2/fio2) ratio|change in driving pressure with different positive end-expiratory pressure (peep) levels,observational,observational model: case-only|time perspective: prospective
Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,MP-C19,completed,Has Results,nan,Other,https://ClinicalTrials.gov/show/NCT04323592,NCT04323592,"composite primary end-point: admission to icu, need for invasive mechanical ventilation (mv), or all-cause death by day 28|in-hospital death within 28 days|admission to intensive care unit (icu)|endotracheal intubation (invasive mechanical ventilation)|change in c-reactive protein (crp)|number of days free from mechanical ventilation",observational,observational model: cohort|time perspective: prospective
"Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns",COVIPREG,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04355234,NCT04355234,"seroprevalence or number of women who are positive for sars-cov-2 in parturient woman|consequences of sars-cov-2 infection in pregnant women and their newborns : pregnancy outcome, maternal or neonatal complications|assessment of the vertical transmission of sars-cov-2 and the possible routes of this transmission in women who are positive for sars-cov-2 during pregnancy|assessment of susceptibility to infection during the 3 trimesters of pregnancy|evaluation of the confinement on the risk of exposure to the virus during pregnancy .|collection of biological samples for new investigations in women who are positive for sars-cov-2 during pregnancy.|assessment of the rate of sars-cov-2 infection in pregnant women the risk factors for the disease.|assessment of the rate of sars-cov-2 infection in newborns and the risk factors for the disease.",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: screening
Early Care Program for the Management of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection.,PAIN-COVID,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04394169,NCT04394169,impact of intervention program on health-related quality of life (vas)|impact of intervention program on health-related quality of life (index)|impact of intervention program on chronic pain (intensity)|impact of intervention program on chronic pain (limitation of daily activities)|impact of intervention program on chronic pain (pain catastrophization)|impact of intervention program on anxiety or depression incidence|impact of intervention on probable post-traumatic stress syndrome incidence,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (investigator)|primary purpose: prevention
Cardiovascular Manifestations of COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04335630,NCT04335630,"prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.|prevalence of pericarditis, pericardial effusion, valvular disease.|identification of characteristic electrocardiographic patterns related to covid-19|role of active cardiovascular disease in clinical outcomes of patients with covid-19 including length of icu stay, length of hospitalization and mortality.|role of pre-existing cardiovascular comorbidities in clinical course of covid-19|role of treatment with ace inhibitors or arbs in the clinical course of covid-19|role of insurance type on clinical outcomes of patients with covid-19|effect of age, gender and race on clinical course of covid-19 and prevalence of cardiovascular complications|role of active smoking on clinical course of covid-19 and prevalence of cardiovascular complications",observational,observational model: case-control|time perspective: retrospective
Short Term Corticosteroids in SARS-CoV2 Patients,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04445506,NCT04445506,effect on transfers to icu and escalation of care needing mechanical ventilation|effect on length of stay|change in crp levels,observational,observational model: case-control|time perspective: retrospective
The Global PCHF-COVICAV Registry,PCHF-COVICAV,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04390555,NCT04390555,in-hospital mortality.|the length of stay in the intensive care unit.|the duration of hospitalization.|the need and duration of invasive mechanical ventilation.|hospitalization for cardiovascular causes or cardiovascular deaths within 3 months after hospitalization.|hospitalization for cardiovascular causes or cardiovascular deaths within 6 months after hospitalization.,observational,observational model: cohort|time perspective: other
"Observational Study Concerning COVID-19 Infection in Transplanted Kidney, Pancreas or Pancreatic Islet Patients",nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04377776,NCT04377776,global prevalence of covid-19 tx|hospitalization rate in covid-19 tx|correlation covid-19 tx and type of transplantation|prevalence of covid-19 tx in italian provinces|symptoms in covid-19 tx|correlation covid-19 tx and comorbidities|covid-19 tx therapies|covid-19 tx in family settings,observational,observational model: cohort|time perspective: cross-sectional
SINUS WASH Pilot Study in Adults Testing Positive for COVID-19,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04393792,NCT04393792,change in viral load in the oral and nasopharyngeal cavity|symptom severity in primary participants and co-residents,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Simple, Safe, Same: Lung Ultrasound for COVID-19",LUSCOVID19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04322487,NCT04322487,lung ultrasound grading system for covid-19 pneumonia,observational,observational model: case-only|time perspective: prospective
COVID-19 and the Healthy Minds Program for Educators,CAHMP-ED,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04426318,NCT04426318,change from baseline on an aggregate measure of psychological distress that averages the patient-reported outcomes measurement information system (promis) anxiety and depressive measures and the nih perceived stress scale|change from baseline on the five facet mindfulness questionnaire act with awareness subscale|change from baseline on the drexel defusion scale (dds)|change from baseline on the meaning in life questionnaire|change from baseline on the nih toolbox loneliness scale|change from baseline on the conway covid questionnaire|change from baseline on the self-compassion scale short form|change from baseline on the perseverative thought questionnaire|change from baseline on the world health organization 5-item (who-5) well-being scale|change from baseline on the neutral face rating task|change from baseline on the growth mindset scale for well-being,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (investigator)|primary purpose: treatment
W-SUDs for COVID-19,nan,recruiting,No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04460027,NCT04460027,change of number of days drinking|change of number of days drug use|alcohol use disorder and associated disabilities interview schedule-5 (audadis-5 (audadis-v)|short inventory of problems - alcohol and drugs (sip-ad)|drug abuse screening test (dast-10)|brief situational confidence questionnaire (bscq)|craving rating|pain rating|patient health questionnaire-9 (phq-9)|general anxiety disorder-7 (gad-7)|cair pandemic impact questionnaire (cair-piq)|client satisfaction questionnaire (csq)|usage rating profile intervention (urpi),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: treatment"
A Study of Auxora in Patients With Severe COVID-19 Pneumonia,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04345614,NCT04345614,number of days from the start of the first infusion of study drug (sfisd) to recovery|proportion of patients requiring invasive mechanical ventilation or dying|proportion of patients requiring invasive mechanical ventilation|differences in outcomes as measured by an 8-point ordinal scale|proportion of patients who have died at day 30 (mortality)|number of days in the hospital|number of days in the intensive care unit (icu)|incidence of treatment emergent adverse events (teae) and serious adverse events (sae)|cm4620-ie serum concentration,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
GERAS Frailty Rehabilitation at Home During COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04500366,NCT04500366,"change in physical function|change in mental health|change in sarcopenia|change in frailty|change in self-efficacy|self-reported change in function, health and well-being|clinician-reported change in function, health and well-being|change in fitness|program satisfaction|change in emergency room visits|change in hospitalizations|change in number of calls to 911",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: prevention"
COVID-19 Related Lockdown Effects On Chronic Diseases,CLEO-CD,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04390126,NCT04390126,"% adherence to each pharmacological class|number of occurrence of medical events at 1 year|expressed in %: non-pharmacological treatment/lifestyle:|expressed in %: difficulties accessing care: medical appointments, prescriptions, medication|measurement of psychological distress: kessler's specific questionnaire (score between 0 and 24)",observational,observational model: cohort|time perspective: prospective
Insomnia After the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04443361,NCT04443361,bergen insomnia scale (bis),observational,observational model: other|time perspective: prospective
Dornase Alfa for ARDS in Patients With SARS-CoV-2,DORNASESARS2,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04402970,NCT04402970,improvement in pao2/fio2|change in static lung compliance|duration of mechanical ventilation|length of icu stay|length of hospitalization|secondary bacterial infections|mortality,interventional,allocation: non-randomized|intervention model: single group assignment|masking: single (participant)|primary purpose: treatment
Mental Health Status and Related Factors Among Physical Medicine & Rehabilitation Physicians in the Covid-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04500652,NCT04500652,"depression, anxiety and stress scales 21 score|insomnia severity index score",observational,observational model: other|time perspective: cross-sectional
French Single Centre Experience of Critically Ill Patients With Covid 19,CovidAmiens20,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04354558,NCT04354558,"variation of age between critically ill patients with sars cov2 admitted in icu with non critically ill patients with sars cov2 admitted in icu|variation of medical history between critically ill patients with sars cov2 admitted in icu with non critically ill patients with sars cov2 admitted in icu|variation of chronic drug used between critically ill patients with sars cov2 admitted in icu with non critically ill patients with sars cov2 admitted in icu|variation of chest ct scan at admission, between critically ill patients with sars cov2 admitted in icu with non critically ill patients with sars cov2 admitted in icu|variation of respiratory support at icu admission, between critically ill patients with sars cov2 admitted in icu with non critically ill patients with sars cov2 admitted in icu",observational,observational model: cohort|time perspective: prospective
Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening.,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04339686,NCT04339686,diagnostic performance of chest ct in screening for pulmonary lesions in clinical suspicions of covid.|compare the diagnostic performance of chest ct and rt-pcr in covid 19 at the initial consultation (screening).,observational,observational model: cohort|time perspective: retrospective
Cardiac Rehabilitation and Ongoing Physical Activity During COVID-19,CODIS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04501432,NCT04501432,work load (w)|work load % of predicted value|heart rate (bpm)|framingham recurrent coronary heart disease risk score|metabolic equivalent (met) minutes / week|patient experience,observational,observational model: other|time perspective: other
COVID-19-Related Health and Practices Among Dental Hygienists,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04542915,NCT04542915,covid-19 probable or confirmed case|anxiety|depression|dental practice infection control efforts|personal protective equipment|employment status,observational,observational model: ecologic or community|time perspective: prospective
Prognostic Value of Point of Care Cardiac and Lung Ultrasound in COVID-19,CLUSCO,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04379544,NCT04379544,"patient requires invasive mechanical ventilation and suffers from acute respiratory failure.|patient is discharged|patient is hospitalized, but does not require mechanical ventilation through the duration of hospital stay.|lung ultrasound findings|cardiac ultrasound findings",observational,observational model: cohort|time perspective: prospective
Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04365608,NCT04365608,intubation success rate during at the first laryngoscopy|intubation difficulty scale score|complications related to tracheal intubation|time to completion of tracheal intubation (ti) procedure|duration of the interruption of chest compression during eti procedure|laryngeal view during intubation|pogo score,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,CORIPREV-LR,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04321174,NCT04321174,microbiologic evidence of infection|adverse events|symptomatic covid-19 disease|seropositivity|days of hospitalization attributable to covid-19 disease|respiratory failure requiring ventilatory support attributable to covid-19 disease|mortality|short-term psychological impact of exposure to covid-19 disease|long-term psychological impact of exposure to covid-19 disease|health-related quality of life,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
Exhaled Breath Particles as a Clinical Indicator for Lung Injury and Acute Respiratory Distress Syndrome (ARDS),nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04503057,NCT04503057,covid-19 rt-pcr detection in ebp|detection of proteins biomarkers in ebp|particle flow rate as an early indicator for lung injury,observational,observational model: case-control|time perspective: prospective
COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2,COVID19-HCW,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04318314,NCT04318314,seroconversion to sars-cov-2 positivity,observational,observational model: cohort|time perspective: prospective
Evaluation of the Evolution of Pregnancies in the First Trimester Following MAR Management During a COVD-19 Pandemic Period,AMPCOVID-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04415359,NCT04415359,study of the evolution of pregnancies in the first trimester following mar management during a covd-19 pandemic period,observational,observational model: case-only|time perspective: other
Italian Web-based Cross-sectional Survey on COVID-19,EPICOVID19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04471701,NCT04471701,number of participants (%) with covid-19-like symptoms|number of participants (%) with sars-cov-2 nasopharyngeal swab (nps) test positivity,observational,observational model: cohort|time perspective: cross-sectional
Assocation Between In-person Instruction and COVID-19 Risk,Campus&Corona,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04529421,NCT04529421,covid-19 incidence|quality of life|satisfaction with teaching|covid-19 testing incidence|learning outcome,observational,observational model: cohort|time perspective: prospective
Serology COVID-19 From the Cornwall Hospital Union,ROCOCO,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04363593,NCT04363593,serological test evaluation|population seroprevalence,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
Cognitive Outcomes During COVID-19 confiNemeNt in Elderly and Their Caregivers Using Technologies for DEMentia,CONNECTDEM,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04385797,NCT04385797,"change on cognitive function in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|change on quality of life in alzheimer¬¥s disease in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|change on quality of life in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|change on mood in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|change on technophilia in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|change on perceived stress in people with mild cognitive impairment or mild dementia during and after confinement.|change on caregiver burden prior to, during and after confinement.|change on healthcare and social support services access prior to, during and after confinement.|change from health, cognitive, social, informative and entertainment related uses of ict during and after confinement.",observational,observational model: cohort|time perspective: other
Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19,COVI-DOSE,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04373707,NCT04373707,venous thromboembolism|major bleeding|major bleeding and clinically relevant non-major bleeding|net clinical benefit|venous thromboembolism at other sites|arterial thrombosis|all-cause mortality|factors associated with the risk of venous thromboembolism,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
COVID-19 - Implications on Surgeons' Burnout and Career Satisfaction,SURG-SAT-19,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04433286,NCT04433286,change in burnout before covid-19 and during covid-19|change in job satisfaction before covid-19 and during covid-19,observational,observational model: other|time perspective: cross-sectional
Provider Burnout During COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04370938,NCT04370938,feasibility of undertaking task,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: other
Neuro-COVID-19: Neurological Complications of COVID-19,Neuro-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04418609,NCT04418609,"prevalence of neurological complications|prevalence and outcome of severe neurological complications|impact of neurological complications|characteristic patterns in cerebral imaging and electroencephalography (eeg), as well as cerebrospinal fluid (csf)|brain for pathological changes and histopathological findings (if patient dies).",observational,observational model: cohort|time perspective: other
Professional and Ethical Challenges of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics;,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04351568,NCT04351568,to evaluate the effect of social media usage in medical practice during covid 19 epidemic,observational,observational model: ecologic or community|time perspective: cross-sectional
Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04475081,NCT04475081,induction of myeloid-derived suppressor cells (mdscs)|induction of mdscs|covid-19 infection positive|health questionnaire,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
ARDS Caused by COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04368975,NCT04368975,discontinuation from mechanical ventilation,observational,observational model: cohort|time perspective: prospective
Sleep Quality During COVID-19 Containment in Children Whether or Not Usually Followed in Child Psychiatry,CONFIDODO,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04370210,NCT04370210,comparison of sleep quality during covid-19 containment between children usually followed in child psychiatry and children without follow-up|assessment of child depression in both groups|assessment of child anxiety in both groups|assessment of the influence of socio-demographic factors on sleep in both groups|measure of the correlation between child sleep quality and parents sleep quality (anxiety level) in both groups|assessment of sleep disturbance based on psychiatry diagnoses in the group of children usually followed in child psychiatry|assessment of child anxiety based on psychiatry diagnoses in the group of children usually followed in child psychiatry|assessment of child depression based on psychiatry diagnoses in the group of children usually followed in child psychiatry,observational,observational model: cohort|time perspective: prospective
Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,ACTCOVID19,recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04324463,NCT04324463,"outpatient trial - colchicine vs. control and aspirin vs. control|inpatient trial - interferon-œ≤ vs. control and colchicine vs. control|inpatient trial - aspirin and rivaroxaban vs. control|outpatient and inpatient trials - colchicine vs. control, interferon-œ≤ vs. control|outpatient and inpatient trials - aspirin vs. control, aspirin and rivaroxaban vs. control",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04264858,NCT04264858,time to clinical improvement (ttci)|clinical status assessed by the ordinal scale|the differences in oxygen intake methods|duration (days) of supplemental oxygenation|duration (days) of mechanical ventilation|the mean pao2/fio2|the lesions of the pulmonary segment numbers involved in pulmonary ct [ every 7 days]|time to 2019-ncov rt-pcr negativity in respiratory tract specimens [every 3 days]|dynamic changes of 2019-ncov antibody titer in blood|length of hospital stay (days)|all cause mortality,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Needs, Perceptions and Acute Stress of Healtcare Workers Caring for COVID-19 Patients in South America",nan,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04486404,NCT04486404,prevalence of acute stress,observational,observational model: cohort|time perspective: prospective
Impact of the COVID-19 Pandemic on Diet Quality and Food Insecurity: a NutriQu√©bec Sub-study,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04371848,NCT04371848,change in diet quality|change in food insecurity|change in intake of sodium|change in intake of sugar|change in intake of saturated fat|change in intake of vegetables and fruits|change in intake of dairy products|change in physical activity|change in sleep quality|change in health-related quality of life,observational,observational model: cohort|time perspective: prospective
Analysis of the Quality and Quantity of Antibiotic Prescriptions for Bacterial Respiratory Tract Superinfection in Patients Hospitalized in COVID-19 Wards,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04544072,NCT04544072,"total antimicrobial consumption for suspicion of secondary bacterial respiratory infections in hospitalized patients in covid wards with a clinical or pcr-based covid diagnosis, expressed as 'daily defined doses/hospitalization'.|total antimicrobial consumption for suspicion of secondary bacterial respiratory infections in hospitalized patients in covid wards with a clinical or pcr-based covid diagnosis, expressed as 'daily defined doses/1000 hospitalized patient days'.|total antimicrobial consumption for suspicion of secondary bacterial respiratory infections in hospitalized patients in covid wards with a clinical or pcr-based covid diagnosis, expressed as 'daily doses of administration/hospitalization'.|total antimicrobial consumption for suspicion of secondary bacterial respiratory infections in hospitalized patients in covid wards, expressed as 'daily doses of administration (dda)/1000 hospitalized patient days'.|the degree of appropriateness of antimicrobial prescriptions for presumed respiratory tract (super)infection|the degree of appropriateness of antimicrobial prescriptions for presumed respiratory tract (super)infection, denominator 2|rate of clostridioides difficile infections|is there a significant difference in age comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|is there a significant difference in weight comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in amount of comorbidities comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in rate of chronical pulmonary disease as a comorbidity, comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in rate of haematological or solid neoplasia as a comorbidity, comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in rate of diabetes mellitus as a comorbidity, comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in rate of patients with presence or not of at least one suggestive symptom of covid-19 symptomatology, comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in rate of patients with recent ab prescription, comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|is there a significant difference in the rate of patients having had at least one positive significant respiratory germ culture, comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|is there a significant difference in the rate of patients needing oxygen supletion at day 1 of hospitalization, comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in the mean duration of hospitalization, comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in the rate of icu admission, comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|is there a significant difference in the mean value of oxygen saturation percentage over fractional oxygen percentage, comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|is there a significant difference in qsofa score level at admission, comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|is there a significant difference in the rate of lymphopenia, comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in the mean value of c-reactive protein measured at day 1 of hospitalization on a covid-ward ,comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in the mean value of white blood cell count measured at day 1 of hospitalization on a covid-ward ,comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in the mean value of neutrophil count measured at day 1 of hospitalization on a covid-ward ,comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in the mean value of lymphocyte count measured at day 1 of hospitalization on a covid-ward ,comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in the mean value of creatinine measured at day 1 of hospitalization on a covid-ward ,comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in the mean value of ldh measured at day 1 of hospitalization on a covid-ward ,comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in the mean value of bilirubin measured at day 1 of hospitalization on a covid-ward ,comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in the mean value of ferritin (first value during hospitalization),comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in the mean value of troponins (first value during hospitalization),comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?|significant difference in the mean value of d-dimers (first value during hospitalization),comparing the group receiving antibiotics for a suspicion of covid-19 superinfection and the group without antibiotics?",observational,observational model: cohort|time perspective: prospective
Parental Stress During the COVID-19 Pandemic and Its Association With Depression and Anxiety,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04377074,NCT04377074,measure of parental stress|patient health questionnaire 9|generalized anxiety disorder 7,observational,observational model: other|time perspective: cross-sectional
Level and Predictors of Trauma-symptoms Among Health Workers and Public Service Providers During the COVID-19 Outbreak,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04374097,NCT04374097,ptsd checklist for dsm-5 (pcl-5)|patient health questionnaire 9 (phq-9)|the generalized anxiety disorder 7 (gad-7)|health anxiety,observational,observational model: other|time perspective: cross-sectional
Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer,CAPANCOVID-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04406571,NCT04406571,pancreatic adenocarcinoma treatment,observational,observational model: cohort|time perspective: prospective
Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment,nan,recruiting,No Results Available,not applicable,Other|U.S. Fed,https://ClinicalTrials.gov/show/NCT04416919,NCT04416919,success percentage|end-tidal co2 variation. description: mmhg.|oxygen pulse oximetry variation. description: mmhg.|mask visibility. description: likert scale.|willingness of usage. description: likert scale.,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
The COVID-19 and Healthcare Workers: An Active Intervention,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04497415,NCT04497415,help-seeking behavior|gad-7|phq-9|pc-ptsd|moral injury,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: health services research
Addressing COVID-19 Mental Health Problems Among US Veterans,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04484207,NCT04484207,help seeking behavior|gad-7|phq-9|pc-ptsd,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: health services research
"The Psychological, Social, and Economic Impacts of COVID-19",C19Survey,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04369690,NCT04369690,mental health - stress|mental health - anxiety|mental health - depression|moral distress in healthcare workers|moral resilience in healthcare workers|social life|covid-9 symptoms|adverse health long-term outcome|health care utilization - inpatient|health care utilization - er|health care utilization - outpatient|sleep,observational,observational model: cohort|time perspective: prospective
COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04335747,NCT04335747,disease activity|immune modulating treatments|biomarkers,observational,observational model: cohort|time perspective: prospective
Physical Activity in University Students Around COVID-19 Confinement,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04361019,NCT04361019,: international physical activity questionnaire - short form|pittsburgh sleep quality index: subjective sleep quality and sleep duration domains|short form 36 health survey: bodily pain domain|euroqol 5d: self rated health,observational,observational model: cohort|time perspective: prospective
"Behavior, Environment And Treatments for Covid-19",BEAT19,recruiting,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04321811,NCT04321811,define natural symptom course|time to hospitalization|time to symptomatic recovery,observational,observational model: cohort|time perspective: prospective
Determinants of COVID-19 Pneumonia (MC-19),MC-19,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04387799,NCT04387799,serology|efficacy of ct scan and serology|efficacy of different pharmaceutical treatments,observational,observational model: case-control|time perspective: prospective
COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis Patients,COMS-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04498286,NCT04498286,the correlation of covid-19 disease course with ms immunomodulatory treatment,observational,observational model: cohort|time perspective: prospective
Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04381000,NCT04381000,anxiety and depression|quality of life and overall health|pain intensity|quality and patterns of sleep|patients' illness perceptions|disability,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Reducing Burnout Among Frontline Healthcare Workers During COVID-19,RESTORE,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04474080,NCT04474080,assess and measure overall burnout|assess stress|assess depression|assess quality of life,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: prevention
"Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic",ONCOVID,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04340219,NCT04340219,"distress at baseline measured by the covid-19 peritraumatic distress index (cpdi); in terms of proportions (0-28 vs ‚â• 29).|depression at baseline measured by the 7-item depression subscale of the 21-item depression, anxiety, and stress scale (dass-21) (dass-21-depression); in terms of proportions (0-4 vs ‚â• 5).|anxiety at baseline measured by the 7-item anxiety subscale of the dass-21 (dass-21-anxiety); in terms of proportions (0-3 vs ‚â• 4).|stress at baseline measured by the 7-item stress subscale of the dass-21 (dass-21-stress); in terms of proportions (0-7 vs ‚â• 8).|distress measured at baseline by the cpdi; in terms of continuous values.|depression at baseline measured by the dass-21-depression; in terms of continuous values.|anxiety at baseline measured by the dass-21-anxiety; in terms of continuous values.|stress at baseline measured by the dass-21-stress; in terms of continuous values.|domain-specific quality of life at baseline measured by the 7-item physical health domain of the world health organization quality of life-bref (whoqol-bref) questionnaire (whoqol-bref-physical health); in terms of continuous values.|domain-specific quality of life at baseline measured by the 6-item psychological health domain of the whoqol-bref questionnaire (whoqol-bref-psychological health); in terms of continuous values.|domain-specific quality of life at baseline measured by the 3-item social relationships domain of the whoqol-bref questionnaire (whoqol-bref-social relationships); in terms of continuous values.|domain-specific quality of life at baseline measured by the 8-item environment domain of the whoqol-bref questionnaire (whoqol-bref-environment); in terms of continuous values.|overall perception of quality of life and overall perception of health at baseline measured by the two items from the overall qol and general health in the whoqol-bref questionnaire-in terms of continuous values.|change from baseline in distress measured by cdpi; in terms of continuous values.|change from baseline in depression measured by the dass-21-depression; in terms of continuous values.|change from baseline in anxiety measured by the dass-21-anxiety; in terms of continues values.|change from baseline in stress measured by the dass-21-stress; in terms of continuous values.|change from baseline in domain-specific quality of life at baseline measured by the whoqol-bref-physical health; in terms of continuous values.|change from baseline in domain-specific quality of life at baseline measured by the whoqol-bref-psychological health; in terms of continuous values.|change from baseline in domain-specific quality of life measured by the whoqol-bref-social relationship; in terms of continuous values.|change from baseline in domain-specific quality of life measured by the whoqol-bref-environment; in terms of continuous values.|change from baseline in overall perception of quality of life and overall perception of health measured by the 2 items from the overall qol and general health in the whoqol-bref questionnaire; in terms of continuous values.|the real-life impact of covid-19 on systemic treatment administration will be assessed using descriptive statistics",observational,observational model: cohort|time perspective: prospective
Registry for a Cardiovascular Patient Who COVID-19 Infection in Qatar and Gulf,nan,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04430374,NCT04430374,the impact of covid-19 on cardiovascular patient,observational,observational model: cohort|time perspective: other
Risk Factors for Anxiety and Depression Among Pregnant Women During the COVID-19 Pandemic,MindCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04377412,NCT04377412,anxiety|depression,observational,observational model: ecologic or community|time perspective: prospective
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM),PREVICHARM,not yet recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04400019,NCT04400019,number of secondary cases of sars-cov2 infection among residents at six days|number of secondary cases of sars-cov2 infection among residents at 14 days|number of secondary cases of sars-cov2 infection among residents at 28 days|sars-cov-2 infection in nursing home staff who provide direct care at six days|sars-cov-2 infection in nursing home staff who provide direct care at 14 days|sars-cov-2 infection in nursing home staff who provide direct care at 28 days|mortality|compliance with treatment|symptoms of sars-cov-2 infection at six days|symptoms of sars-cov-2 infection at 14 days|symptoms of sars-cov-2 infection at 28 days|hospitalization|adverse events at six days|adverse events at 14 days|adverse events at 28 days,interventional,"allocation: randomized|intervention model: crossover assignment|masking: double (participant, outcomes assessor)|primary purpose: prevention"
The Change of Critical Patient Managements and Subsequent Influences Under Epidemic of Coronavirus Disease 19 (COVID-19),nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04479332,NCT04479332,the success rate of tracheal intubation between resuscitation area and negative pressure isolation rooms|the patient prognosis between resuscitation area and negative pressure isolation rooms|the physical and psychological stress of medical staff|the amount of environmental contamination between resuscitation area and negative pressure isolation rooms,interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,FAMICOV,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04511949,NCT04511949,measure of the proportion of contact persons who have developed anti-sars-cov-2 antibodies (secondary transmission rate) within the same household of a subject who had a covid-19 disease assessed by a rapid diagnostic-oriented test,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Moral Judgements and Choices of Caregivers in the Time of COVID-19 Pandemic,XPHI-COVID19,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04542122,NCT04542122,oxford utilitarianism scale,interventional,"allocation: randomized|intervention model: crossover assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: other"
Harnessing Online Peer Education Online Support Intervention for COVID-19 (HOPE COVID-19),nan,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04376515,NCT04376515,anxiety,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: supportive care
Mental Health Support for SickKids Children and Families During COVID-19 Using Established eHealth Interventions,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04408027,NCT04408027,participation barriers|number of eligible participants|number of participants approached|number of participants consented|rates of refusal|reasons for refusal|number of sessions completed in total|adherence index|amount of time (in weeks) to complete the intervention|intervention acceptability|participant satisfaction|working alliance inventory after first intervention session|working alliance inventory after sixth intervention session|working alliance inventory after final intervention session|family impact during a pandemic at baseline|family impact during a pandemic after final intervention session|efficacy of virtual-care cbt intervention|clinician virtual care experience,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
LIBERATE Trial in COVID-19,LIBERATE,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04334629,NCT04334629,disease progression|time to mechanical ventilation|overall survival|reduction in proportion of patients who require ventilation|reduction in length of critical care stay|reduction in length of hospital stay|modulation of serum pro- and anti-inflammatory cytokines|reduction in duration of ventilation|increase in ventilator-free days,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: treatment"
COVID-19 Health Professional Impact Study,CHIP,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04527432,NCT04527432,the number of employees tested who have evidence of sars-cov-2 antibodies|factors associated with a positive test|likelihood of clinically relevant (causing illness) infection with sars-cov-2 in subjects with both positive and negative sars-cov-2 antibody tests,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
COVID-19 and Psychotic Symptoms in France,SCHIZOVID-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04356885,NCT04356885,total score of the cardiff anomalous perceptions scale (caps)|paranoia scale,observational,observational model: cohort|time perspective: prospective
Coagulopathy in COVID19 - A Multi-Centre Observational Study in UK,COVID19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04405232,NCT04405232,"prevalence and characteristics of coagulation abnormalities and their predictive value for respiratory failure requiring ventilation, multiorgan failure and death in patients presenting with covid 19 infection|incidence of respiratory failure requiring cpap or mechanical ventilation|incidence of thrombosis (clinical or radiological diagnosis) including thrombosis within 90 days after hospital admission (hospital associated thrombosis) 4. incidence of minor bleeding 5. heparin induced thrombocytopenia 6. acute coronary syndrome|incidence of major bleeding 8. multiorgan failure 9. development of dic 10. duration of hospital stay (days) 11. hospital mortality|incidence of clinically relevant non-major bleeding|incidence of heparin induced thrombocytopenia|incidence of acute coronary syndrome|incidence of renal failure requiring renal replacement therapy|incidence of multiorgan failure|incidence of development of dic|duration of hospital stay (days)|hospital mortality",observational,observational model: cohort|time perspective: prospective
Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19),ISCA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04383730,NCT04383730,"number of days off the ventilator (vfd28, for ventilator-free days), taking into account death as a competing event|all-cause mortality|ventilator-free days|icu-free days|duration of invasive mechanical ventilation|duration of controlled mechanical ventilation|physiological measures of lung function|development of complications|duration of vasopressor use|duration of renal replacement therapy|duration (in days) of any adjuvant therapies|duration of continuous neuromuscular blockade|type of sedation practices|duration of sedation practices|modalities of sedation practices",observational,observational model: cohort|time perspective: retrospective
Percutaneous Tracheostomy With COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04447638,NCT04447638,complications observed in the cases in which we applied percutaneous tracheostomy with aerosol box,observational,observational model: case-only|time perspective: retrospective
Surgical Consent During the COVID-19 Pandemic,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04556604,NCT04556604,compliance to consenting practice,observational,observational model: ecologic or community|time perspective: cross-sectional
3D Telemedicine During COVID-19: Cohort Study,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04444323,NCT04444323,presence questionnaire|university hospital of north northway questionnaire|telehealth usability questionnaire|system usability scale|mental effort rating scale|nasa tlx|range of motion measurements for elbow joint,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Self-sampling for the Study of COVID-19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04447495,NCT04447495,validate iamp testing kit,observational,observational model: case-control|time perspective: prospective
Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04380870,NCT04380870,patient reported main complaint|conduct qualitative analyses of data,observational,observational model: ecologic or community|time perspective: prospective
Cerebral Compliance Impairment in COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04429477,NCT04429477,detection of cerebral compliance impairment by the b4c sensor|detection of cerebral hemodynamics impairment by transcranial doppler|calculate mortality in this population,observational,observational model: cohort|time perspective: prospective
HFNC Treatment in COVID-19 Pneumonia,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04424836,NCT04424836,short term mortality|icu stay|blood gases,observational,observational model: case-control|time perspective: retrospective
Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04387409,NCT04387409,"number of days absent from work due to respiratory disease (with or without documented sars-cov-2 infection)|cumulative incidence of documented sars-cov-2 infection|number of days absent from work due to documented sars-cov-2 infection|number of days absent from work due to exposure to person with documented sars-cov-2 infection|number of days absent from work due to symptoms of respiratory disease, documented sars-cov-2 infection, or fever (‚â• 38 ¬∞c)|number of days of self-reported fever (‚â• 38 ¬∞c)|number of days of self-reported acute respiratory symptoms|cumulative incidence of self-reported acute respiratory symptoms|cumulative incidence of death for any reason|cumulative incidence of death due to documented sars-cov-2 infection|cumulative incidence of icu admission for any reason|cumulative incidence of icu admission due to documented sars-cov-2 infection|cumulative incidence of hospital admission for any reason|cumulative incidence of hospital admission due to documented sars-cov-2 infection",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: prevention"
COVID-19 Psychological Wellbeing for Healthcare Students,PoWerS,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04429828,NCT04429828,"qualitative interviews with healthcare students|warwick-edinburgh mental wellbeing scale|single item measure of global job stressfulness (houdmont et al, 2019)|single item global job satisfaction measure (dolbier et al, 2005)|single item measure of presenteeism (aronsson & gustafsson, 2004)|single item measure of turnover intentions|work engagement (shaufeli et al, 2006)",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,nan,recruiting,No Results Available,phase 2,Other|Industry,https://ClinicalTrials.gov/show/NCT04414631,NCT04414631,disease severity|time to clinical improvement|proportion of participants alive and not having required invasive or non-invasive ventilation|proportion of subjects with an ali (defined by pao2/fio2 ratio of <300mmhg),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Impact of COVID-19 Lockdown on Obesity and Eating Behaviors,CIO,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04431284,NCT04431284,comparison of the bmi (kg/m¬≤) evolution between the two groups|score comparison of the dutch eating behavior questionnaire,observational,observational model: other|time perspective: retrospective
Remote COVID-19 Symptom Tracking for Cancer Patients at Home During the Pandemic,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04464486,NCT04464486,"health care utilization comparison|patient social isolation|covid-19 symptoms, social distancing and hygiene practices|patient global health|patient anxiety/depression|impact of pandemic and health related quality of life|cancer symptom severity",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
The Mental Health Status of the General Population During the COVID-19 Pandemic and Its Association With Adherence to Government-initiated Non-pharmacological Epidemiological Interventions (NPI's),nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04356365,NCT04356365,patient health questionnaire 9|generalized anxiety disorder 7|measures of adherence,observational,observational model: other|time perspective: cross-sectional
Inpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC),nan,not yet recruiting,No Results Available,phase 3,Other|NIH,https://ClinicalTrials.gov/show/NCT04546581,NCT04546581,"ordinal outcome scale - day 7|all-cause mortality through day 28|ordinal outcome scale|change in national early warning score (news)|time to worsening|discharge status|days alive outside the hospital|pulmonary-only components of the primary ordinal outcome|thrombotic components of the primary ordinal outcome|time to recovery|clinical organ dysfunction|safety and tolerability - adverse events|safety and tolerability - infusion reactions, interruptions, or cessation|safety and tolerability - serious adverse events|safety and tolerability - prevalence of adverse events|change in neutralizing antibody level",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04348227,NCT04348227,mdr pathogens in endotracheal aspirates|microorganisms in endotracheal aspirates,observational,observational model: cohort|time perspective: other
"Caracteristics of the Patients Hospitalized With Unvonluntary Commitment Procedure, in the Context COVID-19",HoCoPsy,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04417374,NCT04417374,number of hospitalized patients|cause of hospitalization,observational,observational model: cohort|time perspective: prospective
Renal Outcome in Patients With COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04353583,NCT04353583,incidence of aki|renal function changes during hospital stay|incidence of chronic kidney disease,observational,observational model: cohort|time perspective: prospective
Protective Effect of Aspirin on COVID-19 Patients,PEAC,enrolling by invitation,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04365309,NCT04365309,clinical recovery time (ttcr)|the time of sars-cov2 overcasting,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,LDCTiP,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04379531,NCT04379531,evaluate the correlation between standard ct and low-dose ct scans for the detection of community-acquired pneumonia.|threshold value of the infiltration zone size detected by low-dose ct scan compared to standard ct scan.|number of infiltration zones of pulmonary parenchyma corresponding to viral pneumonia detected by low-dose ct scan in comparison with standard ct scan.,interventional,allocation: non-randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: diagnostic
3D Telemedicine During COVID-19: Non-clinical Validation,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04444297,NCT04444297,presence questionnaire|university hospital of north northway questionnaire|telehealth usability questionnaire|system usability scale|mental effort rating scale|nasa tlx|range of motion measurements for elbow joint,interventional,"allocation: randomized|intervention model: crossover assignment|masking: double (investigator, outcomes assessor)|primary purpose: other"
Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,SPIN-CHAT,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04335279,NCT04335279,"anxiety: patient-reported outcomes measurement information system (promis) anxiety 4a v1.0|depression symptoms: patient health questionnaire (phq-8)|loneliness: university of california, los angeles (ucla) loneliness scale (uls-6)|boredom: multidimensional state boredom scale (msbs-8)|physical activity: international physical activity questionnaire - modified for the elderly (ipaq-e)|adverse effects|fear: covid-19 fears questionnaire for chronic medical conditions",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
"Impact of Confinement and Preventive Measures in Period of SARS-COV2 Infection on Clinical Features, Diagnostic and Therapeutic Management and Prognosis of Patients With Lung Cancer: an Ambispective Study Extended Over 2 Time Periods.",CBP-COVID,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04366219,NCT04366219,comparison of clinical characteristics|comparison of diagnostic procedures|comparison of treatments (according to stage of disease)|comparison of patients management deadlines|comparison of survival,observational,observational model: other|time perspective: other
COVID-19 Risk Reduction Among African American Parishioners,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04542343,NCT04542343,"percentage of participants achieving improvement of health conditions using the severity of medical chronic conditions surveys|percentage of participants achieving target levels of knowledge, attitude, and behaviors with nih toolbox surveys|prevalence of covid-19 testing using participant covid-19 test history survey|prevalence of pneumococcal and influenza vaccinations using participant immunization history survey",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Impact of COVID-19 Pandemic on the Psychological Wellbeing of Healthcare Professionals in India,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04469660,NCT04469660,therapeutic sessions emphasizing on stress|resilience building and planning,observational,observational model: cohort|time perspective: prospective
COVID-19 and Rare Skin Diseases European Observational Study During an Epidemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04451902,NCT04451902,analysis of the impact of covid-19 infection on rare skin diseases: complications|analysis of the impact of covid-19 infection on rare skin diseases: potential comorbidity factors|analysis of the impact of covid-19 infection on rare skin diseases: impact on the management of chronic conditions (change in treatment),observational,observational model: cohort|time perspective: other
Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04341012,NCT04341012,breath volatile organic compound profiles|utility of breath profiles for disease diagnosis or prognosis,observational,observational model: cohort|time perspective: prospective
Fibromyalgia During the COVID-19 Pandemic,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04422522,NCT04422522,number of fm patients,observational,observational model: case-only|time perspective: retrospective
Experimental Trial of rhIFNŒ± Nasal Drops to Prevent 2019-nCOV in Medical Staff,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04320238,NCT04320238,new-onset covid-19|number of participants with coronavirus related symptoms|number of participants with adverse effect,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Clinical and Radiomic Model of COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04337502,NCT04337502,predictive performance,observational,observational model: cohort|time perspective: retrospective
Distress in Crisis Situations During COVID-19,nan,completed,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04337047,NCT04337047,quantify and qualify distress over a large population in times of pandemic crisis.|qualify demographic data vs distress over a large population in times of pandemic crisis.,observational,observational model: cohort|time perspective: prospective
Cross Sectional CFAR HIV/COVID Study,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04514016,NCT04514016,number of participants who tested positive with sars cov-2 infection|number of participants who tested positive with sars cov-2 antibody,observational,observational model: cohort|time perspective: cross-sectional
Treating COVID-19 With a Bidirectional Oxygenation Valve,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04326452,NCT04326452,pulse oximetry level|respiratory rate|heart rate|blood pressure|systemic carbon dioxide,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Inhaled Ibuprofen to Treat COVID-19,C√≥rdobaTrail,recruiting,No Results Available,not applicable,Industry|Other,https://ClinicalTrials.gov/show/NCT04382768,NCT04382768,"change in the scale of ordinary covid results at 7, 14 and 28 days in patients with acute respiratory infection, induced by sars-cov-2, treated with inhaled ibuprofen.|change to negativization of the swab to the following treatment points on day 7, day 14, 21 and 28 after treatment with inhaled ibuprofen.|chage in length of hospital stay|chage in duration of ventilation|chage in length of critical care stay|average score of national early warning (news2) between days 1, 7, 14 and 28.|average change in quick sepsis-related organ failure assessment score (qsofa) score between day 1, 7, 14 and 28.|time from first dose to conversion to normal or mild pneumonia|antibiotic requirement|glucocorticoids requirement|incidence of adverse event|incidence of serious adverse event|number of deaths from any cause at 28 days|lymphocyte count",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT,IMPACT,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04347798,NCT04347798,impact of anti-malarials on the development and severity of covid-19 in the anti-malarial group compared to the non-anti-malarial group|incidence of covid-19 infection in the anti-malarial group compared to the non-anti-malarial group|incidence of covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action,observational,observational model: case-control|time perspective: prospective
NO Prevention of COVID-19 for Healthcare Providers,NOpreventCOVID,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04312243,NCT04312243,covid-19 diagnosis|positive sars-cov-2 rt-pcr test,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Sequencing and Tracking of Phylogeny in COVID-19 Study,STOP COVID 19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04359849,NCT04359849,to produce whole genome sequences for the sars-cov-2 virus from viral rna samples|to develop a phylogenetic map of the sars-cov-2 virus,observational,observational model: cohort|time perspective: retrospective
Viral Specific T-cells for Treatment of COVID-19,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04406064,NCT04406064,successful production of viral specific t-cells|presence of viral-specific t-cells,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
SafeFit Trial: Virtual Clinics to Deliver Universal Interventions in People With Cancer,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04425616,NCT04425616,physical function|emotional function|health related quality of life|health economics analysis|patient activation|self-reported physical activity|nutrition assessment|self-efficacy for self-management of chronic disease|distress levels|functional capacity|the impact of covid-19 pandemic on psychological functioning|process evaluation,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,PIC-19,completed,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04368377,NCT04368377,p/f ratio|pao2 difference|a-a o2 difference|cpap duration|in-hospital change in intensity of the respiratory support|paco2 difference|hco3- difference|lactate difference|hb difference|plt difference|adverse effects,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Capturing MultiORgan Effects of COVID-19,C-MORE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04510025,NCT04510025,"prevalence of damage (quantitative measures of injury) on lung, heart, liver, kidneys and brain mri.|prevalence of damage (quantitative measures of injury) on lungs, heart, liver, kidneys and brain on mri.|prevalence of acute/chronic cardiac, renal and liver injury on blood tests.|vo2 max on cardiopulmonary exercise testing|prevalence of abnormal lung function test (any of the following: forced expiratory volume in 1 second (fev1)< 80% of predicted fev1, or forced vital capacity (fvc)<80% predicted, ratio of fev1/fvc >0.7 or diffusion lung capacity (<80% predicted))|quality of life - short form-36 sf-36 score|prevalence of impaired cognitive function on montreal cognitive assessment (moca<26)|6-minute walk distance|severity of anxiety on gad-7 (score)|severity of depression on phq-9 (score)|association between the extent of multi-organ injury (continuous variable) and markers of inflammation (white cell count).|correlation between the extent of symptoms (dyspnoea-12 score and fatigue score) and multi-organ injury.",observational,observational model: cohort|time perspective: prospective
Prognostic Factors Keeping Track for COVID-19 Pneumonia,NIKE_C19,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04324684,NCT04324684,rate of recovery|time to improvement|efficacy of treatments|organ failure,observational,observational model: case-control|time perspective: prospective
Morbi-mortality by COVID-19 Among Homeless People in Marseille: a Cohort Study,COVIDHomeless,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04408131,NCT04408131,the covid mortality rate,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Can the Prediction Market Improve Predictions of COVID-19?,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04410692,NCT04410692,predictions of covid-19 cases and deaths|fear,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
Scaling Mental Healthcare in COVID-19 With Voice Biomarkers,nan,not yet recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04510519,NCT04510519,patient health questionnaire (phq-9)|generalized anxiety disorder (gad-7),observational,observational model: cohort|time perspective: prospective
"COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being",CoVS,"active, not recruiting",No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04357041,NCT04357041,automated self-administered 24-hour dietary recall (asa24)|international physical activity questionnaire (ipaq)|health-related quality of life sf-12 scale|state trait inventory for cognitive and somatic anxiety (stisa).|beck depression inventory (bdi),observational,observational model: case-only|time perspective: other
Mechanisms for Organ Dysfunction in Covid-19,UMODCOVID19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04316884,NCT04316884,acute kidney injury|ards|30 day mortality|1 year mortality|chronic kidney disease|sofa-score,observational,observational model: cohort|time perspective: prospective
COVID-19 Serological Status of Hospital Staff Working or Not in the COVID-19 Sector,SEROCO,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04481529,NCT04481529,number of subjects with a covid-19 seroconversion,observational,observational model: case-only|time perspective: prospective
COVID-19 Infection in Patients Infected With HIV and/or on PrEP,COVIDHIVPrEP,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04379245,NCT04379245,covid attack rate,observational,observational model: cohort|time perspective: retrospective
Predictors of Mental Well-being During the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04443699,NCT04443699,the short warwick-edinburgh mental well-being scale (swemwbs),observational,observational model: other|time perspective: prospective
Registry of COVID-19 Patients at AOUI Verona,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04497194,NCT04497194,"epidemiological predictors of poor outcomes in covid-19 patients admitted to university hospital of verona|clinical predictors of poor outcomes in covid-19 patients admitted to university hospital of verona|body temperature (¬∞c) on admission in covid-19 patients admitted to university hospital of verona|blood pressure (mmhg) on admission in covid-19 patients admitted to university hospital of verona|pulse rate (beats per minute) on admission in covid-19 patients admitted to university hospital of verona|respiratory rate (breaths per minute) on admission in covid-19 patients admitted to university hospital of verona|peripheral oxygen saturation (%) on admission in covid-19 patients admitted to university hospital of verona|c reactive protein (crp, m/gl) in covid-19 patients admitted to university hospital of verona|procalcitonin (pct, ng/ml) in covid-19 patients admitted to university hospital of verona|white blood count (wbc, cell/mm3) in covid-19 patients admitted to university hospital of verona|neutrophils (cell/mm3) in covid-19 patients admitted to university hospital of verona|lymphocytes (cell/mm3) in covid-19 patients admitted to university hospital of verona|platelets (cell/mm3) in covid-19 patients admitted to university hospital of verona|l-lattato deidrogenasi (ldh, mu/ml) in covid-19 patients admitted to university hospital of verona|creatine kinase (ck, u/l) in covid-19 patients admitted to university hospital of verona|d-dimer (œºg/l) in covid-19 patients admitted to university hospital of verona|fibrinogen (g/l) in covid-19 patients admitted to university hospital of verona|ferritin (mcg/l) in covid-19 patients admitted to university hospital of verona|ast (u/l) in covid-19 patients admitted to university hospital of verona|alt (u/l) in covid-19 patients admitted to university hospital of verona|creatinine (mg/dl) in covid-19 patients admitted to university hospital of verona|arterial blood gas anaysis ph in covid-19 patients admitted to university hospital of verona|arterial blood gas anaysis po2 (mmhg) in covid-19 patients admitted to university hospital of verona|arterial blood gas anaysis pco2 (mmhg) in covid-19 patients admitted to university hospital of verona|arterial blood gas anaysis hco3 (mmol/l) in covid-19 patients admitted to university hospital of verona|arterial blood gas anaysis spo2 (%) in covid-19 patients admitted to university hospital of verona|host-related factors associated with the pathogenesis of covid-19|virological factors associated with the pathogenesis of covid-19",observational,observational model: cohort|time perspective: other
Handling Oxygenation Targets in COVID-19,HOT-COVID,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04425031,NCT04425031,days alive without organ support|90-days mortality|days alive out of the hospital|number of patients with one or more serious adverse events|1-year mortality|quality of life assessement using the euroqol eq-5d-5l telephone interview|cognitive function 1-year after randomisation as assessed using the repeatable battery for the assessment of neuropsychological status (rbans) score in selected sites|carbon monoxide diffusion capacity|a health economic analysis,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
Blood Donor Recruitment During Epidemic of COVID-19,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04306055,NCT04306055,differences of attitude about blood donation towards different questionnaires|rates of blood donation during 3 weeks,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: health services research
Taste and Smell Impairment in Critically Ill COVID-19 Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04532632,NCT04532632,taste and smell impairment,observational,observational model: other|time perspective: prospective
Impact of COVID-19 on Mental Health of Patients With Skin Picking,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04522492,NCT04522492,change in global clinical impression scale|change in beck anxiety inventory|change in beck depression inventory|change of skin picking impact scale|change of emotional regulation|change in hamilton anxiety scale,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Ozone Therapy in the Prevention of COVID-19 Infection,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04400006,NCT04400006,the survey that was taken by telephone calls,observational,observational model: case-only|time perspective: prospective
BIO 300 Oral Suspension in Discharged COVID-19 Patients,nan,not yet recruiting,No Results Available,phase 2,Industry|Other|NIH,https://ClinicalTrials.gov/show/NCT04482595,NCT04482595,change in dlco|change in 6 minute walk test|change in fvc|change in fev1|change in fev1/fvc ratio|change in pulse oximetry at rest and during the 6mwt|change in pulmonary fibrosis on ct scan|change in st. george's respiratory questionnaire (sgrq) scores|change in clinical laboratory values for serum enzymes|change in clinical laboratory values|change in clinical laboratory values for albumin|change in complete blood counts with differential|all-cause mortality|incidence of re-hospitalization|adverse events related to bio 300 oral suspension,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
The Psychological Impact of the COVID-19 on Students.,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04365361,NCT04365361,stress level|anxiety and depressive symptoms|insomnia symptoms and the associated daytime impairment|psychological response to trauma|resilience|attitude and practice students regarding preventive measures,observational,observational model: ecologic or community|time perspective: prospective
Parental Burnout During the COVID-19 Pandemic: Risk Factors and Predictors,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04442386,NCT04442386,the parental burnout inventory (pbi),observational,observational model: other|time perspective: prospective
IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.,IMAGE-19,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04357613,NCT04357613,to evaluate the benefit of early imatinib therapy to prevent severe covid-19 disease in hospitalized aged patients.|to evaluate the feasibility of imatinib therapy.|to evaluate safety of imatinib therapy|to evaluate the clinical evolution|to evaluate the progression rate to severe covid-19 disease|to evaluate mortality|to evaluate viral load|to evaluate plasmatic levels of imatinib,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT03808922,NCT03808922,percent of subjects who return to room air (rtra) (main study)|percent of subjects with improved covid-19 clinical status scale (sub-study)|all-cause mortality rate (main study)|time (in days) to rtra (main study)|percent of subjects who achieve clinical stability (main study)|percent of subjects discharged (without mortality and hospice) (main study)|time (in days) to first hospital discharge (without hospice) (main study)|total number of inpatient days (main study)|baseline sad-rv infection-related mortality rate (main study)|change in pulmonary function (fev1% predicted) (main study)|time to improved covid19 clinical status (sub-study)|time to rtra|time to clinical stability|time to sars-cov-2 rna in the respiratory specimens being undetectable|time to clinical deterioration|time to discharge from hospital (without readmission before day 28).|time to death (all causes),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Determining the Reproductive Health of Men Post-COVID-19 Infection,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04414904,NCT04414904,semen parameters|sperm parameters|hormones measurement|seminal reactive oxygen species|sperm dna fragmentation rate,observational,observational model: case-control|time perspective: prospective
Recruit Blood Donors Via SMS During Epidemic of COVID-19,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04370886,NCT04370886,blood donation rate,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: health services research
Risk Factors for Community- and Workplace Transmission of COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04320732,NCT04320732,rate of covid-19 infection,observational,observational model: case-control|time perspective: prospective
Obstetric and Perinatal Outcomes of Women With COVID-19,GROCO,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04369859,NCT04369859,compare the complications rates|clinical presentation,observational,observational model: cohort|time perspective: prospective
Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04386291,NCT04386291,gad-7|whiteley 8|phq-8|ss-8|applied cognition 1.0|promis-4 sleep disturbance|erq|perceived stress scale|brief hypervigilance scale,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Impact of Colchicine in Hospitalized Colombian Patients With COVID-19,(COLCOVID19),not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04539873,NCT04539873,number of participants who die or require transfer to intesive care unit|number of participants who die,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Improving Activity Engagement Among Persons With SCI During COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04408287,NCT04408287,treatment satisfaction|ability to participate in social roles and activities|fatigue|satisfaction with social roles and activities|positive affect and well-being|pain interference|resilience|self-esteem,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Isolated During COVID-19: Effects of COVID-19's Social Restrictions on Loneliness and Psychosocial Symptomatology,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04440098,NCT04440098,loneliness as evaluated by the ucla loneliness scale|alcohol use as evaluated by the audit|drug use as evaluated by the dast-10|anxiety as evaluated by gad-7|depression as assessed by ces-d-10,observational,observational model: case-only|time perspective: cross-sectional
Correlation Between Oxidative Stress Status and COVID-19 Severity,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04375137,NCT04375137,mda concentration|biopterin concentration|neopterin rate of increase,observational,observational model: case-control|time perspective: cross-sectional
Living With Sickle Cell Disease in the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04417673,NCT04417673,"stress|anxiety|depressive symptomology|pain episodes, and severity|healthcare utilization (primary care, emergency department, telehealth other)|receptivity to future health recommendations and medical treatment(s).",observational,observational model: cohort|time perspective: prospective
Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers,PROVIDE,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04371523,NCT04371523,positive for sars-cov-2|hospital admissions|intensive care unit admissions|intubation and mechanical ventilation|icu length of stay|hospital length of stay|mortality|incidence of adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Recovery of Exertion Ability Following COVID-19 Infection in Military Staff,CovEx,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04548505,NCT04548505,magnitude of the decrease in aerobic performance on return to work,observational,observational model: cohort|time perspective: prospective
"Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19",nan,recruiting,No Results Available,nan,Other|NIH,https://ClinicalTrials.gov/show/NCT04373148,NCT04373148,testing immunity to sars-cov-2 over time|testing the virus over time,observational,observational model: case-control|time perspective: prospective
Acupressure for COVID-19 Related Quality of Life and Stress,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04472559,NCT04472559,quality of life|perception of stress,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Psychological Symptoms and Families of COVID-19 Patients,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04501445,NCT04501445,symptoms of post-traumatic stress disorder (ptsd) initial|symptoms of anxiety and depression initial|surrogate satisfaction with the patient's icu care:|symptoms of post-traumatic stress disorder (ptsd) final|symptoms of anxiety and depression final|interview initial|interview final,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19),nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04435106,NCT04435106,measure the time to weaning from high-flow nasal cannula|measure the time to breathing ambient (room) air|measure change in lymphocyte count|measure change in c-reactive protein,observational,observational model: case-control|time perspective: retrospective
Effects of COVID-19 Induced Deconditioning After Long-term High Intensity Resistance Exercise,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04444661,NCT04444661,smi|bmd-ls|bmd-hip|sarcopenia-z-score|fat infiltration thigh muscles|fat infiltration para-vertebral muscles|maximum hip-/leg extensor strength|metabolic syndrome z-score|self rated physical performance,observational,observational model: cohort|time perspective: retrospective
EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19,EPI CV COVID,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04498091,NCT04498091,characterizing type 2 myocardial infarction associated with cov-2 sars infection,observational,observational model: cohort|time perspective: prospective
Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04530461,NCT04530461,serological profile,observational,observational model: cohort|time perspective: prospective
Hydroxychloroquine in Outpatient Adults With COVID-19,nan,terminated,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04333654,NCT04333654,change from baseline to day 3 in nasopharyngeal sars-cov-2 viral load (if quantitative pcr is available)|number of participants by pcr result status (positive or negative) (if quantitative pcr is not available)|change from baseline to day 5 in nasopharyngeal sars-cov-2 viral load|number of participants by pcr result status (positive or negative)|number of participants with covid-19 symptoms by severity|time to resolution of covid-19 symptoms|time to resolution of fever|percentage of participants with resolution of fever|percentage of participants hospitalized|number of participants with adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
VRQOL in Cataract Patients During the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04468308,NCT04468308,improvement vision-related quality of life|delay of vision-related quality of life|visual acuity,observational,observational model: cohort|time perspective: prospective
Virtual Mindfulness Rounds in the Time of COVID-19 Pandemic,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04431297,NCT04431297,change in perceived stress scale,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Mental Health and Academic Performance in COVID-19,PANDEMIC,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04420416,NCT04420416,academic self-concept scale score|phq-9 score|gad-7 score|preference of teaching method|self perceived academic performance|academic grades changes,observational,observational model: cohort|time perspective: cross-sectional
Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women,nan,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04420806,NCT04420806,body composition|hip-/leg extension strength|metabolic syndrome|bone mineral density (bmd)|menopausal symptoms|back and joint pain,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Impact of Smoking and Nicotine on the Risk of Being Infected With COVID-19,MAGIC,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04429815,NCT04429815,percentage of patients with a positive serological test for covid-19.,observational,observational model: cohort|time perspective: prospective
External Dead Space in Ventilated COVID-19 Patients,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04424082,NCT04424082,change in carbon dioxide elimination (vco2) i.e. ml co2 eliminated/minute|changes in alveolar dead space (a vcap derived parameter)|changes in arterial carbon dioxide tension (paco2).,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus),REMOTE-COVID,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04337489,NCT04337489,deterioration resulting in healthcare review|hospitalisation|participant anxiety|participant depression,observational,observational model: cohort|time perspective: prospective
Assessment of Mortality Rates in SARS-CoV-2 Infected Populations Treated With Repurposed Medications,nan,not yet recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04432350,NCT04432350,"the rate of mortality in patients with a confirmed (positive test result) covid-19 infection observed by prescribewellness pharmacies will be determined.|the relationship between high-risk cardio-pulmonary and vascular comorbidities (e.g., hypertension, dyslipidemia, diabetes, and chronic lung diseases) and mortality with use of repurposed medications for the treatment of covid-19 will be investigated.|the mrs‚ñ¢ will be calculated using drug claim data from confirmed covid-19 patients and explore the predictive value of mrs‚ñ¢ for ade, lqts and all-cause of death.|to compare the rates of death in covid-19 confirmed patients treated with repurposed medications versus covid-19 confirmed patients not treated with repurposed drugs.|the relationship between medications used to treat these underlying health conditions (e.g. ace inhibitors, angiotensin type 1 receptor blockers, aliskiren, and mineralocorticoid antagonists) and mortality in patients with a confirmed covid-19 infection.|to compare the mrs‚ñ¢ and its predictive value for ade between confirmed covid-19 patients treated with repurposed drugs and confirmed patients not treated with repurposed drugs.|to examine drug regimen patterns associated with higher risk of mrs‚ñ¢, ades, and higher rates of death in confirmed covid-19 patients with and without repurposed medication.",observational,observational model: cohort|time perspective: retrospective
Medical Masks vs N95 Respirators for COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04296643,NCT04296643,rt-pcr confirmed covid-19 infection|acute respiratory illness|absenteeism|lower respiratory infection|pneumonia|icu admission|mechanical ventilation|death,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19,STOP-COVID,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04343898,NCT04343898,28-day mortality|60-day mortality|90-day mortality|1-year mortality,observational,observational model: cohort|time perspective: other
Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy,COVID-preg,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04319016,NCT04319016,maternal and perinatal outcomes,observational,observational model: cohort|time perspective: other
"Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19",nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04519437,NCT04519437,incidence of adverse event of special interests (aesis) that occur within 4 days of study drug administration|concentrations of regn10933 in serum over time|concentrations of regn10987 in serum over time|proportion of participants with treatment-emergent adverse events (teaes)|severity of teaes|proportion of participants who achieve or exceed target concentration in serum of regn10933|proportion of participants who achieve or exceed target concentration in serum of regn10987|immunogenicity as measured by anti-drug antibodies (ada) to regn10933|immunogenicity as measured by anti-drug antibodies (ada) to regn10987,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Accurate Classification System for Patients With COVID-19 Pneumonitis,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04302688,NCT04302688,survival status,observational,observational model: other|time perspective: retrospective
Impact of Isolation in Patients With IBD During the COVID-19 Crisis,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04488471,NCT04488471,what impact has the isolation of patients during social isolation had in terms of psychological morbidity?|have levels of psychological morbidity in young people changed from levels prior to the covid pandemic?,observational,observational model: cohort|time perspective: prospective
Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04384458,NCT04384458,"proportion of participants in whom there was a positivity for sars-cov-2.|participants who developed mild, moderate, or severe forms of covid-19.|measurement of the qt interval.|widening of the corrected qt interval or with changes in heart rate on the ecg.|comparison of hematological and biochemical parameters.|occurrence of adverse events.|assessment of covid-19 symptom severity.|proportion of participants who discontinue study intervention.|proportion of participants who required hospital care.|proportion of participants who required mechanical ventilation.",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Understanding the Mental Health of Migrant Workers During the COVID-19 Outbreak,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04448704,NCT04448704,dass-21 scores,observational,observational model: cohort|time perspective: cross-sectional
The Impact of Information Sources on Mental Health During the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04442360,NCT04442360,patient health questionnaire 9|generalized anxiety disorder 7,observational,observational model: other|time perspective: prospective
C-reactive Protein Levels Among Individuals With COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04373798,NCT04373798,hospitalisation|death|transfer to intensive care unit|oxygen treatment during hospitalisation,observational,observational model: cohort|time perspective: prospective
Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,nan,recruiting,No Results Available,phase 4,Other|Industry,https://ClinicalTrials.gov/show/NCT04406246,NCT04406246,health workers that require hospitalization,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Predictors and Mechanisms of Depression and Anxiety During the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04442204,NCT04442204,patient health questionnaire 9|generalized anxiety disorder 7,observational,observational model: other|time perspective: prospective
Online Survey on Psychological Impact of COVID-19 Epidemic on School-age Children,PSICOcs,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04475484,NCT04475484,proportion of children presenting signs of psychological suffering during confinement.,observational,observational model: ecologic or community|time perspective: cross-sectional
Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study,MODIF,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04357314,NCT04357314,the primary endpoint is a composite of death from all causes and mechanical complications of acute myocardial infarction (mi)|rates of patients presenting with acute myocardial infarction|patient profile during admission for acute myocardial infarction|medical care times analysis|clinical evolution of patients|stemi (st segment elevation myocardial infarction) admissions incidence rates|proportion of patients who underwent systemic thrombolysis|proportion of patients infected with covid-19,observational,observational model: cohort|time perspective: retrospective
Hesperidin and Diosmin for Treatment of COVID-19,nan,not yet recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04452799,NCT04452799,pcr test|respiratory rate|patients pao2|serum il1œ≤|serum tnf-œ±|mortality rate,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
"1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study",TMX COVID,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04395742,NCT04395742,"comparison of vital status|comparaison of duration of hospital stay|comparaison of severity|comparaison of secondary effects (adverse events that needed disruption of treatment (anemia, tachycardia, osteoporosis) : secondary effects of coffee).|comparaison of use of antibiotics",observational,observational model: other|time perspective: retrospective
sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?,COVIDsFlt1,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04394195,NCT04394195,association between concentration of circulating sflt1 and use of vasopressor,observational,observational model: cohort|time perspective: prospective
IVERMECTIN Aspirin Dexametasone and Enoxaparin as Treatment of Covid 19,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04425863,NCT04425863,illness development|reduction of need icu admission|reduction of mortality rate|optimyzing doses of drugs used in the clinical trial|adverse effects,observational,observational model: cohort|time perspective: prospective
Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19,TOVID-49,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04333849,NCT04333849,"preferred means of communication for elderly people in isolation, hospitalized in the acute care geriatric unit or residing at st nicolas nursing home (angers uh).|proportion of elderly people with loss of functional independence to communicate with their relatives.|level of satisfaction of patients who have benefited from a telephone call.|level of satisfaction of patients who have benefited from a videophone call.|satisfaction level of older people according to the means of communication used.|impact of age on the preferred means of communication.",observational,observational model: cohort|time perspective: prospective
Intravascular Access in Suspected/Confirmed COVID-19 Patient,nan,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04366947,NCT04366947,success rate of first intravascular access attempt|time to successful access|number of attempts to successful access|time to infusion|complication rates|rosc,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Consequences of the COVID-19 Lockdown on Health and Well-being of Patients With Parkinson Disease and Post-stroke,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04535297,NCT04535297,patient activation measure (pam¬æ)|answers to multiple-choice questions,observational,observational model: case-only|time perspective: cross-sectional
FilmArray and Management of ICU Patients With Pneumonia in the Covid-19 Context,FAP-REA,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04453540,NCT04453540,therapeutic decision,observational,observational model: case-only|time perspective: retrospective
ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04460677,NCT04460677,decreased distress on patient health questionnaire (phq-9)|decreased distress on ema reports|decreased anxiety symptoms on the generalized anxiety disorder questionnaire (gad-7)|adult self report (asr),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
The Investigation of the Neonates With or With Risk of COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04279899,NCT04279899,the death of newborns with covid-19|the sars-cov-2 infection of neonates born to mothers with covid-19|the chinese standardized denver developmental screening test (ddst) in neonates with or with risk of covid-19|the small for gestational age newborns in the neonates born to mothers with covid-19|the preterm delivery of neonates born to mothers with covid-19|the disease severity of neonates with covid-19,observational,observational model: case-only|time perspective: prospective
Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses,nan,recruiting,No Results Available,not applicable,NIH,https://ClinicalTrials.gov/show/NCT04377100,NCT04377100,patterns of neural connectivity as predictors,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: basic science
Acute Kidney Injury and Renal Outcomes for COVID-19 Patients in Intensive Care Units,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04459975,NCT04459975,"primary endpoint is the incidence, the severity and the mortality associated with aki during covid-19 severe infection",observational,observational model: cohort|time perspective: retrospective
Evaluation of Novel Diagnostic Tests for COVID-19,COVIDx,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04326387,NCT04326387,samba covid-19 poc pcr test|patient acceptability|immune response positivity,observational,observational model: cohort|time perspective: prospective
Effects on the Qt Interval of COVID-19 Coronavirus Infection,QT-COVID-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04422535,NCT04422535,assessing the qt and qtc interval in patients admitted to intensive care units for covid-19 infection|incidence of arrhythmias and impact of the covi-drugs administered on qt interval,observational,observational model: cohort|time perspective: retrospective
Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.,NOSARSCOVID,withdrawn,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04290871,NCT04290871,sars-free patients at 14 days|survival at 28 days|survival at 90 days|sars-free days at 28 days|sars -free days at 90 days|renal replacement therapy|liver failure|mechanical support of circulation|pao2/fio2 ratio in ambient air,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, outcomes assessor)|primary purpose: treatment"
Recruit Blood Donors Via SMS During Epidemic of COVID-19 ÔºàRepeat TrialÔºâ,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04410458,NCT04410458,blood donation rate,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: health services research
COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB),AntiCoV-HB,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04416308,NCT04416308,"rate of presence of anti-sars-cov-2 antibodies (ig g _ ig m) among employees working in a ght haute bretagne health establishment.|a) validation of the biotech ng test:|a) validation of the biotech ng test: agreement between observers (kappa coefficient) for igg|a) validation of the biotech ng test: agreement between observers (kappa coefficient) for igm.|b) risk of presence of anti sars-cov-2 antibodies in function:|c) risk of presence of anti sars-cov-2 antibodies in function:|d) description of the experience and behavioral changes related to the epidemic,|e) evolution of seroprevalence over time:",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: diagnostic
The Psychological Impact of COVID-19 Outbreak on COVID-19 Survivors and Their Families,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04365348,NCT04365348,stress level|negative emotion|psychological response to trauma|severity of insomnia symptoms and the associated daytime impairment|resilience|quality of family functioning|social support|psychological effects,observational,observational model: cohort|time perspective: prospective
"Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic",nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04459455,NCT04459455,change in anxiety control questionnaire (acq) from baseline to immediately post-intervention|change in generalized anxiety disorder-7 (gad-7) from baseline to 2-week follow-up|change in activity social distancing intentions - 3 item version (soc-d) from baseline to immediately post-intervention|covid-19 related questions|inventory of depression and anxiety symptoms (idas)|self hate scale (shs)|comprehension questions|everyday discrimination scale-short version|perceived changes in generalized anxiety symptoms|activity hand washing intentions - 3 item version (wash-i),interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: treatment"
Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04337151,NCT04337151,titanium level,observational,observational model: case-control|time perspective: retrospective
Microbial Etiology of Ventilator-associated Pneumonia in COVID-19 Infected Patients,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04344509,NCT04344509,prevalence of the microorganisms responsible for vap among patients infected or not by the sars-cov-2|prevalence of multi-drug resistant bacteria responsible for vap among patients infected or not by the sars-cov-2,observational,observational model: case-control|time perspective: retrospective
Cyclosporine For The Treatment Of Covid-19(+),nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04492891,NCT04492891,who covid-19 clinical severity scale,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Delayed Colorectal Cancer Care During Coronavirus Disease (COVID-19) Pandemic (DECOR-19),DECOR-19,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04488549,NCT04488549,predictive power of respondents' and hospitals' demographics on delaying colorectal cancer care across 6 geographical regions,observational,observational model: other|time perspective: prospective
Prevalence and Outcomes of Olfactory and Gustatory Dysfunctions in Patients With COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04524754,NCT04524754,olfaction|gustation,observational,observational model: case-only|time perspective: retrospective
Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04341493,NCT04341493,mechanical ventilation requirement,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Clinical Characteristics of Critically Ill Patients With COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04413435,NCT04413435,polymerase chain reaction (pcr) test|a scoring system for patients to be admitted to the intensive care unit,observational,observational model: other|time perspective: retrospective
Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,nan,"active, not recruiting",No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04315480,NCT04315480,arrest in deterioration of pulmonary function|improving in pulmonary function|need of oro-tracheal intubation|death,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
A Gamified Network for Surgical Education During COVID-19: A Randomized Controlled Trial,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04425499,NCT04425499,retention of the correct technique for running subcuticular sutures|technical ability to perform a subcuticular suture|satisfaction with the gen platform,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: other
Recruit Blood Donors Via SMS During Epidemic of COVID-19 #Second Repeat Trial#,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04431180,NCT04431180,blood donation rate,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: health services research
Distance Learning for Dental Student During COVID-19 Pandemic,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04401371,NCT04401371,assessment of distance education learning environment experiences among dental students enrolled in pediatric dentistry online course during covid-19 crisis,observational,observational model: other|time perspective: cross-sectional
Changes in Out-patient Visits in Taiwan During the Time of Global COVID-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04497467,NCT04497467,the number of the out-patient visits,observational,observational model: cohort|time perspective: retrospective
Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04451239,NCT04451239,symptom improvement|signs improvement,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,COVID-SER,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04341142,NCT04341142,"the positivity (yes/no) of the serological test.|measurement of igm and igg antibody titer at each sampling of weekly and monthly visits of covid-19+ patients and implementation of the kinetics of mean appearance.|- among the symptomatic pcr negative patients recruited into the study at the first visit, the measurement of the igm antibody and igg titer will be performed in serum at d28, and the positive results will then constitute the false-negative pcr results.|- measurement of igm and igg antibody titer at each sampling of late patient visits.|- the neutralizing capacity of the antibodies will be determined by in vitro serum neutralization tests on seropositive serum. a group of 50 patients made up of seropositive and asymptomatic caregivers at the time of infection will represent this group.",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04417270,NCT04417270,comparison of values between two devices,interventional,allocation: non-randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: other
Clinical Characteristics and Prognostic Factors of Patients With COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04328454,NCT04328454,time to negative conversion of severe acute respiratory syndrome coronavirus 2|length of stay in hospital|survival|intubation,observational,observational model: cohort|time perspective: retrospective
Impact Nerium Oleander on Symptoms and Mortality: A Feasibility Study,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04486144,NCT04486144,covid19 symptoms|mortality|covid19 live virus|rt-pcr covid19 test,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Feasibility of a Brief Trauma-informed Yoga Intervention for Anxiety During the Coronavirus Disease (COVID-19) Pandemic,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04453514,NCT04453514,number of participants enrolled over 3 months|number of participants enrolled per week over 3 months|proportion of participants who enroll in the study over 3 months|proportion of participants who complete the study over 3 months|proportion of missing data over 3 months|proportion of participants who complete the 45-minute video over 3 months|mean change in state anxiety from immediately before to immediately after yoga using the state trait anxiety scale - 6 item short form|mean change in state mindfulness from immediately before to immediately after yoga using the state mindfulness scale (state mindfulness of mind subscale)|mean change in body awareness from immediately before to immediately after yoga using the state mindfulness scale (state mindfulness of body subscale),interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19,COVSurf,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04362059,NCT04362059,oxygenation improvement|pulmonary ventilation improvement|safety assessment of frequency and severity of adverse events,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Yoga in NHS Health Care Workers With COVID-19 Related Stress,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04481516,NCT04481516,alleviated stress 1 - short term|alleviated stress 2 - short term|alleviated stress 3 - short term|alleviated stress 1 - medium term|alleviated stress 2 - medium term|alleviated stress 3 - medium term,observational,observational model: cohort|time perspective: prospective
COVID-19: Laser Interferometry for Rapid Single Coronavirus Detection,COLIDE,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04401644,NCT04401644,kappa value|sensitivity and specificity,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
"Knowledge, Attitude and Practice of Gastrointestinal Endoscopists Toward PPE in COVID-19 Era",nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04479345,NCT04479345,the knowledge and attitude toward ppe during endoscopy,observational,observational model: cohort|time perspective: cross-sectional
Patient Preference Trial for COVID-19 (PPT-COVID),PPT-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04418193,NCT04418193,"number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.|number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.|clinical evolution on the world health organisation (who) ordinal scale for clinical improvement (osci) for covid-19 between day 0 and day 14|clinical evolution on the who ordinal scale for clinical improvement for covid-19 between day 0 and day 28.|number of all-cause mortality at day 14|number of all-cause mortality at day 28|rate of positive severe acute respiratory syndrome (sars)-coronavirus 2 (cov-2) reverse transcriptase (rt) - polymerase chain reaction (pcr) on nasopharyngeal samples at day 5|rate of positive sars-cov-2 rt-pcr on nasopharyngeal samples at day 10|the rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.|number of all-cause mortality at day 28 in patients aged 75 and older|clinical evolution on the who osci scale for covid-19 between day 0 and day 28 for patients aged 75 or older|rate of severe adverse events at day 28|number of all-cause mortality at day 14 in patients aged 75 and older",observational,observational model: cohort|time perspective: other
Impact of Cancellation of Non-urgent Surgical Cases on Patients During the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04433312,NCT04433312,quality of life of the patients,observational,observational model: other|time perspective: cross-sectional
A Clinical Study to Evaluate MW33 Injection,nan,"active, not recruiting",No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04533048,NCT04533048,adverse event|serious adverse event,interventional,"allocation: randomized|intervention model: sequential assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Impact of Spectacles on Compliance to Mask-wearing Directives,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04501172,NCT04501172,demographic characteristics|compliance to mask-wearing directives|questionnaire subscale: near vision|questionnaire subscale: distance vision|questionnaire subscale: ocular discomfort|questionnaire subscale: driving|questionnaire subscale: limitation|questionnaire subscale: collaboration|questionnaire subscale: need for help|questionnaire subscale: emotional impact|assessment of the relationship between the compliance to mask-wearing directives and the use of spectacles|assessment of the relationship between the compliance to mask-wearing directives and the other demographic characteristics|assessment of the relationship between the compliance to mask-wearing directives and the questionnaire items|assessment of the relationship between demographic characteristics and the 20 questionnaire items,observational,observational model: other|time perspective: prospective
Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04497519,NCT04497519,local tolerability|pharmacokinetic parameter,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Intranasal Heparin Tolerability Study,nan,not yet recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04490239,NCT04490239,"activated partial thromboplastin time (aptt), acute phase|activated partial thromboplastin time (aptt), chronic phase|platelet count, acute phase|platelet count, chronic phase|number of incidents of epistaxis, acute phase|number of incidents of epistaxis, chronic phase|other adverse effects, acute phase|other adverse effects, chronic phase",interventional,intervention model: sequential assignment|masking: none (open label)|primary purpose: prevention
Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04346589,NCT04346589,number of mechanical ventilation days.|survival|shift to continuous positive airway pressure (cpap) ventilation|referral to a sub-intensive care unit or discharge|viral titer|anti covid 19 igg antibodies|anti covid 19 igm antibodies|c5a concentration|c3a concentration|serum c5b-9 concentration,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Oncology Care Pathway's Modifications Impact During COVID-19 Pandemic : the ONCOCARE-COV Study,ONCOCARE-COV,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04445870,NCT04445870,data record,observational,observational model: other|time perspective: retrospective
Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial,BREATH,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04399798,NCT04399798,response to treatment: absence of moderate to severe oxygenation impairment (berlin criteria)|response to treatment: survival|to quantify the rate of each of: moderate or severe oxygenation impairment within 8 days|to quantify the rate of each of: moderate or severe oxygenation impairment within 15 days|mortality|peripheral capillary oxygen saturation (spo2)|partial pressure of oxygen/fraction inspired oxygen (pao2/fio2)|to assess the rate of patients admitted to the intensive care unit|to measure the length of hospital stay|28-day mortality|to quantify the rate of re-admission within 28 days|to quantify the cumulative incidence and severity of adverse events|interleukin (il)-1; il-2; il-10; il-6; il-8; il-17; il-2 receptor levels;|tnfalpha; vascular endothelial growth factor (vegf); interferon gamma (ifngamma) levels|viral load analyses,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Telematic Monitoring Through a Mobile Application of Patients With COVID-19,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04423289,NCT04423289,re-consultation|telephone calls,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04360850,NCT04360850,responses to the survey questions,observational,observational model: ecologic or community|time perspective: prospective
Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,nan,"active, not recruiting",No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04542226,NCT04542226,clinical status of the patient (according to 7-point ordinal scale)|clinical status of the patient (according to ordinal scale)|clinical status of the patient (according to news scale)|oxygen saturation|hospitlization duration|mortality|incidence of serious adverse events|incidence of adverse events|incidence of discontinuation of drug administration,observational,observational model: cohort|time perspective: prospective
COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,COMBATCOVID19,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04363437,NCT04363437,percentage of patients requiring supplemental oxygen beyond 8l nasal cannula|percentage of patients who will require mechanical ventillation|hospital length of stay|mortality|maximum crp|maximum troponin elevation,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Status of Management of Surgery in Beijing During COVID-19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04401124,NCT04401124,treatment of fevers at arrival|treatment of post-operative fevers|assorted surgical parameters|hospitals' protection measures and extent of implementation,observational,observational model: cohort|time perspective: retrospective
A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research,nan,recruiting,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04327804,NCT04327804,detection of sars-cov-2 virus|trajectory of covid-19 and antibody development,observational,observational model: case-only|time perspective: prospective
Change in the Ratio of Mean Platelet Volume (MPV) to Platellet(PLT) in Covid-19 Pneumonia Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04408378,NCT04408378,estimation of inflammatory changes in covid 19 pneumonia by using mvp/plt ratio,observational,observational model: case-control|time perspective: retrospective
The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver.,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04345640,NCT04345640,spontaneous recovery or death in both groups|severity of prior as well as present decompensation in both groups|duration of prior as well as present decompensation in both groups|improvement in severity assessment indices model for end stage liver disease (meld) scores in both groups|improvement in severity assessment indices child-turcotte-pugh (ctp) scores in both groups|improvement in severity assessment indices sequential organ failure assessment (sofa) scores in both groups|improvement in severity assessment indices acute physiology and chronic health evaluation (apache) scores ii in both groups|improvement in severity assessment indices chronic liver failure-sequential organ failure assessment (clif sofa) scores in both groups.,observational,observational model: cohort|time perspective: prospective
Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04372576,NCT04372576,28-day all-cause mortality|days of mechanical ventilation|icu length-of-stay|antibiotic utilization|ventilator-associated pneumonia rate,observational,observational model: cohort|time perspective: prospective
Evaluation of the Sleep Hygiene in the Lebanese Population During the COVID-19 Confinement Period.,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04372043,NCT04372043,sleep hygiene,observational,observational model: cohort|time perspective: prospective
Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04325906,NCT04325906,treatment failure|intubation rate|efficacy of pp,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04548934,NCT04548934,depth of chest compression|chest compression rate|relaxation,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: treatment
Endoscopy-related Phone Consultation During the COVID-19 Outbreak,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04344964,NCT04344964,failed to attend patients|patient satisfaction with the phone consult|consultant satisfaction with the phone consult,observational,observational model: case-control|time perspective: prospective
Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19),COVAL-NANCY,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04448769,NCT04448769,"anti-sars-cov-2 igt (igm/iga/igg) seropositivity|proportion of asymptomatic, symptomatic cases among seropositive people|proportion of asymptomatic cases among seropositive people|identification of risk groups - anti-sars-cov-2 igt seropositivity by age, sex and as a function of weight status, smoking status, work activity and social status.|proportion of seropositive subjects according to the level of social disadvantage measured by the epices score|proportion of infected households|anti-sars-cov-2 igt seropositivity in the household|clinical expression patterns of infection by symptom/antibody association|serological response to infection|anti-sars-cov-2 igt seropositivity|‚ä¢ evaluation of serum neutralisation of persons positive for anti-sars-cov-2 antibodies, of the infectivity of viral strains in cell culture: percentage neutralisation compared to a viral strain not exposed to seropositive serum.",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: screening
Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19,ZnCOVID-19,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04551339,NCT04551339,covid-19 illness requiring hospitalization|illness without hospitalization|supplemental oxygen therapy during hospitalization|invasive ventilation during hospitalization|mortality,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
Nutritional Follow up After Hospital Discharge for Coronavirus Disease-19,NutriCoviDom,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04451694,NCT04451694,nutritional evaluation|muscle strenght|food intake|biological nutritional status|anosmia,observational,observational model: cohort|time perspective: prospective
A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19,nan,recruiting,No Results Available,not applicable,Industry,https://ClinicalTrials.gov/show/NCT04524598,NCT04524598,change in depressive symptoms|change in anxiety symptoms|change in parent report of child depressive symptoms,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04340414,NCT04340414,paco2|driving pressure|tidal volume,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Renin Angiotensin System - CoronaVirus,SRA-COV,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04337008,NCT04337008,overactivity of the renin / aldosterone system,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: diagnostic
An Observational Study of Patients With Coronavirus Disease 2019,COVID-19,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04331886,NCT04331886,natural history of covid-19: characteristics of covid-19|natural history of covid-19: participant demographics|natural history of covid-19: treatment use|time point of clinical response,observational,observational model: cohort|time perspective: other
Validity of at Home Visual Acuity Measurements for Telemedicine During Corona Virus (COVID-19) Pandemic,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04391166,NCT04391166,best corrected visual acuity (bcva) per eye,observational,observational model: cohort|time perspective: prospective
Status and Predictors of Mental Health Symptoms Among Migrants and Refugees During the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04443764,NCT04443764,patient health questionnaire 9|generalized anxiety disorder 7|health anxiety symptoms,observational,observational model: other|time perspective: prospective
Efficacy and Safety of IFN-Œ±2Œ≤ in the Treatment of Novel Coronavirus Patients,nan,not yet recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04293887,NCT04293887,the incidence of side effects|time from patient enrollment to clinical remission|proportion of patients with normal body|proportion of patients without dyspnea|proportion of patients without cough|proportion|the negative conversion rate of new coronavirus nucleic acid|frequency of serious adverse drug events.,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
One Year Follow-ups of Patients Admitted to Spanish Intensive Care Units Due to COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04457505,NCT04457505,one year mortality|six month mortality,observational,observational model: cohort|time perspective: prospective
"The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19",COVRehab,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04505761,NCT04505761,semi-structured interview with 15 patients on their experiences of vr for rehabilitation from covid-19.|use of vr|semi-structured interviews with physiotherapists on their experiences of vr for rehabilitation from covid-19.|change in baseline performance test (guidelines kngf) - patient specific complaints.|change in baseline performance test (guidelines kngf) - 6 minute walk test|change in baseline performance test (guidelines kngf) - one-repetition maximum test|change in baseline performance test (guidelines kngf) - 30 sec sit to stand|change in baseline performance test (guidelines kngf) - borgscale for fatigue|change in activities of daily life.|change in hads.|change in cfq.|change in sf12.|change in positive health.,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04384965,NCT04384965,proportion achieving remission on hamilton rating scale for depresion 24-it (hrsd-24)|change in hrsd-24|response on hrsd-24|remission on patient health questionnaire (phq-9)|response on phq-9|change in phq-9|remission on general anxiety disorder 7 item (gad-7)|response on gad-7|change in gad-7|remission on beck depression inventory (bdi-ii)|response on bdi-ii|change on bdi-ii|remission on beck scale for suicidal ideation (ssi)|change on ssi|change in who disability assessment schedule (whodas)|proportion of patients maintaining response during relapse prevention,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Evaluation of Staff COVID-19 Wellbeing Centres in a Healthcare Workplace: COVID-WELL Study,COVID-WELL,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04410016,NCT04410016,"warwick-edinburgh mental wellbeing scale|single item measure of global job stressfulness (houdmont et al, 2019)|single item global job satisfaction measure (dolbier et al, 2005)|single item measure of presenteeism (aronsson & gustafsson, 2004)|single item measure of turnover intentions (ryan et al, 2017)|work engagement (shaufeli et al, 2006)",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
"Pilot Study of a Brief, Scaleable Intervention for Coronavirus (COVID-19) Mental Health Sequelae in College Students",nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04558411,NCT04558411,distress|emotion regulation|distress (within-person change)|maintenance of improvement in emotion regulation,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Using Caring Contacts to Reduce Psychiatric Morbidity Following Hospitalization During the COVID-19 Pandemic,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04456062,NCT04456062,hopkins symptom checklist-25 (hscl-25),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: health services research
Quality of Life and Patient-centered Outcomes After Hospitalization for COVID-19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04376658,NCT04376658,"one-year utility score of health-related quality of life|incidence of all-cause mortality|incidence of rehospitalizations|percentage of return to work or study|score of instrumental activities of daily living|score of dyspnea|percentage of long-term ventilatory support need|symptoms of anxiety and depression|symptoms of posttraumatic stress disorder|utility score of health-related quality of life at 3, 6, and 9 months|score of self-rated health",observational,observational model: cohort|time perspective: prospective
Sarilumab COVID-19,nan,completed,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04327388,NCT04327388,"time to improvement of 2 points in clinical status assessment from baseline using the 7-point ordinal scale|percent of patients alive at day 29|proportion of patients with one point improvement from baseline in clinical status assessment at days 4, 7, 15, 21, 29 using the 7-point ordinal scale|mean change in the 7-point ordinal scale from baseline to days 4, 7, 15, 21, and 29 (or until discharge)|time to resolution of fever|time to resolution of fever and improvement in oxygenation|days with fever|time to change in news2 from baseline|time to news2 of <2 and maintained for 24 hours|mean change from baseline to days 4, 7, 15, 21, and 29 in news2|time-to-improvement in oxygenation|alive off supplemental oxygen at day 29|days of hypoxemia|days of supplemental oxygen use|days of resting respiratory rate >24 breaths/min|time to saturation ‚â•94% on room air|ventilator free days in the first 28 days (to day 29)|the number of patients with initiation of mechanical ventilation, non-invasive ventilation, or use of high flow nasal cannula|proportion of patients requiring rescue medication during the 28-day period|the number of patients transferred to the icu or the need to transfer to the icu (if the icu is not available)|days of hospitalization among survivors|incidence of serious adverse events|the incidence of major or opportunistic bacterial or fungal infections|the incidence of major or opportunistic bacterial or fungal infections in patients with grade 4 neutropenia|the incidence of hypersensitivity reactions, infusion reactions, gastrointestinal perforation|the number of patients with clinically significant laboratory abnormalities",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease,HYCOVID,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04325893,NCT04325893,"number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.|number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.|clinical evolution on the who ordinal scale for clinical improvement for covid-19 between day 0 and day 14|clinical evolution on the who ordinal scale for clinical improvement for covid-19 between day 0 and day 28.|number of all-cause mortality at day 14|number of all-cause mortality at day 28|rate of positive sars-cov-2 rt-pcr on nasopharyngeal samples at day 5|rate of positive sars-cov-2 rt-pcr on nasopharyngeal samples at day 10|the rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.|number of all-cause mortality at day 28 in patients aged 75 and older|clinical evolution on the who osci scale for covid-19 between day 0 and day 28 for patients aged 75 or older|rate of severe adverse events at day 28|number of all-cause mortality at day 14 in patients aged 75 and older",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Accelerated LFR for Bipolar Patients During the COVID-19 Pandemic,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04427137,NCT04427137,proportion achieving remission on hamilton rating scale for depresion 24-it (hrsd-24)|change in hamilton rating scale for depresion 24-it (hrsd-24)|response on hamilton rating scale for depresion 24-it (hrsd-24)|change in young mania rating scale (ymrs)|remission on patient health questionnaire (phq-9)|response on patient health questionnaire (phq-9)|change in patient health questionnaire (phq-9)|remission on general anxiety disorder 7 item (gad-7)|response on general anxiety disorder 7 item (gad-7)|change in general anxiety disorder 7 item (gad-7)|remission on beck depression inventory (bdi-ii)|response on beck depression inventory (bdi-ii)|change on beck depression inventory (bdi-ii)|remission on beck scale for suicidal ideation (ssi)|change on beck scale for suicidal ideation (ssi)|change in who disability assessment schedule (whodas) range 0-38|proportion of patients maintaining response during relapse prevention,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia,New,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04343664,NCT04343664,depression|anxiety symptoms|stress related problems|behavior and emotional problem among children and adolescents,observational,observational model: ecologic or community|time perspective: cross-sectional
Evaluation of the Fluid Response of SARS-CoV-2 (COVID-19) Patients in Intensive Care; Pleth Variability Index,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04373213,NCT04373213,pleth variability index,observational,observational model: case-control|time perspective: retrospective
Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients,nan,recruiting,No Results Available,phase 1|phase 2,Other|NIH|Industry,https://ClinicalTrials.gov/show/NCT04379518,NCT04379518,incidence of adverse events (aes)|kinetics of viral load in nasopharyngeal swabs|kinetics of viral load in the peripheral blood and nasopharyngeal swabs|kinetics of changes of the immune subsets and circulating inflammatory mediators in peripheral blood|30-day mortality|hospitalization due to infection|determine known mediators of antiviral immunity,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19.,SAMILCOV,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04550390,NCT04550390,qualitative result of molecular tests for the sars-cov-2 virus.,observational,observational model: cohort|time perspective: prospective
Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04341714,NCT04341714,efficiency of the telephone consultation|satisfaction of the telephone consultation,observational,observational model: cohort|time perspective: prospective
Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04326725,NCT04326725,protection against covid-19,observational,observational model: case-control|time perspective: prospective
Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals,nan,completed,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04321369,NCT04321369,accuracy of patient administered tests,observational,observational model: case-only|time perspective: retrospective
Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04468893,NCT04468893,decrease in the score of anxiety symptoms|change in the symptoms of depression|change in the symptoms of general anxiety disorder|change in the score of posttraumatic stress symptoms|changes in the widespread fear scale|change in the score of the pittsburgh sleep quality index.|change on the suicidal thoughts scale,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
"Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff",VINCI,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04538469,NCT04538469,duration of delirium|incidence of delirium|length of critical care stay|length of hospital stay|doses of specified drugs during icu admission|length of time ventilated|mortality,observational,observational model: cohort|time perspective: retrospective
Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,PredictCovidT,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04369456,NCT04369456,predictive value of il-6 contents of whole blood samples after ex vivo stimulation,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,REP-COVID,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04374539,NCT04374539,impact of plasma exchange,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04403009,NCT04403009,lymphocyte cell|d-dimer|plt|crp|ldh|ck|pt|alt|ast|nk cell|pct|il-6|the clinical difference of radiologic characteristics between the fatal patients with covid -19 and the non fatal cases,observational,observational model: cohort|time perspective: cross-sectional
Home-based Aerobic Training Among Adolescents With Chronic Diseases During COVID-19 Pandemic,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04458246,NCT04458246,safety and efficacy of a home-based exercise training program|patients perceptions during social isolation|adolescents quality of life|disease activity|disease overall assessment|strengths and difficulties,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04251871,NCT04251871,the incidents of acute respiratory distress syndrome (ards) development|the time to fever resolution rate|time to recovery of lung injury,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
PTSD Symptoms Among Health Workers and Public Service Providers After the COVID-19 Outbreak: A 3 Month Follow up,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04442243,NCT04442243,ptsd checklist for dsm-5 (pcl-5)|patient health questionnaire 9 (phq-9)|generalized anxiety disorder 7 (gad-7)|the warwick-edinburgh mental wellbeing scale (wemwbs),observational,observational model: other|time perspective: prospective
Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04292340,NCT04292340,"the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1|the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|numbers of participants with different clinical outcomes|number of participants with treatment-related adverse events as assessed by ctcae v5.0",observational,observational model: case-only|time perspective: prospective
Feasibility of Online Based Mindfulness Interventions During COVID-19 Outbreak,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04346082,NCT04346082,"rate of recruitment|rate of attendence|depression, anxiety and stress scale (dass-21)|sense of coherence scale",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04326114,NCT04326114,covid-19 disease diagnosis|covid-19 disease symptoms severity|adverse effects,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
Clinical and Psycho-social Impact of COVID-19 Related Confinement on Patients With Digestive Tumors,COVIDICA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04389684,NCT04389684,overall survival of patients with metastatic colorectal cancer or metastatic pancreatic cancer,observational,observational model: cohort|time perspective: prospective
Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers,COVID-BCG,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04384549,NCT04384549,"incidence of documented covid-19 among health care workers exposed to sars cov2 and vaccinated with bcg compared to placebo.|numbers of covid-19 patients requiring hospitalization in icu and o2, artificial ventilation or extracorporal membrane oxygenation, or deaths in bcg-vaccinated health care workers compared to placebo|incidence of asymptomatic sars cov2 seropositive subjects among bcg-vaccinated health care workers compared to placebo.|incidence of subjects with any respiratory infection among bcg-vaccinated health care workers compared to placebo.|numbers of sick days and numbers of sick leaves among bcg-vaccinated health care workers compared to placebo.|numbers of subjects with bcg-related advers events among bcg-vaccinated health care workers compared to placebo.|numbers and intensity of changes in innate immune markers after sars cov2 infection among bcg-vaccinated health care workers compared to placebo.",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
Screening Patients for a Strategic Shift to Pulmonary Telerehabilitation Because of COVID-19,PRAISE@COVID,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04388579,NCT04388579,patient's self-efficacy|respiratory exercises|physical activity,observational,observational model: cohort|time perspective: cross-sectional
Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04441424,NCT04441424,death versus survival of treated patients|the length of stay in hospitals,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04389333,NCT04389333,maneuverability score|gastric examination time(get)|the comfort and acceptability of patients|diagnostic yield,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
A Novel School-clinic-community Online Model of Child Obesity Treatment in Singapore During COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04395430,NCT04395430,intensity of intervention|change in cardiorespiratory fitness|change in quality of life|change in bmi|change in self-esteem|change in eating behaviour|change in gross motor skills|change in caloric intake|change in physical activity|change in blood pressure|change in waist circumference|change in servings of fruits and vegetables,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
A Study on the Prospective Cohort Library of COVID-19 in Southeran,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04342702,NCT04342702,36-item short form survey instrument (sf-36)|the value of fev1 by lung function test|the ratio of fev1 to fvc by lung function test|the predicted value of fev1 by lung function test|the predicted ratio of fev1 to fvc by lung function test|lymphocyte value|neutrophil value|ddi value|the proportion of applying aceis/arbs medication|number of clinical symptoms after hospital discharge|number of cases returning to positive result in rt-pcr test|number of positive outcome of igg for antibody of covid-19,observational,observational model: cohort|time perspective: prospective
Issues and Challenges in Cancer Patients on Active Treatment During the COVID-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04406844,NCT04406844,oncology patients,observational,observational model: cohort|time perspective: cross-sectional
"Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04371315,NCT04371315,characteristics and outcomes of acute respiratory infections due to covid-19 in children.|clinical risk factors of acute respiratory infection due to covid-19 in children.|immunologic response to acute respiratory infection due to covid-19 in children.|duration of viral shedding and evolution in children longitudinally.,observational,observational model: other|time perspective: prospective
Prosocial Behavior Can Safeguard Mental Health and Foster Emotional Well-being During the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04517006,NCT04517006,change in happiness from baseline using the subjective happiness scale|change in valued life assessment from baseline using 4-item scale|change in depression from baseline using the cesd (8-item)|change in anxiety from baseline using the hads-a,interventional,allocation: randomized|intervention model: factorial assignment|masking: none (open label)|primary purpose: supportive care
The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19,OCAT,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04367636,NCT04367636,"changes in depression-, anxiety- and psychosomatic stress symptoms|changes in rumination.|changes in cognitive emotion regulation strategies.|changes in emotional attention",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: supportive care
A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04394013,NCT04394013,loneliness (ucla-8 loneliness scale)|mindfulness (ffmq)|quality of life (eq-5d-5l questionnaire),interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: supportive care"
Characterization of Reverse Triggering and Other Asynchronies in COVID-19 Patients Under Invasive Mechanical Ventilation,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04448782,NCT04448782,incidence and pattern of presentation of reverse triggering in covid-19 patients under invasive mechanical ventilation|incidence of reverse triggering related to the level of sedation in covid-19 patients under invasive mechanical ventilation|reverse triggering and secondary asynchronies in covid-19 patients under invasive mechanical ventilation|incidence and pattern of presentation of asynchronies in covid-19 patients under invasive mechanical ventilation|influence of asynchronies in different outcomes in in covid-19 patients under invasive mechanical ventilation,observational,observational model: cohort|time perspective: prospective
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),Coalition-I,"active, not recruiting",No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04322123,NCT04322123,evaluation of the clinical status|ordinal scale in 7 days|need of intubation and mechanical ventilation|use of mechanical ventilation during hospital stay|use of non-invasive ventilation|hospital length of stay|all-cause mortality|thromboembolic complications|acute renal disfunction|number of days alive and free of respiratory support up to 15 days,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients,COVID-DEX,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04358627,NCT04358627,mechanical ventilation|duration of mechanical ventilation|delirium on recovery from sedation,observational,observational model: case-control|time perspective: prospective
Difficulties in Emotion-regulation and Interpersonal Problems During and After the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04442282,NCT04442282,patient health questionnaire 9 (phq-9)|the generalized anxiety disorder - 7|difficulties in emotion regulation scale|interpersonal problems,observational,observational model: other|time perspective: prospective
Factors Associated With Adherence to Hygiene-related Behaviors and Viral Mitigation Protocols During the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04442217,NCT04442217,adherence to who-advised hygiene-related|adherence to viral mitigation protocols,observational,observational model: other|time perspective: prospective
"Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04381819,NCT04381819,death|recovery from covid-19|progression to icu care or ventilation|clearance of sars-cov-2 from respiratory specimen|immune response to covid-19,observational,observational model: cohort|time perspective: prospective
Information Sources and Their Relationship to Depressive and Anxiety Symptoms During the COVID-19 Pandemic: A Network Study,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04444336,NCT04444336,the patient health questionnaire 9|generalized anxiety disorder 7,observational,observational model: other|time perspective: cross-sectional
Healthcare Renunciation During the Confinement Period in Connection With the COVID-19 Epidemic in Adult Emergency Departments,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04460196,NCT04460196,rate of patients who gave up consulting in the emergency department,observational,observational model: cohort|time perspective: prospective
Video-Based Exercise for Individuals With Social Isolation Due to Coronavirus (COVID-19),nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04346953,NCT04346953,international physical activity questionnaire - short form|nottingham health profile|beck depression inventory|beck anxiety inventory|pittsburgh sleep quality index|timed get up and go test|flamingo balance test,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
Impact in the Medical Care Among the Rheumatic Diseases Patients in a Tertiary Hospital in M√©xico During the COVID-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04557358,NCT04557358,change in the pattern of the usual medical care among the rheumatic disease patients|change in the patient's activity disease|change in the patient's activity disease measures by their rheumatologist|change in patient¬¥s quality of life|change in patient¬¥s depression and anxiety|change in patient¬¥s posttraumatic stress,observational,observational model: cohort|time perspective: prospective
Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients,CORIMUNO-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04324047,NCT04324047,survival|who progression scale covid 19,observational,observational model: cohort|time perspective: prospective
Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19),nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04516837,NCT04516837,complete response|response|no response|relapses|early response|initial response|durable response|tor (time to response)|dor (duration of response)|treatments associated adverse events|reduction in bleeding symptoms,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Upper Limb Robotic Rehabilitation During COVID-19 Outbreak,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04392453,NCT04392453,system usability scale (sus)|technology acceptance model (tam)|likert scale|fugl-meyer assessment for upper extremity (fma-ue)|motricity index for the upper extremity (mi-ue)|modified ashworth scale (mas)|numeric pain rating scale (nprs)|modified barthel index (mbi)|montreal cognitive assessment (moca)|kinematic parameters,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Breastfeeding Education in the Time of COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04519216,NCT04519216,change in practice patterns|self efficacy|satisfaction with simulation,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: other
Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.,I-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04315870,NCT04315870,maternal and perinatal outcomes,observational,observational model: cohort|time perspective: other
Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic,ASPIRE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04388605,NCT04388605,"prevalence of sars-cov-2 infection throughout pregnancy in women|incidence of sars-cov-2 infection throughout pregnancy in women|risk ratios of adverse obstetric in women infect with sars-cov-2 during early pregnancy onward compared to non-infected pregnant women|risk ratios of adverse neonatal outcomes in women infected with sars-cov-2 during early pregnancy onward compared to non-infected pregnant women|clinical, behavioral, and sociodemographic determinants",observational,observational model: cohort|time perspective: prospective
Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04445324,NCT04445324,assessment of patients' current status : recovery (personal recovery)|assessment of patients' current status : citizenship (personal recovery)|assessment of patients' current status : covid-19 stress scales|assessment of patients' current status : anxiety (clinical recovery)|assessment of patients' current status : depression (clinical recovery)|assessment of patients' current status : alcohol dependence (clinical recovery)|assessment of patients' current status : drug dependence (clinical recovery)|assessment of patients' current status : psychosis (clinical recovery)|assessment of patients' current status : social functioning (clinical recovery),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (care provider, investigator)|primary purpose: supportive care"
Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04443868,NCT04443868,to measure the efficacy of nors compared to saline placebo in the hospitalization of participants with mild covid-19 infection|to measure reduction of clinical symptoms as compared to saline placebo in participants with mild covid-19 infection|to measure the tolerance of nors compared to saline placebo in participants with mild covid-19 infection,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Psychological Impact of the Corona Virus (SARS-CoV-2) and COVID-19 Pandemic in Individuals With Psychiatric Disorders,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04410835,NCT04410835,"global symptom load (anxiety, somatisation, depression, global symptom index)|depressive symptoms|sleep disorders and sleep quality|life style changes|food craving|covid-19 associated fears and emotional responses to the pandemic",observational,observational model: cohort|time perspective: prospective
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants,ENSEMBLE,not yet recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04505722,NCT04505722,"number of participants with first occurrence of molecularly confirmed moderate to severe/critical coronavirus disease (covid-19) with seronegative status|number of participants with first occurrence of molecularly confirmed moderate to severe/critical covid-19 regardless of their serostatus|number of participants with first occurrence of molecularly confirmed moderate to severe/critical coronavirus disease covid-19 with seronegative status|number of participants with first occurrence of covid-19 requiring medical intervention|sars-cov-2 viral load as assessed by quantitative reverse-transcriptase polymerase chain reaction (rt-pcr) in participants with molecularly confirmed, moderate to severe/critical covid-19|number of participants with first occurrence of molecularly confirmed mild covid-19|number of participants with first occurrence of molecularly confirmed covid-19 defined by the us food and drug administration (fda) harmonized case definition|number of participants with first occurrence of molecularly confirmed covid-19 with any severity (moderate, mild, severe/critical)|serologic conversion between baseline and 1- year post-vaccination using an enzyme-linked immunosorbent assay (elisa)|number of participants with serious adverse events (saes)|number of participants with medically-attended adverse events (maaes)|number of participants with medically-attended adverse events (maaes) leading to study discontinuation|number of participants with solicited local adverse events (aes) during 7 days after vaccination|number of participants with solicited systemic aes during 7 days after vaccination|number of participants with unsolicited local adverse events (aes) during 28 days post-vaccination|sars-cov-2 neutralizing antibody titers as assessed by virus neutralization assay (vna)|sars-cov-2 binding antibodies assessed by elisa",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04469621,NCT04469621,"relative change from baseline in crp level|time to 50% decrease from baseline in crp level|time to improvement of oxygenation|change from baseline in spo2/fio2 ratio|number of days without need for oxygen support and alive|numbers of ventilator-free days and alive|change from baseline in markers of inflammation: white blood cell count and differential blood lymphocytes|change from baseline in marker of inflammation: neutrophil to lymphocyte ratio|change from baseline in marker of inflammation: interleukin 6 (il-6)|change from baseline in d-dimer|incidence of deaths|percentage of participants receiving thrombolytic treatment|percentage of participants receiving vasopressor treatment|incidence of serious adverse events (saes), adverse events of special interest (aesi) and treatment-emergent adverse events (teaes) leading to treatment discontinuation|incidence of teaes leading to study discontinuation (primary reason)",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Predicting the Progression to Chronic Fibrosis of Lung Lesions Related to Covid-19 Infection From Chest CT Images,PREDISCAN,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04483752,NCT04483752,"description of the different types of lesions|quantification of circulating antibodies and correlation between the level of immunization against sars cov2, the severity of the initial disease and the existence or not of long-term pulmonary sequelae",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04488796,NCT04488796,change in sedentary behaviour break frequency|change in sedentary behaviour break duration|change in work-related quality of life|change in health outcomes|change in sitting time|change in standing time|change in moving time|change in prolonged sitting bouts|change in percentage of time spent sitting|change in percentage of time spent standing|change in percentage of time spent moving|change in sedentary break frequency|change in sedentary break duration,interventional,allocation: randomized|intervention model: factorial assignment|masking: none (open label)|primary purpose: prevention
Stress Biomarkers Leading to Professional Burnout Among People Involved in a Mobile Intensive Care Unit During the COVID-19 Pandemic,AUTONOMIC,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04365335,NCT04365335,professional burnout|mindfulness level|perceived stress level following the emotional stimulation|parasympathetic flexibility evolution during emotional recall|sympathetic tone at rest|corticotropic activation at rest|mood disorders (anxiety / depression)|post-traumatic stress disorder|sleep quality,observational,observational model: cohort|time perspective: prospective
A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During COVID-19,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04548544,NCT04548544,change in emotional problems,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: basic science
The Validity of Modern Mobile Applications in Management of COVID-19 Home Isolation Patients: a Survey for Health Care Professionals,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04548492,NCT04548492,rate of reassurance delivered from doctors to patients through whatsapp,observational,observational model: case-crossover|time perspective: prospective
Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04530136,NCT04530136,disease severity on the 7-point who ordinal scale|clinical improvement|invasive or non-invasive ventilation|acute lung injury,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (investigator)|primary purpose: treatment
Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04351906,NCT04351906,delta change in arterial partial pressure of carbon dioxide during ecco2r treatment|change in vasopressor use during ecco2r|assessment of changes in tidal volume during ecco2r|assessment of changes in ph during ecco2r|assessment of changes in positive end-expiratory pressure during ecco2r|number of participants with adverse events directly related to ecco2r|rate of technical adverse events related to ecco2r|delta change in venous partial pressure of carbon dioxide before and after ecco2r membrane,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,NOCOVID,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04337918,NCT04337918,prevention study: measure the effect of nors on the prevention of covid-19 infection among health care professionals at risk of exposure to covid-19|treatment sub study: measure the efficacy of nors at reducing the progression of covid- 19|prevention study: measure the effect of nors on the prevention of progression of covid- 19|prevention study: measure the tolerability of nors treatments|treatment sub study: measure the virucidal effect of nors treatments|treatment sub study: determine effect of nors on the speed of clinical recovery|treatment sub study: determine the reduction in clinical symptoms|treatment & sub study: determine positive sero-conversion for sars-cov-2,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
COMPASS Study: an Online Cognitive-behavioural Therapy (CBT) Program Treating Anxiety and Low Mood in Long-term Conditions During the COVID-19 Pandemic,COMPASS,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04535778,NCT04535778,"change in patient health questionnaire anxiety and depression scale (phq-ads)|change in work and social adjustment scale (wsas)|change in eq-5d-3l|change in illness perception questionnaire - revised (ipq-r), emotional subscale",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,GARM-COVID19,enrolling by invitation,No Results Available,early phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04326036,NCT04326036,incidence of treatment-emergent adverse events|pulmonary function analysis|digital oximetry,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Covid-19 Pandemic and Pancreatic Surgery in Italy,PanCOVID,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04380766,NCT04380766,changes in pancreatic cancer management during the covid-19 pandemic,observational,observational model: case-control|time perspective: prospective
Influence of the COVId-19 Pandemic on the STRESS of Dental Surgeons (COVISTRESS - Dental Surgery),nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04541472,NCT04541472,stress measures|sociodemographic characteristics|occupation perception|work conditions|changes in practices,observational,observational model: cohort|time perspective: cross-sectional
Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19,COVID19_LLC-MW,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04391946,NCT04391946,prognostic factors for healing of covid-19 infection|medical care of coronavirus infection|national epidemiological monitoring,observational,observational model: cohort|time perspective: prospective
Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04460014,NCT04460014,number of intrusive memories of traumatic event(s)|intrusion questionnaire - frequency item|intrusion questionnaire - characteristics|impact of event scale - revised (ies-r): degree of subjective distress of post-trauma intrusion and avoidance symptoms|posttraumatic stress disorder checklist 5 (pcl-5) short version|characteristics of intrusive trauma memories,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents,NH-Shingrix,not yet recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04523246,NCT04523246,evidenced of active and trained innate immunity|respiratory disease severity (6 month),interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: basic science"
Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19),nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04377672,NCT04377672,safety of treatment with high-titer anti-sars-cov-2 plasma as assessed by adverse events|proportion of subjects with disease worsening event|pharmacokinetics of anti-sars-cov-2 antibodies as defined by changes in antibody titers|proportion of subjects with a natural antibody response to sars-cov-2 infection,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Study of Resilience and Loneliness in Youth (18 - 25 Years Old) During the COVID-19 Pandemic Lock-down Measures.,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04371250,NCT04371250,self-rated measure of resilience|self-rated measure of loneliness,observational,observational model: cohort|time perspective: prospective
Convalescent Antibodies Infusion in COVID 19 Patients,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04418531,NCT04418531,"time to weaning of oxygen support|chest xr or ct scan evaluation|survival,|viral titer|anti covid 19 igg antibodies|anti covid 19 igm antibodies|c5a concentration|c3a concentration|serum c5b-9 concentration marker of complement activation|serum il-6 levels|serum il-1b levels|serum ifnœ≥ levels|serum mcp-1 levels|serum tnfœ± levels|serum il-10 levels|serum il-2 levels|serum il-7 levels",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,nan,"active, not recruiting",No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04346693,NCT04346693,the change of viral load in patients with sars-covid-19.|the frequency of development of acute respiratory distress syndrome (adrs)|duration of hospitalization|the frequency of early mortality|the frequency of late mortality|clinical status at the time of completion of participation in the study,interventional,allocation: randomized|intervention model: factorial assignment|masking: none (open label)|primary purpose: treatment
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),nan,completed,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04321278,NCT04321278,"evaluation of the clinical status|all-cause mortality|number of days free from mechanical ventilation|duration of mechanical ventilation|duration of hospitalization|other secondary infections|time from treatment start to death|medium and long-term outcomes of sars-cov2 infection on morbimortality, daily life activities, mental health, and quality of life|assess whether the tested therapies may be affected by leucocyte phenotype",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Different Susceptibility to SARS CoV-2 Infection Among Health Care Workers Highly Exposed to COVID-19.,CoVEX,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04402827,NCT04402827,susceptibility to sars cov-2 infection according to ace2 receptor|cellular immune response to sars cov-2 infection|susceptibility to infections according to kir phenoytpes|characteristics of exposure in time and intensity of hcw with sars cov-2 infection|cellular immune response in hcw with positive igg against sars cov-2,observational,observational model: case-control|time perspective: prospective
ASC Therapy for Patients With Severe Respiratory COVID-19,ASC COVID-19,withdrawn,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04341610,NCT04341610,changes in clinical critical treatment index|days of respirator treatment|improvement of clinical symptoms including duration of fever and respiratory need|mortality|marker of immunological function -cd4+ and cd8+ t cell count|c-reactive protein and leucocyte|cytokine profile|glomerular filtration rate|duration of hospitalization,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,ProPAC-COVID,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04322396,NCT04322396,"number of days alive and discharged from hospital within 14 days|categorization of hospitalization status|admitted to intensive care unit, if admitted to icu then length of stay|have used non-invasive ventilation (niv) during hospitalization|mortality|length of hospitalization|days alive and discharged from hospital|number of readmissions (all causes)|number of days using non-invasive ventilation (niv)|change in patient's oxygen partial pressure|change in patient's carbondioxid partial pressure|level of ph in blood|time for no oxygen supplement (or regular oxygen supplement ""ltot"")",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine,nan,recruiting,No Results Available,phase 2,NIH,https://ClinicalTrials.gov/show/NCT04025580,NCT04025580,microneutralization titers,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: basic science
"Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers",BURDENCOV,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04341519,NCT04341519,ptsd family members sup 22|ptsd family members|ptsd patients|ptsd healthcare providers|hads family members|hads patients|sf36 patients|questionnaire family members|questionnaire patients|questionnaire healthcare providers|mbi healthcare providers|karasec instrument healthcare providers,observational,observational model: cohort|time perspective: prospective
Increasing Physical Activity in Canadian Adults Who Have Been Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention,COVID-19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04400305,NCT04400305,"recruitment rate (monthly)|participant retention|participant intervention satisfaction/evaluation|change in self-reported physical activity from baseline to 6 weeks|change in physical activity beliefs, attitudes, barriers, and motivation from baseline to 6 weeks.|change in physical activity behaviour regulation from baseline to 6 weeks.|change in physical activity habits from baseline to 6 weeks|change in physical activity identity from baseline to 6 weeks|change in quality of life measured using the short form 12 questionnaire",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: other
Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04274322,NCT04274322,28-day all cause mortality|all cause infection|the rate of complications|length of icu stay|duration of mechanical ventilation,observational,observational model: cohort|time perspective: prospective
To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04412239,NCT04412239,"efficiency of the telephone consultation,|patient satisfaction|adherence rate",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Efficacy of Therapist Guided e-Therapy Versus Self-Help Therapy on Psychological Distress Among Individuals in Oman During COVID-19 Pandemic,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04378257,NCT04378257,change in depressive symptoms measured by patient health questionnaire-9|change in anxiety symptoms measured by generalized anxiety disorder-7|proportion of subjects with significant depression|proportion of subjects with significant anxiety,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,CORIMUNO-SARI,"active, not recruiting",No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04324073,NCT04324073,survival without needs of ventilator utilization at day 14.|who progression scale <=5 at day 4|cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14|who progression scale at day 4|who progression scale|survival|28-day ventilator free-days|respiratory acidosis at day 4|pao2/fio2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to icu discharge|time to hospital discharge,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),nan,recruiting,No Results Available,phase 3,Other|Industry,https://ClinicalTrials.gov/show/NCT04344041,NCT04344041,"number of death of any cause, during the 14 days following the inclusion and intervention.|number of death of any cause, during the 28 days following the inclusion and intervention.|clinical evolution between day 0 and day 14 based on the change of the who ordinal scale for clinical improvement (osci) for covid-19|clinical evolution between day 0 and day 28 based on the change of the osci for covid-19|rate of patients with at least one severe adverse event at day 28, according to the regulations|number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis d (25-ohd <25nmol/l) at baseline|number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis d (25-ohd <25nmol/l) at baseline|clinical evolution between day 0 and day 14 based on the change of the osci for covid-19, in patients with severe hypovitaminosis d (25-ohd <25nmol/l) at baseline|clinical evolution between day 0 and day 28 based on the change of the osci for covid-19, in patients with severe hypovitaminosis d (25-ohd<25nmol/l) at baseline|number of death of any cause during the 14 days following the inclusion and intervention, depending on serum vitamin d concentration achieved at day 7 (25-ohd<75nmol/l or 25-ohd‚â•75nmol/l)|number of death of any cause during the 28 days following the inclusion and intervention, depending on serum vitamin d concentration achieved at day 7 (25-ohd<75nmol/l or 25-ohd‚â•75nmol/l)|clinical evolution between day 0 and day 14 based on the change of the osci for covid-19, depending on serum vitamin d concentration achieved at day 7 (25-ohd<75nmol/l or 25-ohd‚â•75nmol/l)|clinical evolution between day 0 and day 28 based on the change of the osci for covid-19, depending on serum vitamin d concentration achieved at day 7 (25-ohd<75nmol/l or 25-ohd‚â•75nmol/l)|number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis d (25-ohd<25nmol/l) at day 0, depending on serum vitamin d concentration achieved at day 7 (<75nmol/l or ‚â•75nmol/l)|number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis d (25-ohd<25nmol/l) at day 0, depending on serum vitamin d concentration achieved at day 7 (<75nmol/l or ‚â•75nmol/l)|clinical evolution between day 0 and day 14 based on the change of the osci for covid-19, in patients with severe hypovitaminosis d (25-ohd<25nmol/l) at day 0, depending on serum vitamin d concentration achieved at day 7 (<75nmol/l or ‚â•75nmol/l)|clinical evolution between day 0 and day 28 based on the change of the osci for covid-19, in patients with severe hypovitaminosis d (25-ohd<25nmol/l) at day 0, depending on serum vitamin d concentration achieved at day 7 (<75nmol/l or ‚â•75nmol/l)|number of death of any cause during the 14 days following the inclusion and intervention, depending on evolution of serum vitamin d concentration between day 0 and day 7|number of death of any cause during the 28 days following the inclusion and intervention, depending on evolution of serum vitamin d concentration between day 0 and day 7|clinical evolution between day 0 and day 14 based on the change of the osci for covid-19, depending on evolution of serum vitamin d concentration between day 0 and day 7|clinical evolution between day 0 and day 28 based on the change of the osci for covid-19, depending on evolution of serum vitamin d concentration between day 0 and day 7|number of death of any cause during the 14 days following the inclusion and intervention, compared to mortality data in french hospital geriatric units from the current national survey by the french society of geriatrics and gerontology",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19,nan,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04535700,NCT04535700,"patients treated with pioglitazone, together with conventional treatment for covid-19 infection, who during their admission evolve towards the need to receive support with mechanical ventilation, enter the icu and / or die.|incidence of pioglitazone treatment-emergent adverse events in patients with dm2 and symptomatic sars-cov-2 infection.|biomarker analysis: systemic inflammation parameters during the administration of pioglitazone treatment.",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults",nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04515147,NCT04515147,number of participants with solicited local adverse events|intensity of solicited local adverse events per the fda toxicity grading scale|duration of solicited local adverse events|number of participants with solicited systemic adverse events|intensity of solicited systemic adverse events per the fda toxicity grading scale|duration of solicited systemic adverse events|number of participants with solicited systemic adverse events considered related to trial vaccine|number of participants with unsolicited adverse events|intensity of unsolicited adverse events per the fda toxicity grading scale|number of participants with unsolicited adverse events considered related to trial vaccine|number of participants with one or more serious adverse events (saes)|number of participants with one or more serious adverse events (saes) considered related to trial vaccine|number of participants with one or more adverse events of special interest (aesis)|number of participants with one or more adverse events of special interest (aesis) considered related to trial vaccine|number of participants seroconverting for sars-cov-2 spike protein antibodies|individual sars-cov-2 spike protein-specific antibody levels in serum|geometric mean titers (gmts) of serum sars-cov-2 spike protein antibodies|number of participants seroconverting for sars-cov-2 neutralizing antibodies|individual sars-cov-2 neutralizing antibody levels in serum|geometric mean titers (gmts) of serum sars-cov-2 neutralizing antibodies,interventional,"allocation: randomized|intervention model: sequential assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: prevention"
Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic,nan,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04559074,NCT04559074,reductions in blood pressure in participants with primary hypertension and inadequate bp control by up-titration of amlodipine in 1-2 mg increments.|mean change in daily dbp|difference between mean changes of blood pressure|collect data on tolerability / side effects,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19,RECOVER,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04470544,NCT04470544,change in the proportion of patients alive and free from respiratory failure|change in the proportion of patients alive and free of ventilator use or ecmo|mortality rate|clinical change|adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia,COP-COVID-19,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04358783,NCT04358783,early all-cause mortality|time in days for sars-cov-2 rt-pcr negatives|the serum anti-sars-cov-2 antibody titres|detection of serum antibodies,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
"Tele-Wellness Supported App for Family Child Care Home Providers and Families to Promote Health, Family Engagement, and School Readiness Amid COVID-19",nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04453657,NCT04453657,"change in perceived level of stress as assessed by the perceived stress scale|change in perceived level of informational support as assessed by the promis informational support short form|change in awareness of the maryland early childhood family engagement framework and toolkit as assessed by a survey question|change in social, emotional, and behavior functioning in children as assessed by the social competence and behavior evaluation for children|change in quality of the parent-child care relationship as assessed by the supportive parent-caregiver relationship subscale",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects,nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04480957,NCT04480957,"incidence, severity and dose-relationship of aes|geometric mean titre for sars-cov-2-specific serum neutralizing antibody|mean titre for sars-cov-2-specific serum neutralizing antibody levels|geometric mean fold rise in titre for sars-cov-2-spike protein specific neutralizing antibody levels",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Sparing in Neuromuscular Blockade in COVID 19 ICU,TOF-COVID,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04459533,NCT04459533,nmb agents consumption,observational,observational model: case-control|time perspective: retrospective
Physical Activity Level in Patients With OSAS During Covid-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04451993,NCT04451993,physical activity|sleep quality|daytime sleepiness|fear of movement|health literacy,observational,observational model: case-control|time perspective: prospective
An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic,nan,available,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04395508,NCT04395508,nan,expanded access:treatment ind/protocol,nan
Somerset and South Essex Coronavirus Antigen Testing,SOCRATES,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04403906,NCT04403906,to compare the result of sars-cov2 pcr test to pcl rapid antigen test|number of technically failed samples due to test issues.|time taken for pcl antigen test result,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
"Outpatient Clinic in Obesity Care During COVID-19 Outbreak: Physically Far, Virtually Near",nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407663,NCT04407663,evaluation of feasibility of telemedicine in outpatient visit in bariatric patients,observational,observational model: cohort|time perspective: retrospective
Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19,ECMO-COVID-19,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04343404,NCT04343404,retrospective description of covid-19 patients receiving respiratory ecmo-vv supplementation and what happens to them,observational,observational model: case-only|time perspective: retrospective
Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure,QUANTICO-RETRO,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04534400,NCT04534400,correlation between altered pulmonary volume and ordinal severity scale,observational,observational model: cohort|time perspective: retrospective
European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO,EuroECMO-COVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04366921,NCT04366921,age|gender|weight|height|bmi|pre-existing pulmonary disease y/n|main co-morbidities y/n|date of signs of covid-19 infection|date of positive swab|pre-ecmo length of hospital stay|pre-ecmo length of icu stay|pre-ecmo length of mechanical ventilation days|use of antibiotics|use of anti-viral treatment|use of second line treatment|indications for ecmo-implant|type of ecmo-implant|type of access|date of ecmo implant|ecmo blood flow rate|ecmo gas flow rate|ecmo configuration change|date of ecmo configuration change|new ecmo configuration|indications for ecmo configuration change|ventilator setting on ecmo|anticoagulation during ecmo|frequency of ecmo circuit change|ecmo complications|ecmo weaning|icu discharge|main cause of death|type of discharge|alive/deceased,observational,observational model: cohort|time perspective: prospective
Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East,OMC-KTR,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04542954,NCT04542954,patient outcome|kidney graft outcome|risk factors for getting covid19 infection,observational,observational model: cohort|time perspective: other
Effect of Covid-19 Epidemic on Primary PCI in Patients With STEMI,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04427735,NCT04427735,mace (major adverse cardiovascular events)|all-cause death,observational,observational model: case-crossover|time perspective: cross-sectional
Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection,ALI,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04526912,NCT04526912,"the proportion of patients who achieve treatment success through day 28, defined as avoidance of death and critical illness|number of participants with treatment-emergent adverse events (teaes), treatment-emergent fatal and life-threatening saes, treatment-emergent serious adverse events|change in safety laboratory parameters",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
The COVID-19 Pandemic and Exercise Study,COPE,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04400279,NCT04400279,"changes in depressive symptomology over the course of the exercise intervention|changes in psychological stress as measured by the scsq over the course of the exercise intervention.|changes in psychological distress as measured by the k10 over the course of the exercise intervention.|changes in flourishing over the course of the exercise intervention|changes in resilience over the course of the exercise intervention|changes in life satisfaction over the course of the exercise intervention|changes in weekly strain as a result of health problems, financial/work issues, and relationship trouble using the chronic burden scale over the course of the exercise intervention.|changes in general affect over the course of the exercise intervention|changes in leisure time physical activity over the course of the exercise intervention|changes in physical health symptomology over the course of the exercise intervention|changes in alcohol habits over the course of the exercise intervention|tracking the amount of exercise variety participants feel they engage in",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: prevention"
Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19,nan,available,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04352985,NCT04352985,nan,expanded access:intermediate-size population,nan
PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine,nan,recruiting,No Results Available,phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04353037,NCT04353037,sub study 1: patients|sub study 2: health care workers|sub study 1: patients: rate of secondary infection of co-inhabitants|sub study 1: patients: adverse events|sub study 1: patients: negative for covid-19|sub study 2:health care workers:number of shifts missed|sub study 2:health care workers:rate of adverse events|sub study 2:health care workers:rate of hospitalization,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: treatment"
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19),SequelaeCov,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04435327,NCT04435327,"reduction of diffusion of lung co (dlco, single breath technique)|alterations in 6 minute walking test (6mwt)|alterations of pletismography|alterations of arterial blood gas analysis|abnormal dyspnea score|presence and extension of abnormal pulmonary lung sounds at auscultation|presence and extension of radiological alterations at chest x-ray|presence and extension of radiological alterations at chest ct scan",observational,observational model: cohort|time perspective: prospective
Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04519385,NCT04519385,proportion of participants with overall survival at 14 days|fio2/pao2,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: treatment"
Extracellular Water in Covid 19 Pneumonia,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04416009,NCT04416009,ecw,observational,observational model: cohort|time perspective: prospective
Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease,ColchiVID,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04367168,NCT04367168,"number of patients with improvement in body temperature, myalgia, arthralgia, total lymphocyte count, d-dimer, fibrinogen and ferritin levels|progression to severe disease",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Immunity and Infections in the Psychiatric Population,COVIDIMMUNOPSY,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04381845,NCT04381845,number of covid-positive patients,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19),nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04320056,NCT04320056,the number of interventions|duration of interventions|mean oxygen flow|time within thespo2 target|time with hypoxemia|time with hyperoxemia|rate of icu admission|rate of needed non invasive respiratory support|rate of intubation|news 2 score evolution|ewso2 score evolution|cost-effectiveness|length of stay,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients,CACOVID-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04397575,NCT04397575,"number of cases of sars-cov-2 infection and mortality rate directly related to the infection in patients being followed for digestive, thoracic, head and neck, gynecologic, cerebral, urologic or cutaneous cancer|number of cases of sars-cov-2 infection|percentage of severe and fatal forms.of cases of sars-cov-2 infection|social characteristics of individuals on treatment|link between socio-territorial determinants and the characteristics/severity of sars-cov-2 infection.",observational,observational model: cohort|time perspective: prospective
Innovative Tool to Limit Spread of SARS-CoV-2 in Residential Aged Care Facilities,nan,terminated,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04377165,NCT04377165,"to compare the hours of sick leave used over the course of the 4-week period post randomisation for each group|to compare handwashing behaviour|to compare self-testing rates|to compare the level of surface wipe down|to compare number of covid-19 tests completed in facilities|to compare the number of covid 19 infections in facilities|to compare the other types of outbreaks (flu, gastroenteritis)|to compare the awareness of covid 19 training available to workers in the facilities|to compare the awareness of ppe training available to workers in the facilities|to compare the levels of ppe material used in|to compare the wellbeing and self-efficacy of the two groups",interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: prevention
HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04336748,NCT04336748,symptomatic or asymptomatic sars-cov-2 infection confirmed by pcr|viral load during sars-cov-2 infection|seroconversion during the study period|incidence of any acute respiratory infection|days of sick leave,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus,nan,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04260594,NCT04260594,virus negative conversion rate in the first week|virus negative conversion rate|antipyretic rate|symptom relief time|finger oxygen improvement rate|disease progression rate|mortality rate|incidence of severe adverse reactions|change curve of peripheral blood lymphocyte count,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
SARS-CoV-2 (COVID-19) and Surgery,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04368026,NCT04368026,descriptive data on perceptions of current status of surgical wards during the pandemic and impact of the pandemic on conducting surgery.,observational,observational model: other|time perspective: cross-sectional
Postpartum Depression in the Covid-19 Pandemic and the Impact of Anaesthesia,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04437342,NCT04437342,"correlation between the covid-19 pandemic and postpartum depression with epds scale (edinburgh postnatal depression scale)|correlation between the covid-19 pandemic, postpartum depression and type of anaesthesia (general, epidural, spinal, combined, epidural analgesia for vaginal delivery)|correlation between the covid-19 pandemic, postpartum depression and postpartum pain",observational,observational model: other|time perspective: prospective
Impact of Giving Birth During the Covid 19 Pandemia on Postnatal Women's Depression,DEPRECOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04368208,NCT04368208,report postnatal depression between 4 of 6 weeks during the covid 19 pandemia|report factors associated with postnatal depression between 4 of 6 weeks during the covid 19 pandemia|describe the experience and the satisfaction about delivery during the covid 19 pandemia,observational,observational model: cohort|time perspective: prospective
Clinical Characteristics and Outcomes of Pediatric COVID-19,PERN-COVID-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04330261,NCT04330261,clinical characteristics of children with sars-cov-2|factors associated with severe covid-19 outcomes|health care resource utilization for covid-19 patient management|sensitivity and specificity of covid-19 case screening policies,observational,observational model: cohort|time perspective: prospective
COVID19 and Physical and Emotional Wellbeing of HCP,CoPE-HCP,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04433260,NCT04433260,"presence of anxiety at baseline|presence of depression at baseline|proportion of those who report a combined outcome of presence of anxiety or depression at the baseline as determined by screening questionnaires used.|change in proportion of who report a combined outcome of either presence of anxiety or depression from baseline to the end of study|change in the proportion of those who report signs and symptoms or evidence consistent with probable diagnosis of covid-19 from baseline to the end of study|change in prevalence of anxiety from baseline|change in prevalence of depression from baseline|prevalence of sleep-related issues at baseline|change in prevalence of sleep-related issues from baseline|prevalence of a combined outcome of presence of anyone of anxiety, depression or sleep related issues at baseline.|proportion of those with low mental wellbeing at baseline|change in proportion of those with low mental wellbeing from baseline to the end of study.|prevalence of those who report concern related to work-place practices.|change in the prevalence from baseline of those who report concern related to work-place practices.|change in behavioural habits, such as smoking and alcohol intake from baseline to the end of study|proportion of those who report signs and symptoms or evidence consistent with probable diagnosis of covid-19",observational,observational model: cohort|time perspective: cross-sectional
Virtual Pain Care Management (COVID-19),VCPM,not yet recruiting,No Results Available,not applicable,U.S. Fed,https://ClinicalTrials.gov/show/NCT04539821,NCT04539821,the percent of patients who agree to buprenorphine transfer|percent of complete tapering or bup transition,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04383717,NCT04383717,covid 19 induced fever in both groups|covid 19 induced dyspnea in both groups|covid 19 viral load in both groups|laboratory clearance in both groups: crp in mg/dl,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04435353,NCT04435353,recovery respiratory fail,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Covid-19 Epidemic on Acute Stroke Management,Stroke-Covid19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04370197,NCT04370197,study of the effect of pandemic covid-19 on the management of stroke patients,observational,observational model: case-only|time perspective: other
Thrombosis Risk Assessment and Clinical Presentation of Covid-19 Pneumonia,Covid-19,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04423315,NCT04423315,length of hospital stay,observational,observational model: cohort|time perspective: retrospective
Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,nan,recruiting,No Results Available,not applicable,Industry|Other,https://ClinicalTrials.gov/show/NCT04517422,NCT04517422,"severity progression of covid-19|stay at icu|mortality ratio|lung abnormalities|viral load|levels of immunoglobulins|gastrointestinal manifestations, where 0 means good health status and 5 worse status|fecal microbiome|adverse events|change on serum biomarkers",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: other"
Assessment of Endothelial and Haemostatic Changes During Severe SARS-CoV-2 Infection,Covid-Thelium,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04357847,NCT04357847,association of intercellular adhesion molecule-1 plasma level with 28 days mortality|association of endothelin-1 plasma level with 28 days mortality|association of vascular endothelial growth factor a plasma level with 28 days mortality|association of soluble vascular endothelial growth factor receptor type 1 with 28 days mortality|association of syndecan -1 plasma level with 28 days mortality|association of d-dimers plasma levels with thrombotic events|association of von willebrandt factor with thrombotic events|association of viscoelastic testing with thrombotic events,observational,observational model: cohort|time perspective: prospective
The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04338672,NCT04338672,rates of emergency visits needing surgical consult|the ratio of severe presentations to non-severe presentations|the impact of age on ed attendance rates|differences in ed surgical visits (in terms of capacity and severity) of surgical patients depending on the presentation and the co morbidity,observational,observational model: cohort|time perspective: retrospective
Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04367350,NCT04367350,rate of elevated creatine kinase in hyperacute phase|rate of elevated creatine kinase|rate of two-peak elevation of creatine kinase during acute phase|rate of myositis-specific antibodies|rate of antimyocardial antibodies|area under the curve (auc) of elevated creatine kinase|peak-levels of elevated creatine kinase|peak-levels of troponin|peak-levels of urine myoglobin|rate of muscle hyperechogenicity|peak-muscle hyperechogenicity,observational,observational model: cohort|time perspective: prospective
A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic,nan,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04341922,NCT04341922,‚ä¢ covid-19-adapted version of the self-rated generalized anxiety disorder scale-7 (gad-7)|montgomery √ösberg depression rating scale - self report (madrs-s)|adapted covid-19 version of the work and social adjustment scale (wsas)|insomnia severity index (isi)|adapted swedish version of the coronavirus health impact survey (crisis)|intolerance of uncertainty scale (ius)|patient satisfaction questionnaire (psq)|adverse events (ae),interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: treatment
"Observational Study in Diagnosed Patients COVID-19, Supported on an Outpatient Basis. (COVID-PSL)",COVID-PSL,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04402905,NCT04402905,covid-psl cohort,observational,observational model: cohort|time perspective: retrospective
PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic,PREPARE IBD,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04410484,NCT04410484,flare of ibd needing change in therapy or surgery,observational,observational model: case-control|time perspective: retrospective
Short-term Outcome of Covid-19 Surgical Patients: Case-series of a High-risk Area Community Hospital,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04430062,NCT04430062,mortality,observational,observational model: case-only|time perspective: retrospective
Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19),nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04334434,NCT04334434,physical activity scale for the elderly|nottingham health profile|loneliness scale for the elderly,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,IVERCAR,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04425850,NCT04425850,reduction in contagion|secondary and or side effects,observational,observational model: cohort|time perspective: prospective
ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection,nan,enrolling by invitation,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04326426,NCT04326426,time to improvement on a 7-point ordinal scale as compared to baseline|treatment and prevention of inflammatory lung injury as measured by change in baseline of interleukin-6 (il-6)|rate of decline of covid-19 viral load assessed by rt-pcr from nasopharyngeal samples|in-hospital mortality|mean change in news2 score from baseline|understand the effect of genetics for treatment response through whole genome sequence of the participant and the covid-19 virus|reduction from baseline of nrs for cough|reduction from baseline of nrs for nausea|time to normalization of fever for at least 48 hours|time to improvement in oxygenation for at least 48 hours,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,SAVIORII,recruiting,No Results Available,not applicable,Other|Industry,https://ClinicalTrials.gov/show/NCT04382391,NCT04382391,change in initiation of mechanical ventilation in patients with covid-19 compared to the control group.|evaluate cytokine trends|evaluate supplemental oxygen requirements|decrease mortality of covid-19 patients|delay onset of ventilation,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs,COVIDRIC,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04530682,NCT04530682,"seroprevalence of covid-19 in patients with inflammatory rheumatisms|clinical expression of covid-19 compared to health professionals : phenotypes, thrombo-embolic events and stress repercussion",observational,observational model: cohort|time perspective: prospective
A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19,IFORS,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04431466,NCT04431466,time to undetectable sars-cov-2 viral load in the nasopharyngeal swab.|viral load variation in the nasopharyngeal swab.|proportion of patients with undetectable sars-cov-2 viral load in the nasopharyngeal swab.|proportion of patients with clinical improvement.,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
PREdiction of DIagnosed Covid-19 infecTion in IUC Patients,PREDICT,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04327180,NCT04327180,"correlation between nasal and deep pcr positivity for covid-19 patients performed and all predictors for covid-19 patients performed within 24 hours of admission to icu|coinfections|respiratory dysfunction requiring mechanical ventilation|sequential organ failure assessment (sofa) score|saps ii score|disseminated intravascular coagulation (dic) score|number of days on vasopressive amines|occurrence of an event of venous or arterial thromboembolic disease|number of days with extra renal treatment (era)|number of patients alive after icu stay less than 28 days will be tracked|short form 36|hospital anxiety and depression scale (hads)|impact of event scale - revised (ies-r)|post-traumatic stress disorder checklist version dsm-5 (psl-5)|modified medical research council (mmrc) dyspnea scale|correlation between number of patient deaths and all predictors for covid-19 including anamnestic, clinical, biological, radiological parameters|viral clearance",observational,observational model: cohort|time perspective: prospective
Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04479280,NCT04479280,clot rate formation,observational,observational model: case-control|time perspective: prospective
Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?,HEROs,enrolling by invitation,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04374942,NCT04374942,microbiologically confirmed covid-19 (sars-cov-2 infection)|adverse events|symptom duration of covid-19|days of hospitalization attributable to covid-19|respiratory failure requiring ventilatory support attributable to covid-19|mortality|impact on work eligibility|seropositivity|short-term psychological impact,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Health Care Use During the Covid19 Crisis,US3R,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04372030,NCT04372030,health care use|postponed heath care use|foregone health care use,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
Primary Angioplasty for STEMI During COVID-19 Pandemic (ISACS-STEMI COVID-19) Registry,ISACS-STEMI,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04412655,NCT04412655,number of patients undergoing primary angioplasty|number of patients undergoing primary angioplasty later than 12 hours from symptoms onset;|number of patients undergoing primary angioplasty later than 30 minutes from pci hospital admission|in-hospital mortality,observational,observational model: cohort|time perspective: retrospective
Epigenetic Tools as Prognostic Predictors in Covid19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04411563,NCT04411563,determination of the relationship between the severity of disease and epigenetic factors in covid 19,observational,observational model: cohort|time perspective: prospective
Incidence of Covid-19 in School Children,COVIDECOLE,withdrawn,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04377737,NCT04377737,evaluation of the prevalence of positive real-time-polymerase chain reaction (rt-pcr) in school children during the pandemic period in nice|evaluation of the serological prevalence of the covid-19 infection|evaluation of the covid-19 reinfection among seropositive children at the inclusion time|evaluation of the prevalence of positive rt-pcr of other respiratory viruses (including others coronavirus)|comparison of inflammatory response level between different coronavirus strains|estimation of medico-social risk factors associated with covid-19 infection,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Evaluation of Newborns Presenting With Suspected COVID 19,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04519307,NCT04519307,general characteristics of the infants with respiratory infection at the nicu admission,observational,observational model: case-control|time perspective: prospective
COVID-19 Prevalence in HIV-infected Patients,SeCoVIHA,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04515225,NCT04515225,seroprevalence of sars-cov-2,observational,observational model: cohort|time perspective: prospective
Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04412551,NCT04412551,identification of requirement of mechanical ventilation|prediction of requirement of mechanical ventilation|association of lus to clinical parameters|description of findings on lus,observational,observational model: cohort|time perspective: prospective
COVID-19 Pandemic Response Network,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04320862,NCT04320862,number of participants who experience inpatient admission|number of participants admitted to the intensive care unit|number of participants requiring mechanical ventilation|number of deceased participants,observational,observational model: cohort|time perspective: prospective
Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19,nan,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04385186,NCT04385186,mortality reduction in covid-19 patients treated with inactivated convalescent plasma + support treatment|clinical evolution|clinical evolution by seven-parameter ordinal scale|multi-organ failure progression|change in hemoglobin concentration|change in blood cell count|change in serum creatinine level|change in aspartate aminotransferase level|change in alanin aminotransferase level|change in bilirubin level|change in lactate dehydrogenase level|change in creatine kinase level|change in creatine kinase mb level|change in c reactive protein concentration|change in d dimer concentration|change in procalcitonin concentration|change in il6 level|radiography imaging|tomography imaging|assessment of oxygenation|viral load|antibody titer|oxygen-free days through day 60|mechanical ventilation-free days through day 28|intensive care unit (icu)-free days through day 28|hospital-free days through day 60,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (investigator)|primary purpose: treatment
Covid-19 and Diabetes in West of Algeria,COVIDIAB-13,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04412746,NCT04412746,prevalence of diabetes among all hospitalized covid-19|diabetes-related factors risk,observational,observational model: cohort|time perspective: prospective
Presence of SARS-CoV-2 in Semen: Impact on Fertility Preservation in Male Oncological Patients ?,FERTICOVID,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04487639,NCT04487639,detection of sars-cov-2 in sperm during fertility preservation procedures by rt-qpcr|to correlate the presence of sars-cov-2 in the seminal fluid and the spermatozoa fractions of the same ejaculate|to determine if the presence of this virus in sperm is associated with its presence in nasal swabs|to determine if the presence of this virus in sperm is associated with covid symptoms|to determine if the presence of this virus in sperm is associated with specific serological profiles|to determine if the presence of this virus in sperm is associated with particular oncological pathologies/treatments|to determine if the presence of this virus in sperm could impair its quality,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Impact of Covid-19 on Egyptian Health Care Workers and General Population Mental Health,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04344834,NCT04344834,depression|anxiety|obsessive compulsive disorder,observational,observational model: ecologic or community|time perspective: cross-sectional
Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial,Cov-EMERALD,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04455360,NCT04455360,"feasibility of recruitment, intervention adherence, incidence of treatment related adverse events and trial completion to final assessment timepoints|post-traumatic stress disorder|anxiety and depression|cognitive function|health related quality of life|health and disability|physical activity|nutritional status",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04345549,NCT04345549,time to achieve afebrile|severity of influenza symptom score,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Prone Positioning and Regional Ventilation in Mechanically Ventilated COVID-19 Patients,COVID-19_EIT,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04359407,NCT04359407,tidal electrical impedance|intrapulmonary shunt|volumetric capnography,observational,observational model: case-only|time perspective: prospective
Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients,COCARDE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04358952,NCT04358952,left ventricular function|inflammatory biological parameters,observational,observational model: other|time perspective: prospective
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection,NoCovid,withdrawn,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04290858,NCT04290858,reduction in the incidence of intubation and mechanical ventilation|mortality|negative conversion of covid-19 rt-pcr from upper respiratory tract|time to clinical recovery,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Evaluation of ARFC Masks Equipped With CF5 Filter in the Care Unit to Allow a Wider Distribution of FFP2 Masks (Covid-19).,Masq-Aute,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04427176,NCT04427176,"evaluate the feasibility of the use of an arfc mask by nursing staff, in terms of tolerance|evaluate the feasibility of the use of an arfc mask by nursing staff, in terms of compatibility with technical gestures.|assess the acceptability of the wearing of an arfc mask by nursing staff|to assess the minor complications of wearing the arfc mask .",observational,observational model: other|time perspective: prospective
Coping With 2020 - No Health Without Mental Health,Co_Coping,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04421612,NCT04421612,the patient health questionnaire|the generalized anxiety disorder scale|positive and negative affect|perceived stress scale|client satisfaction scale,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
"Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic",MUCONFIN,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04463628,NCT04463628,"cancellation or postponement of consultations by the health professional or patient,|patient cancellation of teleconsultations/telecare replacement,|cancellation or postponement by the health care institution or by the patient of hospitalizations (scheduled or unscheduled),|change in the modalities of administration of antibiotics cures (oral instead of intravenous administration).|the reduction of each of the elements of care provision and health care utilization:|the change of modality of administration of antibiotic cures|compliance|anxiety and stress (at risk of being affected by covid-19 or at risk of being treated less well)|presence or absence of toxic consumption (drug, alcohol) during the lockdown|evaluation of the knowledge, experience and social representations of the risk of covid-19|assessing the role of social inequalities in the consequences of lockdown|suspected and/or confirmed covid-19 in patients with cystic fibrosis.",observational,observational model: cohort|time perspective: prospective
COVID-19 and SARS-CoV-2 Detection in Saliva,nan,enrolling by invitation,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04517682,NCT04517682,detection of covid-19 sars-cov-2 in saliva samples versus nasopharyngeal samples,observational,observational model: cohort|time perspective: prospective
COVID-19 and Diabetes Outcomes,CORONADO,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04324736,NCT04324736,assess the prevalence of severe forms among hospitalized patients with diab√®tes and covid-19|describe the clinical and biological characteristics of hospitalized subjects with diabetes and covid-19|describe the prognosis of hospitalized subjects with diabetes and covid-19|describe the care management of hospitalized subjects with diabetes and covid-19,observational,observational model: cohort|time perspective: retrospective
Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19,PsyCovid_App,completed,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04393818,NCT04393818,"depression, anxiety and stress|post-traumatic stress syndrome|insomnia|self efficacy",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, outcomes assessor)|primary purpose: supportive care"
Covid-19 and Vitamin D in Nursing-home,COVIT-EHPAD,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04435119,NCT04435119,"number of deaths of any cause in nursing-home residents with sars-cov-2 infection, depending on the use of bolus vitamin d3 supplementation during or just before covid-19|clinical severity score of covid19 in nursing-home residents with sars-cov-2 infection, depending on the use of bolus vitamin d3 supplementation during or just before covid-19",observational,observational model: cohort|time perspective: retrospective
Covid-19 Triage Using Camera-based AI,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04383457,NCT04383457,agreement between the new camera based method and reference standard to estimate body temperature|agreement between the new camera based method and reference standard to estimate heart rate|agreement between the new camera based method and reference standard to estimate blood oxygen saturation|agreement between the new camera based method and reference standard to estimate systolic blood pressure|agreement between the new camera based method and reference standard to estimate diastolic blood pressure|agreement between the new camera based method and reference standard to estimate respiratory rate|prediction of hospital admission using vital signs estimated using reference standard methods|prediction of death using vital signs estimated using reference standard methods|prediction of hospital admission using vital signs estimated using the new camera based method|prediction of death using vital signs estimated using the new camera based method|prediction of hospital admission using raw camera data|prediction of death using raw camera data,observational,observational model: cohort|time perspective: prospective
Feasibility of a Telematics Pre-operative Assessment in a Bariatric Surgery During Covid-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04486417,NCT04486417,rejection rate (%)|drop out rate|excess weight loss percentage (ewl%)|satisfaction degree,observational,observational model: other|time perspective: prospective
Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder in Covid-19 Outbreak,CLIECO,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04416360,NCT04416360,interview of the parents : contextual data|interview of the children/adolescents/ parents : experience of the confinement in general|interview of the referring caregiver : data relating to disease and management of care,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 (COVID19) Cases,MYOCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04375748,NCT04375748,evolution of the proportion of positive sars-cov-2 cases.|ultrasound characteristics.|assess prognosis of the acute myocarditis .|the factors associated with acute myocarditis cases .|biological characteristics|describe at the admission and during the treatment cardiac mri parameters,observational,observational model: cohort|time perspective: prospective
Nursing Perspective on Burnout and Medical Errors in the Intensive Care Unit During Covid-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04371302,NCT04371302,"prevalence of burnout among icu nurses during covid-19|prevalence of depression among icu nurses during covid-19|prevalence of self-perceived medical errors among icu nurses during covid-19|association of burnout, depression and medical errors among anaesthesiology clinicians during covid-19",observational,observational model: cohort|time perspective: cross-sectional
Asymptomatic COVID-19 Infection Among Healthcare Workers,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04354792,NCT04354792,number of igg seropositive health care workers|differentiation between low risk and high risk hcws,observational,observational model: cohort|time perspective: cross-sectional
"Epidemiological Study of the Covid-19 Presto Test - The ""COVIDOR"" Study",COVIDOR,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04387968,NCT04387968,"study the prevalence of covid-19 infection, coronavirus (sars coronavirus-2) in territorial agents in the 3 structures : cctvl, loire valley region centre, orleans metropolitan city|determine if there is a relationship between the profession carried out by the agents of the territorial community of orleans metropolitan city, the loire valley region, the cctvl and contamination by covid-19",observational,observational model: ecologic or community|time perspective: prospective
NK Cells Treatment for COVID-19,nan,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04280224,NCT04280224,"improvement of clinical symptoms including duration of fever|improvement of clinical symptoms including respiratory frequency|number of participants with treatment-related adverse events evaluated with ctcae,version 4.0|time of virus nucleic acid test negative|cd4+ and cd8+ t cell count|rate of mortality within 28-days|size of lesion area by thoracic imaging",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Eculizumab (Soliris) in Covid-19 Infected Patients,SOLID-C19,available,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04288713,NCT04288713,nan,expanded access:individual patients|treatment ind/protocol,nan
COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus,NOSO-COR,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04290780,NCT04290780,nosocomial infection,observational,observational model: cohort|time perspective: prospective
Effectiveness of a Novel Respirator With Chitosan Nanoparticles,nan,not yet recruiting,No Results Available,not applicable,Other|Industry,https://ClinicalTrials.gov/show/NCT04490200,NCT04490200,incidence of laboratory-confirmed covid-19|ability of the filtering element to inactivate the sars-cov-2|usability and comfort of the respirator|adherence to the use of the respirator|stress|burnout|self-reported quality of life|musculoskeletal discomfort|work ability,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, outcomes assessor)|primary purpose: prevention"
Exploring Interventions for Glue Ear During Covid-19,BIG-C,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04427631,NCT04427631,"acceptability of management strategy, questionnaire|quality of life questionnaire omq-14",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04388826,NCT04388826,proportion of subjects that are alive without respiratory failure at day 29.|who clinical improvement|normalization of fever and oxygen|discharge from hospital|patients alive and free of respiratory failure,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Antimalarial and Covid 19 in Rheumatoid Arthritis,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04389320,NCT04389320,immunoglobulin mesurement,observational,observational model: cohort|time perspective: cross-sectional
Biomarkers for Identification of COVID-19 Infection,B-DT-COV2,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04322513,NCT04322513,"biomarkers expression|liver biomarkers expression|biomarkers expression (micrornas, oxidative stress, neuron-specific enolase, il-2, il-6, tnf-alfa, leukocytes, subtypes lymphocytes) after treatment",observational,observational model: case-control|time perspective: prospective
Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients,COVIDSOT,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04319172,NCT04319172,incidence of coronavirus infection in solid organ transplant recipients|clinical manifestations of coronavirus infection in solid organ transplant recipients|presence of other risk factors|establish the frequency and type of complications related to the net state of the patient immunosuppression|frequency of co-infections|mortality|laboratory characteristics|determination of coronavirus viral load|microbiological testing,observational,observational model: cohort|time perspective: prospective
"COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor",COVID-BioB,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04318366,NCT04318366,"characterize patients with sars-cov-2 infection and to create a biobank to identify predictors of disease severity, mortality and treatment response",observational,observational model: cohort|time perspective: prospective
Pharmacy Education During Covid-19 Outbreak,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04409951,NCT04409951,impact of covid-19 on pharmacy education study in egypt,observational,observational model: case-crossover|time perspective: cross-sectional
Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19),nan,withdrawn,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04374474,NCT04374474,change from baseline snap and sniff threshold test at 3 months|change from baseline smell identification test (sit) at 3 months|change from baseline snap and sniff threshold test at 6 months|change from baseline smell identification test (sit) at 6 months|change from baseline qod-ns at 3 months|change from baseline sf-36 health survey at 3 months|change from baseline qod-ns at 6 months|change from baseline sf-36 health survey at 6 months|adherence to the study protocol|recovery,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Knowledge About Covid-19 Infection in Pregnant Women,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04423692,NCT04423692,the number of pregnant women who have knowledge about covid-19,observational,observational model: other|time perspective: prospective
Covid-19 Lockdown and Deviant Sexual Fantasies,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04448405,NCT04448405,impact of confinement on deviant fantasies|intensity of deviant fantasies|frequency of deviant fantasies|paraphilic type impacted|occurrence of sexual act|access mode for deviant fantasies|use of support during confinement|evaluating anxiety/depression level,observational,observational model: cohort|time perspective: prospective
Spironolactone in Covid-19 Induced ARDS,nan,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04345887,NCT04345887,p/f ratio|sofa,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Non-contact Endoscopy at Covid-19 Outbreak,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04320953,NCT04320953,technical success|clinical success|adverse events,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
COVID 19 Viral Clearance Among the Infected Healthcare Workers In Assiut University Hospitals,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04409574,NCT04409574,"the time of covid 19 viral clearance in medical healthcare workers and its relation to clinical presentation, severity among and resolution of symptoms.|knowledge and practice of infection control measures",observational,observational model: case-only|time perspective: cross-sectional
Social Media and Covid19 Pandemic,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04378738,NCT04378738,the role of social media,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
Characteristics in Post Covid-19 Patients,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04514705,NCT04514705,characteristics of lung|respiratory muscle strength,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04444674,NCT04444674,assess the incidence of adverse events (intervention-related and intervention-unrelated) in hiv-negative adults aged 18-65 year receiving candidate chadox1 ncov-19 vaccine or placebo (safety)|determine if there is a reduction of severe and non-severe covid-19 disease in hiv-negative adults who receive candidate vaccine chadox1 ncov-19 compared to placebo recipients (efficacy)|assess the incidence of adverse events (intervention-related and intervention-unrelated) in hiv-positive adults aged 18-65 year receiving candidate chadox1 ncov-19 vaccine or placebo (safety)|assess cellular immunogenicity of chadox1 ncov-19 in people living with hiv (immunogenicity)|assess humoral immunogenicity of chadox1 ncov-19 in people living with hiv|assess humoral immunogenicity of chadox1 ncov-19 in hiv-negative adults (immunogenicity)|assess cellular immunogenicity of chadox1 ncov-19 in hiv-negative adults (immunogenicity),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
Psychological Impairment Due to Covid-19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04368312,NCT04368312,pcl5 questionnaire|bsi - brief symptom inventory|phqd|who - qol bref|staxi|audit questionnaire,observational,observational model: cohort|time perspective: prospective
Covid -19 Pandemic: Economic Burden on Patients Operated for Traumatic Close Fractures,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04482205,NCT04482205,the effect of covid -19 on the total costs of inpatient care|drop in the collective revenue generated in covid era,observational,observational model: other|time perspective: retrospective
The Seniors COvid-19 Pandemic and Exercise Study,SCOPE,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04412343,NCT04412343,well-being (psychological flourishing)|life satisfaction|stress|depression|resilience|social identification|social and emotional lonliness|chronic illness (physical health)|weekly somatic symptoms (physical health)|leisure-time physical activity|alcohol habits|physical adherence|affective attitudes|demographics,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
CoViD-19 Patient in Reims University Hospital in March to April 2020,COVID-Reims,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04553575,NCT04553575,health status in the 2 years after covid-19 diagnosis,observational,observational model: cohort|time perspective: prospective
Acute Respiratory Failure and COVID-19 in Real Life,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04307459,NCT04307459,real life data of the severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection|in-hospital mortality|30 days mortality|6 months mortality|intubation rate|time to intubation|time to ventilation|non invasive to invasive time|recovery rate|recurrence rate|risk factor for covid19|blood tests and outcome|antiviral therapy|coinfections|radiological findings|ultrasound findings|myocardial injury|medical management,observational,observational model: cohort|time perspective: prospective
Sexual Function During COVID 19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04395885,NCT04395885,the percentage of study participants diagnosed with sexual dysfunction,observational,observational model: other|time perspective: cross-sectional
Study of the Incidence of SARS-CoV-2 Infection (COVID-19),CovImmune 2,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04429594,NCT04429594,positive serologies,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: basic science
Hemodynamic Characteristics of Patients With SARS-CoV-2,PiCCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04337983,NCT04337983,body temperature|blood pressure|pulse (heart rate)|respiratory rate|data provided by transpulmonary thermodilution-ci|data provided by transpulmonary thermodilution-gedv|data provided by transpulmonary thermodilution-evlw|data provided by transpulmonary thermodilution-pvpi|incidence of abnormal laboratory test results|incidence of new-onset or reversible systolic left ventricular dysfunction|changes of extravascular lung water measured by transpulmonary thermodilution|changes of pulmonary vascular permeability index measured by transpulmonary thermodilution|correlation between the hemodynamic characteristics and 90-day mortality,observational,observational model: cohort|time perspective: prospective
Parental Stress After the Covid-19 Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04442308,NCT04442308,parental stress,observational,observational model: other|time perspective: prospective
Role of Children in Transmission of COVID-19 to Immunocompromised Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04407546,NCT04407546,to define the role of household contact with children or siblings in the transmission of sars-cov-2 to immunocompromised patients.|to characterize secondary cases of sars-cov-2 in immunocompromised participants|to describe the exposure factors such as pets and travel and how those factors are related to immunocompromised patients to estimate risk profiles by household characteristics,observational,observational model: cohort|time perspective: prospective
Covid-19 and Prevention of Malnutrition After Confinement by Dentists,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04386460,NCT04386460,body mass index|weight changes during confinement|prescription of nutritional supplements and observance,observational,observational model: cohort|time perspective: prospective
Etiology of Lymphopenia in Covid19 Infection,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04404608,NCT04404608,death or recovery,observational,observational model: cohort|time perspective: prospective
"Physiotherapy as a Complimentary Treatment in Reducing Viral-Load, Complications, Death, Expedite Discharge and Improve Quality of Life, Exercise Endurance and Capacity in Stroke Survivors With CoViD-19: A Clinical-Controlled Study",nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04471831,NCT04471831,cycle threshold (ct) values as recorded from the series of the qrt-pcr|nucleic acid values as calculated from the cycle threshold recorded from the series of the qrt-pcr|quality of life perception|exercise capacity|exercise endurance,interventional,"allocation: non-randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Student-delivered Telehealth Program for COVID-19 Education and Health Promotion,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04492527,NCT04492527,"change from baseline: health directed behaviour at 2 months|depression, anxiety, stress scale|medical outcomes study (mos): social support survey|medical outcomes study (mos): short form-36|self-rated abilities for health practices scale|self-management",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Outcomes in Hospitalized Older Patients With COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04385212,NCT04385212,to evaluate the relative contributions of comorbidities on intra-hospitalized death|to evaluate the relative contributions of functional characteristics on intra-hospitalized death|to explore specific clinical profiles that may influence covid-19 disease outcomes in the elderly based on geriatrics syndromes,observational,observational model: cohort|time perspective: retrospective
Influence of the COvid-19 Epidemic on STRESS,COVISTRESS,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04308187,NCT04308187,stress|perception and knowledge of the epidemic|feeling of information on the part of companies / establishments / governments|means of protection|feelings of fear generated and its impact on feelings of stigmatization towards ethnic groups or categories of patients|sociodemographic factors and lifestyle habits,observational,observational model: cohort|time perspective: cross-sectional
Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.,Cov-CONTACT,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04259892,NCT04259892,"time to sars-cov-2 nasopharyngeal excretion, from the day of the first high/moderate risk contact to 12 days after the last high/moderate risk contact with a laboratory-confirmed sars-cov-2 case.|time to apparition of any symptom suggestive of sars-cov-2 from the day of the first high/moderate risk contact to 12 days after the last high/moderate risk contact with a laboratory-confirmed sars-cov-2 case.|factors associated with the time to sars-cov-2 nasopharyngeal excretion|factors associated with the time to apparition of any symptom suggestive of sars-cov-2 infection|proportion of contact subjects with apparition of any symptom suggestive of sars-cov-2 infection|proportion of contact subjects with positive serology defined as the presence of sars-cov-2 igm or igg at day 30 (+/-7) following last contact|host genetic variants|the time (days) between the first positive sars-cov-2 serology and the first negative sars-cov-2 serology.",observational,observational model: cohort|time perspective: prospective
Escin in Patients With Covid-19 Infection,add-on-COV2,recruiting,No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04322344,NCT04322344,mortality rate|clinical status evaluated in agreement with guidelines|the differences in oxygen intake methods|time of hospitalization (days)|time of hospitalization in intensive care units|pulmonary function,interventional,"allocation: non-randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: supportive care"
Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04299152,NCT04299152,determine the number of covid-19 patients who were unable to complete sce therapy|examine the percentage of activated t cells after sce therapy by flow cytometry|assess the percentage of th17 cells after sce therapy by flow cytometry|chest imaging changes by computed tomography (ct) scan of the chest|quantification of the sars-cov-2 viral load by real time rt-pcr,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (care provider)|primary purpose: treatment
Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2 (COVID-19),REACOVIM,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04365166,NCT04365166,mortality|immune response - plasma cytokine profile|immune response - phenotype of circulating cells|severity criteria - duration of stay in intensive care unit|severity criteria - duration of hospitalization stay|severity criteria - duration of period out of hospital|severity criteria - duration without mechanical ventilation|severity criteria - duration without ventilation|severity criteria - duration without intubation|severity criteria - number of transfusions|severity criteria - duration of the period without cathecholamines|severity criteria - duration of the period without dialysis|severity criteria - sofa|severity criteria - lis|sars-cov2 viral load|emergence of concomitant infections|emergence of concomitant infections - phenotype of circulating cells|stress physiological profile - sympathetic tone|stress physiological profile - temperature|stress physiological profile - glucocorticoids|angiotensin converting enzyme type ii (ace2) polymorphism - ace|angiotensin converting enzyme type ii (ace2) polymorphism - ace2/ace1|comorbidities - diabetes|comorbidities - heart disease|comorbidities - organ failure|plasma concentrations of several metabolic pathways - gaba|plasma concentrations of several metabolic pathways - glucocorticoid|plasma concentrations of several metabolic pathways - tryptophan|plasma concentrations of several metabolic pathways - serotonin|plasma concentrations of several metabolic pathways - dopamin|plasma concentrations of several metabolic pathways - cathecholamines|plasma concentrations of several metabolic pathways - arachidonic acid derivatives|plasma concentrations of several metabolic pathways - endocannabinoids,observational,observational model: case-only|time perspective: prospective
Functional Exhaustion of T Cells in COVID19 Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04470323,NCT04470323,cd4+ (t-helper cells) in covid 19 patients and healthy volunteers.|cd8+ (t-cytotoxic cells) in covid 19 patients and healthy volunteers.|detect pd-1 on cd8+ and cd4+ cells in covid 19 patients and healthy volunteers .|detect cd28+ and cd3+ cells in covid 19 patients and healthy volunteers.,observational,observational model: case-control|time perspective: prospective
Convalescent Plasma to Stem Coronavirus (CSSC-001),CSSC-001,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04323800,NCT04323800,efficacy of treatment at day 28|safety of treatment with high-titer anti- sars-cov-2 plasma versus control - 1|safety of treatment with high-titer anti- sars-cov-2 plasma versus control - 2|cumulative incidence of disease severity,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,NOSARSCOVID,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04306393,NCT04306393,change of arterial oxygenation at 48 hours from enrollment|time to reach normoxemia during the first 28 days after enrollment|proportion of sars-ncov-2 free patients during the first 28 days after enrollment|survival at 28 days from enrollment|survival at 90 days from enrollment,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Quality of Life and Patient-centered Outcomes After ICU Admission for COVID-19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04416464,NCT04416464,"health-related quality of life.|length of stay at the icu.|incidence of all-cause mortality|rehospitalization.|percentage of long-term ventilatory support need.|percentage of renal replacement therapy need.|symptoms of anxiety and depression.|score of functional independence.|score of cognitive function.|percentage of major cardiac events.|score of chronic obstructive pulmonary disease (copd)|symptoms of posttraumatic stress disorder|utility score of health-related quality of life at 3, 6, and 9 months.|score of self-rated health.",observational,observational model: cohort|time perspective: prospective
Psychological Impact of COVID19 Among Doctors in Assiut University Hospitals,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04363229,NCT04363229,"the mbi-hss (mp) addresses three scales:emotional exhaustion ,depersonalization and personal accomplishment|ghq-12 questionnaire for measuring of current mental health",observational,observational model: other|time perspective: cross-sectional
A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine,nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04522089,NCT04522089,the solicited adverse events (soaes)|incidence of abnormal laboratory tests results|safety of adimrsc-2f vaccine: ae|immunogenicity,interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: prevention
The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04476745,NCT04476745,il-1 beta|il-6|tnf|serum concentrations of 25-hydroxyvitamin d,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults",nan,recruiting,No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04449276,NCT04449276,number of participants with grade 3 adverse reactions or any serious adverse event (sae) considered related to trial vaccine within at least 24 hours after the first vaccination|number of participants with grade 3 adverse reactions or any serious adverse event (sae) considered related to trial vaccine within at least 60 hours after the first vaccination|number of participants with solicited local adverse events|intensity of solicited local adverse events per the fda toxicity grading scale|duration of solicited local adverse events|number of participants with solicited systemic adverse events|intensity of solicited systemic adverse events per the fda toxicity grading scale|duration of solicited systemic adverse events|number of participants with solicited systemic adverse events considered related to trial vaccine|number of participants with unsolicited adverse events|intensity of unsolicited adverse events assessed by the investigator|number of participants with unsolicited adverse events considered related to trial vaccine|number of participants with one or more serious adverse events (saes)|number of participants with one or more serious adverse events (saes) considered related to trial vaccine|number of participants with one or more adverse events of special interest (aesis)|number of participants with one or more adverse events of special interest (aesis) considered related to trial vaccine|number of participants seroconverting for sars-cov-2 spike protein antibodies|individual sars-cov-2 spike protein-specific antibody levels in serum|geometric mean titers (gmts) of serum sars-cov-2 spike protein antibodies|number of participants seroconverting for sars-cov-2 neutralizing antibodies|individual sars-cov-2 neutralizing antibody levels in serum|geometric mean titers (gmts) of serum sars-cov-2 neutralizing antibodies,interventional,allocation: randomized|intervention model: sequential assignment|masking: single (outcomes assessor)|primary purpose: prevention
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection),nan,withdrawn,No Results Available,phase 3,Other|NIH,https://ClinicalTrials.gov/show/NCT04361552,NCT04361552,7-day length of invasive mechanical ventilation (mv)|30-day mortality rate|rate of intensive care (icu) transfer|rate of invasive mechanical ventilation|rate of tracheostomy|length of icu stay|length of hospital stay,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
At Home Monitoring for Patients With Covid19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04453774,NCT04453774,number of participants with an unplanned hospital admissions|number of participants with planned hospital admissions that are found to be necessary|number of participants with an emergency department visits not resulting in hospital admission|number of planned hospital admissions which are found to be unnecessary,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,TOCIVID,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04322773,NCT04322773,time to independence from supplementary oxygen therapy|number of deaths|days out of hospital and alive|ventilator free days alive and out of hospital|c-reactive protein (crp) level|number of participants with serious adverse events,interventional,allocation: randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Psychological Impact of COVID19 Among Women Undergoing Infertility Treatment,PsyCovART,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04496869,NCT04496869,psychological impact assessed by scores of pss10 scales.|psychological impact assessed by scores of hads scales.,observational,observational model: cohort|time perspective: retrospective
A Comparison of 3D and 2D Telemedicine During Covid 19,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04359225,NCT04359225,university hospitals of north northway questionnaire|mental effort rating scale|telehealth usability questionnaire|subjective feedback interview,interventional,"allocation: randomized|intervention model: crossover assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: other"
Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04445454,NCT04445454,to evaluate the safety of intravenous infusion of msc in patients with severe to critical covid-19 pneumonia|to evaluate the efficacy of intravenous infusion of msc in patients with severe to critical covid-19 pneumonia|to evaluate the effect of msc administration associated with the standard of care (soc including anti-viral therapy),interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"Evaluation of Systemic and Oral Conditions of Pregnant Women and Their Babies, With Exposure to COVID-19 Infection",(COVID-19,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04492449,NCT04492449,periodontal status|quality of life of pregnants,observational,observational model: other|time perspective: other
Effect of COvid-19 on Mental Health in Syrian and Turkish Maintenance HemoDialysis Patients: COST-HD Study,COST-HD,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04444557,NCT04444557,score of beck depression inventory,observational,observational model: cohort|time perspective: prospective
"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers",nan,"active, not recruiting",No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04336410,NCT04336410,percentage of participants with adverse events (aes)|percentage of participants with administration (injection) site reactions|percentage of participants with adverse events of special interest (aesis)|change from baseline in antigen-specific binding antibody titers|change from baseline in antigen-specific interferon-gamma (ifn-œ≥) cellular immune response,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: prevention
Evaluation of Dental Emergency Treatments During COVID19 Crisis,URGDENTCOVID,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04354272,NCT04354272,pain score evolution measured by a 0-10 numeric scale (ns) where 0 is no pain and 10 the worst pain imaginable|pain scores evolution 3 days and 7 days after first visit measured by a numeric scale where 0 is no pain and 10 the worst pain imaginable|welcoming quality from hospital staff|anxiety score|perception of the technical quality of the emergency treatment,observational,observational model: cohort|time perspective: prospective
Mask Usage and Exercise During the COVƒ∞D-19 Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04498546,NCT04498546,resting heart rate|peak heart rate|recovery heart rate|resting systolic blood pressure|recovery systolic blood pressure|resting diastolic blood pressure|recovery diastolic blood pressure|peripheral oxygen saturation|vo2max|dyspnoea severity,observational,observational model: other|time perspective: prospective
"SeroCOVIDial Study: Assessment of COVID-19 Seroconversion in Patients on Chronic Hemodialysis and in Their Caregivers, a Cohort Study",SeroCOVIDial,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04420338,NCT04420338,the prevalence of sars-cov2 seroconversion in chronic hemodialysis patients|the prevalence of sars-cov2 seroconversion in dialysis caregivers,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: diagnostic
Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04355637,NCT04355637,proportion of patients in both arms fulfilling the criteria for treatment failure|icu admission|icu refusal|occurrence of complications|lactate dehydrogenase (ldh)|c reactive protein (crp)|ferritin|d-dimer|leukocyte counts,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
The Development of Pancreatic Injury in the Course of Severe Acute Respiratory Syndrome Coronavirus 2 Infection,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04433754,NCT04433754,to compare presence of fever in patients with and without pancreatic injury|to compare presence of dyspnea in patients with and without pancreatic injury|to compare crp levels in patients with and without pancreatic injury|to compare d-dimer levels in patients with and without pancreatic injury,observational,observational model: case-control|time perspective: retrospective
Ayurveda for Flu Like Illness During Covid-19 Outbreak,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04351542,NCT04351542,time to achieve afebrile|severity of symptom score|patient reported improvement,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: single (care provider)|primary purpose: supportive care
Demographics and Outcomes of COVID 19 in Pregnancy at a Community Based Hospital,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04385914,NCT04385914,pregnancy outcome,observational,observational model: cohort|time perspective: prospective
SARS-CoV 2 in Personal Protective Equipment,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04398043,NCT04398043,asses surface contamination personel protective equipment|virus charge cuantification|place in ppe contamination,observational,observational model: cohort|time perspective: prospective
Dietary Diversity of Young Children During CoVID-19 Outbreak: A Longitudinal Study,CoDDYC,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04447209,NCT04447209,minimal dietary diversity (mdd) of more than 5 food groups in 24 hours|height|weight|meal frequencies in past 24 hours|blood hemoglobin in children at the start of study and 4 months later|serum ferritin in children at the start of study and 4 months later|consumption of sugar and processed foods|food aids received,observational,observational model: cohort|time perspective: prospective
imPROving prenaTal carE During ConfinemenT,PROTECT,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04368832,NCT04368832,score of perceived quality of prenatal care|level of stress during pregnancy|level of health and digital literacy|obstetrical outcomes|characteristics of medical supervision during pregnancy,observational,observational model: other|time perspective: prospective
RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19,P20/09,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04397666,NCT04397666,the sars-cov-2 positivity rate in patients with covid-19 with or without signs of conjunctivitis,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
A Survey to Assess Effects of Covid-19 on Cardiovascular Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04508920,NCT04508920,"nyha class deterioration|dyspnea deterioration|paroxysmal nocturnal dyspnea deterioration|edema|daily activities in the last four weeks? please, mention if you a perceived limitation on : walking deterioration",observational,observational model: cohort|time perspective: prospective
Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19,TOCIDEX,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04476979,NCT04476979,"survival without needs of ventilator utilization at day 14|who progression scale at day 7 and 14|overall survival at 14, 28, 60 and 90 days|cumulative incidence of discharge alive at 14 and 28 days|survival without needs of mechanical ventilation at day 1|cumulative incidence of oxygen supply independency at 14 and 28 days",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Evaluation of Clinical Characteristics and Outcome of COVID19 Pneumonia in Assiut University Hospital,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04481360,NCT04481360,clinical evaluation,observational,observational model: cohort|time perspective: prospective
"The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?",nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04322786,NCT04322786,incidence of influenza,observational,observational model: case-control|time perspective: prospective
Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04342208,NCT04342208,the rapid office strain assessment (rosa)|the standardised nordic questionnaries (nmq),observational,observational model: case-only|time perspective: other
Home-based Exercise Training During Covid-19 Pandemic in Post-bariatric,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04425005,NCT04425005,change from baseline on waist circumference at 4 months of follow-up.|change from baseline on cardiometabolic risk factor at 4 months of follow-up.|change from baseline on cardiopulmonary fitness at 4 months of follow-up.|change from baseline on quality of life at 4 months of follow up.|change from baseline on physical activity levels at 4 months of follow up.|change from baseline on dietary intake at 4 months of follow up.,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
GlobalSurg-CovidSurg Week,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04509986,NCT04509986,post-operative mortality|in-patient mortality|post-operative pulmonary complications|post-operative venous thromboembolism|post-operative complications,observational,observational model: cohort|time perspective: prospective
Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study,ProCov,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04344106,NCT04344106,"proportion of ""responder"" patients to prone position|proportion of ""persistent responders"" patients after prone position|evolution of pao2|duration of prone positioning and pao2 evolution|evolution of spo2|eva dyspnea|intolerance to prone positioning|tolerance to prone positioning",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Turkish of the SARS-CoV-2 Anxiety Scale,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04490473,NCT04490473,anxiety in sars-cov-2|ratio of sars-cov-2 anxiety scale to beck anxiety scale,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability,FatCovid-19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04363606,NCT04363606,voluntary maximum force reduction|neuromuscular function : cortical activity|neuromuscular function : peripheral function|maximal oxygen uptake (vo2max)|quality of sleep|muscle volume|metabolic fatigue,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: diagnostic
Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04435379,NCT04435379,number of days with severe respiratory disease at hospital and/or at home|cumulative incidence of hospital admissions|cumulative incidence of documented sars-cov-2 infection|number of days with self-reported fever (‚â• 38 ¬∫c)|number of days with self-reported acute respiratory symptoms|cumulative incidence of self-reported acute respiratory symptoms|cumulative incidence of death for any reason|cumulative incidence of death due to documented sars-cov-2 infection|cumulative incidence of icu admission for any reason|cumulative incidence of icu admission due to documented sars-cov-2 infection|cumulative incidence of hospital admission due to documented sarscov- 2 infection,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, investigator, outcomes assessor)|primary purpose: prevention"
"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers",nan,"active, not recruiting",No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04461353,NCT04461353,incidences of treatment-emergent adverse events (teaes) as assessed by tgshaav (september 2007) or ctcae version 5.0|change from baseline in clinical laboratory test results for cbc with differential|incidence of abnormal laboratory test results for cbc with differential at screening|incidence of abnormal laboratory test results for cbc with differential - day 8|changes from baseline for blood glucose|incidence of abnormal laboratory test results for chemistry -screening|incidence of abnormal laboratory tests results for chemistry - day 8|incidence of abnormal laboratory tests results for urinalysis - screening|incidence of abnormal laboratory tests results for urinalysis- day 8|changes in vital signs from baseline (pre-dose) - respiratory rate|changes in vital signs from baseline (pre-dose)- temperature|changes in vital signs from baseline (pre-dose) - seated blood pressure|changes in vital signs from baseline (pre-dose) - pulse|changes in vital signs from baseline (pre-dose) - o2 saturation|incidence of abnormal and physical examinations findings during screening- general appearance|incidence of abnormal and physical examinations findings on day 1 - general appearance|incidence of abnormal and physical examinations findings on day 2- general appearance|incidence of abnormal and physical examinations findings on day 8- general appearance|incidence of abnormal and physical examinations findings during screening- neurological|incidence of abnormal and physical examinations findings on day 1- neurological|incidence of abnormal and physical examinations findings on day 2- neurological|incidence of abnormal and physical examinations findings on day 8- neurological|incidence of abnormal and physical examinations findings during screening - heart/cardiovascular|incidence of abnormal and physical examinations findings on day 1 - heart/cardiovascular|incidence of abnormal and physical examinations findings on day 2 - heart/cardiovascular|incidence of abnormal and physical examinations findings on day 8 - heart/cardiovascular|incidence of abnormal and physical examinations findings during screening - lungs|incidence of abnormal and physical examinations findings on day 1 - lungs|incidence of abnormal and physical examinations findings on day 2 - lungs|incidence of abnormal and physical examinations findings on day 8 - lungs|incidence of abnormal and physical examinations findings during screening- abdomen|incidence of abnormal and physical examinations findings on day 1 - abdomen|incidence of abnormal and physical examinations findings on day 2- abdomen|incidence of abnormal and physical examinations findings on day 8- abdomen|incidence of abnormal and physical examinations findings during screening- endocrine|incidence of abnormal and physical examinations findings on day 1 - endocrine|incidence of abnormal and physical examinations findings on day 2- endocrine|incidence of abnormal and physical examinations findings on day 8- endocrine|incidence of abnormal and physical examinations findings during screening- extremities|incidence of abnormal and physical examinations findings on day 1- extremities|incidence of abnormal and physical examinations findings on day 2- extremities|incidence of abnormal and physical examinations findings on day 8- extremities|incidence of abnormal and physical examinations findings during screening- lymphatic|incidence of abnormal and physical examinations findings on day 1- lymphatic|incidence of abnormal and physical examinations findings on day 2 - lymphatic|incidence of abnormal and physical examinations findings on day 8- lymphatic|incidence of abnormal and physical examinations findings during screening - skin|incidence of abnormal and physical examinations findings on day 1 - skin|incidence of abnormal and physical examinations findings on day 2 - skin|incidence of abnormal and physical examinations findings on day 8 - skin|changes from baseline for pulmonary function tests (pfts) - fev1|changes from baseline for pulmonary function tests (pfts) - fvc|changes from baseline for pulmonary function tests (pfts) - fev1/fvc|changes from baseline for ecg readings - qt interval|changes from baseline for ecg readings - qtcb interval|changes from baseline for ecg readings - qrs duration|changes from baseline for ecg readings - pr interval|changes from baseline for ecg readings - heart rate|incidence of abnormal ecg - screening|incidence of abnormal ecg- day 1|incidence of abnormal ecg - day 2|incidence of abnormal ecg - day 8|hcq concentration in whole blood versus time profiles,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Surgical Activity During the Covid-19 Pandemic: Results for 112 Patients in a French Tertiary Care Center,SurgiCovid,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04379232,NCT04379232,symptoms of covid after surgery,observational,observational model: cohort|time perspective: retrospective
Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04466605,NCT04466605,severity of pain|interference of pain|global rating of change in pain|intervention specific satisfaction,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
COVID-2019 Testing and Vaccination Among African American and Latinx Public Housing Residents,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04542395,NCT04542395,"prevalence of covid-19 testing, pneumococcal and influenza vaccinations using test history self-report|percentage of participants achieving decreased levels of covid-19 risk using the nih toolbox surveys on covid-19|percentage of participants achieving decreased levels of covid-19 mistrust and barriers using the nih toolbox surveys on covid-19",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Feasibility and Benefits of Digital Services During the COVID19 Pandemic,AnhandCOV19,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04453475,NCT04453475,"interest in digital interventions (attitudes, behavioral intentions, behavioral experiences)|usability and effectiveness of digital interventions|stressors and barriers due to covid-19",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: health services research
A Study of Ad26.COV2.S in Adults (COVID-19),nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04436276,NCT04436276,"cohorts 1, 2, and 3: number of participants with solicited local adverse events (aes) for 7 days after first vaccination|cohorts 1, 2, and 3: number of participants with solicited local adverse events (aes) for 7 days after second vaccination|cohorts 1, 2, and 3: number of participants with solicited systemic aes for 7 days after first vaccination|cohorts 1, 2, and 3: number of participants with solicited systemic aes for 7 days after second vaccination|cohorts 1, 2, and 3: number of participants with unsolicited aes for 28 days after first vaccination|cohorts 1, 2, and 3: number of participants with unsolicited aes for 28 days after second vaccination|cohort 1 and 3: number of participants with serious adverse events (saes) from the first vaccination until 1 year after the second vaccination|cohort 2: number of participants with saes from the first vaccination until 6 months after the first vaccination|cohorts 1, 2, and 3: number of participants with sars-cov-2 neutralizing antibody titers as assessed by virus neutralization assay (vna)|cohorts 1, 2, and 3: number of participants with sars-cov-2 binding antibodies assessed by elisa|cohorts 1, 2, and 3: number of participants with t-helper (th)-1 and th-2 immune responses as assessed by flow cytometry",interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: other"
ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation,ROCO,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04380909,NCT04380909,"patient health questionnaire (l√∂we et al., 2002)|suicide behavior questionnaire revised (glaesmer et al., 2018)|dass-21: depression, angst, stress-skala (lovibond & lovibond, 1995)|sf-12: short form health survey (ware et al., 1996)|lot-r: revised life orientation test (herzberg et al., 2006)|berner verbitterungsinventar kurzversion (znoj, 2008)|emotion regulation skills sek-27 (berking & znoj, 2008)|swe: skala zur allgemeinen selbstwirksamkeit (jerusalem & schwarzer, 2003)|ucla loneliness scale (d√∂ring & bortz, 1993)|connor-davidson resilience scale (sarubin et al., 2015)|zuf-8: zufriedenheitsfragebogen (attkisson & zwick, 1982)|sus: system usability scale (brooke, 1996)",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04369378,NCT04369378,anxiety|well-being|future outlook & hopefulness|sleep habits|nutrition habits|meditation app continued usage,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04327479,NCT04327479,all-cause mortality|30-day mortality|major adverse cardiovascular events,observational,observational model: cohort|time perspective: prospective
Treatment of Depressive Symptoms in Older Individuals in Isolation During Covid-19,CoviDep,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04508868,NCT04508868,"change from baseline in depressive symptoms using the montgomery-asberg depression rating scale, madrs-s|change from baseline in depressive symptoms using the geriatric depression rating scale 15, gds-15|change from baseline in depressive symptoms using the patient health questionnaire 9, phq-9|change in depression diagnosis assessed using the mini international neuropsychiatric interview, mini|change from baseline in anxiety symptoms using the generalized anxiety disorder 7-item, gad-7|change from baseline in behavioral activation using the behavioral activation for depression scale - short form, bads-sf|change from baseline in health and disability using the who disability assessment schedule 12-item, whodas|adverse and unwanted effects of the experimental intervention using the negative effects questionnaire, neq|mental imagery is assessed at baseline using the plymouth sensory imagery questionnaire, psi-q",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency,MOHC,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04410536,NCT04410536,drop out rates|absence of medication overuse headache (moh),interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"Evaluationof the Load of SARS-CoV-2 Virus in Oral Cavity, Oropharinge and Saliva of Patients With Covid-19 After Disinfection With Oral Antimicrobial Solutions: a Pilot Study",nan,enrolling by invitation,No Results Available,not applicable,Other|Industry,https://ClinicalTrials.gov/show/NCT04537962,NCT04537962,"viral load of sars-cov-2 in the oral mucosa, oropharynx and saliva of hospitalized patients already considered positive for the virus",interventional,allocation: randomized|intervention model: factorial assignment|masking: single (participant)|primary purpose: supportive care
Video Dance Class and Unsupervised Physical Activity During Covid-19 Pandemic in People With Parkinson's Disease,PTT-Online,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04422353,NCT04422353,quality of life (qol)|depressive symptoms - geriatric depression scale - 15 item|physical activity - international physical activity questionnaires (ipaq)|cognitive function - montreal cognitive assessment by telephone|falls - falls efficacy scale - international|functional lower extremity strength -five times sit to stand test,interventional,"allocation: non-randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: treatment"
Social Media Use During COVID-19,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04305574,NCT04305574,"depression, anxiety and stress scale",observational,observational model: cohort|time perspective: cross-sectional
Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04385823,NCT04385823,changes in rox index|nhf failure|nhf flow|nhf inspired fraction in oxygen|oxygenation|respiratory status|prediction of intubation|prediction of nhf success,observational,observational model: cohort|time perspective: retrospective
Experience of Lock Down Related to the Covid-19 Epidemic and Its Impact on the Project of Parenthood,CONFIN-AMP,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04556630,NCT04556630,level of anxiety and/or depression of mpa patients (male and female couples) by hospital anxiety and depression scale (had) score.,observational,observational model: cohort|time perspective: prospective
"Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity During the COVID19 Pandemic",nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT04419870,NCT04419870,"we will perform whole blood transcriptomic analysis, humoral response profiling and soluble mediator profiling.|patient medical records for data abstraction|patient centered outcomes data via questionnaires",observational,observational model: case-control|time perspective: prospective
"Death Number Perception in Depression, Anxiety, and Schizoypal Personnality in General Population (Covid-19 Pandemic)",DeathPercep,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04384419,NCT04384419,number of perception distortions|recall number of deaths,observational,observational model: case-only|time perspective: retrospective
A Study to Collect Bone Marrow for Process Development and Production of BM-MSC to Treat Severe COVID19 Pneumonitis,COMET20d,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04397471,NCT04397471,"determine feasibility of recruiting healthy volunteers in a clinically useful timeframe.|manufacture a cell-based product suitable for clinical use|establishment of a robust process of production|production of stability data to be used in the mhra dossier for the comet clinical trial.|production of cell-based products to be administered to covid-19 patients with severe pneumonitis.|analysis of cells for understanding production, manufacture and related research.",observational,observational model: case-only|time perspective: prospective
Registry of the Evolution of Diagnosed and/or Hospitalized Patients for Pulmonary Embolism During the Covid-19 Pandemic,COVID-EP,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04465656,NCT04465656,"% of patients for each group presenting the occurrence of pe complications defined by the occurrence of at least one of the following events up to 6 months after pe diagnosis.|% of patients for each group and subgroup presenting the occurrence of pe complications defined by the occurrence of at least one of the following events up to 12 months after pe diagnosis.|% of patients in each group presenting the occurrence of each of the following events at each follow-up (3 months, 6 months and 12 months after pe diagnosis).|% of patients diagnosed covid - at m0 by rt-pcr on nasopharyngeal swab and diagnosed covid + by serology 3 months after pe diagnosis|effectiveness of the different category of treatments used in all patients and in the groups: % of occurrence of pe complications for each categories of treatments|effectiveness of the different category of treatments used in all patients and in the groups: % of patients with occurrence of bleeding complications for each categories of treatments|effectiveness of the different category of treatments used in all patients and in the groups: % of patients with no occurrence of complications for each categories of treatments|effectiveness of the different category of treatments used in all patients and in the groups: duration of heparin treatment (number of day)",observational,observational model: cohort|time perspective: retrospective
Impact of Burnout on Cardiovascular and Immune Biomarkers in Healthcare Professionals - Covid-19 Pandemic in Abu Dhabi,nan,recruiting,No Results Available,nan,Other|Industry,https://ClinicalTrials.gov/show/NCT04422418,NCT04422418,change from baseline burnout at 2-3 months and 6 months|change from baseline cardiovascular risk cardiovascular risk through heart rate variability markers at 2-3 months and 6 months|change from baseline through actigraphy at 2-3 months and 6 months|change from baseline through sleep quality at 2-3 months and 6 months|change from baseline cardiovascular risk through fuster-bewat score at 2-3 months and 6 months|change from baseline immune dysfunction at 2-3 months and 6 months|change from baseline cardio-respiratory fitness at 2-3 months and 6 months,observational,observational model: cohort|time perspective: prospective
"Evaluation of Changes in Weight, Sleep, and Other Psycho-behavioural Parameters During Covid-19 Confinement in Subjects Monitored by the RNPC Network",CO-RNPC,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04409197,NCT04409197,"analyse the variation in weight loss kinetics before, during and after confinement in patients enrolled in a weight reduction programme (rnpc) in france|define the effects of containment on the variation in the kinetics of anthropometric parameters other than weight|evolution of blood pressure before versus after confinement|characterize clusters (homogeneous groups of patients) associated with particular dynamics of weight kinetics during confinement|evaluate the impact of teleconsultation monitoring during containment on weight loss",observational,observational model: cohort|time perspective: prospective
A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,nan,"active, not recruiting",No Results Available,phase 2|phase 3,Other,https://ClinicalTrials.gov/show/NCT04347031,NCT04347031,1st primary endpoint for group 1|2nd primary endpoint for group 1|1st primary endpoint for group 2|2nd primary endpoint for group 2|1st secondary endpoint for group 1|2nd secondary endpoint for group 1|3d secondary endpoint for group 1|4th secondary endpoint for group 1|5th secondary endpoint for group 1|6th secondary endpoint for group 1|1st secondary endpoint for group 2|2nd secondary endpoint for group 2|3d secondary endpoint for group 2|4th secondary endpoint for group 2|5th secondary endpoint for group 2|6th secondary endpoint for group 2,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
HDL Target of CoViD19 ? Analysis on the Caregivers of the Reunion University Hospital,H-Cov-Run,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04384705,NCT04384705,change of lipid profile during exposure to sars-cov-2|hdl-cholesterol size|circulating plasma cytokine levels|ace2 gene polymorphisms,observational,observational model: cohort|time perspective: prospective
Online Cognitive Behavioral Therapy (CBT) for Stress Disorders in Health Workers Involved in the Care of Patients During the Covid-19 Epidemic,REST,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04362358,NCT04362358,significant score reduction at the perceived stress scale,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
BCG Vaccine for Health Care Workers as Defense Against COVID 19,BADAS,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04348370,NCT04348370,incidence of covid 19 infection|disease severity,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04279795,NCT04279795,positive rate of 2019 novel coronavirus rna|survival rate,observational,observational model: cohort|time perspective: prospective
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19,nan,not yet recruiting,No Results Available,phase 1|phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04390152,NCT04390152,"intergroup mortality difference with treatment|number of patients with treatment related adverse events|difference in days of mechanical ventilation between groups|median reduction of days of hospitalization|median reduction of days of oxygen needs|difference between ""sequential organ failure assessment"" score between groups|difference between median murray score between groups|difference in apache ii score between groups|difference in lymphocyte count between groups|changes in c reactive protein concentration between groups|changes in d dimer concentration|changes in ferritin concentration|changes in lactate dehydrogenase concentration|impact on interleukin 6 concentrations between groups.|impact on interleukin 8 concentrations between groups.|impact on interleukin 10 concentrations between groups.|impact on tumor necrosis factor alpha concentrations between groups.",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Measurement of Airway Opening Pressure (AOP) in Patients With Acute Respiratory Distress Syndrom and With or Without Covid 19.,POVA-TIE,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04386720,NCT04386720,comparison of the pv curves|comparison of regional aop|comparison of the different aops with the level of peep,observational,observational model: case-only|time perspective: prospective
Ethical and Psychological Support for Health Care Professions in Intensive Care Units in the COVID19 Pandemic Context: Adequacy With Needs and Psychological Impact Crisis and Post-crisis,PsyCOVID,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04441476,NCT04441476,ps-icu scale score,observational,observational model: cohort|time perspective: prospective
Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04387253,NCT04387253,estimate the prevalence of sars-cov-2 infection in women with late fetal loss of unexplained cause.,interventional,allocation: n/a|intervention model: single group assignment|masking: single (participant)|primary purpose: diagnostic
Incidence of Deep Vein Thrombosis at Doppler Echo in Covid-19 Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU,COVIDOP-DVT,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04363528,NCT04363528,incidence of deep vein thrombosis at doppler echo in patients with sars-cov-2 pneumopathy hospitalized in icu,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04279782,NCT04279782,survival rate|chest computed tomography|recovery time|depression evaluation,observational,observational model: cohort|time perspective: prospective
Anosmia and / or Ageusia and Early Corticosteroid Use,nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04528329,NCT04528329,time to recovery,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Stay Well at Home: a Text-messaging Study Social Distancing,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04473599,NCT04473599,depression scores|anxiety scores|self reported mood ratings,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,MetCOVID,"active, not recruiting",No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04343729,NCT04343729,"mortality rate at day 28|mortality rate on days 7, 14 and 28|incidence of orotracheal intubation|change in oxygenation index",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Study of Descartes-30 in Acute Respiratory Distress Syndrome,nan,not yet recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04524962,NCT04524962,to assess the safety of descartes-30 in patients with moderate-to-severe ards.,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Pso-Vac: Educational Needs re Vaccines for Biologic Patients With Psoriasis,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04513847,NCT04513847,"percentage of patients not understanding the interaction of vaccines and their biologic, assessed with voluntary survey.",observational,observational model: case-control|time perspective: other
"Evaluation of the Impact of Lock Down and End of Lock Down on the Management of Patients With Inflammatory and Dysimmune Diseases Followed in the Context of IMMINeNT FHU (Rheumatology, Dermatology, Internal Medicine, Pneumology, Gastroenterology, Neurology).",CONFIMID,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04513561,NCT04513561,"the answer will be considered positive if the patient answers ""totally agree"", or ""agree"", or ""slightly agree"", or ""neither agree nor disagree"".|proportion of patients (in percentage and numbers) whose response is considered positive if the patient answered ""slightly agree"", ""agree"" or ""totally agree"" to question 9 of the lock down questionnaire|proportion of patients (in percentage and numbers) whose response is considered positive if the patient answered ""yes"" to question 34 of the lock down questionnaire|proportion of patients (in percentage and numbers) whose response is considered positive if the patient answered ""slightly agree"" or ""agree"" or ""strongly agree"" to question 38 of the lock down questionnaire|proportion of patients (in percentages and numbers) whose response will be considered positive to questions 13 and 14 of the lock down questionnaire and comparison between the different specialities filled in in question 3.|proportion of patients (in percent and numbers) whose response will be considered positive to questions 9, 13, 14, 38 or ""yes"" to question 34 of the end of lock down and lock down evaluation questionnaire.",observational,observational model: cohort|time perspective: prospective
Containment Measures and Eating Disorders,COVITA,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04492189,NCT04492189,variation in eating disorders|vision of the bodily aspect|variation in physical activity|identify the clinical factors modulating the psychological state during confinement,observational,observational model: other|time perspective: prospective
Descriptive Study of the PSYchological Impact of CONFinement Measures in the General Population,PsyConfPop,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04374643,NCT04374643,depressive symptomatology,observational,observational model: cohort|time perspective: prospective
Inflammatory Bowel Disease (IBD) and Covid-19 Infection,MICI-Covid-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04492267,NCT04492267,retrospective analysis of severity and specific needs in case of sars-cov-2 infection in ibd patients,observational,observational model: case-only|time perspective: retrospective
CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,CORIMUNO-ANA,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04341584,NCT04341584,"survival without needs of ventilator utilization at day 14|who progression scale ‚â§ 5|cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) or withdrawal of niv or high flow (for > 48h), at day 14|decrease of at least one point in who progression scale score|who progression scale|survival|28-day ventilator free-days|respiratory acidosis|pao2/fio2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to icu discharge|time to hospital discharge",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Haemoglobin Concentration on COVID-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04377607,NCT04377607,relationship between severity of disease and values of erythrocyte indices|sensitivity of haemoglobin concentration on severity of the disease,observational,observational model: other|time perspective: retrospective
Neurological Features During COVID19,NeuroSARS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04460599,NCT04460599,primary|secondary,observational,observational model: cohort|time perspective: retrospective
Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus,2019-nCoV,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04292327,NCT04292327,mortality|the time interval of nucleic acid detection become negative,observational,observational model: other|time perspective: retrospective
Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,nan,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04340557,NCT04340557,mechanical ventilation|icu transfer|oxygen therapy,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04269525,NCT04269525,oxygenation index|28 day mortality|hospital stay|2019-ncov antibody test|2019-ncov nucleic acid test|improvement of lung imaging examinations|white blood cell count|lymphocyte count|procalcitonin|interleukin(il)-2|il-4|il-6|il-10|tumor necrosis factor(tnf)-œ±|œ≥-interferon(ifn)|c-reactive protein(crp)|cd4+ t-lymphocytopenia|cd8+ t-lymphocytopenia|natural killer cell(nk),interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Convalescent Plasma Collection and Treatment in Pediatrics and Adults,nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04376034,NCT04376034,plasma donor|plasma recipient,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Study of the Specific Seroprevalence of SARS-CoV-2 in a Sample of Patients and Salaried Staff From a French Anti-cancer Center at the End of the Containment Period of the SARS-CoV-2 Pandemic,canSEROcov,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04517097,NCT04517097,seroprevalence of sars-cov-2,observational,observational model: cohort|time perspective: prospective
Tocilizumab in Coronavirus-19 Positive Patients,nan,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04423042,NCT04423042,"all-cause mortality|ordinal scale for evaluating subject clinical status at days 3, 8, 15, 30, 60 post treatment.",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Convalescent Plasma to Limit Coronavirus Associated Complications,nan,withdrawn,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04325672,NCT04325672,rna in sars-cov-2|icu admissions|hospital mortality|hospital length of stay (los)|type of respiratory support|duration of respiratory support,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: basic science
Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions,nan,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04462848,NCT04462848,"cumulative incidence of grade 3 and grade 4 adverse events|cumulative incidence of serious adverse events|proportion of participants with disease worsening event.|serum concentration at baseline, day 7, day 14, and day 28 for anti-sars-cov-2 antibodies|percentage of participants with a natural antibody response to sars-cov-2 infection",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Non Inferiority Trial for Detection of nCOVID-19 Through Analysis of Exhaled Breath Aerosols,nan,recruiting,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04467112,NCT04467112,detection of ncovid-19 using a face mask|independent patient use of face mask,observational,observational model: cohort|time perspective: cross-sectional
A Study of a Candidate COVID-19 Vaccine (COV003),nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04536051,NCT04536051,"evaluate the efficacy of chadox1 ncov-19 vaccine against covid-19 disease confirmed with pcr|evaluate the safety, tolerability and reactogenicity profile of chadox1 ncov-19 candidate vaccine: occurrence of signs and symptoms of local and systemic reactogenicity requested during 7 days after vaccination|evaluate the safety, tolerability and reactogenicity profile of chadox1 ncov-19 candidate vaccine: occurrence of serious adverse events|evaluate the safety, tolerability and reactogenicity profile of chadox1 ncov-19 candidate vaccine: occurrence of episodes; intensified disease|evaluate the efficacy of chadox1 ncov-19 candidate vaccine against severe and non-severe covid-19 disease: hospitalization for covid-19 disease confirmed by pcr|evaluate the efficacy of chadox1 ncov-19 candidate vaccine against severe and non-severe covid-19 disease: covid-19 serious disease confirmed by pcr|evaluate the efficacy of chadox1 ncov-19 candidate vaccine against severe and non-severe covid-19 disease: death associated with covid-19 disease|evaluate the efficacy of chadox1 ncov-19 candidate vaccine against severe and non-severe covid-19 disease: antibodies against sars-cov-2 non-spike protein (serum efficacy rates)|evaluate the humoral immunogenicity of chadox1 ncov-19: antibodies against the sars-cov-2 spike protein (serum conversion rates)|evaluate the humoral immunogenicity of chadox1 ncov-19: virus neutralizing antibodies (nab) against live and/or pseudotyped sars-cov-2 virus|assess the cellular immunogenicity of chadox1 ncov-19 candidate vaccine",interventional,allocation: randomized|intervention model: sequential assignment|masking: single (participant)|primary purpose: prevention
Viral Infections in Healthy and Immunocompromised Hosts,nan,recruiting,No Results Available,nan,NIH,https://ClinicalTrials.gov/show/NCT01306084,NCT01306084,"sample collection, analysis of immune function, or review of tissue bx or clinical rpts from outside labs in designated pop. w/ viral, suspected, or recovered from a viral infection or a close contact of people w/or suspected to have a viral inf...",observational,observational model: cohort|time perspective: prospective
The PREPARE for COVID Trial,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04392115,NCT04392115,patient-reported disability 90 days after enrollment|mental health|function|health-related quality of life|frailty|all-cause mortality.|health system - emergency department visits|health system - re-admission|health system - transfer to long-term care|covid-19 test results|safety [adverse events],interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: health services research
Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID19.,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04322279,NCT04322279,proportion of subjects with sars-cov-2 positive serology at day 30 following the last high/moderate risk contact with a laboratory-confirmed sars-cov-2 case.|factors associated with a sars-cov-2 positive serology at day 30 (+/-7);|time (days) between the first positive sars-cov-2 serology and the first negative sars-cov-2 serology.,observational,observational model: cohort|time perspective: prospective
Ambulance Calls for Substance Use and Alcohol in a Pandemic (ASAP),ASAP,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04474444,NCT04474444,attendances for alcohol and drug use,observational,observational model: case-only|time perspective: retrospective
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection,nan,not yet recruiting,No Results Available,not applicable,Other|Industry,https://ClinicalTrials.gov/show/NCT04261907,NCT04261907,the incidence of composite adverse outcome|time to recovery|rate of no fever|rate of no cough|rate of no dyspnea|rate of no requring supplemental oxygen|rate of undectable viral rna|rate of mechanical ventilation|rate of icu admission|time and rate of laboratory indicators related to disease improvement to return to normal,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Using PRP and Cord Blood in Treatment of Covid -19,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04393415,NCT04393415,the number of patients with positive covid 19 who will improve after receiving stem cells,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, outcomes assessor)|primary purpose: supportive care"
Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome,Resistir,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04403061,NCT04403061,changes in cytokines associated with sars cov-2 infection|evaluation of cellular response|tlrs activation|kir phenotype determination,observational,observational model: cohort|time perspective: prospective
Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04264533,NCT04264533,ventilation-free days|28-days mortality|icu length of stay|demand for first aid measuments|vasopressor days|respiratory indexes|ventilator parameters|apache ii scores|sofa scores,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, outcomes assessor)|primary purpose: treatment"
Assessment of Lung Recruitablity of Acute Respiratory Distress Syndrome With SARS-CoV-2 Pneumonia by Electrical Impedance Tomography,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04473300,NCT04473300,the distribution of ventilation|silent spaces|respiratory system compliance|oxygenation|dead space ventilation ratio,observational,observational model: cohort|time perspective: prospective
Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay,nan,recruiting,No Results Available,phase 3,Industry,https://ClinicalTrials.gov/show/NCT04452318,NCT04452318,"proportion of participants who have a positive sars-cov-2 rt-qpcr (based on central lab test) and signs and symptoms (strict-term) of sars-cov-2 infection during the efficacy assessment period (eap)|proportion of participants who have a rt-qpcr confirmed sars-cov-2 infection (either symptomatic or asymptomatic) during the eap|incidence and severity of treatment-emergent adverse events (teaes)|proportion of participants who have a symptomatic rt-qpcr confirmed sars-cov-2 infection (broad term) during the eap|proportion of participants who have a positive sars-cov-2 rt-qpcr and absence of signs and symptoms (strict term) during the eap|proportion of participants who have a positive sars-cov-2 rt-qpcr and absence of signs and symptoms (broad term) during the eap|number of days of symptomatic sars-cov-2 infection (strict-term) from the first day of the first sign or symptom until the last day of the last sign or symptom associated with the first positive sars-cov-2 rt-pcr that occurs during the eap|number of days of symptomatic sars-cov-2 infection (broad-term) from the first day of the first sign or symptom until the last day of the last sign or symptom associated with the first positive sars-cov-2 rt-pcr that occurs during the eap|time-weighted average of viral shedding (log10 copies/ml) from the first positive sars cov-2 rt-qpcr nasopharyngeal (np) swab sample (with an onset during the eap) until the visit within the window including 22 days after the positive test during the eap|maximum sars-cov-2 rt-qpcr log10 viral copies/ml in nasopharyngeal (np) swab samples among individuals with ‚â•1 rt-qpcr positive that has an onset during the eap|maximum sars-cov-2 rt-qpcr log10 viral copies/ml in np swab samples|area under the curve (auc) in viral shedding (log10 copies/ml) from the first positive sars-cov-2 rt-qpcr np swab sample until the first confirmed negative test, that has an onset during the eap|number of medically attended visits in emergency rooms or urgent care centers related to a rt-qpcr confirmed sars-cov-2 infection that has an onset during the eap|proportion of participants requiring medically attended visits in emergency rooms or urgent care centers related to a rt-qpcr confirmed sars cov-2 infection that has an onset during the eap|proportion of participants hospitalized related to a rt-qpcr confirmed sars-cov-2 infection that has an onset during the eap|number of days of hospital and intensive care unit (icu) stay in subjects hospitalized for a rt-qpcr confirmed sars-cov-2 infection that has an onset during the eap|number of days missed for daily responsibilities due to a rt-qpcr confirmed sars-cov-2 infection that has an onset during the eap|concentrations of regn10933 in serum over time and selected pk parameters|concentrations of regn10987 in serum over time and selected pk parameters|immunogenicity as measured by anti-drug antibodies (ada) to regn10933 over time|immunogenicity as measured by anti-drug antibodies (ada) to regn10987 over time|incidence and severity of teaes in baseline seropositive participants (based on central lab test)|incidence and severity of symptomatic sars-cov-2 infection|proportion of participants who subsequently develop signs and symptoms (strict-term) of symptomatic sars-cov-2 infection during eap|proportion of participants who subsequently develop signs and symptoms (broad-term) of symptomatic sars-cov-2 infection during eap|number of days of symptomatic sars cov-2 infection (strict-term)|number of days of symptomatic sars cov-2 infection (broad-term)|time-weighted average change from baseline in viral shedding in np swab samples until the visit within the window including day 23",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Sero-epidemiological Survey of England in 2019/2020,STORY,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04061382,NCT04061382,"feasibility of developing an england based sero-epidemiological programme in 0-24 year olds|feasibility of developing an england based sero epidemiological survey in 0-24 year olds|recruitment rate|cost|to assess, in relevant age groups, antibody concentrations against infections and vaccine preventable diseases|sera collection|exploratory",observational,observational model: other|time perspective: prospective
HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,HOME-CoV,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04338841,NCT04338841,the composite rate of adverse outcomes|the rate of hospitalization,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,CloroCOVID19,completed,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04323527,NCT04323527,mortality rate reduction of 50% by day 28|absolute mortality on days 7 and 14|improvement in overall subject's clinical status assessed in standardized clinical questionnaires on days 14 and 28|improvement in daily clinical status assessed in standardized clinical questionnaires during hospitalization|duration of supplemental oxygen (if applicable)|duration of mechanical ventilation (if applicable)|absolute duration of hospital stay in days|prevalence of grade 3 and 4 adverse events|prevalence of serious adverse events|change in serum creatinine level|change in serum troponin i level|change in serum aspartate aminotransferase level|change in serum ck-mb level|change in detectable viral load in respiratory tract swabs|viral concentration in blood samples|absolute number of causes leading to participant death (if applicable),interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
MR-Evaluation of Renal Function In Septic Patients,MERSEP,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT02765191,NCT02765191,change in renal blood flow and renal oxygenation after standardized plasma expansion with fluid bolus|descriptive renal oxygenation and blood flow in critical illness due to sepsis|descriptive renal oxygenation and blood flow in critical illness in no/low grade aki or high grade aki.,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
"To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects",nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04525079,NCT04525079,primary safety outcome|to evaluate the safety of ct-p59|to evaluate the pharmacokinetic(pk) of ct-p59,interventional,"allocation: randomized|intervention model: sequential assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: screening"
Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period : Prospective Cohort.,Resi-CoV,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04349163,NCT04349163,compare the level of resilience between physicians and caregivers of different specialties and in different workplaces according to the covid-19 epidemic.,observational,observational model: cohort|time perspective: prospective
Study of the Consequences of Infection on Compliance of Modalities of Decisions of Limitations and Stops of Treatments (COVID-19-LAT),COVID-19-LAT,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04452487,NCT04452487,decisions of limitations and therapeutic stops|characteristics of the notification of lat procedure|characteristics of the lat procedure (persons who participated to the collegial discussion)|characteristics of consultant's reasoned opinion for the lat procedure|characteristics of the lat procedure|characteristics of units|age of physicians|gendrer of physicians|exparience of physicians|characteristics of physicians|age of patients|patient's history|covid-19 patient's status|characteristics of hospitalization's patients|characteristics of affected organ|characteristics of patients|final patient status|patient's environnement,observational,observational model: case-control|time perspective: prospective
Expanded Access Remdesivir (RDV; GS-5734‚Ñ¢),nan,available,No Results Available,nan,U.S. Fed,https://ClinicalTrials.gov/show/NCT04302766,NCT04302766,nan,expanded access:intermediate-size population|treatment ind/protocol,nan
Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia,nan,not yet recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04275388,NCT04275388,clinical recovery time|complete fever time|cough relief time|virus negative time|incidence of severe or critical neocoronavirus pneumonia,observational,observational model: cohort|time perspective: retrospective
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults,nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04380701,NCT04380701,"solicited local reactions at the injection site (pain, tenderness, erythema/redness, induration/swelling) recorded up to 7¬±1 days after each immunization.|solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) recorded up to 7¬±1 days after each immunization.|the proportion of subjects with at least 1 unsolicited treatment emergent adverse event (teae):|for bnt162a1, bnt162b1, bnt162b2, and bnt162c2 (p/b):|for bnt162c2 (sd):",interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Less Frequency Hemodialysis and COVID-19,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04374058,NCT04374058,"mortality|anemia, nutrition, adequation of dialysis, total ultrafiltration, ultrafiltration rate,|hospitalization|vascular access",observational,observational model: case-control|time perspective: prospective
"Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04245631,NCT04245631,detection sensitivity is greater than 95%|detection specificity is greater than 95%|consistent with existing universal reagent detection rates greater than 95%,observational,observational model: cohort|time perspective: prospective
Evaluation of the Physical Activity Level of the Elderly in Social Isolation,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04480606,NCT04480606,physical activity scale for the elderly|nottingham health profile|short physical performance battery|beck anxiety inventory|beck depression inventory|contentment with life scale,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
"Clinical, Biological and Histological Pulmonary and Renal Damage Associated With the SARS-CoV-2 Syndrome in Patients Admitted in ICU",PR-Covid-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04385004,NCT04385004,"analysis of clinical, biological and histological pulmonary and renal impairment related to sars-cov-2",observational,observational model: case-only|time perspective: other
Covid Radiographic Images Data-set for A.I,CORDA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04419545,NCT04419545,sensibility and specificity of neural network diagnosis,observational,observational model: case-control|time perspective: retrospective
Isolation and Culture of Immune Cells and Circulating Tumor Cells From Peripheral Blood and Leukapheresis Products,nan,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT00571389,NCT00571389,nan,observational,observational model: case-only|time perspective: prospective
Sequelae of Sars-CoV-2 Infections,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04442789,NCT04442789,sequelae after covid-19,observational,observational model: cohort|time perspective: prospective
"imPulse‚Ñ¢ Una Full-spectrum, Over Clothing E-stethoscope",nan,not yet recruiting,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04556149,NCT04556149,diagnostic performance characteristics,observational,observational model: case-control|time perspective: prospective
Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT03331445,NCT03331445,measure the safety of 160ppm inhaled nitric oxide delivery in ntm subjects|measure the effect of 160ppm inhaled nitric oxide delivery on lung spirometry in ntm subjects|measure the antimicrobial effect of 160ppm inhaled nitric oxide on lung ntm bacterial load in the sputum|measure the effect of 160ppm inhaled nitric oxide on quality of life (criss) score,interventional,intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
The COVID-19 ICU PRAYER Study,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04361838,NCT04361838,impact of multi-denominational prayer on clinical outcomes of critically ill covid-19 patients in the intensive care unit on mortality.|difference in patient outcomes - acute physiology and chronic health enquiry. apache ii score.|difference in patient outcomes - sequential organ failure assessment - sofa score|difference in patient outcomes - length of stay in icu.|difference in patient outcomes - length of ventilator support|difference in patient outcomes - length of vasopressor support,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, care provider)|primary purpose: supportive care"
Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),COVID-19,recruiting,No Results Available,phase 3,Other|NIH,https://ClinicalTrials.gov/show/NCT04322682,NCT04322682,number of participants who die or require hospitalization due to covid-19 infection|number of participants who die|number of participants requiring hospitalization due to covid-19 infection|number of participants requiring mechanical ventilation,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
2019-nCoV Outbreak and Cardiovascular Diseases,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04255940,NCT04255940,cardiovascular death|major adverse cardiovascular events|times from symptom onset to hospital arrival|anxiety,observational,observational model: case-only|time perspective: prospective
Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease,COVIDEP,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04479540,NCT04479540,rate of patients with pulmonary embolism|prothrombin level measurement|activated partial thromboplastin time measurement|fibrinogen measurement|d-dimers measurement|protein c measurement|willebrand antigen measurement|soluble tissue factor measurement|soluble thrombomodulin measurement|e-selectin measurement|thrombin-antithrombin complex measurement|assessment of clot formation curve|assessment of thrombin generation|assessment of fibrinolysis|mortality,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: diagnostic
Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling,nan,completed,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04282135,NCT04282135,cluster analysis of mcc ims spectra.,observational,observational model: case-control|time perspective: prospective
Sexual Health and Problems During the Covid -19 Infection,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04427813,NCT04427813,the number of partners that have unusual behaviour,observational,observational model: other|time perspective: prospective
LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION,INC-CVD-202001,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04409275,NCT04409275,"pulmonary fibrotic changes, short and medium term|degree of lung function impairment|biological markers",observational,observational model: case-only|time perspective: prospective
A New Screening Strategy for 2019 Novel Coronavirus Infection,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04281693,NCT04281693,screening accuracy|cost-effectiveness analysis,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: screening
Needle Stick Injuries in Emergency Medical Service Practice,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04363788,NCT04363788,number of visible puncture|wlt,observational,observational model: cohort|time perspective: prospective
Behavior During and After COVID-19 Crisis,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04502108,NCT04502108,physical activity 2020|physical activity 2021|nutrition 2020|nutrition 2021|alcohol 2020|alcohol 2021|sleep 2020|sleep 2021,observational,observational model: cohort|time perspective: prospective
Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.,COVID-19,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04388631,NCT04388631,sperm density|sperm activity|erection hardness and duration|iief-5/qeq questionnaire score|detection rate of sars-cov-2 in male genitourinary system|semen volume|sperm survival rate|serum testosterone/luteinizing hormone (lh)/follicle stimulating hormone (fsh) level|scl-90 questionnaire score,observational,observational model: cohort|time perspective: prospective
Clinical Outcome of Anti-IL6 vs Anti-IL6 Corticosteroid Combination in Patients With SARS-CoV-2 Cytokine Release Syndrome,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04486521,NCT04486521,"ventilator-free days|median duration of ventilation|median change in the pao2/fio2|vasopressor-free days|duration of icu stay|duration of hospital stay|mortality rate|percentage of participants with adverse events [transaminitis, hyperglycemia]|concentration of ferritin, il6, d dimer, fibrinogen, c-reactive protein (crp), lactate dehydrogenase (ldh) and absolute lymphocyte count and their correlation with the effectiveness of the treatment|rate of superinfection (bacterial, viral, invasive fungal infections)|time to the first covid 19 test negative",observational,observational model: other|time perspective: prospective
A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04260308,NCT04260308,ghq-12(general health questionnaire-12)|ies-r(impact of event scale-revised),observational,observational model: case-only|time perspective: prospective
Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) - COVID Related Substudy,nan,not yet recruiting,No Results Available,not applicable,Other|NIH,https://ClinicalTrials.gov/show/NCT04540939,NCT04540939,patient-reported outcomes measurement information system (promis-adult short form level 2) anxiety survey|penn state worry questionnaire (pswq-16) worry survey|promis (adult short form) emotional depression survey|working alliance inventory- short revised (wai-sr)|patient-reported outcomes measurement information system (promis-adult short form level 2) anxiety survey group differences (mbct and pmr)|penn state worry questionnaire (pswq-16) worry survey group differences (mbct and pmr)|promis (adult short form) emotional depression survey group differences (mbct and pmr)|working alliance inventory- short revised (wai-sr) group differences (mbct and pmr),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: treatment"
Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),nan,recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04385836,NCT04385836,clinical improvement,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,nan,recruiting,No Results Available,phase 1|phase 2,Other,https://ClinicalTrials.gov/show/NCT04275245,NCT04275245,2019 ncov nucleic acid detection|recovery of body temperature|recovery of resting respiratory rate|recovery of spo2|chest ct / chest film changes|pao2 / fio2|time to reach the isolation release standard|changes of inflammatory immune status,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
First Responder Resiliency Program During COVID-19,nan,not yet recruiting,No Results Available,not applicable,Other|Industry,https://ClinicalTrials.gov/show/NCT04536376,NCT04536376,changes in biometric trends,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
A Study of Ad26.COV2.S in Adults (COVID-19),nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04509947,NCT04509947,number of participants with solicited local adverse events (aes) for 7 days after first vaccination|number of participants with solicited local aes for 7 days after second vaccination|number of participants with solicited systemic aes for 7 days after first vaccination|number of participants with solicited systemic aes for 7 days after second vaccination|number of participants with unsolicited aes for 28 days after first vaccination|number of participants with unsolicited aes for 28 days after second vaccination|number of participants with serious adverse events (saes)|severe acute respiratory syndrome coronavirus-2 (sars-cov-2) neutralization as measured by virus neutralization assay (vna)|sars-cov-2-binding antibodies as measured by enzyme-linked immunosorbent assay (elisa),interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: prevention"
"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers",nan,completed,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04392219,NCT04392219,safety and tolerability of single ascending dose (sad) of eidd-2801 (part 1): adverse events|safety and tolerability of multiple ascending dose (mad) of eidd-2801 (part 3): adverse events|pharmacokinetics (pk) of eidd-2801 when given as single doses (part 2): maximum observed concentration cmax|pharmacokinetics (pk) of eidd-2801 when given as single ascending dose (sad) (part 1): maximum observed concentration cmax|pharmacokinetics (pk) of eidd-2801 when given as multiple ascending dose (mad) (part 3): maximum observed concentration cmax|safety and tolerability of single doses of eidd-2801 (part 2): adverse events,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
The Impact of a Societal Lockdown on Those With Spinal Cord and Brain Injuries,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04426071,NCT04426071,change in fear of covid-19|change in ability to participate in social roles and activities|change in depressive symptoms|change in positive affect and well-being|change in anxiety|change in fatigue|change in emotional and behavioural dyscontrol|change in satisfaction with social roles and activities|change in sleep disturbance|change in stigma|change in cognitive function|change in social distancing strategies used|change in thoughts and feelings about social distancing,observational,observational model: cohort|time perspective: prospective
Pilot Internet-based Self-Help Program for Managing Corona (COVID-19) Stress,CoronaStress,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04394403,NCT04394403,"the coronavirus health impact survey (crisis)|depression, anxiety, and stress scale- 21 item version: dass-21",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19",nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04363047,NCT04363047,prevalence and abundance of cd4+ t lymphocytes,observational,observational model: cohort|time perspective: retrospective
Effect of Positive Attitudes on Behavior and Wellness,TEAM-ICU,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04441632,NCT04441632,"teamwork climate, as measured by selected items from the validated safety attitude questionnaire (saq)|resiliency, as measured by the validated brief resilience scale (brs)|burnout, as validated by the single-item burnout scale inventory",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
"Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection",WU352,suspended,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04341727,NCT04341727,hours to recovery|time fever resolution,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
An Observational Study to Assess the Protocol for the COVID-19 Treatment in Burkina Faso,CHLORAZ,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04445441,NCT04445441,clearance of viral load|safety of the treatment,observational,observational model: cohort|time perspective: prospective
Microvascular Flow and Reactivity in Patients Presenting in the Acute Phase of COVID-19.,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04406545,NCT04406545,"to evaluate, through laser doppler, the presence of changes in systemic microvascular endothelial function in patients in the acute phase of covid-19.",observational,observational model: cohort|time perspective: prospective
Psychological Impact of Institutional Quarantine as a Precautionary Measure Against COVID-19,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04552392,NCT04552392,depression|anxiety|perceived stress|impact of life events,observational,observational model: case-only|time perspective: cross-sectional
Implementation of the Integrated Care of Older People App and ICOPE Monitor in Primary Care (ICOPE),ICOPE,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04413877,NCT04413877,incidence of frailty,observational,observational model: cohort|time perspective: prospective
Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04382560,NCT04382560,dispositional questionnaire 1|dispositional questionnaire 2|dispositional questionnaire 3|dispositional questionnaire 4|heart rate|cardiac vagal modulation,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (investigator, outcomes assessor)|primary purpose: other"
QoL and the Emotional-affective Sphere o in Rehabilitation Setting During COVID-19 Quarantine,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04408196,NCT04408196,short form-36 health survey (sf36)|short form (36) health survey (sf36)|beck anxiety inventory (bai)|beck depression inventory-ii (bdi-ii)|modified barthel index (mbi),observational,observational model: cohort|time perspective: prospective
Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access,TMD,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04420273,NCT04420273,change in sse performance|identification of concerning mole|effectiveness of adhesive patch-based home sample collection for genomic analysis of concerning moles to rule-out melanoma|change in skin self-examination anxiety|change in confidence performing mole checks|number of physician visits for concerning moles|number of biopsies of concerning moles,interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (care provider, investigator, outcomes assessor)|primary purpose: prevention"
Survey of Satisfaction on Traditional Chinese Medicine Jing-Guan-Fang (JGF) for COVID-19 Prevention,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04388644,NCT04388644,the number confirmed covid-19 cases|the person with covid-19 like symptoms|the improving rate of covid-19 like symptoms|the satisfaction% to taking jgf,observational,observational model: case-only|time perspective: retrospective
"To Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of DWRX2003 Against COVID-19",nan,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04524052,NCT04524052,incidence of treatment-emergent adverse events|pharmacokinetic changes of niclosamide from baseline in each dose group: cmax|pharmacokinetic changes of niclosamide from baseline in each dose group: tmax|pharmcodynamic analysis of niclosamide from baseline in each dose group and time point: crp,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
Mitigating Suicide Risk With Single Session 'Brief Skills for Safer Living',nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04495543,NCT04495543,change in suicidal ideation using beck scale for suicide ideation|change in depression symptoms using the quick inventory of depressive symptoms self-report scale (qids-sr)|change in anxiety symptoms using the generalized anxiety disorder 7-item scale (gad-7)|change in acquired capability of suicide scale (acss)|change in interpersonal needs questionnaire score|change in dimensional anhedonia rating scale (dars) score|change in sheehan disability scale (sds) score|change in treatment utilization,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
Comparison of New Coronavirus (COVID-19) Awareness in Individuals of Different Age Groups: Analysis of Turkey,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04357886,NCT04357886,covid-19 awareness survey,observational,observational model: cohort|time perspective: prospective
The Professional Peer Resilience Initiative,PPRI,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04396600,NCT04396600,change in professional quality of life|change in mental health symptoms and resilience markers,observational,observational model: cohort|time perspective: prospective
Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness,BREATH,recruiting,No Results Available,early phase 1,Other,https://ClinicalTrials.gov/show/NCT04368676,NCT04368676,rate of participant recruitment|rate of retention|completeness of data entry|cost of interventions|unexpected costs|change in athens insomnia scale|change in generalized anxiety disorder 7-item scale|change in patient health questionnaire 9|change in connor-davidson resilience scale,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
CoCo-20: a Longitudinal Follow-up Study of the French Paediatric Population During and After the Coronavirus Pandemic COVID-19,CoCo-20,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04498416,NCT04498416,diagnosis of possible psychological and psychiatric difficulties at baseline|follow up of psychological and psychiatric difficulties at v2|follow up of psychological and psychiatric difficulties at v3|follow up of psychological and psychiatric difficulties at v4|impact of traumatic history prior to confinement|impact of other previous psychiatric disorders|parental reaction,observational,observational model: cohort|time perspective: prospective
Post-Pandemic Perception of Public Space in Singapore,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04394039,NCT04394039,eeg power in alpha band|eeg power in beta band|fnirs haemodynamics|profile of mood states|landscape preference measured with self-assessment manikin scale,interventional,intervention model: sequential assignment|masking: none (open label)|primary purpose: supportive care
Changes in Preference for Surgery of Patients Signed up for Arthroscopic Procedures,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04370678,NCT04370678,change in preference|change in preference between groups,observational,observational model: other|time perspective: cross-sectional
Obesity Surgery During 2020 Italian Pandemic,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04480034,NCT04480034,postoperative covid-19 infection|complications related to bariatric surgery,observational,observational model: cohort|time perspective: prospective
Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome,ARDS-MSC-205,recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04447833,NCT04447833,the incidence of pre-specified treatment related adverse events of interest (traeis).|safety; all-cause mortality|changes in leucocytes|changes in trombocytes|changes in plasma concentration of c-reactive protein (crp)|changes in plasma concentration of prothrombin complex (pk)|changes in plasma concentration of creatinine|changes in plasma concentration of aspartate amino transferase (asat)|changes in plasma concentration of alanine amino transferase (alat)|changes in plasma concentration of n-terminal pro-brain natriuretic peptide (nt-probnp)|changes in blood pressure|changes in body temperature|efficacy; changes in pulmonary compliance|efficacy; changes in driving pressure (plateau pressure- peep)|efficacy; changes in oxygenation (pao2/fio2)|efficacy; duration of ventilator support|efficacy; pulmonary bilateral infiltrates|efficacy; sequential organ failure assessment (sofa) score|efficacy; hospital stay|lung function|lung fibrosis|six minutes walk test|changes in quality of life|blood biomarkers|sensitisation test,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device,nan,not yet recruiting,No Results Available,nan,Industry|Other,https://ClinicalTrials.gov/show/NCT04357977,NCT04357977,covid +,observational,observational model: ecologic or community|time perspective: cross-sectional
"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)",nan,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT03648372,NCT03648372,"dose escalation and cancer treatment expansions: number of participants reporting one or more treatment emergent adverse events (teaes)|dose escalation and cancer treatment expansions: number of participants with dose limiting toxicities (dlts)|dose escalation and cancer treatment expansions: number of participants with one or more serious adverse events (saes)|dose escalation and cancer treatment expansions: number of participants with one or more teaes leading to dose modifications and treatment discontinuations|dose escalation and cancer treatment expansions: number of participants with greater than or equal to (>=) grade 3 teaes|dose escalation and cancer treatment expansions: number of participants with clinically significant laboratory values|dose escalation and cancer treatment expansions: number of participants with clinically significant vital sign measurements|dose escalation and cancer treatment expansions: number of participants who experience cytokine release syndrome crs)|covid-19 expansion: number of participants with >=2 log reduction from baseline in viral load or below level of detection (negative) in nasopharyngeal or oropharyngeal samples|dose escalation and cancer treatment expansions, cmax: maximum observed plasma concentration for tak-981|dose escalation and cancer treatment expansions, tmax: time to reach the maximum plasma concentration (cmax) for tak-981|dose escalation and cancer treatment expansions, auct: area under the plasma concentration-time curve from time 0 to time t over the dosing interval for tak-981|dose escalation and cancer treatment expansions, auc‚àû: area under the plasma concentration-time curve from time 0 to infinity for tak-981|dose escalation and cancer treatment expansions, terminal disposition phase half-life (t1/2z) for tak-981|dose escalation and cancer treatment expansions, total clearance after intravenous administration (cl) for tak-981|dose escalation and cancer treatment expansions, volume of distribution at steady state after intravenous administration (vss) for tak-981|dose escalation and cancer treatment expansions: overall response rate (orr)|dose escalation and cancer treatment expansions: duration of response (dor)|dose escalation and cancer treatment expansions: disease control rate (dcr)|dose escalation and cancer treatment expansions: progression-free survival (pfs)|dose escalation and cancer treatment expansions: time to response (ttr)|dose escalation and cancer treatment expansions: percentage of participants at each dose level demonstrating adduct formation in post-dose skin or tumor biopsies|dose escalation and cancer treatment expansions: percent change in small ubiquitin-like modifier (sumo) 2/3 signal with pre and post-dose skin or tumor biopsies at each dose level|covid-19 expansion: number of participants reporting one or more teaes|covid-19 expansion: number of participants based on severity of teaes|covid-19 expansion: number of participants based on duration of teaes|covid-19 expansion: number of participants who experience crs|covid-19 expansion: change from baseline in national early warning score (news)|covid-19 expansion: percentage of participants reporting each hospitalization severity rating|covid-19 expansion: change from baseline in sars-cov-2 viral load in nasopharyngeal or oropharyngeal samples|covid-19 expansion: percentage of participants requiring oxygen supplementation; assisted or positive pressure non-invasive ventilation; and invasive ventilation, on days 3, 5, 8, 11, 15, and 30|covid-19 expansion: percentage of participants that met intensive care unit (icu) criteria|covid-19 expansion: duration of hospitalization|covid-19 expansion: time to viral ribonucleic acid (rna) negativity in nasopharyngeal or oropharyngeal samples|covid-19 expansion: time to discharge or to a news of less than or equal to (<=) 3 and maintained for 24 hours|covid-19 expansion: number of deaths in hospital due to any cause in first 30 days and in 90 days",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
RASCALS: Rapid Assay for Sick Children With Acute Lung Infection Study,RASCALS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04233268,NCT04233268,performance of the novel pathogen detection assay|time to results|negative cultures|antibiotic therapy|prevalence of covid19 in children admitted to picu,observational,observational model: cohort|time perspective: prospective
CoV-PICS: A Virtual Post-ICU Clinic,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04490278,NCT04490278,acceptance with virtual cov-pics visits - aim|acceptance with virtual cov-pics visits - iam|acceptance with virtual cov-pics visits - fim|pics symptoms - daily living|pics systems - cognitive|pics systems - nutrition|pics systems - promis|pics symptoms - memory,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
A Patient-Centered PaTH to Addressing Diabetes,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT02788903,NCT02788903,weight change|diabetes incidence|hospitalization|intubation|death,observational,observational model: cohort|time perspective: other
Mindfulness Training for Seniors,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04378803,NCT04378803,change in mindfulness skills as measured by five-facet mindfulness questionnaire (5fmq)|change in mindfulness skills as measured by decentering - experiences questionnaire (eq).|change in psychological health as measured by patient health questionnaire 4 items (phq4).|change in positive affect on psychological health as measured by the short variant of the positive and negative affect scale (panas).|change in negative affect on psychological health as measured by the short variant of the positive and negative affect scale (panas).|change in loneliness measured by the loneliness questions from the social isolation battery.|change in loneliness measured by a loneliness question.|change in attention|change in well-being as measured by the perseverative thought questionnaire (ptq)|change in well-being as measured by the experience of intrusions scale (eis)|change in well-being as measured by the short version of the perceived stress scale (pss).|change in well-being as measured by the perma-profiler,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: supportive care
"CoV-ICU Score, Intensive Care Unit, SARS-CoV-2",nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04383483,NCT04383483,covicu score|values,observational,observational model: case-only|time perspective: retrospective
Sleep Quality Among HCWs,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04549350,NCT04549350,presence of poor sleep quality or not|reported medical errors,observational,observational model: other|time perspective: cross-sectional
Needs of Persons With Spinal Cord Injury (SCI),nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04422769,NCT04422769,nih toolbox instrumental support survey - change in instrumental support|ucla 3-item loneliness scale - change in social isolation,observational,observational model: cohort|time perspective: prospective
Music Therapy in Frontline Healthcare Workers,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04551274,NCT04551274,change in perceived stress score - nih emotion toolbox|change in general life satisfaction score - nih emotion toolbox|change in positive affect score - nih emotion toolbox|change in anger score - nih emotion toolbox|change in fear score - nih emotion toolbox|change in meaning & purpose score - nih emotion toolbox|change in sadness score - nih emotion toolbox|change in emotional support score - nih emotion toolbox|change in loneliness score - nih emotion toolbox|eeg - change in power in the delta band|eeg - change in power in the beta band|eeg - change in power in the alpha band|eeg - change in power in the theta band,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: supportive care
Telemedical Risk Assessment and Preoperative Evaluation (TAPE),nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04518514,NCT04518514,feasibility (as defined below) of telemedical risk assessment and preoperative evaluation in anesthesiology as assessed by a questionnaire.|patient acceptance of a telemedical preanesthesia evaluation as assessed by a questionnaire.|patient satisfaction with a telemedical preanesthesia evaluation as assessed by a questionnaire.|time saving for the patient|time saving for the physician|adverse events,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: other
Effects of a Face Mask on Oxygenation During Exercise,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04557605,NCT04557605,time to exhaustion during exercise|change from baseline in blood oxygen saturation|change from baseline in quadriceps oxygenated hemoglobin|change from baseline in quadriceps de-oxygenated hemoglobin|change from baseline in quadriceps total hemoglobin|change from baseline in rating of perceived exertion,interventional,allocation: randomized|intervention model: crossover assignment|masking: single (outcomes assessor)|primary purpose: treatment
Video-Based Exercises and Well-Being During Social Isolation,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04335851,NCT04335851,world health organization quality of life questionnaire bref|rapid assessment of physical activity|global rating of change scale,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
The Efficacy Comparing Daily and After-each-case Room Disinfection.,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04399005,NCT04399005,qualified rate of room disinfection|the number of colony-forming units (cfu),interventional,allocation: non-randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: other
Effectiveness of Convalescent Immune Plasma Therapy,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04442958,NCT04442958,plasma ferritin level|lymphocyte count|d-dimer level|c-reactive protein level|plasma procalcitonin level|plasma fibrinogen level|fractional inspired oxygen level|partial oxygen saturation level|arterial oxygen level,interventional,"allocation: randomized|intervention model: crossover assignment|masking: double (participant, investigator)|primary purpose: treatment"
Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019,RISC,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04383899,NCT04383899,describe medications used prior to admission associated with worse infection in covid-19 patients in france.|quantify medications used prior to admission associated with worse infection in covid-19 patients in france.|describe other patient characteristics with worse infection in covid-19 patients in france.|quantify other patient characteristics with worse infection in covid-19 patients in france.,observational,observational model: case-control|time perspective: prospective
The Impact of Lifestyle Changes on Non-COVID Deaths,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04550312,NCT04550312,numeric values of all-cause death and the death rates of non-covid diseases,observational,observational model: other|time perspective: retrospective
Telemedicine in HIV Care in Buenos Aires,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04513496,NCT04513496,telemedicine reach. re-aim framework|telemedicine effectiveness. re-aim framework|telemedicine adoption. re-aim framework|telemedicine implementation.re-aim framework|telemedicine manteinance. re-aim framework,observational,observational model: cohort|time perspective: prospective
Telerehabilitation for Patients Diagnosed With Coronavirus,COVID-19,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04346927,NCT04346927,visual analogue scale|modified borg scale|leicester cough questionnaire|timed up and go|30 second chair stand test|the beck depression inventory|the beck anxiety inventory,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Chat-based Support for Preveting Smoking Relapse,nan,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04409496,NCT04409496,biochemically-validated tobacco abstinence|self-reported 6-month prolonged tobacco abstinence|self-reported 7-day point-prevalence tobacco abstinence|self-reported relapse rate,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Telemedicine for Follow-up of Systemic Lupus Erythematosus,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04368299,NCT04368299,"the percentage of patients in remission or lldas at one year.|direct and indirect costs after one year.|the change of lupus quality of life (lupusqol) at one year.|patient confidence and satisfaction score at one year.|rates of adverse reaction and severe adverse reaction, including contracting covid-19 infection, after one year.|numbers of clinic visits, hospitalization, overall in-person hospital visits in one year.|the change of (health assessment questionnaire disability index haq-di) at one year.|the change of (hospital anxiety and depression scale) hads at one year.",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: health services research
Specimen Collection Study Protocol,nan,"active, not recruiting",No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04468386,NCT04468386,matrix equivalency,observational,observational model: case-only|time perspective: prospective
Efficacy of DEXamethasone in Patients With Acute Hypoxemic REspiratory Failure Caused by INfEctions,DEXA-REFINE,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04545242,NCT04545242,60-day mortality|ventilator-free days,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Reducing Asymptomatic Infection With Vitamin D in Coronavirus Disease,RAID-CoV-2,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04476680,NCT04476680,seroconversion|interim analysis - seropositivity at 12 weeks|dried blood spot performance|salivary iga performance|prevalence of sars-cov-2|change in seropositivity|change in seroconversion rate,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: prevention"
French COVID Cohort,FrenchCOVID,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04262921,NCT04262921,"clinical features|response to treatment|pathogen replication, excretion and evolution, within the host|immune host responses to infection and therapy|host genetic variants",observational,observational model: other|time perspective: prospective
Pre-exposure Prophylaxis for SARS-Coronavirus-2,nan,"active, not recruiting",No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04328467,NCT04328467,covid-19-free survival|incidence of confirmed sars-cov-2 detection|incidence of possible covid-19 symptoms|incidence of all-cause study medicine discontinuation|ordinal scale of covid-19 disease maximum severity if covid-19 diagnosed at study end|incidence of hospitalization for covid-19 or death|incidence of study medication-related side effects,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Determining the Physical Activity Level of Healthy Adults During Pandemic,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04555954,NCT04555954,physical activity level,observational,observational model: other|time perspective: prospective
"Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress",COVID-19,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04319211,NCT04319211,international physical activity questionnaire (ipaq)|health-related quality of life sf-12 scale|beck depression scale,observational,observational model: case-only|time perspective: cross-sectional
Repeated Measures Trial of Temporary Automated Manual Ventilation Versus Noninvasive Oxygenation or Conventional Vent,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04369274,NCT04369274,arterial oxygenation|expired pressure of carbon dioxide.|airway pressure|heart rate|blood pressure|airway flow,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Project Resurgence Communication Trial,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04418947,NCT04418947,percent with visit or procedure with provider|percent with scheduled visit or procedure with provider|percent with completed telemedicine visit with provider,interventional,"allocation: randomized|intervention model: factorial assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: other"
TRACERx Renal CAPTURE Sub-study,TRACERxRenal,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT03226886,NCT03226886,to validate ith index and wgii as stage and grade independent prognostic markers of progression free survival in patients with ccrcc mutation in a gene of interest|capture sub-study: describe the population characteristics between sars-cov-2 positive and negative cancer patients,observational,observational model: other|time perspective: prospective
Self-compassion for Chronic Pain Virtual Group Treatment Program,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04413006,NCT04413006,change over time in scores on the self-compassion scale (scs)|change over time in scores on the pain disability index|change over time in scores on the chronic pain acceptance questionnaire - 8|change over time in scores on the pain catastrophizing scale -6|change over time in scores on the pain self-efficacy questionnaire-4|change over time in pain intensity|change over time in depression symptoms as measured by the patient health questionnaire-9 (phq-9)|changes over time in anxiety symptoms as measured by the generalized anxiety scale-7|change over time in quality of life as measured by the promis global- 10|changes over time in mindfulness,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
PH94B in the Treatment of Adjustment Disorder With Anxiety,nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04404192,NCT04404192,hamilton anxiety scale|sheehan disability scale|adjustment disorder new module (adnm)|clinical global impression - improvement rating (cgi-i),interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement,(COVID-19),enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04372693,NCT04372693,"students' learning perception questionnaire (slpq),|students' scholar achievement.",interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),CORIMUNO-TOC,"active, not recruiting",No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04331808,NCT04331808,survival without needs of ventilator utilization at day 14. group 1|who progression scale <=5 at day 4. group 1.|cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. group 2.|who progression scale at day 4. group 2.|who progression scale|survival|28-day ventilator free-days|respiratory acidosis at day 4|pao2/fio2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to icu discharge|time to hospital discharge,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Brief Cognitive Behavioral Therapy Versus Crisis Intervention Therapy Through Telepsychiatry on Psychiatric Symptoms,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04394455,NCT04394455,rate reduction in depressive symptoms|rate reduction in anxiety symptoms|rate reduction in post traumatic stress symptoms|rate reduction in perceived stress level,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (investigator)|primary purpose: treatment
A Study of Opaganib in Coronavirus Disease 2019 Pneumonia,COVID-19,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04414618,NCT04414618,"evaluation of the total oxygen requirement (area under the curve) using daily supplemental oxygen flow (l/min) over 14 days|evaluation of the time to 50% reduction from baseline in supplemental oxygen based on oxygen flow in l/min|evaluation of the proportion of patients no longer requiring supplemental oxygen for at least 24 hours by day 14|evaluation of the proportion of afebrile patients at day 14|evaluation of the time to negative swabs for sars-cov-2 by pcr|evaluation of the proportion of patients with negative swabs for sars-cov-2 by pcr at day 14|the percentage of patients who require intubation and mechanical ventilation by day 14|evaluation of the time to mechanical ventilation|evaluation the proportion of patients, with at least one measurement of fever at baseline who are afebrile at day 14|evaluation of mortality 30 days post-baseline",interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Evaluation of Six-month HIV Treatment Dispensing in South Africa,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04468789,NCT04468789,uptake of 6mmd|retention in care|viral suppression|provider acceptability of 6mmd before intervention|provider acceptability of 6mmd after intervention|patient acceptability at baseline|patient acceptability at 6 months|provider costs,observational,observational model: cohort|time perspective: prospective
Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04435028,NCT04435028,prophylaxis effect of ketotifen on patient's hearts during the treatment of anthracyclines,observational,observational model: other|time perspective: prospective
Do Network Centrality Predict Overall Depression Symptom Reduction With Lifting of Social Distancing Protocols?,nan,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04444713,NCT04444713,patient health questionnaire-9 (phq-9)|cognitive-attentional syndrome-1 (cas-1),observational,observational model: ecologic or community|time perspective: prospective
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04148430,NCT04148430,arm 1 (car t cell group) rate of severe neurotoxicities|arm 2 (covid-19 group) proportion of patients able to avoid death or mechanical ventilation,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: treatment
Safety and Effectiveness Assessment of the MakAir Artificial Ventilator,COVRESP,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04475185,NCT04475185,number of dysfunctions,interventional,intervention model: sequential assignment|masking: none (open label)|primary purpose: supportive care
International Lung UltraSound Analysis (ILUSA) Study,ILUSA,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04353141,NCT04353141,diagnostic performance of lus to predict poor outcome,observational,observational model: cohort|time perspective: prospective
Brain Imaging in Babies Study,BIBS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04443179,NCT04443179,neurodevelopmental outcomes,observational,observational model: case-control|time perspective: prospective
Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04424355,NCT04424355,number of zones of pulmonary parenchyma corresponding to viral pneumonia detected by chest mri in comparison with ct scan,observational,observational model: cohort|time perspective: prospective
Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System,PostCOVID19,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04353245,NCT04353245,fibrosis|ergospirometers,observational,observational model: case-control|time perspective: prospective
OUR Stress/ Emotion Management for Black/African American Women With Hypertension,OUR-Project,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04526145,NCT04526145,"determine the feasibility of a synchronous web-based health education program, of our project.|determine the acceptability of a synchronous web-based health education program, of our project.|change from baseline at 3 months weight.|change from baseline at 3 months waist circumference.|change from baseline at 3 months blood pressure.|change from baseline stress at 3 months.|change from baseline emotional regulation at 3 months.|change from baseline dietary approaches to stop hypertension knowledge at 3 months.|change from baseline resilience at 3 months.|describe participant experience and health during the covid-19 pandemic.",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
Clinical Outcomes of Patients With COVID19,nan,withdrawn,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04280913,NCT04280913,time to negative conversion of severe acute respiratory syndrome coronavirus 2|length of stay in hospital|survival|intubation,observational,observational model: cohort|time perspective: retrospective
Study Testing Convalescent Plasma vs Best Supportive Care,nan,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04333251,NCT04333251,reduction in oxygen and ventilation support,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Poractant Alfa - Curosurf and SARS-COV-19 ARDS (Covid-19),nan,not yet recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT04502433,NCT04502433,"number of ventilator-free days|number of free days from invasive ventilation|number of free days from non-invasive ventilation (niv)|change from baseline in pao2/fio2 ratio measured at 6 hours and 12 hours following administration of each dose in the treated group and at the similar timepoints in the control group|change from baseline in pao2/fio2 ratio at additional timepoints|length of icu stay (days)|mortality at day 28|change from baseline in ventilatory parameter (tidal volume (tv))|delta sequential organ failure assessment (sofa) score|incidence of all the aes, aes related to poractant alfa (treated cohort) (adrs), serious aes (saes) and aes leading to death|change from baseline in blood gas analysis acid-base balance parameter (ph)|percentage of patients with pao2/ fio2 improvement of >20% following administration of each dose in the treated group and at similar timepoints in the control group|number of extracorporeal membrane oxygenation (ecmo)-free days- (only for cohort 2 of patients in ecmo)|change from baseline in fio2|change from baseline in ventilatory parameter (respiratory rate (rr))|change from baseline in ventilatory parameter (dynamic compliance (cdyn))|change from baseline in ventilatory parameter (static compliance (cstat))|change from baseline in ventilatory parameter (positive end-expiratory pressure (peep)|change from baseline in ventilatory parameter (peak inspiratory pressure (pip))|change from baseline in ventilatory parameter (plateau pressure (pplat))|change from baseline in blood gas analysis acid-base balance parameter (pco2)|change from baseline in blood gas analysis acid-base balance parameter (po2)|change from baseline in blood gas analysis acid-base balance parameter (hco3)|change from baseline in blood gas analysis acid-base balance parameter (lactate)",interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Telerehabilitation in Oncology Patients,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04547634,NCT04547634,suitability of exercise intensity|verification of exercise intensity|total attendance|absence type|attendance type|change from cancer-related fatigue (crf)|change from functional capacity|change from upper limb functionality (%)|change from lower limb functionality (%)|change from quality of life (self-reported questionnaire)|change from specific breast cancer quality of life (self-reported questionnaire),interventional,allocation: randomized|intervention model: crossover assignment|masking: single (participant)|primary purpose: treatment
Psychological Impact of the Health Measures Generated by the COVID19 in Adolescents,COVADO,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04406558,NCT04406558,"anxiety score from the generalized anxiety disorder 7 (gad-7) questionnaire|depression score from the adolescent depression rating scale (adrs) questionnaire|post traumatic score questionnaire: children's revised impact of events scales -cries13|presence or absence of difficulty in falling asleep, sleeping|presence or absence of feeding difficulty|presence or absence of difficulty performing physical activity|presence or absence of toxic consomption (drug, acohol) during the lockdown|mean duration time in front of screen (hours per day)|presence or absence of difficulties with social interactions|presence or absence of difficulties with familial interactions",observational,observational model: cohort|time perspective: prospective
Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults,nan,enrolling by invitation,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04480112,NCT04480112,change in memory performance|change in cognition|change in phonemic fluency|social isolation|loneliness|depressive symptoms|misinformation about covid-19,interventional,allocation: non-randomized|intervention model: crossover assignment|masking: single (outcomes assessor)|primary purpose: other
The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04453527,NCT04453527,complement activation|leukotrienes measure|coagulation measure|hyperinflammation measure|cell count|cytokines and chemokine measure|endothelial dysfunction measures:,observational,observational model: cohort|time perspective: prospective
The Effect of Omega-3 on Selected Cytokines Involved in Cytokine Storm,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04483271,NCT04483271,il-1 beta|il-6|tnf alpha|lipid profile|fasting blood glucose,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: prevention
Digital vs Analog Impression in Cases of All-on-4 - Prosthesis,nan,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04475913,NCT04475913,bone loss|implant loss,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Tele-Yoga Therapy for Chronic Pain,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04457388,NCT04457388,pain intensity|pain disability|anxiety|depression,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: supportive care
Exploring Optimal Treatment Components for Contactless Online Group-based Behavioral Weight Loss Program,iREACH,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04514900,NCT04514900,weight loss|change in body weight from baseline calculated as % of body weight lost|treatment engagement: daily weighing|treatment engagement: weekly food journal submissions|treatment engagement: completion of the 16 weekly interactive online modules|treatment engagement: attendance at video chat condition,interventional,allocation: randomized|intervention model: factorial assignment|masking: none (open label)|primary purpose: treatment
Post Discharge After Surgery Virtual Care With Remote Automated Monitoring Technology (PVC-RAM) Trial,PVC-RAM,"active, not recruiting",No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04344665,NCT04344665,"days alive at home|hospital re-admission|emergency department visit|urgent care centre visit|covid-19 infection|brief acute hospital care|medication error detection|medication error correction|delirium|surgeon, family physician, or specialist in-person clinic visit|surgeon, family physician, or specialist virtual visit|sepsis|acute heart failure|death|participant pain|acute hospital care|all-cause hospital days",interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
Mobile Mental Health Apps for Suicide Prevention,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04536935,NCT04536935,patient health questionnaire (phq-9)|generalized anxiety disorder (7-item) scale (gad-7)|brief difficulties with emotional regulation scale (ders)|acceptability of intervention measure (aim)|intervention appropriateness measure (iam)|feasibility of intervention measure (fim),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Digital Cardiac Counseling Trial: DCC Trial,DCC,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04393636,NCT04393636,maces|mortality|cardiovascular-related mortality|covid-19 related mortality|health-related quality of life|nyha functional classification|ccs (canadian cardiovascular society grading of angina pectoris)|perioperative complications|hospital length of stay|time on mechanical ventilation|smoking status|anxiety and depression|participation in postoperative cardiac rehabilitation|body-mass index (bmi)|number of participants with unplanned visits|healthcare costs,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults in the Era of Coronavirus Disease 2019,MITIGATE,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04505098,NCT04505098,percentage of patients with moderate or severe confirmed viral uris|worst clinical status due to a confirmed viral uri,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: prevention
"Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients With Chronic Migraine and Medication Overuse",ChroMig-Smart,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04389372,NCT04389372,efficacy of mindfullness by smartphone|change of disability score|change in quality of life,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
DigiVis: Self-testing Vision App for Telephone Consultations,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04482387,NCT04482387,comparison of visual acuity measurement using digivis testing and standard visual acuity testing|levels of agreement between digivis testing and standard visual acuity testing|digivis test repeatability,interventional,intervention model: sequential assignment|masking: none (open label)|primary purpose: diagnostic
Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04428099,NCT04428099,depression severity|health-related quality of life,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Effectiveness of Basic Body Awareness Therapy in Post-traumatic Stress Disorders: A Randomized Clinical Trial,BATEP,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04396314,NCT04396314,change in davidson trauma scale (dts)|change in beck depression inventory (bdi)|change in state-trait anxiety inventory (stai)|change in short form 36 (sf36)|change in visual analogue scale (vas)|change in pittsburgh sleep quality index (psqi),interventional,allocation: randomized|intervention model: parallel assignment|masking: single (outcomes assessor)|primary purpose: treatment
Intracorporeal Anastomosis in Laparoscopic Left Colectomy. Cohort Comparative Study,RIAL-COLECTOMY,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04456933,NCT04456933,percentage of anastomotic leak (al)|rate of global morbidity|rate of surgical site infection|rate of re-interventions,observational,observational model: cohort|time perspective: prospective
Impact on the OLAF Intervention to Prevent Post Traumatic Disorders During the Confinement.,OLAF,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04470869,NCT04470869,incidence of ptsd observed 6 months after patient's discharge from the intensive care unit|incidence of ptsd observed 6 months after patient's death in the intensive care unit|ptsd incidence at month 3|ptsd incidence at month 12|symptoms incidence at month 3|symptoms incidence at month 6|symptoms incidence at month 12|incidence of persistent complicated grief at month 3|incidence of persistent complicated grief at month 6|incidence of persistent complicated grief at month 12,interventional,allocation: non-randomized|intervention model: sequential assignment|masking: none (open label)|primary purpose: prevention
Proper Nutrition And Its Relation To Oral Diseases In Covid -19 Era,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04434014,NCT04434014,regeneration of taste,observational,observational model: ecologic or community|time perspective: prospective
Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (‚â•60 Years Old),nan,recruiting,No Results Available,phase 1|phase 2,Industry,https://ClinicalTrials.gov/show/NCT04550351,NCT04550351,the number of adverse events after intramuscular injection|immunogenic end point,interventional,allocation: randomized|intervention model: sequential assignment|masking: single (participant)|primary purpose: prevention
"A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults",nan,not yet recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04464460,NCT04464460,"number of participants reporting one or more treatment-emergent adverse events (teaes)|number of participants with markedly abnormal laboratory values|number of participants with markedly abnormal values of vital signs|number of participants with markedly abnormal 12-lead electrocardiograms|number of participants with adverse events (aes) related to physical examination findings|ceoi: serum concentration at the end of infusion for tak-671|t1/2z: terminal disposition serum half-life for tak-671|auclast: area under the serum concentration-time curve from time 0 to the time of the last quantifiable concentration for tak-671|auc‚àû: area under the serum concentration-time curve from time 0 to infinity for tak-671|percentage of participants with sustained clinical improvement or live discharge at day 28|percentage of participants with sustained clinical recovery|percentage of participants with sustained remission of respiratory symptoms|mortality rate|time to sustained clinical improvement or discharge from hospital|time to sustained clinical recovery|percentage of participants with any form of new ventilation use|number of days of new ventilation use|number of ventilation-free days|number of days free of invasive mechanical ventilation or extracorporeal membrane oxygenation (ecmo)|time to sustained remission of respiratory symptoms|percentage of participants admitted to intensive care unit (icu)|number of days of icu stay|change from baseline in sequential organ failure assessment (sofa) score at days 7, 14, and 28",interventional,"allocation: randomized|intervention model: sequential assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization,nan,not yet recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04530448,NCT04530448,ph|number of days alive free of stage 2-3 aki|stage 2-3 aki|vent-free|hospital-free,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia,nan,recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT03852537,NCT03852537,feasibility of the timely initiation of corticosteroids and implementation of biomarker-titrated corticosteroid dosing: percentage of eligible patients adhered to the timely initiation|mortality|progression of disease|evolution of respiratory failure|evolution of kidney failure|evolution of shock|length of stay|incidence of treatment-emergent adverse events [safety and tolerability]: hyperglycemia|incidence of treatment-emergent adverse events [safety and tolerability]: delirium|incidence of treatment-emergent adverse events [safety and tolerability]: secondary infection,interventional,"allocation: randomized|intervention model: parallel assignment|masking: double (participant, investigator)|primary purpose: treatment"
"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study",GOTCHA,recruiting,No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04473274,NCT04473274,adverse events outcomes without attribution|adverse events attributable|clinical improvement|levels of treatment|d-dimer|c reactive protein|ferritin|lactate dehydrogenase|a1c,interventional,allocation: non-randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Emotional Freedom Technique (EFT) Effect on Nurses,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04393077,NCT04393077,the subjective units of distress scale|the state anxiety|burnout,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: supportive care
The Effectiveness of Telerehabilitation-Based Exercises in Elderly People,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04346940,NCT04346940,standardized mini mental test|mini nutritional assesment|short physical performance test|single leg stance test|charlson comorbidity index|clinic fragility scale|pittsburgh sleep quality index|social isolation survey|quality of life scale in the elderly|the physical activity scale for the elderly|timed up and go test|30 second chair stand test|the beck depression inventory|the beck anxiety inventory,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Alterations of Gut Microbiome in the Frontline Medical Staff Under the Stress,AGMFMSS,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04443075,NCT04443075,gut microbiome composition of exposed group|gut microbiome composition of non-exposed group|the impact of event scale-revised (ies-r) of exposed group|the impact of event scale-revised (ies-r) of non-exposed group|the 15-item patient health questionnaire (phq-15) of exposed group|the 15-item patient health questionnaire-15 (phq-15) of non-exposed group|the 9-item patient health questionnaire (phq-9) of exposed group|the 9-item patient health questionnaire (phq-9) of non-exposed group|the 7-item generalized anxiety disorder scale (gad-7) of exposed group|the 7-item generalized anxiety disorder scale (gad-7) of non-exposed group|the pittsburgh sleep quality index (psqi) of exposed group|the pittsburgh sleep quality index (psqi) of non-exposed group|the symptom check list 90 (scl-90) of exposed group|the symptom check list 90 (scl-90) of non-exposed group,observational,observational model: cohort|time perspective: prospective
First Level Socio-geriatric Evaluation: ESOGER Databank,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04393649,NCT04393649,covid-19 symptoms|issues related to medication and food delivery and access to home care|physical frailty|psychological frailty|caregiver burden,observational,observational model: cohort|time perspective: prospective
Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04356144,NCT04356144,etp (auc) without rhthrombomodulin (rhtm)|etp (auc) with rhthrombomodulin (rhtm)|etp-ratio|etp-normalisation,observational,observational model: cohort|time perspective: prospective
Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis,AS DEFER,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04333875,NCT04333875,"composite of all-cause mortality, disabling and non-disabling stroke, and hospitalization for heart failure",observational,observational model: cohort|time perspective: prospective
Norwegian Coronavirus Disease 2019 Study,NO COVID-19,"active, not recruiting",No Results Available,phase 4,Other,https://ClinicalTrials.gov/show/NCT04316377,NCT04316377,rate of decline in sars-cov-2 viral load|change in national early warning score score|admission to intensive care unit|in-hospital mortality|duration of hospital admission|mortality at 30 and 90 days|clinical status|change in c-reactive protein concentrations|change in alanine aminotransferase concentrations|change in aspartate aminotransferase concentrations|change in bilirubin concentrations|change in estimated glomerular filtration rate|change in cardiac troponin concentrations|change in natriuretic peptide concentrations,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",nan,completed,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04276688,NCT04276688,time to negative nps|time to negative saliva|time to clinical improvement|hospitalisation|mortality|immune reaction|adverse events|time to negative all clinical specimens,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction,nan,not yet recruiting,No Results Available,phase 1,Other,https://ClinicalTrials.gov/show/NCT04439825,NCT04439825,self- perception of mood before treatment and after achieving an optimal cosmetic result as determined by the pi.|happiness levels before treatment and after achieving an optimal cosmetic result as determined by the pi.|measurement of the glabellar wrinkle severity scores before treatment. the onset of effect and maximum efficacy compared to previous botox cosmetic injections will also be assessed by questionnaires.,interventional,allocation: randomized|intervention model: crossover assignment|masking: single (participant)|primary purpose: treatment
Propranolol as an Anxiolytic to Reduce the Use of Sedatives From Critically-ill Adults Receiving Mechanical Ventilation,PROACTIVE,not yet recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04467086,NCT04467086,primary sedative dose change|sedation scores|primary sedative dose|total sedative daily dose change|total opioid daily dose change|adverse event - bradycardia|adverse event - hypotension|adverse event - bronchospasm|adverse event - ecg conduction delays,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
Virtual White Boards for Patient Satisfaction,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04497922,NCT04497922,emergency department satisfaction: likert scale|quality of emergency department stay: likert scale|preference for virtual white board,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: other
Global Mental Health of Urban Mothers,MUM,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04363177,NCT04363177,edinburgh postnatal depression scale (epds)|mental health status and covid-19|socio-economic status|elective cs,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
Lessening Organ Dysfunction With VITamin C,LOVIT,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT03680274,NCT03680274,number of deceased participants or with persistent organ dysfunction|number of participants with persistent organ dysfunction-free days in intensive care unit|number of participants deceased at 6 months|score of health related quality of life in 6-month survivors|global tissue dysoxia|organ function (including renal function)|rate of inflammation|rate of infection|rate of endothelial injury|occurrence of stage 3 acute kidney injury|acute hemolysis|hypoglycemia|vitamin c volume of distribution|vitamin c clearance|vitamin c plasma concentration,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
"Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831",NEUROSIVIR,recruiting,No Results Available,phase 1,Industry,https://ClinicalTrials.gov/show/NCT04480333,NCT04480333,proportion of participants experiencing any treatment-emergent adverse events|proportion of participants experiencing any treatment-emergent graded laboratory abnormalities|maximum concentration (cmax) - pharmacokinetic assessment|time to maximum concentration (tmax) - pharmacokinetic assessment|auc calculated from time of administration to the last measurable concentration (auc0-last) - pharmacokinetic assessment|area under the curve extrapolated to infinity (auc0-‚àû)|half-life (t1/2) - pharmacokinetic assessment|volume of distribution (vd) - pharmacokinetic assessment|clearance [cl] - pharmacokinetic assessment,interventional,"allocation: randomized|intervention model: crossover assignment|masking: triple (participant, care provider, investigator)|primary purpose: treatment"
Audio Data Collection for Identification and Classification of Coughing,nan,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT04326309,NCT04326309,dataset size|cough sound identification|improvement of the existing model|evaluate the usability of the application,observational,observational model: cohort|time perspective: prospective
Universal Anti-Viral Vaccine for Healthy Elderly Adults,ALLOPRIME,not yet recruiting,No Results Available,phase 1|phase 2,Industry|Other,https://ClinicalTrials.gov/show/NCT04441047,NCT04441047,frequency of vaccine events|proportion of subjects with positive t-cell response|proportion of subjects able to suppress viral propagation,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: prevention
The Effectiveness of Video-Based Exercises in Young Adults,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04346966,NCT04346966,international physical activity questionnaire (short form)|short form-36 (sf-36)|the pittsburgh sleep quality index|distress tolerance scale|beck anxiety inventory|nottingham health profile|sit and reach test|shoulder flexibility test|curl-up test|repetitive squat test|side plank test|timed up and go test|single leg stance test,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: prevention
Characteristics of TraceTogether Users,nan,"active, not recruiting",No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04468581,NCT04468581,demographic information,observational,observational model: cohort|time perspective: retrospective
Remote Blood Pressure Monitoring With the Wearable SENBIOSYS Photoplethysmographic Device,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04379986,NCT04379986,"feasibility of non-invasive bp monitors: blood pressure|percentage of signal with artefact,",interventional,allocation: non-randomized|intervention model: single group assignment|masking: none (open label)|primary purpose: device feasibility
Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.,ImmunoCOVID,enrolling by invitation,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04382508,NCT04382508,to describe covid19 infection in children/adults who are vulnerable for infection in an outpatients setting|number of children/adults tested positive for covid19|number of children/adults admitted in hospital because of covid19|to assess the impact of covid19 infection on the daily activities of immunosuppressed adults and children,observational,observational model: cohort|time perspective: prospective
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",POPS or POP02,recruiting,No Results Available,nan,Other|Industry|NIH,https://ClinicalTrials.gov/show/NCT04278404,NCT04278404,clearance (cl) or apparent oral clearance (cl/f) as measured by pk sampling|volume of distribution (v) or apparent oral volume of distribution (v/f) as measured by pk sampling|elimination rate constant (ke) as measured by pk sampling|half-life (t1/2) as measured by pk sampling|absorption rate constant (ka) as measured by pk sampling|auc (area under the curve) as measured by pk sampling|maximum concentration (cmax) as measured by pk sampling|time to achieve maximum concentration (tmax) as measured by pk sampling,observational,observational model: other|time perspective: prospective
Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,COVID-19 PEP,completed,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT04308668,NCT04308668,incidence of covid19 disease among those who are asymptomatic at baseline|overall change in disease severity over 14 days among those who are symptomatic at baseline|incidence of hospitalization|incidence of death|incidence of confirmed sars-cov-2 detection|incidence of symptoms compatible with covid19 (possible disease)|incidence of all-cause study medicine discontinuation or withdrawal|overall symptom severity at 5 and 14 days|ordinal scale of covid19 disease severity at 14 days among those who are symptomatic at trial entry,interventional,"allocation: randomized|intervention model: parallel assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Non-COVID Patient-safety Incidents Reported by Primary Care Professionals in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study,PSI-RECORd-XP,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04348552,NCT04348552,"describe patient safety incidents (types, severity, contributing and correcting factors) - 1000 psi required|describe patient safety incidents (types, severity, contributing and correcting factors) - 100 psi required",observational,observational model: cohort|time perspective: prospective
Non-COVID Patient-safety Incidents Reported by General Practitioners in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study.cRisis,PSI-RECORd-GP,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04346121,NCT04346121,"describe patient safety incidents (types, severity, contributing and correcting factors) - 1000 psi required|describe patient safety incidents (types, severity, contributing and correcting factors) - 100 psi required",observational,observational model: cohort|time perspective: prospective
Coronavirus Smell Therapy for Anosmia Recovery,Co-STAR,not yet recruiting,No Results Available,phase 2,Other,https://ClinicalTrials.gov/show/NCT04422275,NCT04422275,university of pennsylvania smell identification test (upsit)|questionnaire of olfactory disorders-negative statements (qod-ns).|global rating of smell.|global rating of smell change.,interventional,"allocation: randomized|intervention model: factorial assignment|masking: quadruple (participant, care provider, investigator, outcomes assessor)|primary purpose: treatment"
Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04351880,NCT04351880,anxiety and depression measured through the hospital anxiety and depression scale|functional status measured through the katz activities of daily living scale|re-hospitalization and emergency department visits,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (investigator)|primary purpose: other
Acceptance and Commitment Therapy Delivered by Automated Software Messaging,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04329897,NCT04329897,change in reported pain intensity score (promis pain intensity 3a) patient-reported outcomes measurement information system pain intensity (promis) 3a short form scores collected from all participating subjects.|change in reported pain intensity score (promis pain intensity 1a) patient-reported outcomes measurement information system pain intensity (promis) 1a short form scores collected from all participating subjects.|change in reported pain interference score patient-reported outcomes measurement information system (promis) pain interference 8a short form scores collected from all participating subjects.|change in reported emotional distress (anxiety) score. patient-reported outcomes measurement information system (promis) emotional distress-anxiety 8a short form scores collected from all participating subjects.,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: supportive care
Preliminary Efficacy of a One-Session Mindfulness Telehealth Intervention for Loneliness,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04414826,NCT04414826,revised university of california los angeles loneliness scale - 8 (uls-8)|perceived stress scale (pss),interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions,nan,completed,No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04444986,NCT04444986,auc0-tlast of favipiravir|cmax of favipiravir|auc0-inf of favipiravir|tmax of favipiravir,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: other
Comparison of VieScope vs. Macintosh Laryngoscope for Intubation in Level Cpersonal Protective Equipment Conditions,nan,completed,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04363775,NCT04363775,time to intubation|success of intubation|number of optimalization maneuvers|procedure ease of use|the degree of visibility of the glottis|cormack - lehane grade,interventional,allocation: randomized|intervention model: crossover assignment|masking: single (outcomes assessor)|primary purpose: treatment
Care in Patients Hospitalized for Anorexia Nervosa at the Time of the Coronavirus-19 Epidemic (QUALICOVID),QUALICOVID,not yet recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04387708,NCT04387708,content analysis concerning the reorganization of care for children or adolescent and thier parents,observational,observational model: family-based|time perspective: cross-sectional
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry,nan,recruiting,No Results Available,nan,Industry,https://ClinicalTrials.gov/show/NCT03452774,NCT03452774,"proportion of patients eligible for cte versus actual cte|impact of cte on overall survival (os), estimated by kaplan-meier and cox multivariable survival analysis|impact of cte on progression-free survival (pfs), estimated by kaplan-meier and cox multivariable survival analysis|identification of barriers to cte|real world data analytics|virtual tumor board utilization|time from intervention to actual cte (months)",observational,observational model: cohort|time perspective: prospective
Healthy Lifestyle or Pro-health Obsession During the Pandemic,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04432038,NCT04432038,levels of physical activity|eating attitudes|psychological wellbeing|physical wellbeing|obligatory exercise|attitudes towards body|body image disturbance,observational,observational model: cohort|time perspective: prospective
ICBT for Mental Health Problems Related to the Coronavirus Pandemic,nan,recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04424212,NCT04424212,becks depression inventory-ii|brunnsviken brief quality of life scale|patient health questionnaire|alcohol use disorder identification test|insomnia severity index|the coronavirus health impact survey|impact of event scale-revised|perceived stress scale,interventional,allocation: randomized|intervention model: parallel assignment|masking: none (open label)|primary purpose: treatment
Telehealth Intervention Program for Older Adults,TIP-OA,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04523610,NCT04523610,perceived stress scale (pss)|patient health questionnaire-9 (phq-9)|generalized anxiety disorder-7 (gad-7)|fear of covid-19 scale|interviews and focus groups with volunteers|interviews and focus groups with stakeholders|interviews with program users,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: health services research
Telerehabilitation-based Yoga and Mindfulness Home Program in Postmenopausal Women Having Social Isolation,nan,not yet recruiting,No Results Available,not applicable,Other,https://ClinicalTrials.gov/show/NCT04346979,NCT04346979,the brief resilience scale|nottingham health profile|mindful attention awareness scale|the body awareness questionnaire|richard-campbell sleep questionnaire|lateral bridge test|functional reach test|beck depression scale,interventional,allocation: randomized|intervention model: parallel assignment|masking: single (participant)|primary purpose: treatment
"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Favipiravir,completed,Has Results,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04406194,NCT04406194,auc0-tlast of favipiravir|cmax of favipiravir|auc0-inf of favipiravir|tmax of favipiravir,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: other
"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Favipiravir,completed,Has Results,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04400682,NCT04400682,auc0-tlast|favipiravir cmax|auc0-inf of favipiravir|tmax of favipiravir,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: other
Fiberoptic Bronchoscopy and Bronchoalveolar Lavage in Critically Ill Ventilated Patients,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04502368,NCT04502368,regional compliance variation|regional resistance variation|regional compliance and fob duration|regional compliance and pao2|atelectasis areas and bal flooded areas|pao2 and pao2/fio2 ratio|paco2|endotracheal tube size and fiberscope size|hemodynamic variations,observational,observational model: case-only|time perspective: prospective
Eating Habits of Adults During the Quarantine,nan,completed,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04339842,NCT04339842,changes in the eating habits of adults during the quarantine,observational,observational model: case-only|time perspective: cross-sectional
"The Bioequivalence Study of Umifenovir 200 mg Capsul (ATABAY, Turkey) Under Fasting Conditions",Umifenovir,"active, not recruiting",No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04476719,NCT04476719,primary pk endpoint|secondary pk endpoint,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: other
"Bioequivalence Study of Favipiravir 200 mg Film Tablet (World Medicine, Turkey) Under Fasting Conditions",Favipiravir,completed,No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04407000,NCT04407000,primary pk end points auc0-tlast|primary pk end points cmax|secondary pk end points auc0-inf|secondary pk end points tmax,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: other
Who Benefits More? Optimising Mindfulness Based Interventions for Improved Psychological Outcomes,nan,recruiting,No Results Available,nan,Other,https://ClinicalTrials.gov/show/NCT04417153,NCT04417153,change in subjective measures of sleep quality: pittsburgh sleep quality index total score|change in subjective measures of stress: perceived stress scale (pss)|change in subjective time in bed (tib)|change in subjective total sleep time (tst)|change in subjective sleep onset latency (sol)|change in subjective wake after sleep onset (waso),observational,observational model: cohort|time perspective: prospective
Azithromycin-Prevention in Labor Use Study (A-PLUS),nan,recruiting,No Results Available,phase 3,Other,https://ClinicalTrials.gov/show/NCT03871491,NCT03871491,"maternal: incidence of maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group.|neonatal: incidence of intrapartum/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group|incidence of chorioamnionitis|incidence of endometritis|incidence of other infections|incidence of use of subsequent maternal antibiotic therapy|maternal initial hospital length of stay|incidence of maternal readmissions|incidence of maternal admission to special care units|incidence of maternal unscheduled visit for care|incidence of maternal gi symptoms|incidence of maternal death due to sepsis|incidence of other neonatal infections (e.g. eye infection, skin infection)|neonatal initial hospital length of stay|incidence of neonatal readmissions|incidence of neonatal admission to special care units|incidence of neonatal unscheduled visit for care|incidence of neonatal death due to sepsis|incidence of pyloric stenosis within 42 days of delivery",interventional,"allocation: randomized|intervention model: parallel assignment|masking: triple (participant, care provider, investigator)|primary purpose: prevention"
"Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions",Orvical,"active, not recruiting",No Results Available,phase 1,Industry|Other,https://ClinicalTrials.gov/show/NCT04386876,NCT04386876,primary pk end points,interventional,allocation: randomized|intervention model: crossover assignment|masking: none (open label)|primary purpose: other
A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,nan,completed,No Results Available,phase 1,Other|Industry,https://ClinicalTrials.gov/show/NCT04276987,NCT04276987,adverse reaction (ae) and severe adverse reaction (sae)|time to clinical improvement (ttic)|number of patients weaning from mechanical ventilation|duration (days) of icu monitoring|duration (days) of vasoactive agents usage|duration (days) of mechanical ventilation supply|number of patients with improved organ failure|rate of mortality,interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients,nan,recruiting,No Results Available,phase 2,Industry,https://ClinicalTrials.gov/show/NCT03474965,NCT03474965,"pk (aucd15) after 1st dose|pd (aucd15) after 1st dose|pk (auctau) after multiple dose|pd (auctau) after multiple dose|pk (cmax) after 1st dose and multiple dose|pk pre-dose concentrations|frequency of any adverse events (aes) as a measure of safety and tolerability|annualized rate vaso occusive crisis (voc) events leading to healthcare visit in clinic/er/hospital|annualized rate vaso occusive crisis (voc) events treated at home (based on documentation by health care provider following phone contact with the patient)|annualized rate each subcategory of voc event (uncomplicated pain crisis, acute chest syndrome, hepatic sequestration, splenic sequestration, priapism)|annualized rate hospitalizations and er visits (both overall and voc-related)|annualized rate days of er/hospitalization (both overall and voc-related)|annualized rate of dactylitis events|number, seriousness, severity, and causality assessments of treatement emergent adverse events and other data as considered appropiate.|absolute change from baseline in hemoglobin|immunogenicity: measurement of anti-drug antibodies (ada) to crizanlizumab|electrocardiogram (ecgs) at relevant pk time points|growth and sexual maturation assessments (tanner stage)|pk pre-dose concentrations prior to each study drug dose.|percentage p-selectin inhibition prior to dosing",interventional,allocation: n/a|intervention model: single group assignment|masking: none (open label)|primary purpose: treatment